United America







The Director

of the United States Patent and Trademark Office has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this United States

grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, products made by that process, for the term set forth in 35 u.s.c. 154(a)(2)or (c)(1), subject to the payment of maintenance fees as provided by 35 U.s.c. 4I(b). See the Maintenance Fee Notice on the inside of the cover.



Katherine Kelly Vidal

DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

Maintenance Fee Notice

If the application for this patent was filed on or after December 12, 1980, maintenance fees are due three years and six months, seven years and six months, and eleven years and six months after the date of this grant, or within a grace period of six months thereafter upon payment of a surcharge as provided by law. The amount, number and timing of the maintenance fees required may be changed by law or regulation. Unless payment of the applicable maintenance fee is received in the United States Patent and Trademark Office on or before the date the fee is due or within a grace period of six months thereafter, the patent will expire as of the end of such grace period.

Patent Term Notice

If the application for this patent was filed on or after June 8, 1995, the term of this patent begins on the date on which this patent issues and ends twenty years from the filing date of the application or, if the application contains a specific reference to an earlier filed application or applications under 35 U.S.C. 120, 121, 365(c), or 386(c), twenty years from the filing date of the earliest such application ("the twenty-year term"), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b), and any extension as provided by 35 U.S.C. 154(b) or 156 or any disclaimer under 35 U.S.C. 253.

If this application was filed prior to June 8, 1995, the term of this patent begins on the date on which this patent issues and ends on the later of seventeen years from the date of the grant of this patent or the twenty-year term set forth above for patents resulting from applications filed on or after June 8, 1995, subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b) and any extension as provided by 35 U.S.C. 156 or any disclaimer under 35 U.S.C. 253.

Form PTO-377C (Rev 09/17)



US012110520B2

(12) United States Patent

Wei et al.

(54) PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF

- (71) Applicant: HALOZYME, INC., San Diego, CA (US)
- Inventors: Ge Wei, San Diego, CA (US); H.
 Michael Shepard, Eugene, OR (US);
 Qiping Zhao, San Diego, CA (US);
 Robert James Connor, Oceanside, CA (US)
- (73) Assignee: Halozyme, Inc., San Diego, CA (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1 day.

This patent is subject to a terminal disclaimer.

- (21) Appl. No.: 18/068,418
- (22) Filed: Dec. 19, 2022

(65) **Prior Publication Data**

US 2023/0250409 A1 Aug. 10, 2023

Related U.S. Application Data

(60) Division of application No. 17/327,568, filed on May 21, 2021, which is a continuation of application No. 16/912,590, filed on Jun. 25, 2020, now Pat. No. 11,066,656, which is a continuation of application No. 15/226,489, filed on Aug. 2, 2016, now Pat. No. 10,865,400, which is a division of application No. 13/694,731, filed on Dec. 28, 2012, now Pat. No. 9,447,401, said application No. 17/327,568 is a continuation of application No. 16/824,572, filed on Mar. 19, 2020, now Pat. No. 11,041,149, which is a continuation of application No. 15/226,489, filed on Aug. 2, 2016, now Pat. No. 10,865,400, which is a division of application No. 13/694,731, filed on Dec. 28, 2012, now Pat. No. 9,447,401, said application No. 17/327,568 is a continuation of application No. 15/226,489, filed on Aug. 2, 2016, now Pat. No. 10,865,400, which is a division of application No. 13/694,731, filed on Dec. 28, 2012, now Pat. No. 9,447,401, application No. 18/068,418 is a division of application No. 17/327,586, filed on May 21, 2021, now Pat. No. 12,037,618, which is a continuation of application No. 16/912,590, filed on Jun. 25, 2020, now Pat. No. 11,066,656, which is a continuation of application No. 15/226,489, filed on Aug. 2, 2016, now Pat. No. 10,865,400, which is a division of application No. 13/694,731, filed on Dec. 28, 2012, now Pat. No. 9,447,401, said application No. 17/327,586 is a continuation of application No. 16/824,572, filed on Mar. 19, 2020, now Pat. No. 11,041,149, which is a continuation of application No. 15/226,489, filed on Aug. 2, 2016, now Pat. No. 10,865,400, which is a continuation of application No. 13/694,731, filed on (Continued)

(10) Patent No.: US 12,110,520 B2

(45) **Date of Patent: *Oct. 8, 2024**

(51)	Int. Cl.	
	C12N 9/26	(2006.01)
	A61K 9/00	(2006.01)
	A61K 38/00	(2006.01)
	A61K 38/28	(2006.01)
	A61K 38/47	(2006.01)
	A61K 45/06	(2006.01)
	A61K 47/10	(2017.01)
	A61P 35/00	(2006.01)
	C07K 14/47	(2006.01)
	C12Q 1/34	(2006.01)

- (52) U.S. Cl.
- (58) Field of Classification Search
 - CPC C12N 9/2474; A61P 35/00; A61K 9/0019; A61K 38/28; A61K 38/47; A61K 47/10; A61K 38/00; C07K 14/47; C07K 2319/30; C12Q 1/34; C12Y 302/01035; Y02A 50/30; G01N 2333/926; G01N 2333/928

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,536,809 A	10/1970	Applezwe	ig 424/28
3,598,123 A	8/1971	Zaffaroni	128/268
	(Con	tinued)	

FOREIGN PATENT DOCUMENTS

CN	102065886 A	5/2011
EP	0400472 (Con	12/1990 tinued)

OTHER PUBLICATIONS

U.S. Appl. No. 16/930,766, filed Jul. 16, 2020, 2020/0368330, Nov. 26, 2020.

(Continued)

Primary Examiner — Suzanne M Noakes Assistant Examiner — Ciara A McKnight (74) Attorney, Agent, or Firm — Morgan, Lewis & Bockius LLP

(57) ABSTRACT

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

35 Claims, 13 Drawing Sheets

Specification includes a Sequence Listing.

2007/0189962 A1

Related U.S. Application Data

Dec. 28, 2012, now Pat. No. 9,447,401, said application No. 17/327,586 is a continuation of application No. 15/226,489, filed on Aug. 2, 2016, now Pat. No. 10,865,400, which is a division of application No. 13/694,731, filed on Dec. 28, 2012, now Pat. No. 9,447,401, said application No. 17/327,586 is a continuation of application No. 13/694,731, filed on Dec. 28, 2012, now Pat. No. 9,447,401, application No. 18/068,418 is a division of application No. 16/912, 590, filed on Jun. 25, 2020, now Pat. No. 11,066,656, which is a continuation of application No. 15/226, 489, filed on Aug. 2, 2016, now Pat. No. 10,865,400, which is a division of application No. 13/694,731, filed on Dec. 28, 2012, now Pat. No. 9,447,401, said application No. 16/912,590 is a division of application No. 13/694,731, filed on Dec. 28, 2012, now Pat. No. 9,447,401, application No. 18/068,418 is a division of application No. 16/824,572, filed on Mar. 19, 2020, now Pat. No. 11,041,149, which is a continuation of application No. 15/226,489, filed on Aug. 2, 2016, now Pat. No. 10,865,400, which is a division of application No. 13/694,731, filed on Dec. 28, 2012, now Pat. No. 9,447,401, said application No. 16/824, 572 is a division of application No. 13/694,731, filed on Dec. 28, 2012, now Pat. No. 9,447,401, application No. 18/068,418 is a continuation of application No. 15/226,489, filed on Aug. 2, 2016, now Pat. No. 10,865,400, which is a division of application No. 13/694,731, filed on Dec. 28, 2012, now Pat. No. 9,447,401, application No. 18/068,418 is a division of application No. 13/694,731, filed on Dec. 28, 2012, now Pat. No. 9,447,401.

(60) Provisional application No. 61/796,208, filed on Nov. 1, 2012, provisional application No. 61/631,313, filed on Dec. 30, 2011.

(56)**References Cited**

U.S. PATENT DOCUMENTS

3,630,200 A	12/1971	Higuchi 128/260
3,710,795 A	1/1973	Higuchi et al 128/260
3,845,770 A	11/1974	Theeuwes et al 128/260
3,916,899 A	11/1975	Theeuwes et al 128/260
4,002,531 A	1/1977	Royer 195/68
4,008,719 A	2/1977	Theeuwes et al 128/260
4,044,126 A	8/1977	Cook et al 514/180
4,179,337 A	12/1979	Davis et al 435/181
4,364,923 A	12/1982	Cook 424/46
4,414,209 A	11/1983	Cook et al 514/180
4,769,027 A	9/1988	Baker et al 424/493
4,952,496 A	8/1990	Studier et al 435/91
4,980,286 A	12/1990	Morgan et al 435/371
5,033,252 A	7/1991	Carter 53/425
5,052,558 A	10/1991	Carter 206/439
5,059,595 A	10/1991	Le Grazie 424/468
5,073,543 A	12/1991	Marshall et al 514/21
5,120,548 A	6/1992	McClelland et al 424/473
5,122,614 A	6/1992	Zalipsky 548/520
5,323,907 A	6/1994	Kalvelage 206/531
5,324,844 A	6/1994	Zalipsky 548/520
5,446,090 A	8/1995	Harris 525/54.1
5,591,767 A	1/1997	Mohr et al 514/413
5,612,460 A	3/1997	Zalipsky 530/391.9
5,639,476 A	6/1997	Oshlack et al 424/468
5,643,575 A	7/1997	Martinez et al 424/194.1
5,672,662 A	9/1997	Harris et al 525/408
5,674,533 A	10/1997	Santus et al 424/493
5,721,348 A	2/1998	Primakoff et al 536/22.1

5,733,566 A	3/1998	Lewis 424/426
5,766,581 A	6/1998	Bartley et al 424/85.1
5,795,569 A	8/1998	Bartley et al 424/85.1
5,808,096 A 5,854,046 A	9/1998 12/1998	Zalipsky 548/520 Au-Young et al 435/201
5,900,461 A	5/1999	Harris
5,919,455 A	7/1999	Greenwald et al 424/178.1
5,932,462 A	8/1999	Harris et al 435/188
5,958,750 A	9/1999	Au-Young et al 435/201
5,985,263 A	11/1999	Lee et al 424/85.2
5,990,237 A	11/1999	Bentley et al 525/54.2
6,057,110 A 6,113,906 A	5/2000 9/2000	Au-Young et al 435/6 Greenwald et al 424/194.1
6,193,963 B1	2/2001	Stern et al
6,214,966 B1	4/2001	Harris
6,258,351 B1	7/2001	Harris 424/78.3
6,340,742 B1	1/2002	Burg et al 530/351
6,413,507 B1	7/2002	Bentley et al 424/78.02
6,420,339 B1 6,437,025 B1	7/2002 8/2002	Gegg et al 514/12 Harris et al 523/406
6,437,025 B1 6,448,369 B1	9/2002	Bentley et al
6,461,802 B1	10/2002	Van Thillo et al 430/336
6,461,863 B1	10/2002	Jarvis 435/320.1
6,495,659 B2	12/2002	Bentley 528/425
6,615,063 B1	9/2003	Ntziachristos et al 600/312
6,737,505 B2	5/2004	Bentley et al 528/425
6,828,401 B2 6,858,736 B2	12/2004 2/2005	Nho et al. 526/333 Nho et al. 546/290
7,105,330 B2	9/2006	Stern et al
7,279,457 B2	10/2007	Pohl et al 514/3
7,585,940 B2	9/2009	Skerra et al 530/350
7,767,429 B2	8/2010	Bookbinder et al 435/201
7,781,397 B2	8/2010	Stern et al 424/94.62
7,829,081 B2 7,846,431 B2	11/2010 12/2010	Bookbinder et al 424/94.62 Bookbinder et al 424/94.62
7,840,431 B2 7,871,607 B2	1/2010	Bookbinder et al 424/94.62
8,105,586 B2	1/2012	Bookbinder
8,187,855 B2	5/2012	Baker et al 435/201
8,202,517 B2	6/2012	Bookbinder et al 424/94.62
8,257,699 B2	9/2012	Bookbinder et al 424/94.62
8,318,154 B2 8,343,487 B2	11/2012 1/2013	Frost et al 424/94.5 Baker et al 424/94.62
8,431,124 B2	4/2013	Bookbinder et al 424/94.62
8,431,380 B2	4/2013	Bookbinder et al 435/201
8,450,470 B2	5/2013	Bookbinder et al 536/23.2
8,568,713 B2 8,580,252 B2	10/2013 11/2013	Frost et al 424/94.5 Bookbinder et al 424/85.2
8,765,685 B2	7/2013	Bookbinder et al 514/20.9
8,772,246 B2	7/2014	Bookbinder et al 435/200
9,284,543 B2	3/2016	Wei et al 435/201
9,447,401 B2	9/2016	Wei et al 424/94.62
9,913,822 B2 10,016,491 B2	3/2018 7/2018	Maneval et al 435/195 Bookbinder et al 424/94.62
10,010,491 B2 10,328,130 B2	6/2019	Frost et al 424/94.62
10,588,983 B2	3/2020	Bookbinder et al 435/69.1
11,041,149 B2	6/2021	Wei et al 435/69.1
11,066,656 B2	7/2021	Wei et al 435/69.1
2001/0021763 A1	9/2001	Harris
2001/0044526 A1 2001/0046481 A1	11/2001 11/2001	Shen 530/409 Bentley et al
2001/0040401 A1 2002/0052430 A1	5/2002	Harris et al
2002/0072573 A1	6/2002	Bentley et al 525/409
2002/0156047 A1	10/2002	Zhao 514/58
2003/0017108 A1	1/2003	Zamora et al 424/1.49
2003/0114647 A1	6/2003	Harris et al 530/402
2003/0143596 A1 2003/0158333 A1	7/2003 8/2003	Bentley et al
2003/0220447 A1	11/2003	Harris
2004/0013637 A1	1/2004	Bentley et al 424/78.17
2004/0235734 A1	11/2004	Bossard et al 514/12
2004/0268425 A1	12/2004	Bookbinder et al 800/18
2005/0054048 A1	3/2005	Grasso et al 424/133.1
2005/0114037 A1	5/2005	Desjarlais et al 702/19
2005/0171328 A1 2005/0209416 A1	8/2005 9/2005	Harris 528/322 Harris 525/523
2005/0209416 A1 2005/0260186 A1	9/2005	Bookbinder et al 424/94.61
2005/0200180 A1 2006/0104968 A1	5/2006	Bookbinder et al 424/94.61
2007/0067855 A1	3/2000	Jarvis et al
2007/0189962 A1	8/2007	Pastan et al $424/1331$

8/2007 Pastan et al. 424/133.1

U.S. PATENT DOCUMENTS

2009/0028829	A 1	1/2009	Gruskin et al 424/93.7
2009/0028829		2/2009	Matschiner et al 514/12
2009/0123367		5/2009	Bookbinder et al 424/1.49
	Al	7/2009	Bookbinder et al $424/141.1$
	A1	8/2009	Bookbinder et al 424/94.1
	Al	10/2009	Bookbinder et al 425/69.1
	A1	12/2009	Frost et al
	A1	12/2009	Jensen et al
2009/0311237		12/2009	Frost
2010/0003238	A1	1/2010	Frost et al 424/94.62
2010/0074885	A1	3/2010	Schiff et al 424/130.1
2010/0143457	A1	6/2010	Wei et al 424/450
2010/0172892	A1	7/2010	Uvarkina et al 424/94.62
2011/0053247	A1	3/2011	Baker et al 435/201
2011/0066111	A1	3/2011	Teschner et al 514/183
2011/0152359	A1	6/2011	Bookbinder et al 435/200
2012/0020951	A1	1/2012	Shepard et al 424/130.1
2012/0093770	A1	4/2012	Bookbinder et al 424/94.62
	A1	6/2012	Bookbinder et al 435/200
2012/0171153	A1	7/2012	Frost et al 424/94.62
2012/0213767		8/2012	Wei et al 424/450
2012/0251517		10/2012	Frost et al 424/94.5
2012/0251620		10/2012	Bookbinder et al 424/450
2012/0294830		11/2012	Bookbinder et al 424/85.2
2013/0011378		1/2013	Yang et al 424/94.3
2013/0022588		1/2013	Yang et al
2013/0022592		1/2013	Vaughn et al
2013/0022392		3/2013	Bookbinder et al 435/200
	A1	3/2013	Trover et al
2013/0101577		4/2013	Wei et al
2013/0202583		8/2013	Jiang et al
2013/0202303		9/2013	Li et al
2013/0302275		11/2013	Wei et al
2013/0302279		11/2013	Maneval et al 435/195
2013/0302400		2/2013	Bookbinder et al 424/94.62
2014/0105824		4/2014	Shepard et al 424/94.02
2014/0105824		5/2014	Frost et al
2014/0199282		7/2014	Bookbinder et al. $435/200$
2014/0199282		1/2014	Wei 424/94.62
2015/001052)		12/2015	Wei et al
2010/0302070		10/2017	Maneval et al 435/195
2019/0336587		11/2019	Frost et al
2019/0350587		8/2020	Wei et al
2020/0233814	A1 A1	10/2020	Wei et al 455/69.1 Wei et al
2020/0318091		11/2020	Frost et al 424/94.02
		9/2021	Wei et al 424/94.62
2021/02/73/6		9/2021	Wei et al 424/94.62 Wei et al
2021/0284985	AI	9/2021	wei et al 424/94.62

FOREIGN PATENT DOCUMENTS

EP	0822199	9/2004
EP	1064951	8/2007
EP	3130347	9/2019
EP	3636752	4/2020
EP	3785701	3/2021
JP	2007-153797	6/2007
KR	10-2020-0017538	2/2020
WO	WO 1992/16640	10/1992
WO	WO 1994/028024	12/1994
WO	WO 2000/002017	1/2000
WO	WO 2001/087925	11/2001
WO	WO 2002/049673	6/2002
WO	WO 2004/056312	7/2004
WO	WO 2005/000360	1/2005
WO	WO 2009/128917	10/2009
WO	WO 2009/134380	11/2009
WO	WO 2010/077297	7/2010
WO	WO 2010/149772	12/2010
WO	WO 2012/136768	10/2012
WO	WO 2012/174478	12/2012

WO	WO 2013/102144	7/2013
WO	WO 2015/003167	1/2015

OTHER PUBLICATIONS

U.S. Appl. No. 17/062,425, filed Oct. 2, 2020, 2021/0023184, Jan. 28, 2021.

U.S. Appl. No. 17/327,568, filed May 21, 2021, 2021/0284985, Sep. 16, 2021.

U.S. Appl. No. 17/327,586, filed May 21, 2021, 2021/0277376, Sep. 9, 2021.

U.S. Appl. No. 17/850,903, filed Jun. 27, 2022, 2022/0372151, Nov. 24, 2022.

U.S. Appl. No. 18/064,886, filed Dec. 12, 2022.

U.S. Appl. No. 18/066,960, filed Dec. 15, 2022.

U.S. Appl. No. 18/068,218, filed Dec. 19, 2022.

U.S. Appl. No. 18/068,327, filed Dec. 19, 2022.

U.S. Appl. No. 18/068,443, filed Dec. 19, 2022. U.S. Appl. No. 18/069,651, filed Dec. 21, 2022.

Letter/Written Disclosure of the Information Disclosure Statement

for the above-referenced application, filed herewith on Mar. 16, 2023, 2 pages.

Adams, G.E. and I.J. Stratford, "Bioreductive drugs for cancer therapy: the search for tumor specificity," Int. J. Radiat. Oncol. Biol. Phys., 29(2): 231-238 (1994).

Alexander et al., "Expression of the c-myc oncogene under control of an immunoglobulin enhancer in E μ -myc transgenic mice," Mol. Cell. Biol. 7(4):1436-1444 (1987).

Ansel, H. C., Introduction to Pharmaceutical Dosage Forms, Lea & Febiger, Philadelphia, PA, Fourth Edition, p. 126 (1985).

Anttila et al., "High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer," Cancer Res. 60(1):150-155 (2000).

Arming et al., "In vitro mutagenesis of PH-20 hyaluronidase from human sperm," Eur. J. Biochem. 247(3):810-814 (1997).

Atkinson, M. and E. Leiter, "The NOD mouse model of type 1 diabetes: as good as it gets?" Nature Med. 5:601-604 (1999).

Auvinen et al., "Hyaluronan in Peritumoral Stroma and Malignant Cells Associates with Breast Cancer Spreading and Predicts Survival," Am. J. Pathol. 156(2):529-536 (2000).

Baumgartner et al., "Phase I study in chemoresistant loco-regional malignant disease with hyaluronidase," Reg. Cancer Treat. 1:55-58 (1988).

Beckenlehner et al., "Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo," J. Cancer Res. Oncol. 118:591-596 (1992).

Benhar et al., "Pseudomonas exotoxin A mutants. Replacement of surface-exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner," J. Biol. Chem. 269:13398-13404 (1994).

Bianchi et al., "Synthetic depsipeptide substrates for the assay of human hepatitis C virus protease," Anal. Biochem. 237: 239-244 (1996).

Bitter ct al., "Expression and secretion vectors for yeast," Methods in Enzymol. 153:516-544 (1987).

Bonner, W. and E. Cantey, "Colorimetric method for determination of serum hyaluronidase activity," Clin. Chim. Acta 13:746-752 (1966).

Bookbinder et al., "A recombinant human enzyme for enhanced interstitial transport of therapeutics," J. Control. Release, 114:230-241 (2006).

Bordier, C., "Phase separation of integral membrane proteins in Triton X-114 solution," J. Biol. Chem. 256(4):1604-1607 (1981). Bouffard et al., "An in vitro assay for hepatitis C virus NS3 serine proteinase," Virology 209:52-59 (1995).

Brinster et al., "Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs," Nature 296:39-42 (1982). Brown et al., "Codon utilisation in the pathogenic yeast, Candida albicans," Nucleic Acids Res. 19(15):4298 (1991).

Brumeanu et al., "Derivatization with monomethoxypolyethylene glycol of Igs expressing viral epitopes obviates adjuvant requirements," J. Immunol. 154:3088-3095 (1995).

OTHER PUBLICATIONS

Caliceti, P. and Veronese, F. M., "Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates,"Adv. Drug Deliv. Rev. 55(10):1261-1277 (2003).

Carrillo, H. and Lipman, D., "The multiple sequence alignment problem in biology," Siam J. Applied Math. 48(5):1073-1082 (1988). Cefalu, W., "Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition," ILAR Journal 47(3):186-198 (2006).

Chapman et al., "Therapeutic antibody fragments with prolonged in vivo half-lives," Nature Biotech. 17:780-783 (1999).

Cheng et al., "PEGylated adenoviruses for gene delivery to the intestinal epithelium by the oral route," Pharm. Res. 20(9):1444-1451 (2003).

Cherr et al., "The dual functions of GPI-anchored PH-20: hyaluronidase and intracellular signaling," Matrix Biol., 20(8):515-525 (2001).

Cherr et al., "The PH-20 protein in cynomolgus macaque spermatozoa: identification of two different forms exhibiting hyaluronidase activity," Dev. Biol. 175:142-153 (1996).

Cho et al., "Construction of hepatitis C-SIN virus recombinants with replicative dependency on hepatitis C virus serine protease activity," J. Virol. Meth. 65:201-207 (1997).

Chowpongpang et al., "Cloning and characterization of the bovine testicular PH-20 hyaluronidase core domain," Biotechnol. Lett. 26(15):1247-52 (2004).

Colbere-Garapin et al., "A new dominant hybrid selective marker for higher eukaryotic cells," J. Mol. Biol. 150:1-14 (1981).

Conserved domain search from U.S. Appl. No. 10/795,095 of SEQ ID No. 6, Primakoff et al. U.S. Pat. No. 5,721,348, performed on the NCBI website on Aug. 5, 2008.

Csoka et al., "Hyaluronidases in tissue invasion," Invasion Metastasis 17:297-311 (1997).

Csoka et al., "Purification and microsequencing of hyaluronidase isozymes from human urine," FEBS Lett., 417(3):307-310 (1997). Csoka et al., "The six hyaluronidase-like genes in the human and mouse genomes," Matrix Biol. 20:499-508 (2001).

Czejka et al., "Influence of hyaluronidase on the blood plasma levels of 5-fluorouracil in patients," Pharmazie 45(9):693-694 (1990).

De Maeyer, E. and J. De Maeyer-Guignard, "The growth rate of two transplantable murine tumors, 3LL lung carcinoma and B16F10 melanoma, is influenced by Hyal-1, a locus determining hyaluronidase levels and poly morphism," Int. J. Cancer 51:657-660 (1992).

De Salegui et al., "A Comparison of Serum and Testicular Hyaluronidase," Arch. Biochem. Biophys. 121:548-554 (1967).

De Boer et al., "The tac promoter: a functional hybrid derived from the trp and lac promoters," Proc. Natl. Acad. Sci. USA 80:21-25 (1983).

Delpech et al., "Enzyme-linked hyaluronectin: a unique reagent for hyaluronan assay and tissue location and for hyaluronidase activity detection," Anal. Biochem. 229:35-41 (1995).

Derwent English abstract for Japanese Publication No. JP 2007-153797, published Jun. 21, 2007, entitled "Therapeutic Agent and Preventive Agent of Autoimmune Disease, Inflammation, and Nervous Disease," 3 pages.

Dorfman, A. and M. Ott, "A turbidimetric method for the assay of hyaluronidase," J. Biol. Chem. 172:367-375 (1948).

D'Souza et al., "In vitro cleavage of hepatitis C virus polyprotein substrates by purified recombinant NS3 protcasc," J. Gen. Virol. 76:1729-1736 (1995).

Duttaroy ct al., "Development of a long-acting insulin analog using albumin fusion technology," Diabetes 54(1):251-258 (2005).

Elder et al., "Intra-arterial hyaluronidase in severe peripheral arterial disease," Lancet 1(8169):648-649 (1980).

Ernst et al., "Enzymatic degradation of glycosaminoglycans," Crit. Rev. Biochem. Mol. Biol. 30(5):387-444 (1995).

Eskens et al., "Enzymatic glycocalyx treatment impairs insulinmediated recruitment of microvascular blood volume and decreases insulin sensitivity in rats," FASEB Journal 25: 1023.13 (2011) (Abstract). European Pharmacopoeia, Chapter 5.1.3, "Efficacy of antimicrobial preservation," pp. 447-449 (2005).

Fankhauser, N. and Mäser, P., "Identification of GPI anchor attachment signals by a Kohonen self-organizing map," Bioinformatics 21(9):1846-1852 (2005).

Felix et al., "Pegylated peptides IV. Enhanced biological activity of site-directed pegylated GRF analogs," Int. J. Peptide Protein Res. 46:253-264 (1995).

Few, B., "Hyaluronidase for treating intravenous extravasations," MCN Amer. J. Matern. Child Nurs. 12(1):23 (1987).

Filocamo et al., "Chimeric Sindbis viruses dependent on the NS3 protease of hepatitis C virus," J. Virology 71:1417-1427 (1997).

Forsburg, S.L., "Codon usage table for Schizosaccharomyces pombe," Yeast 10(8):1045-1047 (1994).

Fransson et al., "Solvent effects on the solubility and physical stability of human insulin-like growth factor I," Pharm. Res. 14(5):606-12 (1997).

Frost, G. I. and Stern, R., "A microtiter-based assay for hyaluronidase activity not requiring specialized reagents," Anal. Biochem. 251:263-269 (1997).

Gardner et al., "The complete nucleotide sequence of an infectious clone of cauliflower mosaic virus by M13mp7 shotgun sequencing," Nucleic Acids Res. 9(12):2871-2888 (1981).

GenBank Accession No. AAC60607, PH-20 [*Homo sapiens*], published on Jun. 5, 2000 [online] [retrieved on Dec. 12, 2012][retrieved from the Internet: URL:<ncbi.nlm.nih.gov/protein/AAC60607], 1 page.

Gilbert, W. and Villa-Komaroff, L., "Useful Proteins from Recombinant Bacteria," Scientific American 242(4):74-94 (1980).

Girish et al., "Hyaluronidase inhibitors: a biological and therapeutic perspective," Curr. Med. Chem. 16(18):2261-2288 (2009).

Gmachl et al., "The human sperm protein PH-20 has hyaluronidase activity," FEBS 336(3):545-548 (1993).

Good et al., "Hydrogen ion buffers for biological research," Biochemistry 5(2):467-477 (1966).

Gribskov, M. and Burgess, R. R., "Sigma factors from *E. coli, B. subtilis*, phage SP01, and phage T4 are homologous proteins," Nucl. Acids Res. 14(16):6745-6763 (1986).

Grosschedl et al., "Introduction of a μ immunoglobulin gene into the mouse germ line: specific expression in lymphoid cells and synthesis of functional antibody," Cell 38:647-658 (1984).

Guiotto et al., "An improved procedure for the synthesis of branched polyethylene glycols (PEGs) with the reporter dipeptide Met- β Ala for protein conjugation," Bioorg. Med. Chem. Lett. 12:177-180 (2002).

Guntenhoner et al., "A substrate-gel assay for hyaluronidase activity," Matrix 12:388-396 (1992).

Guo et al., "Protein tolerance to random amino acid change," Proc. Nat'l. Acad. Sci. USA, 101:9205-9210, 2004.

Hahm et al., "Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity," Virology 226:318-326 (1996).

Haller et al., "Escaping the Interstitial Matrix With Enzyme-Mediated Drug Delivery," Drug Delivery Technology, 5(5):1-6 (2005).

Hamatake et al., "Establishment of an in vitro assay to characterize hepatitis C virus NS3-4A protease trans-processing activity," Intervirology 39:249-258 (1996).

Hammer et al., "Diversity of alpha-fetoprotein gene expression in mice is generated by a combination of separate enhancer elements," Science 235:53-58 (1987).

Hanahan, D., "Heritable formation of pancreatic β -cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes," Nature 315(6015):115-122 (1985).

Harris, J. and R. Chess, "Effect of pegylation on pharmaceuticals," Nat. Rev. Drug Discov. 2(3):214-221 (2003).

Hartman S. and R. Mulligan, "Two dominant-acting selectable markers for gene transfer studies in mammalian cells," Proc. Natl. Acad. Sci. 85:8047-8051 (1988).

Have et al., "Cloning and characterization of the cDNA encoding the PH20 protein in the European red fox Vulpes vulpes," Reproduct. Fertil. Dev. 10:165-172 (1998).

OTHER PUBLICATIONS

Herrera-Estrella et al., "Expression of chimaeric genes transferred into plant cells using a Ti-plasmid-derived vector," Nature 303:209-213 (1983).

Herrera-Estrella et al., "Light-inducible and chloroplast-associated expression of a chimaeric gene introduced into *Nicotiana tabacum* using a Ti plasmid vector," Nature 310(5973):115-120 (1984).

Hibi et al., "Chondroitinase C activity of *Streptococcus intermedius*," FEMS Microbiol. Lett. 57(2):121-124 (1989).

Hofinger et al., "Isoenzyme-specific differences in the degradation of hyaluronic acid by mammalian-type hyaluronidases," Glycoconj. J. 25:101-109 (2008).

Holash et al., "VEGF-Trap: a VEGF blocker with potent antitumor effects," Proc. Natl. Acad. Sci. U. S. A. 99(17):11393-11398 (2002). Hooper, N. M., "Determination of glycosyl-phosphatidylinositol membrane protein anchorage" Proteomics 1:748-755 (2001).

Horn et al., "Intravesical chemotherapy of superficial bladder tumors in a controlled trial with cis- platinum versus cis-platinum plus hyaluronidase," J. Surg. Oncol. 28:304-307 (1985).

Huang et al., "Recombinant Human Hyaluronidase PH20 Does Not Stimulate an Acute Inflammatory Response and Inhibits Lipopolysaccharide-Induced Neutrophil Recruitment in the Air Pouch Model of Inflammation," (2014) J. Immunol. 192(11):5285-5295.

Huang, X. and W. Miller., "A time-efficient, linear-space local similarity algorithm," Adv. Appl. Math. 12:337-357 (1991).

Hunnicut et al., "Structural relationship of sperm soluble hyaluronidase to the sperm membrane protein PH-20," Biol. Reprod. 54(6):1343-1349 (1996).

Infante et al., "Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours," Br. J. Cancer 118(2):153-161 (2018).

Ito et al., "Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus," J. Gen. Virol. 77:1043-1054 (1996).

IUPAC-IUB Commission on Biochemical Nomenclature, "A One-Letter Notation for Amino Acid Sequences: Tcntative Rules," J. Biol. Chem. 243(13):3557-3559 (1968).

IUPAC-IUB Commission on Biochemical Nomenclature, "Abbreviated nomenclature of synthetic poypeptides-polymerized amino acids-revised recommendations,"The Journal of Biological Chemistry 247(2):323-325 (1972).

Jadin et al., "A comprehensive model of hyaluronan turnover in the mouse," Matrix Biol. 31(2):81-89 (2012).

Jay et al., "Construction of a general vector for efficient expression of mammalian proteins in bacteria: use of a synthetic ribosome binding site," Proc. Natl. Acad. Sci. USA 78(9):5543-5548 (1981). Karvinen et al., "Hyaluronan, CD44 and versican in epidermal keratinocyte tumours," British Journal of Dermatology 148: 86-94 (2003).

Kelsey et al., "Species- and tissue-specific expression of human α_1 -antitrypsin in transgenic mice," Genes And Devel. 1:161-171 (1987).

Kim et al., "Sperm penetration through cumulus mass and zona pellucida," Int. J. Dev. Biol. 52(5-6):677-682 (2008).

Kodukula et al., "Biosynthesis of Phosphatidylinositol Glycananchored Membrane Proteins," J. Biol. Chem. 266:4464-4470 (1991). Kohno et al., "Effects of hyaluronidase on doxorubicin penetration into squamous carcinoma multicellular tumor spheroids and its cell lethality," J. Cancer Res. Clin. Oncol. 120(5):293-297 (1994).

Kollias et al., "Regulated expression of human ^A γ -, β -, and hybrid $\gamma\beta$ -globin genes in transgenic mice: manipulation of the developmental expression patterns," Cell 46:89-94 (1986).

Krumlauf et al., "Developmental regulation of α -fetoprotein genes in transgenic mice," Mol. Cell. Biol. 5(7):1639-1648 (1985).

Krupers et al., "Complexation of poly(ethylene oxide) with poly(acrylic acid-co-hydroxyethyl methacrylate)s," Eur. Polym J. 32(6):785-790 (1996).

Kyte et al., "A Simple Method for Displaying the Hydropathic Character of a Protein" J. Mol. Biol. 157:105-132 (1982).

Lalancette et al., "Characterization of an 80-kilodalton bull sperm protein identified as PH-20," Biol. Reprod. 65(2):628-636 (2001). Lam et al., "The effect of benzyl alcohol on recombinant human interferon-gamma," Pharm. Res. 14(6):725-729 (1997).

Lammerts van Bueren et al., "The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility," Proc. Natl. Acad. Sci. U. S. A. 105(16):6109-6114 (2008).

Lathrop et al., "cDNA cloning reveals the molecular structure of a sperm surface protein, PH-20, involved in sperm-egg adhesion and the wide distribution of its gene among mammals," J. Cell Biol. 111(6 Pt 2): 2939-2949 (1990).

Laurent, T. and J. Fraser, "Hyaluronan," FASEB J 6:2397-2404 (1992).

Leder et al., "Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development," Cell 45:485-495 (1986).

Li et al., "Importance of Glycosylation and Disulfide Bonds in Hyaluronidase Activity of Macaque Sperm Surface PH-20," J. Androl. 23:211-219 (2002).

Li et al., "Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8," Structure 16(2):216-227 (2008). Liang et al., "Prediction of antigenic epitopes on protein surfaces by consensus scoring," BMC Bioinformatics 10:302 (2009), 10 pages. Lin et al., "A hyaluronidase activity of the sperm plasma membrane protein PH-20 enables sperm to penetrate the cumulus cell layer surrounding the egg," J. Cell Bio. 125(5):1157-1163 (1994). Lin et al., "Molecular cloning of the human and monkey sperm

Lin et al., "Molecular cloning of the human and monkey sperm surface protein PH-20," Proc. Natl. Acad. Sci. USA 90:10071-10075 (1993).

Lipponen et al., "High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer," Euro. J. Can. 37(3):849-856 (2001).

Locke et al., "ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20," Drug Deliv. 26(1):98-106 (2019).

Louveau, I. and F. Gondret, "GH and insulin affect fatty acid synthase activity in isolated porcine adipocytes in culture without any modifications of sterol regulatory element binding protein-1 expression," J. Endocrin. 181:271-280 (2004).

Lowe et al., "Flexible eating and flexible insulin dosing in patients with diabetes: Results of an intensive self-management course," Diabetes Res. Clin. Pract. 80(3):439-443 (2008).

Lu, H. and E. Wimmer., "Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus," Proc. Natl. Acad. Sci. USA 93:1412-1417 (1996).

Lu, Y. A. and Felix, A. M., "Pegylated peptides I: Solid-phase synthesis of N^{α} -pegylated peptides using Fmoc strategy," Peptide Res. 6(3):140-146 (1993).

Lu, Y. A. and Felix, A. M., "Pegylated peptides II. Solid-phase synthesis of amino-, carboxy- and side-chain pegylated peptides," Int. J. Peptide Protein Res. 43:127-138 (1994).

M3WD76 Felca (2015, updated) Hyaluronidase/PH20 from Felis catus, 3 pages.

Ma et al., "Fucosylation in prokaryotes and eukaryotes" Glycobiology 16(12):158R-184R (2006).

Maa and Hsu, "Aggregation of recombinant human growth hormone induced by phenolic compounds," Int. J. Pharm. 140(2): 155-168 (1996).

MacDonald, R. J., "Expression of the pancreatic elastase I gene in transgenic mice," Hepatology 7(1):42S-51S (1987).

Magram et al., "Developmental regulation of a cloned adult α -globin gene in transgenic mice," Nature 315:338-340 (1985).

Marković-Housley et al., "Crystal structure of hyaluronidase, a major allergen of bee venom," Structure 8: 1025-1035 (2000).

Maksimenko et al., "Resistance of dextran-modified hyaluronidase to inhibition by heparin" Biochemistry (Mosc.) 66(4):456-463 (2001).

Mammalian Gene Collection (MGC) Program Team, "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences," Proc. Natl. Acad. Sci. USA 99:16899-16903 (2002).

OTHER PUBLICATIONS

McIlvaine, W. B., "A buffer solution for colorimetric comparison," J. Biol. Chem. 49:183-186 (1921).

Mehvar, R., "Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation," J. Pharm. Pharmaceut. Sci. 3(1):125-136 (2000).

Menzel, E. and C. Farr, "Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses," Cancer Lett. 131:3-11 (1998).

Merrifield, R. B., "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide," J. Am. Chem. Soc. 85:2149-2154 (1963).

Meyer et al., "The soluble hyaluronidase from bull testes is a fragment of the membrane-bound PH-20 enzyme," FEBS Letters 413(2):385-388 (1997).

Michelacci, Y. M. and Dietrich, C. P., "Chondroitinase C from *Flavobacterium heparinum*," J. Biol. Chem. 251(4):1154-1158 (1976). Miller et al., "Use of retroviral vectors for gene transfer and expression," Meth. Enzymol. 217:581-599 (1993).

Mizutani et al., "Characterization of hepatitis C virus replication in cloned cells obtained from a human T-cell leukemia virus type 1-infected cell line, MT-2," J. Virol. 70:7219-7223 (1996).

Mizutani et al., "Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells," Biochem. Biophys. Res. Commun. 212:906-911 (1995).

Molineux, G., "Pegylation: engineering improved biopharmaceuticals for oncology," Pharmacotherapy 23 (8 Pt 2):3S-8S (2003).

Monfardini et al., "A branched monomethoxypoly(ethylene glycol) for protein modification," Bioconjugate Chem. 6:62-69 (1995).

Nadjsombati et al., "Dose-range developmental toxicity of rHuPH20 in mice," Matrix Biology vol. 27, Dec. 2008, p. 23.

Nakayama et al., "CD15 expression in mature granulocytes is determined by α 1,3-fucosyltransferase IX, but in promyelocytes and monocytes by α 1,3-fucosyltransferase IV," J. Biol. Chem. 276(19):16100-16106 (2001).

NCBI Reference Sequence XP_011728213.1, Macaca nemestrina (pig-tailed macaque) PH-20 hyaluronidase. Published on Apr. 24, 2018. Retrieved from URL:<ncbi.nlm.nih.gov/protein/795324051/ [retrieved on Apr. 20, 2020], 2 pages.

Needleman, S. B. and Wunsch, C. D., "A general method applicable to the search for similarities in the amino acid sequence of two proteins," J. Mol. Biol. 48:443-453 (1970).

Nekoroski et al., "A recombinant human hyaluronidase sustained release gel for the treatment of post-surgical edema," Int. J. Dermatol. 53(6):777-785 (2014).

Omaetxebarria et al., "Computational approach for identification and characterization of GPI-anchored peptides in proteomics experiments," Proteomics 7(12):1951-1960 (2007).

Ornitz et al., "Elastase I promoter directs expression of human growth hormone and SV40 T antigen genes to pancreatic acinar cells in transgenic mice," Cold Spring Harbor Symp. Quant. Biol. 50:399-409 (1985).

Ostresh et al., "Peptide libraries: determination of relative reaction rates of protected amino acids in competitive couplings," Biopolymers 34:1681-1689 (1994).

Padavattan, S., "Crystal structure determination of hyaluronidase : a major bee venom allergen, in complex with an IgG Fab fragment and purification and biophysical characterization of bovine testes hyaluronidase," 2006, PhD Thesis, University of Basel, Faculty of Science. DOI: 10.5451/unibas-004349798, 101 pages.

Paul, A. and D. Sochart, "Improving the results of ganglion aspiration by the use of hyaluronidase," J. Hand Surg. 22B(2):219-221 (1997).

Paulick, M. and C. Bertozzi, "The glycosylphosphatidylinositol anchor: A complex membrane-anchoring structure for proteins," Biochemistry 47:6991-7000 (2008).

Pawlowski et al., "The effects of hyalurodinase upon tumor formation in BALB/c mice painted with 7,12-dimethylbenz-(α)anthracene," Int. J. Cancer 23:105-109 (1979). Pedersen et al., "Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy," Cancer Res. 70(2):588-597 (2010).

Pham et al., "Large-scale transient transfection of serum-free suspensiongrowing HEK293 EBNA1 cells: peptone additives improve cell growth and transfection efficiency," Biotechnology and Bioengineering 84(3):332-342 (2003).

Phelps et al., "Restricted lateral diffusion of PH-20, a PI-anchored sperm membrane protein," Science 240:1780-1782 (1988).

Pierleoni et al., "PredGPI: a GPI-anchor predictor," BMC Bioinformatics 9:392 (2008), 11 pages.

Pinkert et al., "An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice," Genes and Devel. 1:268-276 (1987). Pirinen et al., "Prognostic value of hyaluronan expression in nonsmall-cell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma," Int. J. Cancer 95: 12-17 (2001).

Primakoff et al., "Fully effective contraception in male and female guinea pigs immunized with the sperm protein PH-20," Nature 335:543-546 (1988).

Prothmann et al., "Sexual size dimorphism predicts rates of sequence evolution of Sperm Adhesion Molecule 1 (SPAM1, also PH-20) in monkeys, but not in hominoids (apes including humans)," Mol. Phy. Ev. 63: 52-63 (2012).

Readhead et al., "Expression of a myelin basic protein gene in transgenic shiverer mice: correction of the dysmyelinating pheno-type," Cell 48:703-712 (1987).

Reitinger et al., "Designed human serum hyaluronidase 1 variant, HYAL1^{∆L}, exhibits activity up to pH 5.9," J. Biol. Chem. 284(29):19173-19177 (2009).

Remmele et al., "Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry," Pharm. Res. 15(2):200-208 (1998).

Rhodes et al., "Transformation of maize by electroporation of embryos," Methods Mol Biol 55:121-131 (1995).

Richmond, T., "Precompiled codon-usage tables," Genome Biology 1:reports 241(2000).

Ripka et al., "Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose," Arch. Biochem. Biophys. 249(2):533-545 (1986).

Roberts et al., "Chemistry for peptide and protein PEGylation," Advanced Drug Delivery Reviews 54:459-476 (2002).

Ropponen et al., "Tumor Cell-associated Hyaluronan as an Unfavorable Prognostic Factor in Colorectal Cancer," Cancer Research 58:342-347 (1998).

Rosengren et al., "Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration," Aaps J. 17(5):1144-1156 (2015).

Sato et al., "Cloning and expression in *Escherichia coli* of the gene encoding the *Proteus vulgaris* chondroitin ABC lyase," Appl. Microbiol. Biotechnol. 41(1):39-46 (1994).

Sato, H., "Enzymatic procedure for site-specific pegylation of proteins," Adv. Drug Deliv. Rev. 54:487-504 (2002).

Sawhney et al., "Bioerodible hydrogels based on photopolymerized poly(ethylene glycol)-co-poly(α -hydroxy acid) Diacrylate Macromers," Macromolecules 26:581-587 (1993).

Schanté et al., "Improvement of hyaluronic acid enzymatic stability by the grafting of amino-acids," Carbohydrate Polymers, 87(3):2211-2216 (2012).

Scharf et al., "Heat stress promoters and transcription factors," in Nover, L. (eds) Plant Promnoters and Transcription Factors. Results and Problems in Cell Differentiation, vol. 20. Springer, Berlin, Hcidclbcrg (1994).

Scheithauer et al., "In vitro evaluation of the anticancer drug modulatory effect of hyaluronidase in human gastrointestinal cell lines," Anticancer Res. 8:391-396 (1988).

Schuller et al., "Pharmacokinetics of intrahepatic 5-fluorouracil \pm preinjected hyaluronidase (Neopermease, N)," Proc. Amer. Assoc. Cancer Res. 32:173, abstract No. 1034 (1991).

Schwartz, R. M. and Dayhoff, M. O., eds., "Matrices for Detecting Distant Relationships," Atlas of Protein Science and Structure, National Biomedical Research Foundation, pp. 353-358 (1978).

OTHER PUBLICATIONS

Schwartzman, J., "Hyaluronidase: A Review in Its Therapeutic Use in Pediatrics," J. Pediat. 39:491-502 (1951).

Seaton et al., "Rat sperm 2B1 glycoprotein (PH20) contains a C-terminal sequence motif for attachment of a glycosyl phosphatidylinositol anchor. Effects of endoproteolytic cleavage on hyaluronidase activity," Biol Reprod. 62(6):1667-1676 (2000).

Shani, M., "Tissue-specific expression of rat myosin light-chain 2 gene in transgenic mice," Nature 314:283-286 (1985).

Sharp et al., "Codon usage patterns in Escherichia coli, Bacillus subtilis, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Drosophila melanogaster and Homo sapiens; a review of the considerable within-species diversity," Nucleic Acids Res. 16(17):8207-8211 (1988)

Sharp, P.M. and E. Cowe, "Synonymous codon usage in Saccharomyces cerevisiae," Yeast. 7(7):657-678 (1991).

Shekhar et al., "The Matrix Reloaded: Halozyme's Recombinant Enzyme Helps Injected Drugs Spread Faster," Chem. Biol. 14:603-604 (2007).

Shimizu, Y. and H. Yoshikura, "Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons," J. Virol. 68:8406-8408 (1994).

Singh et al., "Mechanisms of m-cresol-induced protein aggregation studied using a model protein cytochrome c," J. Pharm. Sci. 100(5):1679-1689 (2011).

Smith, T. F. and Waterman, M. S., "Comparison of biosequences," Advances in Applied Mathematics 2:482-489 (1981).

St. Croix et al., "Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors," Cancer Lett. 131(1):35-44 (1998).

Steinkuhler et al., "Product inhibition of the hepatitis C virus NS3 protease," Biochem. 37:8899-8905 (1998).

Stern, R., "Devising a pathway for hyaluronan catabolismare we there yet?" Glycobiology 13:105R-115R (2003)

Stern et al., "Hyaluronidases: their genomics, structures, and mechnisms of action, " Chem. Rev. 106:818-839 (2006).

Sturla et al., "Core fucosylation of N-linked glycans in leukocyte adhesion deficiency/congenital disorder of glycosylation IIc fibroblasts," Glycobiology 15(10):924-934 (2005).

Sudo et al., "Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography," Antiviral Res. 32:9-18 (1996).

Sutton, S. and D. Porter, "Development of the antimicrobial effec-tiveness test as USP chapter <51>," PDA J. Pharm. Sci Technol., 56(6):300-311 (2002).

Swift et al., "Tissue-specific expression of the rat pancreatic elastase I gene in transgenic mice," Cell 38(3):639-646 (1984).

Takahashi et al., "A fluorimetric Morgan-Elson assay method for hyaluronidase activity," Anal. Biochem. 322:257-263 (2003).

Takeshita et al., "An enzyme-linked immunosorbent assay for detecting proteolytic activity of hepatitis C virus proteinase," (1997) Anal. Biochem. 247:242-246.

Taliani et al., "A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates," Anal. Biochem. 240:60-67 (1996).

Ten Have et al., "Cloning and characterization of the cDNA encoding the PH20 protein in the European red fox Vulpes vulpes," Reprod. Fertil. Dev. 10(2):165-172 (1998).

Tkalec et al., "Isolation and expression in Escherichia coli of csIA and cslB, genes coding for the chondroitin sulfate-degrading enzymes chondroitinase AC and chondroitinase B, respectively, from Flavobacterium heparinum," Applied and Environmental Microbiology 66(1): 29-35 (2000).

Tsubery et al., "Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. " J. Biol. Chem. 279(37):38118-38124 (2004).

Tsuda et al., "Substrate specificity studies of Flavobacterium chondroitinase C and heparitinases towards the glycosaminoglycanprotein linkage region. Use of a sensitive analytical method developed by chromophore-labeling of linkage glycoserines using dimethylaminoazobenzenesulfonyl chloride," Eur. J. Biochem. 262:127-133 (1999).

Tung et al., "Mechanism of infertility in male guinea pigs immunized with sperm PH-20," Biol. Reprod. 56(5):1133-1141 (1997). Udenfriend, S. and Kodukula, K., "Prediction of ω site in nascent precursor of glycosylphosphatidylinositol protein," Methods Enzymol. 250:571-582 (1995).

UniProt Murine PH20 sequence Retrieved from: <uniprot.org/ uniprot/P48794, [retrieved on Aug. 2, 2010], 5 pages.

United States Pharmacopeia. USP <51>. Antimicrobial effectiveness testing. United States Pharmacopeia Convention, Inc, Rockville, MD.Retreived from: <http://www.pharmacopeia.cn/v2920/ usp29nf24s0_c51.html, [retreived on Apr. 2, 2013], 5 pages.

USP XXII-NF XVII (1990), p. 644-645 United States Pharmacopeial Convention, Inc, Rockville, MD.

Varela et al., "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma, "Nature 469(7331):539-542 (2011).

Veronese et al., "Branched and Linear Poly(Ethylene Glycol): Influence of the Polymer Structure on Enzymological, Pharmacokinetic, and Immunological Properties of Protein Conjugates," J. Bioactive Compatible Polymers 12:196-207 (1997).

Von Sivaraman Padavattan (2006) Thesis of University of Basel, "Crystal structure determination of hyaluronidase, a major bee venom allergen, in complex with an IgG Fab fragment and purification and biophysicial charcterization of bovine testes hyaluronidase," 100 pages.

Wagner et al., "Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1," Proc. Natl. Acad. Sci. USA 78(3):1441-1445 (1981).

Wang et al., "The molecular physiology of hepatic nuclear factor 3 in the regulation of gluconeogenesis," J. Biol. Chem. 275(19):14717-14721 (2000).

Watson et al., Molecular Biology of the Gene, 4th Edition, The Benjamin/Cummings Pub. Co., Menlo Park, CA, p. 224 (1987).

Weiss et al., "Activities of monomeric insulin analogs at position A8 are uncorrelated with their thermodynamic stabilities," J. Biol. Chem. 276(43):40018-40024 (2001).

Wells, J.A., "Additivity of Mutational Effects in Proteins," Biochem. 29(37):8509-8517 (1990).

White et al., "Comparison of the glycosyl-phosphatidylinositol cleavage/attachment site between mammalian cells and parasitic protozoa," J. Cell Sci. 113(Pt.4):721-727 (2000).

Wigler et al., "Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells," Cell 11:223-232 (1977).

Wigler et al., "Transformation of mammalian cells with an amplifiable dominant-acting gene," Proc. Natl. Acad. Sci. USA 77:3567-3570 (1980).

Yamamoto et al., "Identification of a functional promoter in the long terminal repeat of Rous sarcoma virus," Cell 22:787-797 (1980).

Yamane-Ohnuki et al., "Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity," Biotech, Bioeng. 87:614-622 (2004).

Yang, X. and X. Yu, "An introduction to epitope prediction methods and software," Rev. Med. Virol. 19(2):77-96 (2009).

Yocum et al., "Assessment and Implication of the Allergic Sensitivity to a Single Dose of Recombinant Human Hyaluronidase Injection: A Double-Blind, Placebo-Controlled Clinical Trial," J. Infus. Nursing. 30:293-299 (2007).

Yudin et al., "Characterization of the active site of monkey sperm

hyaluronidase," Reproduction 121(5):735-743 (2001). Zalipsky, S., "Chemistry of polyethylene glycol conjugates with biologically active molecules," Adv. Drug Del. Rev. 16:157-182 (1995).

Zanker et al., "Induction of response in previous chemotherapy resistant patients by hyaluronidase," Proc. Amer. Assoc. Cancer Res. 27:390 Abstract 1550 (1986).

Zhang et al., "Hyaluronidase activity of human Hyall requires active site acidic and tyrosine residues," J. Biol. Chem. 284(14):9433-9442 (2009).

OTHER PUBLICATIONS

Zhao, X. and J. Harris, "Novel degradable poly(ethylene glycol) esters for drug delivery," in Chapter 28: Poly(ethylene glycol), ACS Symposium Series , vol. 680, Harris, J. and Zalipsky, S., (eds), 458-472 (1997).

Bee et al., "Recombinant human PH20 is well tolerated at higher intravenous and subcutaneous doses in cynomolgus monkeys," EUFEPS 2008, Munich, Germany. Abstract, 2 pages.

Bee et al., "Recombinant human PH20 is well tolerated at higher intravenous and subcutaneous doses in cynomolgus monkeys," EUFEPS 2008, Munich, Germany. Poster and individual panels, 9 pages.

Bookbinder et al., "Biochemical characterization of recombinant human PH20 (SPAM1) hyaluronidase," Hyaluronan (ISHAS) 2007, Charleston, SC. Abstract, 1 page.

Bookbinder et al., "Biochemical characterization of recombinant human PH20 (SPAM1) hyaluronidase," Hyaluronan (ISHAS) 2007, Charleston, SC. Poster, 1 page.

Bookbinder et al., "Enhancing Drug Transport Through Temporary Matrix Depolymerization," Keystone Symposia 2005. (poster—12 pages) (together poster and abstract—13 pages).

Bookbinder et al., "Enhancing Drug Transport Through Temporary Matrix Depolymerization," Keystone Symposium 2005. Abstract, 1 page.

Pinkstaff et al., "Evaluation of the compatibility and pharmacokinetics of co-formulated biologics with recombinant human hyaluronidase: Dose Response," American Association of Pharmaceutical Scientists Conference, Nov. 2006. Abstract, 2 pages.

Pinkstaff et al., "Evaluation of the compatibility and pharmacokinetics of co-formulated biologics with recombinant human hyaluronidase: Dose Response," American Association of Pharmaceutical Scientists Conference, Nov. 2006. Poster, 1 page.

Byerley et al., "'Cutting out the bull'. Recombinant human hyaluronidase: Moving to an animal-free system," Association of Clinical Embryologists, 2006, Dublin, Ireland. Abstract published in Human Fertility, Jun. 2006; 9(2): 110.

Frost, "Punctuated Equilibrium: The Evolution of Recombinant Human Hyaluronidase," Ophthalmic Anesthesia Society, 2006, Chicago, IL. Abstract, 1 page.

Frost, "Punctuated Equilibrium: The Evolution of Recombinant Human Hyaluronidase," Ophthalmic Anesthesia Society, 2006, Chicago, IL. Presentation, 35 pages.

Haller et al., "Enhanze Technology—A Revolution in Drug Dispersion," Biotechnology Industry Organization (BIO) Annual Meeting, Jun. 19-22, 2005, Philadelphia, PA. Abstract, 3 pages.

Haller et al., "Recombinant Human Hyaluronidase for the Interstitial Transport of Therapeutics," American Association of Pharmaceutical Scientists Conference, Jun. 2006, San Antonio, TX. Abstract, 2 pages.

Haller et al., "Revolutionizing Drug Dispersion with Enhanze Technology," American Association of Pharmaccutical Scientists Annual Meeting, Nov. 6-10, 2005, Nashville, TN, Poster, 1 page. Haller et al., "Revolutionizing Drug Dispersion with Enhanze Technology," Biotechnology Industry Organization (BIO) Annual Meeting, Jun. 19-22, 2005, Philadelphia, PA. Poster, 1 page.

Haller et al., "The Effects of Recombinant Human Hyaluronidase on Drug Dispersion," American Association of Pharmaceutical Scientists Annual Meeting, Nashville, TN, Abstract in AAPS Journal 7(S2) May 5, 2005; 3 pages.

Haller, "Enhanze Technology—An Enzymatic Drug Delivery System (DDS)," Japanese Export Trade Organization, Nov. 2005, Santa Clara, CA. Abstract, 2 pages.

Haller, "Focus on Enhanced and Innovative Recombinant Human Enzymes," Japanese Export Trade Organization, Sep. 2004, Chicago, IL. Presentation, 16 pages.

Haller, "Halozyme's Enhanze Technology for the Enhanced Dispersion of Co-Injected Pharmaceuticals," Japanese Export Trade Organization, Sep. 2004, Chicago, IL. Abstract, 2 pages. Haller, M., "Enzyme-facilitated Parenteral Drug Transport." Strategic Research Institute's 10th Anniversary Drug Delivery Technology and Deal-making Summit, 2005 New Brunswick, NJ. Presentation, 24 pages.

Hofer et al., "Human recombinant hyaluronidase increases the convection of molecules up 0.2 μ m in athymic nude mice," J. Am. Assoc. Lab. Animal Sci., 45(4):120, abstract P97 (2006).

Hofer et al., "Human Recombinant Hyaluronidase (rHuPh20) Increases the Convection of Molecules up to $0.2 \mu m$ in Athymic Nude Mice," American Association for Laboratory Animal Science, 2006, Salt Lake City, UT. Poster P97, 1 page.

Jiang et al., "Effects of Recombinant Human PH20 (rHuPH20) on Interstitial Matrices: Creating a Favorable Environment for The Delivery of Cytostatic Agents," [abstract]. In: Proceedings of the 96th Annual Meeting of the American Association for Cancer Research; Apr. 16-20, 2005; Anaheim, CA.:AACR; 2005. vol. 46, p. 1198, Abstract No. 5075, Apr. 2005.

Keller et al., "Pharmacokinetic, Pharmacodynamic and Toxicologic Effects of a Recombinant Human Hyaluronidase (rHuPH20) in Rodent and Non-Human Primate models," Hyaluronan (ISHAS) 2007, Charleston, SC. Abstract, 1 page.

Keller et al., "Pharmacokinetic, Pharmacodynamic and Toxicologic Effects of a Recombinant Human Hyaluronidase (rHuPH20) in Rodent and Non-Human Primate models," Presented at International Society for Hyaluronan Sciences (ISHAS) Annual Meeting 2007, Charleston, SC. Poster and individual panels, 14 pages.

Kodandapani et al., "Diverse Structural and Functional Roles of N-glycosylations on rHuPH20," Glycan Abstract, 1 page (2009).

Morrow et al., "Human Hyaluronidase Coinjection Accelerates Insulin Pharmacokinetics and Glucodynamics of 3 Rapid Insulin Analogs," American Diabetes Association Scientific Sessions, held on Jun. 28, 2010 in Orlando, FL., Abstract # 353-OR, 2 pages.

Nadjsombati et al., "Evaluation of Developmental and Prenatal/ Postnatal Reproduction Toxixity of rHuPH20 in Micc," American College of Toxicology 30th annual meeting 2009. (Nov. 1-4) Palm Springs, CA. Abstract, 1 page.

Nagy et al., "Prospective, randomized study on bovine and recombinant human (Cumulase®) Hyaluronidases," American Society of Reproductive Medicine, 2006, New Orleans, LA, 06-A-886-ASRM, Abstract O-213.

Nagy et al., "Prospective study on rHuPH20." European Society of Human Reproduction & Embryology Annual Meeting, Jun. 19-22, 2005, Copenhagen, Denmark. Abstract O-213, 1 page.

Halozyme Therapeutics, Inc., "PEGPH20: The Science & The Strategy," presented at J. P. Morgan Healthcare Conference on Jan. 7, 2015. Presentation. 81 pages.

Pinkstaff et al., "Recombinant Human Hyaluronidase for Drug and Fluid Dispersion," American Association of Pharmaceutical Scientists Annual Meeting, Nov. 2006, Boston, MA, Abstract, 2 pages. Pinkstaff et al., "Recombinant Human Hyaluronidase for Drug and Fluid Dispersion," American Association of Pharmaceutical Scientists Annual Meeting, Nov. 2006, Boston, MA, Poster and individual panels, 8 pages.

Stelzer, L., "Platforms for Growth: Building a Premier Oncology Biotech," Presented at the Canaccord Genuity 38th Annual Growth Conference on Aug. 9, 2018, 24 pages.

Torley, H., "Halozyme Therapeutics, Inc. The next chapter begins: creating value through growth," Presented at the 32nd Annual J.P. Morgan Healthcare Conference Jan. 2014, 26 pages.

Wei et al., "Functions of N-linked glycans on human hyaluronidase PH20," presented at San Diego Glycobiology Symposium 2009. Poster 83 and individual panels, 5 pages.

Wei et al., "Structure function analysis of the human hyaluronidase enzymes," Matrix Biology 27 (Supplement 1):S41, Dec. 2008, American Society for Matrix Biology (ASMB) Biennial Meeting, San Diego, CA, (available on-line Nov. 17, 2008), Abstract 132 (corresponding to poster B4), 2 pages.

Wei et al., "Structure function analysis of the human hyaluronidase enzymes," Presented at American Society for Matrix Biology (ASMB) Biennial Meeting, San Diego, CA, Dec. 9, 2008. Poster B4 and individual panels, 5 pages.

OTHER PUBLICATIONS

Wilson, M.S., "Enhanze Technology—An Enzymatic Drug Delivery System (DDS)," Japanese Export Trade Organization, Nov. 2005, Santa Clara, CA. Oral presentation, 22 pages.

News Release, "Halozyme Announces Presentation of Clinical Data at the American Diabetes Association 74th Scientific Sessions," Published on Jun. 15, 2014 [online][retrieved on Aug. 18, 2014] Retrieved from the internet: <URL: halozyme.com/Investors/News-Releases/News-Release-Details/2014/Halozyme-Announces-Presentation-Of-Clinical-Data-At-The-American-Diabetes-Association-74th-Scientific-Sessions/default.aspx [3 pages].

News Release, Halozyme Therapeutics, Inc "Halozyme Licenses New Enhanze Target for \$30 Million Upfront Payment, Future Milestones and Royalties," Published Sep. 14, 2017 [online] Retrieved from :<URL: halozyme.com/investors/news-releases/news-releasedetails/2017/Halozyme-Licenses-New-Enhanze-Target-For-30-Million-Upfront-Payment-Future-Milestones-And-Royalties/default. aspx [retrieved on Sep. 14, 2017], 3 pages.

News Release, Halozyme Therapeutics, Inc., "Bristol-Myers Squibb and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology," Published Sep. 14, 2017 [online] Retrieved from:<URL: halozyme.com/investors/news-releases/newsrelease-details/2017/Bristol-Myers-Squibb-and-Halozyme-Enter-Global-Collaboration-and-License-Agreement-for-ENHANZE-Technology/default.aspx [Retrieved on Sep. 14, 2017], 7 pages.

News Release, "Bristol, Roche tap Halozyme for tech platform," Published Sep. 14, 2017 [online] Retrieved from:<URL: biopharmadive. com/news/bristol-roche-tap-halozyme-for-tech-platform/504958/ [retrieved on Sep. 18, 2017], 3 pages.

News Article, "Alteogen Inc. to Develop Herceptin Biosimilar for Subcutaneous Injection," Published on Aug. 23, 2018 [online] Retrieved from: <URL:thebell.co.kr/free/Content/ArticleView.asp? key=201808220100037100002360 [Original documents retrieved from the internet and English translation], 4 pages.

News Article, "[Promising biocompany] Alteogen Inc. tries to differentiate itself with specialized bio technology and strategy," Published on Sep. 17, 2018 [online] Retrieved from: <URL:edaily. co.kr/news/read?newsId=01105366619341104&mediaCodeNo=257 &OutLnkChk=Y [Original documents retrieved from the internet and English translation], 4 pages.

News Release, Halozyme Therapeutics, Inc., "Halozyme Publication in the Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects of PEGPH20 on the Tumor Microenvironment," Published Oct. 4, 2018 [online] Retrieved from:<URL:halozy me.com/investors/news-releases/news-releasedetails/2018/Halozyme-Publication-In-The-Journal-Clinical-Cancer-Research-Highlights-New-Nonclinical-Data-Supporting-Multiple-Effects-Of-PEGPH20-On-The-Tumor-Microenvironment/default. aspx [retrieved on Oct. 5, 2018], 4 pages.

News Article, "Alteogen, Inc. challenges to the ethical drug market by utilizing 'Human Hyaluronidase'," Published on Oct. 29, 2018 [online] Retrieved from: <URL:fnnews.com/news/ 201810290941498520 [Original documents retrieved from the internet and English translation], 6 pages.

News Article, "Alteogen names bio drug business development expert Arun Swaminathan as new CBO," Published on Dec. 19, 2018 [online] Retrieved from: <URL:biospectator.com/view/news_ view.php?varAtcId=6825 [Original documents retrieved from the internet and English translation], 7 pages.

News Article, "Maximizing patient convenience by changing intravenous injection to subcutaneous injection . . . Alteogen expects increased exports of the technology this year," Published on Jan. 20, 2019 [online] Retrieved from: <URL:http://news.hankyung.com/ article/2019012023181 [Original documents retrieved from the internet and English translation], 5 pages.

News Release, Halozyme Therapeutics, Inc., "Halozyme Announces Actions to Focus Strategy on ENHANZE® Drug Delivery Technology," Published Nov. 4, 2019 [online], Retrieved from: <URL:halozyme.com/investors/news-releases/news-release-details/ 2019/Halozyme-Announces-Actions-To-Focus-Strategy-On-ENHANZE-Drug-Delivery-Technology/default.aspx [retrieved on Nov. 11, 2019], 4 pages.

News Release, Halozyme Therapeutics, Inc., "Halozyme Announces HALO-301 Phase 3 Study Fails to Meet Primary Endpoint," Published Nov. 4, 2019 [online], Retrieved from: <URL:halozyme.com/ investors/news-releases/news-release-details/2019/Halozyme-Announces-HALO-301-Phase-3-Study-Fails-To-Meet-Primary-Endpoint/default.aspx [retrieved on Nov. 11, 2019], 3 pages.

News Article, "Alteogen files a PCT application for subcutaneous pharmaceutical composition," Published on Mar. 24, 2020 [online], retrieved from <URL:medipana.com/news/news_viewer.asp? NewsNum=254556&MainKind=A&NewsKind=5&vCount=12 &vKind [retrieved on Mar. 26, 2020] [Original documents retrieved from the internet and English translation], 2 pages.

News Article, "MK biotech publishes an article demonstrating the safety of Alteogen's human hyaluronidase (ALT-B4) in germ cells," Published on Apr. 29, 2021 [online], retrieved on Apr. 29, 2021 from <URL:news.heraldcorp.com/view.php?ud=20210429000267 [Original article in Korean and English translation], 3 pages.

Invitation to Pay Additional Fees, sent by facsimile Sept. 9, 2013, in connection with International Patent Application No. PCT/US2012/ 072182, 6 pages.

International Search Report and Written Opinion, mailed Dec. 17, 2013, in connection with International Patent Application No. PCT/US2012/072182, 18 pages.

Response, dated Mar. 17, 2014, to Written Opinion, mailed Dec. 17, 2013, in connection with International Patent Application No. PCT/US2012/072182, 94 pages.

Second Written Opinion, mailed May 21, 2014, in connection with International Patent Application No. PCT/US2012/072182, 8 pages. Response, dated Jul. 21, 2014, to second Written Opinion, mailed May 21, 2014, in connection with International Patent Application No. PCT/US2012/072182, 72 pages.

Second Written Opinion, mailed Jul. 30, 2014, in connection with International Patent Application No. PCT/US2012/072182, 9 pages. Response, dated Sept. 1, 2014, to second Written Opinion, mailed Jul. 30, 2014, in connection with International Patent Application No. PCT/US2012/072182, 73 pages.

International Preliminary Report on Patentability, mailed Sep. 12, 2014, in connection with International Patent Application No. PCT/US2012/072182, 11 pages.

Office Action, mailed Nov. 2, 2015, in connection with U.S. Appl. No. 13/694,731, 14 pages.

Response, filed Apr. 20, 2016, to Office Action, mailed Nov. 2, 2015, in connection with U.S. Appl. No. 13/694,731, 43 pages.

Notice of Allowance, mailed May 20, 2016, in connection with U.S. Appl. No. 13/694,731, 16 pages.

Office Action, issued May 15, 2019, in connection with U.S. Appl. No. 15/226,489, 16 pages.

Response, filed Oct. 15, 2019, to Office Action, issued May 15, 2019, in connection with U.S. Appl. No. 15/226,489, 30 pages.

Office Action, issued Jan. 23, 2020, in connection with U.S. Appl. No. 15/226,489, 19 pages.

Response, filed Apr. 24, 2020, to Office Action, issued Jan. 23, 2020, in connection with U.S. Appl. No. 15/226,489, 25 pages.

Notice of Allowance, issued Jul. 16, 2020, in connection with U.S. Appl. No. 15/226,489, 13 pages.

Office Action, issued Oct. 27, 2020, in connection with U.S. Appl. No. 16/824,572, 9 pages.

Response, filed Jan. 27, 2021, to Office Action, issued Oct. 27, 2020, in connection with U.S. Appl. No. 16/824,572, 23 pages.

Notice of Allowance, mailed Feb. 18, 2021, and Examiner-Initiated Interview Summary, summarizing the interview held on Feb. 10, 2021, issued in connection with U.S. Appl. No. 16/824,572, 10 pages.

Non-final Office Action, issued Dec. 9, 2020, in connection with U.S. Appl. No. 16/912,590, 12 pages.

Response, filed Mar. 17, 2021, to Non-final Office Action, issued Dec. 9, 2020 in connection with U.S. Appl. No. 16/912,590, 24 pages.

OTHER PUBLICATIONS

Notice of Allowance, issued Apr. 14, 2021, and Examiner-Initiated Interview Summary, of interview conducted Apr. 8, 2021, in connection with U.S. Appl. No. 16/912,590, 10 pages.

Examination Report, issued Jan. 13, 2017, in connection with Australian Patent Application No. 2012362141, 3 pages.

Response, filed Aug. 14, 2017, to Examination Report, issued Jan. 13, 2017, in connection with Australian Patent Application No. 2012362141, 43 pages.

Notice of Acceptance, dated Sep. 11, 2017, issued in connection with Australian Patent Application No. 2012362141, 3 pages.

Office Action (claims deemed allowable), dated Oct. 19, 2018, issued in connection with Australian Patent Application No. 2017245352, 7 pages.

Notice of Acceptance, issued Jul. 17, 2019, in connection with Australian Patent Application No. 2017245352, 3 pages.

Preliminary Office Action, issued Apr. 14, 2021, in connection with Brazilian Patent Application No. BR112014016195-0 [Machine generated English translation and Office Action as issued in Portuguese], 11 pages.

Response, filed Jul. 26, 2021, to Preliminary Office Action, published Apr. 27, 2021, in connection with Brazilian Patent Application No. BR112014016195-0 [English instructions for Response and Response as filed in Portuguese], 111 pages.

Office Action, dated Jun. 9, 2022 and published on Jul. 26, 2022, in connection with Brazilian Patent Application No. BR 112014016195-0 [Machine generated English translation and Office Action as issued in Portuguese], 10 pages.

Response, filed Oct. 24, 2022, to Official Action, dated Jun. 9, 2022 and published on Jul. 26, 2022, in connection with Brazilian Patent Application No. BR 112014016195-0 [English instructions for Response and Response as filed in Portuguese], 57 pages.

Office Action, dated Nov. 10, 2022 and published on Dec. 6, 2022, in connection with Brazilian Patent Application No. BR 112014016195-0 [Machine generated English translation and Office Action as issued in Portuguese], 6 pages.

Response, filed Feb. 6, 2023, to Office Action, dated Nov. 10, 2022 and published on Dec. 6, 2022, in connection with Brazilian Patent Application No. BR 112014016195-0 [English instructions for Response and Response as-filed in Portuguese], 33 pages.

Office Action, dated Jun. 9, 2022 and published on Jul. 26, 2022, in connection with Brazilian Patent Application No. BR 122021016549-1 [Machine generated English translation and Office Action as issued in Portuguese], 8 pages.

Response, filed Oct. 24, 2022, to Official Action, dated Jun. 9, 2022 and published on Jul. 26, 2022, in connection with Brazilian Patent Application No. BR 122021016549-1 [English instructions for Response and Response as filed in Portuguese], 101 pages.

Office Action, dated Nov. 11, 2022 and published on Dec. 6, 2022, in connection with Brazilian Patent Application No. BR 122021016549-1 [Machine generated English translation and Office Action as issued in Portuguese], 8 pages.

Response, filed Mar. 6, 2023, to Office Action, dated Nov. 11, 2022 and published on Dec. 6, 2022, in connection with Brazilian Patent Application No. BR 122021016549-1 [English instructions for Response and Response as filed in Portuguese], 170 pages.

Examiner's Report, issued Mar. 1, 2016, in connection with Canadian Patent Application No. 2861919, 7 pages.

Response, filed Jul. 14, 2016, to Examiner's Report, issued Mar. 1, 2016, in connection with Canadian Patent Application No. 2861919, 37 pages.

Examiner's Report, issued Jan. 24, 2017, in connection with Canadian Patent Application No. 2861919, 4 pages.

Response, filed Jul. 24, 2017, to Examiner's Report, issued Jan. 24, 2017, in connection with Canadian Patent Application No. 2861919, 26 pages.

Examiner's Report, issued Jan. 23, 2018, in connection with Canadian Patent Application No. 2861919, 4 pages. Response, filed Jun. 21, 2018, to Examiner's Report, dated Jan. 23, 2018, issued in connection with Canadian Patent Application No. 2861919, 39 pages.

Notice of Allowance, dated Dec. 12, 2018, issued in connection with Canadian Patent Application No. 2861919, 1 page.

Office Action, issued May 25, 2015, in connection with Chinese Patent Application No. 201280070954.9 [English language translation and original document in Chinese], 7 pages.

Response, filed Oct. 9, 2015, to Office Action, issued May 25, 2015, in connection with Chinese Patent Application No. 201280070954.9 [English instructions and document as filed in Chinese], 37 pages. Office Action, issued Feb. 3, 2016, in connection with Chinese Patent Application No. 201280070954.9 [English language translation and original document in Chinese], 6 pages.

Response, filed Jun. 20, 2016, to Office Action, issued Feb. 3, 2016, in connection with Chinese Patent Application No. 201280070954.9 [English language instructions, document as filed in Chinese and claims, as filed, in English], 58 pages.

Office Action, issued Oct. 17, 2016, in connection with Chinese Patent Application No. 201280070954.9 [English language translation and original document in Chinese], 4 pages.

Response, filed Dec. 27, 2016, to Office Action, issued Oct. 17, 2016, in connection with Chinese Patent Application No. 201280070954.9 [English language instructions and document as-filed in Chinese], 18 pages.

Letter, dated Mar. 15, 2017, reporting Telephonic Interview with Examiner in connection with Chinese Patent Application No. 201280070954.9, 1 page.

Response, filed Mar. 23, 2017 to Telephonic Interview with Examiner in connection with Chinese Patent Application No. 201280070954.9 [English translation of pending claims and original document as filed in Chinese], 10 pages.

Notice of Granting Patent Right for Invention, issued Apr. 28, 2017, in connection with Chinese Patent Application No. 201280070954.9 [English translation and original document in Chinese], 4 pages.

Notice of Allowance, dated Dec. 7, 2017, issued in connection with Eurasian Patent Application No. 201400772 [English letter and original document in Russian], 2 pages.

Communication Pursuant to Rulc 71(3) (Intention to Grant), issued Apr. 22, 2016, in connection with European Patent Application No. 12816624.6, 5 pages.

Extended European Search Report, dated Jan. 12, 2017, issued in connection with European Patent Application No. 16189970.3, 11 pages.

Response, filed Aug. 15, 2017, to Extended European Search Report, dated Jan. 12, 2017, issued in connection with European Patent Application No. 16189970.3, 55 pages.

Examination Report, dated Sep. 14, 2017, issued in connection with European Patent Application No. 16189970.3, 3 pages.

Response, dated Oct. 13, 2017, to Examination Report, dated Sep. 14, 2017, issued in connection with European Patent Application No. 16189970.3, 19 pages.

Communication Pursuant to Article 94(3) EPC (claims decmed allowable), dated Fcb. 26, 2018, issued in connection with European Patent Application No. 16189970.3, 3 pages.

Response, filed Sep. 10, 2018, to Communication Pursuant to Article 94(3) EPC (claims dccmcd allowablc), issued Feb. 26, 2018, issued in connection with European Patent Application No. 16189970. 3, 821 pages.

Communication Pursuant to Article 71(3) EPC (Intention to Grant), dated Apr. 8, 2019, issued in connection with European Patent Application No. 16189970.3, 7 pages.

Decision to Grant, issued Aug. 22, 2019, in connection with European Patent Application No. 16189970.3, 2 pages.

Examination Report, issued Dec. 4, 2018, in connection with Indian Patent Application No. 6272/DELNP/2014, 6 pages.

Response, filed Sep. 04, 2019, to Examination Report, issued Dec. 4, 2018, in connection with Indian Patent Application No. 6272/ DELNP/2014, 79 pages.

Hearing Notice, issued Jun. 17, 2020, in connection with Indian Patent Application No. 6272/DELNP/2014, 2 pages.

OTHER PUBLICATIONS

Written Submissions, filed Oct. 9, 2020, responsive to Hearing Notice, issued Aug. 10, 2020, in connection with Indian Patent Application No. 6272/DELNP/2014, 27 pages.

Amended claims and abstract, filed Nov. 19, 2020, responsive to Examiner request, in connection with Indian Patent Application No. 6272/DELNP/2014, 22 pages.

Certificate of Grant, issued Dec. 28, 2020, in connection with Indian Patent Application No. 6272/DELNP/2014, 1 page.

Examination Report, issued Aug. 29, 2022, in connection with Indian Patent Application No. 201918041329, 7 pages.

Office Action, dated Aug. 3, 2016, in connection with Israeli Patent Application No. 233192 [English language translation], 3 pages.

Response, filed Jan. 3, 2017, to Office Action, dated Aug. 3, 2016, in connection with Israeli Patent Application No. 233192 [English language translation], 32 pages.

Office Action, dated Nov. 20, 2017, issued in connection with Israeli Patent Application No. 233192 [English language translation], 2 pages.

Response, filed May 21, 2018, to Office Action, dated Nov. 20, 2017, issued in connection with Israeli Patent Application No. 233192 [English language translation], 22 pages.

Office Action (claims deemed allowable), dated Feb. 20, 2019, issued in connection with Israeli Patent Application No. 233192 [English letter reporting Office Action and original document in Hebrew], 5 pages.

Certificate of Grant, issued Oct. 1, 2020, in connection with Israeli Patent Application No. 233192, 3 pages.

Notification Prior to Acceptance, dated Dec. 14, 2020, issued in connection with Israeli Patent Application No. 274798 [English reporting letter; original document as issued in Hebrew; and English translation of allowed claims], 10 pages.

Official Action, issued on Aug. 11, 2021, in connection with Israeli Patent Application No. 280949 [English translation and original document as issued in Hebrew], 6 pages.

Response, filed Dec. 5, 2021, to Official Action, issued on Aug. 11, 2021, in connection with Israeli Patent Application No. 280949, 11 pages.

Notification Prior to Acceptance, issued Aug. 22, 2022, in connection with Israeli Patent Application No. 280949 [Reporting letter in English and Notification as issued in Hebrew], 6 pages.

Official Action, issued Jan. 19, 2016, in connection with Japanese Patent Application No. 2014-550526 [English translation and original document in Japanese], 8 pages.

Response, filed Jul. 15, 2016, to Official Action, issued Jan. 19, 2016, in connection with Japanese Patent Application No. 2014-550526 [English instructions and document as filed in Japanese], 138 pages.

Decision to Grant, issued Nov. 22, 2016, in connection with Japanese Patent Application No. 2014-550526 [Letter reporting decision to grant and original document in Japanese], 5 pages.

Office Action, issued Dec. 12, 2017, in connection with Japanese Patent Application No. 2016-247708 [English translation and original document in Japanese], 6 pages.

Response, filed May 22, 2018, to Office Action, issued Dec. 12, 2017, in connection with Japanese Patent Application No. 2016-247708 [English instructions with amended claims, documents as filed in Japanese and English translation of claims as-filed], 90 pages.

Decision to Grant, issued Sep. 18, 2018, in connection with Japanese Patent Application No. 2016-247708 [English reporting letter and original document in Japanese], 4 pages.

Office Action, dated May 25, 2018, in connection with Mexican Patent Application No. MX/a/2014/007966 [English translation and original document in Spanish], 6 pages.

Response, filed Oct. 10, 2018, to Office Action, dated May 25, 2018, in connection with Mexican Patent Application No. MX/a/2014/ 007966 [English instructions and document as-filed in Spanish], 13 pages.

Notice of Allowance, issued Oct. 18, 2018, in connection with Mexican Patent Application No. MX/a/2014/007966 [English reporting letter and original document in Spanish], 4 pages.

Office Action, dated Nov. 15, 2022, in connection with Mexican Patent Application No. MX/a/2018/012394 [English translation and original document in Spanish], 14 pages.

Examination Report, dated Mar. 26, 2015, in connection with New Zealand Patent Application No. 626126, 32 pages.

Response, dated May 16, 2016, to Examination Report, dated Mar. 26, 2015, in connection with New Zealand Patent Application No. 626126, 70 pages.

Notice of Acceptance, dated Jun. 8, 2016, in connection with New Zealand Patent Application No. 626126, 1 page.

Letters Patent, issued Sep. 27, 2016, in connection with New Zealand Patent No. 626126, 1 page.

Examination Report, dated Jul. 27, 2017, issued in connection with New Zealand Patent Application No. 720075, 4 pages.

Response, filed Feb. 26, 2018, to Examination Report, dated Jul. 27, 2017, issued in connection with New Zealand Patent Application No. 720075, 88 pages.

Notice of Acceptance, dated Mar. 10, 2020, issued in connection with New Zealand Patent Application No. 720075, 1 page.

Search Report and Written Opinion, dated Dec. 4, 2015, in connection with Singaporean Patent Application No. 11201403714T, 7 pages.

Response, filed May 23, 2016, to Search Report and Written Opinion, dated Dec. 4, 2015, in connection with Singaporean Patent Application No. 11201403714T, 21 pages.

Written Opinion, dated Sep. 18, 2017, in connection with Singapore Patent Application No. 11201403714T, 9 pages.

Response, filed Oct. 27, 2017, to Written Opinion, dated Sep. 18, 2017, in connection with Singapore Patent Application No. 11201403714T, 6 pages.

Notice of Eligibility for Grant and Examination Report, dated Jul. 2, 2018, in connection with Singapore Patent Application No. 11201403714T, 8 pages.

Certificate of Grant, dated Oct. 3, 2018, in connection with Singapore Patent Application No. 11201403714T [Grant Certificate and Granted Claims], 6 pages.

Search Report and Written Opinion, issued Oct. 20, 2017, in connection with Singapore Patent Application No. 10201604470T, 14 pages.

Response, filed Mar. 20, 2018, to Search Report and Written Opinion, issued Oct. 20, 2017, in connection with Singapore Patent Application No. 10201604470T [Response, replacement specification pages, amended claims and cited document], 105 pages.

Examination Report, dated Aug. 6, 2018, and Notice of Eligibility for Grant, dated Aug. 7, 2018, issued in connection with Singapore Patent Application No. 10201604470T, 6 pages.

English translation of Official Action, issued Mar. 20, 2020, in connection with Korean Application No. 10-2020-7002955, 6 pages. English Translation of International Search Report and Written Opinion, issued Oct. 29, 2019, in connection with International application No. PCT/KR2019/009215, 10 pages.

SEQIDNO_3 chimp_SEQIDNO_10_	LNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINATGOGVTIFYWDR LNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINVTGQWTIFYWDR ************************************	60
SEQIDNO_3 chimp_SEQIDNO_10_	LGYYPYIDSTTGVTVNGGIPQKTSLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWA LGYYPYIDSTTGVTVNGGIPQKTSLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWA ************************************	120 120
SEQIDNO_3 chimp_SEQIDNO_10_	RNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNHL RNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNHL ************************************	180 180
SEQIDNO_3 chimp_SEQIDNO_10_	WGYYLFPDCYNHHYKKPGYNGSCWNVEIKRNDDLSWLWWESTALYPSIYLNTQQSPVAAT WGYYLFPDCYNHHYKKPGYNGSCWNVEIKRNDDLSWLWWESTALYPSIYLNTQQSPVAAT ***********************************	240 240
SEQIDNO_3 chimp_SEQIDNO_10_	LYURNRUREAIRVSKIPDAK&PLPVFAYTRIVFTDQWLKFLSQDELVYTFGETVALGASG LYURNRVQEAIRVSKIPDAK&PLPVFWYTRIVFTDQWLKFLSQDELVYTFGETVALGASG ***********************************	300
SEQIDNO_3 chimp_SEQIDNO_10_	IVIWGTLSIMRSMKSCLLDNYMETILNPYIINVTLAAKMCSQVLCOEQGVCIRKNWNSS IVIWGTLSIMRSMKSCLLDNYMETILNPYIINVTLAAKMCSQVLCOEQGVCIRKNWNSS **********************************	360 360
SEQIDNO_3 chimp_SEQIDNO_10_	DYLHLNPDNFAIQLEKGGKFTVRGKPTLEDLEQFSEKFYCSCYSTLSCKEKADVKDTDAV DYLHLNPDNFAIQLEKGGKFTVRGKPTLEDLEQFSEKFYCSCYSTLSCKEKADVKDTDAV ************************************	420 420
SEQIDNO_3 chimp_SEQIDNO_10_	WVCIADGVCIDAFLKPPMETEEPQIFY	

SEQIDNO_3 Rhesus_SEQIDNO_12_	LNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINATGQ@VTIFYWDR 60 LNFRAPPIIPNVPFLWAWNAPSEFCLGKFNEPLDMSLFTLMGSPRINITGQ@VTIFYWDR 60 ************************************
SEQIDNO_3 Rhesus_SEQIDNO_12_	LGYYPYIDS TGVTVNGGIPQK SLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWA 120 LGYYPYIDI TGVTVHGGIPQKWSLQDHLDKSKQDILFYMPVDNLGMAVIDWEEWRPTWA 120 ******* *****************************
SEQIDNO_3 Rhesus_SEQIDNO_12_	RNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNHL 180 RNWKPKDVYKNRSIELVQQQNVQLSLPQATDKAKQEFEKAGKDFMLETIKLGRSLRPNHL 180 ************************************
SEQIDNO_3 Rhesus_SEQIDNO_12_	WGYYLFPDCYNHHYKKPGYNGSCENVEIKRNDDLSWLWEESTALYPSIYLNTQQSPVAAT 240 WGYYLFPDCYNHHYRKPGYNGSCEDVEIKRNDDLSWLWEESTALYPSIYLNTQQSVVVAT 240 ************************************
SEQIDNO_3 Rhesus_SEQIDNO_12_	LYVRNRVREAIRVSKIPDAK PLPVFXYTR VFTDQ LKFLSQDELVYTFGETVALGASG 300 LYVRNRVREAIRVSKIPDAK PLPVFYYAR VFTDQ LKFLSREELVSTLGETVALGASG 300 ***********************************
SEQIDNO_3 Rhesus_SEQIDNO_12_	IVIWGTLSIMRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLCEQGVCIRKNWNSS 360 IVIWGSLSITRSMKSCLLLDTYMETILNPYIINVTLAAKMCSQVLCEQGVCIRKDWNSS 360 *****:*******************************
SEQIDNO_3 Rhesus_SEQIDNO_12_	DYLHLNPDNFAIQLEKGGKFTVRGKPTLæDLEQFSEKFYCSCYSTLSCKEKADVKDTDæV 420 DYLHLNPDNFDIRLEKGGKFTVHGKPTVæDLEEFSEKFYCSCYTNLSCKEKADVKDTDæV 420 ******** *:***************************
SEQIDNO_3 Rhesus_SEQIDNO_12_	VCIADGVCIDAFLKPPMETE-EPQIFY447 VCIADGVCIDASLKPPVETEGSPPIFYNTSSSTVSTTMFIWRLEVWDQGISRIGFF 477 ***********************************

SEQIDNO_3 Cyno_SEQIDNO_14_	LNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINATGQ&VTIFYDR 60 LNFRAPPIIPNVPFLWAWNAPSEFCLGKFNEPLDMSLFTLMGSPRINVTGQ&VTIFYDR 60 ************************************	
SEQIDNO_3 Cyno_SEQIDNO_14_	LGYYPYI <mark>DST</mark> TGVTVNGGIPQK SLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWA 120 LGYYPYIDTTGVTVHGGIPQK SLQDHLDKSKQDILFYMPVDNLGMAVIDWEEWRPTWA 120 ******* *****************************	0 0
SEQIDNO_3 Cyno_SEQIDNO_14_	RNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNHL 180 RNWKPKDVYKNRSIELVQQQNVQLSLPQATDKAKQEFEKAGKDFMLETIKLGRSLRPNHL 180 ************************************	0 0
SEQIDNO_3 Cyno_SEQIDNO_14_	WGYYLFPDCYNHHYKKPGYNGSCENVEIKRNDDLSWLWMESTALYPSIYLNTQQSPVAAT 240 WGYYLFPDCYNHHYRKPGYNGSCEDVEIKRNDDLSWLWMESTALYPSIYLNTQQSVVVAT 240 ************************************	0 0
SEQIDNO_3 Cyno_SEQIDNO_14_	LYURNRUREAIRUSKIPDAK®PLPUFAYTRIUFTDQWLKFLSQDELUYTFGETUALGASG 300 LYURNRUREAIRUSKIPDAKNPLPUFWYARIUFTDQWLKFLSREELUSTLGETUALGASG 300 ***********************************	0 0
SEQIDNO_3 Cyno_SEQIDNO_14_	IVIWGTLSIMRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLCOEQGVCIRKNWNSS 360 IVIWGSLSITRSMKSCLLLDTYMETILNPYIINVTLAAKMCSQVLCOEQGVCIRKDWNSS 360 *****:*******************************	0 0
SEQIDNO_3 Cyno_SEQIDNO_14_	DYLHLNPDNFAIQLEKGGKFTVRGKPTLEDLEQFSEKFYCSCYSTLSCKEKADVKDTDXV 420 DYLHLNPDNFDIRLEKGGKFTVHGKPTVEDLEEFSEKFYCSCYTNLSCKEKADVKDTDXV 420 ************************************	0 0
SEQIDNO_3 Cyno_SEQIDNO_14_	WVCIADGVCIDAFLKPPMETE-EPQIFY	

SEQIDNO_3 bovine_SEQIDN0_16_	LNFRAPPVIPNVPFLWAWNAPSEFCLG-KFDEPLDMSLFSFIGSPRINATGOGVTIFYD 59 LDFRAPPLISNTSFLWAWNAPVERCVNRRFQLPPDLRLFSVKGSPQKSATGOTITLFYND 60 *:*****:*.*.**************************
SEQIDNO_3 bovine_SEQIDNO_16_	RLGYYPYIDSITGVTVNGGIPQK SLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTW 119 RLGYYPHIDEKTGKTVFGGIPQLGNLKSHMEKAKNDIAYYIPNDSVGLAVIDWENWRPTW 120 ************************************
SEQIDNO_3 bovine_SEQIDNO_16_	ARNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNH 179 ARNWKPKDVYRDESVELVLQKNPQLSFPEASKIAKVDFETAGKSFMQETLKLGKLLRPNH 180 ************************************
SEQIDNO_3 bovine_SEQIDNO_16_	LWGYYLFPDCYNHHYKKPGYNGSCWNVEIKRNDDLSWLWMESTALYPSIYLNT-QQSPVA 238 LWGYYLFPDCYNHNHNQPTYNGNCWDVEKRRNDDLEWLWWESTALFPSVYLNIRLKSTQN 240 ************************************
SEQIDNO_3 bovine_SEQIDN0_16_	ATLYVRNRVREAIRVSKIPDAK®PLPVF&YTRWVFTDQWLKFLSQDELVYTFGETVALGA 298 AALYVRNRVQEAIRLSKIASVE®PLPVFWYARWVFTDGSSTYLSQGDLVNSVGEIVSLGA 300 *:**********************************
SEQIDNO_3 bovine_SEQIDN0_16_	SGIVIWGTLSIMRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLCWEQGVCIRKNWN 358 SGIIMWGSLNLSLSMQSCMNLGTYLNTTLNPYIINVTLAAKMCSQVLCMNEGVCTRKHWN 360 ***::**:* **:**: **:** **:**********
SEQIDNO_3 bovine_SEQIDNO_16_	SSDYLHLNPDNFAIQLEKGGKFTVRGKPTLEDLEQFSEKFYCSCYSTLSCKEKADVKDTD 418 SSDYLHLNPMNFAIQTGEGGKYTVPGTVTLEDLQKFSDTFYCSCYANIHCKKRVDIKNVH 420 ************************************
SEQIDNO_3 bovine_SEQIDNO_16_	XV VCIADGVCIDAFLKP 436 XV VCMAEDICIDSPVKL QPSDHSSSQEASTTTFSSISPSTTTATVSPCTPEKHSPECLK 480 :*:**:*:*:**:***:**
SEQIDNO_3 bovine_SEQIDNO_16_	

20 FIG.

Petitioner Merck, Ex. 1001, p. 18

U.S. Patent

477

299 299

TLYVRYRVVEAIRVSKVGNA DPVPIF YIR VFTDR SEYLLEDDLVNTIGEIVALGTS

TLYVRNRVREAIRVSKIPDA SPLPVF YTR VFTDO LKFLSQDELVYTFGETVALGAS

** **** *** *** *** *****

GIVIWGTLSIMRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLC@EQGVCIRKNWNS

GIIIWDAMSLAQRAAGCPILHKYMQTTLNPYIVNVTLAAKMCSQTLCWEKGMCSRRKESS

*.

359 359 419

239

239

60 60

LNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINATGOWVTIFYWDR VDYRAAPILSNTTFLWIWNVPTERCVGNVNDPIDLSFFSLIGSPRKTATGQ VTLFY DR

20

Mouse SEQIDNO

SEQIDNO

20

Mouse SEQIDNO

SEQIDNO 3

LGYYPYIDS TGVTVNGGIPQK SLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWA ****

120 119 180 179 RNWKPKDNYRNKSIELVQSTNPGLSITEATQKAIQQFEEAGRKFMEGTLHLGKFLRPNQL LGLYPHIDAMQAEHY-GGIPQR&DYQAHLRKAKTDIEHYIPDDKLGLAIIDWEEWRPTWL RNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNHL ** ** **

WGYYLFPDCYNHHYKKPGYNGSC WNVEIKRNDDLSWLWWESTALYPSIYLNTQQ-SPVAA WGYYLFPDCYNNKFQDPKYDGQC AVEKKRNDNLKWLW ASTGLYPSVYLKKDLKSNRQA * * * * * * * * * * * * * * * * * * * Mouse_SEQIDNO_20 SEQIDNO 3

20

Mouse SEQIDNO

SEQIDNO 3

Mouse SEQIDNO 20 SEQIDNO 3

Mouse_SEQIDN0_20_ SEQIDNO 3

Mouse SEQIDNO SEQIDNO 3

20

SEQIDNO 3

SDYLHLNPDNFAIQLEKGGKFTVRGKPTL #DLEQFSEKFYCSCYSTLSCKEKADVKDTD * • • * * •• *

419 * * * * * * * * *

DVYLHLNPSHFDIMLTETGKYEVLGNPRV@DLEYFSEHFKCSCFSRMTCKETSDVKNVQ

447

V W V C V G D N V C I KAK V E P N P A F Y L L P G K S L L F M T T L G H V L Y H L P Q D I F V F P R K T L V S T P -METEEPQIFY--V V V CIADGVCIDAFLKPP-

× ..

* * * * * * * * * * * * *

²⁰ Mouse SEQIDNO

U.S. Patent

Oct. 8, 2024

SEQIDNO_3 Rat_SEQIDNO_22_	LNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINATGOGVTIFYDR 60 VDYRATPVLSDTTFVWVWNVPTEACVENVTEPIDLSFFSLIGSPRKTAIGOGVTLFYDR 60 :::**.**.**.**************************	
SEQIDNO_3 Rat_SEQIDNO_22_	LGYYPYI DS TGVTVNGGIPQKESLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWA 120 LGNYPHI DAQ Q-TEHHGGIPQKEDLTTHLVKAKEDVERYIPTDKLGLAIIDWEEWRPTWM 119 ** **;**; ; ;******* ** ** ***;*; *;*;*;*;******	
SEQIDNO_3 Rat_SEQIDNO_22_	RNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNHL 180 RNWTPKDIYRNKSIELVQAADPAINITEATVRAKAQFEGAAKEFMEGTLKLGKHIRPKHL 179 ***.*********************************	
SEQIDNO_3 Rat_SEQIDNO_22_	WGYYLFPDCYNHHYKKPGYNGSCENVEIKRNDDLSWLWESTALYPSIYLNTQQ-SPVAA 239 WGFYLFPDCYNNKFQVDNYDGQCEDVEKKRNDDLDWLWESTGLYPSVYLKKDLKSSRKA 239 **:*******:::: .*:*.* :****************	
SEQIDNO_3 Rat_SEQIDNO_22_	TLYVRNRVREAIRVSKIPDAK®PLPVFAYTRWVFTDQWLKFLSQDELVYTFGETVALGAS 299 TLYVRYRVLESIRVSKVSDESMPVPIFWYIRWVFTDHWSEYLLEDDLVNTIGEIVAQGTS 299 ***** ** *:*****:.**:*:*.* *:****:* ::* :	
SEQIDNO_3 Rat_SEQIDNO_22_	GIVIWGTLSIMRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLC@EQGVCIRKNWNS 359 GIIIWDAMSLAQRSAGCPILRQYMKTTLNPYIVNVTLAAKMCSQTLC@EKGMCSRKTESS 359 **:**.::*:* :* :**:* **************	
SEQIDNO_3 Rat_SEQIDNO_22_	SDYLHLNPDNFAIQLEKGGKFTVRGKPTLEDLEQFSEKFYCSCYSTLSCKEKADVKDTDM 419 DAYLHLDPSSFSINVTEAGKYEVLGKPEVEDLEYFSEHFKCSCFSKMTCEETSDMRSIQM 419 . ****:**:*:: :.**: * *** ::*** ***:* ***:*.::*:*:: :	
SEQIDNO_3 Rat_SEQIDNO_22_	VWVCIADGVCIDAFLKPP447 VWVCMGDNVCIKATLGPNSAFHLLPGKGLLLMTTLAHILHHLPHDIFVFPWKMLVSTP 477 *:**:.*.*****************************	

Sheet 7 of 13

SEQIDNO_3 Rabbit_SEQIDNO_24_	LNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINATGQGVTIFYWDR 60 ANFRAPPVIPNVPFLWAWNAPTEFCLGKSGEPLDMSLFSLFGSPRKNKTGQGITIFYWDR 60 ************************************
SEQIDNO_3 Rabbit_SEQIDNO_24_	LGYYPYIDSITGVTVNGGIPQKISLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWA 120 LGYYPYIDBHTGAIVHGRIPQLGPLQDHLTKLRQEILYYMPKDNVGLAVIDWEEWLPTWL 120 ************************************
SEQIDNO_3 Rabbit_SEQIDNO_24_	RNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNHL 180 RNWKPKDIYRIKSIELVKSQHPQYNHSYATEKAKRDFEKAGKDFMEETLKLGRLLRPNHL 180 ******:*:::****:*:*:*:*:*:*:*:*:*******
SEQIDNO_3 Rabbit_SEQIDNO_24_	WGYYLFPDCYNHHYKKP-GYNGSCENVEIKRNDDLSWLWMESTALYPSIYLNTQQSP 236 WGYYLFPDCYNHHYDKPNLYKGSCEDIEKKRNDDLSWLWEESTALFPSVYLTSRARSATA 240 ************************************
SEQIDNO_3 Rabbit_SEQIDNO_24_	VAATLYVRNRVREAIRVSKIPDAK®PLPVFAYTRWVFTDQWLKFLSQDELVYTFGETVAL 296 LSKLYVVRNRVHEAIRVSKIPDDK&PLPNFYTRWVFTDQFQFLSHHDLVYTIGEIVAL 300 :: *****:****************************
SEQIDNO_3 Rabbit_SEQIDNO_24_	GASGIVIWGTLSIMRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLC@EQGVCIRKN 356 GASGIVVWGSQSLARSMKSCLHLDNYMKTILNPYLINVTLAAKMCNQVLC@EQGVCTRKN 360 ************************************
SEQIDNO_3 Rabbit_SEQIDNO_24_	WNSSDYLHLNPDNFAIQLEKGGKFTVRGKPTLEDLEQFSEKFYCSCYSTLSCKEKADVKD 416 WNPNDYLHLNPGNFAIQLGSNGTYKVDGKPTLEDLEQFSKNFQCSCYTNLNCKERTDMNN 420 ***********************************
SEQIDNO_3 Rabbit_SEQIDNO_24_	TD&VDVCIADGVCIDAFLKPPMETEEPQ444 VR_VDVCAVENVCIDTNVGPQAVTYAPKEKKDVAHILSNTTSINSSTTMSLPFPRKHVSG 480 . :*:** .:.****: : * * *:
SEQIDNO_3 Rabbit_SEQIDNO_24_	IFY447 CLLVLCMYSQYLNICYRLVAIGIQHGYYLK 510

FIG. 2G

⊀

⊀

U.S. Patent

SEQIDNO_3 GuineaPig_SEQIDNO_29_	LNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINATG 50 -DKRAPPLIPNVPLLWVWNAPTEFCIGGTNQPLDMSFFSIVGTPRKNITG 49 : ****:*******************************
SEQIDNO_3 GuineaPig_SEQIDNO_29_	QGVTIFYWDRLGYYPYI DS TGVTVNGGIPQKESLQDHLDKAKKDITFYM 100 QSITLYYWDRLGYYPYIDEHTGAIVHGGLPQLMNLQQHLRKSRQDILFYM 99 *.:*:********************************
SEQIDNO_3 GuineaPig_SEQIDNO_29_	PVDNLGMAVIDWEEWRPTWARNWKPKDVYKNRSIELVQQQNVQLSLTEAT 150 PTDSVGLAVIDWEEWRPTWTRNWRPKDIYRNKSIELVKSQHPQYNHSYAV 149 *.*.:*:*******************************
SEQIDNO_3 GuineaPig_SEQIDNO_29_	EKAKQEFEKAGKDFLVETIKLGKLLRPNHLWGYYLFPDCYNHHYKKPGYN 200 AVAKRDFERTGKAEMLETLKLGKSLRPSSLWGYYLFPDCYNTHFTKPNYD 199 **::**::** *::***********************
SEQIDNO_3 GuineaPig_SEQIDNO_29_	GSCWNVEIKRNDDLSWLWWESTALYPSIYLNTQQ-SPVAATLYVRNRVRE 249 GHC&PIELQRNNDLQWLWWDSTALYPSVYLTSRVRSSQNGALYVRNRVHE 249 * * :*::**:**.*************************
SEQIDNO_3 GuineaPig_SEQIDNO_29_	AIRVSKIPDAK&PLPVF&YTR&VFTDQ&LKFLSQDELVYTFGETVALGAS 299 SIRVSKLMDDKMPLPIY&YIR&VFTDQTTFLELDDLVHSVGEIVPLGVS 299 :*****: * *.***::.* *:*******. *:**:.** *.**.*
SEQIDNO_3 GuineaPig_SEQIDNO_29_	GIVIWGTLSIMRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLCEQ 349 GIIIWGSLSLTRSLVSCIGLENYMKGTLLPYLINVTLAAKMCGQVLCENQ 349 **:***:**: **: **: *:**: * *:***: * **:******
SEQIDNO_3 GuineaPig_SEQIDNO_29_	GVCIRKNWNSSDYLHLNPDNFAIQLEKGGKFTVRGKPTLØDLEQFSEKFY 399 GICTRKDWNTNTYLHLNATNFDIELQQNGKFVVHGKPSLØDLQEFSKNFH 399 *:* **:**: *****. ** *:*:.***.**
SEQIDNO_3 GuineaPig_SEQIDNO_29_	CSCYSTLSCKEKADVKDTDXVXVCIADGVCIDAFLKPPMET 440 CSCYTNVACKDRLDVHNVRVXVCTANNICIDAVLNFPSLDDDDEPPITD 449 ****:.::**:: **::. :*:** *:::****.*
SEQIDNO_3 GuineaPig_SEQIDNO_29_	EEPQ 447 DTSQNQDSISDITSSAPPSSHILPKDLSWCLFLLSIFSQHWKYLL 494 : .*

2 I	
()	
FIC	

SEQIDNO_3 FOX	LNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINATGQ&VTIFY%DR 60 QEFRAPPFIPNVSFLWGWNAPTELCAKRENVQLDLNLFSLIGSPLKTVVGQGIAIFY%DR 60 :*****.***.***.****:*:*:*:*:*:*:*:*:*:*
SEQIDNO_3 FOX	LGYYPYI DST TGVTVNGGIPQKESLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWA 120 LGYYPHI NKT TGKHVNGGIPQLESLKKHLDKAKKDISHYIETDSMGLAVIDWDSWRPNWA 120 *****:*: ** ****** **:.****************
SEQIDNO_3 FOX	RNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNHL 180 RNWRPKHIYKEQSIDLAQQQHIHLNLTEVTQIAQADFEKAARCFMQETLKLGKFLRPNYL 180 ***:**.:**::***:*.***:::*.***.*: *: *: *: *: *: ****:***:
SEQIDNO_3 FOX	WGYYLFPDCYNHHYKKPGYNGSCENVEIKRNDDLSWLWEESTALYPSIYLNTQQ-SPVAA 239 WGFYLYPDCYNYNYKNPNYNGSCEDIEERRNDEIDWLWESTALFPSIYLKSKLKSSPFT 240 **:**:****::**:**:**:**:::* :***:::* :***::***:***::: *. :
SEQIDNO_3 FOX	TLYVRNRVREAIRVSKIPDAK&PLPVFXYTRWVFTDQ%LKFLSQDELVYTFGETVALGAS 299 ALYVRNRVLEAIRVSKVKDIK#PLPIFYYARWVFTDV#LTYLTEDDLVNTIGESVSLGVS 300 :****** ******: * * ***:*.*.*.*.*.*.*.*.
SEQIDNO_3 FOX	GIVIWGTLSIMRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLC@EQGVCIRKNWNS 359 GIVMWGSLNLTENVQICTELDTYIKNKLNPYIINVTLAAKMCSQVLC@EGVCIRKHWNS 360 ***:**:*:**:*************************
SEQIDNO_3 FOX	SDYLHLNPDNFAIQLEKGGKFTVRGKPTLØDLEQFSEKFYCSCYSTLSCKEKADVKDTD% 419 NDYLHLNPVNFAIQLERSGRYTVQGKPTLØDLQQFSKKFYCACYANTHCRERVDMTDIH 420 .****** ******:.*::**:*****************
SEQIDNO_3 FOX	VWVCIADGVCIDAFLKPP447 I&VCVGEDVCIDVYLNLVPSGHLPVWKGKYVTSSNIFSVMPPATGPPCVPGRDLNRCLKA 480 :.**:.:.****:*:
SEQIDNO_3 FOX	

LNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINATGQGVTIFYWDR LNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSLTGSPRINVTGQGVTIFYWDR ************************************	LGYYPYI DS TGVTVNGGIPQKSLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWA LGYYPYI DS TGVTVNGGIPQKSLQDHLDKAKQDITFYMPVDNLGMAVIDWEEWRPTWA ************************************	RNWK PKDVYKNBSTET.VOOONVOLST.TEATEKAKOEFEKAGKDFT.VETTKT.GKT.T.R PNHT.
--	--	---

	ώ
с П	SEQIDNO
SEQIDNC	GIBBON

57

857 GIBBON SEQIDNO SEQIDNO

GIBBON SEQIDNO 857 SEQIDNO 3

857 GIBBON SEQIDNO SEQIDNO 3

GIBBON SEQIDNO 857 SEQIDNO 3

GIBBON SEQIDNO 857 SEQIDNO_3

DYLHLNPDNFAIQLEKGGKFTVRGKPTLEDEQFSEKFYCSCYSTLSCKEKADVKDTDEV 857 SEQIDNO_3 GIBBON_SEQIDNO

420 DYLHLNPDNFAIQLEKGGKFTVRGKPTP20FSEKFYCSCYSTLSCKEKADVKDTD20V

447 474 VCIADGVCIDAFLKPPKETEESQIFYNASPSTLSATMFIVSILFLIISSVVSL **WUCIADGVCIDAFLKPPMETEEPQIFY-**GIBBON SEQIDNO 857 SEQIDNO 3

**** **** ***************

2J

FIG.

60 60 Oct. 8, 2024

180 180 240 240

120 120 300

300

LYVRNRVREAIRVSKIPDAK%PLPVF%YTRWVFTDQ%LKFLSQDELVYTFGETVALGASG LYVRNRVREAIRVSKIPDAK®PLPVFWYARWVFTDQWLKFLSRDELVYTLGETVALGASG

WGYYLFPDCYNHHYKKPGYNGSC WNVEIKRNDDLSWLWWESTALYPSIYLNTQQSPVAAT

NGYYLFPDCYNHHYKKPGYNGSC NVEIKRNDDLSWLWWESTALYPSIYLNTQQSPVAAT

RNWK PKDVYKNRS I ELVQQQNVQLSLAEATEKAKQEFEKAGKDFMVET I KLGKLLRPNHL

360 360

IVIWGTLSIMRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLC@EQGVCIRKNWNSS IVIWGSLSIVRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLC@EQGVCIRKDWNSS

420

SEQIDNO_3 MARMOSET_SEQIDNO_859	LNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINATGQ@VTIFYWDR LNFRAPPIIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSLIGSPRINVTGQ@VTIFYWDR ************************************	000
SEQIDNO_3 MARMOSET_SEQIDNO_859	LGYYPYIDS TGVTVNGGIPQK SLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWA LGYYPYIDP TGAVVNGGIPQK ALQDHLDKVRKDIIFYMPVDNLGMGVIDWEEWRPTWA ************************************	120
SEQIDNO_3 MARMOSET_SEQIDNO_859	RNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNHL RNWKPKDIYKNKSIEMVQQRNVQLNLTQATDIAKQEFEKAAKDFMLETIKLGKALRPNHL ************************************	180
SEQIDNO_3 MARMOSET_SEQIDNO_859	WGYYLFPDCYNHHYKKPGYNGSCENVEIKRNDDLSWLWNESTALYPSIYLNTQQSPVAAT WGYYLFPDCYNHHYKKPDYNGSCENIEIKRNNDLSWLWNESTALYPSIYLNTQQSAVAAM **********************************	240
SEQIDNO_3 MARMOSET_SEQIDNO_859	LYVRNRVREAIRVSKIPDAKSPLPVFAYTRWVFTDQWLKFLSQDELVYTFGETVALGASG LYVRNRVQEAIRVSKTPNANSPLPVFWYARWVFTDQWLRFLSQDELVYTLGETVALGASG ***********************************	
SEQIDNO_3 MARMOSET_SEQIDNO_859	IVIWGTLSIMRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLCOEQGVCIRKNWNSS IVIWGSLSIMRSMKSCLLLDTYMETVLNPYIINTTLAAKMCSQVLCOEQGVCIRKDWNSS ***********************************	300 300 300 300 300 300 300 300 300 300

2K FIG.

Petitioner Merck, Ex. 1001, p. 25

447 474

**** **** **** *********

420 420

DYLHLNPDNFAIQLEKGGKFTVRGKPTLIDLEQFSEKFYCSCYSTLSCKEKADVKDTDINV DYLHLNPDNFAIETEKGGKFTVRGKPTY #DLEQFSEKFYCSCYTSLSCKVKADVKDTD #V

SEQIDNO_3 MARMOSET_SEQIDNO_859

SEQIDNO_3 MARMOSET_SEQIDNO_859

00

Oct. 8, 2024

0 0

0 0

0 0

Sheet 12 of 13

0 0

SEQIDNO_3 ORANGUTAN_SEQIDNO_861	LNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINATGQWVTIFYWDR 60 LNFRAPPIIPNMPFLWAWNAPSEFCLGKFDEPLDMSLFSLIGSPRINVTGQWVTIFYWDR 60 ************************************
SEQIDNO_3 ORANGUTAN_SEQIDNO_861	LGYYPYIDSTTGVTVNGGIPQKTSLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWA 120 LGYYPYIDSTTGVTVNGGIPQKTSLQDHLDKAKKDILFYMPVDNLGMAVIDWEEWRPTWA 120 ************************************
SEQIDNO_3 ORANGUTAN_SEQIDNO_861	RNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNHL 180 RNWKPKDVYKNRSIELVQQQNVQLNLTEATEKAKQEFEKAGKDFMVETIKLGKLLRPNHL 180 ************************************
seqidno_3 orangutan_seqidno_861	WGYYLFPDCYNHHYKKPGYNGSCWNVEIKRNDDLSWLWNWSTALYPSIYLNTQQSPVAAT 240 WGYYLFPDCYNHHYKKPGYNGSCWNVEIKRNDDLSWLWNWSTALYPSIYLNTQQSPVAAT 240 ************************************
seqidno_3 orangutan_seqidno_861	LYVRNRVREAIRVSKIPDAKSPLPVFAYTREVFTDQVLKFLSQDELVYTFGETVALGASG 300 LYVRNRVREAIRVSKIPDAKSPLPVFYYAREVFTDQVLKFLSQDELVYTFGETVALGASG 300 ***********************************
SEQIDNO_3 ORANGUTAN_SEQIDNO_861	IVIWGTLSIMRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLCEQGVCIRKNWNSS 360 IVIWGSLSIMRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLCEQGVCIRKDWNSS 360 *****:*******************************
SEQIDNO_3 ORANGUTAN_SEQIDNO_861	DYLHLNPDNFAIQLEKGGKFTVRGKPTLEDLEQFSEKFYCSCYSTLSCKEKADVKDTDXV 420 DYLHLNPDNFAIQLEKGGKFTVRGKPTLEDLEQFSEKFYCSCYSTLSCKEKADVKDTDXV 420 ************************************
seqidno_3 orangutan_seqidno_861	VCIADGVCIDAFLKPPMETEEPQIFY

10

PH20 POLYPEPTIDE VARIANTS. FORMULATIONS AND USES THEREOF

RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No. 17/327,568, entitled "PH20 POLYPEPTIDE VARI-ANTS, FORMULATIONS AND USES THEREOF," and filed May 21, 2021, to Ge Wei, H. Michael Shepard, Qiping Zhao and Robert James Connor, which is a continuation of U.S. application Ser. No. 16/912,590, now issued on Jul. 20, 2021, as U.S. Pat. No. 11,066,656, entitled "PH20 POLY-PEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF," and filed Jun. 25, 2020, to Ge Wei, H. Michael 15 Shepard, Qiping Zhao and Robert James Connor, which is a continuation of U.S. application Ser. No. 15/226,489, now issued on Dec. 15, 2020, as U.S. Pat. No. 10,865,400, entitled "PH20 POLYPEPTIDE VARIANTS, FORMULA-TIONS AND USES THEREOF," and filed on Aug. 2, 2016, 20 to Ge Wei, H. Michael Shepard, Qiping Zhao and Robert James Connor, which is a divisional of U.S. application Ser. No. 13/694,731, now issued on Sep. 20, 2016, as U.S. Pat. No. 9,447,401, and filed on Dec. 28, 2012, which claims the benefit of priority to U.S. Provisional Application Nos. ²⁵ 61/631,313 and 61/796,208, filed on Dec. 30, 2011, and Nov. 1, 2012, respectively, and each entitled "PH20 POLYPEP-TIDE VARIANTS, FORMULATIONS AND USES THEREOF.'

U.S. application Ser. No. 17/327,568 also is a continuation of U.S. application Ser. No. 16/824,572, now issued on Jun. 22, 2021, as U.S. Pat. No. 11,041,149, entitled "PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF," and filed Mar. 19, 2020, to Ge Wei, H. 35 of U.S. application Ser. No. 15/226,489, now issued on Dec. Michael Shepard, Qiping Zhao and Robert James Connor, which is a continuation of U.S. application Ser. No. 15/226, 489, now issued on Dec. 15, 2020, as U.S. Pat. No. 10,865, 400, and filed on Aug. 2, 2016, which is a divisional of U.S. application Ser. No. 13/694,731, now issued on Sep. 20, 40 benefit of priority to U.S. Provisional Application Nos. 2016, as U.S. Pat. No. 9,447,401, filed on Dec. 28, 2012, which claims the benefit of priority to U.S. Provisional Application Nos. 61/631,313 and 61/796,208, filed on Dec. 30, 2011, and Nov. 1, 2012, respectively, and each entitled "PH20 POLYPEPTIDE VARIANTS, FORMULATIONS 45 AND USES THEREOF."

U.S. application Ser. No. 17/327,568 also a continuation of U.S. application Ser. No. 15/226,489, now issued on Dec. 15, 2020, as U.S. Pat. No. 10,865,400, entitled "PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND 50 USES THEREOF," and filed on Aug. 2, 2016, to Ge Wei, H. Michael Shepard, Qiping Zhao and Robert James Connor, which is a divisional of U.S. application Ser. No. 13/694, 731, now issued on Sep. 20, 2016, as U.S. Pat. No. 9,447, 401, and filed on Dec. 28, 2012, which claims the benefit of 55 priority to U.S. Provisional Application Nos. 61/631,313 and 61/796,208, filed on Dec. 30, 2011, and Nov. 1, 2012, respectively, and each entitled "PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF."

U.S. application Ser. No. 17/327,568 also is a continua- 60 tion of U.S. application Ser. No. 13/694,731, now issued on Sep. 20, 2016, as U.S. Pat. No. 9,447,401, entitled "PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF," and filed on Dec. 28, 2012, to Ge Wei, H. Michael Shepard, Qiping Zhao and Robert James Con- 65 nor, which claims the benefit of priority to U.S. Provisional Application Nos. 61/631,313 and 61/796,208, filed on Dec.

30, 2011, and Nov. 1, 2012, respectively, and each entitled "PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF."

This application also is a divisional of U.S. application Ser. No. 17/327,586, entitled "PH20 POLYPEPTIDE VARI-ANTS, FORMULATIONS AND USES THEREOF," and filed May 21, 2021, to Ge Wei, H. Michael Shepard, Qiping Zhao and Robert James Connor, which is a continuation of U.S. application Ser. No. 16/912,590, now issued on Jul. 20, 2021, as U.S. Pat. No. 11,066,656, and filed Jun. 25, 2020, which is a continuation of U.S. application Ser. No. 15/226, 489, now issued on Dec. 15, 2020, as U.S. Pat. No. 10,865, 400, and filed on Aug. 2, 2016, which is a divisional of U.S. application Ser. No. 13/694,731, now issued on Sep. 20, 2016, as U.S. Pat. No. 9,447,401, and filed on Dec. 28, 2012, which claims the benefit of priority to U.S. Provisional Application Nos. 61/631,313 and 61/796,208, filed on Dec. 30, 2011, and Nov. 1, 2012, respectively, and each entitled "PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF."

U.S. application Ser. No. 17/327,586 also is a continuation of U.S. application Ser. No. 16/824,572, now issued on Jun. 22, 2021, as U.S. Pat. No. 11,041,149, and filed Mar. 19, 2020, which is a continuation of U.S. application Ser. No. 15/226,489, now issued on Dec. 15, 2020, as U.S. Pat. No. 10,865,400, and filed on Aug. 2, 2016, which is a divisional of U.S. application Ser. No. 13/694,731, now issued on Sep. 20, 2016, as U.S. Pat. No. 9,447,401, filed on Dec. 28, 2012, which claims the benefit of priority to U.S. Provisional Application Nos. 61/631,313 and 61/796,208, filed on Dec. 30, 2011, and Nov. 1, 2012, respectively, and each entitled "PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF.'

U.S. application Ser. No. 17/327,586 also a continuation 15, 2020, as U.S. Pat. No. 10,865,400, and filed on Aug. 2, 2016, which is a divisional of U.S. application Ser. No. 13/694,731, now issued on Sep. 20, 2016, as U.S. Pat. No. 9,447,401, and filed on Dec. 28, 2012, which claims the 61/631,313 and 61/796,208, filed on Dec. 30, 2011, and Nov. 1, 2012, respectively, and each entitled "PH20 POLYPEP-TIDE VARIANTS, FORMULATIONS AND USES THEREOF."

U.S. application Ser. No. 17/327,586 also is a continuation of U.S. application Ser. No. 13/694,731, now issued on Sep. 20, 2016, as U.S. Pat. No. 9,447,401, and filed on Dec. 28, 2012, which claims the benefit of priority to U.S. Provisional Application Nos. 61/631,313 and 61/796,208, filed on Dec. 30, 2011, and Nov. 1, 2012, respectively, and each entitled "PH20 POLYPEPTIDE VARIANTS, FOR-MULATIONS AND USES THEREOF.'

This application also is a divisional of U.S. application Ser. No. 16/912,590, now issued on Jul. 20, 2021, as U.S. Pat. No. 11,066,656, and filed Jun. 25, 2020, which is a continuation of U.S. application Ser. No. 15/226,489, now issued on Dec. 15, 2020, as U.S. Pat. No. 10,865,400, and filed on Aug. 2, 2016, which is a divisional of U.S. application Ser. No. 13/694,731, now issued on Sep. 20, 2016, as U.S. Pat. No. 9,447,401, and filed on Dec. 28, 2012, which claims the benefit of priority to U.S. Provisional Application Nos. 61/631,313 and 61/796,208, filed on Dec. 30, 2011, and Nov. 1, 2012, respectively, and each entitled "PH20 POLY-PEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF."

U.S. application Ser. No. 16/912,590, now issued on Jul. 20, 2021, as U.S. Pat. No. 11,066,656, filed Jun. 25, 2020, also is a divisional of U.S. application Ser. No. 13/694,731, now issued on Sep. 20, 2016, as U.S. Pat. No. 9,447,401, and filed on Dec. 28, 2012, which claims the benefit of priority to U.S. Provisional Application Nos. 61/631,313 and 61/796,208, filed on Dec. 30, 2011, and Nov. 1, 2012, ⁵ respectively, each entitled "PH20 POLYPEPTIDE VARI-ANTS, FORMULATIONS AND USES THEREOF," and each to Ge Wei, H. Michael Shepard, Qiping Zhao and Robert James Connor.

This application also is a divisional of U.S. application ¹⁰ Ser. No. 16/824,572, now issued on Jun. 22, 2021, as U.S. Pat. No. 11,041,149, and filed Mar. 19, 2020, which is a continuation of U.S. application Ser. No. 15/226,489, now issued on Dec. 15, 2020, as U.S. Pat. No. 10,865,400, and filed on Aug. 2, 2016, which is a divisional of U.S. application Ser. No. 13/694,731, now issued on Sep. 20, 2016, as U.S. Pat. No. 9,447,401, filed on Dec. 28, 2012, which claims the benefit of priority to U.S. Provisional Application Nos. 61/631,313 and 61/796,208, filed on Dec. 30, 2011, and 20 Nov. 1, 2012, respectively, and each entitled "PH20 POLY-PEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF."

U.S. application Ser. No. 16/824,572, now issued on Jun. 22, 2021, as U.S. Pat. No. 11,041,149, and filed Mar. 19, ²⁵ 2020, also is a divisional of U.S. application Ser. No. 13/694,731, now issued on Sep. 20, 2016, as U.S. Pat. No. 9,447,401, and filed on Dec. 28, 2012, which claims the benefit of priority to U.S. Provisional Application Nos. 61/631,313 and 61/796,208, filed on Dec. 30, 2011, and Nov. ³⁰ 1, 2012, respectively, and each entitled "PH20 POLYPEP-TIDE VARIANTS, FORMULATIONS AND USES THEREOF," and each to Ge Wei, H. Michael Shepard, Qiping Zhao and Robert James Connor.

This application is a continuation of U.S. application Ser. ³⁵ No. 15/226,489, now issued on Dec. 15, 2020, as U.S. Pat. No. 10,865,400, entitled "PH20 POLYPEPTIDE VARI-ANTS, FORMULATIONS AND USES THEREOF," and filed on Aug. 2, 2016, to Ge Wei, H. Michael Shepard, 40 Qiping Zhao and Robert James Connor, which is a divisional of U.S. application Ser. No. 13/694,731, now issued on Sep. 20, 2016, as U.S. Pat. No. 9,447,401, and filed on Dec. 28, 2012, which claims the benefit of priority to U.S. Provisional Application Nos. 61/631,313 and 61/796,208, filed on Dec. ⁴⁵ 30, 2011, and Nov. 1, 2012, respectively, and each entitled "PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF."

This application also is a divisional of U.S. application Ser. No. 13/694,731, now issued on Sep. 20, 2016, as U.S. Pat. No. 9,447,401, entitled "PH20 POLYPEPTIDE VARI-ANTS, FORMULATIONS AND USES THEREOF," and filed on Dec. 28, 2012, to Ge Wei, H. Michael Shepard, Qiping Zhao and Robert James Connor, which claims the benefit of priority to U.S. Provisional Application Nos. 61/631,313 and 61/796,208, filed on Dec. 30, 2011, and Nov. 1, 2012, respectively, and each entitled "PH20 POLYPEP-TIDE VARIANTS, FORMULATIONS AND USES THEREOF."

This application also is related to International PCT application Ser. No. PCT/US2012/072182, filed Dec. 28, 2012, entitled "PH20 POLYPEPTIDE VARIANTS, FOR-MULATIONS AND USES THEREOF," which also claims priority to U.S. Provisional Application Nos. 61/631,313 65 and 61/796,208, filed on Dec. 30, 2011, and Nov. 1, 2012, respectively.

The subject matter of each of the above-noted applications and patents is incorporated by reference in its entirety.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING PROVIDED ELECTRONICALLY

An electronic version of the Sequence Listing is filed herewith, the contents of which are incorporated by reference in their entirety. The electronic file was created on Dec. 19, 2022, is 1,632 kilobytes in size, and is titled 3087Kseq001.xml.

FIELD OF THE INVENTION

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

BACKGROUND

Hyaluronan (hyaluronic acid; HA) is a polypeptide that is found in the extracellular matrix of many cells, especially in soft connective tissues. HA also is found predominantly in skin, cartilage, and in synovial fluid in mammals. Hyaluronan also is the main constituent of the vitreous of the eve. HA has a role in various physiological processes, such as in water and plasma protein homeostasis (Laurent T C et al. (1992) FASEB J6: 2397-2404)). Certain diseases are associated with expression and/or production of hyaluronan. Hyaluronan-degrading enzymes, such as hyaluronidases, are enzymes that degrade hyaluronan. By catalyzing HA degradation, hyaluronan-degrading enzymes (e.g., hyaluronidases) can be used to treat diseases or disorders associated with accumulation of HA or other glycosaminoglycans. Also, since HA is a major component of the interstitial barrier, hyaluronan-degrading enzymes (e.g., hyaluronidase) increase tissue permeability and therefore can be used to increase the dispersion and delivery of therapeutic agents. Various hyaluronidases have been used therapeutically (e.g., hyaluronidase sold under the trademarks Hydase® (bovine testicular hyaluronidase), Vitrase® (ovine hyaluronidase), and Wydase© (bovine hyaluronidase)), typically as dispersing and spreading agents in combination with other therapeutic agents. Many of these are ovine or bovine forms, which can be immunogenic for treatment of humans. Improved hyaluronan-degrading enzymes, such as hyaluronidases, and compositions thereof that can be used 50 for treatment are needed.

SUMMARY

Provided are modified PH20 polypeptides that have an
altered property or properties compared to the PH20 polypeptide that do not have the modification(s). The modifications include amino acid replacement, deletion and/or insertions. Detailed structure/function of virtually each amino acid in a PH20 polypeptide is provided herein, as well as the
identification of residues and loci that contribute to alteration of a property, such as stability in particular conditions, is provided. Hence, provided are modified PH20 polypeptides that contain one or more amino acid replacements that result in a PH20 polypeptide that retains activity and/or
exhibits increased or altered stability under a variety of conditions. Activity retained can be, for example, hyaluronidase activity that is as least about 40% or more of the PH20

5

polypeptide that does not include the replacement. Exemplary modifications are amino acid replacements. For purposes herein, amino acid replacements are denoted by the single amino acid letter followed by the corresponding amino acid position in SEQ ID NO:3 in which the replacement occurs. Single amino acid abbreviations for amino acid residues are well known to a skilled artisan (see e.g. Table 1), and are used herein throughout the description and examples. For example, replacement with P at a position corresponding to position 204 in a PH20 polypeptide with 10 reference to amino acid residue positions set forth in SEQ ID NO:3 means that the replacement encompasses F204P in a PH20 polypeptide set forth in SEQ ID NO:3, or the same replacement at the corresponding position in another PH20 polypeptide.

Provided are modified PH20 polypeptides that contain at least one amino acid replacement in a PH20 polypeptide, whereby the modified PH20 polypeptide exhibits increased stability compared to the PH20 polypeptide not containing the amino acid replacement. Increased stability can be 20 manifested as increased resistance to one or more protein conditions that are denaturing to proteins. The stability of modified and unmodified PH20 is compared under the same conditions. Exemplary protein denaturation (or denaturing, used interchangeably herein) conditions include, but are not 25 limited to, elevated temperature greater than 30° C. or about 30° C., agitation, low salt, including essentially or substantially or no salt, and presence of excipients that tend to denature proteins. Exemplary of such excipients are antiadherent(s), binder(s), coating(s), filler(s) and diluent(s), 30 flavor(s), color(s), lubricant(s), glidant(s), preservative(s), detergent(s), sorbent(s) and combinations thereof.

The modified PH20 polypeptide can be one in which the unmodified form thereof has at least about 68% sequence identity to SEQ ID NO: 3 and further contains modifications 35 that alter stability and/or can be a PH20 polypeptide that includes as many as about up to 100, 110, 120, 130, 150 amino acid differences from PH20 but retains enzymatic activity, particularly, at least about 40% of the activity of the unmodified PH20 polypeptide and exhibits increased stabil- 40 peptide that exhibits increased stability, denaturing condiity, such as stability under denaturing conditions. Thus, included are modified PH20 polypeptides that have at least 68% or about 68% amino acid sequence identity to the sequence of amino acids set forth in SEQ ID NO:3. Included are modified PH20 polypeptides that have at least 70%, 45 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity to the sequence of amino acids set forth in SEQ ID NO:3. Exemplary of such modified PH20 polypeptides are polypeptides that contain amino acid replace- 50 ment(s) in a PH20 polypeptide that contains the sequence of amino acid residues as set forth in any of SEQ ID NOs: 3, 7, 10, 12, 14, 24, 32-66, 69, 72, 857, 859, 861, 870 or a sequence of amino acids that is at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 55 97%, 98%, 99% identical to any of SEQ ID NOs: 3, 7, 10, 12, 14, 24, 32-66, 69, 72, 857, 859, 861, or 870.

For example, provided herein is a modified PH20 polypeptide that exhibits increased stability containing an amino acid replacement in a PH20 polypeptide that confers the 60 increased stability, wherein increased stability is manifested as increased resistance to denaturation in the presence of one or more protein denaturation conditions, stability is increased compared to the PH20 polypeptide not containing the amino acid replacement, and the unmodified PH20 65 polypeptide consists of the sequence of amino acids set forth in SEQ ID NO: 7 or is a C-terminal truncated fragment

6

thereof that is a soluble PH20 polypeptide or has at least 85% sequence identity thereto. As above, the modified PH20 polypeptide that exhibits increased stability exhibits increased stability to a denaturation condition that is temperature greater than or about 30° C.; agitation; low or no a salt; or presence of an excipient or a denaturing agent, such as an antiadherent(s), binder(s), coating(s), filler(s) and diluent(s), flavor(s), color(s), lubricant(s), glidant(s), preservative(s), detergent(s), sorbent(s) or sweetener(s) and a combination thereof, and in particular a preservative. In some examples of such modified PH20 polypeptides that exhibit increased stability, the denaturation condition is temperature greater than 30° C., and the modified PH20 polypeptide exhibits greater hyaluronidase activity at the 15 temperature compared to the unmodified PH20 polypeptide not containing the amino acid replacement(s) where the activities are compared under the same conditions. In other examples, the protein denaturation condition is the presence of low concentrations of salt of less than 100 mM, and the modified PH20 polypeptide exhibits increased hyaluronidase activity in the presence of low concentrations of salt compared to the unmodified PH20 polypeptide not containing the amino acid replacement(s) where the activities are compared under the same conditions.

In any of the above examples of a modified PH20 polypeptide that exhibits increased stability, stability can be assessed based on a variety of parameters including hyaluronidase activity, solubility, aggregation and/or crystallization. Stability can be assessed in the presence of a denaturing condition. When stability of two or more polypeptides is compared, stability is assessed under the same conditions. In some instances, among the PH20 polypeptides provided herein, the modified PH20 polypeptide exhibits at least 120%, 130%, 135%, 140%, 145%, 150%, 160%, 170%, 180%, 200%, 250%, 300%, 350%, 400%, 500%, 1500%, 2000%, 3000%, 4000%, 5000% or more of the hyaluronidase activity of the PH20 polypeptide not containing the amino acid replacement(s).

In any of the above examples of a modified PH20 polytions include the presence of excipients that denature proteins. Exemplary of such conditions is the presence of a preservative, such as a phenolic preservative. Provided are modified PH20 polypeptides that exhibit increased stability in the presence of an anti-microbial effective amount of one or more phenolic preservatives. An anti-microbial effective amount is the total amount of one or more phenolic preservative agents, which can be expressed as a percentage (%) of mass concentration (w/v) that is or is between (or at least about or at about) 0.05% to 0.6%, 0.1% to 0.4%, 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 0.3% to 0.4%, inclusive. Exemplary phenolic preservatives include, but are not limited to, phenol, metacresol (m-cresol), benzyl alcohol, and a paraben, such as methylparaben propylparaben, m-cresol, phenol or m-cresol and phenol. Exemplary of the stability achieved by provided modified PH20 polypeptides are those that exhibit at least 15% or about 15% of the hyaluronidase activity for at least 4 hours in the presence of preservative(s) compared to the modified PH20 polypeptide in absence of preservative. Activity is compared under the same conditions except for the presence of preservative(s). For example, provided are modified PH20 polypeptides that exhibit at least (or at least about) 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more of the hyaluronidase activity in the presence of a phenolic preservative(s) compared to absence of the same preservative(s). Thus, provided, among the modified PH20 polypeptides provided herein, are PH20 polypeptides that, by virtue of amino acid replacement(s), are phenophilic compared to PH20 polypeptides without such replacement. Included are modified PH20 polypeptides 5 where the hyaluronidase activity is exhibited after at least 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks or more in the presence of the 10 preservative(s) compared to the hyaluronidase activity of the modified PH20 polypeptide in the absence of preservative for the same time period and under the same conditions except for the presence of preservative(s).

In examples of a modified PH20 polypeptide that exhibits 15 increased stability to a phenolic preservative, increased stability in a phenolic preservative can be exhibited under temperature conditions that include any temperature between, for example, 0° C. and 40° C., such as between or about between 0° C. to 40° C., 2° C. to 6° C., 24° C. to 32° 20 C. and 35° C. to 40° C. Exemplary polypeptides exhibit increased stability at temperatures of between or about between 30° C. to 45° C., 35° C. to 45° C., 30° C. to 37° C., 35° C. to 37° C. or 37° C. to 42° C., each inclusive. The particular modified PH20 polypeptide and conditions 25 depend upon the intended formulation, conditions to which the formulation will be exposed and/or intended application.

Particular and exemplary modified PH20 polypeptides that exhibit increased stability, such as increased stability to a phenolic preservative, include those that contain a single 30 amino acid modification, such as a replacement, and combinations of modifications, such as at least or 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100 and more modifications. These include modified PH20 polypeptides that contain one or more amino 35 acid replacements, where at least one replacement is at an amino acid position corresponding (i.e., by alignment) to a position selected from among 10, 12, 20, 22, 26, 34, 36, 46, 50, 52, 58, 68, 70, 74, 82, 83, 84, 86, 97, 127, 131, 138, 142, 143, 144, 166, 169, 174, 193, 195, 196, 204, 205, 206, 213, 40 219, 234, 237, 238, 240, 249, 261, 267, 277, 279, 291, 309, 310, 314, 315, 317, 318, 347, 367, 375, 376, 399, 401, 407, 416, 419, 421, 431, 433, 439, 440, 443 or 445 with reference to amino acid positions set forth in SEQ ID NO:3, wherein corresponding amino acid positions are identified by align-45 ment of the PH20 polypeptide with the polypeptide set forth in SEQ ID NO:3. Exemplary of such modifications are at least one amino acid replacement selected from among replacement with: glycine (G) at a position corresponding to position 10; K at a position corresponding to position 12; S 50 at a position corresponding to position 20; T at a position corresponding to position 22; M at a position corresponding to position 26; W at a position corresponding to position 34; N at a position corresponding to position 36; L at a position corresponding to position 46; M at a position corresponding 55 to position 50; T at a position corresponding to position 52; S at a position corresponding to position 52; C at a position corresponding to position 58; K at a position corresponding to position 58; R at a position corresponding to position 58; N at a position corresponding to position 58; Y at a position 60 corresponding to position 58; P at a position corresponding to position 58; H at a position corresponding to position 58; P at a position corresponding to position 68; V at a position corresponding to position 70; E at a position corresponding to position 74; L at a position corresponding to position 82; 65 N at a position corresponding to position 82; V at a position corresponding to position 83; Q at a position corresponding

8

to position 83; S at a position corresponding to position 83; G at a position corresponding to position 83; N at a position corresponding to position 84; A at a position corresponding to position 86; K at a position corresponding to position 86; E at a position corresponding to position 97; L at a position corresponding to position 97; R at a position corresponding to position 127; R at a position corresponding to position 131; L at a position corresponding to position 138; K at a position corresponding to position 142; N at a position corresponding to position 142; P at a position corresponding to position 142; S at a position corresponding to position 142; T at a position corresponding to position 142; G at a position corresponding to position 143; K at a position corresponding to position 143; T at a position corresponding to position 144; Q at a position corresponding to position 166; T at a position corresponding to position 166; L at a position corresponding to position 169; G at a position corresponding to position 174; N at a position corresponding to position 174; Q at a position corresponding to position 193; T at a position corresponding to position 195; N at a position corresponding to position 195; E at a position corresponding to position 196; R at a position corresponding to position 196; P at a position corresponding to position 204; A at a position corresponding to position 205; E at a position corresponding to position 205; I at a position corresponding to position 206; A at a position corresponding to position 213; I at a position corresponding to position 219; M at a position corresponding to position 234; T at a position corresponding to position 237; H at a position corresponding to position 238; Q at a position corresponding to position 240; V at a position corresponding to position 249; A at a position corresponding to position 261; K at a position corresponding to position 261; T at a position corresponding to position 267; K at a position corresponding to position 277; H at a position corresponding to position 279; V at a position corresponding to position 279; V at a position corresponding to position 291; E at a position corresponding to position 309; Q at a position corresponding to position 310; Y at a position corresponding to position 314; Y at a position corresponding to position 315; N at a position corresponding to position 317; W at a position corresponding to position 317; D at a position corresponding to position 318; G at a position corresponding to position 347; A at a position corresponding to position 367; R at a position corresponding to position 375; R at a position corresponding to position 376; V at a position corresponding to position 399; E at a position corresponding to position 401; A at a position corresponding to position 407; L at a position corresponding to position 416; K at a position corresponding to position 419; H at a position corresponding to position 421; E at a position corresponding to position 431; T at a position corresponding to position 433; V at a position corresponding to position 433; C at a position corresponding to position 439; P at a position corresponding to position 440; G at a position corresponding to position 443; N at a position corresponding to position 445, with reference to amino acid residue positions set forth in SEQ ID NO:3. For example, the modified PH20 polypeptide can contain at least one amino acid replacement selected from among replacement with: T at a position corresponding to position 52, K at a position corresponding to position 58, R at a position corresponding to position 58, P at a position corresponding to position 68, V at a position corresponding to position 83, P at a position corresponding to position 204, A at a position corresponding to position 261, T at a position corresponding to position 267, K at a position corresponding to position 277 and H at a position corresponding to position 421, with reference to amino acid residue positions set forth in SEQ ID NO:3. An exemplary modified PH20 polypeptide is one that includes P (or a conservative amino acid thereto) at a position corresponding to position 204 in a PH20 polypeptide with reference to amino acid residue positions set forth 5 in SEO ID NO:3.

Thus, provided herein are modified PH20 polypeptides that exhibit increased stability in the presence of a phenolic preservative containing an amino acid replacement in a PH20 polypeptide that confers the increased stability, 10 wherein stability is increased compared to the unmodified polypeptide without the amino acid replacement, and the unmodified PH20 polypeptide has the sequence of amino acids set forth in SEQ ID NO: 7 or is a C-terminal truncated fragment thereof that is a soluble PH20 polypeptide or has 15 at least 85% sequence identity thereto. For example, the unmodified PH20 polypeptide is a soluble PH20 polypeptide that has the sequence of amino acids set forth in any of SEQ ID NOs: 3 or 32-66. In particular examples, the modified PH20 polypeptide has at least 85% sequence identity to SEO 20 ID NO:3. In any of such examples of a modified PH20 polypeptide, the polypeptide contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 25 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 or more amino acid replacements. In examples herein, the modified PH20 polypeptide is a human PH20. The modified PH20 polypeptide exhibits stability in the presence of phenolic preservatives if it exhibits at least 15% of the 30 hyaluronidase activity in the presence of a preservative(s) for at least 4 hours compared to the hyaluronidase activity in the absence of the phenolic preservative(s), wherein the activity is compared under the same conditions except for the presence of the phenolic preservative(s). In any of the 35 above examples, the modified PH20 polypeptide is stable in the presence of an of an anti-microbial effective amount of one or more phenolic preservatives, such as a total amount of one or more phenolic preservative agents as a percentage (%) of mass concentration (w/v) that is from or from about 40 corresponding to position 261; T at a position corresponding 0.05% to $0.6\%,\ 0.1\%$ to $0.4\%,\ 0.1\%$ to $0.3\%,\ 0.15\%$ to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 0.3% to 0.4%, inclusive. The phenolic preservative can be a phenol, metacresol (m-cresol), benzyl alcohol or a paraben, such as m-cresol, phenol, or m-cresol and phenol. The amino 45 acid replacement can be at amino acid residue 204, 58, 10, 12, 20, 22, 26, 34, 36, 46, 50, 52, 68, 70, 74, 82, 83, 84, 86, 97, 127, 131, 138, 142, 143, 144, 166, 169, 174, 193, 195, 196, 205, 206, 213, 219, 234, 237, 238, 240, 249, 261, 267, 277, 279, 291, 309, 310, 314, 315, 317, 318, 347, 367, 375, 50 376, 399, 401, 407, 416, 419, 421, 431, 433, 439, 440, 443 or 445 with reference to amino acid positions set forth in SEQ ID NO:3, wherein corresponding amino acid positions are identified by alignment of the PH20 polypeptide with the polypeptide set forth in SEQ ID NO:3. For example, the 55 amino acid replacement is G at a position corresponding to position 10; K at a position corresponding to position 12; S at a position corresponding to position 20; T at a position corresponding to position 22; M at a position corresponding to position 26; W at a position corresponding to position 34; 60 N at a position corresponding to position 36; L at a position corresponding to position 46; M at a position corresponding to position 50; T at a position corresponding to position 52; S at a position corresponding to position 52; C at a position corresponding to position 58; K at a position corresponding 65 to position 58; R at a position corresponding to position 58; N at a position corresponding to position 58; Y at a position

10

corresponding to position 58; P at a position corresponding to position 58; H at a position corresponding to position 58; P at a position corresponding to position 68; V at a position corresponding to position 70; E at a position corresponding to position 74; L at a position corresponding to position 82; N at a position corresponding to position 82; V at a position corresponding to position 83; Q at a position corresponding to position 83; S at a position corresponding to position 83; G at a position corresponding to position 83; N at a position corresponding to position 84; A at a position corresponding to position 86; K at a position corresponding to position 86; E at a position corresponding to position 97; L at a position corresponding to position 97; R at a position corresponding to position 127; R at a position corresponding to position 131; L at a position corresponding to position 138; K at a position corresponding to position 142; N at a position corresponding to position 142; P at a position corresponding to position 142; S at a position corresponding to position 142; T at a position corresponding to position 142; G at a position corresponding to position 143; K at a position corresponding to position 143; T at a position corresponding to position 144; Q at a position corresponding to position 166; T at a position corresponding to position 166; L at a position corresponding to position 169; G at a position corresponding to position 174; N at a position corresponding to position 174; Q at a position corresponding to position 193; T at a position corresponding to position 195; N at a position corresponding to position 195; E at a position corresponding to position 196; R at a position corresponding to position 196; P at a position corresponding to position 204; A at a position corresponding to position 205; E at a position corresponding to position 205; I at a position corresponding to position 206; A at a position corresponding to position 213; I at a position corresponding to position 219; M at a position corresponding to position 234; T at a position corresponding to position 237; H at a position corresponding to position 238; Q at a position corresponding to position 240; V at a position corresponding to position 249; A at a position corresponding to position 261; K at a position to position 267; K at a position corresponding to position 277; H at a position corresponding to position 279; V at a position corresponding to position 279; V at a position corresponding to position 291; E at a position corresponding to position 309; Q at a position corresponding to position 310; Y at a position corresponding to position 314; Y at a position corresponding to position 315; N at a position corresponding to position 317; W at a position corresponding to position 317; D at a position corresponding to position 318; G at a position corresponding to position 347; A at a position corresponding to position 367; R at a position corresponding to position 375; R at a position corresponding to position 376; V at a position corresponding to position 399; E at a position corresponding to position 401; A at a position corresponding to position 407; L at a position corresponding to position 416; K at a position corresponding to position 419; H at a position corresponding to position 421; E at a position corresponding to position 431; T at a position corresponding to position 433; V at a position corresponding to position 433; C at a position corresponding to position 439; P at a position corresponding to position 440; G at a position corresponding to position 443; or N at a position corresponding to position 445, with reference to amino acid residue positions set forth in SEQ ID NO:3. In particular, the amino acid replacement is T at a position corresponding to position 52, K at a position corresponding to position 58, R at a position corresponding to position 58, P at a position corresponding to position 68, V at a position corresponding to position 83, P at a position corresponding to position 204, A at a position corresponding to position 261, T at a position corresponding to position 267, K at a position corresponding to position 277 or H at a position 5 corresponding to position 421, with reference to amino acid residue positions set forth in SEQ ID NO:3, such as replacement with P at a position corresponding to position 204 or Rat a position corresponding to position 58. The modified PH20 polypeptide that exhibits increased stability to phe-10 nolic preservatives can be substantially purified or isolated. The modified PH20 polypeptide that exhibits increased stability to phenolic preservatives can be modified by glycosylation, sialation, albumination, farnysylation, carboxylation, hydroxylation and phosphorylation, and generally is 15 glycosylated, whereby the polypeptide contains at least an N-acetylglucosamine moiety linked to each of at least three asparagine (N) residues, such as at amino acid residues corresponding to amino acid residues 200, 333 and 358 of SEQ ID NO:3. The modified PH20 polypeptide that exhibits 20 increased stability to phenolic preservatives can be conjugated to a polymer, such as PEG or dextran and/or can be conjugated to a moiety that is a multimerization domain, a toxin, a detectable label or a drug.

Among modified PH20 polypeptides provided herein that 25 exhibit increased stability are those that exhibit increased hyaluronidase activity at the elevated temperature compared to the PH20 polypeptide not containing the amino acid replacement(s), such as at least 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 300%, 400%, 30 500% or more hyaluronidase activity for at least 4 hours compared to the PH20 polypeptide not containing the amino acid replacement(s). Also among the polypeptides are those that exhibit activity, but also typically exhibit increased stability or other property at elevated temperatures, such as 35 a modified PH20 polypeptide that exhibits at least 95%, 96%, 97%, 98%, 99%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 300%, 400%, 500% of the hyaluronidase activity for at least 4 hours at a temperature of between or about between 32° C. to 37° C. 40 corresponding to position 317; W at a position correspondcompared to the hyaluronidase activity of the modified PH20 polypeptide at a temperature of between or about between 2° C. to 8° C., where activity is compared under the same conditions except for the differences in temperature. The hyaluronidase activity can be exhibited after at least 5 45 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks or more at elevated temperatures of between or about between 32° C. to 37° C. compared to 50 the hyaluronidase activity of the modified PH20 polypeptide at a temperature between or about between 2° C. to 8° C., where activity is compared for the same time period and under the same conditions except for the difference in temperature. Exemplary of such modified polypeptides are 55 those that contain at least one amino acid replacement at an amino acid position corresponding to a position selected from among 1, 11, 12, 14, 20, 26, 29, 34, 50, 58, 70, 82, 83, 84, 86, 87, 140, 142, 143, 147, 152, 166, 167, 172, 174, 178, 193, 195, 206, 212, 213, 219, 233, 237, 240, 267, 277, 291, 60 292, 309, 313, 314, 317, 318, 347, 367, 368, 371, 374, 389, 392, 395, 396, 406, 419, 421, 439 and 443 with reference to amino acid positions set forth in SEQ ID NO:3, wherein corresponding amino acid positions are identified by alignment of the PH20 polypeptide with the polypeptide set forth 65 in SEQ ID NO:3. Exemplary mutations include, for example, replacement with R at a position corresponding to

12

position 1; S at a position corresponding to position 11; I at a position corresponding to position 12; V at a position corresponding to position 14; S at a position corresponding to position 20; M at a position corresponding to position 26; with R at a position corresponding to position 29; W at a position corresponding to position 34; M at a position corresponding to position 50; K at a position corresponding to position 58; Q at a position corresponding to position 58; Q at a position corresponding to position 58; V at a position corresponding to position 70; L at a position corresponding to position 82; Q at a position corresponding to position 83; R at a position corresponding to position 84; A at a position corresponding to position 86; S at a position corresponding to position 87; K at a position corresponding to position 140; S at a position corresponding to position 142; T at a position corresponding to position 142; K at a position corresponding to position 143; S at a position corresponding to position 147; T at a position corresponding to position 152; T at a position corresponding to position 166; D at a position corresponding to position 167; A at a position corresponding to position 172; G at a position corresponding to position 174; N at a position corresponding to position 174; R at a position corresponding to position 178; Q at a position corresponding to position 193; T at a position corresponding to position 195; I at a position corresponding to position 206; S at a position corresponding to position 212; A at a position corresponding to position 213; I at a position corresponding to position 219; G at a position corresponding to position 233; T at a position corresponding to position 237; A at a position corresponding to position 240; Q at a position corresponding to position 240; T at a position corresponding to position 267; E at a position corresponding to position 277; S at a position corresponding to position 291; H at a position corresponding to position 292; V at a position corresponding to position 292; S at a position corresponding to position 309; H at a position corresponding to position 313; S at a position corresponding to position 314; I at a position corresponding to position 317; T at a position ing to position 317; R at a position corresponding to position 318; G at a position corresponding to position 347; A at a position corresponding to position 367; R at a position corresponding to position 368; S at a position corresponding to position 371; P at a position corresponding to position 374; A at a position corresponding to position 389; V at a position corresponding to position 392; A at a position corresponding to position 395; H at a position corresponding to position 396; N at a position corresponding to position 406; H at a position corresponding to position 419; K at a position corresponding to position 419; R at a position corresponding to position 421; S at a position corresponding to position 421; A at a position corresponding to position 439; C at a position corresponding to position 439; and G at a position corresponding to position 443, with reference to amino acid positions set forth in SEQ ID NO:3. In particular examples provided herein, any of such modified PH20 polypeptides contain a single amino acid modification, such as a replacement, and combinations of modifications, such as at least or 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16. 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100 and more modifications. The modification, such as replacement, can be in an unmodified PH20 polypeptide that has the sequence of amino acids set forth in SEQ ID NO: 7 or is a C-terminal truncated fragment thereof that is a soluble PH20 polypeptide, such as is set forth in any of SEQ ID NOs: 3 or 32-66, or has at least 85% sequence identity thereto. For example, any of such modified PH20 polypeptides has at least 85% sequence identity to SEQ ID NO:3.

Also provided are modified PH20 polypeptides that exhibit increased stability in low salt conditions, such as, for example, concentrations of NaCl of less than 100 mM, such 5 as, but not limited to concentrations of NaCl less than 90 mM, 80 mM, 70 mM, 60 mM, 50 mM, 40 mM, 30 mM, 25 mM, 20 mM, 15 mM, 10 mM, 5 mM or less. Among the modified PH20 polypeptides are those that exhibit increased hyaluronidase activity at lower concentrations of salt compared to the PH20 polypeptide not containing the amino acid replacement(s). Such activity includes, for example, at least more than 100%, or at least 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 300%, 400%, 500% or more hyaluronidase activity compared to the PH20 15 polypeptide not containing the amino acid replacement(s). Exemplary of such modified PH20 polypeptides are those that exhibit at least 60% of the hyaluronidase activity in low concentrations of salt, such as between or about between 10 mM NaCl and 100 mM NaCl, inclusive (or comparable 20 concentrations of other salts or mixtures of salts), compared to the hyaluronidase activity of the modified PH20 polypeptide in 150 mM NaCl, where activities are compared under the same conditions except for the difference in salt concentration. In particular examples provided herein, any of 25 such modified PH20 polypeptides contain a single amino acid modification, such as a replacement, and combinations of modifications, such as at least or 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100 and more modifications. The modification, such as 30 replacement, can be in an the unmodified PH20 polypeptide that has the sequence of amino acids set forth in SEQ ID NO: 7 or is a C-terminal truncated fragment thereof that is a soluble PH20 polypeptide, such as is set forth in any of SEQ ID NOs: 3 or 32-66, or has at least 85% sequence identity 35 thereto. For example, any of such modified PH20 polypeptides has at least 85% sequence identity to SEQ ID NO:3.

Also provided are modified PH20 polypeptides that contain at least one amino acid replacement in a PH20 polypeptide, where the modified PH20 polypeptide exhibits 40 increased hyaluronidase activity compared to the PH20 polypeptide not containing the amino acid replacement. When comparing activity among polypeptides, activity is compared under the same conditions. Among these are polypeptides, where the unmodified PH20 exhibits at least 45 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity to the sequence of amino acids set forth in SEQ ID NO:3, or the resulting modified PH20 exhibits such sequence identity to the sequence of amino 50 acids set forth in SEQ ID NO:3. Exemplary of such modified PH20 polypeptides are any that contain an amino acid replacement(s) in the sequence of amino acids set forth in any of SEQ ID NOs: 3, 7, 10, 12, 14, 24, 32-66, 69, or 72, or a sequence of amino acids that is at least 80%, 85%, 86%, 55 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to any of SEQ ID NOs: 3, 7, 10, 12, 14, 24, 32-66, 69, or 72. The amino acid replacement(s) also can be made in the sequence of amino acids set forth in any of SEQ ID NOs: 857, 859, 861 or 870, or a sequence of 60 amino acids that is at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to any of SEQ ID NOs: 857, 859, 861 or 870. In particular, provided are modified PH20 polypeptides that contain an amino acid replacement in the sequence of amino 65 acids set forth in SEQ ID NOs: 3, 7, 32-66, 69 or 72. Among the modified PH20 polypeptides are those that that exhibit at

least 120%, 130%, 135%, 140%, 145%, 150%, 160%, 170%, 180%, 200%, 250%, 300%, 350%, 400%, 500%, 1500%, 2000%, 3000%, 4000%, 5000% or more of the hyaluronidase activity of the PH20 polypeptide not containing the amino acid replacement. Activity can be assessed at any temperature, in particular such activity is present when the hyaluronidase is exposed to a temperature that is at a temperature between or about between 2° C. to 8° C. These modified PH20 polypeptides contain at least one amino acid replacement at an amino acid position corresponding to a position selected from among 1, 12, 15, 24, 26, 27, 29, 30, 31, 32, 33, 37, 39, 46, 48, 52, 58, 63, 67, 68, 69, 70, 71, 72, 73, 74, 75, 84, 86, 87, 92, 93, 94, 97, 118, 120, 127, 131, 135, 141, 142, 147, 148, 150, 151, 152, 155, 156, 163, 164, 165, 166, 169, 170, 174, 198, 206, 209, 212, 213, 215, 219, 233, 234, 236, 238, 247, 257, 259, 260, 261, 263, 269, 271, 272, 276, 277, 278, 282, 291, 293, 305, 308, 309, 310, 313, 315, 317, 318, 324, 325, 326, 328, 347, 353, 359, 371, 377, 380, 389, 392, 395, 399, 405, 407, 409, 410, 418, 419, 421, 425, 431, 433, 436, 437, 438, 439, 440, 441, 442, 443, 445, 446 and 447 with reference to amino acid positions set forth in SEQ ID NO:3, wherein corresponding amino acid positions are identified by alignment of the PH20 polypeptide with the polypeptide set forth in SEQ ID NO:3. Exemplary modifications include at least one amino acid replacement selected from among replacement with: histidine (H) at a position corresponding to position 1; Q at a position corresponding to position 1; E at a position corresponding to position 12; T at a position corresponding to position 12; V at a position corresponding to position 15; E at a position corresponding to position 24; H at a position corresponding to position 24; E at a position corresponding to position 26; K at a position corresponding to position 26; K at a position corresponding to position 27; R at a position corresponding to position 27; E at a position corresponding to position 29; I at a position corresponding to position 29; L at a position corresponding to position 29; M at a position corresponding to position 29; P at a position corresponding to position 29; S at a position corresponding to position 29; V at a position corresponding to position 29; G at a position corresponding to position 30; H at a position corresponding to position 30; K at a position corresponding to position 30; M at a position corresponding to position 30; R at a position corresponding to position 30; S at a position corresponding to position 30; A at a position corresponding to position 31; C at a position corresponding to position 31; H at a position corresponding to position 31; I at a position corresponding to position 31; K at a position corresponding to position 31; L at a position corresponding to position 31; P at a position corresponding to position 31; R at a position corresponding to position 31; S at a position corresponding to position 31; T at a position corresponding to position 31; V at a position corresponding to position 31; F at a position corresponding to position 32; G at a position corresponding to position 32; H at a position corresponding to position 32; W at a position corresponding to position 33; F at a position corresponding to position 37; N at a position corresponding to position 39; T at a position corresponding to position 39; R at a position corresponding to position 46; F at a position corresponding to position 48; H at a position corresponding to position 48; N at a position corresponding to position 48; Q at a position corresponding to position 52; K at a position corresponding to position 58; Q at a position corresponding to position 58; W at a position corresponding to position 63; V at a position corresponding to position 67; H at a position corresponding to position 68; Q at a position corresponding to position 68; A at a position corresponding to position 69; C at a position corresponding G at a position corresponding to position 69; I at a position corresponding to position 69; L at a position corresponding to position 69; M at a position corresponding to position 69; P at a position corresponding to position 69; R at a position 5 corresponding to position 69; W at a position corresponding to position 69; Y at a position corresponding to position 69; A at a position corresponding to position 70; C at a position corresponding to position 70; F at a position corresponding to position 70; G at a position corresponding to position 70; 10 H at a position corresponding to position 70; K at a position corresponding to position 70; L at a position corresponding to position 70; N at a position corresponding to position 70; P at a position corresponding to position 70; R at a position corresponding to position 70; S at a position corresponding 15 to position 70; T at a position corresponding to position 70; V at a position corresponding to position 70; R at a position corresponding to position 71; S at a position corresponding to position 71; M at a position corresponding to position 72; Q at a position corresponding to position 72; H at a position 20 corresponding to position 73; L at a position corresponding to position 73; W at a position corresponding to position 73; A at a position corresponding to position 74; C at a position corresponding to position 74; G at a position corresponding to position 74; N at a position corresponding to position 74; 25 P at a position corresponding to position 74; R at a position corresponding to position 74; S at a position corresponding to position 74; V at a position corresponding to position 74; W at a position corresponding to position 74; F at a position corresponding to position 75; L at a position corresponding 30 to position 75; R at a position corresponding to position 75; T at a position corresponding to position 75; G at a position corresponding to position 84; R at a position corresponding to position 84; A at a position corresponding to position 86; C at a position corresponding to position 87; T at a position 35 corresponding to position 87; Y at a position corresponding to position 87; C at a position corresponding to position 92; I at a position corresponding to position 93; L at a position corresponding to position 93; R at a position corresponding to position 93; T at a position corresponding to position 93; 40 to position 278; R at a position corresponding to position R at a position corresponding to position 94; G at a position corresponding to position 97; Q at a position corresponding to position 118; F at a position corresponding to position 120; V at a position corresponding to position 120; Y at a position corresponding to position 120; H at a position 45 corresponding to position 127; N at a position corresponding to position 127; G at a position corresponding to position 131; R at a position corresponding to position 131; V at a position corresponding to position 131; D at a position corresponding to position 135; G at a position corresponding 50 to position 135; R at a position corresponding to position 135, with H at a position corresponding to position 141; Y at a position corresponding to position 141; R at a position corresponding to position 142; R at a position corresponding to position 147; V at a position corresponding to position 55 147; K at a position corresponding to position 148; G at a position corresponding to position 150; K at a position corresponding to position 151; L at a position corresponding to position 151; M at a position corresponding to position 151; Q at a position corresponding to position 151; R at a 60 position corresponding to position 151; R at a position corresponding to position 152; G at a position corresponding to position 155; K at a position corresponding to position 155; D at a position corresponding to position 156; A at a position corresponding to position 163; E at a position 65 corresponding to position 163; K at a position corresponding to position 163; R at a position corresponding to position

16

163; M at a position corresponding to position 164; D at a position corresponding to position 165; N at a position corresponding to position 165; A at a position corresponding to position 166; F at a position corresponding to position 166; H at a position corresponding to position 166; L at a position corresponding to position 166; Q at a position corresponding to position 166; R at a position corresponding to position 166; T at a position corresponding to position 166; Y at a position corresponding to position 166; L at a position corresponding to position 169; R at a position corresponding to position 170; K at a position corresponding to position 174; D at a position corresponding to position 198; K at a position corresponding to position 206; L at a position corresponding to position 206; N at a position corresponding to position 212; M at a position corresponding to position 213; N at a position corresponding to position 213; M at a position corresponding to position 215; S at a position corresponding to position 219; K at a position corresponding to position 233; R at a position corresponding to position 233; M at a position corresponding to position 234; R at a position corresponding to position 236; E at a position corresponding to position 237; S at a position corresponding to position 238; I at a position corresponding to position 247; T at a position corresponding to position 257; P at a position corresponding to position 259; Y at a position corresponding to position 260; K at a position corresponding to position 261; N at a position corresponding to position 261; K at a position corresponding to position 263; R at a position corresponding to position 263; A at a position corresponding to position 269; L at a position corresponding to position 271; M at a position corresponding to position 271; T at a position corresponding to position 272; D at a position corresponding to position 276; S at a position corresponding to position 276; Y at a position corresponding to position 276; K at a position corresponding to position 277; R at a position corresponding to position 277; T at a position corresponding to position 277; H at a position corresponding to position 278; K at a position corresponding to position 278; N at a position corresponding 278; S at a position corresponding to position 278; T at a position corresponding to position 278; Y at a position corresponding to position 278; M at a position corresponding to position 282; V at a position corresponding to position 291; A at a position corresponding to position 293; C at a position corresponding to position 293; F at a position corresponding to position 293; M at a position corresponding to position 293; P at a position corresponding to position 293; Q at a position corresponding to position 293; V at a position corresponding to position 293; E at a position corresponding to position 305; G at a position corresponding to position 308; N at a position corresponding to position 308; E at a position corresponding to position 309; L at a position corresponding to position 309; N at a position corresponding to position 309; Q at a position corresponding to position 309; R at a position corresponding to position 309; T at a position corresponding to position 309; A at a position corresponding to position 310; G at a position corresponding to position 310; K at a position corresponding to position 313; R at a position corresponding to position 313; H at a position corresponding to position 315; I at a position corresponding to position 317; K at a position corresponding to position 317; R at a position corresponding to position 317; M at a position corresponding to position 318; H at a position corresponding to position 320; K at a position corresponding to position 320; R at a position corresponding to position 320; R at a position corresponding to position 324; A at a position corresponding to position 325; D at a position corresponding to position 325; E at a position corresponding to position 325; G at a position corresponding to position 325; H at a position corresponding to position 325; K at a position corresponding to position 325; M at a position corresponding to position 325; N at a position corresponding to position 325; Q at a position corresponding to position 325; S at a position corresponding to position 325; V at a position corresponding to position 326; I at a position corresponding to position 328; K at a 10 position corresponding to position 328; L at a position corresponding to position 328; S at a position corresponding to position 328; Y at a position corresponding to position 328; G at a position corresponding to position 347; S at a position corresponding to position 347; V at a position 15 corresponding to position 353; with T at a position corresponding to position 359; R at a position corresponding to position 371; P at a position corresponding to position 377; T at a position corresponding to position 377; W at a position corresponding to position 380; Y at a position corresponding 20 to position 380; K at a position corresponding to position 389; M at a position corresponding to position 392; R at a position corresponding to position 395; M at a position corresponding to position 399; T at a position corresponding to position 399; W at a position corresponding to position 25 399; G at a position corresponding to position 405; D at a position corresponding to position 407; Q at a position corresponding to position 407; A at a position corresponding to position 409; Q at a position corresponding to position 409; T at a position corresponding to position 410; P at a 30 position corresponding to position 418; F at a position corresponding to position 419; I at a position corresponding to position 419; K at a position corresponding to position 419; R at a position corresponding to position 419; S at a position corresponding to position 419; H at a position 35 corresponding to position 421; K at a position corresponding to position 421; N at a position corresponding to position 421; Q at a position corresponding to position 421; R at a position corresponding to position 421; S at a position corresponding to position 421; K at a position corresponding 40 325; Q at a position corresponding to position 325; and V at to position 425; A at a position corresponding to position 431; H at a position corresponding to position 431; K at a position corresponding to position 431; Q at a position corresponding to position 431; R at a position corresponding to position 431; S at a position corresponding to position 45 431; V at a position corresponding to position 431; L at a position corresponding to position 433; R at a position corresponding to position 433; T at a position corresponding to position 433; V at a position corresponding to position 433; K at a position corresponding to position 436; I at a 50 position corresponding to position 437; M at a position corresponding to position 437; T at a position corresponding to position 438; V at a position corresponding to position 439; H at a position corresponding to position 440; R at a position corresponding to position 440; F at a position 55 corresponding to position 441; R at a position corresponding to position 442; A at a position corresponding to position 443; M at a position corresponding to position 443; M at a position corresponding to position 445; P at a position corresponding to position 445; A at a position corresponding 60 to position 446; D at a position corresponding to position 447; N at a position corresponding to position 447; and/or with Q at a position corresponding to position 447, with reference to amino acid positions set forth in SEQ ID NO:3.

Among the polypeptides that exhibit increased hyaluroni- 65 dase activity are those that exhibit at least 2.0-fold of the hyaluronidase activity of the PH20 polypeptide not contain18

ing the amino acid replacement. For example, among these are modified PH20 polypeptides that contain at least one amino acid replacement at an amino acid position corresponding to a position selected from among 24, 29, 31, 48, 58, 69, 70, 75, 84, 97, 165, 166, 271, 278, 317, 320, 325 and 326 with reference to positions set forth in SEQ ID NO:3, wherein corresponding amino acid positions are identified by alignment of the PH20 polypeptide with the polypeptide set forth in SEQ ID NO:3, such as modified PH20 polypeptides that contain at least one amino acid replacement selected from among replacement with: E at a position corresponding to position 24; E at a position corresponding to position 29; V at a position corresponding to position 31; N at a position corresponding to position 48; K at a position corresponding to position 58; Q at a position corresponding to position 58; A at a position corresponding to position 69; F at a position corresponding to position 69; G at a position corresponding to position 69; P at a position corresponding to position 69; R at a position corresponding to position 69; A at a position corresponding to position 70; F at a position corresponding to position 70; G at a position corresponding to position 70; H at a position corresponding to position 70; H at a position corresponding to position 70; N at a position corresponding to position 70; R at a position corresponding to position 70; T at a position corresponding to position 70; V at a position corresponding to position 70; L at a position corresponding to position 75; T at a position corresponding to position 75; G at a position corresponding to position 84; G at a position corresponding to position 97; D at a position corresponding to position 165; L at a position corresponding to position 166; R at a position corresponding to position 166; T at a position corresponding to position 166; L at a position corresponding to position 271; H at a position corresponding to position 278; R at a position corresponding to position 278; K at a position corresponding to position 317; K at a position corresponding to position 320; E at a position corresponding to position 325, with G at a position corresponding to position 325; K at a position corresponding to position 325; N at a position corresponding to position a position corresponding to position 326; with reference to amino acid positions set forth in SEQ ID NO:3.

Among any of the polypeptides provided herein that exhibit increased hyaluronidase activity, any of such modified PH20 polypeptides contain a single amino acid modification, such as a replacement, and combinations of modifications, such as at least or 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100 and more modifications. The modification, such as replacement, can be in an unmodified PH20 polypeptide that has the sequence of amino acids set forth in SEQ ID NO: 7 or is a C-terminal truncated fragment thereof that is a soluble PH20 polypeptide, such as is set forth in any of SEQ ID NOs: 3 or 32-66, or has at least 85% sequence identity thereto. For example, any of such modified PH20 polypeptides has at least 85% sequence identity to SEQ ID NO:3.

Also provided are modified PH20 polypeptides that contain at least one amino acid replacement in the PH20 polypeptide whose sequence is set forth in SEQ ID NO:7, a C-terminally truncated fragment thereof, a soluble fragment thereof, or in a PH20 polypeptide that has a sequence of amino acids that is at least 91% identical to the sequence of amino acids set forth in SEQ ID NO:7, where at least one amino replacement(s) is at an amino acid position corresponding to a position selected from among 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 20, 22, 23, 24, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46,

47, 48, 49, 50, 51, 52, 54, 58, 59, 60, 61, 63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 77, 79, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, 92, 93, 94, 96, 97, 98, 99, 102, 103, 104, 105, 106, 107, 108, 110, 114, 117, 118, 119, 120, 122, 124, 125, 127, 128, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 5 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 186, 192, 193, 195, 196, 197, 198, 200, 202, 204, 205, 206, 208, 209, 211, 10 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 224, 226, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 242, 245, 247, 248, 251, 253, 255, 256, 257, 258, 259, 260, 261, 263, 264, 265, 266, 267, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 282, 283, 284, 285, 286, 287, 15 288, 289, 290, 291, 292, 293, 294, 297, 298, 300, 301, 302, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 320, 321, 323, 324, 325, 326, 327, 328, 331, 334, 335, 338, 339, 342, 343, 347, 348, 349, 351, 353, 356, 357, 358, 359, 360, 361, 367, 368, 369, 371, 373, 374, 375, 20 376, 377, 378, 379, 380, 381, 383, 385, 387, 388, 389, 391, 392, 393, 394, 395, 396, 397, 398, 399, 401, 403, 404, 405, 406, 407, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 425, 426, 427, 428, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446 25 and 447 with reference to amino acid positions set forth in SEQ ID NO:3 or 7, where corresponding amino acid positions are identified by alignment of the PH20 polypeptide with the polypeptide set forth in SEQ ID NO:3; and provided that if the modified PH20 polypeptide contains an amino 30 acid replacement at a position corresponding to position 13, 47, 131, or 219 the replacement is not replacement with an Alanine (A). Among these modified PH20 polypeptides are those that exhibit at least 40% of the hyaluronidase activity of the PH20 polypeptide not containing the amino acid 35 replacement, where, as in all instances herein activity is compared under the same conditions.

Included among these polypeptides are those that contain an amino acid replacement in the sequence of amino acids set forth in any of SEQ ID NOs: 3, 7, 32-66, 69 and 72, or 40 in a sequence of amino acids that exhibits at least 91% sequence identity to any of SEQ ID NOs: 3, 7, 32-66, 69, or 72. In particular, the modified PH20 polypeptide contains amino acid replacements in SEQ ID NO: 3, 7, 32-66, 69, or 72, which are polypeptides that are a C-terminally truncated 45 fragment of SEQ ID NO:7, or a PH20 polypeptide that has a sequence of amino acids that is at least 910% identical to the sequence of amino acids set forth in SEQ ID NO:7. In particular, among any of such modified PH20 polypeptides provided herein are any including those in which the amino 50 acid replacement is an amino acid replacement set forth in Table 3 below. For example, such modified PH20 polypeptides include those that have at least one amino acid replacement at an amino acid position corresponding to a position selected from among 1, 6, 8, 9, 10, 11, 12, 14, 15, 20, 22, 24, 55 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 46, 47, 48, 49, 50, 52, 58, 59, 63, 67, 68, 69, 70, 71, 72, 73, 74, 75, 79, 82, 83, 84, 86, 87, 89, 90, 92, 93, 94, 97, 102, 104, 107, 114, 118, 120, 127, 128, 130, 131, 132, 135, 138, 139, 140, 141, 142, 143, 144, 146, 147, 148, 149, 150, 151, 152, 60 155, 156, 158, 160, 162, 163, 164, 165, 166, 167, 169, 170, 172, 173, 174, 175, 178, 179, 193, 195, 196, 198, 204, 205, 206, 209, 212, 213, 215, 219, 220, 221, 222, 232, 233, 234, 235, 236, 237, 238, 240, 247, 248, 249, 257, 258, 259, 260, 261, 263, 267, 269, 271, 272, 273, 274, 276, 277, 278, 279, 65 282, 283, 285, 287, 289, 291, 292, 293, 298, 305, 307, 308, 309, 310, 313, 314, 315, 317, 318, 320, 321, 324, 325, 326,

20

328, 335, 347, 349, 351, 353, 356, 359, 367, 368, 369, 371, 373, 374, 375, 376, 377, 380, 381, 383, 385, 389, 392, 393, 395, 396, 399, 401, 404, 405, 406, 407, 409, 410, 412, 416, 418, 419, 421, 425, 427, 428, 431, 433, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446 or 447 with reference to amino acid positions set forth in SEQ ID NO:3. Exemplary of such replacements are those that contain at least one amino acid replacement selected from among replacement with: histidine (H) at a position corresponding to position 1; A at a position corresponding to position 1; E at a position corresponding to position 1; G at a position corresponding to position 1; K at a position corresponding to position 1; Q at a position corresponding to position 1; R at a position corresponding to position 1; A at a position corresponding to position 6; M at a position corresponding to position 8; Q at a position corresponding to position 9; G at a position corresponding to position 10; H at a position corresponding to position 10; S at a position corresponding to position 11; E at a position corresponding to position 12; I at a position corresponding to position 12; K at a position corresponding to position 12; T at a position corresponding to position 12; V at a position corresponding to position 14; V at a position corresponding to position 15; M at a position corresponding to position 15; S at a position corresponding to position 20; T at a position corresponding to position 22; E at a position corresponding to position 24; H at a position corresponding to position 24; R at a position corresponding to position 24; A at a position corresponding to position 26; E at a position corresponding to position 26; K at a position corresponding to position 26; M at a position corresponding to position 26; Q at a position corresponding to position 26; R at a position corresponding to position 26; D at a position corresponding to position 27; K at a position corresponding to position 27; R at a position corresponding to position 27; R at a position corresponding to position 28; E at a position corresponding to position 29; I at a position corresponding to position 29; K at a position corresponding to position 29; L at a position corresponding to position 29; M at a position corresponding to position 29; P at a position corresponding to position 29; R at a position corresponding to position 29; S at a position corresponding to position 29; T at a position corresponding to position 29; V at a position corresponding to position 29; G at a position corresponding to position 30; H at a position corresponding to position 30; K at a position corresponding to position 30; L at a position corresponding to position 30; M at a position corresponding to position 30; R at a position corresponding to position 30; S at a position corresponding to position 30; A at a position corresponding to position 31; C at a position corresponding to position 31; G at a position corresponding to position 31; H at a position corresponding to position 31; I at a position corresponding to position 31; K at a position corresponding to position 31; L at a position corresponding to position 31; P at a position corresponding to position 31; R at a position corresponding to position 31; S at a position corresponding to position 31; T at a position corresponding to position 31; V at a position corresponding to position 31; W at a position corresponding to position 31; C at a position corresponding to position 32; F at a position corresponding to position 32; G at a position corresponding to position 32; H at a position corresponding to position 32; W at a position corresponding to position 33; G at a position corresponding to position 33; W at a position corresponding to position 34; Q at a position corresponding to position 35; V at a position corresponding to position 35; H at a position corresponding to position 36; N at a position corresponding to position 36; F at a position corresponding to position 37; M at a position corresponding to position 37; Y at a position to position 39; L at a position corresponding to position 39; N at a position corresponding to position 39; T at a position corresponding to position 39; L at a position corresponding to position 40; T at a position corresponding to position 41; 5 L at a position corresponding to position 46; R at a position corresponding to position 46; D at a position corresponding to position 47; F at a position corresponding to position 47; T at a position corresponding to position 47; W at a position corresponding to position 47, with F at a position corresponding to position 48; H at a position corresponding to position 48; K at a position corresponding to position 48; N at a position corresponding to position 48; R at a position corresponding to position 49; D at a position corresponding to position 50; S at a position corresponding to position 50; 15 L at a position corresponding to position 82; N at a position M at a position corresponding to position 50; N at a position corresponding to position 52; Q at a position corresponding to position 52; R at a position corresponding to position 52; S at a position corresponding to position 52; T at a position corresponding to position 52; C at a position corresponding 20 to position 58; K at a position corresponding to position 58; L at a position corresponding to position 58; P at a position corresponding to position 58; Q at a position corresponding to position 58; R at a position corresponding to position 58; H at a position corresponding to position 58; N at a position 25 corresponding to position 58; Y at a position corresponding to position 58; N at a position corresponding to position 59; K at a position corresponding to position 63; L at a position corresponding to position 63; M at a position corresponding to position 63; R at a position corresponding to position 63; 30 W at a position corresponding to position 63; V at a position corresponding to position 67; H at a position corresponding to position 68; P at a position corresponding to position 68; Q at a position corresponding to position 68; A at a position corresponding to position 69; C at a position corresponding 35 to position 69; E at a position corresponding to position 69; F at a position corresponding to position 69; G at a position corresponding to position 69; I at a position corresponding to position 69; L at a position corresponding to position 69; M at a position corresponding to position 69; P at a position 40 corresponding to position 69; R at a position corresponding to position 69; T at a position corresponding to position 69; W at a position corresponding to position 69; Y at a position corresponding to position 69; A at a position corresponding to position 70; C at a position corresponding to position 70; 45 F at a position corresponding to position 70; G at a position corresponding to position 70; H at a position corresponding to position 70; K at a position corresponding to position 70; L at a position corresponding to position 70; N at a position corresponding to position 70; P at a position corresponding 50 to position 70; R at a position corresponding to position 70; S at a position corresponding to position 70; T at a position corresponding to position 70; V at a position corresponding to position 70; Y at a position corresponding to position 70; G at a position corresponding to position 71; N at a position 55 corresponding to position 71; R at a position corresponding to position 71; S at a position corresponding to position 71; K at a position corresponding to position 72; M at a position corresponding to position 72; Q at a position corresponding to position 72; A at a position corresponding to position 73; 60 H at a position corresponding to position 73; K at a position corresponding to position 73; L at a position corresponding to position 73; Q at a position corresponding to position 73; R at a position corresponding to position 73; T at a position corresponding to position 73; W at a position corresponding 65 to position 73; A at a position corresponding to position 74; C at a position corresponding to position 74; E at a position

22

corresponding to position 74; F at a position corresponding to position 74; G at a position corresponding to position 74; H at a position corresponding to position 74; K at a position corresponding to position 74; L at a position corresponding to position 74; M at a position corresponding to position 74; N at a position corresponding to position 74; P at a position corresponding to position 74; R at a position corresponding to position 74; S at a position corresponding to position 74; V at a position corresponding to position 74; W at a position corresponding to position 74; F at a position corresponding to position 75; L at a position corresponding to position 75; M at position corresponding to position 75; R at a position corresponding to position 75; T at a position corresponding to position 75; L at a position corresponding to position 79; corresponding to position 82; V at a position corresponding to position 83; Q at a position corresponding to position 83; S at a position corresponding to position 83; G at a position corresponding to position 83; E at a position corresponding to position 84; F at a position corresponding to position 84; G at a position corresponding to position 84; N at a position corresponding to position 84; R at a position corresponding to position 84; A at a position corresponding to position 86; H at a position corresponding to position 86; K at a position corresponding to position 86; N at a position corresponding to position 86; S at a position corresponding to position 86; T at a position corresponding to position 86; W at a position corresponding to position 86; C at a position corresponding to position 87; G at a position corresponding to position 87; L at a position corresponding to position 87; M at a position corresponding to position 87; R at a position corresponding to position 87; S at a position corresponding to position 87; T at a position corresponding to position 87; V at a position corresponding to position 87; Y at a position corresponding to position 87; C at a position corresponding to position 89; A at a position corresponding to position 90; E at a position corresponding to position 90; H at a position corresponding to position 90; K at a position corresponding to position 90; N at a position corresponding to position 90; R at a position corresponding to position 90; C at a position corresponding to position 92; L at a position corresponding to position 92; I at a position corresponding to position 93; L at a position corresponding to position 93; Q at a position corresponding to position 93; R at a position corresponding to position 93; S at a position corresponding to position 93; T at a position corresponding to position 93; D at a position corresponding to position 94; O at a position corresponding to position 94; R at a position corresponding to position 94; A at a position corresponding to position 97; C at an amino acid residue corresponding to position 97; D at a position corresponding to position 97; E at a position corresponding to position 97; G at a position corresponding to position 97; L at a position corresponding to position 97; S at a position corresponding to position 97; S at a position corresponding to position 102; T at a position corresponding to position 102; R at a position corresponding to position 104; L at a position corresponding to position 107; A at a position corresponding to position 114; Q at a position corresponding to position 118; H at a position corresponding to position 120; F at a position corresponding to position 120; I at a position corresponding to position 120; S at a position corresponding to position 120; V at a position corresponding to position 120; Y at a position corresponding to position 120; E at a position corresponding to position 127; H at a position corresponding to position 127; N at a position corresponding to position 127; Q at a position corresponding to position 127; R at a position corresponding to position 127; I at a position corresponding to position 128; R at a position corresponding to position 130; G at a position corresponding to position 131; I at a position corresponding to position 131; M at a position corresponding to position 131; Q at a position corresponding to position 131; R at a position corresponding to position 131; V at a position corresponding to position 131; N at a position corresponding to position 132; L at a position corresponding to position 132; D at a position corresponding to position 135; G at a position corresponding to position 135; R at a position corresponding to position 10 135, with L at a position corresponding to position 138; T at a position corresponding to position 139; K at a position corresponding to position 140; H at a position corresponding to position 141; R at a position corresponding to position 141; S at a position corresponding to position 141; W at a 15 position corresponding to position 141; Y at a position corresponding to position 141; D at a position corresponding to position 142; G at a position corresponding to position 142; K at a position corresponding to position 142; N at a position corresponding to position 142; P at a position 20 corresponding to position 142; Q at a position corresponding to position 142; R at a position corresponding to position 142; S at a position corresponding to position 142; T at a position corresponding to position 142; G at a position corresponding to position 143; K at a position corresponding to position 143; R at a position corresponding to position 144; T at a position corresponding to position 144; P at a position corresponding to position 146; R at a position corresponding to position 146; A at a position corresponding to position 147; F at a position corresponding to position 30 147; L at a position corresponding to position 147; R at a position corresponding to position 147; S at a position corresponding to position 147; V at a position corresponding to position 147; H at a position corresponding to position 148; K at a position corresponding to position 148; Q at a 35 position corresponding to position 148; T at a position corresponding to position 149; V at a position corresponding to position 149; A at a position corresponding to position 150; D at a position corresponding to position 150; G at a position corresponding to position 150; N at a position 40 corresponding to position 150; S at a position corresponding to position 150; W at a position corresponding to position 150; Y at a position corresponding to position 150; A at a position corresponding to position 151; H at a position corresponding to position 151; K at a position corresponding 45 to position 151; L at a position corresponding to position 151; M at a position corresponding to position 151; Q at a position corresponding to position 151; Rat a position corresponding to position 151; S at a position corresponding to position 151; T at a position corresponding to position 151; 50 V at a position corresponding to position 151; W at a position corresponding to position 151; Y at a position corresponding to position 151; Rat a position corresponding to position 152; T at a position corresponding to position 152; W at a position corresponding to position 152; D at a 55 position corresponding to position 155; G at a position corresponding to position 155; K at a position corresponding to position 155; R at a position corresponding to position 155; D at a position corresponding to position 156; Q at a position corresponding to position 158; S at a position 60 corresponding to position 158; S at a position corresponding to position 160; E at a position corresponding to position 162; A at a position corresponding to position 163; E at a position corresponding to position 163; K at a position corresponding to position 163; Q at a position corresponding 65 to position 163; R at a position corresponding to position 163; S at a position corresponding to position 163; M at a

24

position corresponding to position 164; V at a position corresponding to position 164; D at a position corresponding to position 165; F at a position corresponding to position 165; N at a position corresponding to position 165; S at a position corresponding to position 165; V at a position corresponding to position 165; A at a position corresponding to position 166; E at a position corresponding to position 166; F at a position corresponding to position 166; H at a position corresponding to position 166; L at a position corresponding to position 166; Q at a position corresponding to position 166; R at a position corresponding to position 166; T at a position corresponding to position 166; W at a position corresponding to position 166; Y at a position corresponding to position 166; D at a position corresponding to position 167; L at a position corresponding to position 169; R at a position corresponding to position 170; A at a position corresponding to position 172; R at a position corresponding to position 173; G at a position corresponding to position 174; K at a position corresponding to position 174; N at a position corresponding to position 174; R at a position corresponding to position 174; T at a position corresponding to position 174; T at a position corresponding to position 175; K at a position corresponding to position 178; R at a position corresponding to position 178; K at a position corresponding to position 179; Q at a position corresponding to position 193; T at a position corresponding to position 195; N at a position corresponding to position 195; with E at a position corresponding to position 196; R at a position corresponding to position 196; with D at a position corresponding to position 198; P at a position corresponding to position 204; A at a position corresponding to position 205; E at a position corresponding to position 205; L at a position corresponding to position 205; T at a position corresponding to position 205; I at a position corresponding to position 206; K at a position corresponding to position 206; L at a position corresponding to position 206; R at a position corresponding to position 206; R at a position corresponding to position 209; N at a position corresponding to position 212; S at a position corresponding to position 212; A at a position corresponding to position 213; M at a position corresponding to position 213; N at a position corresponding to position 213; H at a position corresponding to position 215; M at a position corresponding to position 215; I at a position corresponding to position 219; K at a position corresponding to position 219; S at a position corresponding to position 219; H at a position corresponding to position 220; I at a position corresponding to position 220; L at a position corresponding to position 220; V at a position corresponding to position 220; Q at a position corresponding to position 221; G at a position corresponding to position 222; F at a position corresponding to position 232; G at a position corresponding to position 233; K at a position corresponding to position 233; R at a position corresponding to position 233; M at a position corresponding to position 234; A at a position corresponding to position 235; R at a position corresponding to position 236; C at a position corresponding to position 237; E at a position corresponding to position 237; H at a position corresponding to position 237; Q at a position corresponding to position 237; T at a position corresponding to position 237; E at a position corresponding to position 238; H at a position corresponding to amino acid position 238; S at a position corresponding to position 238; A at a position corresponding to position 240; Q at a position corresponding to position 240; I at a position corresponding to position 247; A at a position corresponding to position 248; V at a position corresponding to position 249; G at a position corresponding to position 257; T at a position corresponding to position 257; R at a position corresponding to position 257; N at a position corresponding to position 258; S at a position corresponding to position 258; P at a position corresponding to position 259; M at a position corresponding to position 260; Y at a position corresponding to position 260; A at a position corresponding to position 261; K at a position corresponding to position 261; N at a position corresponding to position 261; K at a position corresponding to position 263; R at a position corresponding to position 263; T at a 10 position corresponding to position 267; A at a position corresponding to position 269; L at a position corresponding to position 271; M at a position corresponding to position 271; D at a position corresponding to position 272; T at a position corresponding to position 272; H at a position 15 corresponding to position 273; Y at a position corresponding to position 273; F at a position corresponding to position 274; D at a position corresponding to position 276; H at a position corresponding to position 276; M at a position corresponding to position 276; R at a position corresponding 20 to position 276; S at a position corresponding to position 276; Y at a position corresponding to position 276; A at a position corresponding to position 277; E at a position corresponding to position 277; H at a position corresponding to position 277; K at a position corresponding to position 25 277; M at a position corresponding to position 277; N at a position corresponding to position 277; Q at a position corresponding to position 277; R at a position corresponding to position 277; S at a position corresponding to position 277; T at a position corresponding to position 277; E at a 30 position corresponding to position 278; F at a position corresponding to position 278; G at a position corresponding to position 278; H at a position corresponding to position 278; K at a position corresponding to position 278; N at a position corresponding to position 278; R at a position 35 corresponding to position 278; S at a position corresponding to position 278; T at a position corresponding to position 278; Y at a position corresponding to position 278; H at a position corresponding to position 279; M at a position corresponding to position 282; S at a position corresponding 40 position corresponding to position 325; K at a position to position 283; H at a position corresponding to position 285; T at a position corresponding to position 287; S at a position corresponding to position 289; S at a position corresponding to position 291; V at a position corresponding to position 291; C at a position corresponding to position 45 292; F at a position corresponding to position 292; H at a position corresponding to position 292; K at a position corresponding to position 292; R at a position corresponding to position 292; V at a position corresponding to position 292; A at a position corresponding to position 293; C at a 50 position corresponding to position 293; D at a position corresponding to position 293; F at a position corresponding to position 293; K at a position corresponding to position 293; M at a position corresponding to position 293; P at a position corresponding to position 293; Q at a position 55 corresponding to position 293; V at a position corresponding to position 293; Y at a position corresponding to position 293; G at a position corresponding to position 298; E at a position corresponding to position 305; G at a position corresponding to position 307; D at a position corresponding 60 at a position corresponding to position 356; E at a position to position 308; G at a position corresponding to position 308; K at a position corresponding to position 308; N at a position corresponding to position 308; R at a position corresponding to position 308; E at a position corresponding to position 309; G at a position corresponding to position 65 309; H at a position corresponding to position 309; L at a position corresponding to position 309; M at a position

26

corresponding to position 309; N at a position corresponding to position 309; Q at a position corresponding to position 309; R at a position corresponding to position 309; S at a position corresponding to position 309; T at a position corresponding to position 309; V at a position corresponding to position 309; A at a position corresponding to position 310; G at a position corresponding to position 310; Q at a position corresponding to position 310; S at a position corresponding to position 310; A at a position corresponding to position 313; G at a position corresponding to position 313; H at a position corresponding to position 313; K at a position corresponding to position 313; P at a position corresponding to position 313; R at a position corresponding to position 313; T at a position corresponding to position 313; Y at a position corresponding to position 313; with S at a position corresponding to position 314; Y at a position corresponding to position 314; A at a position corresponding to position 315; H at a position corresponding to position 315; Y at a position corresponding to position 315; A at a position corresponding to position 317; I at a position corresponding to position 317; K at a position corresponding to position 317; N at a position corresponding to position 317; Q at a position corresponding to position 317; R at a position corresponding to position 317; S at a position corresponding to position 317; T at a position corresponding to position 317; W at a position corresponding to position 317; D at a position corresponding to position 318; H at a position corresponding to position 318; K at a position corresponding to position 318; M at a position corresponding to position 318; R at a position corresponding to position 318; H at a position corresponding to position 320; K at a position corresponding to position 320; R at a position corresponding to position 320; R at a position corresponding to position 321; S at a position corresponding to position 321; N at a position corresponding to position 324; R at a position corresponding to position 324; A at a position corresponding to position 325; D at a position corresponding to position 325; E at a position corresponding to position 325; G at a position corresponding to position 325; H at a corresponding to position 325; M at a position corresponding to position 325; N at a position corresponding to position 325; Q at a position corresponding to position 325; S at a position corresponding to position 325; V at a position corresponding to position 325; L at a position corresponding to position 326; V at a position corresponding to position 326; C at a position corresponding to position 328; G at a position corresponding to position 328; I at a position corresponding to position 328; K at a position corresponding to position 328; L at a position corresponding to position 328; S at a position corresponding to position 328; Y at a position corresponding to position 328; S at a position corresponding to position 335; A at a position corresponding to position 347; G at a position corresponding to position 347; S at a position corresponding to position 347; M at a position corresponding to position 349; R at a position corresponding to position 349; S at a position corresponding to position 351; V at a position corresponding to position 353; with H at a position corresponding to position 356; S corresponding to position 359; H at a position corresponding to position 359; T at a position corresponding to position 359; A at a position corresponding to position 367; G at a position corresponding to position 367; K at a position corresponding to position 367; S at a position corresponding to position 367; A at a position corresponding to position 368; E at a position corresponding to position 368; K at a position corresponding to position 368; L at a position corresponding to amino acid position 368; M at a position corresponding to amino acid position 368; R at a position corresponding to position 368; T at a position corresponding to amino acid position 368; H at a position corresponding to position 369; R at a position corresponding to position 369; F at a position corresponding to position 371; H at a position corresponding to position 371; K at a position corresponding to position 371; L at a position corresponding to position 371; R at a position corresponding to position 371; S at a 10 position corresponding to position 371; M at a position corresponding to position 373; H at a position corresponding to position 374; P at a position corresponding to position 374; A at a position corresponding to position 375; G at a position corresponding to position 375; K at a position 15 corresponding to position 375; R at a position corresponding to position 375; D at a position corresponding to position 376; E at a position corresponding to position 376; Q at a position corresponding to position 376; R at a position corresponding to position 376; T at a position corresponding 20 to position 376; V at a position corresponding to position 376; Y at a position corresponding to position 376; D at a position corresponding to position 377; E at a position corresponding to position 377; H at a position corresponding to position 377; K at a position corresponding to position 25 377; P at a position corresponding to position 377; R at a position corresponding to position 377; S at a position corresponding to position 377; T at a position corresponding to position 377; W at a position corresponding to position 380; Y at a position corresponding to position 380; S at a 30 position corresponding to position 381; I at a position corresponding to position 383; K at a position corresponding to position 383; L at a position corresponding to position 383; S at a position corresponding to position 383; A at a position corresponding to position 385; Q at a position 35 corresponding to position 385; V at a position corresponding to position 385; A at a position corresponding to position 389; G at a position corresponding to position 389; L at a position corresponding to position 389; K at a position corresponding to position 389; Q at a position corresponding 40 position corresponding to position 433; V at a position to position 389; S at a position corresponding to position 389; A at a position corresponding to position 392; F at a position corresponding to position 392; M at a position corresponding to position 392; Q at a position corresponding to position 392; R at a position corresponding to position 45 392; V at a position corresponding to position 392; F at a position corresponding to position 393; M at a position corresponding to position 393; A at a position corresponding to position 395; H at a position corresponding to position 395; R at a position corresponding to position 395; A at a 50 position corresponding to position 396; H at a position corresponding to position 396; O at a position corresponding to position 396; S at a position corresponding to position 396; K at a position corresponding to position 399; M at a position corresponding to position 399; T at a position 55 corresponding to position 399; V at a position corresponding to position 399; W at a position corresponding to position 399; A at a position corresponding to position 401; E at a position corresponding to position 401; A at a position corresponding to position 404; G at a position corresponding 60 to position 405; F at a position corresponding to position 406; N at a position corresponding to position 406; A at a position corresponding to position 407; D at a position corresponding to position 407; E at a position corresponding to position 407; F at a position corresponding to position 65 407; H at a position corresponding to position 407; Q at a position corresponding to position 407; P at a position

28

corresponding to position 407; A at a position corresponding to position 409; Q at a position corresponding to position 409; T at a position corresponding to position 410; Q at a position corresponding to position 412; R at a position corresponding to position 412; V at a position corresponding to position 412; L at a position corresponding to position 416; E at a position corresponding to position 418; L at a position corresponding to position 418; P at a position corresponding to position 418; R at a position corresponding to position 418; V at a position corresponding to position 418; F at a position corresponding to position 419; H at a position corresponding to position 419; I at a position corresponding to position 419; K at a position corresponding to position 419; R at a position corresponding to position 419; S at a position corresponding to position 419; Y at a position corresponding to position 419; A at a position corresponding to position 421; H at a position corresponding to position 421; K at a position corresponding to position 421; N at a position corresponding to position 421; Q at a position corresponding to position 421; R at a position corresponding to position 421; S at a position corresponding to position 421; G at a position corresponding to position 425; K at a position corresponding to position 425; Q at a position corresponding to position 427; T at a position corresponding to position 427; L at a position corresponding to position 428; A at a position corresponding to position 431; G at a position corresponding to position 431; E at a position corresponding to position 431; H at a position corresponding to position 431; K at a position corresponding to position 431; L at a position corresponding to position 431; N at a position corresponding to position 431; Q at a position corresponding to position 431; R at a position corresponding to position 431; S at a position corresponding to position 431; V at a position corresponding to position 431; A at a position corresponding to position 433; H at a position corresponding to position 433; I at a position corresponding to position 433; K at a position corresponding to position 433; L at a position corresponding to position 433; R at a position corresponding to position 433; T at a corresponding to position 433; W at a position corresponding to position 433; K at a position corresponding to position 436; I at a position corresponding to position 437; M at a position corresponding to position 437; A at a position corresponding to position 438; D at a position corresponding to position 438; E at a position corresponding to position 438; L at a position corresponding to position 438; N at a position corresponding to position 438; T at a position corresponding to position 438; A at a position corresponding to position 439; C at a position corresponding to position 439; K at a position corresponding to position 439; P at a position corresponding to position 439; O at a position corresponding to position 439; T at a position corresponding to position 439; V at a position corresponding to position 439; D at a position corresponding to position 440; H at a position corresponding to position 440; M at a position corresponding to position 440; P at a position corresponding to position 440; R at a position corresponding to position 440; S at a position corresponding to position 440; A at a position corresponding to position 441; F at a position corresponding to position 441; C at a position corresponding to position 442; G at a position corresponding to position 442; R at a position corresponding to position 442; A at a position corresponding to position 443; E at a position corresponding to position 443; F at a position corresponding to position 443; G at a position corresponding to position 443; M at a position corresponding to position 443; N at a position corresponding to position 443; E at a position corresponding to position 444; H at a position corresponding to position 444; V at a position corresponding to position 444; H at a position corresponding to position 445; M at a position corresponding to position 445; N at a position 5 corresponding to position 445; P at a position corresponding to position 445; Q at a position corresponding to position 445; S at a position corresponding to position 445; T at a position corresponding to position 445; V at a position corresponding to position 445; W at a position correspond-10 ing to position 445; A at a position corresponding to position 446; M at a position corresponding to position 446; W at a position corresponding to position 446; D at a position corresponding to position 447; E at a position corresponding to position 447; G at a position corresponding to position 15 447; I at a position corresponding to position 447; N at a position corresponding to position 447; P at a position corresponding to position 447; Q at a position corresponding to position 447; T at a position corresponding to position 447, and/or replacement with V at a position corresponding 20 to position 447, each with reference to amino acid positions set forth in SEQ ID NO:3. Among these modified PH20 polypeptides are those that exhibit at least 40% of the activity of the PH20 that does not contain the particular amino acid replacement. Activity can vary between, for 25 example, 40% to 5000%, 40% to 2000%, 40% to 1000%, 40% to 500%, 40% to 100%, 80% to 2000%, 80% to 600%, 80% to 200%, 80% to 300%, of the hyaluronidase activity of the PH20 polypeptide not containing the amino acid replacement. Such activity includes at least 50%, 60%, 70%, 30 80%, 90%, 100%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, 2000%, 3000% or more of the hyaluronidase activity of the PH20 polypeptide not containing the amino acid replacement, where, as in all instances 35 herein, the activities are compared under the same conditions.

In particular, provided are modified PH20 polypeptides that contain at least one amino acid replacement in a PH20 polypeptide set forth in SEQ ID NO:7, a C-terminally 40 that contain amino acid replacement(s) in a PH20 polypeptruncated fragment thereof, or in a PH20 polypeptide that has a sequence of amino acids that is at least 91% identical to the sequence of amino acids set forth in SEQ ID NO:7 or a corresponding truncated fragment, where: the modified PH20 polypeptides exhibit less than 20% of the hyaluroni- 45 dase activity of the PH20 polypeptide not containing the amino acid replacement, where activities are compared under the same conditions; the amino acid replacement(s) is at an amino acid position corresponding to a position selected from among 2,3,4,5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 50 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 27, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 94, 95, 96, 98, 99, 100, 101, 102, 55 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 143, 144, 145, 149, 150, 152, 153, 154, 155, 156, 157, 158, 159, 161, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 60 173, 174, 175, 176, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 197, 198, 199, 200, 201, 202, 203, 204, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 65 236, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 260, 261,

30

262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 278, 279, 280, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 331, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 408, 410, 411, 412, 413, 414, 415, 416, 417, 419, 420, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 434, 437, 438, 439, 440, 441, 442, 443, 444, or 447 with reference to amino acid positions set forth

- in SEQ ID NO:3 or 7; corresponding amino acid positions are identified by alignment of the PH20 polypeptide with the polypeptide set forth in SEQ ID NO:3; and provided that:
 - (i) if the modified PH20 polypeptide contains an amino acid replacement at a position corresponding to position 200, 333, 358 or 393 the replacement is not replacement with an Alanine (A).
 - (ii) if the modified PH20 polypeptide contains an amino acid replacement at a position corresponding to position 111 or 249 the replacement is not replacement with an asparagine (N);
 - (iii) if the modified PH20 polypeptide contains an amino acid replacement at a position corresponding to position 113 the replacement is not replacement with a glutamine (Q);
 - (iv) if the modified PH20 polypeptide contains an amino acid replacement at a position corresponding to position 176 the replacement is not replacement with a glycine (G); and
 - (v) if the modified PH20 polypeptide contains an amino acid replacement at a position corresponding to position 252 the replacement is not replacement with a threonine (T).

Exemplary of such modified PH20 polypeptides are any tide that has the sequence of amino acids set forth in any of SEQ ID NOs: 3, 7, 32-66, 69, or 72, or in a sequence of amino acids that exhibits at least 91% sequence identity to any of SEQ ID NOs: 3, 7, 32-66, 69, or 72. For example, the modified PH20 polypeptide contains amino acid replacement(s) in SEQ ID NOs: 3, 7, 32-66, 69, or 72, which are polypeptides that are a C-terminally truncated fragment of SEQ ID NO:7, or a PH20 polypeptide that has a sequence of amino acids that is at least 91% identical to the sequence of amino acids set forth in SEQ ID NO:7. In examples of such modified PH20 polypeptides provided herein, the modified PH20 polypeptides can exhibit similar or the same activity as the PH20 without the modification, or can exhibit increased activity or activity that is less than 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05% or less of the hyaluronidase activity of the PH20 polypeptide not containing the amino acid replacement. Exemplary of such modified PH20 polypeptides are any set forth in Table 5.

Among any and all of the modified PH20 polypeptides provided herein and above, the modified PH20 polypeptide is one that does not consist of the sequence of amino acids set forth in any of SEQ ID NOs: 3, 6-66, 69-72, 856-861, 869 or 870. In particular, among any of the modified PH20 polypeptides provided herein above or elsewhere herein are any that contain an amino acid replacement(s) in a PH20 polypeptide having the sequence of amino acids set forth any of SEQ ID NO: 3, 7, 69 or 72 provided that: (i) where the modified PH20 polypeptide includes only a single amino acid replacement the replacement does not corresponds to amino acid replacements V12A, N47A, DI IN, E113Q, N131A, R176G, N200A, N219A, E249Q, R252T, N333A or 5 N358A, with reference to amino acid positions set forth in SEQ ID NO:3; (ii) where the modified PH20 polypeptide includes only two amino acid replacements the replacements do not correspond to amino acid replacements P13A/ L464W, N47A/N131A, N47A/N219A, N131A/N219A or 10 N333A/N358A with reference to positions set forth in SEQ ID NO:3; and (iii) where the modified PH20 polypeptide includes only three amino acid replacements the replacements do not correspond to amino acid replacements N47A/ N131A/N219A, with reference to amino acid positions set 15 forth in SEQ ID NO:3.

Any of the above modified PH20 polypeptides and any provided herein and described above and below can contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 20 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, or more of the amino acid replacements. The modified PH20 polypeptides can include 25 a signal sequence, including the native sequence or a heterologous sequence or a modified sequence, and also include a mature PH20 polypeptide that lacks the signal sequence.

Among any of the modified PH20 polypeptides provided herein above or described below are modified PH20 polypeptides that contain or have the sequence of amino acids set forth in any of SEQ ID NOs: 73-855 or a sequence of amino acids that exhibits at least 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to a sequence of amino acids set forth in any of SEQ ID NOs: 73-855 and that contains at least one amino acid replacement, such as any described above or elsewhere herein, with reference to positions compared to the sequence of amino acids set forth in SEQ ID NO:3. In any of the examples of the modified PH20 polypeptide service of amino acids set forth in SEQ ID NO:3. In any of the examples of the modified PH20 polypeptide service herein, the sequence of amino acids set forth in any of SEQ ID NOs: 8-31, 69-72, 856-861, 869 or 870.

The modified PH20 polypeptides provided herein can be substantially purified or isolated, can exhibit catalytic activ- 45 ity at neutral pH, can be secreted upon expression from cells and are soluble in the supernatant, and/or can include modified amino acids, such as a modification selected from among glycosylation, sialation, albumination, farnysylation, carboxylation, hydroxylation, conjugation to a polymer, 50 such as PEGylation or conjugation to dextran, conjugation to another moiety, such as a multimerization domain, toxin, detectable label or drug, and phosphorylation. The modified PH20 polypeptide can be glycosylated, such as by containing at least an N-acetylglucosamine moiety linked to each of 55 at least three asparagine (N) residues, where, for example, the three asparagine residues correspond to amino acid residues 200, 333 and 358 of SEQ ID NO:3. Multimerization domains include Fc domains.

Also provided are nucleic acid molecules that encode any 60 of the modified PH20 polypeptides provided herein. Vectors, eukaryotic and prokaryotic, that contain the nucleic acid molecules are provided. The vectors include expression vectors and include mammalian vectors, including viral vectors. Viral vectors include adenovirus vectors, retrovirus 65 vectors, vaccinia virus vectors, herpes simplex virus and cytomegalovirus vectors, and other such viral vectors. Of

interest are oncolytic vectors that accumulate in or are targeted to tumors. Also provided are cells that contain the nucleic acid molecules and cells that contain the vectors. The cells can be prokaryotic or eukaryotic, particularly mammalian cells, such as Chinese Hamster Ovary (CHO) cells.

Also provided herein is a modified PH20 polypeptide that is produced by any of the provided cells. Thus, provided herein are methods of producing a modified PH20 polypeptide by culturing any of the cells provided herein under conditions whereby an encoded modified PH20 polypeptide is produced and secreted by the cell, and recovering the expressed polypeptide. Also provided herein is a method of producing a modified PH20 polypeptide by introducing any of the nucleic acids provided herein or any of the vectors provided herein into a cell capable of incorporating N-linked sugar moieties into the polypeptide, culturing the cell under conditions whereby an encoded modified PH20 polypeptide is produced and secreted by the cell, and recovering the expressed polypeptide. In such examples, the nucleic acid is operably linked to a promoter. The cultured cell can be a eukaryotic cell, such as a mammalian cell, for example, a Chinese hamster ovary (CHO) cell.

Also provided are pharmaceutical compositions that contain any of the modified PH20 polypeptides provided herein or any of the nucleic acids or vectors provided herein. The compositions can be formulated with other agents and/or with other components, such as preservatives. The compositions can be formulated so that the components, particularly the PH20 and any other active agent, remain active or are stable under preselected conditions. In addition, as described herein, the PH20 polypeptides are modified so that they exhibit increased stability under various conditions. For example, provided are compositions in which the modified PH20 polypeptide is stable (i.e., retains activity as described herein) at a temperature from or from about 2° C. to 8° C., inclusive, for at least 1 month or is stable at a temperature from or from about 30° C. to 42° C., inclusive, for at least 3 days. Provided are compositions in which the modified ture from or from about 2° C. to 8° C., inclusive, for at least 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 25 months, 26 months, 27 months, 28 months, 29 months or 30 months. Also provided are compositions in which the modified PH20 polypeptide in the composition is stable at a temperature from or from about 30° C. to 42° C., inclusive, for at least 3 days, at least 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 35 days, 40 days, 45 days, 50 days, 60 days or more. The pharmaceutical compositions can contain a pharmaceutically acceptable excipient.

The conditions, formulations, components, and modified PH20 polypeptide are chosen to achieve a desired stability. The pharmaceutical compositions can be formulated for direct administration or can require dilution. They can be formulated for multiple or single dosage administration. Exemplary compositions include concentrations of modified PH20 between or about between 0.1 μ g/mL to 100 μ g/mL, 1 μ g/mL to 50 μ g/mL or 1 μ g/mL to 20 μ g/mL, or 10 U/mL to 5000 U/mL, 50 U/mL to 4000 U/mL, 100 U/mL to 2000 U/mL, 300 U/mL to 2000 U/mL, 600 U/mL to 2000 U/mL,

10

or 100 U/mL to 1000 U/mL. Exemplary salts include NaCl at a concentration, for example, of less than or about or 200 mM, 180 mM, 150 mM, 140 mM, 130 mM, 120 mM, 110 mM, 100 mM, 90 mM, 80 mM, 70 mM, 60 mM, 50 mM, 40 mM, 30 mM, 25 mM, 20 mM, 15 mM, 10 mM, 5 mM or 5 less, or between or about between 0.1 mM to 200 mM, 0.1 mM to 100 mM, 120 mM to 200 mM, 10 mM to 50 mM, 10 mM to 90 mM, 80 mM to 200 mM, 80 mM to 140 mM, 50 mM to 100 mM, 80 mM to 100 mM, 50 mM to 80 mM, 100 mM to 140 mM or 120 mM to 140 mM.

The pharmaceutical compositions can contain an antimicrobially effective amount of a preservative or mixture of preservatives, such as one, two, three, four or more of a phenolic preservative(s), a non-phenolic preservative(s) or a phenolic preservative(s) and a non-phenolic preservative(s), 15 such as, but not limited to, phenol, m-cresol, methylparaben, benzyl alcohol, thimerosal, benzalkonium chloride, 4-chloro-1-butanol, chlorhexidine dihydrochloride, chlorhexidine digluconate, L-phenylalanine, EDTA, bronopol, phenylmercuric acetate, glycerol, imidurea, chlorhexidine, 20 sodium dehydroacetate, o-cresol, p-cresol, chlorocresol, cetrimide, benzethonium chloride, ethyl paraben, propylparaben, butylparaben and any combinations thereof. Phenols include, for example, phenol, metacresol (m-cresol), benzyl alcohol, and parabens, such as methylparaben or propylpa- 25 raben. Anti-microbial effective concentrations of one or more preservative agents (as a percentage (%) of mass concentration (w/v)) can be between 0.05% to 0.6%, 0.1% to 0.4%, 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 0.3% to 0.4% inclusive. 30 Examples thereof are pharmaceutical compositions where the preservatives are phenol, m-cresol or phenol and m-cresol and the amount as a % of mass concentration (w/v) in the formulation is between or about between 0.10% to 0.25% phenol and between or about between 0.05% to 0.2% 35 m-cresol, is between or about between 0.10% to 0.2% phenol and between or about between 0.6% to 01.8% m-cresol, between or about between 0.1% to 0.15% phenol and 0.8% to 0.15% m-cresol, is between or about between 0.10% to 0.15% phenol and between or about between 0.06 40 to 0.09% m-cresol or is between or about between 0.12% to 0.18% phenol and between or about between 0.14 to 0.22% m-cresol.

The pharmaceutical compositions can contain a further therapeutically active agent. The active agent can be formu- 45 lated in the composition or provided as a combination with the PH20-containing composition, but in a separate composition for administration separately, sequentially, intermittently, simultaneously or together. Therapeutically active agents include, for example, an agent selected from among 50 a chemotherapeutic agent, an analgesic agent, an antiinflammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonacidal agent, an anti-Parkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti-depressant agent, and antiarthritics agent, an anti-fungal agent, an 55 antihypertensive agent, an antipyretic agent, an anti-parasite agent, an antihistamine agent, an alpha-adrenergic agonist agent, an alpha blocker agent, an anesthetic agent, a bronchial dilator agent, a biocide agent, a bactericide agent, a bacteriostat agent, a beta adrenergic blocker agent, a calcium 60 channel blocker agent, a cardiovascular drug agent, a contraceptive agent, a decongestant agent, a diuretic agent, a depressant agent, a diagnostic agent, a electrolyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an oph- 65 thalmic agent, a parasympathomimetic agent, a psychic energizer agent, a sedative agent, a sympathomimetic agent,

34

a tranquilizer agent, an urinary agent, a vaginal agent, a viricide agent, a vitamin agent, a non-steroidal anti-inflammatory agent, an angiotensin converting enzyme inhibitor agent, a polypeptide, a protein, a nucleic acid, a drug, an organic molecule and a sleep inducer. Exemplary of such agents are antibodies, particularly monoclonal antibodies, an Immune Globulin preparation, a bisphosphonate, a cytokine, a chemotherapeutic agent, a coagulation factor and an insulin. Insulins include, for example, basal insulins and fastacting insulin, such as regular insulin, particularly recombinant human insulin, and insulin analogs, such as insulin lispro, insulin aspart or insulin glulisine. Particular fastacting insulins are those with an A chain having a sequence of amino acids set forth in SEQ ID NO:862 and a B chain having a sequence of amino acids set forth in SEQ ID NO:863 or an insulin with an A chain with a sequence of amino acids set forth as amino acid residue positions 88-108 of SEQ ID NO:864 and a B chain with a sequence of amino acids set forth as amino acid residue positions 25-54 of SEQ ID NO:864 or an insulin analog that is selected from among an insulin having an A chain with a sequence of amino acids set forth in SEQ ID NO:862 and a B chain having a sequence of amino acids set forth in any of SEQ NOs:865-867. The amount of fast-acting insulin in the compositions can be empirically determined, but typically can be 10 U/mL to 1000 U/mL, 50 U/mL to 500 U/mL, 100 U/mL to 1000 U/mL or 500 U/mL to 1000 U/mL, inclusive.

In particular examples, provided herein is a pharmaceutical composition containing any of the modified PH20 polypeptides provided herein that exhibit increased stability to a phenolic preservative and an insulin, such as a fastacting insulin. The modified PH20 polypeptides and insulin can be provided in therapeutically effective amounts. For example, provided herein is a pharmaceutical composition that contains any of the modified PH20 polypeptides provided herein that exhibits increased stability to a phenolic preservative in an amount that is from or from about 100 U/mL to 1000 U/mL and a fast-acting insulin in an amount that is from or from about 10 U/mL to 1000 U/mL. For example, the fast-acting insulin can be an insulin analog, such as insulin lispro, insulin aspart or insulin glulisine or other analog. Any of such pharmaceutical compositions can be formulated at a pH that is from or from about 7.0 to 7.6. Any of such pharmaceutical compositions also can be formulated to contain salt, such as NaCl, at a concentration that is from or from about 0.1 mM to 200 mM and/or an anti-microbial effective amount of at least one preservative where the composition generally contains at least one phenolic preservative. The anti-microbial effective amount is a total amount of one or more preservative agents as a percentage (%) of mass concentration (w/v) that is or is between 0.05% and 0.6%. The phenolic preservative(s) can be a phenol, metacresol (m-cresol), benzyl alcohol, or a paraben. In any of the above examples of a pharmaceutical composition, the composition also can contain a surfactant, such as a polypropylene glycol, polyethylene glycol, glycerin, sorbitol, poloxamer or polysorbate, in an amount as a % of mass concentration (w/v) in the formulation that is at least or at least about 0.001%; a buffering agent that is a non-metal binding agent or is a metal binding agent, such as Tris, histidine, phosphate or citrate, wherein the concentration of the buffering agent is between or between about 1 mM to 100 mM; glycerin in a concentration less than 60 mM; an antioxidant, such as cysteine, tryptophan or methionine, at a concentration between or from about between 2 mM to 50 mM, inclusive; and/or zinc at a concentration of between or about between 0.001 to 0.1 mg per 100 units of insulin (mg/100 U). Also provided herein are closed loop systems, insulin pumps including continuous subcutaneous infusion insulin (CSII) pumps and insulin pens that contain any of the pharmaceutical compositions. The pharmaceutical compositions can be used in methods or uses for treating 5 diabetes, such as type 1 diabetes mellitus, type 2 diabetes mellitus or gestational diabetes.

Other therapeutic agents in any of the pharmaceutical compositions provided herein include, but are not limited to Adalimumabs, Agalsidase Betas, Alefacepts, Ampicillins, 10 Anakinras, Antipoliomyelitic Vaccines, Anti-Thymocytes, Azithromycins, Becaplermins, Caspofungins, Cefazolins, Cefepimes, Cefotetans, Ceftazidimes, Ceftriaxones, Cetuximabs, Cilastatins, Clavulanic Acids, Clindamycins, Darbepoetin Alfas, Daclizumabs, Diphtheria, Diphtheria antitox- 15 ins, Diphtheria Toxoids, Efalizumabs, Epinephrines, Erythropoietin Alphas, Etanercepts, Filgrastims, Fluconazoles, Follicle-Stimulating Hormones, Follitropin Alphas, Follitropin Betas, Fosphenytoins, Gadodiamides, Gadopentetates, Gatifloxacins, Glatiramers, GM-CSF's, Goserelins, 20 Goserelin acetates, Granisetrons, Haemophilus Influenza B's, Haloperidols, Hepatitis vaccines, Hepatitis A Vaccines, Hepatitis B Vaccines, Ibritumomab Tiuxetans, Ibritumomabs, Tiuxetans, Immunoglobulins, Hemophilus influenza vaccines, Influenza Virus Vaccines, Infliximabs, Insulin lis- 25 pro, 75% neutral protamine lispro (NPL)/25% insulin lispro, 50% neutral protamine Hagedorn (NPH)/50% regular insulin, 70% NPH/30% regular insulin; Regular insulin, NPH insulin, Ultra insulin, Ultralente insulin, and Insulin Glargines, Interferons, Interferon alpha, Interferon Betas, 30 Interferon Gammas, Interferon alpha-2a, Interferon alpha 2-b, Interferon Alphacon, Interferon alpha-n, Interferon Betas, Interferon Beta-1a's, Interferon Gammas, Interferon alpha-con, Iodixanols, Iohexols, Iopamidols, Ioversols, Ketorolacs, Laronidases, Levofloxacins, Lidocaines, Lin- 35 ezolids, Lorazepams, Measles Vaccines, Measles virus, Mumps viruses, Measles-Mumps-Rubella Virus Vaccines, Rubella vaccines, Medroxyprogesterones, Meropenems, Methylprednisolones, Midazolams, Morphines, Octreotides, Omalizumabs, Ondansetrons, Palivizumabs, Pantoprazoles, 40 Pegaspargases, Pegfilgrastims, Peg-Interferon Alpha-2a's, Peg-Interferon Alpha-2b's, Pegvisomants, Pertussis vaccines, Piperacillins, Pneumococcal Vaccines and Pneumococcal Conjugate Vaccines, Promethazines, Reteplases, Somatropins, Sulbactams, Sumatriptans, Tazobactams, 45 Tenecteplases, Tetanus Purified Toxoids, Ticarcillins, Tositumomabs, Triamcinolones, Triamcinolone Acetonides, Triamcinolone hexacetonides, Vancomycins, Varicella Zoster immunoglobulins, Varicella vaccines, other vaccines, Alemtuzumabs, Alitretinoins, Allopurinols, Altretamines, 50 Amifostines, Anastrozoles, Arsenics, Arsenic Trioxides, Asparaginases, Bacillus Calmette-Guerin (BCG) vaccines, BCG Live, Bexarotenes, Bleomycins, Busulfans, Busulfan intravenous, Busulfan orals, Calusterones, Capecitabines, Carboplatins, Carmustines, Carmustines with Polifeprosans, 55 Celecoxibs, Chlorambucils, Cisplatins, Cladribines, Cyclophosphamides, Cytarabines, Cytarabine liposomals, Dacarbazines, Dactinomycins, Daunorubicin liposomals, Daunorubicins, Daunomycins, Denileukin Diftitoxes. Dexrazoxanes, Docetaxels, Doxorubicins, Doxorubicin 60 liposomals, Dromostanolone propionates, Elliott's B Solutions, Epirubicins, Epoetin alfas, Estramustines, Etoposides, Etoposide phosphates, Etoposide VP-16s, Exemestanes, Floxuridines, Fludarabines, Fluorouracils, 5-Fluorouracils, Fulvestrants, Gemcitabines, Gemtuzumabs, Ozogamicins, 65 Gemtuzumab ozogamicins, Hydroxyureas, Idarubicins, Ifosfamides, Imatinib mesylates, Irinotecans, Letrozoles,

36

Leucovorins, Levamisoles, Lomustines, CCNUs, Mechlorethamines, Nitrogen mustards, Megestrols, Megestrol acetates, Melphalans, L-PAMs, Mercaptopurines, 6-Mercaptopurines, Mesnas, Methotrexates, Methoxsalens, Mitomycins, Mitomycin C's, Mitotanes, Mitoxantrones, Nandrolones, Nandrolone Phenpropionates, Nofetumomabs, Oprelvekins, Oxaliplatins, Paclitaxels, Pamidronates, Pegademases, Pentostatins, Pipobromans, Plicamycins, Mithramycins, Porfimers, Porfimer sodiums, Procarbazines, Quinacrines, Rasburicases, Rituximabs, Sargramostims, Streptozocins, Tales, Tamoxifens, Temozolomides, Teniposides, Testolactones, Thioguanines, 6-Thioguanines, Triethylenethiophosphoramides (Thiotepas), Topotecans, Toremifenes, Trastuzumabs, Tretinoins, Uracil Mustards, Valrubicins, Vinblastines, Vincristines, Vinorelbines, Zoledronates, Acivicins, Aclarubicins, Acodazoles, Acronines, Adozelesins, Aldesleukins, Retinoic Acids, Alitretinoins, 9-Cis-Retinoic Acids, Alvocidibs, Ambazones, Ambomycins, Ametantrones, Aminoglutethimides, Amsacrines, Anaxirones, Ancitabines, Anthramycins, Apaziquones, Argimesnas, Asperlins, Atrimustines, Azacitidines, Azetepas, Azotomycins, Banoxantrones, Batabulins, Batimastats, Benaxibines, Bendamustines, Benzodepas, Bicalutamides, Bietaserpines, Biricodars, Bisantrenes, Bisnafide Dimesylates, Bizelesins, Bortezomibs, Brequinars, Bropirimines, Budotitanes, Cactinomycins, Canertinibs, Caracemides, Carbetimers, Carboquones, Carmofurs, Carubicins, Carzelesins, Cedefingols, Cemadotins, Chlorambucils, Cioteronels, Cirolemycins, Clanfenurs, Clofarabines, Crisnatols, Decitabines, Dexniguldipines, Dexormaplatins, Dezaguanines, Diaziquones, Dibrospidiums, Dienogests, Dinalins, Disermolides, Dofequidars, Doxifluridines, Droloxifenes, Duazomycins, Ecomustines, Edatrexates, Edotecarins, Eflornithines, Elacridars, Elinafides, Elsamitrucins, Emitefurs, Enloplatins, Enpromates, Enzastaurins, Epipropidines, Eptaloprosts, Erbulozoles, Esorubicins, Etanidazoles, Etoglucids, Etoprines, Exisulinds, Fadrozoles, Fazarabines, Fenretinides, Fluoxymesterones, Flurocitabines, Fosquidones, Fostriecins, Fotretamines, Galarubicins, Galocitabines, Geroquinols, Gimatecans, Gimeracils, Gloxazones, Glufosfamides, Ilmofosines, Ilomastats, Imexons, Improsulfans, Indisulams, Inproquones, Interleukins, Interleukin-2s, recombinant Interleukins, Intoplicines, Iobenguanes, Iproplatins, Irsogladines, Ixabepilones, Ketotrexates, L-Alanosines, Lanreotides, Lapatinibs, Ledoxantrones, Leuprolides, Leuprorelins, Lexacalcitols, Liarozoles, Lobaplatins, Lometrexols, Lonafarnibs, Losoxantrones, Lurtotecans, Mafosfamides, Mannosulfans, Marimastats, Masoprocols, Maytansines, Mechlorethamines, Melengestrols, Melphalans, Menogarils, Mepitiostanes, Metesinds, Metomidates, Metoprines, Meturedepas, Miboplatins, Miproxifenes, Misonidazoles, Mitindomides, Mitocarcins, Mitocromins, Mitoflaxones, Mitogillins, Mitoguazones, Mitomalcins, Mitonafides, Mitoquidones, Mitospers, Mitozolomides, Mivobulins, Mizoribines, Mofarotenes, Mopidamols, Mubritinibs, Mycophenolic Acids, Nedaplatins, Neizarabines, Nemorubicins, Nitracrines, Nocodazoles, Nogalamycins, Nolatrexeds, Nortopixantrones, Ormaplatins, Ortataxels, Oteracils, Oxisurans, Oxophenarsines, Patupilones, Peldesines, Peliomycins, Pelitrexols, Pemetrexeds, Pentamustines, Peplomycins, Perfosfamides, Perifosines, Picoplatins, Pinafides, Piposulfans, Pirfenidones, Piroxantrones, Pixantrones, Plevitrexeds, Plomestanes, Porfiromycins, Prednimustines, Propamidines, Prospidiums, Pumitepas, Puromycins, Pyrazofurins, Ranimustines, Riboprines, Ritrosulfans, Rogletimides, Roquin-Rufocromomycins, Sabarubicins, imexs. Safingols. Satraplatins, Sebriplatins, Semustines, Simtrazenes, Sizo-

firans, Sobuzoxanes, Sorafenibs, Sparfosates, Sparfosic Acids, Sparsomycins, Spirogermaniums, Spiromustines, Spiroplatins, Squalamines, Streptonigrins, Streptovarycins, Sufosfamides, Sulofenurs, Tacedinalines, Talisomycins, Tallimustines, Tariquidars, Tauromustines, Tecogalans, Tega-5 furs, Teloxantrones, Temoporfins, Teroxirones, Thiamiprines, Tiamiprines, Tiazofurins, Tilomisoles, Tilorones, Timcodars, Timonacics, Tirapazamines, Topixantrones, Trabectedins, Ecteinascidin 743, Trestolones, Triciribines, Trilostanes, Trimetrexates, Triplatin Tetranitrates, Triptore-10 lins, Trofosfamides, Tubulozoles, Ubenimexs, Uredepas, Valspodars, Vapreotides, Verteporfins, Vinblastines, Vindesines, Vinepidines, Vinflunines, Vinformides, Vinglycinates, Vinleucinols, Vinleurosines, Vinrosidines, Vintriptols, Vinzolidines, Vorozoles, Xanthomycin A's, Guamecyclines, 15 Zeniplatins, Zilascorbs [2-H], Zinostatins, Zorubicins, Zosuquidars, Acetazolamides, Acyclovirs, Adipiodones, Alatrofloxacins, Alfentanils, Allergenic extracts, Alpha 1-proteinase inhibitors, Alprostadils, Amikacins, Amino acids, Aminocaproic acids, Aminophyllines, Amitriptylines, Amo- 20 barbitals, Amrinones, Analgesics, Anti-poliomyelitic vaccines, Anti-rabic serums, Anti-tetanus immunoglobulins, tetanus vaccines, Antithrombin Ills, Antivenom serums, Argatrobans, Arginines, Ascorbic acids, Atenolols, Atracuriums, Atropines, Aurothioglucoses, Azathioprines, Aztreo- 25 nams, Bacitracins, Baclofens, Basiliximabs, Benzoic acids, Benztropines, Betamethasones, Biotins, Bivalirudins, Botulism antitoxins, Bretyliums, Bumetanides, Bupivacaines, Buprenorphines, Butorphanols, Calcitonins, Calcitriols, Calciums, Capreomycins, Carboprosts, Camitines, Cefa- 30 mandoles, Cefoperazones, Cefotaximes, Cefoxitins, Ceftizoximes, Cefuroximes, Chloramphenicols, Chloroprocaines, Chloroquines, Chlorothiazides, Chlorpromazines, Chondroitinsulfuric acids, Choriogonadotropin alfas, Chromiums, Cidofovirs, Cimetidines, Ciprofloxacins, Cisatracu- 35 riums, Clonidines, Codeines, Colchicines, Colistins, Collagens, Corticorelin ovine triflutates, Corticotrophins, Cosyntropins, Cyanocobalamins, Cyclosporines, Cysteines, Dacliximabs, Dalfopristins, Dalteparins, Danaparoids, Dantrolenes, Deferoxamines, Desmopressins, Dexamethasones, 40 Dexmedetomidines, Dexpanthenols, Dextrans, Iron dextrans, Diatrizoic acids, Diazepams, Diazoxides, Dicyclomines, Digibinds, Digoxins, Dihydroergotamines, Diltiazems, Diphenhydramines, Dipyridamoles, Dobutamines, Dopamines, Doxacuriums, Doxaprams, Doxercalciferols, 45 Doxycyclines, Droperidols, Dyphyllines, Edetic acids, Edrophoniums, Enalaprilats, Ephedrines, Epoprostenols, Ergocalciferols, Ergonovines, Ertapenems, Erythromycins, Esmolols, Estradiols, Estrogenics, Ethacrynic acids, Ethanolamines, Ethanols, Ethiodized oils, Etidronic acids, Eto- 50 midates, Famotidines, Fenoldopams, Fentanyls, Flumazenils, Fluoresceins, Fluphenazines, Folic acids, Fomepizoles, Fomivirsens, Fondaparinuxs, Foscamets, Fosphenytoins, Furosemides, Gadoteridols, Gadoversetamides, Ganciclovirs, Gentamicins, Glucagons, Glucoses, Glycines, Glyco- 55 pyrrolates, Gonadorelins, Gonadotropin chorionics, Haemophilus B polysaccharides, Hemins, Herbals, Histamines, Hydrocortisones, Hydralazines, Hydromorphones, Hydroxocobalamins, Hydroxyzines, Hyoscyamines, Ibutilides, Imiglucerases, Indigo carmines, Indomethacins, 60 Iodides, Iopromides, Iothalamic acids, Ioxaglic acids, Ioxilans, Isoniazids, Isoproterenols, Japanese encephalitis vaccines, Kanamycins, Ketamines, Labetalols, Lepirudins, Levobupivacaines, Levothyroxines, Lincomycins, Liothyronines, Luteinizing hormones, Lyme disease vaccines, 65 Mangafodipirs, Manthtols, Meningococcal polysaccharide vaccines, Meperidines, Mepivacaines, Mesoridazines, Met38

araminols, Methadones, Methocarbamols, Methohexitals, Methylergonovines, Metoclopramides, Methyldopates, Metoprolols, Metronidazoles, Minocyclines, Mivacuriums, Morrhuic acids, Moxifloxacins, Muromonab-CD3s, Mycophenolate mofetils, Nafcillins, Nalbuphines, Nalmefenes, Naloxones, Neostigmines, Niacinamides, Nicardipines, Nitroglycerins, Nitroprussides, Norepinephrines, Orphenadrines, Oxacillins, Oxymorphones, Oxytetracyclines, Oxytocins, Pancuroniums, Panthenols, Pantothenic acids, Papaverines, Peginterferon alpha 2As, Penicillin Gs, Pentamidines, Pentazocines, Pentobarbitals, Perflutrens, Perphenazines, Phenobarbitals, Phentolamines, Phenylephrines, Phenytoins, Physostigmines, Phytonadiones, Polymyxin, Pralidoximes, Prilocaines, Procainamides, Procaines, Prochlorperazines, Progesterones, Propranolols, Pyridostigmine hydroxides, Pyridoxines, Quinidines, Quinupristins, Rabies immunoglobulins, Rabies vaccines, Ranitidines, Remifentanils, Riboflavins, Rifampins, Ropivacaines, Samariums, Scopolamines, Seleniums, Somatrems, Spectinomycins, Sermorelins, Sincalides, Streptokinases, Streptomycins, Succinylcholines, Sufentanils, Sulfamethoxazoles, Tacrolimuses, Terbutalines, Teriparatides, Testosterones, Tetanus antitoxins, Tetracaines, Tetradecyl sulfates, Theophyllines, Thiamines, Thiethylperazines, Thiopentals, Thyroid stimulating hormones, Tinzaparins, Tirofibans, Tobramycins, Tolazolines, Tolbutamides, Torsemides, Tranexamic acids, Treprostinils, Trifluoperazines, Trimethobenzamides, Trimethoprims, Tromethamines, Tuberculins, Typhoid vaccines, Urofollitropins, Urokinases, Valproic acids, Vasopressins, Vecuroniums, Verapamils, Voriconazoles, Warfarins, Yellow fever vaccines, Zidovudines, Zincs, Ziprasidone hydrochlorides, Aclacinomycins, Actinomycins, Adriamycins, Azaserines, 6-Azauridines, Carzinophilins, Chromomycins, Denopterins, 6 Diazo 5 Oxo-L-Norleucines, Enocitabines, Floxuridines, Olivomycins, Pirarubicins, Piritrexims, Pteropterins, Tegafurs, Tubercidins, Alteplases, Arcitumomabs, bevacizumabs, Botulinum Toxin Type A's, Botulinum Toxin Type B's, Capromab Pendetides, Daclizumabs, Dornase alphas, Drotrecogin alphas, Imciromab Pentetates, Iodine-131's, an antibiotic agent; an angiogenesis inhibitor; anti-cataract and anti-diabetic retinopathy substances; carbonic anhydrase inhibitors; mydriatics; photodynamic therapy agents; prostaglandin analogs; growth factor; anti-neoplastics; anti-metabolites; anti-viral; amebicides and anti-protozoals; antituberculosis and anti-leprotic; antitoxins and antivenins; antihemophilic factor, anti-inhibitor coagulant complex, antithrombin III, coagulations Factor V, coagulation Factor IX, plasma protein fraction, von Willebrand factor; antiplatelet agent a colony stimulating factor (CSF); an erythropoiesis stimulator; hemostatics and albumins; Immune Globulins; thrombin inhibitors; anticoagulants; a steroidal anti-inflammatory drug selected from among alclometasones, algestones, beclomethasones, betamethasones, budesonides, clobetasols, clobetasones, clocortolones, cloprednols, corticosterones, cortisones, cortivazols, deflazacorts, desonides, desoximetasones, dexamethasones, diflorasones, diflucortolones, difluprednates, enoxolones, fluazacorts, flucloronides, flumethasones, flunisolides, fluocinolones, fluocinonides, fluocortins, fluocortolones, fluorometholones, fluperolones, fluprednidenes, fluprednisolones, flurandrenolides, fluticasones, formocortals, halcinonides, halobetasols, halometasones, halopredones, hydrocortamates, hydrocortisones, loteprednol etabonate, mazipredones, medrysones, meprednisones, methylprednisolones, mometasone furoate, paramethasones, prednicarbates, prednisolones, prednisones, prednivals, prednylidenes, rimexolones, tixocortols and triamcinolones; Docosanols, prostaglandins, prostaglandin analogs, antiprostaglandins and prostaglandin precursors; miotics, cholinergics and anti-cholinesterase; and antiallergenics.

The compositions and modified PH20 polypeptides can 5 be used to treat any condition normally treated by the PH20 polypeptide or the therapeutically active agent. These include, for example, conditions in which hyaluronan plays a role or is associated with the etiology of the disease due to, for example, accumulation or overproduction of hyaluronan. 10 Hence provided are methods, uses of the compositions and modified PH20 polypeptides for treating a hyaluronanassociated disease or condition by administering any of the modified PH20 polypeptides or compositions provided herein. Hyaluronan-associated diseases and conditions 15 include, for example, inflammatory disease and tumors or cancers, including a late-stage cancer, metastatic cancers and undifferentiated cancers, such as ovarian cancer, in situ carcinoma (ISC), squamous cell carcinoma (SCC), prostate cancer, pancreatic cancer, non-small cell lung cancer, breast 20 cancer and colon cancer. The PH20 polypeptide can be modified to exhibit increased half-life for such treatments. For example, the PH20 polypeptide can be modified with a polymer such as a PEG moiety for such treatments.

Also provided are methods for increasing delivery of a 25 therapeutic agent to a subject by: administering to a subject any of the modified PH20 polypeptides or compositions provided herein, and administering the therapeutic agent. The therapeutic agent can be administered in the same composition or separately, and can be administered before or 30 after, simultaneously, or intermittently, with administration of the PH20 polypeptide(s). Administration includes any route, including intravenous and subcutaneous administration, such as simultaneously with, intermittently with, or subsequent to administration of the therapeutic agent. The 35 therapeutic agents include any of those set forth above, elsewhere herein and/or known to those of skill in the art.

Also provided are methods for treating an excess of glycosaminoglycans; for treating a tumor; for treating glycosaminoglycan accumulation in the brain; for treating a 40 cardiovascular disorder; for treating an ophthalmic disorder; for treating pulmonary disease; for increasing penetration of chemotherapeutic agents into solid tumors; for treating cellulite; for treating a proliferative disorder; or for increasing bioavailability of drugs and other therapeutic agents by 45 administering the modified PH20 polypeptides or compositions provided herein.

Also provided are pharmaceutical compositions for use in treating a hyaluronan-associated disease or disorder; for use in delivering a therapeutic agent to a subject; for treating an 50 excess of glycosaminoglycans; for treating a tumor; for treating glycosaminoglycan accumulation in the brain; for treating a cardiovascular disorder; for treating an ophthalmic disorder; for treating pulmonary disease; for increasing penetration of chemotherapeutic agents into solid tumors; 55 for treating cellulite; for treating a proliferative disorder; or for increasing bioavailability of drugs and other therapeutic agents; and for any other use of compositions containing PH20 polypeptides.

Provided herein is a method for identifying or selecting a 60 modified hyaluronan-degrading enzyme that exhibits stability under a denaturation condition that includes the steps of: a) testing the activity of a modified hyaluronan-degrading enzyme in a composition containing a denaturing agent and/or under a denaturing condition; b) testing the activity of 65 the modified hyaluronan-degrading enzyme in the same composition and/or under the same conditions as a) except 40

absent the denaturing agent or condition; and c) selecting or identifying a modified hyaluronan-degrading enzyme that exhibits activity in a) that is at least 5% of the activity in b). In such an example, the activity is hyaluronidase activity. In some examples of the methods, a modified hyaluronandegrading enzyme is selected or identified if the activity in a) is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more of the activity in b), for example, a modified hyaluronan-degrading enzyme is selected or identified if the activity in a) is at least 40% or more of the activity in b). The method also can include steps of: d) comparing the activity of the modified hyaluronan-degrading enzyme in a) to the activity of the unmodified hyaluronan-degrading enzyme tested under the same conditions; and e) identifying or selecting a modified hyaluronan-degrading enzyme that exhibits at least 120%, 130%, 135%, 140%, 145%, 150%, 160%, 170%, 180%, 200%, 250%, 300%, 350%, 400%, 500%, 1500%, 2000%, 3000%, 4000%, 5000% or more of the hyaluronidase activity compared to the unmodified hyaluronan-degrading enzyme.

Also provided herein is a method for identifying or selecting a modified hyaluronan-degrading enzyme that exhibits stability, such as increased stability, under a denaturation condition, that includes the steps of: a) testing the activity of a modified hyaluronan-degrading enzyme in a composition containing a denaturing agent and/or under a denaturing condition; b) testing the activity of the corresponding unmodified hyaluronan-degrading enzyme in a composition containing the same denaturing agent and/or under the same denaturing condition as a), whereby the activity is tested under the same conditions as a); and c) selecting or identifying a modified hyaluronan-degrading enzyme that exhibits greater activity than the unmodified hyaluronan-degrading enzyme, thereby identifying or selecting a modified hyaluronan-degrading enzyme that exhibits increased stability under a denaturation condition. In such an example, the activity can be a hyaluronidase activity. In examples of the method, a modified hyaluronandegrading enzyme is selected or identified if the activity is at least 120%, 130%, 135%, 140%, 145%, 150%, 160%, 170%, 180%, 200%, 250%, 300%, 350%, 400%, 500%, 1500%, 2000%, 3000%, 4000%, 5000% or more of the activity compared to the unmodified hyaluronan-degrading enzyme. In such an example, the method also can include additional steps of: d) testing the activity of the selected or identified modified hyaluronan-degrading enzyme in a composition containing a denaturing agent and/or under a denaturing condition; e) testing the activity of the same selected or identified modified hyaluronan-degrading enzyme in the same composition and/or under the same conditions as d) except absent the denaturing agent or condition; and f) selecting or identifying a modified hyaluronan-degrading enzyme that exhibits activity in d) that is at least 5% of the activity in e). In such an example, the activity is hyaluronidase activity. In some examples of the methods, a modified hyaluronan-degrading enzyme is selected or identified if the activity in d) is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more of the activity in e), for example, a modified hyaluronan-degrading enzyme is selected or identified if the activity in d) is at least 40% or more of the activity in e).

In any of the methods provided herein for identifying or selecting a modified hyaluronan-degrading enzyme, the denaturing agent or condition is caused by temperature, agitation, no or low salt or the presence of an excipient. For example, the denaturing agent or condition is caused by elevated temperature that is from or from about 30° C. to 42° C., such as greater than or greater than about 30° C., 31° C., 32° C., 33° C., 34° C., 35° C., 36° C., 37° C., 38° C., 39° C., 40° C., 41° C. or 42° C. In other examples, the dena-5 turing agent or condition is the absence of salt or low salt less than 100 mM, such as low salt less than 90 mM, 80 mM, 70 mM, 60 mM, 50 mM, 40 mM, 30 mM, 25 mM, 20 mM, 15 mM, 10 mM, 5 mM. In further examples, the denaturing agent or condition is a denaturing excipient selected from 10 among an antiadherents, binders, coatings, fillers and diluents, flavors, colors, lubricants, glidants, preservatives, sorbents and sweeteners.

In particular examples of any of the methods provided herein for identifying or selecting a modified hyaluronan- 15 degrading enzyme, the denaturing agent or condition is a preservative(s), for example, a phenolic preservative(s). The phenolic preservative(s) can be a phenol, metacresol (m-cresol), benzyl alcohol, or a paraben. For example, the denaturing agent or condition is a preservative(s) that is 20 phenol and/or m-cresol. In such examples, the total amount of phenolic preservative in the composition, as a percentage (%) of mass concentration (w/v), is from or from about 0.05% to 0.6%, 0.1% to 0.4%, 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 25 0.3% to 0.4% inclusive.

In any of the methods provided herein for identifying or selecting a modified hyaluronan-degrading enzyme, prior to testing the activity of a hyaluronan-degrading enzyme composition in a) and/or b), the hyaluronan-degrading enzyme is 30 exposed to the denaturation condition or denaturing agent for a predetermined time. The predetermined time is a time period that is user selected depending on the particular hyaluronan-degrading enzyme that is being evolved or selected, the particular denaturation condition or denaturing 35 agent, the amount or extent of the denaturation condition or denaturing agent, the application or use of the hyaluronandegrading enzyme and other similar factors. For example, the predetermined time can be from or from about 1 minute to 1 month, 1 minute to 3 weeks, 1 minute to 2 weeks, 1 40 minute to 1 week, 1 minute to 24 hours, 1 minute to 12 hours, 30 minutes to 6 hours or 1 hour to 4 hours, such as at least or about at least 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, two days, three days, four days, 45 five days, six days, 7 days, two weeks or one month.

In any of the methods provided herein for identifying or selecting a modified hyaluronan-degrading enzyme, the modified hyaluronan-degrading enzyme is one that contains an amino acid replacement, insertion or deletion of amino 50 acids compared to an unmodified hyaluronan-degrading enzyme. For example, the modified hyaluronan-degrading enzyme contains an amino acid replacement, such as a single amino acid replacement or two, three, four, five, six, seven, eight, nine or more amino acid replacements compared to an 55 unmodified form of the hyaluronan-degrading enzyme. In particular aspects of the method, a library or collection of modified hyaluronan-degrading enzymes are screened in order to evolve or identify or select a modified hyaluronandegrading enzyme that exhibits stability, such as increased 60 stability, under a denaturation condition. Thus, in examples of the methods herein, a plurality of modified hyaluronandegrading enzymes are tested in a) and/or b). In such examples, the plurality of modified hyaluronan-degrading enzymes are modified compared to the corresponding 65 unmodified hyaluronan-degrading enzyme to generate a collection of modified hyaluronan-degrading enzymes,

whereby each modified protein in the collection is tested in each of a) and/or b). In the collection or library, each modified hyaluronan-degrading enzyme contains a single amino acid replacement compared to the unmodified form of the hyaluronan-degrading enzyme, such that the plurality of modified enzymes are such that the amino acid at each modified position is replaced by up to 1-19 other amino acids other than the original amino acid at the position, whereby each modified hyaluronan-degrading enzyme contains a different amino acid replacement, and every amino acid along the length of the hyaluronan-degrading enzyme, or a selected portion thereof, is replaced.

In any of the methods provided herein, the modified hyaluronan-degrading enzyme is modified compared to an unmodified hyaluronan-degrading enzyme by insertion, deletion or replacement of an amino acid(s). The unmodified hyaluronan-degrading enzyme can be a chondroitinase or can be a hyaluronidase. In examples herein, the unmodified hyaluronidase is a PH20 hyaluronidase or truncated form thereof lacking a C-terminal glycosylphosphatidylinositol (GPI) anchor attachment site or a portion of the GPI anchor attachment site, whereby the truncated form exhibits hyaluronidase activity. PH20 hyaluronidase can be a human, monkey, bovine, ovine, rat, fox, mouse or guinea pig PH20. In particular examples, the PH20 hyaluronidase is a human PH20 or a C-terminal truncated form thereof. For example, the unmodified hyaluronan-degrading enzyme is one that has the sequence of amino acids set forth in any of SEQ ID NOs: 3, 7, 10, 12, 14, 24, 32-66, 69, 72, 857, 859, 861, 870 or a sequence of amino acids that is at least 80% sequence identity to any of SEQ ID NOs: 3, 7, 10, 12, 14, 24, 32-66, 69, 72, 857, 859, 861, 870, such as at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to any of SEQ ID NOs: 3, 7, 10, 12, 14, 24, 32-66, 69, 72, 857, 859, 861, or 870. In particular examples, the unmodified hyaluronan-degrading enzyme is a PH20 hyaluronidase having the sequence of amino acids set forth in any of SEQ ID NOs: 3, 7, 32-66, 69 or 72, or a sequence of amino acids that exhibits at least 85% sequence identity to any of SEQ ID NOs: 3, 7, 32-66, 69 or 72, such as a sequence of amino acids that exhibits at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOs: 3, 7, 32-66, 69 or 72.

In any of the methods provided herein for identifying or selecting a modified hyaluronan-degrading enzyme that exhibits stability, the method is performed in vitro. Also provided are any of the methods that are iterative, whereby the steps of the method are repeated a plurality of times, wherein in each repetition, further modified hyaluronandegrading enzymes of a selected modified hyaluronan-degrading enzyme are generated and tested, whereby the modified hyaluronan-degrading enzyme is evolved to exhibit increased stability under a denaturation condition. Also provided herein is a modified hyaluronan-degrading enzyme identified by any of the methods provided herein.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 depicts the amino acid sequence of full-length human PH20 (set forth in SEQ ID NO:7) and soluble C-terminal truncated variants thereof. The C-terminal amino acid residue of exemplary C-terminal truncated variants of full-length PH20 are indicated by bold font. The complete amino acid sequences of exemplary C-terminal truncated variants of full-length PH20 also are provided in SEQ ID NOs: 3 and 32-66. The C-terminal amino acid residue of an exemplary soluble PH20, whose complete sequence is set forth in SEQ ID NO:3, also is indicated by underline. Exemplary, non-limiting, positions for amino acid replacements are indicated by highlighting. Corresponding positions can be identified by alignment of a sequence of interest ⁵ with any of SEQ ID NOs: 3, 7 or 32-66, and in particular with SEQ ID NO:3.

FIG. 2 (A-L) depicts exemplary alignments of human soluble PH20 set forth in SEQ ID NO:3 with other PH20 10 polypeptides. A "*" means that the aligned residues are identical, a ":" means that aligned residues are not identical, but are similar and contain conservative amino acids residues at the aligned position, and a "." means that the aligned residues are similar and contain semi-conservative amino 15 acid residues at the aligned position. Exemplary, non-limiting, corresponding positions for amino acid replacements are indicated by highlighting. For example, FIG. 2A depicts the alignment of a human soluble PH20 set forth in SEQ ID NO:3 with chimpanzee PH20 set forth in SEQ ID NO: 10. 20 FIG. 2B depicts the alignment of a human soluble PH20 set forth in SEQ ID NO:3 with Rhesus monkey PH20 set forth in SEQ ID NO: 12. FIG. 2C depicts the alignment of a human soluble PH20 set forth in SEQ ID NO:3 with Cynomolgus monkey PH20 set forth in SEQ ID NO: 14. 25 FIG. 2D depicts the alignment of human soluble PH20 set forth in SEQ ID NO:3 with bovine PH20 set forth in SEQ ID NO: 16. FIG. 2E depicts the alignment of a human soluble PH20 set forth in SEQ ID NO:3 with mouse PH20 set forth in SEQ ID NO:20. FIG. 2F depicts the alignment of a human soluble PH20 set forth in SEQ ID NO:3 with rat PH20 set forth in SEQ ID NO:22. FIG. 2G depicts the alignment of a human soluble PH20 set forth in SEQ ID NO:3 with rabbit PH20 set forth in SEQ ID NO:24. FIG. 2H 35 depicts the alignment of a human soluble PH20 set forth in SEQ ID NO:3 with guinea pig PH20 set forth in SEQ ID NO:29. FIG. 2I depicts the alignment of a human soluble PH20 set forth in SEQ ID NO:3 with Fox PH20 set forth in SEQ ID NO:31. FIG. 2J depicts the alignment of a human 40 soluble PH20 set forth in SEQ ID NO:3 with Gibbon PH20 set forth in SEQ ID NO:857.

FIG. **2**K depicts the alignment of a human soluble PH20 set forth in SEQ ID NO:3 with Marmoset PH20 set forth in SEQ ID NO:859. FIG. **2**L depicts the alignment of a human ⁴⁵ soluble PH20 set forth in SEQ ID NO:3 with Orangutan PH20 set forth in SEQ ID NO:861.

DETAILED DESCRIPTION

Outline

- A. DEFINITIONS
- **B. PH20 HYALURONIDASE**
 - 1. Structure
 - 2. Function
 - 3. Soluble PH20 Polypeptides
- C. MODIFIED PH20 POLYPEPTIDES
 - 1. Active Mutants
 - a. Increased Activity
 - b. Increased Stability
 - i. Phenophiles
 - ii. Thermophiles
 - iii. Absence of Salt
 - 2. Inactive Mutants
 - 3. Additional Modifications and Conjugates
 - a. Decreased Immunogenicity
 - b. Conjugation to Polymers

- D. METHODS FOR IDENTIFYING MODIFIED HYALURONAN-DEGRADING ENZYMES WITH ALTERED PROPERTIES OR ACTIVITIES
 - 1. Hyaluronan-Degrading Enzymes and Libraries of Modified Hyaluronan-Degrading Enzymes
 - 2. Screening or Testing for a Desired Activity or Property
 - 3. Selection or Identification
 - 4. Iterative Methods
- E. PRODUCTION OF MODIFIED POLYPEPTIDES AND ENCODING NUCLEIC ACID MOLECULES
 - 1. Isolation or Preparation of Nucleic Acids Encoding PH20 Polypeptides
 - 2. Generation of Mutant or Modified Nucleic Acid and Encoding Polypeptides
 - 3. Vectors and Cells
 - 4. Expression
 - a. Prokaryotic Cells
 - b. Yeast Cells
 - c. Insects and Insect Cells
 - d. Mammalian expression
 - e. Plants and plant cells
 - 5. Purification
 - 6. Modification of Polypeptides by PEGylation
- F. PHARMACEUTICAL COMPOSITIONS AND FOR-MULATIONS, DOSAGES AND ADMINISTRATION
 - Formulations—liquids, injectables, solutions and emulsions
 - a. Lyophilized Powders
 - b. Exemplary Formulations
 - i. Salt (e.g. NaCl)
 - ii. pH and Buffer
 - iii. Preservative(s)
 - iv. Stabilizers
 - 2. Compositions for Other Routes of Administration
 - 3. Dosages and Administration
 - 4. Exemplary PH20-Insulin Co-Formulations
 - 5. Packaging, Articles of Manufacture and Kits
- G. METHODS OF ASSESSING PH20 ACTIVITY AND STABILITY
 - 1. Hyaluronidase Activity
 - 2. Solubility
 - 3. Purity, Crystallization or Aggregation
 - 4. Pharmacodynamics/Pharmacokinetics
- H. METHODS OF TREATMENT AND COMBINA-TION THERAPY
 - 1. Methods of Delivering Therapeutic Agents Delivery of Insulin
 - 2. Methods of Treating Hyaluronan-Associated Disease and Conditions (eg., Tumors)
- 3. Other Uses

50

55

- 4. Contraception
- I. EXAMPLES

A. DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the invention(s) 60 belong. All patents, patent applications, published applications and publications, GenBank sequences, databases, websites and other published materials referred to throughout the

entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. In the event that there

65 are a plurality of definitions for terms herein, those in this section prevail. Where reference is made to a URL or other such identifier or address, it understood that such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet. Reference thereto evidences the availability and public dissemination of such information.

As used herein, a hyaluronan-degrading enzyme refers to 5 an enzyme that catalyzes the cleavage of a hyaluronan polymer (also referred to as hyaluronic acid or HA) into smaller molecular weight fragments. Exemplary hyaluronan-degrading enzymes are hyaluronidases, and particular chondroitinases and lyases that have the ability to depo-10 lymerize hyaluronan. Exemplary chondroitinases that are hyaluronan-degrading enzymes include, but are not limited to, chondroitin ABC lyase (also known as chondroitinase ABC), chondroitin AC lyase (also known as chondroitin sulfate lyase or chondroitin sulfate eliminase) and chondroi-15 tin C lyase. Chondroitin ABC lyase contains two enzymes, chondroitin-sulfate-ABC endolyase (EC 4.2.2.20) and chondroitin-sulfate-ABC exolyase (EC 4.2.2.21). An exemplary chondroitin-sulfate-ABC endolyases and chondroitin-sulfate-ABC exolvases include, but are not limited to, those 20 from Proteus vulgaris and Pedobacter heparinus (the Proteus vulgaris chondroitin-sulfate-ABC endolyase is set forth in SEQ ID NO:922; Sato et al. (1994) Appl. Microbiol. Biotechnol. 41(1):39-46). Exemplary chondroitinase AC enzymes from bacteria include, but are not limited to, those 25 from Pedobacter heparinus, set forth in SEQ ID NO: 923, Victivallis vadensis, set forth in SEQ ID NO:924, and Arthrobacter aurescens (Tkalec et al. (2000) Applied and Environmental Microbiology 66(1):29-35; Ernst et al. (1995) Critical Reviews in Biochemistry and Molecular 30 *Biology* 30(5):387-444). Exemplary chondroitinase C enzymes from bacteria include, but are not limited to, those from Streptococcus and Flavobacterium (Hibi et al. (1989) FEMS-Microbiol-Lett. 48(2):121-4; Michelacci et al. (1976) J Biol. Chem. 251:1154-8; Tsuda et al. (1999) Eur. J. 35 Biochem. 262:127-133).

As used herein, hyaluronidase refers to a class of enzymes that degrade hyaluronan. Hyaluronidases include, but are not limited to, bacterial hyaluronidases (EC 4.2.2.1 or EC 4.2.99.1), hyaluronidases from leeches, other parasites and 40 crustaceans (EC 3.2.1.36), and mammalian-type hyaluronidases (EC 3.2.1.35). Hyaluronidases include any of nonhuman origin including, but not limited to, murine, canine, feline, leporine, avian, bovine, ovine, porcine, equine, piscine, ranine, bacterial, and any from leeches, other para- 45 sites, and crustaceans. Exemplary human hyaluronidases include HYAL1, HYAL2, HYAL3, HYAL4, and PH20, Also included amongst hyaluronidases are soluble hyaluronidases, including, ovine and bovine PH20, and soluble PH20. Exemplary hyaluronidases include any set forth in SEQ ID 50 NOs: 6, 7-31, 69, 70, 71, 72, 856-861, 869-921, mature forms thereof (lacking the signal sequence), or allelic or species variants thereof. Hyaluronidases also include truncated forms thereof that exhibit hyaluronidase activity, including C-terminal truncated variants that are soluble.

As used herein, PH20 refers to a type of hyaluronidase that occurs in sperm and is neutral-active. PH-20 occurs on the sperm surface, and in the lysosome-derived acrosome, where it is bound to the inner acrosomal membrane. PH20 includes those of any origin including, but not limited to, 60 human, chimpanzee, Cynomolgus monkey, Rhesus monkey, murine, bovine, ovine, guinea pig, rabbit and rat origin. Exemplary PH20 polypeptides, including precursor and mature forms, include those from human (SEQ ID NOs:6 and 7), chimpanzee (SEQ ID NOs:8, 9, 10, 869 and 870), 65 Rhesus monkey (SEQ ID NOs: 11 and 12), Cynomolgus monkey (SEQ ID NOs:13 and 14), cow (e.g., SEQ ID

NOs:15-18); mouse (SEQ ID NOs:19 and 20); rat (SEQ ID NOs:21 and 22); rabbit (SEQ ID NOs:23 and 24); sheep (SEQ ID NOs:25-27), guinea pig (SEQ ID NOs:28 and 29); fox (SEQ ID NOs: 30 and 31); Gibbon (SEQ ID NOs:856 and 857), Marmoset (SEQ ID NOs:858 and 859) and orangutan (SEQ ID NOs:860 and 861). Reference to PH20 includes precursor PH20 polypeptides and mature PH20 polypeptides (such as those in which a signal sequence has been removed), truncated forms thereof that have activity, and includes allelic variants and species variants, variants encoded by splice variants, and other variants, including polypeptides that have at least 40%, 45%, 50%, 55%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the precursor polypeptides set forth in SEQ ID NO:7, or the mature forms thereof. PH20 polypeptides also include those that contain chemical or posttranslational modifications and those that do not contain chemical or posttranslational modifications. Such modifications include, but are not limited to, PEGylation, albumination, glycosylation, farnysylation, carboxylation, hydroxylation, phosphorylation, and other polypeptide modifications known in the art. Examples of commercially available bovine or ovine soluble hyaluronidases are Vitrase® hyaluronidase (ovine hyaluronidase) and Amphadase® hyaluronidase (bovine hyaluronidase).

As used herein, a soluble PH20 refers to a polypeptide characterized by its solubility under physiological conditions. Generally, a soluble PH20 lacks all or a portion of a glycophosphatidyl anchor (GPI) attachment sequence, or does not otherwise sufficiently anchor to the cell membrane. For example, a soluble PH20 can be a C-terminally truncated variant of a PH20 lacking a contiguous sequence of amino acids that corresponds to all or a portion of a glycophosphatidyl anchor (GPI) attachment sequence. Hence, upon expression from a cell, a soluble PH20 is secreted into the medium. Soluble PH20 proteins can be distinguished, for example, by its partitioning into the aqueous phase of a Triton® X-114 detergent solution warmed to 37° C. (Bordier et al., (1981) J. Biol. Chem., 256:1604-7). Membrane-anchored, such as lipid anchored hyaluronidases, will partition into the detergent rich phase, but will partition into the detergent-poor or aqueous phase following treatment with Phospholipase-C. Included among soluble PH20 hyaluronidases are membrane anchored hyaluronidases in which one or more regions associated with anchoring of the hyaluronidase to the membrane has been removed or modified, where the soluble form retains hyaluronidase activity. Soluble hyaluronidases include recombinant soluble hyaluronidases and those contained in or purified from natural sources, such as, for example, testes extracts from sheep or cows. Exemplary of such soluble hyaluronidases are soluble human PH20 (SEQ ID NOs: 3 or 32-66). Other soluble hyaluronidases include ovine (SEQ ID NOs:25-27) and bovine (SEQ ID NO: 16 or 18) PH20.

As used herein, soluble human PH20 (sHuPH20) includes human PH20 polypeptides that lack a contiguous sequence of amino acids from the C-terminus of human PH20 that includes all or a portion of the glycosylphosphatidylinositol (GPI) anchor sequence (C-terminally truncated PH20 polypeptides) such that upon expression, the polypeptides are soluble under physiological conditions. For example, soluble human PH20 polypeptides are C-terminally truncated polypeptides of human PH20 set forth as SEQ ID NO:6 in its precursor form or in SEQ ID NO:7 in its mature form lacking the signal sequence, or allelic variants thereof (e.g. set forth in any of SEQ ID NOs: 68-72). Solubility can be assessed by any suitable method that demonstrates solubility under physiologic conditions. Exemplary of such methods is the Triton® X-114 assay, that assesses partitioning into the aqueous phase and that is described above. In addition, a soluble human PH20 polypeptide is, if produced in CHO cells, such as CHO—S cells, a polypeptide that is 5 expressed and is secreted into the cell culture medium. Soluble human PH20 polypeptides, however, are not limited to those produced in CHO cells, but can be produced in any cell or by any method, including recombinant expression and polypeptide synthesis. Reference to secretion in CHO cells is definitional. Hence, if a polypeptide could be expressed and secreted in CHO cells and is soluble in the media, i.e., partitions into the aqueous phase when extracted with Triton® X-114 detergent, it is a soluble PH20 polypeptide whether or not it is so-produced. The precursor 15 polypeptides for sHuPH20 polypeptides can include a signal sequence, such as a heterologous or non-heterologous (i.e., native) signal sequence. Exemplary of the precursors are those that include a signal sequence, such as the native 35 amino acid signal sequence at amino acid positions 1-35 20 (see, e.g., amino acids 1-35 of SEQ ID NO: 6).

As used herein, "native" or "wildtype" with reference to a PH20 polypeptide refers to a PH20 polypeptide encoded by a native or naturally occurring PH20 gene, including allelic variants, that is present in an organism, including a 25 human and other animals, in nature. Reference to wild-type PH20 without reference to a species is intended to encompass any species of a wild-type PH20. Included among wild-type PH20 polypeptides are the encoded precursor polypeptide, fragments thereof, and processed forms 30 thereof, such as a mature form lacking the signal peptide as well as any pre- or post-translationally processed or modified forms thereof. Also included among native PH20 polypeptides are those that are post-translationally modified, including, but not limited to, those that are modified by 35 glycosylation, carboxylation and/or hydroxylation. The amino acid sequences of exemplary wild-type human PH20 are set forth in SEQ ID NOs: 6 and 7 and those of allelic variants, including mature forms thereof, are set forth in SEQ ID NOs:68-72. Other animals produce native PH20, 40 tains at least one amino acid modification, such as at least including, but not limited to, native or wildtype sequences set forth in any of SEO ID NOs: 8-31, 856-861, 869 or 870.

As used herein, modification is in reference to modification of a sequence of amino acids of a polypeptide or a sequence of nucleotides in a nucleic acid molecule and 45 resulting modified PH20 polypeptide exhibits hyaluronidase includes deletions, insertions, and replacements of amino acids and nucleotides, respectively. Modifications also can include post-translational modifications or other changes to the molecule that can occur due to conjugation or linkage, directly or indirectly, to another moiety. Methods of modi- 50 fying a polypeptide are routine to those of skill in the art, such as by using recombinant DNA methodologies.

As used herein, a "modified hyaluronan-degrading enzyme" refers to a hyaluronan-degrading enzyme that contains a modification compared to a reference or unmodi- 55 a starting PH20 polypeptide that is selected for modification fied hyaluronan-degrading enzyme. The modification can be an amino acid replacement (substitution), insertion (addition) or deletion of one or more amino acid residues. The amino acid residue can be a natural or non-natural amino acid. In some cases, the modification can be a post-transla- 60 tional modification. A modified hyaluronan-degrading enzyme can have up to 150 amino acid differences compared to a reference or unmodified hyaluronan-degrading enzyme, so long as the resulting modified hyaluronan-degrading enzyme exhibits hyaluronidase activity. Typically, a modi- 65 fied hyaluronan-degrading enzyme contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,

24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acid modifications.

As used herein, an unmodified hyaluronan-degrading enzyme refers to a starting polypeptide that is selected for modification as provided herein. The starting polypeptide can be a naturally-occurring, wild-type form of a polypeptide. In addition, the starting polypeptide can be altered or mutated, such that it differs from a native wild type isoform but is nonetheless referred to herein as a starting unmodified polypeptide relative to the subsequently modified polypeptides produced herein. Thus, existing proteins known in the art that have been modified to have a desired increase or decrease in a particular activity or property compared to an unmodified reference protein can be selected and used as the starting unmodified polypeptide. For example, a protein that has been modified from its native form by one or more single amino acid changes and possesses either an increase or decrease in a desired property, such as a change in an amino acid residue or residues to alter glycosylation, can be selected for modification, and hence referred to herein as unmodified, for further modification. An unmodified hyaluronan-degrading enzyme includes human and nonhuman hyaluronan-degrading enzymes, including hyaluronan-degrading enzymes from non-human mammals and bacteria. Exemplary unmodified hyaluronan-degrading enzyme are any set forth in SEQ ID NOs: 2, 3, 6, 7-66, 68-72, 856-861, 869-924 or mature, C-terminally truncated forms thereof that exhibit hyaluronidase activity, or a hyaluronan-degrading enzyme that exhibits at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 2, 3, 6, 7-66, 68-72, 856-861, 869-924. It is understood that an unmodified hyaluronan-degrading enzyme generally is one that does not contain the modification(s), such as amino acid replacement(s) of a modified hyaluronan-degrading enzyme.

As used herein, "modified PH20 polypeptide" or "variant PH20 polypeptide" refers to a PH20 polypeptide that conone amino acid replacement as described herein, in its sequence of amino acids compared to a reference unmodified PH20 polypeptide. A modified PH20 polypeptide can have up to 150 amino acid replacements, so long as the activity. Typically, a modified PH20 polypeptide contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acid replacements. It is understood that a modified PH20 polypeptide also can include any one or more other modifications, in addition to at least one amino acid replacement as described herein.

As used herein, an unmodified PH20 polypeptide refers to as provided herein. The starting polypeptide can be a naturally-occurring, wild-type form of a polypeptide. In addition, the starting polypeptide can be altered or mutated, such that it differs from a native wild type isoform but is nonetheless referred to herein as a starting unmodified polypeptide relative to the subsequently modified polypeptides produced herein. Thus, existing proteins known in the art that have been modified to have a desired increase or decrease in a particular activity or property compared to an unmodified reference protein can be selected and used as the starting unmodified polypeptide. For example, a protein that has been modified from its native form by one or more single amino acid changes and possesses either an increase or decrease in a desired property, such as a change in an amino acid residue or residues to alter glycosylation, can be selected for modification, and hence referred to herein as unmodified, for further modification. Exemplary unmodified 5 PH20 polypeptides is a human PH20 polypeptide or allelic or species variants thereof or other variants, including mature and precursor polypeptides. For example, exemplary reference PH20 polypeptides is a mature full length PH20 polypeptide set forth in SEQ ID NOs: 7, 69 or 72, or in 10 C-terminally truncated forms thereof such as set forth in any of SEQ ID NOs: 3 and 32-66, or in a PH20 polypeptide that exhibits at least 68%, 69%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 15 3, 7, 32-66, 69 or 72. A reference PH20 polypeptide also can include the corresponding precursor form such as set forth in any of SEQ ID NOs: 2, 6, 68, 70, 71 or other precursor forms, or in a PH20 polypeptide that exhibits at least 68%, 69%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 20 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 2, 6, 68, 70, 71. It is understood that an unmodified hyaluronan-degrading enzyme generally is one that does not contain the modification(s), such as amino acid replacement(s) of a modified 25 hyaluronan-degrading enzyme.

As used herein, an N-linked moiety refers to an asparagine (N) amino acid residue of a polypeptide that is capable of being glycosylated by post-translational modification of a polypeptide. Exemplary N-linked moieties of human PH20 30 include amino acids N47, N131, N200, N219, N333, N358 and N365 of the sequence of amino acids set forth in SEQ ID NO: 3 or 7 (corresponding to amino acid residues N82, N166, N235, N254, N368, N393 and N490 of human PH20 set forth in SEQ ID NO: 6).

As used herein, an N-glycosylated polypeptide refers to a PH20 polypeptide containing oligosaccharide linkage of at least three N-linked amino acid residues, for example, N-linked moieties corresponding to amino acid residues N200, N333 and N358 of SEQ ID NO:3 or 7. An N-glyco- 40 PH20 polypeptide to enzymatically catalyze the cleavage of sylated polypeptide can include a polypeptide where three, four, five and up to all of the N-linked moieties are linked to an oligosaccharide. The N-linked oligosaccharides can include oligomannose, complex, hybrid or sulfated oligosaccharides, or other oligosaccharides and monosaccharides. 45

As used herein, an N-partially glycosylated polypeptide refers to a polypeptide that minimally contains an N-acetylglucosamine glycan linked to at least three N-linked moieties. A partially glycosylated polypeptide can include variglycan forms, including monosaccharides, 50 ous oligosaccharides, and branched sugar forms, including those formed by treatment of a polypeptide with EndoH, EndoF1, EndoF2 and/or EndoF3.

As used herein, "conditions" refers to any parameter that can influence the activity or properties of a protein or agent. 55 refers to a protein that is homogenous in an aqueous solu-For purposes herein, conditions generally refer to the presence, including amount, of excipients, carriers or other components in a formulation other than the active agent (e.g., modified PH20 hyaluronidase); temperature; time (e.g., time of storage or exposure); storage vessel; properties 60 of storage (e.g., agitation) and/or other conditions associated with exposure or use.

As used herein, "denaturation" or "denaturing" or grammatical variations thereof with reference to a protein refers to a biochemical change in a protein so that a property or 65 activity of the protein is diminished or eliminated. The biochemical change can be a change in the tertiary structure

of the protein to unfold. The property or activity can be completely abolished or can be reduced by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more.

As used herein, property refers to a physical or structural property, such as the three-dimensional structure, pI, halflife, conformation and other such physical characteristics. For example, a change in a property can be manifested as the solubility, aggregation or crystallization of a protein.

As used herein, activity refers to a functional activity or activities of a polypeptide or portion thereof associated with a full-length (complete) protein. Functional activities include, but are not limited to, biological activity, catalytic or enzymatic activity, antigenicity (ability to bind or compete with a polypeptide for binding to an anti-polypeptide antibody), immunogenicity, ability to form multimers, and the ability to specifically bind to a receptor or ligand for the polypeptide.

As used herein, hyaluronidase activity refers to the ability to enzymatically catalyze the cleavage of hyaluronic acid. The United States Pharmacopeia (USP) XXII assay for hyaluronidase determines hyaluronidase activity indirectly by measuring the amount of higher molecular weight hyaluronic acid, or hyaluronan, (HA) substrate remaining after the enzyme is allowed to react with the HA for 30 min at 37° C. (USP XXII-NF XVII (1990) 644-645 United States Pharmacopeia Convention, Inc, Rockville, MD). A Reference Standard solution can be used in an assay to ascertain the relative activity, in units, of any hyaluronidase. In vitro assays to determine the hyaluronidase activity of hyaluronidases, such as PH20, including modified PH20 polypeptides, are known in the art and described herein. Exemplary assays include the microturbidity assay described herein that measures cleavage of hyaluronic acid by hyaluronidase indirectly by detecting the insoluble precipitate formed when the uncleaved hyaluronic acid binds with serum albumin. Reference Standards can be used, for example, to generate a standard curve to determine the activity in Units of the hyaluronidase being tested.

As used herein, neutral active refers to the ability of a hyaluronic acid at neutral pH, such as at a pH between or about between pH 6.0 to pH 7.8.

As used herein, "increased activity" with reference to a modified PH20 hyaluronidase means that, when tested under the same conditions, the modified PH20 hyaluronidase exhibits greater hyaluronidase activity compared to an unmodified PH20 hyaluronidase not containing the amino acid replacement(s). For example, a modified PH20 hyaluronidase exhibits at least or about at least 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000% or more of the activity of the unmodified or reference PH20 hyaluronidase.

As used herein, "solubility" with reference to a protein tion, whereby protein molecules diffuse and do not sediment spontaneously. Hence a soluble protein solution is one in which there is an absence of a visible or discrete particle in a solution containing the protein, such that the particles cannot be easily filtered. Generally, a protein is soluble if there are no visible or discrete particles in the solution. For example, a protein is soluble if it contains no or few particles that can be removed by a filter with a pore size of $0.22 \,\mu\text{m}$.

As used herein, aggregation or crystallization with reference to a protein refers to the presence of visible or discrete particles in a solution containing the protein. Typically, the particles are greater than 10 µm in size, such as greater than 15 μ m, 20 μ m, 25 μ m, 30 μ m, 40 μ m, 50 μ m or greater. Aggregation or crystallization can arise due to reduced solubility, increased denaturation of a protein or the formation of covalent bonds.

As used herein, "denaturing condition" or "denaturation condition" refers to any condition or agent that, when exposed to a protein, affects or influences the degradation or denaturation of the protein, generally as a result of a loss or partial loss of the tertiary or secondary structure of the protein. Denaturing conditions can result in effects such as loss or reduction in activity, loss or reduction of solubility, aggregation and/or crystallization. The denaturing condition need not be one that is completely deadly to the protein, but nevertheless is one that leads to a reduction in the activity of 15 the protein over time. Thus, a condition is denaturing if the activity of the protein is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more in the presence of the condition than in its absence. A denaturing condition can be due to an external stress or physical 20 condition (e.g., agitation, temperature, time of storage, absence of a stabilizer) or can be due to the presence of a denaturing agent. For example, the denaturing condition can be caused by heat, acid or a chemical denaturant. Exemplary denaturing conditions include, but are not limited to, the 25 presence of a strong acid or base, a concentrated inorganic salt, an organic solvent (e.g., alcohol or chloroform), urea, high or low pH (extremes of pH), elevated temperature (e.g., heat), the presence of excipients that can be denaturing (e.g., phenolic preservatives or detergent), and low or substan- 30 tially no stabilizing agent that otherwise is required for stability of the protein (e.g., NaCl).

As used herein, "denaturing agent" or "denaturant" refers to any substance, molecule or compound that causes denaturation. For example, a denaturing agent can include a 35 strong acid or base, a concentrated inorganic salt, an organic solvent (e.g., alcohol or chloroform), a preservative, detergent or other excipient.

As used herein, "resistance to a denaturation condition" refers to any amount of decreased reduction or elimination 40 of a property or activity of the protein associated with or caused by denaturation. For example, denaturation is associated with or causes increased crystallization or aggregation, reduced solubility or decreased activity. Hence, resistance to denaturation means that the protein exhibits 45 decreased aggregation or crystallization, increased solubility or increased or greater activity (e.g., hyaluronidase activity) when exposed to a denaturing condition compared to a reference protein (e.g. unmodified enzyme). The resistance to a denaturation condition need not be absolute or perma- 50 nent, but can be achieved because the denaturation of the modified hyaluronan-degrading enzyme occurs more slowly than the unmodified enzyme in the denaturation condition such that an activity or property of the modified hyaluronandegrading enzyme is achieved for longer. For example, a 55 modified hyaluronan-degrading enzyme, such as a modified PH20 hyaluronidase, exhibits resistance to a denaturation condition if it exhibits, for example, 1%, 2%, 3%, 4%, 5%, $6\%, 7\%, 8\%, 9\%, 10\%, \ldots 20\%, \ldots 30\%, \ldots 40\%, \ldots$ $50\%, \ldots 60\%, \ldots, 70\%, \ldots 80\%, \ldots 90\%, 91\%, 92\%, 60$ 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% more resistance to denaturation in the presence of a denaturation condition or denaturing agent than an unmodified polypeptide. In some instances, a modified polypeptide exhibits 105%, 110%, 120%, 130%, 140%, 150%, 200%, 300%, 65 400%, 500%, or more increased resistance to denaturation compared to an unmodified polypeptide.

52

As used herein, stability of a modified PH20 hyaluronidase means that it exhibits resistance to denaturation caused by a denaturation condition or denaturing agent. A modified PH20 polypeptide exhibits stability if it retains some activity in the presence of a denaturation condition or denaturing agent, such as at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the original or initial hyaluronidase activity prior to exposure to the denaturing condition(s). Generally, a modified PH20 hyaluronidase is stable if it retains at least 50% or more of the hyaluronidase activity under a denaturation condition compared to the absence of the denaturation condition. Assays to assess hyaluronidase activity are known to one of skill in the art and described herein. It is understood that the stability of the enzyme need not be permanent or long term, but is manifested for a duration of time in which activity is desired. For example, a modified PH20 hyaluronidase is stable if it exhibits an activity for at least 2 hours, 3 hours, 4 hours, 6 hours, 12 hours, 24 hours, one day, two days, three days, four days, five days, six days, one week, one month, six months or one year upon exposure, or during exposure, to one or more denaturing condition(s) or agent(s) (e.g., presence of a denaturing excipient such as a preservative). For example, a modified PH20 hyaluronidase is stable if it exhibits an activity upon or during exposure to one or more denaturing condition(s) or agent(s) (e.g., presence of a denaturing excipient such as a preservative) for at least 1 month at temperatures from or from about 2° C. to 8° C., inclusive or for at least 3 days at a temperature from or from about 30° C. to 42° C., inclusive.

Hence, "stable" or "stability," with reference to a formulation or a co-formulation provided herein, refers to one in which a modified hyaluronan-degrading enzyme, such as a modified PH20 hyaluronidase, therein is stable upon exposure to one or more denaturing condition(s) or agent(s) therein (e.g., presence of a denaturing excipient such as a preservative) for at least 1 month at temperatures from or from about 2° C. to 8° C., inclusive or for at least 3 days at a temperature from or from about 30° C. to 42° C., inclusive.

As used herein, "increased stability" with reference to a modified PH20 hyaluronidase means that, in the presence of the same denaturing or denaturation condition(s) (e.g., presence of a denaturing excipient such as a preservative), the modified PH20 hyaluronidase exhibits greater hyaluronidase activity compared to an unmodified PH20 hyaluronidase not containing the amino acid replacement(s). For example, a modified PH20 hyaluronidase exhibits increased stability if it exhibits at least or about at least 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000% or more of the activity of the unmodified or reference PH20 hyaluronidase in the presence of a denaturing or denaturation condition(s) (e.g., in the presence of a denaturing excipient such as a preservative).

As used herein, "elevated temperatures" refers to temperatures that are greater than room temperature or ambient temperature. Generally, an elevated temperature is a temperature that is at least, greater than, or about 30° C, such as 30° C. to 42° C, and generally 32° C. to 37° C. or 35° C. to 37° C, inclusive.

As used herein, room temperature refers to a range generally from about or at to 18° C. to about or at 32° C. Those of skill in the art appreciate that room temperature varies by location and prevailing conditions. For example, room temperatures can be higher in warmer climates such as Italy or Texas.

As used herein, recitation that proteins are "compared under the same conditions" means that different proteins are treated identically or substantially identically such that any one or more conditions that can influence the activity or properties of a protein or agent are not varied or not 5 substantially varied between the test agents. For example, when the hyaluronidase activity of a modified PH20 polypeptide is compared to an unmodified PH20 polypeptide any one or more conditions such as the amount or concentration of the polypeptide; presence, including amount, of excipients, carriers or other components in a formulation other than the active agent (e.g., modified PH20 hyaluronidase); temperature; time of storage; storage vessel; properties of storage (e.g., agitation) and/or other conditions associated 15 with exposure or use are identical or substantially identical between and among the compared polypeptides.

As used herein, "predetermined time" refers to a time that is established or decided in advance. For example, the predetermined time can be a time chosen in advance that is 20 associated with the desired duration of activity of a hyaluronan-degrading enzyme depending on the desired application or use of the protein. A predetermined time can be hours, days, months or years. For example, a predetermined time can be at least about or about 2 hours, 3 hours, 4 hours, five 25 hours, six hours, 12 hours, 24 hours, 2 days, three days, four days, five days, six days, one week, two weeks, three weeks, one month, six months, one year or more.

As used herein, "storage" means that a formulation is not immediately administered to a subject once prepared, but is 30 kept for a period of time under particular conditions (e.g., particular temperature; time, and/or form (e.g., liquid or lyophilized form)) prior to use. For example, a liquid formulation can be kept for days, weeks, months or years, prior to administration to a subject under varied temperatures such as refrigerated (0° C. to 10° C., such as 2° to 8° C.), room temperature (e.g., temperature up to 32° C., such as 18° C. to about or at 32° C.), or elevated temperature (e.g., 30° C. to 42° C., such as 32° C. to 37° C. or 35° C. to 37° C.). 40

As used herein, an "excipient" refers to a compound in a formulation of an active agent that does not provide the biological effect of the active agent when administered in the absence of the active agent. Exemplary excipients include, but are not limited to, salts, buffers, stabilizers, tonicity 45 modifiers, metals, polymers, surfactants, preservatives, amino acids and sugars.

As used herein, a stabilizing agent refers to compound added to the formulation to protect the modified PH20 polypeptide or other active agent from degradation, if necsosary, such as due to denaturation conditions to which a formulation herein is exposed when handled, stored or used. Thus, included are agents that prevent proteins from degradation from other components in the compositions. Exemplary of such agents are amino acids, amino acid derivatives, 55 amines, sugars, polyols, salts and buffers, surfactants, inhibitors or substrates and other agents as described herein.

As used herein, an antimicrobial effectiveness test or preservative effectiveness test (PET) demonstrates the effectiveness of the preservative system in a product. A product 60 is inoculated with a controlled quantity of specific organisms. The test then compares the level of microorganisms found on a control sample versus the test sample over a period of 28 days. Generally, target markets have differing PET requirements. For example, the PET requirements of 65 the United States Pharmacopoeia (USP) and the European Pharmacopoeia (EP) differ. Parameters for performing an

antimicrobial effectiveness test, including in different markets, are known to one of skill in the art as described herein.

As used herein, an anti-microbially or anti-microbial effective amount of a preservative refers to an amount of the preservative that kills or inhibits the propagation of microbial organisms in a sample that may be introduced from storage or use. For example, for multiple-dose containers, an anti-microbially effective amount of a preservative inhibits the growth of microorganisms that may be introduced from repeatedly withdrawing individual doses. USP and EP (EPA and EPB) have anti-microbial requirements that determine preservative effectiveness, and that vary in stringency. For example, an anti-microbial effective amount of a preservative is an amount such that at least a $1.0 \log_{10}$ unit reduction in bacterial organisms occurs at 7 days following inoculation in an antimicrobial preservative effectiveness test (APET). In a particular example, an anti-microbial effective amount of a preservative is an amount such that at least a $1.0 \log_{10}$ unit reduction in bacterial organisms occurs at 7 days following inoculation, at least a 3.0 \log_{10} unit reduction of bacterial organisms occurs at 14 days following inoculation, at least no further increase in bacterial organisms occurs after 28 days following inoculation, and at least no increase in fungal organisms occurs after 7 days following inoculation. In a further example, an anti-microbial effective amount of a preservative is an amount such that at least a 1.0 log₁₀ unit reduction of bacterial organisms occurs at 24 hours following inoculation, at least a 3.0 log10 unit reduction of bacterial organisms occurs at 7 days following inoculation, no further increase in bacterial organisms occurs after 28 days following inoculation, at least a 1.0 \log_{10} unit reduction of fungal organisms occurs at 14 days following inoculation, and at least no further increase in fungal organisms occurs after 28 days following inoculation. In an additional example, an anti-microbial effective amount of a preservative is an amount such that at least a 2.0 \log_{10} unit reduction of bacterial organisms occurs at 6 hours following inoculation, at least a 3.0 log₁₀ unit reduction of bacterial organisms occurs at 24 hours following inoculation, no recovery of bacterial organisms occurs after 28 days following inoculation of the composition with the microbial inoculum, at least a 2.0 log10 unit reduction of fungal organisms occurs at 7 days following inoculation, and at least no further increase in fungal organisms occurs after 28 days following inoculation.

As used herein, "preservative" refers to a naturally occurring or synthetically or recombinantly produced substance that, when added to a molecule or protein composition, prevents microbial growth, including bacterial or fungal growth, in the composition.

As used herein, a "phenolic preservative" refers to a preservative that contains one hydroxyl group attached to an aromatic carbon ring, such as a benzene ring. Exemplary phenolic preservatives, include but are not limited to, phenol, m-cresol, p-hydroxybenzoic acid, methylparaben, ethylparaben, and propylparaben. For example, cresols, including meta-cresol (m-cresol), has a methyl group substituted onto the benzene ring of a phenol molecule.

As used herein, a "phenophile" refers to a protein, such as a modified PH20 polypeptide, that exhibits stability in the presence of an anti-microbially effective amount of a preservative(s). The term "phenophile" can be used interchangeably herein with "phenophile" and has the same meaning. For example, a modified PH20 polypeptide that is a phenophile or phenolphile typically exhibits increased stability compared to an unmodified PH20 hyaluronidase not containing the amino acid replacement(s) when tested under the same denaturing condition(s) containing a phenolic preservative(s). For example, a modified PH20 hyaluronidase exhibits at least or about at least 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 5 1000% or more of the activity of the unmodified or reference PH20 hyaluronidase in the presence of a phenolic preservative(s).

As used herein, a "thermophile" refers to a protein, such as a modified PH20 polypeptide, that exhibits stability under 10 elevated temperatures greater than or about 30° C., such as 30° C. to 42° C., and generally 32° C. to 37° C. or 35° C. to 37° C. For example, a modified PH20 polypeptide that is a thermophile typically exhibits increased stability compared to an unmodified PH20 hyaluronidase not containing 15 the amino acid replacement(s) when tested under the same elevated temperature denaturing condition(s). For example, a modified PH20 hyaluronidase exhibits at least or about at least 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 400%, 500%, 600%, 20 700%, 800%, 900%, 1000% or more of the activity of the unmodified or reference PH20 hyaluronidase under elevated temperatures.

As used herein, the term "detergent" is used interchangeably with the term "surfactant" or "surface acting agent." 25 Surfactants are typically organic compounds that are amphiphilic, i.e., containing both hydrophobic groups ("tails") and hydrophilic groups ("heads"), which render surfactants soluble in both organic solvents and water. A surfactant can be classified by the presence of formally charged groups in 30 its head. A non-ionic surfactant has no charge groups in its head, whereas an ionic surfactant carries a net charge in its head. A zwitterionic surfactant contains a head with two oppositely charged groups. Some examples of common surfactants include: Anionic (based on sulfate, sulfonate or 35 carboxylate anions): perfluorooctanoate (PFOA or PFO), perfluorooctane sulfonate (PFOS), sodium dodecyl sulfate (SDS), ammonium lauryl sulfate, and other alkyl sulfate salts, sodium laureth sulfate (also known as sodium lauryl ether sulfate, or SLES), alkyl benzene sulfonate; cationic 40 (based on quaternary ammonium cations): cetyl trimethylammonium bromide (CTAB) a.k.a. hexadecyl trimethyl ammonium bromide, and other alkyltrimethylammonium salts, cetylpyridinium chloride (CPC), polyethoxylated tallow amine (POEA), benzalkonium chloride (BAC), benze- 45 thonium chloride (BZT); Zwitterionic (amphoteric): dodecyl betaine; cocamidopropyl betaine; coco ampho glycinate; nonionic: alkyl poly(ethylene oxide), alkylphenol poly(ethylene oxide), copolymers of poly(ethylene oxide) and poly (propylene oxide) (commercially known as Poloxamers or 50 Poloxamines), alkyl polyglucosides, including octyl glucoside, decyl maltoside, fatty alcohols (e.g., cetyl alcohol and oleyl alcohol), cocamide MEA, cocamide DEA, polysorbates (Tween 20, Tween 80, etc.), Triton® detergents, and dodecyl dimethylamine oxide.

As used herein, a "buffer" refers to a substance, generally a solution, that can keep its pH constant, despite the addition of strong acids or strong bases and external influences of temperature, pressure, volume or redox potential. A buffer prevents change in the concentration of another chemical 60 substance, e.g., proton donor and acceptor systems that prevent marked changes in hydrogen ion concentration (pH). The pH values of all buffers are temperature and concentration dependent. The choice of buffer to maintain a pH value or range can be empirically determined by one of 65 skill in the art based on the known buffering capacity of known buffers. Exemplary buffers include but are not lim-

ited to, bicarbonate buffer, cacodylate buffer, phosphate buffer or Tris buffer. For example, Tris buffer (tromethamine) is an amine based buffer that has a pKa of 8.06 and has an effective pH range between 7.9 and 9.2. For Tris buffers, pH increases about 0.03 unit per $^{\circ}$ C. temperature decrease, and decreases 0.03 to 0.05 unit per ten-fold dilution.

As used herein, the residues of naturally occurring α -amino acids are the residues of those 20 α -amino acids found in nature which are incorporated into protein by the specific recognition of the charged tRNA molecule with its cognate mRNA codon in humans.

As used herein, nucleic acids include DNA, RNA and analogs thereof, including peptide nucleic acids (PNA) and mixtures thereof. Nucleic acids can be single or doublestranded. When referring to probes or primers, which are optionally labeled, such as with a detectable label, such as a fluorescent or radiolabel, single-stranded molecules are contemplated. Such molecules are typically of a length such that their target is statistically unique or of low copy number (typically less than 5, generally less than 3) for probing or priming a library. Generally a probe or primer contains at least 14, 16 or 30 contiguous nucleotides of sequence complementary to or identical to a gene of interest. Probes and primers can be 10, 20, 30, 50, 100 or more nucleic acids long.

As used herein, a peptide refers to a polypeptide that is from 2 to 40 amino acids in length.

As used herein, the amino acids which occur in the various sequences of amino acids provided herein are identified according to their known, three-letter or one-letter abbreviations (Table 1). The nucleotides which occur in the various nucleic acid fragments are designated with the standard single-letter designations used routinely in the art.

As used herein, an "amino acid" is an organic compound containing an amino group and a carboxylic acid group. A polypeptide contains two or more amino acids. For purposes herein, amino acids include the twenty naturally-occurring amino acids, non-natural amino acids and amino acid analogs (i.e., amino acids wherein the α -carbon has a side chain).

As used herein, "amino acid residue" refers to an amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues ⁴⁵ described herein are presumed to be in the "L" isomeric form. Residues in the "D" isomeric form, which are so designated, can be substituted for any L-amino acid residue as long as the desired functional property is retained by the polypeptide. NH₂ refers to the free amino group present at ⁵⁰ the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxyl terminus of a polypeptide. In keeping with standard polypeptide nomenclature described in *J Biol. Chem.*, 243: 3557-3559 (1968), and adopted 37 C.F.R. §§ 1.821-1.822, abbreviations for ⁵⁵ amino acid residues are shown in Table 1:

TABLE 1

		Table of Corresp	ondence
)	SYMBO	L	
	1-Letter	3-Letter	AMINO ACID
	Y	Tyr	Tyrosine
	G	Gly	Glycine
5	F	Phe	Phenylalanine
	М	Met	Methionine

25

45

60

57

TABLE 1-continued						
Table of Correspondence						
SYMBOI						
1-Letter	3-Letter	AMINO ACID				
А	Ala	Alanine				
S	Ser	Serine				
Ι	Ile	Isoleucine				
L	Leu	Leucine				
Т	Thr	Threonine				
V	Val	Valine				
Р	Pro	Proline				
K	Lys	Lysine				
Н	His	Histidine				
Q	Gln	Glutamine				
E	Glu	Glutamic Acid				
Z	Glx	Glu and/or Gln				
W	Trp	Tryptophan				
R	Arg	Arginine				
D	Asp	Aspartic Acid				
Ν	Asn	Asparagine				
В	Asx	Asn and/or Asp				
С	Cys	Cysteine				
X Xaa Unknown or Other						

It should be noted that all amino acid residue sequences represented herein by formulae have a left to right orientation in the conventional direction of amino-terminus to carboxyl-terminus. In addition, the phrase "amino acid residue" is broadly defined to include the amino acids listed in 30 the Table of Correspondence (Table 1) and modified and unusual amino acids, such as those referred to in 37 C.F.R. §§ 1.821-1.822, and incorporated herein by reference. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino acid residues, to an amino-terminal group such as NH₂ or to a carboxyl-terminal group such as COOH.

As used herein, "naturally occurring amino acids" refer to 40 the 20 L-amino acids that occur in polypeptides.

As used herein, "non-natural amino acid" refers to an organic compound that has a structure similar to a natural amino acid but has been modified structurally to mimic the structure and reactivity of a natural amino acid. Nonnaturally occurring amino acids thus include, for example, amino acids or analogs of amino acids other than the 20 naturally-occurring amino acids and include, but are not limited to, the D-stereoisomers of amino acids. Exemplary non-natural amino acids are described herein and are known to those of skill in the art.

As used herein, an isokinetic mixture is one in which the molar ratios of amino acids has been adjusted based on their reported reaction rates (see, e.g., Ostresh et al., (1994) 55 Biopolymers 34:1681).

As used herein, suitable conservative substitutions of amino acids are known to those of skill in this art and can be made generally without altering the biological activity of the resulting molecule. Those of skill in the art recognize that, in general, single amino acid substitutions in nonessential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson et al. Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin/Cum-65 mings Pub. co., p. 224). Such substitutions can be made in accordance with those set forth in TABLE 2 as follows:

Original residue	Exemplary conservative substitution
Ala (A)	Gly; Ser
Arg (R)	Lys
Asn (N)	Gln; His
Cys (C)	Ser
Gln (Q)	Asn
Glu (E)	Asp
Gly (G)	Ala; Pro
His (H)	Asn; Gln
Ile (I)	Leu; Val
Leu (L)	Ile; Val
Lys (K)	Arg; Gln; Glu
Met (M)	Leu; Tyr; Ile
Phe (F)	Met; Leu; Tyr
Ser (S)	Thr
Thr (T)	Ser
Trp (W)	Tyr
Tyr (Y)	Trp; Phe
Val (V)	Ile; Leu

Other substitutions also are permissible and can be determined empirically or in accord with known conservative substitutions.

As used herein, a DNA construct is a single or double stranded, linear or circular DNA molecule that contains segments of DNA combined and juxtaposed in a manner not found in nature. DNA constructs exist as a result of human manipulation, and include clones and other copies of manipulated molecules.

As used herein, a DNA segment is a portion of a larger DNA molecule having specified attributes. For example, a DNA segment encoding a specified polypeptide is a portion of a longer DNA molecule, such as a plasmid or plasmid fragment, which, when read from the 5' to 3' direction, encodes the sequence of amino acids of the specified polypeptide.

As used herein, the term polynucleotide means a singleor double-stranded polymer of deoxyribonucleotides or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and can be isolated from natural sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules. The length of a polynucleotide molecule is given herein in terms of nucleotides (abbreviated "nt") or base pairs (abbreviated "bp"). The term nucleotides is used for single- and doublestranded molecules where the context permits. When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term base pairs. It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide can differ slightly in length and that the ends thereof can be staggered; thus all nucleotides within a double-stranded polynucleotide molecule cannot be paired. Such unpaired ends will, in general, not exceed 20 nucleotides in length.

As used herein, "at a position corresponding to" or recitation that nucleotides or amino acid positions "correspond to" nucleotides or amino acid positions in a disclosed sequence, such as set forth in the Sequence listing, refers to nucleotides or amino acid positions identified upon alignment with the disclosed sequence to maximize identity using a standard alignment algorithm, such as the GAP algorithm. For purposes herein, alignment of a PH20 sequence is to the amino acid sequence set forth in any of SEQ ID NOs: 3, 7 or 32-66, and in particular SEQ ID NO:3. Hence, reference herein that a position or amino acid replacement corresponds to positions with reference to SEQ ID NO:3 also means that the position or amino acid replacement corresponds to positions with reference to any of SEQ ID NOs: 7 or 32-66, since the sequences therein are identical to the correspond-5 ing residues as set forth in SEQ ID NO:3. By aligning the sequences, one skilled in the art can identify corresponding residues, for example, using conserved and identical amino acid residues as guides. In general, to identify corresponding positions, the sequences of amino acids are aligned so that the highest order match is obtained (see, e.g.: Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, 15 Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; Carrillo et al. (1988) SIAM J Applied 20 Math 48:1073). FIG. 2 (A-L) exemplifies exemplary alignments and identification of exemplary corresponding residues for replacement.

As used herein, "sequence identity" refers to the number of identical or similar amino acids or nucleotide bases in a 25 comparison between a test and a reference polypeptide or polynucleotide. Sequence identity can be determined by sequence alignment of nucleic acid or protein sequences to identify regions of similarity or identity. For purposes herein, sequence identity is generally determined by align- 30 ment to identify identical residues. Alignment can be local or global, but for purposes herein alignment is generally a global alignment where the full-length of each sequence is compared. Matches, mismatches and gaps can be identified between compared sequences. Gaps are null amino acids or 35 nucleotides inserted between the residues of aligned sequences so that identical or similar characters are aligned. Generally, there can be internal and terminal gaps. Sequence identity can be determined by taking into account gaps as the number of identical residues/length of the shortest 40 sequence×100. When using gap penalties, sequence identity can be determined with no penalty for end gaps (e.g., terminal gaps are not penalized). Alternatively, sequence identity can be determined without taking into account gaps as the number of identical positions/length of the total 45 aligned sequence×100.

As used herein, a "global alignment" is an alignment that aligns two sequences from beginning to end, aligning each letter in each sequence only once. An alignment is produced, regardless of whether or not there is similarity or identity 50 between the sequences. For example, 50% sequence identity based on "global alignment" means that in an alignment of the full sequence of two compared sequences each of 100 nucleotides in length, 50% of the residues are the same. It is understood that global alignment also can be used in deter- 55 mining sequence identity even when the length of the aligned sequences is not the same. The differences in the terminal ends of the sequences will be taken into account in determining sequence identity, unless the "no penalty for end gaps" is selected. Generally, a global alignment is used 60 on sequences that share significant similarity over most of their length. Exemplary algorithms for performing global alignment include the Needleman-Wunsch algorithm (Needleman et al. J. Mol. Biol. 48: 443 (1970). Exemplary programs for performing global alignment are publicly 65 available and include the Global Sequence Alignment Tool available at the National Center for Biotechnology Informa-

tion (NCBI) website (ncbi.nlm.nih.gov/), and the program available at deepc2.psi.iastate.edu/aat/align/align.html.

As used herein, a "local alignment" is an alignment that aligns two sequence, but only aligns those portions of the sequences that share similarity or identity. Hence, a local alignment determines if sub-segments of one sequence are present in another sequence. If there is no similarity, no alignment will be returned. Local alignment algorithms include BLAST or Smith-Waterman algorithm (*Adv. Appl. Math.* 2: 482 (1981)). For example, 50% sequence identity based on "local alignment" means that in an alignment of the full sequence of two compared sequences of any length, a region of similarity or identity of 100 nucleotides in length has 50% of the residues that are the same in the region of similarity or identity.

For purposes herein, sequence identity can be determined by standard alignment algorithm programs used with default gap penalties established by each supplier. Default parameters for the GAP program can include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non identities) and the weighted comparison matrix of Gribskov et al. Nucl. Acids Res. 14: 6745 (1986), as described by Schwartz and Dayhoff, eds., Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps. Whether any two nucleic acid molecules have nucleotide sequences or any two polypeptides have amino acid sequences that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical," or other similar variations reciting a percent identity, can be determined using known computer algorithms based on local or global alignment (see e.g., wikipedia.org/wiki/ Sequence_alignment_software, providing links to dozens of known and publicly available alignment databases and programs). Generally, for purposes herein sequence identity is determined using computer algorithms based on global alignment, such as the Needleman-Wunsch Global Sequence Alignment tool available from NCBI/BLAST (blast. ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&Page_TYPE= BlastHome); LAlign (William Pearson implementing the Huang and Miller algorithm (Adv. Appl. Math. (1991) 12:337-357)); and program from Xiaoqui Huang available at deepc2. psi.iastate.edu/aat/align/align.html. Generally, when comparing nucleotide sequences herein, an alignment with penalty for end gaps is used. Local alignment also can be used when the sequences being compared are substantially the same length.

Therefore, as used herein, the term "identity" represents a comparison or alignment between a test and a reference polypeptide or polynucleotide. In one non-limiting example, 'at least 90% identical to" refers to percent identities from 90 to 100% relative to the reference polypeptide or polynucleotide. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polypeptide or polynucleotide length of 100 amino acids or nucleotides are compared, no more than 10% (i.e., 10 out of 100) of amino acids or nucleotides in the test polypeptide or polynucleotide differs from that of the reference polypeptides. Similar comparisons can be made between a test and reference polynucleotides. Such differences can be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they can be clustered in one or more locations of varying length up to the maximum allowable, e.g., 10/100 amino acid difference (approximately 90% identity). Differences also can be due to deletions or truncations of amino acid 5

residues. Differences are defined as nucleic acid or amino acid substitutions, insertions or deletions. Depending on the length of the compared sequences, at the level of homologies or identities above about 85-90%, the result can be independent of the program and gap parameters set; such high levels of identity can be assessed readily, often without relying on software.

As used herein, an allelic variant or allelic variation references any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation 10 arises naturally through mutation, and can result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or can encode polypeptides having altered amino acid sequence. The term "allelic variant" also is used herein to denote a 15 protein encoded by an allelic variant of a gene. Typically the reference form of the gene encodes a wildtype form and/or predominant form of a polypeptide from a population or single reference member of a species. Typically, allelic variants, which include variants between and among species 20 typically have at least 80%, 90% or greater amino acid identity with a wildtype and/or predominant form from the same species; the degree of identity depends upon the gene and whether comparison is interspecies or intraspecies. Generally, intraspecies allelic variants have at least about 25 80%, 85%, 90% or 95% identity or greater with a wildtype and/or predominant form, including 96%, 97%, 98%, 99% or greater identity with a wildtype and/or predominant form of a polypeptide. Reference to an allelic variant herein generally refers to variations in proteins among members of 30 the same species.

As used herein, "allele," which is used interchangeably herein with "allelic variant" refers to alternative forms of a gene or portions thereof. Alleles occupy the same locus or position on homologous chromosomes. When a subject has 35 two identical alleles of a gene, the subject is said to be homozygous for that gene or allele. When a subject has two different alleles of a gene, the subject is said to be heterozygous for the gene. Alleles of a specific gene can differ from each other in a single nucleotide or several nucleotides, and 40 than about 20% of non-enzyme proteins or 10% of noncan include modifications such as substitutions, deletions and insertions of nucleotides. An allele of a gene also can be a form of a gene containing a mutation.

As used herein, species variants refer to variants in polypeptides among different species, including different 45 mammalian species, such as mouse and human. Exemplary of species variants provided herein are primate PH20, such as, but not limited to, human, chimpanzee, macaque, cynomolgus monkey, gibbon, orangutan, or marmoset. Generally, species variants have 70%, 75%, 80%, 85%, 90%, 91%, 50 92%, 93%, 94%, 95%, 96%, 97%, or 98% sequence identity. Corresponding residues between and among species variants can be determined by comparing and aligning sequences to maximize the number of matching nucleotides or residues, for example, such that identity between the sequences is 55 equal to or greater than 95%, equal to or greater than 96%, equal to or greater than 97%, equal to or greater than 98% or equal to greater than 99%. The position of interest is then given the number assigned in the reference nucleic acid molecule. Alignment can be effected manually or by eye, 60 using recombinant DNA methods means the use of the well particularly where sequence identity is greater than 80%.

As used herein, substantially pure means sufficiently homogeneous to appear free of readily detectable impurities, as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel electrophoresis and high 65 performance liquid chromatography (HPLC), used by those of skill in the art to assess such purity, or sufficiently pure

such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance. Methods for purification of the compounds to produce substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure compound can, however, be a mixture of stereoisomers or isomers. In such instances, further purification might increase the specific activity of the compound.

As used herein, isolated or purified polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. Preparations can be determined to be substantially free if they appear free of readily detectable impurities as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel electrophoresis and high performance liquid chromatography (HPLC), used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance. Methods for purification of the compounds to produce substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure compound, however, can be a mixture of stereoisomers. In such instances, further purification might increase the specific activity of the compound.

Hence, reference to a substantially purified polypeptide, such as a substantially purified PH20 polypeptide refers to preparations of PH20 proteins that are substantially free of cellular material, includes preparations of proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the term substantially free of cellular material includes preparations of enzyme proteins having less than about 30% (by dry weight) of non-enzyme proteins (also referred to herein as contaminating proteins), generally less enzyme proteins or less than about 5% of non-enzyme proteins. When the enzyme protein is recombinantly produced, it also is substantially free of culture medium, i.e., culture medium represents less than about or at 20%, 10% or 5% of the volume of the enzyme protein preparation.

As used herein, the term substantially free of chemical precursors or other chemicals includes preparations of enzyme proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. The term includes preparations of enzyme proteins having less than about 30% (by dry weight), 20%, 10%, 5% or less of chemical precursors or non-enzyme chemicals or components.

As used herein, synthetic, with reference to, for example, a synthetic nucleic acid molecule or a synthetic gene or a synthetic peptide refers to a nucleic acid molecule or polypeptide molecule that is produced by recombinant methods and/or by chemical synthesis methods.

As used herein, production by recombinant means or known methods of molecular biology for expressing proteins encoded by cloned DNA.

As used herein, vector (or plasmid) refers to discrete elements that are used to introduce a heterologous nucleic acid into cells for either expression or replication thereof. The vectors typically remain episomal, but can be designed to effect integration of a gene or portion thereof into a 10

chromosome of the genome. Also contemplated are vectors that are artificial chromosomes, such as yeast artificial chromosomes and mammalian artificial chromosomes. Selection and use of such vehicles are well known to those of skill in the art.

As used herein, an expression vector includes vectors capable of expressing DNA that is operatively linked with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Such additional segments can include promoter and terminator sequences, and optionally can include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or 15 agent and one or more excipients. can contain elements of both. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA. Appropriate expression 20 vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

As used herein, vector also includes "virus vectors" or 25 "viral vectors." Viral vectors are engineered viruses that are operatively linked to exogenous genes to transfer (as vehicles or shuttles) the exogenous genes into cells. Viral vectors include, but are not limited to, adenoviral vectors, retroviral vectors and vaccinia virus vectors.

As used herein, "operably" or "operatively linked" when referring to DNA segments means that the segments are arranged so that they function in concert for their intended purposes, e.g., transcription initiates downstream of the promoter and upstream of any transcribed sequences. The 35 promoter is usually the domain to which the transcriptional machinery binds to initiate transcription and proceeds through the coding segment to the terminator.

As used herein, a conjugate refers to a modified PH20 polypeptide linked directly or indirectly to one or more other 40 polypeptides or chemical moieties. Such conjugates include fusion proteins, those produced by chemical conjugates and those produced by any other method whereby at least one modified PH20 polypeptide is linked, directly or indirectly to another polypeptide or chemical moiety so long as the 45 conjugate retains hyaluronidase activity. Exemplary of conjugates provided herein include PH20 polypeptides linked directly or indirectly to a multimerization domain (e.g. an Fc moiety), a toxin, a label or a drug.

As used herein, a fusion protein refers to a polypeptide 50 encoded by a nucleic acid sequence containing a coding sequence from one nucleic acid molecule and the coding sequence from another nucleic acid molecule in which the coding sequences are in the same reading frame such that when the fusion construct is transcribed and translated in a 55 host cell, the protein is produced containing the two proteins. The two molecules can be adjacent in the construct or separated by a linker polypeptide that contains, 1, 2, 3, or more, but typically fewer than 10, 9, 8, 7, or 6 amino acids. The protein product encoded by a fusion construct is 60 referred to as a fusion polypeptide. Examples of fusion polypeptides include Fc fusions.

As used herein, a polymer that is conjugated to a modified PH20 polypeptide refers to any polymer that is covalently or otherwise stably linked, directly or via a linker, to such 65 polypeptide. Such polymers, typically increase serum halflife, and include, but are not limited to, sialic moieties,

polyethylene glycol (PEG) moieties, dextran, and sugar and other moieties, such as for glycosylation.

As used herein, the term assessing or determining is intended to include quantitative and qualitative determina-5 tion in the sense of obtaining an absolute value for the activity of a product, and also of obtaining an index, ratio, percentage, visual or other value indicative of the level of the activity. Assessment can be direct or indirect.

As used herein, a "composition" refers to any mixture of two or more products or compounds. It can be a solution, a suspension, liquid, powder, a paste, aqueous, non-aqueous, or any combination thereof.

As used herein, a formulation refers to a composition containing at least one active pharmaceutical or therapeutic

As used herein, a co-formulation refers to a composition containing two or more active or pharmaceutical or therapeutic agents and one or more excipients. For example, a co-formulation of a fast-acting insulin and a hyaluronan degrading enzyme contains a fast-acting insulin, a hyaluronan degrading enzyme, and one or more excipients.

As used herein, "a combination" refers to any association between two or among more items or elements. Exemplary combinations include, but are not limited to, two or more pharmaceutical compositions, a composition containing two or more active ingredients, such as two modified PH20 polypeptides; a modified PH20 polypeptide and an anticancer agent, such as a chemotherapeutic compound; a modified PH20 polypeptide and a therapeutic agent (e.g. an insulin); a modified PH20 polypeptide and a plurality therapeutic and/or imaging agents, or any association thereof. Such combinations can be packaged as kits.

As used herein, a kit is a packaged combination, optionally, including instructions for use of the combination and/or other reactions and components for such use.

As used herein, "disease or disorder" refers to a pathological condition in an organism resulting from cause or condition including, but not limited to, infections, acquired conditions, genetic conditions, and characterized by identifiable symptoms.

As used herein, a hyaluronan-associated disease, disorder or condition refers to any disease or condition in which hyaluronan levels are elevated as cause, consequence or otherwise observed in the disease or condition. Hyaluronanassociated diseases and conditions are associated with elevated hyaluronan expression in a tissue or cell, increased interstitial fluid pressure, decreased vascular volume, and/or increased water content in a tissue. Hyaluronan-associated diseases, disorders or conditions can be treated by administration of a composition containing a hyaluronan degrading enzyme, such as a hyaluronidase, for example, a soluble hyaluronidase, either alone or in combination with or in addition to another treatment and/or agent. Exemplary diseases and conditions, include, but are not limited to, hyaluronan-rich cancers, for example, tumors, including solid tumors such as late-stage cancers, metastatic cancers, undifferentiated cancers, ovarian cancer, in situ carcinoma (ISC), squamous cell carcinoma (SCC), prostate cancer, pancreatic cancer, non-small cell lung cancer, breast cancer, colon cancer and other cancers. Exemplary hyaluronan-associated diseases and conditions also are diseases that are associated with elevated interstitial fluid pressure, such as diseases associated with disc pressure, and edema, for example, edema caused by organ transplant, stroke, brain trauma or other injury. Exemplary hyaluronan-associated diseases and conditions include diseases and conditions associated with elevated interstitial fluid pressure, decreased vascular volume, and/or increased water content in a tissue, including cancers, disc pressure and edema. In one example, treatment of the hyaluronan-associated condition, disease or disorder includes amelioration, reduction, or other beneficial effect on one or more of increased interstitial fluid pressure (IFP), 5 decreased vascular volume, and increased water content in a tissue.

As used herein, "treating" a subject with a disease or condition means that the subject's symptoms are partially or totally alleviated, or remain static following treatment. 10 Hence treatment encompasses prophylaxis, therapy and/or cure. Prophylaxis refers to prevention of a potential disease and/or a prevention of worsening of symptoms or progression of a disease. Treatment also encompasses any pharmaceutical use of a modified interferon and compositions 15 provided herein.

As used herein, a pharmaceutically effective agent or therapeutic agent includes any bioactive agent that can exhibit a therapeutic effect to treat a disease or disorder. Exemplary therapeutic agents are described herein. Thera-20 peutic agents include, but are not limited to, anesthetics, vasoconstrictors, dispersing agents, conventional therapeutic drugs, including small molecule drugs, including, but not limited to, bisphosphonates, and therapeutic proteins, including, but not limited to, insulin, IgG molecules, anti- 25 bodies, cytokines and coagulation factors.

As used herein, "insulin" refers to a hormone, precursor or a synthetic or recombinant analog thereof that acts to increase glucose uptake and storage and/or decrease endogenous glucose production. Insulin and analogs thereof are 30 well known to one of skill in the art, including in human and allelic and species variants thereof. Insulin is translated as a precursor polypeptide designated preproinsulin (110 amino acid for human insulin), containing a signal peptide that directs the protein to the endoplasmic reticulum (ER) 35 wherein the signal sequence is cleaved, resulting in proinsulin. Proinsulin is processed further to release a C- or connecting chain peptide (a 31 amino acid C-chain in human insulin). The resulting insulin contains an A-chain (21 amino acid in length in human insulin; set forth in SEQ ID NO:862) 40 or more amino acid substitutions, to be more rapid acting and a B-chain (30 amino acid in length in human insulin; set forth in SEQ ID NO:863) which are cross-linked by disulfide bonds. A fully cross-linked human insulin contains three disulfide bridges: one between position 7 of the A-chain and position 7 of the B-chain, a second between position 20 of 45 the A-chain and position 19 of the B-chain, and a third between positions 6 and 11 of the A-chain. Reference to an insulin includes monomeric and multimeric insulins, including hexameric insulins, as well as humanized insulins. Exemplary insulin polypeptides are those of mammalian, 50 including human, origin. Reference to insulin includes preproinsulin, proinsulin and insulin polypeptides in singlechain or two-chain forms, truncated forms thereof that have activity, and includes allelic variants and species variants of human insulin, variants encoded by splice variants, and 55 other variants, such as insulin analogs. An exemplary insulin is human insulin having a sequence of amino acids of the Aand B-chains of human insulin are set forth in SEQ ID NOs: 862 and 863, respectively, and variants or analogs thereof that exhibit at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 60 95%, 96%, 97%, 98% or 99% sequence identity thereto to one or both of the A-chain or B-chain and that acts to increase glucose uptake and storage and/or decrease endogenous glucose production. A further exemplary insulin is porcine insulin having a sequence of amino acids for the 65 preproinsulin as set forth in SEQ ID NO:864, whereby the A chain corresponds to amino acid residue positions 88-108

66

and the B-chain correspond to amino acid, and variants or analogs thereof that exhibit at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto to one or both of the A-chain or B-chain and that acts to increase glucose uptake and storage and/or decrease endogenous glucose production.

As used herein, "fast-acting insulin" refers to any insulin that exhibits peak insulin levels at or about not more than four hours following subcutaneous administration to a subject. Fast-acting insulins include any insulin or any fastacting insulin composition for acute administration to a diabetic subject in response to an actual, perceived, or anticipated hyperglycemic condition in the subject arising at the time of, or within about four hours following, administration of the fast-acting insulin (such as a prandial hyperglycemic condition resulting or anticipated to result from, consumption of a meal), whereby the fast-acting insulin is able to prevent, control or ameliorate the acute hyperglycemic condition. Fast-acting insulins include recombinant insulins and isolated insulins (also referred to as "regular" insulins) such as the insulin sold as human insulin, porcine insulins and bovine insulins, as well as rapid acting insulin analogs (also termed fast-acting insulin analogs herein) designed to be rapid acting by virtue of amino acid changes. Exemplary regular insulin preparations include, but are not limited to, human regular insulins, such as those sold under the trademarks Humulin® R, Novolin® R and Velosulin®, Insulin Human, USP and Insulin Human Injection, USP, as well as acid formulations of insulin, such as, for example, Toronto Insulin, Old Insulin, and Clear Insulin, and regular pig insulins, such as Iletin II© insulin (porcine insulin). Regular insulins typically have an onset of action of between 30 minutes to an hour, and a peak insulin level of 2-5 hours post administration.

As used herein, rapid acting insulin analogs (also called fast-acting insulin analogs) are insulins that have a rapid onset of action. Rapid insulins typically are insulin analogs that have been engineered, such as by the introduction of one than regular insulins. Rapid acting insulin analogs typically have an onset of action of 10-30 minutes post injection, with peak insulin levels observed 30-90 minutes post injection. Exemplary rapid acting insulin analogs are analogs of human insulin containing one or more amino acid changes in the A-chain and/or B-chain of human insulin set forth in SEQ ID NO:862 or 863, respectively, and that exhibit an onset of action 10-30 minutes post injection with peak insulin levels observed 30-90 minutes post injection. Exemplary rapid acting insulin analogs include, but are not limited to, for example, insulin lispro (e.g., Humalog® insulin), insulin aspart (e.g., NovoLog® insulin), and insulin glulisine (e.g., Apidra® insulin) the fast-acting insulin composition sold as VIAject® and VIAtab® (see, e.g., U.S. Pat. No. 7,279,457). The amino acid sequence of exemplary rapid acting insulin analogs have an A chain with a sequence of amino acids set forth in SEQ ID NO:862 and a B chain having a sequence of amino acids set forth in any of SEQ ID NOs:865-867. Also included are any other insulins that have an onset of action of 30 minutes or less and a peak level before 90 minutes, typically 30-90 minutes, post injection.

As used herein, a human insulin refers to an insulin that is synthetic or recombinantly produced based upon the human polypeptide, including allelic variants and analogs thereof.

As used herein, fast-acting human insulins or human fast-acting insulin compositions include any human insulin 10

or composition of a human insulin that is fast-acting, but excludes non-human insulins, such as regular pig insulin.

As used herein, the terms "basal-acting insulins," or "basal insulins" refer to insulins administered to maintain a basal insulin level as part of an overall treatment regimen for treating a chronic condition such diabetes. Typically, a basal-acting insulin is formulated to maintain an approximately steady state insulin level by the controlled release of insulin when administered periodically (e.g., once ortwice daily). Basal-acting insulins include crystalline insulins (e.g., NPH and Lente*, protamine insulin, surfen insulin), basal insulin analogs (insulin glargine, HOE 901, NovoSol Basal) and other chemical formulations of insulin (e.g., gum arabic, lecithin or oil suspensions) that retard the absorption 15 rate of regular insulin. As used herein, the basal-acting insulins can include insulins that are typically understood as long-acting (typically reaching a relatively low peak concentration, while having a maximum duration of action over about 20-30 hours) or intermediate-acting (typically causing 20 peak insulin concentrations at about 4-12 hours after administration).

As used herein, treatment means any manner in which the symptoms of a condition, disorder or disease or other indication, are ameliorated or otherwise beneficially altered. 25

As used herein, therapeutic effect means an effect resulting from treatment of a subject that alters, typically improves or ameliorates the symptoms of a disease or condition or that cures a disease or condition. A therapeutically effective amount refers to the amount of a composi- 30 tion, molecule or compound which results in a therapeutic effect following administration to a subject.

As used herein, the term "subject" refers to an animal, including a mammal, such as a human being.

As used herein, a patient refers to a human subject 35 exhibiting symptoms of a disease or disorder.

As used herein, amelioration of the symptoms of a particular disease or disorder by a treatment, such as by administration of a pharmaceutical composition or other therapeutic, refers to any lessening, whether permanent or 40 temporary, lasting or transient, of the symptoms that can be attributed to or associated with administration of the composition or therapeutic.

As used herein, prevention or prophylaxis refers to methods in which the risk of developing a disease or condition is 45 reduced

As used herein, a "therapeutically effective amount" or a "therapeutically effective dose" refers to the quantity of an agent, compound, material, or composition containing a compound that is at least sufficient to produce a therapeutic 50 effect. Hence, it is the quantity necessary for preventing, curing, ameliorating, arresting or partially arresting a symptom of a disease or disorder.

As used herein, unit dose form refers to physically discrete units suitable for human and animal subjects and 55 packaged individually as is known in the art.

As used herein, a single dosage formulation refers to a formulation containing a single dose of therapeutic agent for direct administration. Single dosage formulations generally do not contain any preservatives.

As used herein, a multi-dose formulation refers to a formulation that contains multiple doses of a therapeutic agent and that can be directly administered to provide several single doses of the therapeutic agent. The doses can be administered over the course of minutes, hours, weeks, 65 days or months. Multidose formulations can allow dose adjustment, dose-pooling and/or dose-splitting. Because

multi-dose formulations are used over time, they generally contain one or more preservatives to prevent microbial growth.

As used herein, an "article of manufacture" is a product that is made and sold. As used throughout this application, the term is intended to encompass a therapeutic agent with a soluble PH20, such as esPH20, or an esPH20 alone, contained in the same or separate articles of packaging.

As used herein, fluid refers to any composition that can flow. Fluids thus encompass compositions that are in the form of semi-solids, pastes, solutions, aqueous mixtures, gels, lotions, creams and other such compositions.

As used herein, a "control" or "standard" refers to a sample that is substantially identical to the test sample, except that it is not treated with a test parameter, or, if it is a plasma sample, it can be from a normal volunteer not affected with the condition of interest. A control also can be an internal control. For example, a control can be a sample, such as a virus, that has a known property or activity.

As used herein, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an" agent includes one or more agents.

As used herein, the term "or" is used to mean "and/or" unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive.

As used herein, ranges and amounts can be expressed as "about" a particular value or range. About also includes the exact amount. Hence "about 5 bases" means "about 5 bases" and also "5 bases."

As used herein, "optional" or "optionally" means that the subsequently described event or circumstance does or does not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, an optionally substituted group means that the group is unsubstituted or is substituted.

As used herein, the abbreviations for any protective groups, amino acids and other compounds, are, unless indicated otherwise, in accord with their common usage, recognized abbreviations, or the IUPAC-IUB Commission on Biochemical Nomenclature (see, (1972) Biochem. 11:1726).

For clarity of disclosure, and not by way of limitation, the detailed description is divided into the subsections that follow.

B. PH20 Hyaluronidase

Provided herein are modified PH20 polypeptides. PH20 (also known as sperm surface protein, sperm adhesion molecule 1 or SPAM1) is a hyaluronidase that hydrolyzes hyaluronan (also called hyaluronic acid, hyaluronate or HA) found in connective tissues such as the extracellular matrix. Hyaluronan polymers are composed of repeating disaccharide units, D-glucuronic acid (GlcA) and N-acetyl-D-glucosamine (GlcNAc), linked together via alternating β -1 \rightarrow 4 and β -1 \rightarrow 3 glycosidic bonds. Hyaluronan chains can reach about 25,000 disaccharide repeats or more in length, and polymers of hyaluronan can range in size from about 5,000 60 to 20,000,000 Da in vivo. Hyaluronan, also called hyaluronic acid or hyaluronate, is a non-sulfated glycosaminoglycan that is widely distributed throughout connective, epithelial, and neural tissues. Hyaluronan is an essential component of the extracellular matrix and a major constituent of the interstitial barrier. PH20 is an endo-β-N-acetylhexosaminidase that hydrolyzes the $\beta 1 \rightarrow 4$ glycosidic bond of hyaluronic acid into various oligosaccharide lengths such as tetrasaccharides and hexasaccharides. PH20 has both hydrolytic and transglycosidase activities. In addition to degrading hyaluronic acid, PH20 also can degrade chondroitin sulfates, such as C4-S and C6-S. PH20 can exhibit hyaluronidase activity at acidic pH and neutral pH. 1. Structure

PH20 cDNA has been cloned from numerous mammalian species. Exemplary PH20 precursor polypeptides include, but are not limited to, human (SEQ ID NO:6), bovine (SEQ ID NOs:15 or 17), rabbit (SEQ ID NO:23), Cynomolgus 10 monkey (SEQ ID NO: 13), guinea pig (SEQ ID NO:28), rat (SEQ ID NO:21), mouse (SEQ ID NO: 19), chimpanzee (SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:869) Rhesus monkey (SEQ ID NO: 11), Fox (SEQ ID NO: 30), Gibbon (SEQ ID NO:856), Marmoset (SEQ ID NO:858) or orang-15 utan (SEQ ID NO:860) PH20 polypeptides. The mRNA transcript is typically translated to generate a precursor protein containing a 35 amino acid signal sequence at the N-terminus. Following transport to the ER, the signal peptide is removed to yield a mature PH20 polypeptide. Exem- 20 plary mature PH20 polypeptides include, but are not limited to, human (SEQ ID NO:7), bovine (SEQ ID NOs:16 or 18), rabbit (SEQ ID NO:24), Cynomolgus monkey (SEQ ID NO: 14), guinea pig (SEQ ID NO:29), rat (SEQ ID NO:22), mouse (SEQ ID NO:20), chimpanzee (SEQ ID NO: 10 or 25 SEQ ID NO:870), Rhesus monkey (SEQ ID NO: 12), Fox (SEQ ID NO:31), Gibbon (SEQ ID NO:857), Marmoset (SEQ ID NO:859) or orangutan (SEQ ID NO:861) PH20 polypeptides. For example, the human PH20 mRNA transcript is normally translated to generate a 509 amino acid 30 precursor protein (SEQ ID NO:6) containing a 35 amino acid signal sequence at the N-terminus (amino acid residue positions 1-35 of SEQ ID NO:6). Thus, following transport to the ER and removal of the signal peptide, a 474 amino acid mature polypeptide with an amino acid sequence set 35 forth in SEQ ID NO:7 is produced. Sequences of PH20 from ovine are also known (see e.g., SEQ ID NOs: 25-27).

In particular, human PH20 has the sequence of amino acids set forth in SEQ ID NO:6. The mature human PH20 lacking a signal sequence is set forth in SEQ ID NO:7. 40 Allelic variants and other variants of PH20 are known. Other sequences of PH20 have been reported. For example, a PH20 variant is known as set forth in the precursor sequence set forth in SEQ ID NO:68 that contains an Ala at position 48 and a Trp at position 499, or the mature sequence thereof 45 set forth in SEQ ID NO:69 containing the corresponding differences at positions 13 and 464, respectively, compared to the sequence set forth in SEQ ID NO:7 (see e.g., Gmachl et al. (1993) FEBS Lett., 336:545-548; GenBank Accession No. AAC60607). Further, a natural variant of PH20 has been 50 identified containing a Glutamine (Gln; Q) at position 5 as compared to the precursor sequence of amino acids set forth in SEQ ID NO:6 (see e.g., SEQ ID NO:70, see also Varela et al. (2011) Nature, 469:539-542). Another natural variant contains an Alanine (Ala; A) at position 47 compared to the 55 sequence of amino acids set forth in SEQ ID NO:6 (as set forth in SEQ ID NO: 71) and corresponding to position 12 compared to the sequence of amino acids set forth in SEQ ID NO: 3 or 7 (as set forth in SEQ ID NO:72).

The sequence and structure of PH20 polypeptides is 60 highly conserved. Sequence identity between and among PH20 proteins from various species is about 50% to 90%. The hydrophobic N-terminal signal sequence of 35 amino acids in length is generally conserved among PH20 hyaluronidase polypeptides. PH20 hyaluronidases contain a 65 common core hyaluronidase domain region of about 340 amino acids in length that corresponds to amino acid resi-

dues 38-374 of the precursor human PH20 sequence set forth in SEQ ID NO:6. A mature PH20 polypeptide lacking the signal sequence and containing a contiguous sequence of amino acids having a C-terminal amino acid residue corresponding to amino acid residue scoresponding to positions 36-464 of the amino acid sequence set forth in SEQ ID NO:6 (e.g., amino acid sequence set forth in SEQ ID NO:6) is the minimal sequence required for hyaluronidase activity (see e.g., U.S. patent application Ser. No. 10/795,095, which is
10 issued as U.S. Pat. No. 7,767,429; see also U.S. Publication No. US20100143457).

Within the common hyaluronidase domain region, at least 57 amino acids are conserved between and among species (see e.g., Arming et al. (1997) Eur. J. Biochem., 247:810-814; ten Have et al. (1998) Reprod. Fertil. Dev., 10:165-72; Chowpongpang et al. (2004) Biotechnology Letters, 26:1247-1252). For example, PH20 hyaluronidases contain 12 conserved cysteine residues corresponding to amino acid residue 25, 189, 203, 316, 341, 346, 352, 400, 402, 408, 423 and 429 of the sequence of amino acids of a mature PH20 lacking the signal sequence such as set forth in SEQ ID NO: 3 or 7 (corresponding to amino acid residues 60, 224, 238, 351, 376, 381, 387, 435, 437, 443, 458 or 464 of full-length human PH20 set forth in SEQ ID NO:6). Cysteine residues corresponding to 25 and 316 and cysteine residues corresponding to 189 and 203 form disulfide bridges. The other cysteine residues also form disulfide bridges, are involved in posttranslational protein maturation and/or in activity modulation. For example, further four disulfide bonds are formed between the cysteine residues C376 and C387; between C381 and C435; between C437 and C443; and between C458 and C464 of the polypeptide exemplified in SEQ ID NO:6 (corresponding to positions C341 and C352; between C346 and C400; between C402 and C408; and between C423 and C429 of the mature polypeptide set forth in SEQ ID NO:3 or 7, respectively).

Amino acid residues corresponding to amino acid residue D111, E113 and E249 of the sequence of amino acids set forth in SEQ ID NO: 3 or 7 are acidic residues part of the enzyme active site and are conserved between and among PH20 species. Amino acid residues R176, R246, R252 of the sequence of amino acids set forth in SEQ ID NO: 3 or 7 are also conserved between and among species and contribute to substrate binding and/or hyaluronidase activity. Amino acid mutations D111N, E113Q, R176G, E249N and R252T result in enzymes that have no detectable enzymatic activity or residual enzymatic activity (see e.g., Arming et al. (1997) *Eur. J. Biochem.*, 247:810-814).

The results herein confirm the requirement of PH20 amino acid residues corresponding to positions 25, 111, 113, 176, 189, 203, 246, 249, 252, 316, 341, 346, 352, 400, 402, 408, 423 and 429 of the sequence of amino acids set forth in a mature PH20 lacking the signal sequence such as set forth in SEQ ID NO: 3 or 7 for hyaluronidase activity, since mutagenesis of these residues results in an enzyme that is not active (e.g., it is not expressed or is inactive when expressed, see e.g., Tables 5 and 10). The exception is that amino acid replacement corresponding to R176K and C316D resulted in mutants that generated some residual hyaluronidase activity.

Glycosylation also is required for PH20 hyaluronidase activity based on the recognition motif NxS or NxT. There are six N-linked oligosaccharides at amino acid residues corresponding to positions N47, N131, N200, N219, N333 and N358 of the sequence of amino acids set forth in SEQ ID NO: 3 or 7 (corresponding to amino acid residues N82, N166, N235, N254, N368 and N393 of human PH20 set forth in SEQ ID NO: 6). In particular, at least N-linked

glycosylation sites corresponding to amino acid residues N200, N333 and N358 are required for secretion and/or activity of the enzyme (see e.g., U.S. Publication No. US20100143457). For example, a PH20 polypeptide containing amino acid mutations N200A, N333A, N358A or 5 N333A/N393A result in inactive proteins. Single mutations of glycosylation sites N47A, N131A, N219A, N47A/ N131A, N47A/N219A, N131A/N291A retain activity. The N-linked glycosylation site corresponding to amino acid residue N368 of human PH20 set forth in SEQ ID NO:6 is 10 conserved between and among species (see e.g., Chowpongpang et al. (2004) Biotechnology Letters, 26:1247-1252). PH20 hyaluronidases also contains O-linked glycosylation sites. For example, human PH20 has one O-linked oligosaccharide at the amino acid residue corresponding to 15 amino acid T440 of the sequence of amino acids set forth in SEQ ID NO:3 or 7 (corresponding to amino acid residue T475 in SEQ ID NO:6).

In addition to the catalytic sites, PH20 also contains a hyaluronan-binding site. This site is located in the Peptide 2 20 region, which corresponds to amino acid positions 205-235 of the precursor polypeptide set forth in SEQ ID NO:6 and positions 170-200 of the mature polypeptide set forth in SEQ ID NO:3 or 7. This region is highly conserved among hyaluronidases and is similar to the heparin binding motif 25 Mutation of the arginine residue at position 176 (corresponding to the mature PH20 polypeptide set forth in SEQ ID NO:3 or 7) to a glycine results in a polypeptide with only about 1% of the hyaluronidase activity of the wild type polypeptide (Arming et al., (1997) *Eur. J. Biochem.* 247: 30 810-814).

PH20 polypeptides contain a glycosyl phosphatidylinositol (GPI) anchor attached to the C-terminus of the protein that anchors the protein to the extracellular leaflet of the plasma membrane of cells. At least human, monkey, mouse 35 and guinea pig PH20 are strongly attached to the plasma membrane via the GPI anchor, which can be released by treating with phosphatidylinositol-specific phospholipase C (PI-PLC; see e.g., Lin et al. (1994) Journal of Cell Biology, 125:1157-1163; Lin et al. (1993) Proc. Natl. Acad. Sci., 40 90:10071-10075). Other PH20 enzymes, such as bovine PH20, are loosely attached to the plasma membrane and are not anchored via a phospholipase sensitive anchor. As discussed below, soluble active forms that, when expressed, are not attached to the membrane but are secreted can be 45 generated by removal of all of a portion of the GPI anchor attachment signal site (see also U.S. Pat. No. 7.767.429; U.S. Publication No. US20100143457). These include, for example, soluble PH20 polypeptides set forth in any of SEQ ID NOs: 3 or 32-66, or precursor forms thereof containing 50 a signal sequence.

GPI-anchored proteins, for example human PH20, are translated with a cleavable N-terminal signal peptide that directs the protein to the endoplasmic reticulum (ER). At the C-terminus of these proteins is another signal sequence that 55 directs addition of a preformed GPI-anchor to the polypeptide within the lumen of the ER. Addition of the GPI anchor occurs following cleavage of the C-terminal portion at a specific amino acid position, called the ω -site (typically located approximately 20-30 amino acids from the C-termi- 60 nus). Although there appears to be no consensus sequence to identify the location of the ω -site, GPI anchored proteins contain a C-terminal GPI-anchor attachment signal sequence or domain that typically contains a predominantly hydrophobic region of 8-20 amino acids, preceded by a 65 hydrophilic spacer region of 8-12 amino acids immediately downstream of the ω -site. This hydrophilic spacer region

often is rich in charged amino acids and proline (White et al. (2000) *J. Cell Sci.* 113(Pt.4):721-727). There is generally a region of approximately 11 amino acids before the ω -1 position that is characterized by a low amount of predicted secondary structure, a region around the cleavage site (ω -site), from ω -1 to ω +2 that is characterized by the presence of small side chain residues, the spacer region between positions ω +3 and ω +9, and a hydrophobic tail from ω +10 to the C-terminal end (Pierleoni et al., (2008) *BMC Bioinformatics* 9:392).

Although there is no GPI-anchor attachment signal consensus sequence, various in silico methods and algorithms have been developed that can be used to identify such sequences in polypeptides (see, e.g., Udenfriend et al. (1995) Methods Enzymol. 250:571-582; Eisenhaber et al. (1999) J. Mol. Chem. 292: 741-758; Kronegg and Buloz, (1999), "Detection/prediction of GPI cleavage site (GPIanchor) in a protein (DGPI)," 129.194.185.165/dgpi/; Fankhauser et al. (2005) Bioinformatics 21:1846-1852; Omaetxebarria et al. (2007) Proteomics 7:1951-1960; Pierleoni et al. (2008) BMC Bioinformatics 9:392), including those that are readily available on bioinformatic websites, such as the ExPASy Proteomics tools site (expasy.ch/tools/). Thus, one of skill in the art can determine whether a PH20 polypeptide likely contains a GPI-anchor attachment signal sequence, and, therefore, whether the PH20 polypeptide is a GPI-anchored protein.

The covalent attachment of a GPI-anchor to the C-terminus of human PH20 and, therefore, the membrane-bound nature of PH20, has been confirmed using phosphatidylinositol-specific phospholipase C (PI-PLC) hydrolysis studies (see e.g., Lin et al., (1994) J. Biol. Chem. 125:1157-1163). Phosphatidylinositol-specific phospholipase C (PI-PLC) and D (PI-PLD) hydrolyze the GPI anchor, releasing the PH20 polypeptide from the cell membrane. The prior art literature reports that a ω -site cleavage site of human PH20 is identified between Ser-490 and Ala-491 and for monkey PH20 is identified between Ser491 and Thr492 (Lin et al. (1993) Proc. Natl. Acad. Sci, (1993) 90:10071-10075). Thus, the literature reports that a GPI-anchor attachment signal sequence of human PH20 is located at amino acid positions 491-509 of the precursor polypeptide set forth in SEQ ID NO:6, and the ω -site is amino acid position 490. Thus, in this modeling of human PH20, amino acids 491-509 are cleaved following transport to the ER and a GPI anchor is covalently attached to the serine residue at position 490

2. Function

PH20 is normally expressed in sperm from a single testis-specific gene. PH20 is a sperm-associated protein involved in fertilization. PH20 is normally localized on the sperm surface, and in the lysosome-derived acrosome, where it is bound to the inner acrosomal membrane. PH20 is multifunctional and exhibits hyaluronidase activity, hyaluronan (HA)-mediated cell-signaling activity, and acts as a sperm receptor for the zona pellucida surrounding the oocyte when present on acrosome reacted (AR) sperm. For example, PH20 is naturally involved in sperm-egg adhesion and aids penetration by sperm of the layer of cumulus cells by digesting hyaluronic acid. In addition to being a hyaluronidase, PH20 also appears to be a receptor for HA-induced cell signaling, and a receptor for the zona pellucida surrounding the oocyte. Due to the role of PH20 in fertilization, PH20 can be used as an antigen for immunocontraception.

PH20 is a neutral active hyaluronidase, although it can exhibit acid-active activity in some cases. The hyaluronidase

activity of PH20 is exhibited by the plasma membrane- and inner acrosomal membrane-associated PH20. The plasma membrane PH20 exhibits hyaluronidase activity only at neutral pH, while the inner acrosomal membrane-associated PH20 exhibits acid-active enzyme activity. The structural basis for these differences is due to the presence of two catalytic sites in PH20. A first catalytic site is designated the Peptide 1 region, corresponding to amino acid residues 142-172 of SEQ ID NO:6, which is involved in enzyme activity of PH20 at neutral pH. A second catalytic site is designated the peptide 3 region, corresponding to amino acid residues 277-297 of SEQ ID NO:6, which is involved in enzyme activity at lower pH. A change in the structure of the inner acrosomal membrane-associated PH20 occurs after 15 the acrosome reaction, whereby PH20 is endoproteolytically cleaved but held together by disulfide bonds. The result of the endoproteolysis is that the peptide 3 region is activated and can thus effect neutral and acid-activity to PH20 (see e.g., Cherr et al. (2001) Matrix Biology, 20:515-525. Also, 20 after the acrosome reaction, lower molecular weight forms are generated by release from the inner acrosomal membrane (e.g., a 53 kDa soluble form of PH20 is generated in monkey). The lower molecular weight form(s) also is acid active.

The hyaluronidase activity of PH20 accounts for the spreading activity observed in animal testes extracts that have been used clinically for decades to increase the dispersion and absorption of drugs (see e.g., Bookbinder et al. (2006) J Controlled Release, 114:230-241). For example, 30 pharmaceutical preparations containing hyaluronidase were developed as fractionated extracts from bovine testes for therapeutic use as spreading agents and in other applications (Schwartzman (1951) J. Pediat., 39:491-502). Original bovine testicular extract preparations included, for example, 35 extracts sold under the trademarks Wydase®, Hylase®, "Dessau," Neopermease®, Alidase® and Hyazyme®. It is now known that the spreading activity of testicular extract preparations are due to PH20 hyaluronidase activity. For example, in 2001 a sperm hyaluronidase in bull was iden- 40 tified as the hyaluronidase PH20 (Lalancette et al. (2001) Biol. Reprod., 65:628-36). By catalyzing the hydrolysis of hyaluronic acid, PH20 hyaluronidase lowers the viscosity of hyaluronic acid, thereby increasing tissue permeability. Hence, soluble forms of PH20 are used as a spreading or 45 dispersing agent in conjunction with other agents, drug and proteins to enhance their dispersion and delivery, and to improve the pharmacokinetic and pharmacodynamic profile of the coadministered agent, drug or protein (see e.g., U.S. Pat. No. 7,767,429; Bookbinder et al. (2006) J Controlled 50 Release, 114:230-241).

3. Soluble PH20 Polypeptides

PH20 can exist in membrane-bound or membrane-associated form, or can be secreted into the media when expressed from cells, and thereby can exist in soluble form. 55 Soluble PH20 can be detected and discriminated from insoluble, membrane-bound PH20 using methods well known in the art, including, but not limited to, those using a Triton® X-114 detergent assay. In this assay, soluble PH20 hyaluronidases partition into the aqueous phase of a Triton® 60 X-114 detergent solution warmed to 37° C. (Bordier et al., (1981) J. Biol. Chem., 256:1604-7) while membrane-anchored PH20 hyaluronidases partition into the detergent rich phase. Thus, in addition to using algorithms to assess whether a PH20 polypeptide is naturally GPI-anchored and 65 hence membrane-bound, solubility experiments also can be performed.

74

Soluble PH20 enzymes include hyaluronidases that contain a GPI-anchor attachment signal sequence, but that are loosely attached to the membrane such that they do not contain a phospholipase sensitive anchor. For example, soluble PH20 polypeptides include ovine or bovine PH20. Various forms of such soluble PH20 hyaluronidases have been prepared and approved for therapeutic use in subjects, including humans. For example, animal-derived hyaluronidase preparations include Vitrase® hyaluronidase (ISTA Pharmaceuticals), which is a purified ovine testicular hyaluronidase, and Amphadase® hyaluronidase (Amphastar Pharmaceuticals), which is a bovine testicular hyaluronidase. Soluble PH20 enzymes also include truncated forms of non-human or human membrane-associated PH20 hyaluronidases that lack one or more amino acid residues of a glycosylphosphatidylinositol (GPI) anchor attachment signal sequence and that retain hyaluronidase activity (see e.g., U.S. Pat. No. 7,767,429; U.S. Publication No. US20100143457). Thus, instead of having a GPI-anchor covalently attached to the C-terminus of the protein in the ER and being anchored to the extracellular leaflet of the plasma membrane, these polypeptides are secreted when expressed from cells and are soluble. In instances where the soluble hyaluronan degrading enzyme retains a portion of the GPI anchor attachment signal sequence, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid residues in the GPI-anchor attachment signal sequence can be retained, provided the polypeptide is soluble (i.e., secreted when expressed from cells) and active.

Exemplary soluble hyaluronidases that are C-terminally truncated and lack all or a portion of the GPI anchor attachment signal sequence include, but are not limited to, PH20 polypeptides of primate origin, such as, for example, human and chimpanzee PH20 polypeptides. For example, soluble PH20 polypeptides can be made by C-terminal truncation of a polypeptide set forth in SEQ ID NO:7, 10, 12, 14, 69, 72, 857, 859, 861 or 870 or variants thereof that exhibit at least 80%, 85%, 90%, 95% or more sequence identity to any of SEQ ID NO: 7, 10, 12, 14, 69, 72, 857, 859, 861 or 870, wherein the resulting polypeptide is active, soluble and lacks all or a portion of amino acid residues from the GPI-anchor attachment signal sequence.

Exemplary soluble PH20 polypeptides are C-terminal truncated human PH20 polypeptides that are mature (lacking a signal sequence), soluble and exhibit neutral activity, and that contain a contiguous sequence of amino acids set forth in SEO ID NO:6 or SEO ID NO:7 that minimally has a C-terminal truncated amino acid residue at or after amino acid residue 464 of the sequence of amino acids set forth in SEQ ID NO:6. For example, soluble PH20 polypeptides include C-terminal truncated polypeptides that minimally contain a contiguous sequence of amino acids 36-464 of SEQ ID NO:6, or includes a sequence of amino acids that has at least 85%, for example at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% sequence identity to a contiguous sequence of amino acids that has a C-terminal amino acid residue after amino acid 464 of SEQ ID NO:6 and retains hyaluronidase activity. Exemplary C-terminally truncated human PH20 polypeptides are mature polypeptides (lacking a signal sequence) that include a contiguous sequence of amino acids set forth in SEQ ID NO:6 with a C-terminal residue after 464 such as after amino acid position 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499 or 500 of the sequence of amino acids set forth in SEQ ID NO:6, or a variant thereof that exhibits at least 85%

45

sequence identity, such as at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% sequence identity thereto and retains hyaluronidase activity. For example, exemplary C-terminal PH20 polypeptides have a sequence of amino acids 36 to 465, 466, 467, 468, 469, 470, 5 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499 or 500 of the sequence of amino acids set forth in SEQ ID NO:6, or a variant thereof that exhibits at least 85% sequence identity, such as at least 86%, 10 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% sequence identity thereto and retains hyaluronidase activity. Soluble PH20 polypeptides include any that has the sequence of amino acids set forth in SEQ ID NOs: 3 or 32-66 or a sequence of amino acids that exhibits at least 15 85% sequence identity, such as at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% sequence identity to the sequence of amino acids set forth in any of SEQ ID NOs: 3 or 32-66.

In particular, a soluble human PH20 polypeptide is a 20 polypeptide that is truncated after amino acid 482 of the sequence set forth in SEQ ID NO:6. Such a polypeptide can be generated from a nucleic acid molecule containing a signal sequence and encoding amino acids 36-482, for example, as set forth in SEQ ID NO:1 (containing an IgG 25 kappa signal sequence) or SEQ ID NO:67 (containing the native signal sequence). Post translational processing removes the signal sequence, leaving a 447 amino acid soluble recombinant human PH20 (SEO ID NO:3). A product produced upon expression of a vector set forth in SEQ 30 ID NO:4 or 5, and containing a nucleic acid molecule set forth in SEQ ID NO:67, results in a secreted product, designated rHuPH20, in the culture medium that exhibits heterogeneity at the C-terminus such that the product includes a mixture of species that can include any one or 35 more of SEQ ID NOs: 3 and 44-48 in various abundance. Typically, rHuPH20 is produced in cells that facilitate correct N-glycosylation to retain activity, such as mammalian cells, for example CHO cells (e.g., DG44 CHO cells). Hylenex® hyaluronidase (Halozyme) is a human recombi- 40 having a sequence of amino acids including or set forth in nant hyaluronidase produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing nucleic acid encoding a truncated human PH20 polypeptide (designated rHuPH20).

C. Modified PH20 Polypeptides

Provided herein are modified or variant PH20 polypeptides. The modified PH20 polypeptides provided herein exhibit altered activities or properties compared to a wildtype, native or reference PH20 polypeptide. Included among the modified PH20 polypeptides provided herein are PH20 50 or 870. polypeptide that are active mutants, whereby the polypeptides exhibit at least 40% of the hyaluronidase activity of the corresponding PH20 polypeptide not containing the amino acid modification (e.g., amino acid replacement). In particular, provided herein are PH20 polypeptides that exhibit 55 hyaluronidase activity and that exhibit increased stability compared to the PH20 not containing the amino acid modification. Also provided are modified PH20 polypeptides that are inactive, and that can be used, for example, as antigens in contraception vaccines.

The modifications can be a single amino acid modification, such as single amino acid replacements (substitutions), insertions or deletions, or multiple amino acid modifications, such as multiple amino acid replacements, insertions or deletions. Exemplary modifications are amino acid 65 replacements, including single or multiple amino acid replacements. The amino acid replacement can be a conser-

vative substitution, such as set forth in Table 2, or a non-conservative substitution, such as any described herein. Modified PH20 polypeptides provided herein can contain at least or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more modified positions compared to the PH20 polypeptide not containing the modification.

The modifications described herein can be in any PH20 polypeptide, including, including precursor, mature, or C-terminal truncated forms, so long as the modified form exhibits hyaluronidase activity. For example, the PH20 polypeptides contain modifications compared to a wildtype, native or reference PH20 polypeptide set forth in any of SEQ ID NOs: 2, 3, 6-66, 68-72, 856-861, 869 or 870, or in a polypeptide that has a sequence of amino acids that is at least 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to any of SEQ ID NOs: 3, 6-66, 68-72, 856-861, 869 or 870. For example, the modifications are made in a human PH20 polypeptide having the sequence of amino acids including or set forth in SEQ ID NO:7, SEQ ID NO:69 or SEQ ID NO:72; a bovine PH20 polypeptide having a sequence of amino acids including or set forth in SEQ ID NOs:16 or 18; a rabbit PH20 polypeptide having a sequence of amino acids including or set forth in SEQ ID NO:24; a Cynomolgus monkey PH20 polypeptide having a sequence of amino acids including or set forth in SEQ ID NO: 14; a guinea pig PH20 polypeptide having a sequence of amino acids including or set forth in SEQ ID NO:29; a rat PH20 polypeptide having a sequence of amino acids including or set forth in SEQ ID NO:22; a mouse PH20 polypeptide having a sequence of amino acids including or set forth in SEQ ID NO:20; a chimpanzee PH20 polypeptide having a sequence of amino acids including or set forth in SEQ ID NO: 10 or 870; a Rhesus monkey PH20 polypeptide having a sequence of amino acids including or set forth in SEQ ID NO: 12; a Fox PH20 polypeptide having a sequence of amino acids including or set forth in SEQ ID NO:31; a Gibbon PH20 polypeptide having a sequence of amino acids including or set forth in SEQ ID NO:857; a Marmoset PH20 polypeptide SEQ ID NO: 859; an Orangutan PH20 polypeptide having a sequence of amino acids including or set forth in SEQ ID NO:861; or a sheep PH20 polypeptide having a sequence of amino acids including or set forth in any of SEQ ID NOs: 25-27; or in sequence variants or truncated variants that exhibit at least 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOs: 7, 10, 12, 14, 16, 18, 20, 22, 24-27, 29, 31, 69, 72, 857, 859, 861

In particular, provided herein are PH20 polypeptides that contain modifications compared to a PH20 polypeptide set forth in SEQ ID NO: 3, 7, 32-66, 69 or 72, or a polypeptide that has a sequence of amino acids that is at least 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to any of SEQ ID NOs: 3, 7, 32-66, 69 or 72. For example, the modifications provided herein also can be made in a PH20 polypeptide set forth as SEQ ID NO: 10, 12, 14, 24, 857, 60 859, 861 or 870.

In particular, provided herein are modified soluble PH20 polypeptides that are PH20 polypeptides containing a modification provided herein, and that when expressed from cells are secreted into the media as a soluble protein. For example, the modifications are made in a soluble PH20 polypeptide that is C-terminally truncated within or near the C-terminus portion containing the GPI-anchor signal sequence of a PH20 polypeptide that contains a GPI-anchor signal sequence. The C-terminal truncation can be a truncation or deletion of 8 contiguous amino acids at the C-terminus, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, $26,\,27,\,28,\,29,\,30,\,31,\,32,\,33,\,34,\,35,\,36,\,37,\,38,\,39,\,40,\,41,\ \ 5$ 42, 43, 44, 45, 46, 47, 48, 49, 50 or more amino acids at the C-terminus, so long as the resulting C-terminally truncated polypeptide exhibits hyaluronidase activity and is secreted from cells (e.g., into the media) when expressed. In some examples, the modifications provided herein are made in a 10 soluble PH20 polypeptide that is a C-terminally truncated polypeptide of SEQ ID NO:7, 10, 12, 14, 69, 72, 857, 859, 861 or 870 or a variant thereof that exhibits at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence 15 identity to any of SEQ ID NOs: 7, 10, 12, 14, 69, 72, 857, 859, 861 or 870. In particular, the modifications provided herein are made in a soluble or C-terminally truncated human PH20 polypeptide having the sequence of amino acids set forth in SEQ ID NOs: 3 or 32-66 or a sequence of 20 amino acids that exhibits at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% sequence identity to the sequence of amino acids set forth in any of SEQ ID NOs: 3 or 32-66. For example, modified PH20 polypeptides provided herein con- 25 tain amino acid replacements or substitutions, additions or deletions, truncations or combinations thereof with reference to the PH20 polypeptide set forth in SEQ ID NO:3.

Modifications also can be made in the corresponding precursor form containing a signal peptide of any of SEQ ID 30 NOS: 3, 7, 10, 12, 14, 16, 18, 20, 22, 24-27, 29, 31, 32-66, 69, 72, 857, 859, 861 or 870. For example, modifications provided herein can be made in a precursor form set forth in any of SEQ ID NOS: 2, 6, 8, 9, 11, 13, 15, 17, 19, 21, 23, 28, 30, 856, 858, 860 or 869 or in a variant thereof that 35 exhibits at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS: 2, 6, 8, 9, 11, 13, 15, 17, 19, 21, 23, 28, 30, 856, 858, 860 or 869.

In examples of modified PH20 polypeptides provided 40 herein, the modified PH20 polypeptide does not contain the sequence of amino acids set forth in any of SEQ ID NOS: 3-66, 68-72, 856-861, 869 or 870. Typically, the modified PH20 polypeptide is a human PH20 polypeptide, and does not contain the sequence of amino acids set forth in any of 45 SEQ ID NOs: 8-31, 856-861, 869 or 870.

Generally, any modification, such as amino acid replacement, deletion or substitution, can be made in a PH20 polypeptide, with the proviso that the modification is not an amino acid replacement where the only modification is a 50 single amino acid replacement that is V12A, N47A, DI IN, E113Q, N131A, R176G, N200A, N219A, E249Q, R252T, N333A or N358A. Also, where the modified PH20 polypeptide contains only two amino acid replacements, the amino acid replacements are not P13A/L464W, N47A/N131A, 55 N47A/N219A, N131A/N219A or N333A/N358A. In a further example, where the modified PH20 polypeptide contains only three amino acid replacements, the amino acid replacements are not N47A/N131A/N219A. Exemplary modifications provided herein are described in detail below. 60

For purposes herein, reference to positions and amino acids for modification herein, including amino acid replacement or replacements, are with reference to the PH20 polypeptide set forth in SEQ ID NO:3. It is within the level of one of skill in the art to make any of the modifications 65 provided herein in another PH20 polypeptide by identifying the corresponding amino acid residue in another PH20

polypeptide, such as any set forth in SEQ ID NOs: 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24-27, 28, 29, 30, 31, 32-66, 68-72, 856, 857, 858, 859, 860, 861, 869 or 870 or a variant thereof that exhibits at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOs: 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24-27, 28, 29, 30, 31, 32-66, 68-72, 856, 857, 858, 859, 860, 861, 869 or 870. Corresponding positions in another PH20 polypeptide can be identified by alignment of the PH20 polypeptide with the reference to the PH20 polypeptide set forth in SEQ ID NO:3. For example, FIG. 2 (A-L) depicts alignment of exemplary PH20 polypeptides with SEQ ID NO:3, and identification of exemplary corresponding positions. Also, since SEQ ID NOs: 3, 7, 32-66, 69 and 72 are all forms of a mature human PH20 with a different C-terminal amino acid residue, the numbering of amino acid residues in any of SEQ ID NOs: 7, 32-66, 69 and 72 is the same as SEQ ID NO:3, and hence the corresponding residues of each are identical to that set forth in SEQ ID NO:3 (see e.g., FIG. 1). Further, SEQ ID NOS set forth in any of SEQ ID NOs: 2, 6, 70 or 71 are precursor forms thereof that differ by only the presence of a signal sequence. For purposes of modification (e.g., amino acid replacement), the corresponding amino acid residue can be any amino acid residue, and need not be identical to the residue set forth in SEQ ID NO: 3. Typically, the corresponding amino acid residue identified by alignment with residues in SEQ ID NO:3 is an amino acid residue that is identical to SEQ ID NO:3, or is a conservative or semiconservative amino acid residue thereto (see e.g., FIGS. 2A-2L). It is also understood that the exemplary replacements provided herein can be made at the corresponding residue in a PH20 polypeptide, so long as the replacement is different than exists in the unmodified form of the PH20 polypeptide. Based on this description and the description elsewhere herein, it is within the level of one of skill in the art to generate a modified PH20 polypeptide containing any one or more of the described mutation, and test each for a property or activity as described herein.

Modifications in a PH20 polypeptide also can be made to a PH20 polypeptide that also contains other modifications, including modifications of the primary sequence and modifications not in the primary sequence of the polypeptide. For example, modifications described herein can be in a PH20 polypeptide that is a fusion polypeptide or chimeric polypeptide. The modified PH20 polypeptides provided herein also include polypeptides that are conjugated to a polymer, such as a PEG reagent.

Also provided herein are nucleic acid molecules that encode any of the modified PH20 polypeptides provided herein. In particular examples, the nucleic acid sequence can be codon optimized, for example, to increase expression levels of the encoded sequence. The particular codon usage is dependent on the host organism in which the modified polypeptide is expressed. One of skill in the art is familiar with optimal codons for expression in mammalian or human cells, bacteria or yeast, including for example E. coli or Saccharomyces cerevisiae. For example, codon usage information is available from the Codon Usage Database available at kazusa.or.jp.codon (see Richmond (2000) Genome *Biology*, 1:reports241 for a description of the database). See also, Forsburg (1994) Yeast, 10:1045-1047; Brown et al. (1991) Nucleic Acids Research, 19:4298; Sharp et al. (1988) Nucleic Acids Res., 12:8207-8211; Sharp et al. (1991) Yeast, 657-78). In some examples, the encoding nucleic acid molecules also can be modified to contain a heterologous signal sequence to alter (e.g., increased) expression and secretion of the polypeptide. Exemplary of a heterologous signal sequence is a nucleic acid encoding the IgG kappa signal sequence (set forth in SEQ ID NO:868).

The modified polypeptides and encoding nucleic acid 5 molecules provided herein can be produced by standard recombinant DNA techniques known to one of skill in the art. Any method known in the art to effect mutation of any one or more amino acids in a target protein can be employed. Methods include standard site-directed or random mutagen-10 esis of encoding nucleic acid molecules, or solid phase polypeptide synthesis methods. For example, nucleic acid molecules encoding a PH20 polypeptide can be subjected to mutagenesis, such as random mutagenesis of the encoding nucleic acid, error-prone PCR, site-directed mutagenesis, 15 overlap PCR, gene shuffling, or other recombinant methods. The nucleic acid encoding the polypeptides can then be introduced into a host cell to be expressed heterologously. Hence, also provided herein are nucleic acid molecules encoding any of the modified polypeptides provided herein. 20 In some examples, the modified PH20 polypeptides are produced synthetically, such as using solid phase or solutions phase peptide synthesis.

In the subsections below, exemplary modified PH20 polypeptide exhibiting altered properties and activities, and 25 encoding nucleic acid molecules, provided herein are described.

1. Active Mutants

Provided herein are modified PH20 polypeptides that contain one or more amino acid replacements in a PH20 30 polypeptide and that exhibit hyaluronidase activity. The modified PH20 polypeptides can exhibit 40% to 5000% of the hyaluronidase activity of a wildtype or reference PH20 polypeptide, such as the polypeptide set forth in SEQ ID NOs: 3 or 7. For example, modified PH20 polypeptides 35 provided herein exhibit at least 40% of the hyaluronidase activity, such as at least 50%, 60%, 70%, 80%, 90%, 100%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, ity of a wildtype or reference PH20 polypeptide, such as the corresponding polypeptide not containing the amino acid modification (e.g., amino acid replacement), for example, a polypeptide set forth in SEQ ID NO:3 or 7. For example, exemplary positions that can be modified, for example by 45 amino acid replacement or substitution, include, but are not limited to, any of positions corresponding to position 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 20, 22, 23, 24, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 54, 58, 59, 60, 61, 63, 65, 50 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 77, 79, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, 92, 93, 94, 96, 97, 98, 99, 102, 103, 104, 105, 106, 107, 108, 110, 114, 117, 118, 119, 120, 122, 124, 125, 127, 128, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 55 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 186, 192, 193, 195, 196, 197, 198, 200, 202, 204, 205, 206, 208, 209, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 60 222, 224, 226, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 242, 245, 247, 248, 251, 253, 255, 256, 257, 258, 259, 260, 261, 263, 264, 265, 266, 267, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 297, 298, 300, 65 301, 302, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 320, 321, 323, 324, 325, 326, 327,

328, 331, 334, 335, 338, 339, 342, 343, 347, 348, 349, 351, 353, 356, 357, 358, 359, 360, 361, 367, 368, 369, 371, 373, 374, 375, 376, 377, 378, 379, 380, 381, 383, 385, 387, 388, 389, 391, 392, 393, 394, 395, 396, 397, 398, 399, 401, 403, 404, 405, 406, 407, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 425, 426, 427, 428, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446 or 447 with reference to amino acid positions set forth in SEQ ID NO:3. Typically, the amino acid residue that is modified (e.g., replaced with another amino acid) at the position corresponding to any of the above positions in a PH20 polypeptide is an identical residue, a conservative residue or a semi-conservative amino acid residue to the amino acid residue set forth in SEQ ID NO:3.

To retain hyaluronidase activity, modifications typically are not made at those positions that are less tolerant to change or required for hyaluronidase activity. For example, generally modifications are not made at a position corresponding to position 7, 16, 17, 18, 19, 21, 25, 53, 55, 56, 57, 62, 64, 76, 78, 80, 88, 95, 100, 101, 109, 111, 112, 113, 115, 116, 121, 123, 126, 129, 185, 187, 188, 189, 190, 191, 194, 199, 201, 203, 207, 210, 223, 225, 227, 228, 229, 241, 243, 244, 246, 249, 250, 252, 254, 262, 268, 295, 296, 299, 303, 319, 322, 329, 330, 332, 333, 336, 337, 340, 341, 344, 345, 346, 350, 352, 354, 355, 362, 363, 364, 365, 366, 370, 372, 382, 384, 386, 390, 400, 402, 408, 423, 424, 429, 430, with reference to amino acid positions set forth in SEQ ID NO:3. Also, in examples where modifications are made at any of positions 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 20, 22, 23, 27, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 54, 58, 59, 60, 61, 63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 77, 79, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, 92, 94, 96, 98, 99, 102, 103, 104, 105, 106, 107, 108, 110, 114, 117, 118, 119, 122, 124, 125, 127, 128, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 143, 144, 145, 149, 150, 152, 153, 154, 155, 156, 157, 158, 159, 161, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 186, 192, 193, 195, 197, 198, 200, 202, 204, 206, 208, 209, 211, 212, 213, 214, 1000%, 2000%, 3000% or more of the hyaluronidase activ- 40 215, 216, 217, 218, 219, 220, 221, 222, 224, 226, 230, 231, 232, 233, 234, 235, 236, 238, 239, 240, 242, 245, 247, 248, 251, 253, 255, 256, 257, 258, 260, 261, 263, 264, 265, 266, 267, 269, 270, 271, 272, 273, 274, 275, 276, 278, 279, 280, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 297, 298, 300, 301, 302, 304, 305, 306, 307, 308, 310, 311, 312, 313, 314, 315, 316, 317, 318, 320, 321, 323, 324, 325, 326, 327, 331, 334, 335, 338, 339, 342, 343, 347, 348, 349, 351, 353, 356, 357, 358, 359, 360, 361, 367, 368, 369, 371, 373, 374, 375, 376, 377, 378, 379, 380, 381, 383, 385, 387, 388, 389, 391, 392, 393, 394, 395, 396, 397, 398, 399, 401, 403, 404, 405, 406, 410, 411, 412, 413, 414, 415, 416, 417, 419, 420, 422, 425, 426, 427, 428, 431, 432, 434, 437, 438, 439, 440, 441, 442, 443, 444, or 447 with reference to amino acid positions set forth in SEQ ID NO:3, the modification(s) is/are not the corresponding amino acid replacement(s) set forth in Table 5 or 10 herein, which are amino acid replacements that result in an inactive polypeptide. For example, if the modification is a modification at a position corresponding to position 2 with reference to SEQ ID NO:3, the modification is not replacement to a histidine (H), lysine (K), tryptophan (W) or tyrosine (Y).

> Exemplary amino acid replacements at any of the above corresponding positions are set forth in Table 3. Reference to the corresponding amino acid position in Table 3 is with reference to positions set forth in SEQ ID NO:3. It is understood that the replacements can be made in the corresponding position in another PH20 polypeptide by align

10

ment therewith with the sequence set forth in SEQ ID NO:3 (see e.g., FIGS. 1 and 2), whereby the corresponding position is the aligned position. In particular examples, the amino acid replacement(s) can be at the corresponding position in a PH20 polypeptide as set forth in any of SEQ ID 5 NOs: 2, 3, 6-66, 68-72, 856-861, 869 or 870 or a variant thereof having at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, so long as the resulting modified PH20 polypeptide exhibits at least 40% of the hyaluronidase activity of the

82

corresponding PH20 polypeptide not containing the amino acid replacement. In particular, the replacement(s) can be in a corresponding position in a human PH20 polypeptide, for example, any set forth in any of SEQ ID NOs: 3, 7, 32-66, 69 or 72, or a variant thereof that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOs: 3, 7, 32-66, 69 or 72. In one example, any one or more of the replacements are in SEQ ID NO:3, so long as the resulting modified PH20 polypeptide exhibits at least 40% of the hyaluronidase activity of the PH20 polypeptide set forth in SEQ ID NO:3

TABLE	3
-------	---

Active Mutants					
Corresponding		Corresponding		Corresponding	
Position	Replacement	Position	Replacement	Position	Replacement
1	ACEFGHKNP	2	ACGILPQST	3	ЕНLҮ
	QRSTVW		V		
4	AISTV	5	Н	6	AHKLNQR
7	M	8	ILMP	9	K L Q R S V
10 13	D E G H N Q R S W H S T Y	11 14	D G H K S D I M V	12 15	A E I K L N R S T A M V
20	S	22	HMTY	23	D
24	AEGHIKLMN	26	AEGHIKMPQ	23	ADEFHIKLP
	RTVY		RSTVWY		QRSTW
28	A D E F I L M N P	29	A E G H I K L M P	30	AFGHKLMP
	RSTVW		RSTVW		QRSTVW
31	A C G H I K L P R S	32	ACFGHKLMN	33	GMPQRSTW
24	TVWY	35	QRSTVWY	36	ADCHKINDT
34 37	A E H K Q R W F I K M P R W V	35 38	F H L Q T V Y Y	30 39	A D G H K L N R T A L N Q R T Y
40	LW	41	ACDEGHNTVW	42	A
43	NT	44	E	45	IK
46	ACEFHLMNR	47	A D F G H K M Q	48	FGHIKMNQR
	STVY		RSTWY		SVY
49	I K R S V	50	A C D E H L M Q R	51	ANRS
			S V Y		
52	N P Q R S T	54	AFNQSV	58	CGHIKLNPQ
50	O N	(0)	V	(1	RSWY
59	QN	60 (5	K R	61	FIMV
63	A H I K L M N R S T V W	65	K	66	H R
67	FLRVY	68	EGHKLPQRST	69	ACEFGILMP
0,	I DR I I	00	Lonner Quoi	0,	RTWY
70	A C F G H K L N P	71	ADGHLMNQ	72	ADEHKLMQ
	RSTVY		R S		RSY
73	A C D G H K L M Q	74	ACEFGHKLM	75	A C F H L M N Q
	RSTW		N P R S V W		RSTY
77	НК	01	D	00	
79	LTV	81	Р	82	AEGHILMNQ
83	FGHKLNQRS	84	DEFGHILMN	85	R S T V V
05	TV	04	PQRTWY	05	·
86	ADEFGHIKL	87	ACEGHILMP	89	CKMPRW
	M N P R S T V W		QRSTVY		
90	AEGHIKLNQ	91	Q R	92	CHLMTV
	RSTW				
93	DEFGHILMN	94	ACDEFHLMN	96	DLV
07	PQRSTV	00	QRST	00	4 D C
97	ACDEFGILNP	98	ACDEHILMQ	99	ARS
102	Q R S W Y A C E G H K L M N		RSVW		
102	ORSTW				
103	N	104	ACGIKMRST	105	ACGHIPQRS
					TWV
106	V				
107	FIL	108	G	110	V
114	AGHMS	117	D	118	HKLMNQV
119	FPQY	120	D F G H I L N P R	122	М
			STVWY		
124	HLR	125	AHRS	127	AEGHLMNQ
					RSTVW
128	A C G I K L Q R S	130	I R	131	CEFGHILMQ
122	W	100	т	124	RSTVY
132	ACEFHIKLN	133	Ι	134	LTV
	QSTVY				

Petitioner Merck, Ex. 1001, p. 67

TABLE 3-continued

		А	ctive Mutants		
C				Commenting	-
Corresponding Position	Replacement	Correspondin Position	g Replacement	Correspondin Position	g Replacement
135	ACDFGHKLN	136	ACDFHIMNQ	137	ACITACHIL
139	Q	140	R	141	M N R S W Y A D E F G H L M O P S T V W Y
142	C D E G H I K L M N P Q R S T	143	C E G I K L N V	144	Q R S T V W Y R T W
145	A C D E G H L M N P R	146	A C E G H I K N P Q R S T V Y	147	A C D F G I L M P Q R S V W Y
148	C F G H I K L Q R S T V W Y	149	C G K L M Q R S T V	150	A C D E F G I L N P R S W Y
151	A C G H K L M N Q R S T V W Y	152	A C F I M R T V W Y	153	ILS
154	IRTV	155	A C D F G H K L M R S T V W	156	A C D G I L M Q R S T V W
157	W	158	AFGHLQS	159	A D E G H L M N Q R S V
160	C F G H I K L M N Q R S W V Y	161	A C D E R S V	162	A D E G H L M P Q R S V W Y
163	A E G K L Q R S T V W	164	LMVW	165	A C D F N R S V W Y
166	A C E F G H L N Q R T W Y	167	A D G H K M N P R S T Y	168	Н
169 172	L R V A C	170 173	A Q N R V Q N R	171 174	I V A G H K M N Q R
172	ЕНТVҮ	175	KL	174	S T V W Y V
178 179	G K M R A C E G I K L M N	180	FGIKM	181	, K M Q
182	PRSTV L	183	EL	181	W
182 186 192	Y S T	193	FGQRSY	195	'' A G H I L N Q R S
192	EGLNRSTWY	193	ADEFGHKLM	195	TWV ADEHLNQRS
			QRSTW		ТWY
200 205	D T L R S T V W Y	202 206	M H I K L M Q R S T	204 208	P W A C K L M Q R S T V
209 212	A E F G L N R S T N S T	211 213	L W A E G H K L M N		1 V
214	Q	215	Q	217	М
218	F M V	219	Q	220	ADHILMSTV
221	A C I M Q T V	222	R S T W D F G I K L N R S	224	Ι
226	W		V		
230 233	I A F G K L R Y	231 234	T L M	232 235	S A E G H K T
236	A G H K R S	234	A C E F H L N Q R S T W	238	DEHKQRST
239	Ν				
240	K A M P Q R S V I L M	242 248	F A H W Y	245 251	H L M Y
247 253	I L M I	248 255	A H W Y A G N Q R S	251 256	L M Y A H L V
255	A C G I K L M N Q R T V	258	GHNRS	250	E G I K L N P Q R S T V W Y
260	A D E G H L M Q R S Y	261	A F K M N Q R T V W	263	AHKMRTV
264	AH	265	Ι	266	Y
267	МТ	269	ACDS	270	MNST
271	FGLMSV	272	D M R S T	273	НТҮ
274 275	AFS LV	276	C D E G H I L M R	277	A C D E G H K M
278	A E F G H I K N R S T V Y	279	S Y A H Q R T	280	N O R S T Y G Q
282	D G M Q	283	EPRST	284	A E G H L M N Q S T Y
285	A F G H M N Q Y	286	R S W	287	S I Y I N T
288	LW	289	KS	290	IM
291	CQRSV	292	A C F G H K N P R	293	A C D F G K L M
294	М		VW		PQSVY

294 M

Corresponding

Corresponding

TABLE 3-continued Active Mutants

Corresponding Position	Replacement
300	R
303	D V
306	DES
309	DEGHKLMN
	QRSTVW
212	C K I N T

86

Position	Replacement	Position	Replacement	Position	Replacement
297	А	298	G I	300	R
301	AV	302	IW	303	D V
304	GI	305	DEN	306	DES
307	GKNQSTVWY	308	DGHKNPRT	309	DEGHKLMN
210					QRSTVW
310	AFGQRSVY	311	GHKQST	312	GKLNT
313	AEGHKLPRS	314	A D H I N Q R S T	315	AEGHKLMR
	ΤVΥ		Y		ТҮ
316	D	317	A D H I K M N Q R	318	DFGHIKMNQ
			STW		RST
320	EGHIKLMNR	321	ADHKRSTY	323	FIL
	SWVY				
324	ADHMNRS	325	ADEGHKMN	326	СКLVY
021		020	QSVW	020	011211
327	М	328	ACGHIKLQR	331	CEV
321	101	320		331	CEV
224	D.T.	225	STVWY	220	0
334	ΡT	335	S	338	Q
339	M	342	Α	343	ТV
347	A E G L M R S	348	D G S	349	AEKMNRT
351	A C I Q S	353	ΤV	356	A D H S
357	ACKST	358	CGLT	359	DEHKMTV
360	Т				
361	Н	367	ACGKRS	368	AEGHKLMR
					STVHRS
371	EFGHIKLMR	373	AEFKLMRSV	374	AHIMNPRST
	SV				VWY
375	AGIKLMNRS	376	A D E L M Q R S T	377	DEHKPRST
515	Т	570	VY	511	DEHRIKUT
378	K N R	379	GHRST	380	ILPTVWY
381	EHKNQRSV	383	A E H I K L M N S	385	A G H N Q R S T
	~		TV		V
387	S	388	FHIMRTVWY	389	AGHKLMPQ
					RSTY
391	C	392	A F G K L M Q R S	393	A D F H K L M N
			TVWY		RST
394	LW	395	AGHKRTW	396	ADHLQRST
397	R	398	L		
399	ACEKMNQRS	401	A E G Q N	403	F
	TVW		-		
404	АРТ	405	AFGKMPQRS	406	A C E F G I N Q S
			WY		TVY
407	A D E F G H L M N	409	A D E G H I P Q R	410	DKMNPQRS
407	PQRVW	409	STV	410	TVY
411		412		412	
411	AHNPRSTV	412	D G H I L N Q P R	413	A E H K N Q R S
	* ** * . *	41.5	S V W Y	11.6	Т
414	IKLM	415	GSWVY	416	FGHIKLNQR
	_				ТVҮ
417	I	418	A E F G I L M N P	419	EFGHIKLNR
			QRSVY		S W Y
420	IP	421	A E G H I K L M N	422	ΙT
			QRSTY		
425	GIKMNRSY	426	EGKNPQSY	427	HIKQST
428	LMPT	431	AEGHIKLNQ	432	EGHNSV
			RSVWY		
433	ACDEGHIKL	434	FGIMV	435	ACEGHRSTV
100	PRSTVW	101		100	Y
436	CDEGHIKLM	437	ADGHIKLMQ	438	ACDEGLNPQ
450	QRSTWY	437	RSY	450	RSTVW
420		140		4.4.1	
439	A C F G H K L P Q	440	A D E F G H I L M	441	A D F G H K L N
4.40	STVW	4.42	PRSVY	4.4.4	QSTVY
442	CGHKLPQRT	443	AEFGHLMNQ	444	DEFGHIKMN
	VWY		RSTW		RVWY
445	A G H L M N P Q R	446	ACDEGHIKL	447	DEFGILMNP
	STVWY		MQRTVW		QRTVW

PH20 polypeptide containing an amino acid replacement or replacements at a position or positions corresponding to 1, 6, 8, 9, 10, 11, 12, 14, 15, 20, 22, 24, 26, 27, 28, 29, 30, 31, $32, \ 33, \ 34, \ 35, \ 36, \ 37, \ 38, \ 39, \ 40, \ 41, \ 46, \ 47, \ 48, \ 49, \ 50, \ 52, \ _{65} \ \ 215, \ 219, \ 220, \ 221, \ 222, \ 232, \ 233, \ 234, \ 235, \ 236, \ 237, \ 238, \ 236, \ 237, \ 236, \ 236, \ 236, \ 237, \ 236, \$ 58, 59, 63, 67, 68, 69, 70, 71, 72, 73, 74, 75, 79, 82, 83, 84, 86, 87, 89, 90, 92, 93, 94, 97, 102, 104, 107, 114, 118, 120,

In particular examples, provided herein is a modified ⁶⁰ 127, 128, 130, 131, 132, 135, 138, 139, 140, 141, 142, 143, 144, 146, 147, 148, 149, 150, 151, 152, 155, 156, 158, 160, 162, 163, 164, 165, 166, 167, 169, 170, 172, 173, 174, 175, 178, 179, 193, 195, 196, 198, 204, 205, 206, 209, 212, 213, 240, 247, 248, 249, 257, 258, 259, 260, 261, 263, 267, 269, 271, 272, 273, 274, 276, 277, 278, 279, 282, 283, 285, 287, 289, 291, 292, 293, 298, 305, 307, 308, 309, 310, 313, 314, 315, 317, 318, 320, 321, 324, 325, 326, 328, 335, 347, 349, 351, 353, 356, 359, 367, 368, 369, 371, 373, 374, 375, 376, 377, 380, 381, 383, 385, 389, 392, 393, 395, 396, 399, 401, 404, 405, 406, 407, 409, 410, 412, 416, 418, 419, 421, 425, 5 427, 428, 431, 433, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446 or 447 with reference to amino acid positions set forth in SEQ ID NO:3. For example, the amino acid positions can be replacements at positions corresponding to replacement of Leucine (L) at position 1 (L1), P6, V8, 19, 10 P10, N11, V12, F14, L15, A20, S22, F24, L26, G27, K28, F29, D30, E31, P32, L33, D34, M35, S36, L37, F38, S39, F40, I41, I46, N47, A48, T49, G50, G52, V58, D59, Y63, 167, D68, S69, 170, T71, G72, V73, T74, V75, 179, K82, 183, S84, G86, D87, L89, D90, A92, K93, K94, T97, V102, 15 N104, M107, E114, T118, A120, D127, V128, K130, N131, R132, E135, Q138, Q139, Q140, N141, V142, Q143, L144, L146, T147, E148, A149, T150, E151, K152, Q155, E156, E158, A160, K162, D163, F164, L165, V166, E167, 1169, K170, G172, K173, L174, L175, N178, H179, H193, K195, 20 K196, G198, F204, N205, V206, K209, D212, D213, S215, N219, E220, S221, T222, T232, Q233, Q234, S235, P236, V237, A238, T240, V247, R248, E249, P257, D258, A259, K260, S261, L263, A267, T269, 1271, V272, F273, T274, Q276, V277, L278, K279, S282, Q283, E285, V287, T289, 25 G291, E292, T293, A298, G305, L307, S308, 1309, M310, M313, K314, S315, L317, L318, D320, N321, E324, T325, 1326, N328, T335, Q347, Q349, V351, 1353, N356, S359, P367, D368, N369, A371, O373, L374, E375, K376, G377, F380, T381, R383, K385, E389, E392, Q393, S395, E396, 30 Y399, S401, S404, T405, L406, S407, K409, E410, A412, D416, D418, A419, D421, A425, G427, A428, D431, F433, P436, P437, M438, E439, T440, E441, E442, P443, Q444, 1445, F446 or Y447 with reference to amino acid positions set forth in SEQ ID NO:3.

Exemplary amino acid replacements in the modified PH20 polypeptides provided herein include, but are not limited, replacement with: histidine (H) at a position corresponding to position 1; A at a position corresponding to position 1; E at a position corresponding to position 1; G at 40 a position corresponding to position 1; K at a position corresponding to position 1; Q at a position corresponding to position 1; R at a position corresponding to position 1; A at a position corresponding to position 6; M at a position corresponding to position 8; Q at a position corresponding to 45 position 9; G at a position corresponding to position 10; H at a position corresponding to position 10; S at a position corresponding to position 11; E at a position corresponding to position 12; I at a position corresponding to position 12; K at a position corresponding to position 12; T at a position 50 corresponding to position 12; V at a position corresponding to position 14; V at a position corresponding to position 15; M at a position corresponding to position 15; S at a position corresponding to position 20; T at a position corresponding to position 22; E at a position corresponding to position 24; 55 H at a position corresponding to position 24; R at a position corresponding to position 24; A at a position corresponding to position 26; E at a position corresponding to position 26; K at a position corresponding to position 26; M at a position corresponding to position 26; Q at a position corresponding 60 to position 26; R at a position corresponding to position 26; D at a position corresponding to position 27; K at a position corresponding to position 27; R at a position corresponding to position 27; R at a position corresponding to position 28; E at a position corresponding to position 29; I at a position 65 corresponding to position 29; K at a position corresponding to position 29; L at a position corresponding to position 29;

88

M at a position corresponding to position 29; P at a position corresponding to position 29; R at a position corresponding to position 29; S at a position corresponding to position 29; T at a position corresponding to position 29; V at a position corresponding to position 29; G at a position corresponding to position 30; H at a position corresponding to position 30; K at a position corresponding to position 30; L at a position corresponding to position 30; M at a position corresponding to position 30; R at a position corresponding to position 30; S at a position corresponding to position 30; A at a position corresponding to position 31; C at a position corresponding to position 31; G at a position corresponding to position 31; H at a position corresponding to position 31; I at a position corresponding to position 31; K at a position corresponding to position 31; L at a position corresponding to position 31; P at a position corresponding to position 31; R at a position corresponding to position 31; S at a position corresponding to position 31; T at a position corresponding to position 31; V at a position corresponding to position 31; W at a position corresponding to position 31; C at a position corresponding to position 32; F at a position corresponding to position 32; G at a position corresponding to position 32; H at a position corresponding to position 32; W at a position corresponding to position 33; G at a position corresponding to position 33; W at a position corresponding to position 34; Q at a position corresponding to position 35; V at a position corresponding to position 35; H at a position corresponding to position 36; N at a position corresponding to position 36; F at a position corresponding to position 37; M at a position corresponding to position 37; Y at a position corresponding to position 38; A at a position corresponding to position 39; L at a position corresponding to position 39; N at a position corresponding to position 39; T at a position corresponding to position 39; L at a position corresponding to position 40; T at a position 35 corresponding to position 41; L at a position corresponding to position 46; R at a position corresponding to position 46; D at a position corresponding to position 47; F at a position corresponding to position 47; T at a position corresponding to position 47; W at a position corresponding to position 47, with F at a position corresponding to position 48; H at a position corresponding to position 48; K at a position corresponding to position 48; N at a position corresponding to position 48; R at a position corresponding to position 49; D at a position corresponding to position 50; S at a position corresponding to position 50; M at a position corresponding to position 50; N at a position corresponding to position 52; O at a position corresponding to position 52; R at a position corresponding to position 52; S at a position corresponding to position 52; T at a position corresponding to position 52; C at a position corresponding to position 58; K at a position corresponding to position 58; L at a position corresponding to position 58; P at a position corresponding to position 58; Q at a position corresponding to position 58; R at a position corresponding to position 58; H at a position corresponding to position 58; N at a position corresponding to position 58; Y at a position corresponding to position 58; N at a position corresponding to position 59; K at a position corresponding to position 63; L at a position corresponding to position 63; M at a position corresponding to position 63; R at a position corresponding to position 63; W at a position corresponding to position 63; V at a position corresponding to position 67; H at a position corresponding to position 68; P at a position corresponding to position 68; Q at a position corresponding to position 68; A at a position corresponding to position 69; C at a position corresponding to position 69; E at a position corresponding to position 69; F at a position corresponding to position 69; G at a position corresponding to position 69; I at a position corresponding to position 69; L at a position corresponding to position 69; M at a position corresponding to position 69; P at a position corresponding to position 69; R at a position corresponding to position 69; T at a position corresponding to position 69; W at a position corresponding to position 69; Y at a position corresponding to position 69; A at a position corresponding to position 70; C at a position corresponding to position 70; F at a position corresponding to position 70; G at a position corresponding to position 70; H at a position corresponding to position 70; K at a position 10 corresponding to position 70; L at a position corresponding to position 70; N at a position corresponding to position 70; P at a position corresponding to position 70; R at a position corresponding to position 70; S at a position corresponding to position 70; T at a position corresponding to position 70; 15 V at a position corresponding to position 70; Y at a position corresponding to position 70; G at a position corresponding to position 71; N at a position corresponding to position 71; R at a position corresponding to position 71; S at a position corresponding to position 71; K at a position corresponding 20 to position 72; M at a position corresponding to position 72; Q at a position corresponding to position 72; A at a position corresponding to position 73; H at a position corresponding to position 73; K at a position corresponding to position 73; L at a position corresponding to position 73; Q at a position 25 corresponding to position 73; R at a position corresponding to position 73; T at a position corresponding to position 73; W at a position corresponding to position 73; A at a position corresponding to position 74; C at a position corresponding to position 74; E at a position corresponding to position 74; 30 F at a position corresponding to position 74; G at a position corresponding to position 74; H at a position corresponding to position 74; K at a position corresponding to position 74; L at a position corresponding to position 74; M at a position corresponding to position 74; N at a position corresponding 35 to position 74; P at a position corresponding to position 74; R at a position corresponding to position 74; S at a position corresponding to position 74; V at a position corresponding to position 74; W at a position corresponding to position 74; F at a position corresponding to position 75; L at a position 40 corresponding to position 75; M at position corresponding to position 75; R at a position corresponding to position 75; T at a position corresponding to position 75; L at a position corresponding to position 79; L at a position corresponding to position 82; N at a position corresponding to position 82; 45 V at a position corresponding to position 83; Q at a position corresponding to position 83; S at a position corresponding to position 83; G at a position corresponding to position 83; E at a position corresponding to position 84; F at a position corresponding to position 84; G at a position corresponding 50 to position 84; N at a position corresponding to position 84; R at a position corresponding to position 84; A at a position corresponding to position 86; H at a position corresponding to position 86; K at a position corresponding to position 86; N at a position corresponding to position 86; S at a position 55 corresponding to position 86; T at a position corresponding to position 86; W at a position corresponding to position 86; C at a position corresponding to position 87; G at a position corresponding to position 87; L at a position corresponding to position 87; M at a position corresponding to position 87; 60 R at a position corresponding to position 87; S at a position corresponding to position 87; T at a position corresponding to position 87; V at a position corresponding to position 87; Y at a position corresponding to position 87; C at a position corresponding to position 89; A at a position corresponding 65 to position 90; E at a position corresponding to position 90; H at a position corresponding to position 90; K at a position

90

corresponding to position 90; N at a position corresponding to position 90; R at a position corresponding to position 90; C at a position corresponding to position 92; L at a position corresponding to position 92; I at a position corresponding to position 93; L at a position corresponding to position 93; Q at a position corresponding to position 93; R at a position corresponding to position 93; S at a position corresponding to position 93; T at a position corresponding to position 93; D at a position corresponding to position 94; Q at a position corresponding to position 94; R at a position corresponding to position 94; A at a position corresponding to position 97; C at an amino acid residue corresponding to position 97; D at a position corresponding to position 97; E at a position corresponding to position 97; G at a position corresponding to position 97; L at a position corresponding to position 97; S at a position corresponding to position 97; S at a position corresponding to position 102; T at a position corresponding to position 102; R at a position corresponding to position 104; L at a position corresponding to position 107; A at a position corresponding to position 114; O at a position corresponding to position 118; H at a position corresponding to position 120; F at a position corresponding to position 120; I at a position corresponding to position 120; S at a position corresponding to position 120; V at a position corresponding to position 120; Y at a position corresponding to position 120; E at a position corresponding to position 127; H at a position corresponding to position 127; N at a position corresponding to position 127; Q at a position corresponding to position 127; R at a position corresponding to position 127; I at a position corresponding to position 128; R at a position corresponding to position 130; G at a position corresponding to position 131; I at a position corresponding to position 131; M at a position corresponding to position 131; Q at a position corresponding to position 131; R at a position corresponding to position 131; V at a position corresponding to position 131; N at a position corresponding to position 132; L at a position corresponding to position 132; D at a position corresponding to position 135; G at a position corresponding to position 135; R at a position corresponding to position 135, with L at a position corresponding to position 138; T at a position corresponding to position 139; K at a position corresponding to position 140; H at a position corresponding to position 141; R at a position corresponding to position 141; S at a position corresponding to position 141; W at a position corresponding to position 141; Y at a position corresponding to position 141; D at a position corresponding to position 142; G at a position corresponding to position 142; K at a position corresponding to position 142; N at a position corresponding to position 142; P at a position corresponding to position 142; Q at a position corresponding to position 142; R at a position corresponding to position 142; S at a position corresponding to position 142; T at a position corresponding to position 142; G at a position corresponding to position 143; K at a position corresponding to position 143; R at a position corresponding to position 144; T at a position corresponding to position 144; P at a position corresponding to position 146; R at a position corresponding to position 146; A at a position corresponding to position 147; F at a position corresponding to position 147; L at a position corresponding to position 147; R at a position corresponding to position 147; S at a position corresponding to position 147; V at a position corresponding to position 147; H at a position corresponding to position 148; K at a position corresponding to position 148; Q at a position corresponding to position 148; T at a position corresponding to position 149; V at a position corresponding to position 149; A at a position corresponding to position 150; D at a position corresponding to position 150; G at a position corresponding to position 150; N at a position corresponding to position 150; S at a position corresponding to position 150; W at a position corresponding to position 150; Y at a position corresponding to position 150; A at a position corresponding to position 151; H at a position corresponding to position 151; K at a position corresponding to position 151; L at a position corresponding to position 151; M at a position corresponding to position 151; Q at a position corresponding to position 10 151; R at a position corresponding to position 151; S at a position corresponding to position 151; T at a position corresponding to position 151; V at a position corresponding to position 151; W at a position corresponding to position 151; Y at a position corresponding to position 151; R at a 15 position corresponding to position 152; T at a position corresponding to position 152; W at a position corresponding to position 152; D at a position corresponding to position 155; G at a position corresponding to position 155; K at a position corresponding to position 155; R at a position 20 corresponding to position 155; D at a position corresponding to position 156; Q at a position corresponding to position 158; S at a position corresponding to position 158; S at a position corresponding to position 160; E at a position corresponding to position 162; A at a position corresponding 25 to position 163; E at a position corresponding to position 163; K at a position corresponding to position 163; Q at a position corresponding to position 163; R at a position corresponding to position 163; S at a position corresponding to position 163; M at a position corresponding to position 30 164; V at a position corresponding to position 164; D at a position corresponding to position 165; F at a position corresponding to position 165; N at a position corresponding to position 165; S at a position corresponding to position 165; V at a position corresponding to position 165; A at a 35 position corresponding to position 166; E at a position corresponding to position 166; F at a position corresponding to position 166; H at a position corresponding to position 166; L at a position corresponding to position 166; Q at a position corresponding to position 166; R at a position 40 corresponding to position 166; T at a position corresponding to position 166; W at a position corresponding to position 166; Y at a position corresponding to position 166; D at a position corresponding to position 167; L at a position corresponding to position 169; R at a position corresponding 45 to position 170; A at a position corresponding to position 172; R at a position corresponding to position 173; G at a position corresponding to position 174; K at a position corresponding to position 174; N at a position corresponding to position 174; R at a position corresponding to position 50 174; T at a position corresponding to position 174; T at a position corresponding to position 175; K at a position corresponding to position 178; R at a position corresponding to position 178; K at a position corresponding to position 179; Q at a position corresponding to position 193; T at a 55 position corresponding to position 195; N at a position corresponding to position 195; with E at a position corresponding to position 196; R at a position corresponding to position 196; with D at a position corresponding to position 198; P at a position corresponding to position 204; A at a 60 position corresponding to position 205; E at a position corresponding to position 205; L at a position corresponding to position 205; T at a position corresponding to position 205; I at a position corresponding to position 206; K at a position corresponding to position 206; L at a position 65 corresponding to position 206; R at a position corresponding to position 206; R at a position corresponding to position

209; N at a position corresponding to position 212; S at a position corresponding to position 212; A at a position corresponding to position 213; M at a position corresponding to position 213; N at a position corresponding to position 213; H at a position corresponding to position 215; M at a position corresponding to position 215; A at a position corresponding to position 219; I at a position corresponding to position 219; K at a position corresponding to position 219; S at a position corresponding to position 219; H at a position corresponding to position 220; I at a position corresponding to position 220; L at a position corresponding to position 220; V at a position corresponding to position 220; Q at a position corresponding to position 221; G at a position corresponding to position 222; F at a position corresponding to position 232; G at a position corresponding to position 233; K at a position corresponding to position 233; R at a position corresponding to position 233; M at a position corresponding to position 234; A at a position corresponding to position 235; R at a position corresponding to position 236; C at a position corresponding to position 237; E at a position corresponding to position 237; H at a position corresponding to position 237; Q at a position corresponding to position 237; T at a position corresponding to position 237; E at a position corresponding to position 238; H at a position corresponding to amino acid position 238; S at a position corresponding to position 238; A at a position corresponding to position 240; Q at a position corresponding to position 240; I at a position corresponding to position 247; A at a position corresponding to position 248; V at a position corresponding to position 249; G at a position corresponding to position 257; T at a position corresponding to position 257; R at a position corresponding to position 257; N at a position corresponding to position 258; S at a position corresponding to position 258; P at a position corresponding to position 259; M at a position corresponding to position 260; Y at a position corresponding to position 260; A at a position corresponding to position 261; K at a position corresponding to position 261; N at a position corresponding to position 261; K at a position corresponding to position 263; R at a position corresponding to position 263; T at a position corresponding to position 267; A at a position corresponding to position 269; L at a position corresponding to position 271; M at a position corresponding to position 271; D at a position corresponding to position 272; T at a position corresponding to position 272; H at a position corresponding to position 273; Y at a position corresponding to position 273; F at a position corresponding to position 274; D at a position corresponding to position 276; H at a position corresponding to position 276; M at a position corresponding to position 276; R at a position corresponding to position 276; S at a position corresponding to position 276; Y at a position corresponding to position 276; A at a position corresponding to position 277; E at a position corresponding to position 277; H at a position corresponding to position 277; K at a position corresponding to position 277; M at a position corresponding to position 277; N at a position corresponding to position 277; Q at a position corresponding to position 277; R at a position corresponding to position 277; S at a position corresponding to position 277; T at a position corresponding to position 277; E at a position corresponding to position 278; F at a position corresponding to position 278; G at a position corresponding to position 278; H at a position corresponding to position 278; K at a position corresponding to position 278; N at a position corresponding to position 278; R at a position corresponding to position 278; S at a position corresponding to position 278; T at a position corresponding to position 278; Y at a position corresponding to position 278; H at a position corresponding to position 279; M at a position corresponding to position 282; S at a position corresponding to position 283; H at a position corresponding to position 285; T at a position corresponding to position 287; S at a position corresponding to position 289; S at a position corresponding to position 291; V at a position corresponding to position 291; C at a position corresponding to position 292; F at a position corresponding to position 292; H at a position corresponding to position 10 292; K at a position corresponding to position 292; R at a position corresponding to position 292; V at a position corresponding to position 292; A at a position corresponding to position 293; C at a position corresponding to position 293; D at a position corresponding to position 293; F at a 15 position corresponding to position 293; K at a position corresponding to position 293; M at a position corresponding to position 293; P at a position corresponding to position 293; Q at a position corresponding to position 293; V at a position corresponding to position 293; Y at a position 20 corresponding to position 293; G at a position corresponding to position 298; E at a position corresponding to position 305; G at a position corresponding to position 307; D at a position corresponding to position 308; G at a position corresponding to position 308; K at a position corresponding 25 to position 308; N at a position corresponding to position 308; R at a position corresponding to position 308; E at a position corresponding to position 309; G at a position corresponding to position 309; H at a position corresponding to position 309; L at a position corresponding to position 30 309; M at a position corresponding to position 309; N at a position corresponding to position 309; Q at a position corresponding to position 309; R at a position corresponding to position 309; S at a position corresponding to position 309; T at a position corresponding to position 309; V at a 35 position corresponding to position 309; A at a position corresponding to position 310; G at a position corresponding to position 310; Q at a position corresponding to position 310; S at a position corresponding to position 310; A at a position corresponding to position 313; G at a position 40 position corresponding to position 371; R at a position corresponding to position 313; H at a position corresponding to position 313; K at a position corresponding to position 313; P at a position corresponding to position 313; R at a position corresponding to position 313; T at a position corresponding to position 313; Y at a position corresponding 45 to position 313; with S at a position corresponding to position 314: Y at a position corresponding to position 314: A at a position corresponding to position 315; H at a position corresponding to position 315; Y at a position corresponding to position 315; A at a position corresponding to position 50 317; I at a position corresponding to position 317; K at a position corresponding to position 317; N at a position corresponding to position 317; Q at a position corresponding to position 317; R at a position corresponding to position 317; S at a position corresponding to position 317; T at a 55 position corresponding to position 317; W at a position corresponding to position 317; D at a position corresponding to position 318; H at a position corresponding to position 318; K at a position corresponding to position 318; M at a position corresponding to position 318; R at a position 60 corresponding to position 318; H at a position corresponding to position 320; K at a position corresponding to position 320; R at a position corresponding to position 320; R at a position corresponding to position 321; S at a position corresponding to position 321; N at a position corresponding 65 to position 324; R at a position corresponding to position 324; A at a position corresponding to position 325; D at a

94

position corresponding to position 325; E at a position corresponding to position 325; G at a position corresponding to position 325; H at a position corresponding to position 325; K at a position corresponding to position 325; M at a position corresponding to position 325; N at a position corresponding to position 325; Q at a position corresponding to position 325; S at a position corresponding to position 325; V at a position corresponding to position 325; L at a position corresponding to position 326; V at a position corresponding to position 326; C at a position corresponding to position 328; G at a position corresponding to position 328; I at a position corresponding to position 328; K at a position corresponding to position 328; L at a position corresponding to position 328; S at a position corresponding to position 328; Y at a position corresponding to position 328; S at a position corresponding to position 335; A at a position corresponding to position 347; G at a position corresponding to position 347; S at a position corresponding to position 347; M at a position corresponding to position 349; R at a position corresponding to position 349; S at a position corresponding to position 351; V at a position corresponding to position 353; with H at a position corresponding to position 356; S at a position corresponding to position 356; E at a position corresponding to position 359; H at a position corresponding to position 359; T at a position corresponding to position 359; A at a position corresponding to position 367; G at a position corresponding to position 367; K at a position corresponding to position 367; S at a position corresponding to position 367; A at a position corresponding to position 368; E at a position corresponding to position 368; K at a position corresponding to position 368; L at a position corresponding to amino acid position 368; M at a position corresponding to amino acid position 368; R at a position corresponding to position 368; T at a position corresponding to amino acid position 368; H at a position corresponding to position 369; R at a position corresponding to position 369; F at a position corresponding to position 371; H at a position corresponding to position 371; K at a position corresponding to position 371; L at a corresponding to position 371; S at a position corresponding to position 371; M at a position corresponding to position 373; H at a position corresponding to position 374; P at a position corresponding to position 374; A at a position corresponding to position 375; G at a position corresponding to position 375; K at a position corresponding to position 375; R at a position corresponding to position 375; D at a position corresponding to position 376; E at a position corresponding to position 376; Q at a position corresponding to position 376; R at a position corresponding to position 376; T at a position corresponding to position 376; V at a position corresponding to position 376; Y at a position corresponding to position 376; D at a position corresponding to position 377; E at a position corresponding to position 377; H at a position corresponding to position 377; K at a position corresponding to position 377; P at a position corresponding to position 377; R at a position corresponding to position 377; S at a position corresponding to position 377; T at a position corresponding to position 377; W at a position corresponding to position 380; Y at a position corresponding to position 380; S at a position corresponding to position 381; I at a position corresponding to position 383; K at a position corresponding to position 383; L at a position corresponding to position 383; S at a position corresponding to position 383; A at a position corresponding to position 385; Q at a position corresponding to position 385; V at a position corresponding to position 385; A at a position corresponding to position 389; G at a position corresponding to position 389; L at a position corresponding to position 389; K at a position corresponding to position 389; Q at a position corresponding to position 389; S at a position corresponding to position 389; A at a position corresponding to position 392; F at a position corresponding to position 392; M at a position corresponding to position 392; Q at a position corresponding to position 392; R at a position corresponding to position 392; V at a position corresponding to position 392; F at a position corresponding to position 10 393; M at a position corresponding to position 393; A at a position corresponding to position 395; H at a position corresponding to position 395; R at a position corresponding to position 395; A at a position corresponding to position 396; H at a position corresponding to position 396; Q at a 15 position corresponding to position 396; S at a position corresponding to position 396; K at a position corresponding to position 399; M at a position corresponding to position 399; T at a position corresponding to position 399; V at a position corresponding to position 399; W at a position 20 corresponding to position 399; A at a position corresponding to position 401; E at a position corresponding to position 401; A at a position corresponding to position 404; G at a position corresponding to position 405; F at a position corresponding to position 406; N at a position corresponding 25 to position 406; A at a position corresponding to position 407; D at a position corresponding to position 407; E at a position corresponding to position 407; F at a position corresponding to position 407; H at a position corresponding to position 407; Q at a position corresponding to position 30 407; P at a position corresponding to position 407; A at a position corresponding to position 409; Q at a position corresponding to position 409; T at a position corresponding to position 410; Q at a position corresponding to position 412; R at a position corresponding to position 412; V at a 35 position corresponding to position 412; L at a position corresponding to position 416; E at a position corresponding to position 418; L at a position corresponding to position 418; P at a position corresponding to position 418; R at a position corresponding to position 418; V at a position 40 corresponding to position 418; F at a position corresponding to position 419; H at a position corresponding to position 419; I at a position corresponding to position 419; K at a position corresponding to position 419; R at a position corresponding to position 419; S at a position corresponding 45 to position 419; Y at a position corresponding to position 419; A at a position corresponding to position 421; H at a position corresponding to position 421; K at a position corresponding to position 421; N at a position corresponding to position 421; Q at a position corresponding to position 50 421; R at a position corresponding to position 421; S at a position corresponding to position 421; G at a position corresponding to position 425; K at a position corresponding to position 425; Q at a position corresponding to position 427; T at a position corresponding to position 427; L at a 55 position corresponding to position 428; A at a position corresponding to position 431; G at a position corresponding to position 431; E at a position corresponding to position 431; H at a position corresponding to position 431; K at a position corresponding to position 431; L at a position 60 corresponding to position 431; N at a position corresponding to position 431; Q at a position corresponding to position 431; R at a position corresponding to position 431; S at a position corresponding to position 431; V at a position corresponding to position 431; A at a position corresponding 65 to position 433; H at a position corresponding to position 433; I at a position corresponding to position 433; K at a

96

position corresponding to position 433; L at a position corresponding to position 433; R at a position corresponding to position 433; T at a position corresponding to position 433; V at a position corresponding to position 433; W at a position corresponding to position 433; K at a position corresponding to position 436; I at a position corresponding to position 437; M at a position corresponding to position 437; A at a position corresponding to position 438; D at a position corresponding to position 438; E at a position corresponding to position 438; L at a position corresponding to position 438; N at a position corresponding to position 438; T at a position corresponding to position 438; A at a position corresponding to position 439; C at a position corresponding to position 439; K at a position corresponding to position 439; P at a position corresponding to position 439; Q at a position corresponding to position 439; T at a position corresponding to position 439; V at a position corresponding to position 439; D at a position corresponding to position 440; H at a position corresponding to position 440; M at a position corresponding to position 440; P at a position corresponding to position 440; R at a position corresponding to position 440; S at a position corresponding to position 440; A at a position corresponding to position 441; F at a position corresponding to position 441; C at a position corresponding to position 442; G at a position corresponding to position 442; R at a position corresponding to position 442; A at a position corresponding to position 443; E at a position corresponding to position 443; F at a position corresponding to position 443; G at a position corresponding to position 443; M at a position corresponding to position 443; N at a position corresponding to position 443; E at a position corresponding to position 444; H at a position corresponding to position 444; V at a position corresponding to position 444; H at a position corresponding to position 445; M at a position corresponding to position 445; N at a position corresponding to position 445; P at a position corresponding to position 445; Q at a position corresponding to position 445; S at a position corresponding to position 445; T at a position corresponding to position 445; V at a position corresponding to position 445; W at a position corresponding to position 445; A at a position corresponding to position 446; M at a position corresponding to position 446; W at a position corresponding to position 446; D at a position corresponding to position 447; E at a position corresponding to position 447; G at a position corresponding to position 447; I at a position corresponding to position 447; N at a position corresponding to position 447; P at a position corresponding to position 447; Q at a position corresponding to position 447; T at a position corresponding to position 447, and/or replacement with V at a position corresponding to position 447, each with reference to amino acid positions set forth in SEQ ID NO:3.

Exemplary of such modified PH20 polypeptides are any having the sequence of amino acids set forth in any of SEQ ID NOs: 74-855, or having a sequence of amino acids that exhibits at least 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOs:74-855 and contains the amino acid replacement and exhibits hyaluronidase activity.

Any of the above modified PH20 polypeptides provided herein can exhibit altered, such as improved or increased, properties or activities compared to the corresponding PH20 polypeptide not containing the amino acid modification (e.g., amino acid replacement). For example, the altered activities or properties can be an increased catalytic activity and/or an increased stability under denaturing conditions. a. Increased Activity

Provided herein are modified or variant PH20 polypeptides that contain one or more amino acid replacements in a PH20 polypeptide and that exhibit increased hyaluronidase activity compared to the corresponding PH20 polypeptide 5 not containing the amino acid replacement(s), for example, the PH20 polypeptide set forth in any of SEQ ID NOs: 2, 3, 6-66, 68-72, 856-861, 869 or 870 or a variant thereof having at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 10 98%, 99% or more sequence identity thereto. In particular, the modified or variant PH20 polypeptides provided herein exhibit increased hyaluronidase activity compared to the corresponding PH20 polypeptide not containing the amino acid replacement, for example, the PH20 polypeptide set 15 forth in any of SEQ ID NOs: 3, 7, 32-66, 69 or 72 and in particular the PH20 polypeptide set forth in SEQ ID NO: 3.

The modified PH20 polypeptide can exhibit hyaluronidase activity that is at least or about at least or 120%, 130%, 250%, 300%, 350%, 400%, 500%, 1500%, 2000%, 3000%, 4000%, 5000% of the hyaluronidase activity of the corresponding PH20 polypeptide not containing the amino acid replacement(s), for example the PH20 polypeptide set forth in any of any of SEQ ID NOs: 2, 3, 6-66, 68-72, 856-861, 25 869 or 870 or a variant thereof, under the same conditions. For example, the hyaluronidase activity is increased at least or about at least 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 30 19-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 200-fold, 300-fold, 400fold or more.

In particular examples, the modified PH20 polypeptides contain an amino acid replacement at one or more amino 35 acid positions identified as being associated with increased hyaluronidase activity. As described herein, such positions have been identified using mutagenesis and selection or screening methods to identify those positions that result in increased hyaluronidase activity. The PH20 polypeptide also 40 can contain other modifications, such as other amino acid replacements, that alone are not associated with increased activity so long as the resulting modified PH20 polypeptide exhibits increased hyaluronidase activity compared to the PH20 not containing the amino acid modification(s), such as 45 amino acid replacement(s). The modified PH20 polypeptide provided herein can contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 50 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, or more amino acid replacements. Additional modifications, such as insertions or deletions, also can be included. The amino acid replacement can be in a PH20 polypeptide as set 55 forth in any of SEQ ID NOs: 2, 3, 6-66, 68-72, 856-861, 869 or 870 or a variant thereof having at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. For example, the replacement(s) 60 can be in a human PH20 polypeptide, for example, any set forth in any of SEQ ID NOs: 3, 7, 32-66, 69 or 72 or a variant thereof.

For example, the modified PH20 polypeptides provided herein contain an amino acid replacement (substitution) at 65 one or more amino acid positions corresponding to positions 1, 12, 15, 24, 26, 27, 29, 30, 31, 32, 33, 37, 39, 46, 48, 52,

58, 63, 67, 68, 69, 70, 71, 72, 73, 74, 75, 84, 86, 87, 92, 93, 94, 97, 118, 120, 127, 131, 135, 141, 142, 147, 148, 150, 151, 152, 155, 156, 163, 164, 165, 166, 169, 170, 174, 198, 206, 209, 212, 213, 215, 219, 233, 234, 236, 238, 247, 257, 259, 260, 261, 263, 269, 271, 272, 276, 277, 278, 282, 291, 293, 305, 308, 309, 310, 313, 315, 317, 318, 320, 324, 325, 326, 328, 347, 353, 359, 371, 377, 380, 389, 392, 395, 399, 405, 407, 409, 410, 418, 419, 421, 425, 431, 433, 436, 437, 438, 439, 440, 441, 442, 443, 445, 446 or 447 with reference to amino acid positions set forth in SEQ ID NO:3. For example, the amino acid positions can be replacements at positions corresponding to replacement of Leucine (L) at position 1 (L1), V12, L15, F24, L26, G27, F29, D30, E31, P32, L33, L37, S39, 146, A48, G52, V58, Y63, 167, D68, S69, 170, T71, G72, V73, T74, V75, S84, G86, D87, A92, K93, K94, T97, T118, A120, D127, N131, E135, N141, V142, T147, E148, T150, E151, K152, Q155, E156, D163, F164, L165, V166, 1169, K170, L174, G198, V206, K209, D212, D213, S215, N219, Q233, Q234, P236, A238, V247, 135%, 140%, 145%, 150%, 160%, 170%, 180%, 200%, 20 P257, A259, K260, S261, L263, T269, 1271, V272, O276, V277, L278, S282, G291, T293, G305, S308, 1309, M310, M313, S315, L317, L318, D320, E324, T325, 1326, N328, Q347, 1353, S359, A371, G377, F380, E389, E392, S395, Y399, T405, S407, K409, E410, D418, A419, D421, A425, D431, F433, P436, P437, M438, E439, T440, E441, E442, P443, 1445, F446 or Y447 with reference to amino acid positions set forth in SEQ ID NO:3. Exemplary of such modified PH20 polypeptides are polypeptides that exhibit at least 1.5-fold or more the activity of the corresponding PH20 polypeptide not containing the amino acid replacement.

> Exemplary of amino acid replacements in the modified PH20 polypeptides provided herein include, but are not limited, replacement: with histidine (H) at a position corresponding to position 1; Q at a position corresponding to position 1; E at a position corresponding to position 12; T at a position corresponding to position 12; V at a position corresponding to position 15; E at a position corresponding to position 24; H at a position corresponding to position 24; E at a position corresponding to position 26; K at a position corresponding to position 26; K at a position corresponding to position 27; R at a position corresponding to position 27; E at a position corresponding to position 29; I at a position corresponding to position 29; L at a position corresponding to position 29; M at a position corresponding to position 29; P at a position corresponding to position 29; S at a position corresponding to position 29; V at a position corresponding to position 29; G at a position corresponding to position 30; H at a position corresponding to position 30; K at a position corresponding to position 30; M at a position corresponding to position 30; R at a position corresponding to position 30; S at a position corresponding to position 30; A at a position corresponding to position 31; C at a position corresponding to position 31; H at a position corresponding to position 31; I at a position corresponding to position 31; K at a position corresponding to position 31; L at a position corresponding to position 31; P at a position corresponding to position 31; R at a position corresponding to position 31; S at a position corresponding to position 31; T at a position corresponding to position 31; V at a position corresponding to position 31; F at a position corresponding to position 32; G at a position corresponding to position 32; H at a position corresponding to position 32; W at a position corresponding to position 33; F at a position corresponding to position 37; N at a position corresponding to position 39; T at a position corresponding to position 39; R at a position corresponding to position 46; F at a position corresponding to position 48; H at a position corresponding to position 48; N at a position corresponding

to position 48; Q at a position corresponding to position 52; K at a position corresponding to position 58; Q at a position corresponding to position 58; W at a position corresponding to position 63; V at a position corresponding to position 67; H at a position corresponding to position 68; Q at a position corresponding to position 68; A at a position corresponding to position 69; C at a position corresponding to position 69; F at a position corresponding to position 69; G at a position corresponding to position 69; I at a position corresponding to position 69; L at a position corresponding to position 69; 10 M at a position corresponding to position 69; P at a position corresponding to position 69; R at a position corresponding to position 69; W at a position corresponding to position 69; Y at a position corresponding to position 69; A at a position corresponding to position 70; C at a position corresponding 15 to position 70; F at a position corresponding to position 70; G at a position corresponding to position 70; H at a position corresponding to position 70; K at a position corresponding to position 70; L at a position corresponding to position 70; N at a position corresponding to position 70; P at a position 20 corresponding to position 70; R at a position corresponding to position 70; S at a position corresponding to position 70; T at a position corresponding to position 70; V at a position corresponding to position 70; R at a position corresponding to position 71; S at a position corresponding to position 71; 25 M at a position corresponding to position 72; Q at a position corresponding to position 72; H at a position corresponding to position 73; L at a position corresponding to position 73; W at a position corresponding to position 73; A at a position corresponding to position 74; C at a position corresponding 30 to position 74; G at a position corresponding to position 74; N at a position corresponding to position 74; P at a position corresponding to position 74; R at a position corresponding to position 74; S at a position corresponding to position 74; V at a position corresponding to position 74; W at a position 35 corresponding to position 74; F at a position corresponding to position 75; L at a position corresponding to position 75; R at a position corresponding to position 75; T at a position corresponding to position 75; G at a position corresponding A at a position corresponding to position 86; C at a position corresponding to position 87; T at a position corresponding to position 87; Y at a position corresponding to position 87; C at a position corresponding to position 92; I at a position corresponding to position 93; L at a position corresponding 45 to position 93; R at a position corresponding to position 93; T at a position corresponding to position 93; R at a position corresponding to position 94; G at a position corresponding to position 97; Q at a position corresponding to position 118; F at a position corresponding to position 120; V at a position 50 corresponding to position 120; Y at a position corresponding to position 120; H at a position corresponding to position 127; N at a position corresponding to position 127; G at a position corresponding to position 131; R at a position corresponding to position 131; V at a position corresponding 55 to position 131; D at a position corresponding to position 135; G at a position corresponding to position 135; R at a position corresponding to position 135, with H at a position corresponding to position 141; Y at a position corresponding to position 141; R at a position corresponding to position 60 142; R at a position corresponding to position 147; V at a position corresponding to position 147; K at a position corresponding to position 148; G at a position corresponding to position 150; K at a position corresponding to position 151; L at a position corresponding to position 151; M at a 65 position corresponding to position 151; Q at a position corresponding to position 151; R at a position corresponding

100

to position 151; R at a position corresponding to position 152; G at a position corresponding to position 155; K at a position corresponding to position 155; D at a position corresponding to position 156; A at a position corresponding to position 163; E at a position corresponding to position 163; K at a position corresponding to position 163; R at a position corresponding to position 163; M at a position corresponding to position 164; D at a position corresponding to position 165; N at a position corresponding to position 165; A at a position corresponding to position 166; F at a position corresponding to position 166; H at a position corresponding to position 166; L at a position corresponding to position 166; Q at a position corresponding to position 166; R at a position corresponding to position 166; T at a position corresponding to position 166; Y at a position corresponding to position 166; L at a position corresponding to position 169; R at a position corresponding to position 170; K at a position corresponding to position 174; D at a position corresponding to position 198; K at a position corresponding to position 206; L at a position corresponding to position 206; N at a position corresponding to position 212; M at a position corresponding to position 213; N at a position corresponding to position 213; M at a position corresponding to position 215; S at a position corresponding to position 219; K at a position corresponding to position 233; R at a position corresponding to position 233; M at a position corresponding to position 234; R at a position corresponding to position 236; E at a position corresponding to position 237; S at a position corresponding to position 238; I at a position corresponding to position 247; T at a position corresponding to position 257; P at a position corresponding to position 259; Y at a position corresponding to position 260; K at a position corresponding to position 261; N at a position corresponding to position 261; K at a position corresponding to position 263; R at a position corresponding to position 263; A at a position corresponding to position 269; L at a position corresponding to position 271; M at a position corresponding to position 271; T at a position corresponding to position 272; D at a position to position 84; R at a position corresponding to position 84; 40 corresponding to position 276; S at a position corresponding to position 276; Y at a position corresponding to position 276; K at a position corresponding to position 277; R at a position corresponding to position 277; T at a position corresponding to position 277; H at a position corresponding to position 278; K at a position corresponding to position 278; N at a position corresponding to position 278; R at a position corresponding to position 278; S at a position corresponding to position 278; T at a position corresponding to position 278; Y at a position corresponding to position 278; M at a position corresponding to position 282; V at a position corresponding to position 291; A at a position corresponding to position 293; C at a position corresponding to position 293; F at a position corresponding to position 293; M at a position corresponding to position 293; P at a position corresponding to position 293; Q at a position corresponding to position 293; V at a position corresponding to position 293; E at a position corresponding to position 305; G at a position corresponding to position 308; N at a position corresponding to position 308; E at a position corresponding to position 309; L at a position corresponding to position 309; N at a position corresponding to position 309; Q at a position corresponding to position 309; R at a position corresponding to position 309; T at a position corresponding to position 309; A at a position corresponding to position 310; G at a position corresponding to position 310; K at a position corresponding to position 313; R at a position corresponding to position 313; H at a position corresponding to position 315; I at a position corresponding to position 317; K at a position corresponding to position 317; R at a position corresponding to position 317; M at a position corresponding to position 318; H at a position corresponding to position 320; K at a position corresponding to position 320; R at a position corresponding to position 320; R at a position corresponding to position 324; A at a position corresponding to position 325; D at a position corresponding to position 325; E at a position corresponding to position 325; G at a position corresponding to position 10 325; H at a position corresponding to position 325; K at a position corresponding to position 325; M at a position corresponding to position 325; N at a position corresponding to position 325; Q at a position corresponding to position 325; S at a position corresponding to position 325; V at a 15 position corresponding to position 326; I at a position corresponding to position 328; K at a position corresponding to position 328; L at a position corresponding to position 328; S at a position corresponding to position 328; Y at a position corresponding to position 328; G at a position 20 corresponding to position 347; S at a position corresponding to position 347; V at a position corresponding to position 353; with T at a position corresponding to position 359; R at a position corresponding to position 371; P at a position corresponding to position 377; T at a position corresponding to position 377; W at a position corresponding to position 380; Y at a position corresponding to position 380; K at a position corresponding to position 389; M at a position corresponding to position 392; R at a position corresponding to position 395; M at a position corresponding to position 30 399; T at a position corresponding to position 399; W at a position corresponding to position 399; G at a position corresponding to position 405; D at a position corresponding to position 407; Q at a position corresponding to position 407; A at a position corresponding to position 409; Q at a 35 position corresponding to position 409; T at a position corresponding to position 410; P at a position corresponding to position 418; F at a position corresponding to position 419; I at a position corresponding to position 419; K at a position corresponding to position 419; R at a position 40 corresponding to position 419; S at a position corresponding to position 419; H at a position corresponding to position 421; K at a position corresponding to position 421; N at a position corresponding to position 421; Q at a position corresponding to position 421; R at a position corresponding 45 to position 421; S at a position corresponding to position 421; K at a position corresponding to position 425; A at a position corresponding to position 431; H at a position corresponding to position 431; K at a position corresponding to position 431; Q at a position corresponding to position 50 431; R at a position corresponding to position 431; S at a position corresponding to position 431; V at a position corresponding to position 431; L at a position corresponding to position 433; R at a position corresponding to position 433; T at a position corresponding to position 433; V at a 55 position corresponding to position 433; K at a position corresponding to position 436; I at a position corresponding to position 437; M at a position corresponding to position 437; T at a position corresponding to position 438; V at a position corresponding to position 439; H at a position 60 corresponding to position 440; R at a position corresponding to position 440; F at a position corresponding to position 441; R at a position corresponding to position 442; A at a position corresponding to position 443; M at a position corresponding to position 443; M at a position correspond-65 ing to position 445; P at a position corresponding to position 445; A at a position corresponding to position 446; D at a

position corresponding to position 447; N at a position corresponding to position 447; and/or with Q at a position corresponding to position 447, each with reference to amino acid positions set forth in SEQ ID NO:3. The modified PH20 polypeptides can contain any one or more of the recited amino acid substitutions, in any combination, with or without additional modifications, so long at the PH20 polypeptide exhibits hyaluronidase activity, such as increased hyaluronidase activity compared to the PH20 polypeptide not containing the modification(s), for example, at least 1.5-fold increased hyaluronidase activity.

In some examples, the modified PH20 polypeptides provided herein contain one or more amino acid replacement(s) at a position(s) corresponding to position(s) 24, 29, 31, 48, 58, 69, 70, 75, 84, 97, 165, 166, 271, 278, 317, 320, 325, and/or 326 with reference to positions set forth in SEQ ID NO:3. For example, exemplary amino acid replacements include, but are not limited to, replacement with: E at a position corresponding to position 24; E at a position corresponding to position 29; V at a position corresponding to position 31; N at a position corresponding to position 48; K at a position corresponding to position 58; Q at a position corresponding to position 58; A at a position corresponding to position 69; F at a position corresponding to position 69; G at a position corresponding to position 69; P at a position corresponding to position 69; R at a position corresponding to position 69; A at a position corresponding to position 70; F at a position corresponding to position 70; G at a position corresponding to position 70; H at a position corresponding to position 70; H at a position corresponding to position 70; N at a position corresponding to position 70; R at a position corresponding to position 70; T at a position corresponding to position 70; V at a position corresponding to position 70; L at a position corresponding to position 75; T at a position corresponding to position 75; G at a position corresponding to position 84; G at a position corresponding to position 97; D at a position corresponding to position 165; L at a position corresponding to position 166; R at a position corresponding to position 166; T at a position corresponding to position 166; L at a position corresponding to position 271; H at a position corresponding to position 278; R at a position corresponding to position 278; K at a position corresponding to position 317; K at a position corresponding to position 320; E at a position corresponding to position 325, with G at a position corresponding to position 325; K at a position corresponding to position 325; N at a position corresponding to position 325; O at a position corresponding to position 325; V at a position corresponding to position 326; each with reference to amino acid positions set forth in SEQ ID NO:3. The modified PH20 polypeptides can contain any one or more of the recited amino acid substitutions, in any combination, with or without additional modifications, so long at the PH20 polypeptide exhibits hyaluronidase activity, such as increased hyaluronidase activity compared PH20 polypeptide not containing the modification(s), for example, at least 2.0-fold increased hyaluronidase activity.

Exemplary modified PH20 polypeptides that exhibit increased activity compared to the unmodified PH20 polypeptide (e.g., set forth in SEQ ID NO:3) are any having the sequence of amino acids set forth in any of SEQ ID NOs: 73, 78, 86, 89, 91, 95, 96, 99, 100, 105, 106, 108, 109, 111, 112, 113, 115, 117, 118, 119, 120, 123-126, 128-136, 139-141, 149, 154, 155, 159, 164, 165, 167, 173, 178, 181, 191-193, 195-197, 199-205, 207-221, 225, 226, 228, 229, 231, 233, 237-239, 242, 247-254, 256, 257, 267, 269, 270, 277, 283, 293, 295, 296, 298, 300, 303, 308, 316, 318, 321, 322, 324, 325, 330, 334, 335, 338-340, 344, 348, 355, 367, 369, 371,

377, 384-388, 394, 398, 399, 401, 406-408, 410, 412, 414, 416, 419, 421-426, 428, 430, 431, 435, 448, 455, 456, 459, 462, 463, 465, 469, 478-480, 482, 484, 490, 493, 497, 501, 503, 505, 506-508, 510-512, 514, 518, 522, 523, 527, 531, 533, 537-543, 545, 551, 558, 559, 561, 563-566, 569, 572, 5 574, 576, 579, 581-583, 585, 587, 588, 594, 596, 602, 605, 606, 609, 613, 618-620, 624-634, 637, 640-644, 647, 648, 652, 657, 675, 695, 698, 699, 700, 712, 717, 725, 731, 732, 734, 738, 742, 746, 748-750, 757, 760, 762-765, 768-773, 775, 779, 782, 783, 786-789, 794-797, 799-801, 807, 814, 10 816, 819, 822, 825, 826, 830, 836, 838, 844, 847, 851, 853 or having a sequence of amino acids that exhibits at least 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEO ID NOs: 73, 78, 86, 89, 91, 15 95, 96, 99, 100, 105, 106, 108, 109, 111, 112, 113, 115, 117, 118, 119, 120, 123-126, 128-136, 139-141, 149, 154, 155, 159, 164, 165, 167, 173, 178, 181, 191-193, 195-197, 199-205, 207-221, 225, 226, 228, 229, 231, 233, 237-239, 242, 247-254, 256, 257, 267, 269, 270, 277, 283, 293, 295, 20 296, 298, 300, 303, 308, 316, 318, 321, 322, 324, 325, 330, 334, 335, 338-340, 344, 348, 355, 367, 369, 371, 377, 384-388, 394, 398, 399, 401, 406-408, 410, 412, 414, 416, 419, 421-426, 428, 430, 431, 435, 448, 455, 456, 459, 462, 463, 465, 469, 478-480, 482, 484, 490, 493, 497, 501, 503, 25 505, 506-508, 510-512, 514, 518, 522, 523, 527, 531, 533, 537-543, 545, 551, 558, 559, 561, 563-566, 569, 572, 574, 576, 579, 581-583, 585, 587, 588, 594, 596, 602, 605, 606, 609, 613, 618-620, 624-634, 637, 640-644, 647, 648, 652, 657, 675, 695, 698, 699, 700, 712, 717, 725, 731, 732, 734, 30 738, 742, 746, 748-750, 757, 760, 762-765, 768-773, 775, 779, 782, 783, 786-789, 794-797, 799-801, 807, 814, 816, 819, 822, 825, 826, 830, 836, 838, 844, 847, 851, 853 and contains the amino acid replacement and exhibits increased hyaluronidase activity compared to the corresponding 35 unmodified polypeptide.

b. Increased Stability

Provided herein are PH20 polypeptides that exhibit increased stability. In particular, the PH20 polypeptides exhibit increased stability in vivo and/or in vitro. For 40 example, the PH20 polypeptides can exhibit increased stability under various storage conditions. The modified PH20 polypeptides provided herein that exhibit increased stability display, among other parameters, increased resistance to denaturation conditions, including but not limited to, dena- 45 turation conditions caused by temperature (e.g., elevated temperature such as heat), agitation, no or low salt, and/or presence of excipients. Exemplary excipients include, but are not limited to, antiadherents, binders, coatings, fillers and diluents, flavors, colors, lubricants, glidants, preserva- 50 tives, sorbents or sweeteners. For example, various excipients, such as preservatives, can act as protein denaturing agents. Modified PH20 polypeptides provided herein that exhibit increased protein stability exhibit reduced aggregation, reduced precipitation and/or increased activity when 55 exposed to a denaturation condition compared to the corresponding PH20 not containing the amino acid replacement. For example, modified PH20 polypeptides provided herein exhibit at least or at least about or 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 60 140%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500% or more increased activity when exposed to a denaturation condition compared to the corresponding PH20 polypeptide not containing the amino acid replacement when exposed to the same denaturation condition. 65

The PH20 polypeptides provided herein that exhibit increased stability are modified or variant PH20 polypep-

104

tides that contain an amino acid replacement (substitution), deletion or insertion or other modification. Typically, the PH20 polypeptides provided herein that exhibit increased stability contain one or more amino acid replacements in a PH20 polypeptide compared to the corresponding PH20 polypeptide not containing the amino acid replacement(s), for example, the PH20 polypeptide set forth in any of SEQ ID NOs: 2, 3, 6-66, 68-72, 856-861, 869 or 870 or a variant thereof having at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. In particular, the modified or variant PH20 polypeptides provided herein exhibit increased stability compared to the corresponding PH20 polypeptide not containing the amino acid replacement, for example, the PH20 polypeptide set forth in any of SEQ ID NOs: 3, 7, 32-66, 69 or 72 and in particular the PH20 polypeptide set forth in SEQ ID NO:3.

In particular examples, the modified PH20 polypeptides contain an amino acid replacement at one or more amino acid positions identified as being associated with increased stability. As described herein, such positions can be identified using mutagenesis and selection or screening methods to identify those positions that result in stability (e.g., increased activity) of the polypeptide compared to the corresponding PH20 not containing the modification upon exposure to one or more denaturation conditions. The PH20 polypeptide also can contain other modifications, such as other amino acid replacements, that alone are not associated with conferring stability, so long as the resulting modified PH20 polypeptide exhibits increased stability under one or more denaturation conditions compared to the PH20 not containing the amino acid modification(s), such as amino acid replacement(s), and exhibits hyaluronidase activity. The modified PH20 polypeptide provided herein can contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, or more amino acid replacements. Additional modifications, such as insertions or deletions, also can be included. The amino acid replacement can be in a PH20 polypeptide as set forth in any of SEQ ID NOs: 2, 3, 6-66, 68-72, 856-861, 869 or 870 or a variant thereof having at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. For example, the replacements can be in a human PH20 polypeptide, for example, any set forth in any of SEQ ID NOs: 3, 7, 32-66, 69 or 72 or a variant thereof.

Exemplary of modified PH20 polypeptides provided herein are PH20 polypeptides that exhibit increased stability upon exposure to phenol compounds, high temperature (heat), and/or lack of NaCl.

i. Phenophiles

Provided herein are modified PH20 polypeptides that exhibit increased stability in the presence of phenolic compounds. Multidose formulations must contain antimicrobial preservatives to protect them from microbial contamination. For parenteral drug products, including insulin and other therapeutic agents, the most common preservatives are phenolic compounds, such as phenol, metacresol (m-cresol), benzyl alcohol, and parabens including methylparaben and propylparaben. The preservatives typically must be present at sufficient concentrations to satisfy regulatory rules. For example, regulatory requirements assert that the antimicro-

bial efficacy of the formulation must satisfy the preservative efficacy test (PET) requirements of the target markets. Currently different regulatory agencies have different pharmacopeial criteria for antimicrobial effectiveness for pharmaceutical products designed for multiple dosing. The PET requirements of the United States Pharmacopoeia (USP) and the European Pharmacopoeia (EP) differ considerably, imposing additional constraints in developing multidose formulations. Table 4 shows the criteria for injectable drugs to meet USP and EP criteria. Typically, formulations that meet EP (EPA or EPB) anti-microbial requirements contain more preservative than those formulated only to meet USP anti-microbial requirements.

TABLE 4

	United Time States point USP		Europe		
Requirement			EPB (Minimum)	EPA (Preferred)	
Bacterial Log	6 h			2	
Reduction*	24 h	1.0	1	3	
	7 d	1.0	3	No recovery	
	14 d	3.0	No increase	No recovery	
	28 d	No increase	No increase	No recovery	
Fungal Log	7 d	No increase		2	
Reduction*	14 d	No increase	1	No increase	
	28 d	No increase	No increase	No increase	

 $*Log_{10}$ unit reduction from initial measured inoculum; No increase: not more than 0.5 $\,$ 30 log_{10} unit increase than previously measured value.

Anti-microbial preservatives can interact with proteins resulting in aggregations and negative effects on stability. Thus, although a necessary component, preservatives pose a significant problem in the development of stable, multidose 35 formulations of proteins because they typically induce aggregation of the protein in aqueous solution. In particular, increasing or high amounts of preservatives can negatively impact the stability of a protein, including effects on physical stability (aggregation or precipitation) that can impact 40 protein activity. For example, to meet the EP preservative efficacy requirements, relatively high amounts of phenolic compounds, such as phenol or m-cresol, can be required, which can influence stability of the protein formulation. For example, preservatives such as phenol, m-cresol, and benzyl 45 alcohol have been shown to induce aggregation of human growth hormone (Maa and Hsu (1996) Int. J. Pharm. 140:155-168), recombinant interleukin-1 receptor (Remmele (1998) Pharm. Res. 15:200-208), human insulin-like growth factor I (Fransson (1997) Pharm. Res. 14:606-612), 50 rhIFN-y (Lam (1997) Pharm. Res. 14:725-729) and cytochrome c (Singh et al. (2011) J. Pharm Sci., 100:1679-89). The destabilizing effect that preservatives have on proteins in solution has been a limiting factor in the development of multidose formulations, and to date, most protein 55 therapeutics have been formulated for single use only.

PH20 hyaluronidase, such as rHuPH20, rapidly loses activity in the presence of preservatives, likely due to unfolding of the protein and subsequent aggregate formation. For example, as shown in the Examples herein, pre-60 servatives reduce PH20 enzymatic activity, particularly at elevated temperatures (see also U.S. Provisional Appl. No. 61/520,962; and U.S. application Ser. Nos. 13/507,263 and 13/507,262). For example, following incubation with 0.4% m-cresol for 4 hours, PH20 (e.g., rHuPH20) retains only 65 about 10% of its activity (see e.g., Example 5). When incubated in the presence of 0.1% phenol and 0.15% or

0.315% m-cresol for 6 days at 37° C., PH20 (e.g., rHuPH20) retains about 0% to 15% activity, depending on the presence of other excipients or amounts of other excipients in the formulation (see e.g., Examples 9 and 10). For example, the presence of a higher concentration of salt generally increases the stability of PH20. In particular, the melting temperature of PH20, such as rHuPH20, is reduced significantly when phenolic preservatives, such as m-Cresol, are added to the formulation. For example, the unfolding temperature of rHuPH20 is reduced from 44° C. to 24° C. The lower PH20 unfolding temperatures leads to increased PH20 aggregation, especially at elevated temperatures, and reduced enzyme activity. The destabilizing effect is likely due to the hydrophobic nature of the phenolic preservatives. The 15 hydrophobicity of the phenolic compounds can lead to interaction with rHuPH20 through nonspecific binding to the protein, ultimately perturbing the structural integrity of rHuPH20. This translates to a significant loss of rHuPH20 enzymatic activity in the presence of preservatives.

The modified PH20 polypeptides provided herein that exhibit increased stability in the presence of phenolic preservatives exhibit more than 15% enzymatic activity in the presence of at least one phenolic preservative for at least 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks or more compared to the enzymatic activity of the modified PH20 polypeptide in the absence of preservative for the same time period and under the same conditions (except for the presence of preservative). In some examples, the modified PH20 polypeptides provided herein exhibit at least 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more enzymatic activity in the presence of a phenolic preservative compared to in the absence of preservative. For example, the phenolic preservative compound can be phenol, metacresol (m-cresol), benzyl alcohol, and/or parabens including methylparaben or propylparaben.

In particular examples, the increased stability in the presence of preservative is exhibited under temperature conditions of between or about between 0° C. to 40° C., such as between or about between 2° C. to 6° C., 24° C. to 32° C. or 35° C. to 40° C., and generally at or about at 4° C. or 5° C., 30° C. or 37° C. It is understood that since high temperature also can have a destabilizing effect on PH20 activity (see below), the percentage of enzymatic activity of a modified PH20 polypeptide provided herein in the presence of preservative is greater at lower temperatures than at higher temperatures.

Generally, the modified PH20 polypeptides provided herein exhibit increased stability, and the noted enzymatic activities, in the presence of an anti-microbial effective amount of preservative that kills or inhibits the propagation of microbial organisms in a sample of the composition. For example, the modified PH20 polypeptides provided herein exhibit increased stability in the presence of an anti-microbial effective amount of preservative that kills or inhibits the propagation of microbial organisms such that at least a 1.0 \log_{10} unit reduction in bacterial organisms occurs at 7 days following inoculation. In some examples, the modified PH20 polypeptides provided herein exhibit increased stability in the presence of an anti-microbial effective amount of preservative that kills or inhibits the propagation of microbial organisms such that, when tested in an antimicrobial preservative effectiveness test (APET), following inoculation of the composition with a microbial inoculum there is

at least a $1.0 \log_{10}$ unit reduction in bacterial organisms at 7 days following inoculation, at least a 3.0 log₁₀ unit reduction of bacterial organisms at 14 days following inoculation, at least no further increase in bacterial organisms after 28 days following inoculation, and at least no increase in fungal organisms after 7 days following inoculation. In other examples, the modified PH20 polypeptides provided herein exhibit increased stability in the presence of an anti-microbial effective amount of preservative that kills or inhibits the propagation of microbial organisms such that, when tested in 10 an antimicrobial preservative effectiveness test (APET), following inoculation of the composition with a microbial inoculum there is at least a 1.0 log₁₀ unit reduction of bacterial organisms at 24 hours following inoculation, at least a 3.0 log₁₀ unit reduction of bacterial organisms at 7 15 days following inoculation, no further increase in bacterial organisms after 28 days following inoculation, at least a 1.0 log₁₀ unit reduction of fungal organisms at 14 days following inoculation, and at least no further increase in fungal organisms after 28 days following inoculation. In yet 20 another example, the modified PH20 polypeptides provided herein exhibit increased stability in the presence of an anti-microbial effective amount of the preservative that kills or inhibits the propagation of microbial organisms such that, when tested in an antimicrobial preservative effectiveness 25 test (APET), following inoculation of the composition with a microbial inoculum there is at least a 2.0 \log_{10} unit reduction of bacterial organisms at 6 hours following inoculation, at least a 3.0 log10 unit reduction of bacterial organisms at 24 hours following inoculation, no recovery of bacterial organisms after 28 days following inoculation of the composition with the microbial inoculum, at least a 2.0 log₁₀ unit reduction of fungal organisms at 7 days following inoculation, and at least no further increase in fungal organisms after 28 days following inoculation.

For example, the modified PH20 polypeptides provided herein exhibit increased stability, and above recited enzymatic activity, in the presence of a total amount of one or more phenolic preservative agents as a percentage (%) of mass concentration (w/v) that is or is between 0.05% to 40 $0.6\%,\,0.1\%$ to $0.4\%,\,0.1\%$ to $0.3\%,\,0.15\%$ to $0.325\%,\,0.15\%$ to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 0.3% to 0.4% inclusive.

Generally, modified PH20 polypeptides provided herein exhibit increased stability in the presence of m-cresol and/or 45 phenol. For example, modified PH20 polypeptides provided herein exhibit increased stability in the presence of m-cresol in an amount as a % of mass concentration (w/v) in a formulation containing the modified PH20 polypeptide of between or about between 0.05% to 0.6%, 0.1% to 0.4%, 50 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 0.3% to 0.4%. In other examples, modified PH20 polypeptides provided herein exhibit increased stability in the presence of phenol in an amount at a % of mass concentration (w/v) in a formulation containing 55 the modified PH20 polypeptide of between or about between 0.05% to 0.6%, 0.1% to 0.4%, 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or0.3% to 0.4% m-cresol. In further examples, modified PH20 polypeptides provided herein exhibit increased stability in the presence of phenol and m-cresol in an amount as a % of mass concentration (w/v) in a formulation containing the modified PH20 polypeptide of between or about between 0.05% to 0.25% phenol and between or about between 0.05% to 0.3% m-cresol, between or about between 0.10% 65 to 0.2% phenol and between or about between 0.6% to 0.18% m-cresol, between or about between 0.1% to 0.15%

phenol and 0.8% to 0.15% m-cresol, between or about between 0.10% to 0.15% phenol and between or about between 0.06% to 0.09% m-cresol, or between or about between 0.12% to 0.18% phenol and between or about between 0.14% to 0.22% m-cresol.

In examples herein, modified PH20 polypeptides exhibit more than 15%, such as at least 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more enzymatic activity in the presence of at least about between or between 0.3% to 0.4%, inclusive, m-cresol and/or phenol for at least 4 hours at 37° C. compared to the enzymatic activity of the modified PH20 polypeptide in the absence of the preservative for the same time period and under the same conditions (except for the presence of preservative). For example, modified PH20 polypeptides exhibit more than 15%, such as at least 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more enzymatic activity in the presence of about or 0.4% m-cresol for at least 4 hours at 37° C. compared to the enzymatic activity of the modified PH20 polypeptide in the absence of the preservative for the same time period and under the same conditions (except for the presence of preservative). Modified PH20 polypeptides provided herein also exhibit more than 15%, such as at least 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more enzymatic activity in the presence of at least about between or between 0.2% to 0.4%, inclusive, m-cresol and/or phenol for at least 1 day, 2 days, 3 days, 4 days, 5 days or 6 days at 37° C. compared to the enzymatic activity of the modified PH20 polypeptide in the absence of preservative for the same time period and under the same conditions (except for the presence of preservative). For example, modified PH20 polypeptides provided herein exhibit more than 15%, such as at least 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more enzymatic activity in the presence of about or 0.10% phenol and about or 0.15% m-cresol for at least 1 day, 2 days, 3 days, 4 days, 5 days or 6 days at 37° C. compared to the enzymatic activity of the modified PH20 polypeptide in the absence of preservative for the same time period and under the same conditions (except for the presence of preservative). In other examples, modified PH20 polypeptides provided herein exhibit more than 15%, such as at least 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more enzymatic activity in the presence of about or 0.315% m-cresol for at least 1 day, 2 days, 3 days, 4 days, 5 days or 6 days, generally for at least 6 days, at 37° C. compared to the enzymatic activity of the modified PH20 polypeptide in the absence of preservative for the same time period and under the same conditions (except for the presence of preservative).

For example, such modified PH20 polypeptides provided herein that exhibit increased stability to phenol compounds contain an amino acid replacement (substitution) at one or more amino acid positions corresponding to positions 10, 12, 20, 22, 26, 34, 36, 46, 50, 52, 58, 68, 70, 74, 82, 83, 84, 60 86, 97, 127, 131, 138, 142, 143, 144, 166, 169, 174, 193, 195, 196, 204, 205, 206, 213, 219, 234, 237, 238, 240, 249, 261, 267, 277, 279, 291, 309, 310, 314, 315, 317, 318, 347, 367, 375, 376, 399, 401, 407, 416, 419, 421, 431, 433, 439, 440, 443 or445 with reference to amino acid positions set forth in SEQ ID NO:3. For example, the amino acid positions can be replacements at one or more positions corresponding to replacement of (P) at position 10 (P10), V12,

A20, S22, L26, D34, S36, 146, G50, G52, V58, D68, 170, T74, K82, 183, S84, Q86, T97, D127, N131, Q138, V142, Q143, L144, V166, 1169, L174, H193, K195, K196, F204, N205, V206, D213, N219, Q234, V237, A238, T240, E249, S261, A267, V277K279, G291, 1309, M310, K314, S315, 5 L317, Q347, P367, E375, K376, Y399, S401, S407, D416, A419, D421, D431, F433, E439, T440, P443 or 1445 with reference to amino acid positions set forth in SEQ ID NO:3.

Exemplary of amino acid replacements in the modified PH20 polypeptides provided herein include, but are not 10 limited to, replacement with: glycine (G) at a position corresponding to position 10; K at a position corresponding to position 12; S at a position corresponding to position 20; T at a position corresponding to position 22; M at a position corresponding to position 26; W at a position corresponding 15 to position 34; N at a position corresponding to position 36; L at a position corresponding to position 46; M at a position corresponding to position 50; T at a position corresponding to position 52; S at a position corresponding to position 52; C at a position corresponding to position 58; K at a position 20 corresponding to position 58; R at a position corresponding to position 58; N at a position corresponding to position 58; Y at a position corresponding to position 58; P at a position corresponding to position 58; H at a position corresponding to position 58; P at a position corresponding to position 68; 25 V at a position corresponding to position 70; E at a position corresponding to position 74; L at a position corresponding to position 82; N at a position corresponding to position 82; V at a position corresponding to position 83; Q at a position corresponding to position 83; S at a position corresponding 30 to position 83; G at a position corresponding to position 83; N at a position corresponding to position 84; A at a position corresponding to position 86; K at a position corresponding to position 86; E at a position corresponding to position 97; L at a position corresponding to position 97; R at a position 35 corresponding to position 127; R at a position corresponding to position 131; L at a position corresponding to position 138; K at a position corresponding to position 142; N at a position corresponding to position 142; P at a position corresponding to position 142; S at a position corresponding 40 544, 576, 589, 600, 603, 607, 612, 614, 647, 658, 683, 687, to position 142; T at a position corresponding to position 142; G at a position corresponding to position 143; K at a position corresponding to position 143; T at a position corresponding to position 144; Q at a position corresponding to position 166; T at a position corresponding to position 45 166; L at a position corresponding to position 169; G at a position corresponding to position 174; N at a position corresponding to position 174; Q at a position corresponding to position 193; T at a position corresponding to position 195; N at a position corresponding to position 195; E at a 50 position corresponding to position 196; R at a position corresponding to position 196; P at a position corresponding to position 204; A at a position corresponding to position 205; E at a position corresponding to position 205; I at a position corresponding to position 206; A at a position 55 corresponding to position 213; I at a position corresponding to position 219; M at a position corresponding to position 234; T at a position corresponding to position 237; H at a position corresponding to position 238; Q at a position corresponding to position 240; V at a position corresponding 60 to position 249; A at a position corresponding to position 261; K at a position corresponding to position 261; T at a position corresponding to position 267; K at a position corresponding to position 277; H at a position corresponding to position 279; V at a position corresponding to position 65 279; V at a position corresponding to position 291; E at a position corresponding to position 309; Q at a position

corresponding to position 310; Y at a position corresponding to position 314; Y at a position corresponding to position 315; N at a position corresponding to position 317; W at a position corresponding to position 317; D at a position corresponding to position 318; G at a position corresponding to position 347; A at a position corresponding to position 367; R at a position corresponding to position 375; R at a position corresponding to position 376; V at a position corresponding to position 399; E at a position corresponding to position 401; A at a position corresponding to position 407; L at a position corresponding to position 416; K at a position corresponding to position 419; H at a position corresponding to position 421; E at a position corresponding to position 431; T at a position corresponding to position 433; V at a position corresponding to position 433; C at a position corresponding to position 439; P at a position corresponding to position 440; G at a position corresponding to position 443; N at a position corresponding to position 445, each with reference to amino acid residue positions set forth in SEO ID NO:3.

The amino acid replacement(s) can be in a PH20 polypeptide as set forth in any of SEQ ID NOs: 2, 3, 6-66, 68-72, 856-861, 869 or 870 or a variant thereof having at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. For example, the replacement(s) can be in a human PH20 polypeptide, for example, any set forth in any of SEQ ID NOs: 3, 7, 32-66, 69 or 72 or a variant thereof.

Exemplary modified PH20 polypeptides that exhibit increased stability to phenol compounds compared to the unmodified PH20 polypeptide (e.g., set forth in SEQ ID NO:3) are any having the sequence of amino acids set forth in any of SEQ ID NOs: 83, 88, 93, 94, 101, 144, 148, 158, 171, 176, 175, 177, 178, 180, 182, 183, 184, 185, 194, 221, 240, 259, 260, 261, 262, 263, 264, 268, 270, 272, 307, 309, 327, 334, 341, 351, 352, 353, 356, 357, 358, 359, 361, 424, 426, 430, 434, 436, 443, 444, 445, 446, 447, 449, 450, 451, 454, 461, 467, 480, 487, 489, 492, 495, 504, 505, 509, 527, 733, 736, 741, 754, 763, 768, 781, 796, 797, 809, 818, 829 or 837 or having a sequence of amino acids that exhibits at least 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOs: 83, 88, 93, 94, 101, 144, 148, 158, 171, 176, 175, 177, 178, 180, 182, 183, 184, 185, 194, 221, 240, 259, 260, 261, 262, 263, 264, 268, 270, 272, 307, 309, 327, 334, 341, 351, 352, 353, 356, 357, 358, 359, 361, 424, 426, 430, 434, 436, 443, 444, 445, 446, 447, 449, 450, 451, 454, 461, 467, 480, 487, 489, 492, 495, 504, 505, 509, 527, 544, 576, 589, 600, 603, 607, 612, 614, 647, 658, 683, 687, 733, 736, 741, 754, 763, 768, 781, 796, 797, 809, 818, 829 or 837 and contains the amino acid replacement, exhibits hyaluronidase activity and exhibits increased stability in the presence phenol compounds compared to the corresponding unmodified polypeptide.

In particular, provided herein is a modified PH20 polypeptide that contains an amino acid replacement with P at a position corresponding to amino acid residue 204 with reference to SEQ ID NO:3. Typically, the modified PH20 polypeptide is a human polypeptide. For example, provided herein is a modified PH20 polypeptide that contains an amino acid replacement F204P in a sequence of amino acids set forth in any of SEQ ID NOs: 3, 7, 69, 72 or 32-66, or a sequence of amino acids that exhibits at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOs:3, 7, 69, 72 or 32-66 so long as the modified polypeptide contains the amino acid replacement corresponding to F204P. In other cases, the modified PH20 polypeptide is a non-human polypeptide. For example, provided herein is a modified PH20 polypeptide that contains an amino acid replacement 5 F204P in a sequence of amino acids set forth in SEQ ID NO: 10, 12, 14, 857, 859, 861 or 870 or a sequence that exhibits at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOs: 10, 12, 14, 857, 859, 861 or 870 so long as the modified polypeptide contains the amino acid replacement corresponding to F204P. In a further example, provided herein is a modified PH20 polypeptide that contains an amino acid replacement F205P in a sequence of amino acids set forth in SEQ ID NO:24 or Y204P in SEQ ID NO:31, or 15 a sequence that exhibits at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:24 or 31. Exemplary of such a modified PH20 polypeptide is a polypeptide having the sequence of amino acids set forth in SEQ ID NO:449, or 20 having a sequence of amino acids that exhibits at least 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:449 and contains the amino acid replacement F204P, exhibits increased hyaluronidase 25 activity and exhibits increased stability to phenol compounds compared to the corresponding unmodified polypeptide (e.g., SEQ ID NO:3). In any of the above examples, the modified PH20 polypeptide that contains an amino acid replacement with P at a position corresponding to amino 30 acid residue 204 with reference to SEQ ID NO:3 does not have the sequence of amino acids set forth in SEQ ID NO:15-22, 28 or 29.

In another example, provided herein is a modified PH20 polypeptide that contains an amino acid replacement at a 35 position corresponding to amino acid residue 58 with reference to SEQ ID NO:3. Exemplary of amino acid replacements are replacement with lysine (K) or with arginine (R) at a position corresponding to amino acid residue 58 with reference to SEQ ID NO:3. Typically, the modified PH20 40 PH20 polypeptide not containing the modification incubated polypeptide is a human polypeptide. For example, provided herein is a modified PH20 polypeptide that contains an amino acid replacement V58K or V58R in a sequence of amino acids set forth in any of SEQ ID NOs: 3, 7, 69, 72 or 32-66, or a sequence of amino acids that exhibits at least 45 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOs:3, 7, 69, 72 or 32-66. In other cases, the modified PH20 polypeptide is a non-human polypeptide. For example, provided herein is a modified PH20 polypeptide that contains an 50 amino acid replacement V58K or V58R in a sequence of amino acids set forth in SEO ID NOs:10, 12, 14, 20, 22, 24, 29, 857, 859, 861 or 870 or a sequence that exhibits at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, $97\%,\,98\%,\,99\%$ or more sequence identity to any of SEQ ID $~_{55}$ NOs: 10, 12, 14, 20, 22, 24, 29, 857, 859, 861 or 870. In a further example, provided herein is a modified PH20 polypeptide that contains an amino acid replacement A58R in a sequence of amino acids set forth in SEQ ID NO: 16 or 31, or a sequence that exhibits at least 75%, 80%, 85%, 90%, 60 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 16 or 31. Exemplary of such a modified PH20 polypeptide is a polypeptide having the sequence of amino acids set forth in SEQ ID NO:182, or having a sequence of amino acids that exhibits at least 68%, 65 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more

sequence identity to SEQ ID NO: 182, which contains the amino acid replacement V58R and exhibits increased hyaluronidase activity and exhibits increased stability in the presence of phenol compounds compared to the corresponding unmodified polypeptide (e.g., SEQ ID NO:3).

ii. Thermophiles

At elevated temperatures, PH20 hyaluronidases can lose activity. Provided herein are modified PH20 polypeptides that exhibit increased stability at elevated temperatures of between or about between 30° C. to 45° C., inclusive, such as between or about between 35° C. to 42° C., in particular at or about 37° C. For example, provided herein are modified PH20 polypeptides that are stable at elevated temperatures greater than 32° C. such as 35° C. to 45° C., 37° C. to 42° C. and in particular at or about 37° C. for at least 3 hours, 4 hours, 5 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, at least 5 days, at least 6 days or at least 7 days. Modified PH20 polypeptides that exhibit stability at elevated temperatures can be used in applications where temperatures are elevated, can fluctuate or can increase. This can occur, for example, in methods of administration utilizing pumps or other continuous infusion devices.

In particular, modified PH20 polypeptides provided herein that exhibit stability at elevated temperatures exhibit increased hyaluronidase activity at elevated temperature compared to the corresponding PH20 polypeptide not containing the modification, e.g., amino acid replacement. The PH20 polypeptides can exhibit increased hyaluronidase activity upon incubation at elevated temperatures greater than 32° C. such as 35° C. to 45° C. or 37° C. to 42° C., in particular at or about 37° C. for at least 4 hours, 5 hours, 6 hours, 12 hours, 1 day, 2 days, 3 hours, 4 hours, 5 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, at least 5 days, at least 6 days or at least 7 days compared to the corresponding PH20 polypeptide not containing the modification incubated under the same conditions. For example, the hyaluronidase activity can be increased at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500% or more compared to the corresponding under the same conditions. For example, the hyaluronidase activity can be increased at least 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold or more compared to the corresponding PH20 polypeptide not containing the modification incubated under the same conditions.

In other examples, modified PH20 polypeptides provided herein that exhibit stability at elevated temperatures retain hyaluronidase activity at elevated temperatures compared to the activity of the modified PH20 polypeptide incubated at non-elevated temperatures under the same conditions (except for the differences in temperature). For example, modified PH20 polypeptides exhibit greater than or about 50%, such as greater than or at least 55%, 60%, 65%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the activity at elevated temperatures greater than 32° C. such as 35° C. to 45° C. or 37° C. to 42° C., in particular at or about 37° C. compared to the activity of the PH20 at non-elevated temperatures of between or about between 2° C. to 8° C. In some examples, modified PH20 polypeptides provided herein that exhibit stability at elevated temperatures exhibit increased activity at elevated temperatures compared to the activity of the modified PH20 polypeptide incubated at non-elevated temperatures under the same conditions (except for the difference in temperature). For example, modified PH20 polypeptides exhibit greater than or about 10% increased activity, such as greater than or at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500% or more of activity at elevated temperatures greater than 32° C. such as 35° C. to 45° C. or 37° C. to 42° C., in particular at or about 37° C. compared to the activity of the PH20 at non-elevated temperatures of between or about between 2° C. to 8° C. For example, modified PH20 polypeptides exhibit greater than or at least about 1.1-fold the hyaluronidase activity, such as greater than or at least 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 10 5-fold or more of activity at elevated temperatures greater than 32° C. such as 35° C. to 45° C. or 37° C. to 42° C., in particular at or about 37° C. compared to the activity of the PH20 at non-elevated temperatures of between or about between 2° C. to 8° C.

For example, such modified PH20 polypeptides provided herein that exhibit increased stability at elevated temperatures contain an amino acid replacement (substitution) at one or more amino acid positions corresponding to positions 1, 11, 12, 14, 20, 26, 29, 34, 50, 58, 70, 82, 83, 84, 86, 87, 140, 20 142, 143, 147, 152, 166, 167, 172, 174, 178, 193, 195, 206, 212, 213, 219, 233, 237, 240, 267, 277, 291, 292, 309, 313, 314, 317, 318, 347, 367, 368, 371, 374, 389, 392, 395, 396, 406, 419, 421, 439 or 443 with reference to amino acid positions set forth in SEQ ID NO:3. For example, the amino 25 acid positions can be replacements at one or more positions corresponding to replacement of (L) at position 1 (L1), N11, V12, F14, A20, L26, F29, D34, G50, V58, 170, K82, 183, S84, Q86, D87, Q140, V142, Q143, T147, K152, V166, E167, G172, L174, N178, H193, K195, V206, D212, D213, 30 N219, Q233, V237, T240, A267, V277, G291, E292, 1309, M313, K314, L317, L318, Q347, P367, D368, A371, L374, E389, E392, S395, E396, L406, A419, D421, E439 or P443, with reference to amino acid positions set forth in SEQ ID NO:3. The resulting modified PH20 polypeptide exhibits 35 increased stability at elevated temperatures greater than 32° C. such as 35° C. to 45° C., 37° C. to 42° C. and in particular at or about 37° C. for at least 3 hours, 4 hours, 5 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, at least 5 days, at least 6 days, at least 7 days or more.

Exemplary amino acid replacements in the modified PH20 polypeptides provided herein include, but are not limited, replacement with: R at a position corresponding to position 1; S at a position corresponding to position 11; I at a position corresponding to position 12; V at a position 45 corresponding to position 14; S at a position corresponding to position 20: M at a position corresponding to position 26: with R at a position corresponding to position 29; W at a position corresponding to position 34; M at a position corresponding to position 50; K at a position corresponding 50 to position 58; Q at a position corresponding to position 58; Q at a position corresponding to position 58; V at a position corresponding to position 70; L at a position corresponding to position 82; Q at a position corresponding to position 83; R at a position corresponding to position 84; A at a position 55 corresponding to position 86; S at a position corresponding to position 87; K at a position corresponding to position 140; S at a position corresponding to position 142; T at a position corresponding to position 142; K at a position corresponding to position 143; S at a position corresponding to position 60 147; T at a position corresponding to position 152; T at a position corresponding to position 166; D at a position corresponding to position 167; A at a position corresponding to position 172; G at a position corresponding to position 174; N at a position corresponding to position 174; R at a 65 position corresponding to position 178; Q at a position corresponding to position 193; T at a position corresponding

114

to position 195; I at a position corresponding to position 206; S at a position corresponding to position 212; A at a position corresponding to position 213; I at a position corresponding to position 219; G at a position corresponding to position 233; T at a position corresponding to position 237; A at a position corresponding to position 240; Q at a position corresponding to position 240; T at a position corresponding to position 267; E at a position corresponding to position 277; S at a position corresponding to position 291; H at a position corresponding to position 292; V at a position corresponding to position 292; S at a position corresponding to position 309; H at a position corresponding to position 313; S at a position corresponding to position 314; I at a position corresponding to position 317; T at a position corresponding to position 317; W at a position corresponding to position 317; R at a position corresponding to position 318; G at a position corresponding to position 347; A at a position corresponding to position 367; R at a position corresponding to position 368; S at a position corresponding to position 371; P at a position corresponding to position 374; A at a position corresponding to position 389; V at a position corresponding to position 392; A at a position corresponding to position 395; H at a position corresponding to position 396; N at a position corresponding to position 406; H at a position corresponding to position 419; K at a position corresponding to position 419; R at a position corresponding to position 421; S at a position corresponding to position 421; A at a position corresponding to position 439; C at a position corresponding to position 439; or G at a position corresponding to position 443, each with reference to amino acid residue positions set forth in SEQ ID NO:3

The amino acid replacement(s) can be in a PH20 polypeptide as set forth in any of SEQ ID NOs: 2, 3, 6-66, 68-72, 856-861, 869 or 870 or a variant thereof having at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. For example, the replacement(s) can be in a human PH20 polypeptide, for example, 40 any set forth in any of SEQ ID NOs: 3, 7, 32-66, 69 or 72 or a variant thereof.

Exemplary modified PH20 polypeptides that exhibit increased stability to phenol compounds compared to the unmodified PH20 polypeptide (e.g., set forth in SEQ ID NO:3) are any having the sequence of amino acids set forth in any of SEQ ID NOs: 79, 85, 87, 90, 93, 101, 114, 144, 171, 178, 181, 221, 259, 262, 269, 270, 282, 343, 356, 357, 359, 368, 395, 426, 429, 432, 434, 436, 441, 443, 444, 454, 460, 461, 467, 477, 487, 491, 492, 509, 525, 550, 554, 557, 584, 593, 599, 605, 611, 612, 617, 647, 658, 667, 676, 679, 709, 720, 723, 727, 740, 761, 763, 772, 773, 808, 809, or 829 or having a sequence of amino acids that exhibits at least 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOs: 79, 85, 87, 90, 93, 101, 114, 144, 171, 178, 181, 221, 259, 262, 269, 270, 282, 343, 356, 357, 359, 368, 395, 426, 429, 432, 434, 436, 441, 443, 444, 454, 460, 461, 467, 477, 487, 491, 492, 509, 525, 550, 554, 557, 584, 593, 599, 605, 611, 612, 617, 647, 658, 667, 676, 679, 709, 720, 723, 727, 740, 761, 763, 772, 773, 808, 809, or 829 and contains the amino acid replacement, exhibits hyaluronidase activity and exhibits increased stability to elevated temperatures compared to the corresponding unmodified polypeptide.

iii. Absence of Salt

PH20 denatures in the presence of low salt or no salt. Thus, PH20 requires a high salt concentration of between or about between 140 mM to 200 mM to maintain stability. Other therapeutic agents, for example insulin, exhibit decreased solubility and increased crystallization/aggregation in the presence of high salt. Thus, the high salt requirements of PH20 can affect the solubility and/or activity of 5 co-formulated therapeutic agents, while the presence of low salt can decrease the activity of PH20. This can create problems for generating PH20 co-formulations.

Provided herein are modified PH20 polypeptides that exhibit increased stability in the presence of low concentra- 10 tions of salt (e.g. NaCl) less than 100 mM, for example, less than 90 mM, 80 mM, 70 mM, 60 mM, 50 mM, 40 mM, 30 mM, 25 mM, 20 mM, 15 mM, 10 mM, 5 mM or less. Generally, the modified PH20 polypeptides provided herein exhibit stability in the presence of low concentrations of salt, 15 for example, low concentrations of NaCl of between or about between 10 mM NaCl and 100 mM NaCl, such as between or about between 15 mM to 80 mM NaCl. The modified PH20 polypeptides provided herein that exhibit stability at low concentrations of salt, such as low concen- 20 301, 302, 303, 304, 305, 306, 307, 308, 310, 311, 312, 313, trations of NaCl (i.e., less than 100 mM or less), exhibit increased hyaluronidase activity compared to the corresponding PH20 not containing the modification(s) (e.g., amino acid replacements). For example, modified PH20 polypeptides exhibit greater than or about 10% increased 25 activity, such as greater than or at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500% or more of activity at low concentrations of salt, such as low concentrations of NaCl (i.e., less than 100 mM), compared to the activity of the corresponding PH20 not 30 containing the amino acid modification(s) (e.g., amino acid replacement(s) under the same conditions). For example, modified PH20 polypeptides exhibit greater than or at least about 1.1-fold the hyaluronidase activity, such as greater than or at least 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 35 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold or more of activity at low concentrations of NaCl less than 100 mM compared to the activity of the corresponding PH20 not containing the amino acid modification(s) (e.g., amino acid replacement(s) under the same conditions.

2. Inactive Mutants

Provided herein are modified PH20 polypeptides that contain one or more amino acid replacements in a PH20 polypeptide and that are inactive, whereby the polypeptides do not exhibit hyaluronidase activity or exhibit low or 45 diminished hyaluronidase activity. The modified PH20 polypeptides provided herein that are inactive generally exhibit less than 20%, such as less than 10%, of the hyaluronidase activity of a wildtype or reference PH20 polypeptide, such as the polypeptide set forth in SEQ ID NO: 3 or 7. For 50 example, modified PH20 polypeptides provided herein that are inactive exhibit less than 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05% or less of the hyaluronidase activity of a wildtype or reference PH20 polypeptide, such as the corre- 55 sponding polypeptide not containing the amino acid modification (e.g., amino acid replacement), for example, a polypeptide set forth in SEQ ID NO:3 or 7.

For example, provided herein are PH20 polypeptides that are inactive and that are modified, for example by amino 60 acid replacement or substitution, compared to a wildtype or reference PH20 polypeptide. For example, a modified PH20 polypeptide provided herein that is inactive contains one or more amino acid replacements at position(s) corresponding to position 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 65 17, 18, 19, 20, 21, 22, 23, 25, 27, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55,

116

56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 94, 95, 96, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 143, 144, 145, 149, 150, 152, 153, 154, 155, 156, 157, 158, 159, 161, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 197, 198, 199, 200, 201, 202, 203, 204, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 278, 279, 280, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 331, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 408, 410, 411, 412, 413, 414, 415, 416, 417, 419, 420, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 434, 437, 438, 439, 440, 441, 442, 443, 444, or 447 with reference to amino acid positions set forth in SEQ ID NO:3, so long as the resulting modified PH20 polypeptide is inactive and exhibits less than 20%, and generally less than 10%, of the hyaluronidase activity of the corresponding PH20 polypeptide not containing the amino acid replacement. Typically, the amino acid residue that is modified (e.g., replaced) at the position corresponding to any of the above positions in a PH20 polypeptide is an 40 identical residue, a conservative residue or a semi-conservative amino acid residue to the amino acid residue set forth in SEQ ID NO:3.

Exemplary amino acid replacements at any of the above corresponding positions are set forth in Table 5. Reference to corresponding position in Table 5 is with reference to positions set forth in SEQ ID NO:3. It is understood that the replacements can be made in the corresponding position in another PH20 polypeptide by alignment therewith with the sequence set forth in SEQ ID NO:3 (see e.g., FIGS. 1 and 2), whereby the corresponding position is the aligned position. The amino acid replacement(s) can be at the corresponding position in a PH20 polypeptide as set forth in any of SEQ ID NOs: 2, 3, 6-66, 68-72, 856-861, 869 or 870 or a variant thereof having at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, so long as the resulting modified PH20 polypeptide is inactive. For example, the replacement(s) can be in a corresponding position in a human PH20 polypeptide, for example, any set forth in any of SEQ ID NOs: 3, 7, 32-66, 69 or 72, or a variant thereof. In particular, any one or more of the replacements are in SEQ ID NO:3, so long as the resulting modified PH20 polypeptide is inactive and exhibits less than 20%, and generally less than 10%, of the hyaluronidase activity of the PH20 polypeptide set forth in SEQ ID NO:3

117 TABLE 5

Inactive Mutants							
Corre-		Corre-		Corre-			
sponding Position	Replacement	sponding Position	Replacement	sponding Position	Replacement		
2	НКWҮ	3	AGKPTV	4	DEFGLPWY		
5	D G I L M N P Q R T V W Y	6	EFTVY	7	C D F G H I K L Q R S T W Y		
8 11	D E G H N R S W A C F I L P T W Y	9 12	C D E G N P G H W	10 13	FILMY EGILMV		
14	A E G H K N P Q W	15	E F G K N P Q R S Y	16	A C D E F G H K M P R S T Y		
17	D E G H I L N P Q R S T V W Y	18	C D F G H I L M P Q S T V Y	19	A C F G H I L M P Q R S V W Y		
20	D E F H K L N P R T V Y	21	A C D E G H I L M R S T V W	22	CEGKP		
23	A F L M N P R S T V	25	D E F G H I K L N P R S T V Y	27	С		
33 36	C D H N V Y C F V W Y	34 37	I L N S T V C E G N S	35 38	A D G P R S E G K L N Q R T		
39	C D F W	40	A D E G K N R S T	41	W Q		
42	D E H I K L M P Q R S T V	43	AEFGIKLQR V	44	A C F G H I L N Q R S T W Y		
45	A D F G P W	46	P W	47	V		
48 51	P C F I M P T W Y	49 52	C D G H P C E F W Y	50 53	V ACDEGHLNP		
54	D E G P R Y	55	A D G H N P Q R T V Y	56	Q R S T W Y A C E G H I K L P R S T V W		
57	A D F G I M P Q R V W	58	A	59	AEILMPRTV WY		
60	A D F G H I L N P Q S T V Y	61	A E F G H N P Q R T W Y	62	A C D F I K L M P Q R S T V Y		
63	CGP	64	A C D E F G H I K L P Q R S T V W	65	A C D G H I K N R S T V W Y		
66	A C D E G I K L N P S T V	67	DEGPRTW	68	ACGILPVY		
69	NT	70	Q	71	Р		
72 76	C F H I P V W A C F G I K L P Q R S T V W	73 77	P D E L P Q R T V	75 78	D G P A D I M P T Y		
79	A D F G H K N P S W Y	80	A D E F G I K L M N R S T V Y	81	A C E G H L N P S V W Y		
82	YE K	84	Y	85	A C D E F G H N Q S T		
86	СР	87	Р	88	ACEFGIKLM PRSTVY		
89 92	A D E G Q S T W Y E F H K P Q R W Y	90 94	C G G P	91 95	D E F G H I L T A C E F G H K L M P O S V W Y		
96 100	S	98 101	P A C F H I K L M N	99 102	CEGINPVW P		
103	W Y A E F G H I L Q R T	104	Q R S T F P W	105	C M N		
106	V W Y A C D F H L M N P S W Y	107	A C H K P Q S V W	108	D E F K L M P Q T V Y		
109	CDELMRTW	110	FKLMPW	111	ΗIQ		
112 115	C E G H L N P S A C D F G H I K L	113 116	R V A C D E G H I L N	114 117	I L P T V D G I K N Q R S V		
118	M R S V Y C D E G P R W Y	119	PQSVW AKILNPR	121	W A C E F G H K L M D W Y		
122	A C E F I K Q R S T V	123	A C D E H L M P Q R S T V Y	124	M P W Y C D E F N		
125 128	C D G L N W E P	126 129	F H I L N P Y A C D E G H L P Q	127 130	К С D G H L N S T		
131	Р	132	S T V W P	133	W Y D E F G H L M N P		
134	A C D F G H K P Q	135	Р	136	R T V W P		
137 143	R S W F G H N P R W Y C H P R S T	138 144	V A E F I K P Q S V	139 145	P T W		
149 152	E L	149 153	Y P E F M P R T V	150 154	V D E G P S W Y		

TABLE 5-continued

Inactive Mutants						
Corre- sponding Position	Replacement	Corre- sponding Position	Replacement	Corre- sponding Position	Replacement	
155	РҮ	156	Р	157	ACDEGHIKL	
158 163	D K P R Y C P	159 164	W Y A C D E G H N P Q	161 165	M P Q R S T V W C H P T	
166	D	167	R V	168	ACDEFGKLF	
169	A D F G H K N P Q	170	C D E G M P W Y	171	R S V W Y C D H M N R S W	
172	STY DEILPQTVW Y	173	D E G H I L M P S V W Y	174	Y P	
175	C D G K P R S	176	A C E F G H I P Q S T V W	177	A C D F G H L M Q R S T V W	
178	EILVW	180	ACEPRS	181	ACDEFHIKL RS	
182	A C D E H N P Q R S T V Y	183	C D E G I K N P Q R S V	184	A C D E F G H K I M P R S V	
185	A D E F G I K P R S T V W Y	186	A D G H I K L N P Q R S V W	187	A F G H I L M N Q R S T V W Y	
188	A C F G H L M N P Q R S T V W	189	A E G H K L M N P R S T V W Y	190	C E F G H K L N Q R S T V W	
191	A E F G K L M P Q R S T V W Y	192	C F G K L M N P Q R V W Y	193	A D K L M P V	
194 198	A C I L P S T V V W	195 199	S E G H I K L P R S	197 200	C AFGHKLMP	
201	A F L M N P R S T V W	202	W AEFGHKNPQ RVWY	203	Q R S W Y A D E G H L M N Q R S T V	
204	A C E G H I K Q R S T	206	C D F G P Y	207	AFGMPQRST VW	
208	D G P W	209	C P	210	A C D E G K M N P S T V W Y	
211	C F G H I K M P R S T V W	212	A G H I K L M P V W	213	P S	
214	A C D E G H K N P R S T Y	215	СР	216	D E G H I K L M N P Q R T V	
217	A C G H P Q S T V W	218	AIKLPSV	219	Р	
220 223	G K N P R W C D E G H K L P Q R S T V W Y	221 224	D E H K P R A D E F G M P Q R S T W Y	222 225	P Y A D E G H K P Q R T V W	
226	ACDEFGLNQ RSTVWY	227	A F G H I K L M P Q R T V W Y	228	A E F G H L M N I R S T W	
229	EFGKLPQTV	230	A E G H K M N P R S T V W Y	231	ACDFGHIKI PQRSV	
232	C G H K L N P Q V Y	233	DIPST	234	A D E G H N P S T V W	
235 239	F L M R W Y C F G H I L P R S T	236 240	C I L N Q T Y E F G N W Y	238 241	FGLPVWY ACDEGIPRS	
242	V W Y A C D G I L M P R S T V W	243	C D F G H L M P Q R S W Y	244	T V W A D G I V Y	
245	ACFLPQRST	246	A C D E G H I K L M P S T V W	247	A C F H N P Q R S T W Y	
248	CDEGIMPT	249	A G H I K M Q S Y	250	C F G H K L M N P Q R S T V W	
251	D F G H K P S T W	252	A D E F G H I K L N P S T Y	253	A D E G H L M N Q R S W	
254	C D E G I K L P Q R T V W Y	255	CDLPVW	256	C D E G [
257 261	D P	258 262	L P V W A D E G H I K Q R	260 263	C P E F P Q W	
264	D E F G L M R T V	265	S T V W Y A D F G H K L M	266	ACGHMPQR	
267	W Y D G H I K N R S W	268	N Q R S A C F G H K L N P	269	S T V W E K L M N P Q R	
270 273	A C E F G H I P Y A C D G I L P Q S V W	271 274	Q S T V W A D E H K T W C E G H N Q W Y	272 275	H L N P W A F G I K L M Q T V W	
276 280	F P W D I M N R S T V W	278 281	M P A D G H I K N P Q	279 282	A C F G L W Y F L V W Y	
283	A C D F W	284	R S V W C D F W	284	СІР	

TABLE 5-continued

Inactive Mutants						
Corre-		Corre-		Corre-		
sponding Position	Replacement	sponding Position	Replacement	sponding Position	Replacement	
285	K P R T V	286	ACDFHKMPT	287	ACDEGKLN	
288	DEFGHIKPRT	289	Y ACEGHLPQR	290	Q R S D O Y	
291	ACDEFMNTW	292	S Y I L T	293	EN	
294	Y A E G H K L N P Q	295	C G H I L N P T V	296	C F G I K M Q R	
297	R S T W C E H L N P Q R S	298	Y CELMNPQST	299	T V W Y A C D F G H L M	
300	T Y A C D E F L M N P Q S T V W	301	W Y E G H K M N P Q R S W Y	302	PQT CDEFGHLM RSTY	
303	ACDEFGKLM RWY	304	A C D G I M N P Q S T V Y	305	LPQRSTVY	
306	ACHILVWY	307	CIP	308	CFLMVWY	
310	CEFKL	311	CEFILPVW	312	CEMVW	
313 316	C E G I K L M P R S T	314 317	C L W G P	315 318	C I V C P W	
319	V W Y C E F G H I K M P	320	C P V	321	ЕМР	
322	Q R S V W Y C D E G I L N P R S	323	A C E G H K N R S	324	CFPVWY	
325	T V W C R E G H N W	327	T V A E F G H N Q R S	329	CFGHIKLN	
330	A C D E G I L M N P R S V W	331	T V W Y A C D E F H K Q R	332	R S T V W Y A C D E F G H K N P R S T Y	
333	GHIKPRSTW Y	334	S T W Y A C D E G M N R S	335	FGHIKLPVY	
336	A E F G K N P R S T V W Y	337	C F G I K L M R T W	338	C D E F G H I K P R T V	
339	D E F G H L N P S T V W Y	340	A C D E F G H K P R S T V W	341	AEGHKLMI QRSTVY	
342	D E F H K L M P Q R T Y	343	CDFIPW	344	F G H L M N P (R S T W Y	
345	A C E H K N Q R T V Y	346	A D F G I K L M P R S T V W	347	CFIPTVW	
348	C H I L P Q R T V W Y	349	D F G P V W Y	350	A D E F H K L M N P R S T V Y	
351	CDEFHNRWY	352	A D E F G K M P Q R S T V W Y	353	C F G H K L M (R S W	
354	C D E G H I K L M P Q S V W Y	355	D F G H L M N P Q R S T V W Y	356	C G K L P R T V W	
357 360	DEFGLMQR ACEFGIKLM POPV	358 361	E H I K P Q R W A C E G M N P Q R S V W	359 362	A F G L P W A C E G H K L N	
363	P Q R V A C D E F G H I P Q R S T V W	364	ACDEFGKLM PRSTVY	365	N P R S T V W A C D E G M N O R S T W Y	
366	A C E F G K M P Q R T W	367	EFILMQV	368	CPW	
369	CEFIKLPQV W	370	A D E G H K L N P Q R S V Y	371	Р	
372	A D E F G H K L N P R S T V W	373	CPW	374	D E	
375 378	C F P V Y D E F I L M Q T W	376 379	I P W A C E F I L M W	377 380	C I L V C D E G Q R S	
381	Y G L P W Y	382	EGHKLMNPQ	383	G P	
384	C F M Q S T	385	R S T W Y C L M P W Y	386	ACFGHILM	
387	C E F G H I L M N	388	C G P Q	389	Q R S T V Y F V	
390	V W Y A C E F G H L N P	391	A D G H K N P Q R	392	СР	
393	R S T V W Y C P	394	S T V W Y A D E G I K N P Q	395	C ; , [
396	C F G I P Y	397	R S T V A C E F G I L M P	398	ACEGHILN	
399	D P	400	Q T V A D E F G I L M P	401	R S T V W Y C F H K R W Y	
402	A D E F L M P Q R	403	Q R S T V Y A C E G H K L M	404	CDFGHLM	
	STVWY		N P Q R T		RVWY	

Inactive Mutants						
Corre- sponding Position	Replacement	Corre- sponding Position	Replacement	Corre- sponding Position	Replacement	
405	CIV	406	P R	408	A E F G I K L P R S T V W Y	
410	W	411	DEFG	412	ΕH	
413	HIKLP	414	A D E G H K R S T	415	CDEP	
416	C S	417	A D E F G H K M P Q R	419	D P	
420	A D F G H K L N R S T W Y	422	C D G H L M N Q R S Y	423	A D E F G H L M P O R S T V W	
424	A C E G H N Q R S W Y	425	ELPWY	426	CFMR	
427	A C F L P V W Y	428	A C D E G H N R S Y	429	A D K L N P S T V W Y	
430	A D E L M N S T V	431	Р	432	CFIKLMPY	
434	HKPQRW	437	Т	438	Y	
439	NR	440	Q	441	R	
442	M N S	443	Ď			

TABLE 5-continued

3. Additional Modifications and Conjugates

The modified PH20 polypeptides include those that contain chemical or posttranslational modifications. In some 25 examples, modified PH20 polypeptides provided herein do not contain chemical or posttranslational modifications. Chemical and post-translational modifications include, but are not limited to, PEGylation, sialation, albumination, glycosylation, farnysylation, carboxylation, hydroxylation, 30 phosphorylation, and other polypeptide modifications known in the art.

Also, in addition to any one or more amino acid modifications, such as amino acid replacements, provided herein, modified PH20 polypeptides provided herein can be conju- 35 gated or fused to any moiety using any method known in the art, including chemical and recombinant methods, provided the resulting polypeptide retains hyaluronidase activity. For example, in addition to any one or more amino acid modifications, such as amino acid replacements, provided herein, 40 modified PH20 polypeptides provided herein also can contain other modifications that are or are not in the primary sequence of the polypeptide, including, but not limited to, modification with a carbohydrate moiety, a polyethylene glycol (PEG) moiety, a sialic acid moiety, an Fc domain 45 from immunoglobulin G, or any other domain or moiety. For example, such additional modifications can be made to increase the stability or serum half-life of the protein.

In some instances, the domain or other moiety is a targeted agent, including any agent that targets the conjugate 50 to one or more cell types by selectively binding to a cell surface receptor or other cell surface moiety. For example, the domain or other moiety is a targeted agent that targets the conjugate to tumor cells. In such examples, a modified PH20 polypeptide, such as any provided herein, is linked directly 55 or indirectly to a targeted agent. Such targeting agents include, but are not limited to, growth factors, cytokines, chemokines, antibodies, and hormones, or allelic variants, muteins, or fragments thereof so long as the targeting agent is internalized by a cell surface receptor. Exemplary, non-60 limiting, additional modifications are described below.

The modified PH20 polypeptides provided herein can be made to have decreased immunogenicity. Decreased immunogenicity can be effected by sequence changes that elimiminate antigenic epitopes from the polypeptide or by altering post-translational modifications. One of skill in the art is

familiar with methods of identifying antigenic epitopes in a polypeptide (see e.g., Liang et al. (2009) *BMC Bioinformatics*, 10:302; Yang et al. (2009) *Rev. Med. Virol.*, 19:77-96). In some examples, one or more amino acids can be modified in order to remove or alter an antigenic epitope.

In another example, altering the glycosylation of a protein also can effect immunogenecity. For example, altering the glycosylation of the peptide is contemplated, so long as the polypeptides minimally contain at least N-acetylglucosamine at amino acid residues corresponding to amino acid residues set forth as N200, N333 and N358 of SEQ ID NO:3 or 7.

For example, the PH20 polypeptides can be modified such that they lack fucose, particularly bifucosylation. In particular, the PH20 polypeptides provided herein are not bifucosylated. This can be achieved by expressing and producing the PH20 polypeptide in host cells that do not effect bifucosylation. Fucose is a deoxyhexose that is present in a wide variety of organisms, including mammals, insects and plants. Fucosylated glycans are synthesized by fucosyltransferases; see, e.g., Ma et al., Glycobiology, 16(12):158β-184R, (2006); Nakayama et al., J. Biol. Chem., 276:16100-16106 (2001); and Sturla et al., Glycobiology, 15(10):924-935 (2005). In humans, fucose frequently exists as aterminal modification to glycan structures, and the presence of fucose a1,6-linked to N-acetylglucosamine has been shown to be important in glycoprotein processing and recognition. In insects, N-glycan core structures exhibit bifucosylation with a1,6- and a1,3-linkages. Insect cell core fucosylation with al, 3-linkages generates a carbohydrate epitope that is immunogenic in humans (see, e.g., US Publication No. 20070067855). For example, PH20 polypeptides provided herein can be generated in host cells that are incapable of bifucosylating the polypeptide. Thus, while insect cells or other cells that bifucosylate can be used for expression of the polypeptides, typically mammalian cells, such as CHO cells, are used.

In some examples, defucosylated, or fucose-deficient PH20 polypeptides can be generated in insect cells with modified glycosylation pathways, through the use of baculovirus expression vectors containing eukaryotic oligosaccharide processing genes, thereby creating "mammalianized" insect cell expression systems (see, e.g., U.S. Pat. No. 6,461,863). Alternatively, antigenicity can be eliminated by expression of PH20 polypeptides in insect cells lacking al,

45

3-fucosylatransferase (FT3) (see, e.g., US Publication No. 20070067855). In other examples, defucosylated or fucosedeficient PH20 polypeptides can be generated, for example, in cell lines that produce defucosylated proteins, including Lec13 CHO cells deficient in protein fucosylation (Ripka et 5 al. Arch. Biochem. Biophys. 249:533-545 (1986); U.S. Pat. Pub. No. 2003/0157108; and WO 2004/056312), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004)).

b. Conjugation to Polymers

In some examples, the modified PH20 polypeptides provided herein are conjugated to polymers. Exemplary polymers that can be conjugated to the PH20 polypeptides, include natural and synthetic homopolymers, such as poly-15 ols (i.e., poly-OH), polyamines (i.e., poly-NH₂) and polycarboxylic acids (i.e., poly-COOH), and further heteropolymers, i.e., polymers containing one or more different coupling groups, e.g., hydroxyl groups and amine groups. Examples of suitable polymeric molecules include poly- 20 meric molecules selected from among polyalkylene oxides (PAO), such as polyalkylene glycols (PAG), including polyethylene glycols (PEG), methoxypolyethylene glycols (mPEG) and polypropylene glycols, PEG-glycidyl ethers PEG-oxycarbonylimidazole (Epox-PEG), (CDI-PEG), 25 branched polyethylene glycols (PEGs), polyvinyl alcohol (PVA), polycarboxylates, polyvinylpyrrolidone, poly-D,Lamino acids, polyethylene-co-maleic acid anhydride, polystyrene-co-maleic acid anhydride, dextrans including carboxymethyl-dextrans, heparin, homologous albumin, 30 celluloses, including methylcellulose, carboxymethylcellulose, ethylcellulose, hydroxyethylcellulose, carboxyethylcellulose and hydroxypropylcellulose, hydrolysates of chitosan, starches such as hydroxyethyl-starches and hydroxypropyl-starches, glycogen, agaroses and derivatives 35 thereof, guar gum, pullulan, inulin, xanthan gum, carrageenan, pectin, alginic acid hydrolysates and bio-polymers.

Typically, the polymers are polyalkylene oxides (PAO), such as polyethylene oxides, such as PEG, typically mPEG, which have few reactive groups capable of cross-linking. 40 Bioconjugate Chem. 6:62-69, 1995; Veronese et al., J. Typically, the polymers are non-toxic polymeric molecules such as (methoxy)polyethylene glycol (mPEG) which can be covalently conjugated to the PH20 polypeptides (e.g., to attachment groups on the protein surface) using a relatively simple chemistry.

Suitable polymeric molecules for attachment to the PH20 polypeptides include, but are not limited to, polyethylene glycol (PEG) and PEG derivatives such as methoxy-polyethylene glycols (mPEG), PEG-glycidyl ethers (Epox-PEG), PEG-oxycarbonylimidazole (CDI-PEG), branched PEGs, 50 and polyethylene oxide (PEO) (see e.g., Roberts et al., Advanced Drug Delivery Review 2002, 54:459-476; Harris and Zalipsky (eds.) "Poly(ethylene glycol), Chemistry and Biological Applications" ACS Symposium Series 680, 1997; Mehvar et al., J. Pharm. Pharmaceut. Sci., 3(1):125-136, 55 2000; Harris and Chess (2003) Nat Rev Drug Discov. 2(3):214-21; and Tsubery, J Biol. Chem 279(37):38118-24, 2004). The polymeric molecule can be of a molecular weight typically ranging from about 3 kDa to about 60 kDa. In some embodiments the polymeric molecule that is conjugated to a 60 PH20 polypeptide provided herein has a molecular weight of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 or more than 60 kDa.

Various methods of modifying polypeptides by covalently attaching (conjugating) a PEG or PEG derivative (i.e., 65 "PEGylation") are known in the art (see e.g., U.S. 2006/ 0104968; U.S. Pat. Nos. 5,672,662; 6,737,505; and U.S.

2004/0235734). Techniques for PEGylation include, but are not limited to, specialized linkers and coupling chemistries (see e.g., Roberts, Adv. Drug Deliv. Rev. 54:459-476, 2002), attachment of multiple PEG moieties to a single conjugation site (such as via use of branched PEGs; see e.g., Guiotto et al., Bioorg. Med. Chem. Lett. 12:177-180, 2002), site-specific PEGylation and/or mono-PEGylation (see e.g., Chapman et al., Nature Biotech. 17:780-783, 1999), and sitedirected enzymatic PEGylation (see e.g., Sato, Adv. Drug Deliv. Rev., 54:487-504, 2002) (see, also, for example, Lu and Felix (1994) Int. J. Peptide Protein Res. 43:127-138; Lu and Felix (1993) Peptide Res. 6:140-6, 1993; Felix et al. (1995) Int. J. Peptide Res. 46:253-64; Benhar et al. (1994) J. Biol. Chem. 269:13398-404; Brumeanu et al. (1995) JImmunol. 154:3088-95; see also, Caliceti et al. (2003) Adv. Drug Deliv. Rev. 55(10):1261-77 and Molineux (2003) Pharmacotherapy 23 (8 Pt 2):3S-8S). Methods and techniques described in the art can produce proteins having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 PEG or PEG derivatives attached to a single protein molecule (see e.g., U.S. 2006/ 0104968).

Numerous reagents for PEGylation have been described in the art. Such reagents include, but are not limited to, N-hydroxysuccinimidyl (NHS) activated PEG, succinimidyl mPEG, mPEG2-N-hydroxysuccinimide, mPEG succinimidyl alpha-methylbutanoate, mPEG succinimidyl propionate, mPEG succinimidyl butanoate, mPEG carboxymethyl 3-hydroxybutanoic acid succinimidyl ester, homobifunctional PEG-succinimidyl propionate, homobifunctional PEG propionaldehyde, homobifunctional PEG butyraldehyde, PEG maleimide, PEG hydrazide, p-nitrophenyl-carbonate PEG, mPEG-benzotriazole carbonate, propionaldehyde PEG, mPEG butryaldehyde, branched mPEG2 butyraldehyde, mPEG acetyl, mPEG piperidone, mPEG methylketone, mPEG "linkerless" maleimide, mPEG vinyl sulfone, mPEG thiol, mPEG orthopyridylthioester, mPEG orthopyridyl disulfide, Fmoc-PEG-NHS, Boc-PEG-NHS, vinylsulfone PEG-NHS, acrylate PEG-NHS, fluorescein PEG-NHS, and biotin PEG-NHS (see e.g., Monfardini et al., Bioactive Compatible Polymers 12:197-207, 1997; U.S. Pat. Nos. 5,672,662; 5,932,462; 6,495,659; 6,737,505; 4,002, 531; 4,179,337; 5,122,614; 5,324,844; 5,446,090; 5,612, 460; 5,643,575; 5,766,581; 5,795,569; 5,808,096; 5,900, 461; 5,919,455; 5,985,263; 5,990,237; 6,113,906; 6,214, 966; 6,258,351; 6,340,742; 6,413,507; 6,420,339; 6,437, 025: 6.448.369: 6.461.802: 6.828.401: 6.858.736: U.S. 2001/0021763; U.S. 2001/0044526; U.S. 2001/0046481; U.S. 2002/0052430; U.S. 2002/0072573; U.S. 2002/ 0156047; U.S. 2003/0114647; U.S. 2003/0143596; U.S. 2003/0158333; U.S. 2003/0220447; U.S. 2004/0013637; US 2004/0235734; U.S. 2005/0114037; U.S. 2005/0171328; U.S. 2005/0209416; EP 1064951; EP 0822199; WO 01076640; WO 0002017; WO 0249673; WO 9428024; WO 0187925; and WO 2005000360).

D. Methods for Identifying Modified Hyaluronan-Degrading Enzymes with Altered Properties or Activities

Provided herein are methods for identifying a modified or variant hyaluronan-degrading enzyme, such as a modified hyaluronidase or modified PH20 polypeptide, that exhibits an altered activity or property compared to an unmodified hyaluronan-degrading enzyme. In particular, the methods provided herein can be used to screen for one or more modified hyaluronan-degrading enzymes, such as one or more modified hyaluronidase or PH20 polypeptide, that exhibits increased activity and/or increased stability in the presence of a denaturation agent or condition. For example, the methods can be used to identify a modified or variant hyaluronan-degrading enzyme, such as a modified or variant hyaluronidase or modified or variant PH20 polypeptide, that exhibits increased stability by virtue of increased resistance to denaturation conditions, including but not limited to, 5 denaturation conditions caused by temperature (e.g., elevated temperature such as heat), agitation, no or low salt, presence of an excipient and/or a denaturing agent. Exemplary denaturing agents or excipients include, but are not limited to, antiadherents, binders, coatings, fillers and 10 diluents, flavors, colors, lubricants, glidants, preservatives, sorbents or sweeteners. For example, various excipients, such as preservatives, can act as protein denaturing agents. In the method, the activity also can be compared to an unmodified hyaluronan-degrading enzyme under the same 15 denaturation condition, and a modified hyaluronan-degrading enzyme identified or selected that exhibits greater activity than the corresponding unmodified hyaluronan-degrading enzyme.

In the method, one or more modified hyaluronan-degrad- 20 ing enzymes are provided. In some examples, a library of modified molecules is prepared. Methods of mutagenesis and generation of libraries or collections of variant molecules is described herein and is known to one of skill in the art using standard recombinant DNA techniques. In one 25 example, the enzymes that are tested can be pooled and screened, whereby the method permits selection of only those enzymes that exhibit a desired activity. In another example, the tested enzymes can be physically separated and screened individually, such as by formatting in arrays, such 30 as addressable arrays.

In one aspect of the method, the modified hyaluronandegrading enzymes are tested or screened for hyaluronidase activity in the presence and absence of one or more denaturation conditions or denaturing agent. After testing under 35 both sets of conditions, the activities are assessed in order to identify modified hyaluronan-degrading enzymes that exhibit activity in the presence of the denaturation condition. The desired level or amount of activity selected as a cut-off in the methods can be empirically determined by the user, 40 and is dependent on factors such as the particular hyaluronan-degrading enzyme, the desired application or use of the hyaluronan-degrading enzyme, the particular denaturation condition or denaturing agent and other similar factors. Typically, a modified hyaluronan-degrading enzyme is iden- 45 tified that exhibits at least 5% or 10% of the activity in the presence of a denaturing agent or condition compared to in its absence, and generally at least 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, for example at least 40% of the activity. 50

Additionally or alternatively, the activity of the modified hyaluronan-degrading enzyme in the presence of one or more denaturation conditions or denaturing agents is compared to the activity of the corresponding unmodified hyaluronan-degrading enzyme in the presence of the same 55 denaturation agent(s) or condition(s). In such examples, it is understood that the activity of the modified and unmodified enzyme are tested under the same conditions (e.g., time, temperature, composition), except for the difference in the particular enzyme tested (unmodified versus modified). A 60 modified hyaluronan-degrading enzyme is identified that exhibits greater activity, such as at least 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 400%, 500% or more of the activity of the unmodified hyaluronan-degrading enzyme. 65

The method can be performed a plurality of times, whereby the steps of the method are repeated 1, 2, 3, 4, or

5 times. The method provided herein also is iterative. In one example, after the method is performed, any identified modified hyaluronan-degrading enzyme can be modified or further modified to increase or optimize the activity.

A description of the steps of the method and components of the method are provided in the subsections that follow. 1. Hyaluronan-Degrading Enzymes and Libraries of Modified Hyaluronan-Degrading Enzymes

In the methods herein, one or more modified hyaluronandegrading enzymes, such as a hyaluronidase or a PH20 polypeptide, are tested for a desired activity or property, such as increased stability (e.g., increased resistance to a denaturation condition). The modified hyaluronan-degrading enzyme can be modified compared to an unmodified hyaluronan-degrading enzyme, such as any hyaluronandegrading enzyme known in the art. Hyaluronan-degrading enzymes are a family of enzymes that degrade hyaluronic acid, which is an essential component of the extracellular matrix and a major constituent of the interstitial barrier. Hyaluronan-degrading enzymes act to degrade hyaluronan by cleaving hyaluronan polymers, which are composed of repeating disaccharides units: D-glucuronic acid (GlcA) and N-acetyl-D-glucosamine (GlcNAc), linked together via alternating β -1 \rightarrow 4 and β -1 \rightarrow 3 glycosidic bonds. By catalyzing the hydrolysis of hyaluronic acid, a major constituent of the interstitial barrier, hyaluronan-degrading enzymes lower the viscosity of hyaluronic acid, thereby increasing tissue permeability. Accordingly, hyaluronan-degrading enzymes for the uses and methods provided herein include any enzyme having the ability to catalyze the cleavage of a hyaluronan disaccharide chain or polymer. In some examples, the hyaluronan-degrading enzyme cleaves the β -1 \rightarrow 4 glycosidic bond in the hyaluronan chain or polymer. In other examples, the hyaluronan-degrading enzyme catalyzes the cleavage of the β -1 \rightarrow 3 glycosidic bond in the hyaluronan chain or polymer.

Hyaluronan-degrading enzymes include enzymes that are membrane-bound or that are soluble forms that are secreted from cells. Thus, where hyaluronan-degrading enzymes include a glycosylphosphatidylinositol (GPI) anchor signal sequence and/or are otherwise membrane-anchored or insoluble, such hyaluronan-degrading enzymes can be provided in soluble form by C-terminal truncation or deletion of all or a portion of the GPI anchor signal sequence to render the enzyme secreted and soluble. Thus, hyaluronan-degrading enzymes include C-terminally truncated variants, e.g., truncated to remove all or a portion of a GPI anchor signal sequence. Examples of such soluble hyaluronidases are soluble PH20 hyaluronides, such as any set forth in U.S. Pat. No. 7,767,429; U.S. Publication Nos. 2004/0268425 and 2010/0143457.

Exemplary hyaluronan-degrading enzymes are non-human animal or human hyaluronidases, bacterial hyaluronidases, hyaluronidases from leeches or chondroitinases that exhibit hyaluronan-degrading activity, including soluble or truncated forms thereof that are active. Exemplary nonhuman animal hyaluronidases are any set forth in any of SEQ ID NOs: 8-31, 856-861, 869, 870, 871-886, or mature, C-terminally truncated variants that are soluble and active, or active forms thereof. Exemplary human hyaluronidases are any set forth in any of SEQ ID NOs: 2, 3, 6, 7, 32-66, 68-72 or 887-890, or mature, C-terminally truncated variants that are soluble and active, or active forms thereof, and in particular any of SEQ ID NOs: 3, 7, 32-66, 69 or 72. Exemplary bacterial hyaluronidases are any set forth in any of SEQ ID NOs: 891-919 or mature, C-terminally truncated variants that are soluble and active, or active forms thereof.

Exemplary hyaluronidases from leeches are set forth in SEQ ID NO:920 or 921, or mature, C-terminally truncated variants that are soluble and active, or active forms thereof. Exemplary chondroitinases that have hyaluronan-degrading enzyme activity are set forth in SEQ ID NO:922-924, or 5 mature, C-terminally truncated variants that are soluble and active, or active forms thereof.

For example, one or more modified PH20 polypeptides are tested for a desired activity or property, such as increased stability (e.g., increased resistance to a denaturation condi- 10 tion). The modified PH20 polypeptide can be modified compared to an unmodified PH20 polypeptide, such as any known PH20 polypeptide native, wildtype or reference polypeptide. For example, the modified PH20 polypeptide is modified compared to a full-length, soluble or active form of 15 a PH20 polypeptide, such as any set forth in any of SEQ ID NOs: 3, 7, 32-66, 69 or 72, or a polypeptide that exhibits at least 85%, such as at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEO ID NOs: 3, 7, 32-66, 69 or 20 72. In particular examples of the method herein, the starting or unmodified PH20 polypeptide has the sequence of amino acids set forth in SEQ ID NO:3.

Libraries or collections of modified hyaluronan-degrading enzymes can be screened. Hyaluronan-degrading enzymes 25 hyaluronan-degrading enzyme that exhibits stability or can be modified by any process known to one of skill in the art that can alter the structure of a protein. Examples of modifications include replacement, addition, and deletion of one or more amino acids of the protein to form libraries or collections of modified hyaluronan-degrading enzymes. It is 30 within the level of one of skill in the art to generate modified or variant proteins for use in the methods herein. Methods of mutagenesis are well known in the art and include, for example, site-directed mutagenesis such as for example QuikChange (Stratagene) or saturation mutagenesis. Muta- 35 genesis methods include, but are not limited to, site-mediated mutagenesis, PCR mutagenesis, cassette mutagenesis, site-directed mutagenesis, random point mutagenesis, mutagenesis using uracil containing templates, oligonucleotidedirected mutagenesis, phosphorothioate-modified DNA 40 mutagenesis, mutagenesis using gapped duplex DNA, point mismatch repair, mutagenesis using repair-deficient host strains, restriction-selection and restriction-purification, deletion mutagenesis, mutagenesis by total gene synthesis, double-strand break repair, and many others known to 45 persons of skill. In the methods herein, mutagenesis can be effected across the full length of a protein or within a region of a protein. The mutations can be made rationally or randomly.

In some examples, the methods provided herein are 50 performed such that the identity of each mutant protein is known a priori before the protein is tested. For example, the methods provided herein can be conducive to mutagenesis and screening or testing methods that are addressable. This can permit the ease of comparisons between the activities of 55 tested proteins without the need for sequencing of identified proteins. For example, site-directed mutagenesis methods can be used to individually generate mutant proteins. Mutagenesis can be performed by the replacement of single amino acid residues at specific target positions one-by-one, 60 such that each individual mutant generated is the single product of each single mutagenesis reaction. Mutant DNA molecules can be designed, generated by mutagenesis and cloned individually, such as in addressable arrays, such that they are physically separated from each other and each one 65 is the single product of an independent mutagenesis reaction. The amino acids selected to replace the target positions

on the particular protein being optimized can be either all of the remaining 19 amino acids, or a more restricted group containing only selected amino acids. In some methods provided herein, each amino acid that is replaced is independently replaced by 19 of the remaining amino acids or by less than 19 of the remaining amino acids, such as 10, 11, 12, 13, 14, 15, 16, 17 or 18 of the remaining amino acids.

2. Screening or Testing For A Desired Activity or Property The hyaluronidase activity or other activity of a composition containing a modified hyaluronan-degrading enzyme is screened or tested under conditions that expose the hyaluronan-degrading enzyme to a denaturation condition or a denaturing agent (presence of denaturation condition or denaturing agent). The denaturing condition or denaturing agent need not be a condition or agent that is completely deadly to the enzyme, but generally is any condition or agent that destabilizes enzyme activity over time. For example, the denaturation condition can be a condition caused by temperature (e.g., elevated temperature such as greater than or about or 30° C., for example, 30° C. to 42° C. such as or about 37° C.), agitation, no or low salt (e.g., NaCl), and/or caused by the presence of a denaturing agent, such as the presence of excipients (e.g., presence of preservatives).

For purposes of selecting or identifying a modified increased stability under the denaturation condition, activity can be compared to activity of the modified hyaluronandegrading enzyme in the absence of the denaturation condition and/or activity of the corresponding unmodified hyaluronan-degrading enzyme in the presence of the denaturation condition. For example, the modified hyaluronandegrading enzyme also can be screened or tested under the same conditions, except not including a denaturing condition or denaturing agent (absence of denaturation condition or denaturing agent). If desired, the activity of the corresponding unmodified hyaluronan-degrading enzyme (e.g., the hyaluronan-degrading enzyme not containing the amino acid replacement(s)) can also be tested under the same conditions that expose the hyaluronan-degrading enzyme to the same denaturation condition or a denaturing agent.

For example, each member of a library or collection of modified hyaluronan-degrading enzymes is incubated under or exposed to one or more denaturation conditions. The incubation or exposure can occur in vivo or in vitro. Typically, the assay is performed in vitro. The same modified enzyme also is exposed or incubated to a reference or control condition that does not contain the denaturation condition. The activities under both conditions are compared in order to identify modified hyaluronan-degrading enzymes that exhibit stability upon exposure to a denaturation condition or conditions. Further, in screening or identifying the activity of the enzyme under the two different sets of conditions, generally the only conditions that are varied in the assay relate to the presence or absence of one or more denaturation conditions. The other conditions of the assay, including but not limited to, time, temperature and/or other incubation conditions, can be the same for both sets of conditions.

For example, exposure can be achieved by incubation of a modified hyaluronan-degrading enzyme in an assay buffer or composition that has been modified or adjusted to contain a denaturing agent such as an excipient or low or no salt. Exemplary denaturing agents or excipients include, but are not limited to, antiadherents, binders, coatings, fillers and diluents, flavors, colors, lubricants, glidants, preservatives, sorbents or sweeteners. The choice of buffer that is used can be empirically determined by one skilled in the art depending on the particular parameter or parameters being modified. Exemplary assay buffers are Good's buffers (see e.g., Good et al. (1966) *Biochemistry*, 5:467-477). Examples of such buffers include, but are not limited to ACES, ADA, BES, Bicine, BIS-TRIS, CAPS, HEPES, MES, MOPS, PIPES, TRIS or Trizma® buffers. Further, the amount or 5 concentration of the excipient or salt can be empirically determined by one of skill in the art depending on the choice of excipient or salt and the desired level or activity of the modified hyaluronan-degrading enzyme.

In one example, the assay buffer or composition is modi-10 fied by inclusion of an amount of a denaturing agent or denaturing excipient that is a preservative, for example, a phenolic preservative. The phenolic preservative can be phenol, metacresol (m-cresol), benzyl alcohol, and parabens including methylparaben and propylparaben. In particular, 15 the phenolic preservative is phenol and/or m-cresol. The total amount of one or more phenolic preservative agents as a percentage (%) of mass concentration (w/v) can be between 0.05% to 0.6%, 0.1% to 0.4%, 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 20 0.3% to 0.4% inclusive. In such an example, the activity of the modified hyaluronan-degrading enzyme is tested or assessed in the presence of such a total amount (e.g., between or about between 0.05% to 0.6%) of one or more preservatives, for example, one or more phenolic preserva- 25 tives. In some examples, the modified hyaluronan-degrading enzyme also can be tested or assessed under a control or reference condition in which the assay buffer or composition is not modified to contain a preservative. In certain instances, as a control, the activity of modified hyaluronan- 30 degrading enzymes also can be compared to the corresponding unmodified hyaluronan-degrading enzyme not containing the modification(s) under conditions that contain a preservative agent and/or under conditions that do not contain a preservative agent.

In another example, the assay buffer is modified by the presence of a denaturation condition that is low or no salt. As discussed elsewhere herein, hyaluronan-degrading enzymes, such as PH20, generally require salt (e.g., NaCl, Lys-Lys or $MgCl_2$) for activity. Hence, the absence of salt or 40 low salt is denaturing to the enzyme. In one example, the assay buffer is modified by inclusion of an amount of salt that is less than 100 mM, for example, less than 90 mM, 80 mM, 70 mM, 60 mM, 50 mM, 40 mM, 30 mM, 25 mM, 20 mM, 15 mM, 10 mM, 5 mM or less. In such an example, the 45 activity of the modified hyaluronan-degrading enzyme is tested in the absence of salt or in the presence of salt that is less than 100 mM. In some examples, the modified hyaluronan-degrading enzyme also can be tested or assessed under a control or reference condition in which the assay buffer 50 contains a higher salt concentration, generally between or about between 140 mM to 200 mM. In certain instances, as a control, the activity of modified hyaluronan-degrading enzymes also can be compared to the corresponding unmodified hyaluronan-degrading enzyme not containing 55 the modification(s) under conditions that contain low or no salt, such as less than 100 mM and/or under conditions that contain salt in an amount that is between or about between 140 mM to 200 mM.

Exposure of a hyaluronan-degrading enzyme to a denaturation condition also can be achieved by incubation of a modified hyaluronan-degrading enzyme under conditions that are known to be denaturing, such as under conditions of elevated temperature such as a temperature greater than or about or 30° C. (e.g., 30° C. to 42° C. such as or about 37° 65 C.) or agitation. For example, the activity of the modified hyaluronan-degrading enzyme is tested at elevated tempera-

tures greater than or about or 30° C. to 42° C. In some examples, the modified hyaluronan-degrading enzyme also can be tested or assessed under a control or reference condition where the temperatures is less than 30° C., such as between or about between 0° C. to 25° C., for example, 0° C. to 5° C. or 18° C. to 25° C. In certain instances, as a control, the activity of modified hyaluronan-degrading enzymes also can be compared to the corresponding unmodified hyaluronan-degrading enzyme not containing the modification(s) under elevated temperatures greater than or about or 30° C. to 42° C. and/or temperatures is less than 30° C., such as between or about between 0° C. to 25° C., for example, 0° C. to 5° C. or 18° C. to 25° C.

The modified hyaluronan-degrading enzyme can be exposed to one or more than one of the conditions. The exposure to one condition can occur simultaneously, subsequently, intermittently or periodically to exposure to one or more other conditions.

In one example, in the method herein, the modified hyaluronan-degrading enzyme is incubated or exposed to the denaturation condition or denaturing agent prior to performing an assay for hyaluronidase activity. For example, the modified hyaluronan-degrading enzyme is incubated in the presence of a denaturing agent or exposed to one or more denaturation conditions or control conditions, such as one or more of the denaturation conditions or control conditions as described above. The incubation or exposure can be for any desired length of time, and can be empirically determined by one of skill in the art. For example, the modified hyaluronandegrading enzyme can be incubated or exposed to one or more denaturation conditions, denaturing agents or control conditions for or about for 1 minute to 1 month, such as 1 minute to 3 weeks, 1 minute to 2 weeks, 1 minute to 1 week, 1 minute to 24 hours, 1 minute to 12 hours, such as 30 35 minutes to 6 hours or 1 hour to 4 hours, and generally at least or about at least 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours or 12 hours. After the time of incubation or exposure, the sample or composition containing the modified hyaluronan-degrading enzyme (or control unmodified enzyme) is assessed for hyaluronidase assay. In another example, the modified hyaluronan-degrading enzyme is exposed or incubated under one or more denaturation conditions and is simultaneously or concurrently assessed for hyaluronidase activity. In any examples where a modified hyaluronan-degrading enzyme is assessed, it is understood that an unmodified hyaluronan-degrading enzyme not containing the modifications(s) also can be assessed under similar assay conditions for comparison.

Assays to assess hyaluronidase activity are well known in the art. Examples of such assays are described in Section G. In one example, hyaluronidase activity can be assessed in a microturbidity assay, wherein the amount of undegraded HA is measured by the addition of a reagent that precipitates HA (e.g., Cetylpyridinium chloride (CPC) or acidified serum) after the enzyme is allowed to react with HA. In another example, hyaluronidase activity can be assessed using a microtiter assay in which residual biotinylated hyaluronic acid is measured following incubation with hyaluronidase (see e.g., Frost and Stem (1997) *Anal. Biochem.* 251:263-269, U.S. Pat. Publication No. 20050260186). The resulting activities under each of the tested conditions is determined and compared.

3. Selection or Identification

In the method, after screening modified hyaluronan-degrading enzymes under one or more denaturation conditions, the hyaluronidase activities of the tested enzymes are compared. The method is practiced in order to identify a modified hyaluronan-degrading enzyme that is more resistant to denaturation by a condition or a denaturing agent, whereby the activity of the enzyme is indicative of the stability of the enzyme as a measure of its resistance to denaturation. It is understood that some reduction of enzyme activity, as a result of denaturation, can be tolerated in various applications, and thus the method can be practiced to select for a modified hyaluronan-degrading enzymes that exhibits a requisite activity upon exposure to a denaturation condition to permit its use or application (e.g., therapeutic activity). For example, a modified enzyme can be selected that loses activity more slowly than the corresponding unmodified or reference hyaluronan-degrading enzyme, but whose retained activity is sufficient for a particular application or purpose.

In examples of the methods herein, the activity of the modified hyaluronan degrading enzyme is assessed upon exposure to a first denaturation condition and also assessed upon exposure to a second condition that is a control or 20 non-denaturation condition, and the resulting hyaluronidase activities compared. For comparison, in some examples, the activity can be represented as a ratio of activity or a percentage of activity under a denaturation condition compared to under a control or non-denaturation condition. For 25 example, where the parameter that differs between the first and second condition is the presence of preservative (e.g., phenolic preservative), activity can be represented as a ratio of activity or percentage of activity observed in the presence of preservative (e.g., phenolic preservative) versus activity in the absence of preservative (e.g., phenolic preservative). In another example, where the parameter that differs between the first and second condition is temperature, activity can be represented as a ratio of activity or percentage of 35 activity observed in the presence of elevated temperature (e.g., 30° C. to 42° C.) compared to activity in the presence of a lower temperature such as 0° C. to 25° C., for example 0° C. to 5° C. or 18° C. to 25° C.

A modified hyaluronan-degrading enzyme is selected or 40 identified that retains or exhibits any desired activity in the presence of the denaturation condition compared to in its absence. The particular cut-off of activity for selection of enzymes herein is dependent on the particular user and/or practice of the method and can be empirically determined 45 depending on factors such as the particular denaturation condition or denaturing agent, the particular modified hyaluronan-degrading enzyme, the desired application of the identified or selected hyaluronan-degrading enzyme and other similar factors. Generally, a selected or identified 50 modified hyaluronan-degrading enzyme exhibits stability if any detectable activity is measured or assessed upon exposure or incubation with a denaturation condition or denaturing agent. For example, a selected or identified modified hyaluronan-degrading enzyme exhibits stability, or resis- 55 tance to a denaturation condition or denaturing agent, if it exhibits at least 5% or 10% of the activity of the same enzyme in the absence of the denaturation condition or denaturing agent, and generally if the modified hyaluronandegrading enzyme exhibits an activity that is at least 15% of 60 the initial hyaluronidase activity prior to incubation in the presence of the denaturation condition. For example, a modified hyaluronan-degrading enzyme is selected or identified that exhibits at least (or at least about) 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 110%, 120%, 130%, 140%, 150%, 200%, 300%, 400%, 500% or

more of the initial hyaluronidase activity of the modified hyaluronan-degrading enzyme tested under a control or non-denaturation condition.

In other examples of the methods herein, the activity of the modified hyaluronan degrading enzyme is assessed upon exposure to a denaturation condition and the activity of the unmodified or reference hyaluronan-degrading enzyme also is assessed upon exposure to the same denaturation conditions. In such examples, the activities are compared when the enzymes are exposed to the same conditions. For comparison, the activity under a denaturation condition can be represented as a ratio of activity or a percentage of activity of a modified hyaluronan-degrading enzyme compared to an unmodified or reference hyaluronan-degrading enzyme. In such examples, a modified hyaluronan-degrading enzyme is selected that exhibits greater activity under a denaturation condition than the unmodified or reference hyaluronandegrading enzyme. Thus, the modified hyaluronan-degrading enzyme is one that is more resistant to the condition. For example, where the denaturation condition is the presence of preservative (e.g., phenolic preservative), the activity observed in the presence of preservative (e.g., phenolic preservative) can be represented as a ratio of activity or percentage of activity of the modified hyaluronan-degrading enzyme compared to the unmodified or reference hyaluronan-degrading enzyme. In another example, where the denaturation condition is high temperature, activity observed in the presence of elevated temperature (e.g., 30° C. to 42° C.) can be represented as a ratio of activity or percentage of activity of the modified hyaluronan-degrading enzyme compared to the unmodified or reference hyaluronan-degrading enzyme.

In such examples, a modified hyaluronan-degrading enzyme, such as a modified PH20, is identified or selected that exhibits a ratio of activity that is greater than or at least 1.1, such that the enzyme exhibits greater activity than the unmodified or reference hyaluronan-degrading enzyme under the denaturation condition. For example, the ratio is at least or at least about 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0 or greater. A modified hyaluronan-degrading enzyme (e.g., a modified PH20) can be selected if its activity is at least 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 400%, 500% or more of the activity of the unmodified or reference hyaluronan-degrading enzyme when tested under the same conditions. Thus, modified hyaluronan-degrading enzymes are identified that exhibit greater or improved stability compared to the unmodified hyaluronan-degrading enzyme or a reference hyaluronan-degrading enzyme as manifested by increased resistance to a denaturation condition or denaturing agent.

4. Iterative Methods

The method provided herein also is iterative. In one example, after the method is performed, any modified hyaluronan-degrading enzymes identified as exhibiting stability, such as increased stability, under a denaturation condition can be modified or further modified to increase or optimize the stability. A secondary library can be created by introducing additional modifications in a first identified modified hyaluronan-degrading enzyme. For example, modifications that were identified as conferring stability, such as increasing stability, can be combined to generate a combinatorial library. The secondary library can be tested using the assays and methods described herein.

In another example of an iterative aspect of the method, modified hyaluronan-degrading enzymes that are identified as not exhibiting stability such as increased stability (e.g., such that they are not active or do not have increased activity under the a denaturation condition), can be further modified 5 and retested for stability under a denaturation condition. The further modifications can be targeted near particular regions (e.g., particular amino acid residues) associated with activity and/or stability of the molecule. For example, residues that are associated with activity and/or stability of the molecule 10 generally are critical residues that are involved in the structural folding or other activities of the molecule. Hence, such residues are required for activity, generally under any condition. Critical residues can be identified because, when mutated, a normal activity of the protein is ablated or 15 reduced. For example, critical residues can be identified that, when mutated in a hyaluronan-degrading enzyme, exhibit reduced or ablated hyaluronidase activity under a normal or control assay condition. A further library of modified proteins can be generated with amino acid mutations targeted at 20 or near to the identified critical amino acid residues, such as adjacent to the identified critical amino acid residues. In some examples, the mutations can be amino acid replacement to any other of up to 19 other amino acid residues. The secondary library can be tested using the assays and methods 25 described herein.

E. Production of Modified PH20 Polypeptides and Encoding Nucleic Acid Molecules

Polypeptides of a modified PH20 polypeptide set forth herein can be obtained by methods well known in the art for protein purification and recombinant protein expression. Polypeptides also can be synthesized chemically. Modified or variant, including truncated, forms can be engineered 35 from a wildtype polypeptide using standard recombinant DNA methods. For example, modified PH20 polypeptides can be engineered from a wildtype polypeptide, such as by site-directed mutagenesis.

1. Isolation or Preparation of Nucleic Acids Encoding PH20 40 Polypeptides

Polypeptides can be cloned or isolated using any available methods known in the art for cloning and isolating nucleic acid molecules. Such methods include PCR amplification of nucleic acids and screening of libraries, including nucleic 45 acid hybridization screening, antibody-based screening and activity-based screening. For example, when the polypeptides are produced by recombinant means, any method known to those of skill in the art for identification of nucleic acids that encode desired genes can be used. Any method 50 available in the art can be used to obtain a full length or partial (i.e., encompassing the entire coding region) cDNA or genomic DNA clone encoding a PH20, such as from a cell or tissue source.

Methods for amplification of nucleic acids can be used to 55 isolate nucleic acid molecules encoding a desired polypeptide, including for example, polymerase chain reaction (PCR) methods. Examples of such methods include use of a Perkin-Elmer Cetus thermal cycler and Taq polymerase (Gene Amp). A nucleic acid containing material can be used 60 as a starting material from which a desired polypeptideencoding nucleic acid molecule can be isolated. For example, DNA and mRNA preparations, cell extracts, tissue extracts, fluid samples (e.g., blood, serum, saliva), samples from healthy and/or diseased subjects can be used in ampli-65 fication methods. The source can be from any eukaryotic species including, but not limited to, vertebrate, mammalian,

human, porcine, bovine, feline, avian, equine, canine, and other primate sources. Nucleic acid libraries also can be used as a source of starting material. Primers can be designed to amplify a desired polypeptide. For example, primers can be designed based on expressed sequences from which a desired polypeptide is generated. Primers can be designed based on back-translation of a polypeptide amino acid sequence. If desired, degenerate primers can be used for amplification. Oligonucleotide primers that hybridize to sequences at the 3' and 5' termini of the desired sequence can be uses as primers to amplify by PCR sequences from a nucleic acid sample. Primers can be used to amplify the entire full-length PH20, or a truncated sequence thereof, such as a nucleic acid encoding any of the soluble PH20 polypeptides provided herein. Nucleic acid molecules generated by amplification can be sequenced and confirmed to encode a desired polypeptide.

Additional nucleotide sequences can be joined to a polypeptide-encoding nucleic acid molecule, including linker sequences containing restriction endonuclease sites for the purpose of cloning the synthetic gene into a vector, for example, a protein expression vector or a vector designed for the amplification of the core protein coding DNA sequences. Furthermore, additional nucleotide sequences specifying functional DNA elements can be operatively linked to a polypeptide-encoding nucleic acid molecule. Examples of such sequences include, but are not limited to, promoter sequences designed to facilitate intracellular protein expression, and secretion sequences, for example heterologous signal sequences, designed to facilitate protein secretion. Such sequences are known to those of skill in the art. For example, exemplary heterologous signal sequences include, but are not limited to, human and mouse kappa IgG heterologous signal sequences set forth in SEQ ID NO: 868. Additional nucleotide residue sequences such as sequences of bases specifying protein binding regions also can be linked to enzyme-encoding nucleic acid molecules. Such regions include, but are not limited to, sequences of residues that facilitate or encode proteins that facilitate uptake of an enzyme into specific target cells, or otherwise alter pharmacokinetics of a product of a synthetic gene.

In addition, tags or other moieties can be added, for example, to aid in detection or affinity purification of the polypeptide. For example, additional nucleotide residue sequences such as sequences of bases specifying an epitope tag or other detectable marker also can be linked to enzymeencoding nucleic acid molecules. Examples of such sequences include nucleic acid sequences encoding a His tag or Flag Tag.

The identified and isolated nucleic acids can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art can be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pCMV4, pBR322 or pUC plasmid derivatives or the Bluescript vector (Stratagene, La Jolla, CA). Other expression vectors include the HZ24 expression vector exemplified herein (see e.g., SEQ ID NOs:4 and 5). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. Insertion can be effected using TOPO cloning vectors (Invitrogen, Carlsbad, CA).

If the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules can be enzymatically modified. Alternatively, any site desired can be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers can contain specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and ⁵ protein gene can be modified by homopolymeric tailing.

Recombinant molecules can be introduced into host cells via, for example, transformation, transfection, infection, electroporation and sonoporation, so that many copies of the gene sequence are generated. In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated protein gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene can be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

In addition to recombinant production, modified PH20 20 polypeptides provided herein can be produced by direct peptide synthesis using solid-phase techniques (see e.g., Stewart et al. (1969) Solid-Phase Peptide Synthesis, WH Freeman Co., *San Francisco; Merrifield J* (1963) *J Am Chem Soc.*, 85:2149-2154). In vitro protein synthesis can be 25 performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer, Foster City CA) in accordance with the instructions provided by the manufacturer. Various fragments of a polypeptide can be 30 chemically synthesized separately and combined using chemical methods.

2. Generation of Mutant or Modified Nucleic Acid and Encoding Polypeptides

The modifications provided herein can be made by stan-35 dard recombinant DNA techniques such as are routine to one of skill in the art. Any method known in the art to effect mutation of any one or more amino acids in a target protein can be employed. Methods include standard site-directed mutagenesis (using e.g., a kit, such as QuikChange available from Stratagene) of encoding nucleic acid molecules, or by solid phase polypeptide synthesis methods.

3. Vectors and Cells

For recombinant expression of one or more of the desired proteins, such as any modified PH20 polypeptide described 45 herein, the nucleic acid containing all or a portion of the nucleotide sequence encoding the protein can be inserted into an appropriate expression vector, i.e., a vector that contains the necessary elements for the transcription and translation of the inserted protein coding sequence. The 50 necessary transcriptional and translational signals also can be supplied by the native promoter for enzyme genes, and/or their flanking regions.

Also provided are vectors that contain a nucleic acid encoding the enzyme. Cells containing the vectors also are 55 provided. The cells include eukaryotic and prokaryotic cells, and the vectors are any suitable for use therein. Generally, the cell is a cell that is capable of effecting glyosylation of the encoded protein.

Prokaryotic and eukaryotic cells containing the vectors 60 are provided. Such cells include bacterial cells, yeast cells, fungal cells, Archea, plant cells, insect cells and animal cells. The cells are used to produce a protein thereof by growing the above-described cells under conditions whereby the encoded protein is expressed by the cell, and 65 recovering the expressed protein. For purposes herein, for example, the enzyme can be secreted into the medium.

138

A host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing can impact the folding and/or function of the polypeptide. Different host cells, such as, but not limited to, CHO (DG44, DXB11, CHO-K1), HeLa, MCDK, 293 and W138 have specific cellular machinery and characteristic mechanisms for such post-translational activities and can be chosen to ensure the correct modification and processing of the introduced protein. Generally, the choice of cell is one that is capable of introducing N-linked glycosylation into the expressed polypeptide. Hence, eukaryotic cells containing the vectors are provided. Exemplary eukaryotic cells are mammalian Chinese Hamster Ovary (CHO) cells. For example, CHO cells deficient in dihydrofolate reductase (e.g., DG44 cells) are used to produce polypeptides provided herein. Note that bacterial expression of an PH20 polypepyideprovided herein will not result in a catalytically active polypeptide, but when combined with proper glycosylation machinery, the PH20 can be artificially glycosylated.

Provided are vectors that contain a sequence of nucleotides that encodes the modified PH20 polypeptide, coupled to the native or heterologous signal sequence, as well as multiple copies thereof. The vectors can be selected for expression of the enzyme protein in the cell or such that the enzyme protein is expressed as a secreted protein.

A variety of host-vector systems can be used to express the protein encoding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus and other viruses); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the hostvector system used, any one of a number of suitable transcription and translation elements can be used.

Any methods known to those of skill in the art for the insertion of DNA fragments into a vector can be used to construct expression vectors containing a chimeric gene containing appropriate transcriptional/translational control signals and protein coding sequences. These methods can include in vitro recombinant DNA and synthetic techniques and in vivo recombinants (genetic recombination). Expression of nucleic acid sequences encoding protein, or domains, derivatives, fragments or homologs thereof, can be regulated by a second nucleic acid sequence so that the genes or fragments thereof are expressed in a host transformed with the recombinant DNA molecule(s). For example, expression of the proteins can be controlled by any promoter/enhancer known in the art. In a specific embodiment, the promoter is not native to the genes for a desired protein. Promoters which can be used include, but are not limited to, the SV40 early promoter (Bemoist and Chambon, Nature 290:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al. Cell 22:787-797 (1980)), the herpes thymidine kinase promoter (Wagner et al., Proc. Natl. Acad. Sci. USA 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster et al., Nature 296:39-42 (1982)); prokaryotic expression vector promoters, such as the β -lactamase promoter (Jay et al., (1981) Proc. Natl. Acad. Sci. USA 78:5543) or the tac promoter (DeBoer et al., Proc. Natl. Acad. Sci. USA 80:2125 (1983); see also Gilbert and Villa-Komaroff, "Useful Proteins from Recombinant Bacteria," Scientific American 242:74-94 (1980)); plant expression vector promoters, such as the nopaline synthetase promoter (Herrera-Estrella et al., *Nature* 303:209-213 (1984)) or the cauliflower mosaic virus 35S RNA promoter (Gardner et al., Nucleic Acids Res. 9:2871 (1981)), and the promoter of the photosynthetic enzyme ribulose bisphosphate carboxylase (Herrera-Estrella et al., Nature 310:115-120 (1984)); promoter elements from yeast and other fungi such as the Gal4 promoter, the alcohol dehydrogenase promoter, the phosphoglycerol kinase promoter, the alkaline phosphatase promoter, and the following animal transcriptional control regions that exhibit tissue specificity and have been used in transgenic animals: 15 elastase I gene control region which is active in pancreatic acinar cells (Swift et al., Cell 38:639-646 (1984); Ornitz et al., Cold Spring Harbor Symp. Quant. Biol. 50:399-409 (1986); MacDonald, Hepatology 7:425-515 (1987)); insulin gene control region which is active in pancreatic beta cells 20 (Hanahan et al., Nature 315:115-122 (1985)), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., Cell 38:647-658 (1984); Adams et al., Nature 318:533-538 (1985); Alexander et al., Mol. Cell *Biol.* 7:1436-1444 (1987)), mouse mammary tumor virus 25 control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., Cell 45:485-495 (1986)), albumin gene control region which is active in liver (Pinkert et al., Genes and Devel. 1:268-276 (1987)), alpha-fetoprotein gene control region which is active in liver (Krumlauf 30 et al., Mol. Cell. Biol. 5:1639-1648 (1985); Hammer et al., Science 235:53-58 1987)), alpha-1 antitrypsin gene control region which is active in liver (Kelsey et al., Genes and Devel. 1:161-171 (1987)), beta globin gene control region which is active in myeloid cells (Magram et al., Nature 35 315:338-340 (1985); Kollias et al., Cell 46:89-94 (1986)), myelin basic protein gene control region which is active in oligodendrocyte cells of the brain (Readhead et al., Cell 48:703-712 (1987)), myosin light chain-2 gene control region which is active in skeletal muscle (Shani, Nature 40 314:283-286 (1985)), and gonadotrophic releasing hormone gene control region which is active in gonadotrophs of the hypothalamus (Mason et al., Science 234:1372-1378 (1986)).

In a specific embodiment, a vector is used that contains a 45 promoter operably linked to nucleic acids encoding a desired protein, or a domain, fragment, derivative or homolog thereof, one or more origins of replication, and optionally, one or more selectable markers (e.g., an antibiotic resistance gene). Depending on the expression system, specific initia- 50 tion signals also are required for efficient translation of a PH20 sequence. These signals include the ATG initiation codon and adjacent sequences. In cases where the initiation codon and upstream sequences of PH20 or soluble forms thereof are inserted into the appropriate expression vector, 55 no additional translational control signals are needed. In cases where only a coding sequence, or a portion thereof, is inserted, exogenous transcriptional control signals including the ATG initiation codon must be provided. Furthermore, the initiation codon must be in the correct reading frame to 60 ensure transcription of the entire insert. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of enhancers appropriate to the cell system in use (Scharf et al. (1994) Results 65 Probl Cell Differ 20:125-62; Bittner et al. (1987) Methods in Enzymol, 153:516-544).

140

Exemplary plasmid vectors for transformation of E. coli cells include, for example, the pQE expression vectors (available from Qiagen, Valencia, CA; see also literature published by Qiagen describing the system). pQE vectors have a phage T5 promoter (recognized by E. coli RNA polymerase) and a double lac operator repression module to provide tightly regulated, high-level expression of recombinant proteins in E. coli, a synthetic ribosomal binding site (RBS II) for efficient translation, a 6×His tag coding sequence, to and T1 transcriptional terminators, ColE1 origin of replication, and a beta-lactamase gene for conferring ampicillin resistance. The pQE vectors enable placement of a 6×His tag at either the N- or C-terminus of the recombinant protein. Such plasmids include pQE 32, pQE 30, and pQE 31 which provide multiple cloning sites for all three reading frames and provide for the expression of N-terminally 6×His-tagged proteins. Other exemplary plasmid vectors for transformation of E. coli cells, include, for example, the pET expression vectors (see, U.S. Pat. No. 4,952,496; available from Novagen, Madison, WI; see, also literature published by Novagen describing the system). Such plasmids include pET 11a, which contains the T7lac promoter, T7 terminator, the inducible E. coli lac operator, and the lac repressor gene; pET 12a-c, which contains the T7 promoter, T7 terminator, and the E. coli ompT secretion signal; and pET 15b and pET19b (Novagen, Madison, WI), which contain a His-Tag[™] leader sequence for use in purification with a His column and a thrombin cleavage site that permits cleavage following purification over the column, the T7-lac promoter region and the T7 terminator.

Typically, vectors can be plasmids, viral vectors, or others known in the art, used for expression of the modified PH20 polypeptide in vivo or in vitro. For example, the modified PH20 polypeptide is expressed in mammalian cells, including, for example, Chinese Hamster Ovary (CHO) cells. An exemplary vector for mammalian cell expression is the HZ24 expression vector. The HZ24 expression vector was derived from the pCI vector backbone (Promega). It contains DNA encoding the Beta-lactamase resistance gene (AmpR), an F1 origin of replication, a Cytomegalovirus immediateearly enhancer/promoter region (CMV), and an SV40 late polyadenylation signal (SV40). The expression vector also has an internal ribosome entry site (IRES) from the ECMV virus (Clontech) and the mouse dihydrofolate reductase (DHFR) gene.

Viral vectors, such as adenovirus, retrovirus or vaccinia virus vectors, can be employed. In some examples, the vector is a defective or attenuated retroviral or other viral vector (see U.S. Pat. No. 4,980,286). For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217: 581-599 (1993)). These retroviral vectors have been modified to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA.

In some examples, viruses armed with a nucleic acid encoding a modified PH20 polypeptide can facilitate their replication and spread within a target tissue for example. The target tissue can be a cancerous tissue whereby the virus is capable of selective replication within the tumor. The virus can also be a non-lytic virus wherein the virus selectively replicates under a tissue specific promoter. As the viruses replicate, the coexpression of the PH20 polypeptide with viral genes will facilitate the spread of the virus in vivo.

4. Expression

Modified PH20 polypeptides can be produced by any method known to those of skill in the art including in vivo and in vitro methods. Desired proteins can be expressed in any organism suitable to produce the required amounts and forms of the proteins, such as for example, those needed for administration and treatment. Expression hosts include prokaryotic and eukaryotic organisms such as *E. coli*, yeast, plants, insect cells, mammalian cells, including human cell 5 lines and transgenic animals. Expression hosts can differ in their protein production levels as well as the types of post-translational modifications that are present on the expressed proteins. The choice of expression host can be made based on these and other factors, such as regulatory 10 and safety considerations, production costs and the need and methods for purification.

Many expression vectors are available and known to those of skill in the art and can be used for expression of proteins. The choice of expression vector will be influenced by the 15 choice of host expression system. In general, expression vectors can include transcriptional promoters and optionally enhancers, translational signals, and transcriptional and translational termination signals. Expression vectors that are used for stable transformation typically have a selectable 20 marker which allows selection and maintenance of the transformed cells. In some cases, an origin of replication can be used to amplify the copy number of the vector.

Modified PH20 polypeptides also can be utilized or expressed as protein fusions. For example, an enzyme fusion 25 can be generated to add additional functionality to an enzyme. Examples of enzyme fusion proteins include, but are not limited to, fusions of a signal sequence, a tag such as for localization, e.g., a $6 \times$ His or His₆ tag or a myc tag, or a tag for purification, for example, a GST fusion, and a 30 sequence for directing protein secretion and/or membrane association.

For long-term, high-yield production of recombinant proteins, stable expression is desired. For example, cell lines that stably express a modified PH20 polypeptide can be 35 transformed using expression vectors that contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to selective 40 media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells that successfully express the introduced sequences. Resistant cells of stably transformed cells can be proliferated using tissue culture techniques appropriate to 45 the cell types.

Any number of selection systems can be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M et al. (1977) Cell, 11:223-32) and adenine phosphoribosyltrans- 50 ferase (Lowy, I et al. (1980) Cell, 22:817-23) genes, which can be employed in TK- or APRT-cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection. For example, DHFR, which confers resistance to methotrexate (Wigler, M et al. (1980) 55 Proc. Natl. Acad. Sci, 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F et al. (1981) J. Mol. Biol., 150:1-14); and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively, can be used. 60 Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of typtophan or hisD, which allows cells to utilize histinol in place of histidine (Hartman S C and RC Mulligan (1988) Proc. Natl. Acad. Sci, 85:8047-51). Visible markers, such as 65 but not limited to, anthocyanins, beta glucuronidase and its substrate, GUS, and luciferase and its substrate luciferin,

also can be used to identify transformants and also to quantify the amount of transient or stable protein expression attributable to a particular vector system (Rhodes C A et al. (1995) *Methods Mol. Biol.* 55:121-131).

The presence and expression of PH20 polypeptides can be monitored. For example, detection of a functional polypeptide can be determined by testing the conditioned media for hyaluronidase enzyme activity under appropriate conditions. Exemplary assays to assess the solubility and activity of expressed proteins are provided herein.

a. Prokaryotic Cells

Prokaryotes, especially *E. coli*, provide a system for producing large amounts of proteins. Transformation of *E. coli* is a simple and rapid technique well known to those of skill in the art. Expression vectors for *E. coli* can contain inducible promoters. Such promoters are useful for inducing high levels of protein expression and for expressing proteins that exhibit some toxicity to the host cells. Examples of inducible promoters include the lac promoter, the trp promoter, the hybrid tac promoter, the T7 and SP6 RNA promoters and the temperature regulated aPL promoter.

Proteins, such as any provided herein, can be expressed in the cytoplasmic environment of E. coli. The cytoplasm is a reducing environment, and for some molecules, this can result in the formation of insoluble inclusion bodies. Reducing agents such as dithiothreotol and β -mercaptoethanol and denaturants, such as guanidine-HCl and urea can be used to resolubilize the proteins. An alternative approach effects protein expression in the periplasmic space of bacteria which provides an oxidizing environment and chaperoninlike and disulfide isomerases, which can aid in the production of soluble protein. Typically, a leader sequence is fused to the protein to be expressed which directs the protein to the periplasm. The leader is then removed by signal peptidases inside the periplasm. Examples of periplasmic-targeting leader sequences include the pelB leader from the pectate lyase gene and the leader derived from the alkaline phosphatase gene. In some cases, periplasmic expression allows leakage of the expressed protein into the culture medium. The secretion of proteins allows quick and simple purification from the culture supernatant. Proteins that are not secreted can be obtained from the periplasm by osmotic lysis. Similar to cytoplasmic expression, in some cases proteins can become insoluble and denaturants and reducing agents can be used to facilitate solubilization and refolding. Temperature of induction and growth also can influence expression levels and solubility, typically temperatures between 25° C. and 37° C. are used. Typically, bacteria produce aglycosylated proteins. Thus, if proteins require glycosylation for function, glycosylation can be added in vitro after purification from host cells.

b. Yeast Cells

Yeasts such as *Saccharomyces cerevisae*, *Schizosaccharomyces pombe*, *Yarrowia lipolytica*, *Kluyveromyces lactis* and *Pichia pastoris* are well known yeast expression hosts that can be used for production of proteins, such as any described herein. Yeast can be transformed with episomal replicating vectors or by stable chromosomal integration by homologous recombination. Typically, inducible promoters are used to regulate gene expression. Examples of such promoters include GAL1, GAL7 and GAL5 and metallothionein promoters, such as CUP1, AOX1 or other *Pichia* or other yeast promoters. Expression vectors often include a selectable marker such as LEU2, TRP1, HIS3 and URA3 for selection and maintenance of the transformed DNA. Proteins expressed in yeast are often soluble. Co-expression with chaperonins such as Bip and protein disulfide

isomerase can improve expression levels and solubility. Additionally, proteins expressed in yeast can be directed for secretion using secretion signal peptide fusions such as the yeast mating type alpha-factor secretion signal from *Saccharomyces cerevisae* and fusions with yeast cell surface 5 proteins such as the Aga2p mating adhesion receptor or the Arxula adeninivorans glucoamylase. A protease cleavage site such as for the Kex-2 protease, can be engineered to remove the fused sequences from the expressed polypeptides as they exit the secretion pathway. Yeast also is capable 10 of glycosylation at Asn-X-Ser/Thr motifs.

c. Insects and Insect Cells

Insect cells, particularly using baculovirus expression, are useful for expressing polypeptides such as PH20 polypeptides. Insect cells express high levels of protein and are 15 capable of most of the post-translational modifications used by higher eukaryotes. Baculoviruses have a restrictive host range which improves the safety and reduces regulatory concerns of eukaryotic expression. Typical expression vectors use a promoter for high level expression such as the 20 polyhedrin promoter of baculovirus. Commonly used baculovirus systems include a baculovirus, such as the Autographa californica nuclear polyhedrosis virus (AcNPV) or the Bombyx mori nuclear polyhedrosis virus (BmNPV), and an insect cell line, such as Sf9 derived from 25 Spodoptera frugiperda, Pseudaletia unipuncta (A7S) and Danaus plexippus (DpN1). For high-level expression, the nucleotide sequence of the molecule to be expressed is fused immediately downstream of the polyhedrin initiation codon of the virus. Mammalian secretion signals are accurately 30 processed in insect cells and can be used to secrete the expressed protein into the culture medium. In addition, the cell lines Pseudaletia unipuncta (A7S) and Danaus plexippus (DpN1) produce proteins with glycosylation patterns similar to mammalian cell systems. Exemplary insect cells 35 are those that have been altered to reduce immunogenicity, including those with "mammalianized" baculovirus expression vectors and those lacking the enzyme FT3.

An alternative expression system in insect cells employs stably transformed cells. Cell lines such as the Schnieder 2 40 (S2) and Kc cells (*Drosophila melanogaster*) and C7 cells (*Aedes albopictus*) can be used for expression. The *Drosophila* metallothionein promoter can be used to induce high levels of expression in the presence of heavy metal induction with cadmium or copper. Expression vectors are typically 45 maintained by the use of selectable markers such as neomycin and hygromycin.

d. Mammalian Expression Mammalian expression systems can be used to express proteins including PH20 polypeptides. Expression constructs can be transferred to mam- 50 malian cells by viral infection such as by adenovirus or by direct DNA transfer such as liposomes, calcium phosphate, DEAE-dextran and by physical means such as electroporation and microinjection. Expression vectors for mammalian cells typically include an mRNA cap site, a TATA box, a 55 translational initiation sequence (Kozak consensus sequence) and polyadenylation elements. IRES elements also can be added to permit bicistronic expression with another gene, such as a selectable marker. Such vectors often include transcriptional promoter-enhancers for high-level 60 expression, for example the SV40 promoter-enhancer, the human cytomegalovirus (CMV) promoter and the long terminal repeat of Rous sarcoma virus (RSV). These promoter-enhancers are active in many cell types. Tissue and cell-type promoters and enhancer regions also can be used 65 for expression. Exemplary promoter/enhancer regions include, but are not limited to, those from genes such as

elastase I, insulin, immunoglobulin, mouse mammary tumor virus, albumin, alpha fetoprotein, alpha 1 antitrypsin, beta globin, myelin basic protein, myosin light chain 2, and gonadotropic releasing hormone gene control. Selectable markers can be used to select for and maintain cells with the expression construct. Examples of selectable marker genes include, but are not limited to, hygromycin B phosphotransferase, adenosine deaminase, xanthine-guanine phosphoribosyl transferase, aminoglycoside phosphotransferase, dihydrofolate reductase (DHFR) and thymidine kinase. For example, expression can be performed in the presence of methotrexate to select for only those cells expressing the DHFR gene. Fusion with cell surface signaling molecules such as TCR-ζ and Fc_eRI-γ can direct expression of the proteins in an active state on the cell surface.

Many cell lines are available for mammalian expression including mouse, rat human, monkey, chicken and hamster cells. Exemplary cell lines include but are not limited to CHO, Balb/3T3, HeLa, MT2, mouse NSO (nonsecreting) and other myeloma cell lines, hybridoma and heterohybridoma cell lines, lymphocytes, fibroblasts, Sp2/0, COS, NIH3T3, HEK293, 293S, 2B8, and HKB cells. Cell lines also are available adapted to serum-free media which facilitates purification of secreted proteins from the cell culture media. Examples include CHO-S cells (Invitrogen, Carlsbad, CA, cat #11619-012) and the serum free EBNA-1 cell line (Pham et al., (2003) Biotechnol. Bioeng. 84:332-42.). Cell lines also are available that are adapted to grow in special mediums optimized for maximal expression. For example, DG44 CHO cells are adapted to grow in suspension culture in a chemically defined, animal product-free medium.

e. Plants and Plant Cells

Transgenic plant cells and plants can be used to express proteins such as any described herein. Expression constructs are typically transferred to plants using direct DNA transfer such as microprojectile bombardment and PEG-mediated transfer into protoplasts, and with agrobacterium-mediated transformation. Expression vectors can include promoter and enhancer sequences, transcriptional termination elements and translational control elements. Expression vectors and transformation techniques are usually divided between dicot hosts, such as Arabidopsis and tobacco, and monocot hosts, such as corn and rice. Examples of plant promoters used for expression include the cauliflower mosaic virus promoter, the nopaline syntase promoter, the ribose bisphosphate carboxylase promoter and the ubiquitin and UBQ3 promoters. Selectable markers such as hygromycin, phosphomannose isomerase and neomycin phosphotransferase are often used to facilitate selection and maintenance of transformed cells. Transformed plant cells can be maintained in culture as cells, aggregates (callus tissue) or regenerated into whole plants. Transgenic plant cells also can include algae engineered to produce hyaluronidase polypeptides. Because plants have different glycosylation patterns than mammalian cells, this can influence the choice of protein produced in these hosts.

5. Purification

Host cells transformed with a nucleic acid sequence encoding a modified PH20 polypeptide can be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant cell is generally secreted, but may be contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing nucleic acid encoding

55

PH20 can be designed with signal sequences that facilitate direct secretion of PH20 through prokaryotic or eukaryotic cell membranes.

Thus, methods for purification of polypeptides from host cells will depend on the chosen host cells and expression systems. For secreted molecules, proteins are generally purified from the culture media after removing the cells. For intracellular expression, cells can be lysed and the proteins purified from the extract. When transgenic organisms such as transgenic plants and animals are used for expression, tissues or organs can be used as starting material to make a lysed cell extract. Additionally, transgenic animal production can include the production of polypeptides in milk or eggs, which can be collected, and if necessary, the proteins 15 can be extracted and further purified using standard methods in the art.

Proteins, such as modified PH20 polypeptides, can be purified using standard protein purification techniques known in the art including but not limited to, SDS-PAGE, 20 size fractionation and size exclusion chromatography, ammonium sulfate precipitation and ionic exchange chromatography, such as anion exchange chromatography. Affinity purification techniques also can be utilized to improve the efficiency and purity of the preparations. For example, 25 antibodies, receptors and other molecules that bind PH20 hyaluronidase enzymes can be used in affinity purification. For example, soluble PH20 can be purified from conditioned media.

Expression constructs also can be engineered to add an 30 affinity tag to a protein such as a myc epitope, GST fusion or His₆ and affinity purified with myc antibody, glutathione resin or Ni-resin, respectively. Such tags can be joined to the nucleotide sequence encoding a soluble PH20 as described elsewhere herein, which can facilitate purification of soluble 35 proteins. For example, a modified PH20 polypeptide can be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine- 40 tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle Wash.). The inclusion of a cleavable linker 45 sequence such as Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the expressed PH20 polypeptide is useful to facilitate purification. One such expression vector provides for expression of a fusion protein containing a PH20 polypeptide in and an 50 enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography), while the enterokinase cleavage site provides a means for purifying the polypeptide from the fusion protein.

Purity can be assessed by any method known in the art including gel electrophoresis, orthogonal HPLC methods, staining and spectrophotometric techniques. The expressed and purified protein can be analyzed using any assay or method known to one of skill in the art, for example, any 60 described in Section G. These include assays based on the physical and/or functional properties of the protein, including, but not limited to, analysis by gel electrophoresis, immunoassay and assays of hyaluronidase activity.

Depending on the expression system and host cells used, 65 the resulting polypeptide can be heterogeneous due to peptidases present in the culture medium upon production and

purification. For example, culture of soluble PH20 in CHO cells can result in a mixture of heterogeneous polypeptides. 6. Modification of Polypeptides by PEGylation

Polyethylene glycol (PEG) has been widely used in biomaterials, biotechnology and medicine primarily because PEG is a biocompatible, nontoxic, water-soluble polymer that is typically nonimmunogenic (Zhao and Harris, ACS Symposium Series 680: 458-72, 1997). In the area of drug delivery, PEG derivatives have been widely used in covalent attachment (i.e., "PEGylation") to proteins to reduce immunogenicity, proteolysis and kidney clearance and to enhance solubility (Zalipsky, Adv. Drug Del. Rev. 16:157-82, 1995). Similarly, PEG has been attached to low molecular weight, relatively hydrophobic drugs to enhance solubility, reduce toxicity and alter biodistribution. Typically, PEGylated drugs are injected as solutions.

A closely related application is synthesis of crosslinked degradable PEG networks or formulations for use in drug delivery since much of the same chemistry used in design of degradable, soluble drug carriers can also be used in design of degradable gels (Sawhney et al., Macromolecules 26: 581-87, 1993). It also is known that intermacromolecular complexes can be formed by mixing solutions of two complementary polymers. Such complexes are generally stabilized by electrostatic interactions (polyanion-polycation) and/or hydrogen bonds (polyacid-polybase) between the polymers involved, and/or by hydrophobic interactions between the polymers in an aqueous surrounding (Krupers et al., Eur. Polym J. 32:785-790, 1996). For example, mixing solutions of polyacrylic acid (PAAc) and polyethylene oxide (PEO) under the proper conditions results in the formation of complexes based mostly on hydrogen bonding. Dissociation of these complexes at physiologic conditions has been used for delivery of free drugs (i.e., non-PEGylated). In addition, complexes of complementary polymers have been formed from both homopolymers and copolymers.

Numerous reagents for PEGylation have been described in the art. Such reagents include, but are not limited to, reaction of the polypeptide with N-hydroxysuccinimidyl (NHS) activated PEG, succinimidyl mPEG, mPEG₂-N-hydroxysuccinimide, mPEG succinimidyl alpha-methylbutanoate, mPEG succinimidyl propionate, mPEG succinimidyl butanoate, mPEG carboxymethyl 3-hydroxybutanoic acid succinimidyl ester, homobifunctional PEG-succinimidyl propionate, homobifunctional PEG propionaldehyde, homobifunctional PEG butyraldehyde, PEG maleimide, PEG hydrazide, p-nitrophenyl-carbonate PEG, mPEG-benzotriazole carbonate, propionaldehyde PEG, mPEG butryaldehyde, branched mPEG₂ butyraldehyde, mPEG acetyl, mPEG piperidone, mPEG methylketone, mPEG "linkerless" maleimide, mPEG vinyl sulfone, mPEG thiol, mPEG orthopyridylthioester, mPEG orthopyridyl disulfide, Fmoc-PEG-NHS, Boc-PEG-NHS, vinylsulfone PEG-NHS, acrylate PEG-NHS, fluorescein PEG-NHS, and biotin PEG-NHS (see e.g., Monfardini et al., Bioconjugate Chem. 6:62-69, 1995; Veronese et al., J. Bioactive Compatible Polymers 12:197-207, 1997; U.S. Pat. Nos. 5,672,662; 5,932,462; 6,495,659; 6,737,505; 4,002,531; 4,179,337; 5,122,614; 5,324,844; 5,446,090; 5,612,460; 5,643,575; 5,766,581; 5,795,569; 5,808,096; 5,900,461; 5,919,455; 5,985,263; 5,990,237; 6,113,906; 6,214,966; 6,258,351; 6,340,742; 6,413,507; 6,420,339; 6,437,025; 6,448,369; 6,461,802; 6,828,401; 6,858,736; U.S. 2001/0021763; U.S. 2001/ 0044526; U.S. 2001/0046481; U.S. 2002/0052430; U.S. 2002/0072573; U.S. 2002/0156047; U.S. 2003/0114647; U.S. 2003/0143596; U.S. 2003/0158333; U.S. 2003/ 0220447; U.S. 2004/0013637; US 2004/0235734; WO05000360; U.S. 2005/0114037; U.S. 2005/0171328; U.S. 2005/0209416; EP 1064951; EP 0822199; WO 01076640; WO 0002017; WO 0249673; WO 9428024; and WO 0187925).

In one example, the polyethylene glycol has a molecular ⁵ weight ranging from about 3 kD to about 50 kD, and typically from about 5 kD to about 30 kD. Covalent attachment of the PEG to the drug (known as "PEGylation") can be accomplished by known chemical synthesis techniques. ¹⁰ For example, the PEGylation of protein can be accomplished by reacting NHS-activated PEG with the protein under suitable reaction conditions.

While numerous reactions have been described for PEGylation, those that are most generally applicable confer directionality, utilize mild reaction conditions, and do not necessitate extensive downstream processing to remove toxic catalysts or bi-products. For instance, monomethoxy PEG (mPEG) has only one reactive terminal hydroxyl, and thus 20 its use limits some of the heterogeneity of the resulting PEG-protein product mixture. Activation of the hydroxyl group at the end of the polymer opposite to the terminal methoxy group is generally necessary to accomplish efficient protein PEGylation, with the aim being to make the ²⁵ derivatised PEG more susceptible to nucleophilic attack. The attacking nucleophile is usually the epsilon-amino group of a lysyl residue, but other amines also can react (e.g., the N-terminal alpha-amine or the ring amines of histidine) if local conditions are favorable. A more directed attachment is possible in proteins containing a single lysine or cysteine. The latter residue can be targeted by PEGmaleimide for thiol-specific modification. Alternatively, PEG hydrazide can be reacted with a periodate oxidized 35 hyaluronan-degrading enzyme and reduced in the presence of NaCNBH₃. More specifically, PEGylated CMP sugars can be reacted with a hyaluronan-degrading enzyme in the presence of appropriate glycosyl-transferases. One technique is the "PEGylation" technique where a number of polymeric molecules are coupled to the polypeptide in question. When using this technique, the immune system has difficulties in recognizing the epitopes on the polypeptide's surface responsible for the formation of antibodies, thereby 45 reducing the immune response. For polypeptides introduced directly into the circulatory system of the human body to give a particular physiological effect (i.e., pharmaceuticals) the typical potential immune response is an IgG and/or IgM response, while polypeptides which are inhaled through the respiratory system (i.e., industrial polypeptide) potentially can cause an IgE response (i.e., allergic response). One of the theories explaining the reduced immune response is that the polymeric molecule(s) shield(s) epitope(s) on the surface 55 of the polypeptide responsible for the immune response leading to antibody formation. Another theory or at least a partial factor is that the heavier the conjugate is, the more reduced the resulting immune response is.

Typically, to make the PEGylated PH20 polypeptide ⁶⁰ provided herein, PEG moieties are conjugated, via covalent attachment, to the polypeptides. Techniques for PEGylation include, but are not limited to, specialized linkers and coupling chemistries (see e.g., Roberts, *Adv. Drug Deliv.* 65 *Rev.* 54:459-476, 2002), attachment of multiple PEG moieties to a single conjugation site (such as via use of branched


PEGs; see e.g., Guiotto et al., *Bioorg. Med. Chem. Lett.* 12:177-180, 2002), site-specific PEGylation and/or mono-PEGylation (see e.g., Chapman et al., *Nature Biotech.* 17:780-783, 1999), and site-directed enzymatic PEGylation (see e.g., Sato, *Adv. Drug Deliv. Rev.*, 54:487-504, 2002). Methods and techniques described in the art can produce proteins having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 PEG or PEG derivatives attached to a single protein molecule (see e.g., U.S. 2006/0104968).

As an exemplary illustrative method for making a PEGylated PH20 polypeptide, PEG aldehydes, succinimides and carbonates have each been applied to conjugate PEG moieties, typically succinimidyl PEGs, to rHuPH20. For example, rHuPH20 has been conjugated with exemplary succinimidyl monoPEG (mPEG) reagents including mPEG-Succinimidyl Propionates (mPEG-SPA), mPEG-Succinimidyl Butanoates (mPEG-SBA), and (for attaching "branched" PEGs) mPEG2-N-Hydroxylsuccinimide. These PEGylated succinimidyl esters contain different length carbon backbones between the PEG group and the activated cross-linker, and either a single or branched PEG group. These differences can be used, for example, to provide for different reaction kinetics and to potentially restrict sites available for PEG attachment to rHuPH20 during the conjugation process.

Succinimidyl PEGs (as above) containing either linear or branched PEGs can be conjugated to PH20. PEGs can used to generate PH20s reproducibly containing molecules having, on the average, between about three to six or three to six PEG molecules per hyaluronidase. Such PEGylated rHuPH20 compositions can be readily purified to yield compositions having specific activities of approximately 25,000 or 30,000 Unit/mg protein hyaluronidase activity, and being substantially free of non-PEGylated PH20 (less than 5% non-PEGylated).

Using various PEG reagents, exemplary versions of a PEGylated PH20 polypeptide can be prepared, for example, using mPEG-SBA (30 kD), mPEG-SMB (30 kD), and branched versions based on mPEG2-NHS (40 kD) and mPEG2-NHS (60 kD). PEGylated versions of PH20 can be generated using NHS chemistries, as well as carbonates, and aldehydes, using each of the following reagents: mPEG2-NHS-40K branched, mPEG-NHS-10K branched, mPEG-NHS-20K branched, mPEG2-NHS-60K branched; mPEG-SBA-5K, mPEG-SBA-20K, mPEG-SBA-30K; mPEG-SMB-20K. mPEG-SMB-30K; mPEG-butyrldehyde; mPEG-SPA-20K, mPEG-SPA-30K; and PEG-NHS-5K-biotin. PEGylated PH20 also can be prepared using PEG reagents available from Dowpharma, a division of Dow Chemical Corporation; including PH20 polypeptides PEGylated with Dowpharma's p-nitrophenyl-carbonate PEG (30 kDa) and with propionaldehyde PEG (30 kDa).

In one example, the PEGylation includes conjugation of mPEG-SBA, for example, mPEG-SBA-30K (having a molecular weight of about 30 kDa) or another succinimidyl ester of a PEG butanoic acid derivative, to a PH20 polypeptide. Succinimidyl esters of PEG butanoic acid derivatives, such as mPEG-SBA-30K readily couple to amino groups of proteins. For example, covalent conjugation of m-PEG-SBA-30K and rHuPH20 (which is approximately 60 KDa in size) provides stable amide bonds between rHuPH20 and mPEG, as shown in Scheme 1, below.



Typically, the mPEG-SBA-30K or other PEG is added to the PH20 polypeptide at a PEG:polypeptide molar ratio of 10:1 in a suitable buffer, e.g., 130 mM NaCl/10 mM HEPES at pH 6.8 or 70 mM phosphate buffer, pH 7, followed by sterilization, e.g., sterile filtration, and continued conjugation, for example, with stirring, overnight at 4° C. in a cold 25 room. In one example, the conjugated PEG-PH20 is concentrated and buffer-exchanged.

Other methods of coupling succinimidyl esters of PEG butanoic acid derivatives, such as mPEG-SBA-30K are known in the art (see e.g., U.S. Pat. Nos. 5,672,662; 6,737, ³⁰ 505; and U.S. 2004/0235734). For example, a polypeptide, such as a PH20 polypeptide, can be coupled to an NHS activated PEG derivative by reaction in a borate buffer (0.1 M, pH 8.0) for one hour at 4° C. The resulting PEGylated protein can be purified by ultrafiltration. Another method ³⁵ reacts polypeptide with mPEG-SBA in deionized water to which triethylamine is added to raise the pH to 7.2-9. The resulting mixture is stirred at room temperature for several hours to complete the PEGylation.

Methods for PEGylation of PH20 polypeptides, including, for example, animal-derived hyaluronidases and bacterial hyaluronan-degrading enzymes, are known to one of skill in the art. See, for example, European Patent No. EP 0400472, which describes the PEGylation of bovine testes 45 hyaluorindase and chondroitin ABC lyase. Also, U.S. Publication No. 2006014968 describes PEGylation of a human hyaluronidase derived from human PH20. For example, the PEGylated hyaluronan-degrading enzyme generally contains at least 3 PEG moieties per molecule. In some 50 examples, the PH20 polypeptide contains three to six PEG molecules. In other examples, the enzyme can have a PEG to protein molar ratio between 5:1 and 9:1, for example, 7:1.

F. Pharmaceutical Compositions and Formulations, Dosages and Administration

Pharmaceutical compositions of any of the modified PH20 polypeptides are provided herein for administration. Pharmaceutically acceptable compositions are prepared in 60 view of approvals for a regulatory agency or other agency prepared in accordance with generally recognized pharmacopeia for use in animals and in humans. Typically, the compounds are formulated into pharmaceutical compositions using techniques and procedures well known in the art 65 (see e.g., Ansel *Introduction to Pharmaceutical Dosage Forms*, Fourth Edition, 1985, 126).

150

In particular, provided herein are pharmaceutical compositions that are stable as a liquid formulation for prolonged periods of time for at least 1 month at temperatures from or from about 2° C. to 8° C., inclusive or for at least 3 days at a temperature from or from about 30° C. to 42° C., inclusive. Pharmaceutical compositions, in particular liquid formulations, can be limited by the stability of the active agent, which can be susceptible to effects of storage conditions (time or length of storage, temperature and/or agitation) 10 and/or formulation components contained in the composition. Hence, the stable pharmaceutical compositions generally contain a modified PH20 polypeptide as described in Section C.1.b that exhibits increased stability manifested as an increased resistance to one or more protein denaturation conditions. Such protein denaturation conditions can include, but are not limited to, elevated temperature greater than or equal to or about 30° C., agitation, low or no salt, and presence of excipients. The increased stability is characterized by improved storage time, decreased fragmentation, and/or decreased aggregate formation, while still retaining the activity of the active agent(s), e.g., the PH20 hyaluronidase. Such formulations can be provided as "ready-to use" liquid formulations without further reconstitution and/or without any requirement for further dilution. In some examples, the formulations also can be prepared in a lyophilized or concentrated form.

Pharmaceutical compositions containing a modified PH20 polypeptide can be co-administered with another therapeutic agent. In such examples, the modified PH20 polypeptides can be formulated separately as a pharmaceutical composition and administered prior to, simultaneously with, intermittently with, or subsequent to a second composition containing an active therapeutic agent. In other examples, modified PH20 polypeptides can be co-formulated with pharmaceutical formulations of other therapeutic agents.

In particular, provided herein are co-formulations containing a modified PH20 polypeptide as described herein and a therapeutic agent that is a chemotherapeutic agent, an analgesic agent, an anti-inflammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonacidal agent, an anti-Parkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti-depressant agent, and antiarthritics agent, an anti-fungal agent, an antihypertensive agent, an antipyretic agent, an anti-parasite agent, an antihistamine agent, an alpha-adrenergic agonist agent, an alpha blocker agent, an anesthetic agent, a bronchial dilator agent, a biocide agent, a bactericide agent, a bacteriostat agent, a beta adrenergic blocker agent, a calcium channel blocker agent, a cardiovascular drug agent, a contraceptive agent, a decongestant agent, a diuretic agent, a depressant agent, a diagnostic agent, a electrolyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a psychic energizer agent, a sedative 55 agent, a sympathomimetic agent, a tranquilizer agent, an urinary agent, a vaginal agent, a viricide agent, a vitamin agent, a non-steroidal anti-inflammatory agent, an angiotensin converting enzyme inhibitor agent, a polypeptide, a protein, a nucleic acid, a drug, an organic molecule or a sleep inducer. For example, modified PH20 polypeptides provided herein can be co-formulated with an antibody such as a monoclonal antibody, an Immune Globulin, an antibiotic, a bisphosphonate, a cytokine, a chemotherapeutic agent, a coagulation factor or an insulin. Exemplary therapeutic agents that can be co-formulated with a modified PH20 polypeptide are described in described in Section H. In particular, provided herein are co-formulations containing a modified PH20 polypeptide and an insulin, such as a fastacting insulin, for example, a regular insulin or a fast-acting (rapid-acting) insulin analog. The co-formulations provided herein include stable co-formulations, whereby the active agents, i.e., the modified PH20 polypeptide and the therapeutic agent, exhibit increased stability and retain activity for prolonged periods as described herein.

Formulations containing PH20 provided herein, including separate formulations thereof and co-formulations, are stable for prolonged periods of time, including at varied 10 temperatures and under varied storage or use conditions such as agitation. For example, the formulations provided herein are stable and retain activity of active agent(s) (e.g., PH20 hyaluronidase) at "refrigerator" conditions, for example, at 2° C. to 8° C., such as at or about 4° C., for at 15 least at least 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 20 months, 24 months, 25 months, 26 months, 27 months, 28 months, 29 months or 30 months or more. In another example, the formulations provided herein are stable and retain activity of active agent(s) (e.g., PH20 hyaluronidase) at room temperature for example at 18° C. to 32° C., 25 generally 20° C. to 32° C., such as 28° C. to 32° C., for at least 2 weeks to 1 year, for example, at least 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, at least 7 months, at least 8 months, at least 9 months, or at least 1 year or more. In a further example, the formulations 30 provided herein are stable and retain activity of active agent(s) (e.g., PH20 hyaluronidase) at elevated temperatures of about or greater than 30° C., generally from or from about 30° C. to 42° C., such as 32° C. to 37° C. or 35° C. to 37° C. or about or 37° C. for at least 4 days, 5 days, 6 days, 7 35 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 35 days, 40 days, 45 days, 50 days, 60 days or more.

Compositions can take the form of solutions, suspensions, 40 emulsions, tablets, pills, capsules, powders, and sustained release formulations. A composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, 45 magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and other such agents. Topical formulations also are contemplated. The formulation should suit the mode of administration.

1. Formulations-Liquids, Injectables and Emulsions 50 The formulation generally is made to suit the route of administration. Parenteral administration, generally characterized by injection or infusion, either subcutaneously, intramuscularly, intravenously or intradermally is contemplated herein. Preparations for parenteral administration include 55 sterile solutions ready for injection, sterile dry soluble products, such as lyophilized powders, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just 60 prior to use and sterile emulsions. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. For example, the compositions containing a modified PH20 polypeptide, for- 65 mulated separately or co-formulated with another therapeutic agent, can be provided as a pharmaceutical preparation in

liquid form as a solution, syrup or suspension. In liquid form, the pharmaceutical preparations can be provided as a concentrated preparation to be diluted to a therapeutically effective concentration before use. Generally, the preparations are provided in a dosage form that does not require dilution for use. In another example, pharmaceutical preparations can be presented in lyophilized form for reconstitution with water or other suitable vehicle before use.

Injectables are designed for local and systemic administration. For purposes herein, local administration is desired for direct administration to the affected interstitium. The solutions can be either aqueous or nonaqueous. If administered intravenously, suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.

The concentration of the pharmaceutically active compound is adjusted so that an injection or infusion provides an effective amount to produce the desired pharmacological effect. The exact dose depends on the age, weight and condition of the patient or animal as is known in the art. The unit-dose parenteral preparations can be packaged in, for example, an ampoule, a cartridge, a vial or a syringe with a needle. The volume of liquid solution or reconstituted powder preparation, containing the pharmaceutically active compound, is a function of the disease to be treated and the particular article of manufacture chosen for package. All preparations for parenteral administration must be sterile, as is known and practiced in the art. The percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject.

Pharmaceutical compositions can include carriers or other excipients. For example, pharmaceutical compositions provided herein can contain any one or more of a diluents(s), adjuvant(s), antiadherent(s), binder(s), coating(s), filler(s), flavor(s), color(s), lubricant(s), glidant(s), preservative(s), detergent(s), sorbent(s) or sweetener(s) and a combination thereof or vehicle with which a modified PH20 polypeptide is administered. For example, pharmaceutically acceptable carriers or excipients used in parenteral preparations include aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances. Formulations, including liquid preparations, can be prepared by conventional means with pharmaceutically acceptable additives or excipients.

Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin. Such compositions will contain a therapeutically effective amount of the compound, generally in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. Such pharmaceutical carriers can be sterile liquids, such as water or oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil. Water is a typical carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions also can be employed as liquid carriers, particularly for injectable solutions. Examples of aqueous vehicles include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection. Nonaqueous parenteral vehicles include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil. Suspending and dispersing agents include, but are not limited to, sorbitol syrup, cellulose derivatives or hydrogenated edible fats, sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Emulsifying agents include, but are not limited to, lecithin or acacia. Detergents include, but are not limited to, Polysorbate 80 (TWEEN 80). Non-aqueous vehicles include, but are not limited to, almond oil, oily esters, or fractionated vegetable oils. Antimicrobial agents or preservatives include, but are not limited to, methyl or propyl-p-hydroxybenzoates or sorbic acid, m-cresol, phenol. A diluent includes, but is not limited to, lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose. A lubricant includes, but is not limited to, magnesium 15 stearate, calcium stearate or talc. A binder includes, but is not limited to, starch, natural gums, such as gum acacia, gelatin, glucose, molasses, polyvinylpyrrolidine, celluloses and derivatives thereof, povidone, crospovidones and other such binders known to those of skill in the art. Isotonic 20 agents include, but are not limited to, sodium chloride and dextrose. Buffers include, but are not limited to, phosphate and citrate. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. A sequestering or chelating agent of metal ions includes EDTA. Other 25 suitable pharmaceutical excipients include, but are not limited to, starch, glucose, lactose, dextrose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, saline, water, and ethanol. Pharmaceutical carriers also include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment. A composition, if desired, also can contain minor amounts of non-toxic auxiliary substances 35 such as wetting or emulsifying agents, or pH buffering agents, for example, acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, stabilizers, solubility enhancers, and other such agents such as for example, 40 sodium acetate, sodium phosphate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.

In particular, antimicrobial agents (e.g., preservatives) in bacteriostatic or fungistatic concentrations (e.g., an antimicrobial effective amount) can be added to parenteral 45 preparations packaged in multiple-dose containers, which include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride. 50

The volume of the formulations, including the separately formulated or co-formulated PH20-containing formulations provided herein, can be any volume suitable for the container in which it is provided. In some examples, the formulations are provided in a vial, syringe, pen, reservoir 55 for a pump or a closed loop system, or any other suitable container. For example, the formulations provided herein are between or about between 0.1 mL to 500 mL, such as 0.1 mL to 100 mL, 1 mL to 100 mL, 0.1 mL to 50 mL, such as at least or about at least or about or 0.1 mL, 1 mL, 2 mL, 3 mL, 60 4 mL, 5 mL, 10 mL, 15 mL, 20 mL, 30 mL, 40 mL, 50 mL or more.

a. Lyophilized Powders

Of interest herein are lyophilized powders, which can be reconstituted for administration as solutions, emulsions and 65 other mixtures. They may also be reconstituted and formulated as solids or gels.

The sterile, lyophilized powder is prepared by dissolving a compound of enzyme in a buffer solution. The buffer solution may contain an excipient which improves the stability or other pharmacological component of the powder or reconstituted solution, prepared from the powder. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those of skill in the art provides the desired formulation. A liquid formulation as described herein above can be prepared. The resulting mixture is sterile filtered or treated to remove particulates and to insure sterility, and apportioned into vials for lyophilization. For example, the lyophilized powder can be prepared by dissolving an excipient, such as dextrose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agent, in a suitable buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art. Then, a selected enzyme is added to the resulting mixture, and stirred until it dissolves.

Each vial is made to contain a single dosage or multiple dosages of the compound. The lyophilized powder can be stored under appropriate conditions, such as at about 4° C. to room temperature. Reconstitution of this lyophilized powder with an appropriate buffer solution provides a formulation for use in parenteral administration.

b. Exemplary Formulations

Single dose formulations of PH20 are known in the art. For example, Hylenex® recombinant hyaluronidase (hyaluronidase human injection) contains, per mL, 8.5 mg NaCl (145 mM), 1.4 mg dibasic sodium phosphate (9.9 mM), 1.0 mg human albumin, 0.9 mg edetate disodium (2.4 mM), 0.3 mg CaCl₂ (2.7 mM) and NaOH to adjust the pH to 7.4. Other formulations of human soluble hyaluronidase, such as the rHuPH20 formulations described in U.S. Pat. Pub. No. US2011/0053247, include 130 mM NaCl, 10 mM Hepes, pH 7.0; or 10 mM histidine, 130 mM NaCl, pH 6.0. Any of the modified PH20 polypeptides provided herein can be similarly formulated.

In addition to a therapeutically effective amount of a modified PH20 polypeptide and/or other therapeutic agent, exemplary pharmaceutical compositions provided herein, including separately formulated- and co-formulated-PH20 containing formulations, can contain a concentration of NaCl and are prepared at a requisite pH to maintain the stability of the active agent(s) (e.g., PH20 hyaluronidase and/or other co-formulated therapeutic agent). For multi-dose formulations and other formulations stored for a prolonged time, the compositions generally also contain one or more preservatives. Further stabilizing agents and other excipients also can be included. Exemplary components are described below.

i. Salt (e.g. NaCl)

In examples herein, the pharmaceutical compositions provided herein contain a concentration of salt, such as sodium chloride (NaCl), to maintain the stability of the active agent(s) (e.g., PH20 hyaluronidase). Salt, such as NaCl, is generally required to retain PH20 stability and activity. Low salt concentrations of generally less than 120 mM can have deleterious effects on PH20 activity overtime and depending on temperature conditions. Hence, the absence of salt (e.g. NaCl) or a low concentration of salt (e.g. NaCl) can result in instability of the protein. In some examples herein, however, modified PH20 polypeptides that exhibit increased stability in the absence of low or no salt, such as low or no NaCl (see e.g., Section C.1.b.iii), are not susceptible to denaturation. Also, the presence of salt (e.g. NaCl) can have differing effects on other therapeutic agents. For example, the solubility of insulin and insulin analogs tends to increase with lower salt concentration (e.g., <140 5 mM) and high salt concentrations can result in crystallization/aggregation of insulin, especially at lower temperatures (see e.g., U.S. Provisional Appl. No. 61/520,962; U.S. application Ser. Nos. 13/507,263 and 13/507,262; and International PCT Application No. PCT/US2012/042816). Thus, pharmaceutical compositions provided herein are prepared in accordance with the requirements of the active agent(s). It is within the level of one of skill in the art to assess the stability of the active agent(s) in the formulation and under various storage conditions (see e.g., Section G). In particular ¹⁵ examples herein, the pharmaceutical compositions, including the separately formulated or co-formulated PH20-containing formulations provided herein, contain NaCl at a concentration of between or about between 10 mM to 200 mM, such as 10 mM to 50 mM, 50 mM to 200 mM, 50 mM 20 to 120 mM, 50 mM to 100 mM, 50 mM to 90 mM, 120 mM to 160 mM, 130 mM to 150 mM, 80 mM to 140 mM, 80 mM to 120 mM, 80 mM to 100 mM, 80 mM to 160 mM, 100 mM to 140 mM, 120 mM to 120 mM or 140 mM to 180 mM.

ii. pH and Buffer

In examples herein, the pharmaceutical compositions provided herein are prepared at a pH to maintain the stability of the active agent(s) (e.g., PH20 hyaluronidase). For 30 example, the pharmaceutical compositions provided herein are prepared at a pH of between or about between 6.5 to 7.8 such as between or about between 6.5 to 7.2, 7.0 to 7.8, 7.0 to 7.6 or 7.2 to 7.4. Reference to pH herein is based on measurement of pH at room temperature. It is understood 35 that the pH can change during storage over time, but typically will remain between or between about pH 6.5 to or to about 7.8. For example, the pH can vary by ± 0.1 , 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.3, 1.4, 1.5 or more. Exemplary co-formulations provided herein have a pH of or 40 of about 7.0±0.2, 7.1±0.2, 7.2±0.2, 7.3±0.2, 7.4±0.2, 7.5±0.2 or 7.6±0.2 when prepared. If necessary, pH can be adjusted using acidifying agents to lower the pH or alkalizing agents to increase the pH. Exemplary acidifying agents include, but are not limited to, acetic acid, citric acid, sulfuric acid, 45 hydrochloric acid, monobasic sodium phosphate solution, and phosphoric acid. Exemplary alkalizing agents include, but are not limited to, dibasic sodium phosphate solution, sodium carbonate, or sodium hydroxide.

The compositions are generally prepared using a buffering 50 agent that maintains the pH range. Any buffer can be used in formulations provided herein so long as it does not adversely affect the stability of the active agent(s) (e.g., PH20 hyaluronidase), and supports the requisite pH range required. Examples of particularly suitable buffers include 55 Tris, succinate, acetate, phosphate buffers, citrate, aconitate, malate and carbonate. Those of skill in the art, however, will recognize that formulations provided herein are not limited to a particular buffer, so long as the buffer provides an acceptable degree of pH stability, or "buffer capacity" in the 60 range indicated. Generally, a buffer has an adequate buffer capacity within about 1 pH unit of its pK (Lachman et al. In: The Theory and Practice of Industrial Pharmacy 3rd Edn. (Lachman, L., Lieberman, HA. and Kanig, J. L., Eds.), Lea and Febiger, Philadelphia, p. 458-460, 1986). Buffer suit- 65 ability can be estimated based on published pK tabulations or can be determined empirically by methods well known in

the art. The pH of the solution can be adjusted to the desired endpoint within the range as described above, for example, using any acceptable acid or base.

Buffers that can be included in the co-formulations provided herein include, but are not limited to, Tris (Tromethamine), histidine, phosphate buffers, such as dibasic sodium phosphate, and citrate buffers. Such buffering agents can be present in the co-formulations at concentrations between or about between 1 mM to 100 mM, such as 10 mM to 50 mM or 20 mM to 40 mM, such as at or about 30 mM. For example, such buffering agents can be present in the coformulations in a concentration of or about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, or more.

iii. Preservative(s)

In examples herein, multi-dose formulations or formulations stored for prolonged periods contain an anti-microbially effective amount of preservative or mixture of preservatives in an amount to have a bacteriostatic or fungistatic effect. In particular examples, the preservatives are present in a sufficient concentration to provide the anti-microbial requirements of, for example, the United States Pharmacopoeia (USP) and the European Pharmacopoeia (EP), including the EP anti-microbial requirements (EPA) and the preferred EP anti-microbial requirements (EPB) (see Table 4). Since the presence of preservatives, and in particular phenolic preservatives, can have deleterious effects on the stability of PH20, such formulations typically contain a modified PH20 polypeptide that exhibits increased stability in the presence of preservatives, such as any described in Section C.1.b.i herein. Generally, the amount maintains the stability of the active agent(s) (e.g., PH20 hyaluronidase).

An anti-microbial effective amount of preservative is an amount that exhibits anti-microbial activity by killing or inhibiting the propagation of microbial organisms in a sample of the composition as assessed in an antimicrobial preservative effectiveness test (APET). One of skill in the art is familiar with the antimicrobial preservative effectiveness test and standards to be meet under the USP and EPA or EPB in order to meet minimum requirements. In general, the antimicrobial preservative effectiveness test involves challenging a composition with prescribed inoculums of suitable microorganisms, i.e., bacteria, yeast and fungi, storing the inoculated preparation at a prescribed temperature, withdrawing samples at specified intervals of time and counting the organisms in the sample (see, Sutton and Porter, (2002) PDA Journal of Pharmaceutical Science and Technology 56(4):300-311; The United States Pharmacopeial Convention, Inc., (effective Jan. 1, 2002), The United States Pharmacopeia 25th Revision, Rockville, MD, Chapter <51> Antimicrobial Effectiveness Testing: and European Pharmacopoeia, Chapter 5.1.3, Efficacy of Antimicrobial Preservation). The microorganisms used in the challenge generally include three strains of bacteria, namely E. coli (ATCC No. 8739), Pseudomonas aeruginosa (ATCC No. 9027) and Staphylococcus aureus (ATCC No. 6538), yeast (Candida albicans ATCC No. 10231) and fungus (Aspergillus niger ATCC No. 16404), all of which are added such that the inoculated composition contains 10^5 or 10^6 colony forming units (cfu) of microorganism per mL of composition. The preservative properties of the composition are deemed adequate if, under the conditions of the test, there is

a significant fall or no increase, as specified in Table 3 in the number of microorganisms in the inoculated composition after the times and at the temperatures prescribed. The criteria for evaluation are given in terms of the log reduction in the number of viable microorganism as compared to the 5 initial sample or the previous time point.

Non-limiting examples of preservatives that can be included in the co-formulations provided herein include, but are not limited to, phenol, meta-cresol (m-cresol), methylparaben, benzyl alcohol, thimerosal, benzalkonium chloride, 10 4-chloro-1-butanol, chlorhexidine dihydrochloride, chlorhexidine digluconate, L-phenylalanine, EDTA, bronopol (2-bromo-2-nitropropane-1,3-diol), phenylmercuric acetate, glycerol (glycerin), imidurea, chlorhexidine, sodium dehydroacetate, ortho-cresol (o-cresol), para-cresol (p-cresol), 15 chlorocresol, cetrimide, benzethonium chloride, ethylparaben, propylparaben or butylparaben and any combination thereof. For example, formulations provided herein can contain a single preservative. In other examples, the formulations contain at least two different preservatives or at least 20 three different preservatives. For example, formulations provided herein can contain two preservatives such as L-phenylalanine and m-cresol, L-phenylalanine and methylparaben, L-phenylalanine and phenol, m-cresol and methylparaben, phenol and methylparaben, m-cresol and phenol 25 or other similar combinations. In one example, the preservative in the formulation contains at least one phenolic preservative. For example, the formulation contains phenol, m-cresol or phenol and m-cresol.

In the formulations provided herein, the total amount of 30 the one or more preservative agents as a percentage (%) of mass concentration (w/v) in the formulation can be, for example, between from or between about from 0.1% to 0.4%, such as 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3%, or 0.3% to 0.4%. ³⁵ Generally, the formulations contain less than 0.4% (w/v) preservative. For example, the co-formulations provided herein contain at least or about at least 0.1%, 0.12%, 0.125%, 0.13%, 0.14%, 0.15%, 0.16% 0.17%, 0.175%, 0.18%, 0.19%, 0.2%, 0.25%, 0.3%, 0.325%, 0.35% but less ⁴⁰ than 0.4% total preservative.

In some examples, the formulations provided herein contain between or between about 0.1% to 0.25% phenol and between or about between 0.05% to 0.2% m-cresol, such as between or about between 0.10% to 0.2% phenol and 45 between or about between 0.06% to 0.18% m-cresol, or between or about between 0.1% to 0.15% m-cresol, or between or about between 0.08% to 0.15% m-cresol. For example, formulations provided herein contain or contain about 0.1% phenol and 0.075% m-cresol; 0.1% phenol and 50 0.15% m-cresol; 0.125% phenol and 0.075% m-cresol; 0.13% phenol and 0.075% m-cresol; 0.13% phenol and 0.08% m-cresol; 0.15% phenol and 0.175% m-cresol; or 0.17% phenol and 0.13% m-cresol.

iv. Stabilizers

In examples herein, the pharmaceutical compositions provided herein optionally can contain one or more other stabilizing agent to maintain the stability of the active 60 agent(s) (e.g., PH20 hyaluronidase). Included among the types of stabilizers that can be contained in the formulations provided herein are amino acids, amino acid derivatives, amines, sugars, polyols, salts and buffers, surfactants, and other agents. The formulations provided herein contain at 65 least one stabilizer. For example, the formulations provided herein contain at least one, two, three, four, five, six or more

stabilizers. Hence, any one or more of an amino acids, amino acid derivatives, amines, sugars, polyols, salts and buffers, surfactants, and other agents can be included in the formulations herein. Generally, the formulations herein contain at least contain a surfactant and an appropriate buffer. Optionally, the formulations provided herein can contain other additional stabilizers. Other components include, for example, one or more tonicity modifiers, one or more anti-oxidation agents, or other stabilizer.

Exemplary amino acid stabilizers, amino acid derivatives or amines include, but are not limited to, L-Arginine, Glutamine, Glycine, Lysine, Methionine, Proline, Lys-Lys, Gly-Gly, Trimethylamine oxide (TMAO) or betaine. Exemplary sugars and polyols include, but are not limited to, glycerol, sorbitol, mannitol, inositol, sucrose or trehalose. Exemplary salts and buffers include, but are not limited to, magnesium chloride, sodium sulfate, Tris such as Tris (100 mM), or sodium Benzoate. Exemplary surfactants include, but are not limited to, poloxamer 188 (e.g., Pluronic® F68), polysorbate 80 (PS80), polysorbate 20 (PS20). Other stabilizers include, but are not limited to, hyaluronic acid (HA), human serum albumin (HSA), phenyl butyric acid, taurocholic acid, polyvinylpyrolidone (PVP) or zinc.

In particular examples herein, the formulations contain one or more detergents, such as surfactants, to maintain the stability of the active agent(s) (e.g., PH20 hyaluronidase). For example, surfactants can inhibit aggregation of PH20 and minimize absorptive loss. The surfactants generally are non-ionic surfactants. Surfactants that can be included in the formulations herein include, but are not limited to, partial and fatty acid esters and ethers of polyhydric alcohols such as of glycerol, or sorbitol, poloxamers and polysorbates. For example, exemplary surfactants in the -formulations herein include any one or more of poloxamer 188 (PLURONICS® poloxamer such as PLURONIC® F68 poloxamer), TET-RONICS® surfactant, polysorbate 20, polysorbate 80, PEG 400, PEG 3000, Tween® surfactant (e.g., Tween® 20 surfactant or Tween® 80 surfactant), Triton® X-100 surfactant, SPAN® surfactant, MYRJ® surfactant, BRIJ® surfactant, CREMOPHOR® surfactant, polypropylene glycols or polyethylene glycols. In some examples, the formulations herein contain poloxamer 188, polysorbate 20, polysorbate 80, generally poloxamer 188 (pluronic F68). The formulations provided herein generally contain at least one surfactant, such as 1, 2 or 3 surfactants.

In the formulations provided herein, the total amount of the one or more surfactants as a percentage (%) of mass concentration (w/v) in the formulation can be, for example, between from or between about from 0.005% to 1.0%, such as between from or between about from 0.01% to 0.5%, such as 0.01% to 0.1% or 0.01% to 0.02%. Generally, the formulations contain at least 0.01% surfactant and contain less than 1.0%, such as less than 0.5% or less than 0.1% surfactant. For example, the formulations provided herein can contain at or about 0.001%, 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.035%, 0.04%, 0.045%, 0.05%, 0.055%, 0.06%, 0.065%, 0.07%, 0.08%, or 0.09% surfactant. In particular examples, the formulations provided herein contain or contain about 0.010% to or to about 0.05% surfactant.

Tonicity modifiers can be included in the formulation provided herein to produce a solution with the desired osmolality. The formulations provided herein have an osmolality of between or about between 245 mOsm/kg to 305 mOsm/kg. For example, the osmolality is or is about 245 mOsm/kg, 250 mOsm/kg, 255 mOsm/kg, 260 mOsm/kg, 265 mOsm/kg, 270 mOsm/kg, 275 mOsm/kg, 280 mOsm/

kg, 285 mOsm/kg, 290 mOsm/kg, 295 mOsm/kg, 300 mOsm/kg or 305 mOsm/kg. In some examples, the formulations have an osmolality of or of about 275 mOsm/kg. Tonicity modifiers include, but are not limited to, glycerin, NaCl, amino acids, polyalcohols, trehalose, and other salts 5 and/or sugars. The particular amount can be empirically determined in order to retain enzyme activity, and/or tonicity.

In other instances, glycerin (glycerol) is included in the formulations. For example, formulations provided herein 10 typically contain less than 60 mM glycerin, such as less than 55 mM, less than 50 mM, less than 45 mM, less than 40 mM, less than 35 mM, less than 30 mM, less than 25 mM, less than 20 mM, less than 15 mM, 10 mM or less. The amount of glycerin typically depends on the amount of NaCl pres- 15 ent: the more NaCl present in the formulation, the less glycerin is required to achieve the desired osmolality or osmolarity. Thus, for example, in formulations containing higher NaCl concentrations, little or no glycerin need be included in the formulation. In contrast, in formulations 20 containing slightly lower NaCl concentrations, glycerin can be included. For example, formulations provided herein can contain glycerin at a concentration of 40 mM to 60 mM, such as less than 50 mM, such as 20 mM to 50 mM, for example at or about 50 mM. 25

The formulations provided herein also can contain antioxidants to reduce or prevent oxidation, in particular oxidation of the PH20 polypeptide. For example, oxidation can be effected by high concentrations of surfactant or hyaluronan oligomers. Exemplary antioxidants include, but are not 30 limited to, cysteine, tryptophan and methionine. In particular examples, the anti-oxidant is methionine. The formulations provided herein can include an antioxidant at a concentration from between or from about between 5 mM to or to about 50 mM, such as 5 mM to 40 mM, 5 mM to 20 mM or 35 10 mM to 20 mM. For example, methionine can be provided in the formulations herein at a concentration from between or from about between 5 mM to or to about 50 mM, such as 5 mM to 40 mM, 5 mM to 20 mM or 10 mM to 20 mM. For example, an antioxidant, for example methionine, can be 40 included at a concentration that is or is about 5 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 21 mM, 22 mM, 23 mM, 24 mM, 25 mM, 26 mM, 27 mM, 28 mM, 29 mM, 30 mM, 35 mM, 40 mM, 45 mM or 50 mM. In some examples, the formu- 45 lations contain 10 mM to 20 mM methionine, such as or about 10 mM or 20 mM methionine.

The formulations provided herein also can contain an amino acid stabilizer, which contributes to the stability of the preparation. The stabilizer can be a non-polar or basic amino 50 acid. Exemplary non-polar and basic amino acids include, but are not limited to, alanine, histidine, arginine, lysine, ornithine, isoleucine, valine, methionine, glycine and proline. For example, the amino acid stabilizer is glycine or proline, typically glycine. The stabilizer can be a single 55 amino acid or it can be a combination of 2 or more such amino acids. The amino acid stabilizers can be natural amino acids, amino acid analogues, modified amino acids or amino acid equivalents. Generally, the amino acid is an L-amino acid. For example, when proline is used as the stabilizer, it 60 500:1, 400:1, 300:1, 200:1, or 100:1 or less. is generally L-proline. It is also possible to use amino acid equivalents, for example, proline analogues. The concentration of amino acid stabilizer, for example glycine, included in the formulation ranges from 0.1 M to 1 M amino acid, typically 0.1 M to 0.75 M, generally 0.2 M to 0.5 M, for 65 example, at least at or about 0.1 M, 0.15 M, 0.2 M, 0.25 M, 0.3 M, 0.35 M, 0.4 M, 0.45 M, 0.5 M, 0.6 M, 0.7 M, 0.75

M or more amino acid. The amino acid, for example glycine, can be used in a form of a pharmaceutically acceptable salt, such as hydrochloride, hydrobromide, sulfate, acetate, etc. The purity of the amino acid, for example glycine, should be at least 98%, at least 99%, or at least 99.5% or more.

In examples herein, if necessary, hyaluronidase inhibitors are included in a formulation to stabilize PH20, in particular to reduce the effects of otherwise destabilizing agents and conditions, such as, for example, low salt, high pH, the presence of preservatives and elevated temperatures, present in the formulation. Such a component generally is not required for pharmaceutical compositions containing a modified PH20 polypeptide as provided herein that exhibits increased stability under such conditions. When provided, the hyaluronidase inhibitor is provided at least at its equilibrium concentration. One of skill in the art is familiar with various classes of hyaluronidase inhibitors (see e.g., Girish et al. (2009) Current Medicinal Chemistry, 16:2261-2288, and references cited therein). One of skill in the art knows or can determine by standard methods in the art the equilibrium concentration of a hyaluronidase inhibitor in a reaction or stable composition herein.

An exemplary hyaluronidase inhibitor for use in the compositions herein is hyaluronan (HA). Hyaluronic acid (HA, also known as hyaluronan and hyaluronate) is the natural substrate for PH20. HA is a non-sulfated glycosaminoglycan that is widely distributed throughout connective, epithelial, and neural tissues. It is a polymer of up to 25,000 disaccharide units, themselves composed of D-glucuronic acid and D-N-acetylglucosamine. The molecular weight of HA ranges from about 5 kDa to 200,000 kDa. Any size HA can be used in the compositions as a stabilizer. In some examples, the HA is a disaccharide, composed of D-glucuronic acid and D-N-acetylglucosamine. In other examples, the HA is an oligosaccharide, such as a tetrasaccharide, containing 2 repeating disaccharide units, or alternatively, the HA used in the co-formulations provided herein can contain multiple repeating disaccharide units, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30 or more disaccharide units. In another example, the HA used in the formulations provided herein has a molecular weight that is from or from about 5 kDa to or to about 5,000 kDa; from or from about 5 kDa to or to about 1,000 kDa; from or from about 5 kDa to or to about 500 kDa; or from or from about 5 kDa to or to about 200 kDa. Exemplary HA oligosaccharides for use in the formulations herein have a molecular weight of or of about 6.4 kDa, 74.0 kDa. or 234.4 kDa. The formulations can contain 1 mg/mL to 20 mg/mL HA, 8 mg/mL to 12 mg/mL, such as at least or about 1 mg/mL, 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, 10 mg/mL, 11 mg/mL, 12 mg/mL, 13 mg/mL, 14 mg/mL, 15 mg/mL, 16 mg/mL, 17 mg/mL, 18 mg/mL, 19 mg/mL or 20 mg/mL or more HA. In some examples, the molar ratio of HA to PH20 is or is about 100,000:1, 95,000:1, 90,000:1, 85,000:1, 80,000:1, 75,000: 1, 70,000:1, 65,000:1, 60,000:1, 55,000:1, 50,000:1, 45,000: 1, 40,000:1, 35,000:1, 30,000:1, 25,000:1, 20,000:1, 15,000: 1, 10,000:1, 5,000:1, 1,000:1, 900:1, 800:1, 700:1, 600:1,

In some examples, a nicotinic compound is used as a stabilizing agent. Nicotinic compounds include, but are not limited to, nicotinamide, nicotinic acid, niacin, niacinamide, vitamin B3 and/or salts thereof and/or any combination thereof. In particular applications, the stabilizing agent can include a nicotinic compound an amino acid or amino acids (see e.g., International Publication No. WO2010149772).

50

For example, the amino acid can be arginine, glutamic acid and/or salts thereof or combinations thereof.

2. Compositions for Other Routes of Administration

Depending upon the condition treated other routes of administration, such as topical application, transdermal patches, oral and rectal administration are also contemplated herein.

For example, pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules and tablets for systemic effect. Rectal suppositories include solid bodies for insertion into the rectum which melt or soften at body temperature releasing one or more pharmacologically or 15 therapeutically active ingredients. Pharmaceutically acceptable substances utilized in rectal suppositories are bases or vehicles and agents to raise the melting point. Examples of bases include cocoa butter (theobroma oil), glycerin-gelatin, carbowax (polyoxyethylene glycol) and appropriate mix- 20 tures of mono-, di- and triglycerides of fatty acids. Combinations of the various bases may be used. Agents to raise the melting point of suppositories include spermaceti and wax. Rectal suppositories may be prepared either by the compressed method or by molding. The typical weight of a rectal 25 suppository is about 2 to 3 gm. Tablets and capsules for rectal administration are manufactured using the same pharmaceutically acceptable substance and by the same methods as for formulations for oral administration. Formulations suitable for rectal administration can be provided as unit 30 5.733.566). dose suppositories. These can be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or 40 calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets can be coated by methods well-known in the art. 45

Formulations suitable for buccal (sublingual) administration include, for example, lozenges containing the active compound in a flavored base, usually sucrose and acacia or tragacanth; and pastilles containing the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

Topical mixtures are prepared as described for the local and systemic administration. The resulting mixtures can be solutions, suspensions, emulsion or the like and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, 55 irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration.

The compounds or pharmaceutically acceptable derivatives thereof may be formulated as aerosols for topical application, such as by inhalation (see, e.g., U.S. Pat. Nos. 60 4,044,126, 4,414,209, and 4,364,923, which describe aerosols for delivery of a steroid useful for treatment of inflammatory diseases, particularly asthma). These formulations, for administration to the respiratory tract, can be in the form of an aerosol or solution for a nebulizer, or as a microfine 65 powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of

the formulation will typically have diameters of less than 50 microns, or less than 10 microns.

The compounds can be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application. Topical administration is contemplated for transdermal delivery and also for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the active compound alone or in combination with other pharmaceutically acceptable excipients also can be administered.

Formulations suitable for transdermal administration are provided. They can be provided in any suitable format, such as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches contain the active compound in an optionally buffered aqueous solution of, for example, 0.1 to 0.2 M concentration with respect to the active compound. Formulations suitable for transdermal administration also can be delivered by iontophoresis (see, e.g., Tyle, P, Pharmaceutical Research 3(6):318-326 (1986)) and typically take the form of an optionally buffered aqueous solution of the active compound.

Pharmaceutical compositions also can be administered by controlled release formulations and/or delivery devices (see e.g., in U.S. Pat. Nos. 3,536,809; 3,598,123; 3,630,200; 3,845,770; 3,916,899; 4,008,719; 4,769,027; 5,059,595; 5,073,543; 5,120,548; 5,591,767; 5,639,476; 5,674,533 and

3. Dosages and Administration

The modified PH20 polypeptides provided herein can be For oral administration, pharmaceutical compositions can 35 formulated as pharmaceutical compositions for single dosage or multiple dosage administration. The PH20 polypeptide is included in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. The therapeutically effective concentration can be determined empirically by testing the polypeptides in known in vitro and in vivo systems such as by using the assays provided herein or known in the art (see e.g., Taliani et al., (1996) Anal. Biochem., 240: 60-67; Filocamo et al., (1997) J Virology, 71: 1417-1427; Sudo, (1996) Antiviral Res. 32: 9-18; Bouffard et al., (1995) Virology, 209:52-59; Bianchi et al., (1996) Anal. Biochem., 237: 239-244: Hamatake et al., (1996) Intervirology 39:249-258; Steinkuhler et al., (1998) Biochem., 37:8899-8905; D'Souza et al., (1995) J Gen. Virol., 76:1729-1736; Takeshita et al., (1997) Anal. Biochem., 247:242-246; see also e.g., Shimizu et al., (1994) J. Virol. 68:8406-8408; Mizutani et al., (1996) J. Virol. 70:7219-7223; Mizutani et al., (1996) Biochem. Biophys. Res. Commun., 227:822-826; Lu et al. (1996) Proc. Natl. Acad. Sci (USA), 93:1412-1417; Hahm et al., (1996) Virology, 226:318-326; Ito et al. (1996) J. Gen. Virol., 77:1043-1054; Mizutani et al. (1995) Biochem. Biophys. Res. Commun., 212:906-911; Cho et al., (1997) J. Virol. Meth. 65:201-207) and then extrapolated therefrom for dosages for humans.

> The amount of a modified PH20 to be administered for the treatment of a disease or condition can be determined by standard clinical techniques. In addition, in vitro assays and animal models can be employed to help identify optimal dosage ranges. The precise dosage, which can be determined empirically, can depend on the particular enzyme, the route of administration, the type of disease to be treated and the seriousness of the disease.

Hence, it is understood that the precise dosage and duration of treatment is a function of the disease being treated and can be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values also can vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising 10 the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or use of compositions and combinations containing them. The compositions can be administered hourly, daily, weekly, monthly, yearly or once. 15 Generally, dosage regimens are chosen to limit toxicity. It should be noted that the attending physician would know how to and when to terminate, interrupt or adjust therapy to lower dosage due to toxicity, or bone marrow, liver or kidney or other tissue dysfunctions. Conversely, the attending phy-20 sician would also know how to and when to adjust treatment to higher levels if the clinical response is not adequate (precluding toxic side effects).

Typically, a therapeutically effective dose of a modified PH20 enzyme is at or about Unit (U) to 500,000 Units, 100 25 Units to 100,000 Units, 500 Units to 50,000 Units, 1000 Units to 10,000 Units, 5000 Units to 7500 Units, 5000 Units to 50,000 Units, or 1,000 Units to 10,000 Units, generally 1,000 to 50,000 Units, in a stabilized solution or suspension or a lyophilized form. For example, a PH20 polypeptide, can 30 be administered at a dose of at least or about at least or 10 U, 20 U, 30 U, 40 U, 50 U, 100 U, 150 U, 200 U, 250 U, 300 U, 350 U, 400 U, 450 U, 500 U, 600 U, 700 U, 800 U, 900 U, 1000 U, 2,000 U, 3,000 U, 4,000 Units, 5,000 U or more. The formulations can be provided in unit-dose forms 35 such as, but not limited to, ampoules, syringes and individually packaged tablets or capsules.

The PH20 enzyme can be administered alone, or with other pharmacologically effective agent(s) or therapeutic agent(s), in atotal volume of 0.1-100 mL, 1-50 mL, 10-50 40 mL, 10-30 mL, 1-20 mL, or 1-10 mL, typically 10-50 mL. Typically, volumes of injections or infusions of a PH20containing composition are at least or at least about 0.01 mL, 0.05 mL, 0.1 mL, 0.2 mL, 0.3 mL, 0.4 mL, 0.5 mL, 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, 10 mL, 45 20 mL, 30 mL, 40 mL, 50 mL or more. The formulations provided herein contain a modified PH20 polypeptide in an amount between or about between 30 Units/mL to 3000 U/mL, 300 U/mL to 2000 U/mL or 600 U/mL to 2000 U/mL or 600 U/mL to 1000 U/mL, such as at least or about at least 5030 U/mL, 35 U/mL, 40 U/mL, 50 U/mL, 100 U/mL, 200 U/mL, 300 U/mL, 400 U/mL, 500 U/mL, 600 U/mL, 700 U/mL, 800 U/mL, 900 U/mL, 1000 U/mL, 2000 U/mL or 3000 U/mL. For example, the formulations provided herein contain a PH20 that is in an amount that is at least 100 U/mL 55 to 1000 U/mL, for example at least or about at least or about or 600 U/mL.

The PH20 polypeptide can be provided as a solution in an amount that is at least or about or is 100 U/mL, 150 U/mL, 200 U/mL, 300 U/mL, 400 U/mL, 500 U/mL, 600 U/mL, 60 800 U/mL or 1000 U/mL, or can be provided in a more concentrated form, for example in an amount that is at least or about or is 2000 U/mL, 3000 Units/mL, 4000 U/mL, 5000 U/mL, 8000 U/mL, 10,000 U/mL or 20,000 U/mL for use directly or for dilution to the effective concentration prior to 65 use. The PH20 polypeptide compositions can be provided as a liquid or lyophilized formulation.

164

When the PH20 is co-formulated with a therapeutic agent, dosages can be provided as a ratio of the amount of a PH20 polypeptide to the amount of therapeutic agent administered. For example, a PH20 polypeptide can be administered at 1 hyaluronidase U/therapeutic agent U (1:1) to 50:1 or more, for example, at or about 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1 or more.

The formulations provided herein, including co-formulations and/or stable formulations, can be prepared for single dose administration, multiple dose administration or continuous infusion administrations. Implantation of a slowrelease or sustained-release system, such that a constant level of dosage is maintained (see e.g., U.S. Pat. No. 3,710,795), is also contemplated herein.

For example, formulations of pharmaceutically therapeutically active compounds and derivatives thereof are provided for administration to humans and animals in unit dosage forms or multiple dosage forms. For example, compounds can be formulated as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, oral solutions or suspensions, or oil-water emulsions containing suitable quantities of the compounds or pharmaceutically acceptable derivatives thereof. Each unit dose contains a predetermined quantity of therapeutically active compound(s) sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent. Examples of unit dose forms include ampoules and syringes and individually packaged tablets or capsules. Unit dose forms can be administered in fractions or multiples thereof. A multiple dose form is a plurality of identical unit dosage forms packaged in a single container to be administered in segregated unit dose forms. Examples of multiple dose forms include vials, bottles of tablets or capsules or bottles of pints or gallons. Hence, multiple dose form is a multiple of unit doses that are not segregated in packaging. Generally, dosage forms or compositions containing active ingredient in the range of 0.005% to 100% with the balance made up from non-toxic carrier can be prepared.

Compositions provided herein typically are formulated for administration by subcutaneous route, although other routes of administration are contemplated, such as any route known to those of skill in the art including intramuscular, intraperitoneal, intravenous, intradermal, intralesional, intraperitoneal injection, epidural, vaginal, rectal, local, otic, transdermal administration or any route of administration. Formulations suited for such routes are known to one of skill in the art. Administration can be local, topical or systemic depending upon the locus of treatment. Local administration to an area in need of treatment can be achieved by, for example, but not limited to, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant. Compositions also can be administered with other biologically active agents, either sequentially, intermittently or in the same composition.

The most suitable route in any given case depends on a variety of factors, such as the nature of the disease, the tolerance of the subject to a particular administration route, the severity of the disease, and the particular composition that is used. Typically, the compositions provided herein are administered parenterally. In some examples, modified PH20 polypeptide compositions are administered so that they reach the interstitium of skin or tissues, thereby degrading the interstitial space for subsequent delivery of a therapeutic agent. Thus, in some examples, direct administration under the skin, such as by subcutaneous administration methods, is contemplated. Thus, in one example, local administration can be achieved by injection, such as from a syringe or other article of manufacture containing an injec- 5 tion device such as a needle. In another example, local administration can be achieved by infusion, which can be facilitated by the use of a pump or other similar device. Other modes of administration also are contemplated. For example, modified PH20 polypeptides, included conjugated 10 forms with increased half-life such as PEGylated forms thereof, can be administered intravenously. Pharmaceutical compositions can be formulated in dosage forms appropriate for each route of administration.

Administration methods can be employed to decrease the 15 exposure of selected modified PH20 polypeptides to degradative processes, such as proteolytic degradation and immunological intervention via antigenic and immunogenic responses. Examples of such methods include local administration at the site of treatment. PEGylation of therapeutics 20 increases resistance to proteolysis, increases plasma halflife, and decreases antigenicity and immunogenicity. Examples of PEGylation methodologies are known in the art (see for example, Lu and Felix, Int. J. Peptide Protein Res., 43: 127-138, 1994; Lu and Felix, Peptide 25 Res., 6: 140-6, 25 1993; Felix et al., Int. J. Peptide Res., 46: 253-64, 1995; Benhar et al., J. Biol. Chem., 269: 13398-404, 1994; Brumeanu et al., J Immunol., 154: 3088-95, 1995; see also, Caliceti et al. (2003) Adv. Drug Deliv. Rev. 55(10):1261-77 and Molineux (2003) Pharmacotherapy 23 (8 Pt 2):3S-8S). 30 PEGylation also can be used in the delivery of nucleic acid molecules in vivo. For example, PEGylation of adenovirus can increase stability and gene transfer (see, e.g., Cheng e et al., (2003) Pharm. Res. 20(9): 1444-51).

to administer selected PH20 polypeptides, such as but not limited to, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor mediated endocytosis, and delivery of nucleic acid molecules encoding selected PH20 polypep- 40 tides such as retrovirus delivery systems.

Hence, in certain embodiments, liposomes and/or nanoparticles also can be employed with administration of soluble PH20 polypeptides. Liposomes are formed from phospholipids that are dispersed in an aqueous medium and 45 spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs)). MLVs generally have diameters of from 25 nm to 4 µm. Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 50 angstroms containing an aqueous solution in the core.

Phospholipids can form a variety of structures other than liposomes when dispersed in water, depending on the molar ratio of lipid to water. At low ratios of lipid to water, liposomes form. Physical characteristics of liposomes 55 depend on the pH, ionic strength and the presence of divalent cations. Liposomes can show low permeability to ionic and polar substances, but at elevated temperatures undergo a phase transition which markedly alters their permeability. The phase transition involves a change from a 60 closely packed, ordered structure, known as the gel state, to a loosely packed, less-ordered structure, known as the fluid state. This occurs at a characteristic phase-transition temperature and results in an increase in permeability to ions, sugars and drugs. 65

Liposomes interact with cells via different mechanisms: endocytosis by phagocytic cells of the reticuloendothelial

system such as macrophages and neutrophils; adsorption to the cell surface, either by nonspecific weak hydrophobic or electrostatic forces, or by specific interactions with cellsurface components; fusion with the plasma cell membrane by insertion of the lipid bilayer of the liposome into the plasma membrane, with simultaneous release of liposomal contents into the cytoplasm; and by transfer of liposomal lipids to cellular or subcellular membranes, or vice versa, without any association of the liposome contents. Varying the liposome formulation can alter which mechanism is operative, although more than one can operate at the same time. Nanocapsules can generally entrap compounds in a stable and reproducible way. To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 µm) should be designed using polymers able to be degraded in vivo. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use herein, and such particles can be easily made.

4. Exemplary PH20-Insulin Co-Formulations

Provided herein are stable co-formulations of a fast acting insulin, such as a rapid acting (fast-acting) insulin analog, and a modified PH20 polypeptide. Any of the modified PH20 polypeptides provided herein can be included in a co-formulation with insulin, such as any of the co-formulations described in U.S. application Ser. No. 13/507,263 or 13/507,262 or in International PCT application Ser. No. PCT/US2012/042816.

In particular, the modified PH20 polypeptide is a modified PH20 polypeptide that exhibits increased stability under denaturation conditions, such as any set forth in Sections C.1.b. In particular, the PH20 polypeptide is a modified Various other delivery systems are known and can be used 35 PH20 polypeptide that exhibits increased stability to one or more phenolic preservatives, such as any set forth in Section C.1.b.i. For example, the PH20 polypeptide is a modified PH20 polypeptide that contains an amino acid replacement with P at a position corresponding to position 204 with reference to amino acid positions set forth in SEQ ID NO:3, such as F204P with reference to any of SEQ ID NOs: 3, 7 or 32-66. In other examples, the PH20 polypeptide is a modified PH20 polypeptide that contains an amino acid replacement with R at a position corresponding to position 58 with reference to amino acid positions set forth in SEQ ID NO:3, such as V58R with reference to any of SEQ ID NOs: 3, 7 or 32-66.

> The fast acting insulin can be a regular insulin or a rapid acting (fast-acting) insulin analog. Insulin is a polypeptide that when processed is composed of 51 amino acids containing an A- and B-chain. Generally, insulin contains an A-chain of about 21 amino acids and a B-chain of about 30 amino acids. The A- and B-chains are linked by disulfide bridges. Exemplary regular insulins include, for example, a human insulin (with an A chain having a sequence of amino acids set forth in SEQ ID NO:862 and a B chain having a sequence of amino acids set forth in SEQ ID NO:863) or a porcine insulin (with an A chain having a sequence of amino acids set forth as amino acid residue positions 88-108 of SEQ ID NO:864 and a B chain having a sequence of amino acids set forth as amino acid residue positions 25-54 of SEQ ID NO:864). Exemplary fast-acting insulin analogs are insulin variants that contain one or more amino acid modifications compared to a human insulin set forth in SEQ ID NO: 862 and 863 (A and B chains). For example, exemplary insulin analogs are known to one of skill in the art, and include, but are not limited to, glulisine having an A-chain

set forth in SEQ ID NO:862 and a B-chain that is a variant of SEQ ID NO:863 (B-chain; LysB3, GluB29), HMR-1 153 having an A-chain set forth in SEQ ID NO:862 and a B-chain that is a variant of SEQ ID NO:863 (B-chain; LysB3, IleB28), insulin aspart having an A-chain set forth in 5 SEQ ID NO:862 and a B-chain that is a variant of SEQ ID NO:863 (B-chain; AspB28), and insulin lispro having an A-chain set forth in SEQ ID NO:862 and a B-chain that is a variant of SEQ ID NO:863 (B-chain; LysB28, ProB29). In every instance above, the nomenclature of the analogs is 10 based on a description of the amino acid substitution at specific positions on the A or B chain of insulin, numbered from the N-terminus of the chain, in which the remainder of the sequence is that of natural human insulin. Exemplary of such analog forms, are set forth in SEQ ID NO:862 15 (A-chain) and having a B-chain set forth in any of SEQ ID NOs: 865-867.

The co-formulations are stable as a liquid formulation for prolonged periods of time for at least 1 month at temperatures from or from about 2° C. to 8° C., inclusive, or for at 20 least 3 days at a temperature from or from about 30° C. to 42° C., inclusive. For example, the co-formulations are stable and retain activity of the PH20 hyaluronidase and insulin at "refrigerator" conditions, for example, at 2° C. to 8° C., such as at or about 4° C., for at least at least 2 months, 25 3 months, 4 months, 5 months, 6 months, or 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 25 30 months, 26 months, 27 months, 28 months, 29 months or 30 months or more. In another example, the formulations provided herein are stable and retain activity of the PH20 hyaluronidase and insulin at room temperature for example at 18° C. to 32° C., generally 20° C. to 32° C., such as 28° 35 C. to 32° C., for at least 2 weeks to 1 year, for example, at least 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, at least 7 months, at least 8 months, at least 9 months, or at least 1 year or more. In a further example, the formulations provided herein are stable and 40 U/mL of a fast-acting insulin, and in particular at least or retain activity of the PH20 hyaluronidase and insulin at elevated temperatures of about or greater than 30° C., generally from or from about 30° C. to 42° C., such as 32° C. to 37° C. or 35° C. to 37° C. or about or 37° C. for at least 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 45 days, 12 days, 13 days, 14 days, 15 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 35 days, 40 days, 45 days, 50 days, 60 days or more.

Assays to assess stability of active agents are well-known 50 to one of skill in the art. Section G provides exemplary assays to assess stability of PH20 hyaluronidase. The stability of insulin can be assessed using similar methods well-known to one of skill in the art. For example, insulin stability and solubility can be assessed by visual assessment 55 (e.g., including changes in color, clarity, presence of aggregates or clumping and material adhesion, or frosting), acid clarification, optical microscopy, reversed phase high performance liquid chromatography (RP-HPLC), in vitro or in vivo bioassays and denaturing and non-denaturing size 60 exclusion chromatography (SEC). In vitro or in vivo bioassays for insulin activity include, but are not limited to, a competitive binding assay using cells expressing insulin receptors (e.g., human placental cell membranes) and a radiolabeled insulin (see e.g., Weiss et al., (2001) J. Biol. 65 Chem. 276:40018-40024; Duttaroy et al., (2005) Diabetes 54:251-258); insulin-stimulated glucose uptake (Louveau et

al., (2004) JEndocrin. 181:271-280, Duttaroy et al., (2005) Diabetes 54:251-258); assays to assess glucose production in the presence of insulin (Wang et al., (2000) J Biochem., 275:14717-14721, Duttaroy et al., (2005) Diabetes 54:251-258); and studies using diabetic and/or healthy animal models (Atkinson et al., (1999) Nature Med. 5:601-604; Nagoya-Shibata-Yasuda (NSY) mice, Zucker diabetic fatty (ZDF) rats and Gato-Katazaki (GK) rats (Cefalu (2006) ILAR Journal 47:186-198).

Examples of such formulations contain 100 U/mL to 1000 U/mL of a modified PH20 polypeptide, and in particular at or about or at least 600 U/mL; 10 U/mL to 1000 U/mL of a fast-acting insulin, and in particular at or at least or about 100 U/mL; NaCl at a concentration of between or about between 80-140 mM; a pH of between or about between 7.0 to 7.8; a buffering agent that maintains the pH range of between or about between 7.0 to 7.8; 0.10% to 0.4% preservative as a mass concentration (w/v). Optionally, a further stabilizing agent can be included. For example, the co-formulations provided herein contain 1 mM to 100 mM of a buffering agent. For example, the co-formulations provided herein contain 0.005% to 0.5% surfactant. Exemplary co-formulations provided herein also can contain less than 60 mM glycerin (glycerol) and 2 mM to or to about 50 mM of an antioxidant.

The following stable formulations are exemplary only and provide a platform from which minor adjustments can be made. It is understood that very small changes in the concentrations of the various excipients and other components (e.g., $\pm 15\%$ of the stated concentrations), or small changes in pH, can be made while retaining some if not all of the insulin solubility and stability and PH20 stability. Further changes also can be made by adding or removing excipients. For example, the type of stabilizing surfactant can be changed.

For example, the exemplary co-formulations herein contain 100 U/mL to 1000 U/mL of a modified PH20 polypeptide, and in particular at least or about at least or about 600 U/mL of a modified PH20 polypeptide; 10 U/mL to 1000 about at least or about 100 U/mL of a fast-acting insulin; from or from about 10 mM to or to about 50 mM Tris (e.g., from or from about 20 mM to 40 mM Tris, such as or as about 20 mM, 25 mM, 30 mM, 35 mM or 40 mM Tris); from or from about 80 mM to or to about 160 mM NaCl (e.g., at or about 80 mM, 90 mM, 100 mM, 110 mM 120 mM, 130 mM, 140 mM, 150 mM or 160 mM NaCl); from or from about 2 mM to or to about 50 mM methionine (e.g., at or about 5 mM, 10 mM, 20 mM, 30 mM, 40 mM or 50 mM methionine); from or from about 0 mM to or to about 50 mM glycerin (e.g., at or about 5 mM, 10 mM, 20 mM, 30 mM, 40 mM or 50 mM glycerin); from or from about 0.005% to or to about 0.5% poloxamer 188, such as 0.01% oto 0.05% (e.g., at or about 0.01%, 0.02%, 0.03%, 0.04% or 0.05% poloxamer 188); from or from about 0.05% to or to about 0.25% phenol (e.g., at or about 0.1%, 0.12%, 0.125%, 0.13%, 0.14%, 0.15%, 0.16% or 0.17% phenol); and from or from about 0.05% to or to about 0.4% m-cresol (e.g., at or about 0.075%, 0.08%, 0.09%, 0.1%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16% or 0.17% m-cresol). The formulations are prepared with a pH from or from about 7.0 to or to about 7.6 (e.g., at or about pH 7.0, 7.1, 7.2, 7.3, 7.4, 7.5 or 7.6). In further examples, zinc is included at a concentration of or about 0.017 mg/100 U, 0.018 mg/100 U, 0.02 mg/100 U, 0.022 mg/100 U or 0.024 mg/100 U insulin.

In particular examples, the fast acting insulin is insulin aspart, insulin lispro or insulin glulisine. Exemplary co-

formulations provided herein that contain a modified PH20 polypeptide and insulin lispro are those that contain from or about 25 mM to or to about 35 mM Tris (e.g., at or about 30 mM Tris); from or from about 70 mM to or to about 100 mM NaCl (e.g., at or about 80 mM or 100 mM NaCl); from or 5 from about 10 mM to or to about 30 mM methionine (e.g., at or about 10 mM or 20 mM methionine); from or from about 40 mM to or to about 60 mM glycerin (e.g., at or about 50 mM glycerin); from or from about 0.005% to or to about 0.05% poloxamer 188 (e.g., at or about 0.01% poloxamer 10 188); from or from about 0.017 mg zinc/100 U insulin to or to about 0.024 mg zinc/100 U insulin (e.g., 0.017 mg zinc/100 U insulin, 0.018 mg/100 U, 0.02 mg/100 U, 0.022 mg/100 U or 0.024 mg zinc/100 U insulin); from or from about 0.08% to or to about 0.17% phenol (e.g., 0.1%, 15 0.125% or 0.13% phenol); and from or from about 0.07% to or to about 0.17% m-cresol (e.g., 0.075%, 0.08%, 0.13% or 0.15% m-cresol). For example, the co-formulations can contain at or about 0.1% phenol and 0.015% m-cresol; at or about 0.125% phenol and 0.075% m-cresol; at or about 20 0.13% phenol and 0.075% m-cresol; at or about 0.13% phenol and 0.08% m-cresol; or at or about 0.17% phenol and 0.13% m-cresol. Such formulations of insulin lispro and a modified PH20 polypeptide are prepared with a pH of or about 7.0 to or to about 7.5 (typically a pH of or about pH 25 tides, or nucleic acids encoding such polypeptides, or 7.2).

Exemplary co-formulations provided herein that contain a modified PH20 polypeptide and insulin aspart are those that contain from or from about 25 mM to or to about 35 mM Tris (e.g., at or about 30 mM Tris); from or from about 70 mM 30 to or to about 120 mM NaCl (e.g., at or about 80 mM or 100 mM NaCl); from or from about 2 mM to or to about 30 mM methionine, such as 2 mM to 10 mM or 5 mM to 30 mM methionine (e.g., at or about 5 mM, 10 mM or 20 mM methionine); from or from about 0.005% to or to about 35 0.05% poloxamer 188 (e.g., at or about 0.01% poloxamer 188); from or from about 0.08% to or to about 0.17% phenol (e.g., 0.1%, 0.125% or 0.13% phenol); and from or from about 0.07% to or to about 0.17% m-cresol (e.g., 0.075%, 0.08%, 0.13% or 0.15% m-cresol). For example, the co- 40 formulations can contain at or about 0.1% phenol and 0.015% m-cresol; at or about 0.125% phenol and 0.075% m-cresol; at or about 0.13% phenol and 0.075% m-cresol; at or about 0.13% phenol and 0.08% m-cresol; or at or about 0.17% phenol and 0.13% m-cresol. Such formulations of 45 insulin aspart and a modified PH20 polypeptide are prepared with a pH of or about 7.0 to or to about 7.6 (typically a pH of or about pH 7.4 or 7.3).

Further exemplary formulations provided herein that contain a modified PH20 polypeptide and insulin aspart are 50 those that do not contain phenol. Such exemplary formulations contain from or from about 25 mM to or to about 35 mM Tris (e.g., at or about 30 mM Tris); from or from about 70 mM to or to about 120 mM NaCl (e.g., at or about 80 mM or 100 mM NaCl); from or from about 2 mM to or to about 55 30 mM methionine, such as 2 mM to 10 mM or 5 mM to 30 mM methionine (e.g., at or about 5 mM, 10 mM or 20 mM methionine); from or from about 0.005% to or to about 0.05% poloxamer 188 (e.g., at or about 0.01% poloxamer 188); and from or from about 0.07% to or to about 0.4% 60 m-cresol, such as from or from about 0.2% to 0.4% m-cresol (e.g., 0.3%, 0.315%, 0.35%, 0.4% m-cresol). Such formulations of insulin aspart and a modified PH20 polypeptide are prepared with a pH of or about 7.0 to or to about 7.6 (typically a pH of or about pH 7.4 or 7.3). 65

Exemplary co-formulations provided herein that contain a modified PH20 polypeptide and insulin glulisine are those

170

that contain from or from about 25 mM to or to about 35 mM Tris (e.g., at or about 30 mM Tris); from or from about 100 mM to or to about 150 mM NaCl (e.g., at or about 100 mM or 140 mM NaCl); from or from about 10 mM to or to about 30 mM methionine (e.g., at or about 10 mM or 20 mM methionine); from or from about 40 mM to or to about 60 mM glycerin (e.g., at or about 50 mM glycerin); from or from about 0.005% to or to about 0.05% poloxamer 188 (e.g., at or about 0.01% poloxamer 188); from or from about 0.08% to or to about 0.17% phenol (e.g., 0.1%, 0.125% or 0.13% phenol); and from or from about 0.07% to or to about 0.17% m-cresol (e.g., 0.075%, 0.08%, 0.13% or 0.15% m-cresol). For example, the co-formulations can contain at or about 0.1% phenol and 0.015% m-cresol; at or about 0.125% phenol and 0.075% m-cresol; at or about 0.13% phenol and 0.075% m-cresol; at or about 0.13% phenol and 0.08% m-cresol; or at or about 0.17% phenol and 0.13% m-cresol. Such formulations of insulin glulisine and a modified PH20 polypeptide are prepared with a pH of or about 7.0 to or to about 7.6 (typically a pH of or about pH 7.4).

5. Packaging, Articles of Manufacture and Kits

Pharmaceutical compounds of modified PH20 polypepderivatives or variants thereof can be packaged as articles of manufacture containing packaging material, a pharmaceutical composition which is effective for treating a disease or disorder, and a label that indicates that the pharmaceutical composition or therapeutic molecule is to be used for treating the disease or disorder. Combinations of a selected modified PH20 polypeptide, or a derivative or variant thereof and an therapeutic agent also can be packaged in an article of manufacture.

The articles of manufacture provided herein contain packaging materials. Packaging materials for use in packaging pharmaceutical products are well known to those of skill in the art. See, for example, U.S. Pat. Nos. 5,323,907, 5,052, 558 and 5,033,252, each of which is incorporated herein in its entirety. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment. The articles of manufacture can include a needle or other injection device so as to facilitate administration (e.g., sub-epidermal administration) for local injection purposes. A wide array of formulations of the compounds and compositions provided herein are contemplated including a modified PH20 polypeptide and a therapeutic agent, such as a fast-acting insulin, known to treat a particular disease or disorder. The choice of package depends on the PH20 and/or therapeutic agent, and whether such compositions will be packaged together or separately. In one example, the PH20 can be packaged as a mixture with the therapeutic agent. In another example, the components can be packaged as separate compositions

Modified PH20 polypeptides, therapeutic agents and/or articles of manufacture thereof also can be provided as kits. Kits can include a pharmaceutical composition described herein and an item for administration provided as an article of manufacture. For example a PH20 polypeptide can be supplied with a device for administration, such as a syringe, an inhaler, a dosage cup, a dropper, or an applicator. The compositions can be contained in the item for administration or can be provided separately to be added later. The kit can, optionally, include instructions for application including

dosages, dosing regimens and instructions for modes of administration. Kits also can include a pharmaceutical composition described herein and an item for diagnosis. For example, such kits can include an item for measuring the concentration, amount or activity of the selected protease in 5 a subject.

G. Methods of Assessing PH20 Activity and Stability

Assays can be used to assess the stability and activity of the PH20 polypeptides provided herein. The assays can be used to assess the hyaluronidase activity of the PH20 polypeptide under particular conditions, temperature, and/or over time. Such assays can be used, for example, to deter-15 mine the stability of the PH20 polypeptide under specific denaturation conditions, including, but not limited to, elevated temperatures greater than or about or 30° C. (e.g., 30° C. to 42° C. such as or about 37° C.), agitation, presence of excipients (e.g., preservative), or low or no NaCl (salt). 20 also be used in a Gel Shift Assay. Glycosaminoglycans are For example, stability under specific conditions can be monitored by assessing activity, solubility, and stability (e.g., formation of aggregates, etc.) in the absence of exposure to the denaturation condition and then at various time points thereafter in the presence of the condition. Hence, 25 stability can be assessed over time. Stability also can be assessed by comparing any one or more of activity, solubility or aggregation in the presence of one or more denaturation conditions compared to a native, wildtype or reference PH20 polypeptide. The assays also can be used make minor 30 adjustments to the formulations provided herein while retaining the stability of both active agents.

1. Hyaluronidase Activity

The activity of a modified PH20 polypeptide can be assessed using methods well known in the art. For example, the USP XXII assay for hyaluronidase determines activity indirectly by measuring the amount of undegraded hyaluronic acid, or hyaluronan, (HA) substrate remaining 40 in 7% Glacial Acetic Acid. Degradation is determined by after the enzyme is allowed to react with the HA for 30 min at 37° C. (USP XXII-NF XVII (1990) 644-645 United States Pharmacopeia Convention, Inc, Rockville, MD). A Hyaluronidase Reference Standard (USP) or National Formulary (NF) Standard Hyaluronidase solution can be used in 45 an assay to ascertain the activity, in units, of any hyaluronidase. In one example, activity is measured using a microturbidity assay. This is based on the formation of an insoluble precipitate when hyaluronic acid binds with a reagent that precipitates it, such as acidified serum or 50 cetylpyridinium chloride (CPC). The activity is measured by incubating hyaluronidase with sodium hyaluronate (hyaluronic acid) for a set period of time (e.g., 10 minutes) and then precipitating the undigested sodium hyaluronate with the addition of acidified serum or CPC. The turbidity of the 55 resulting sample is measured at 640 nm after an additional development period. The decrease in turbidity resulting from hyaluronidase activity on the sodium hyaluronate substrate is a measure of hyaluronidase enzymatic activity.

In another example, hyaluronidase activity is measured 60 using a microtiter assay in which residual biotinylated hyaluronic acid is measured following incubation with hyaluronidase (see e.g., Frost and Stem (1997) Anal. Biochem. 251:263-269, U.S. Pat. Publication No. 20050260186). The free carboxyl groups on the glucuronic 65 acid residues of hyaluronic acid are biotinylated, and the biotinylated hyaluronic acid substrate is covalently coupled

to a microtiter plate. Following incubation with hyaluronidase, the residual biotinylated hyaluronic acid substrate is detected using an avidin-peroxidase reaction, and compared to that obtained following reaction with hyaluronidase standards of known activity.

Other assays to measure hyaluronidase activity also are known in the art and can be used in the methods herein (see e.g., Delpech et al., (1995) Anal. Biochem. 229:35-41; Takahashi et al., (2003) Anal. Biochem. 322:257-263).

Many hyaluronidase assays have been based upon the measurement of the generation of new reducing N-acetylamino groups (Bonner and Cantey, Clin. Chim. Acta 13:746-752, 1966), or loss of viscosity (De Salegui et al., Arch. Biochem. Biophys. 121:548-554, 1967) or turbidity (Dorfman and Ott, J. Biol. Chem. 172:367, 1948). With purified substrates all of these methods suffice for determination of the presence or absence of endoglycosidase activity.

Substantially purified glycosaminoglycan substrates can mixed with recombinant PH20, such as a soluble PH20, to test for endoglycosidase activity that results in a shift in substrate mobility within the gel. Examples of such substrates include, but are not limited to, chondroitin-4 and 6 sulfate, dermatan sulfate, heparan-sulfate, which can be obtained from Sigma Chemical. Human umbilical cord Hyaluronan can be obtained from ICN. For example, each test substrate can be diluted to at or about 0.1 mg/mL in a buffer range from pH 3.5-7.5. In such an exemplary assay, at or about 10 µl samples of purified soluble PH20 or conditioned media from PH20 expressing cells can be mixed with at or about 90 µl of test substrate in desired buffer and incubated for 3 hours at 37° C. Following incubation, samples are neutralized with sample buffer (Tris EDTA pH 35 8.0, Bromophenol Blue and glycerol) followed by electrophoresis. Glycosaminoglycans can be detected using any method known in the art, for example, glycosaminoglycans can be detected by staining the gels using 0.5% Alcian Blue in 3% Glacial Acetic Acid overnight followed by destaining comparison of substrate mobility in the presence and absence of enzyme.

Hyaluronidase activity can also be detected by substrate gel zymography (Guentenhoner et al., (1992) Matrix 12:388-396). In this assay, a sample is applied to an SDS-PAGE gel containing hyaluronic acid and the proteins in the sample separated by electrophoresis. The gel is then incubated in an enzyme assay buffer and subsequently stained to detect the hyaluronic acid in the gel. Hyaluronidase activity is visualized as a cleared zone in the substrate gel.

The ability of a PH20 polypeptide, including a modified PH20 polypeptide provided herein, to act as a spreading or diffusing agent also can be assessed. For example, trypan blue dye can be injected subcutaneously with or without a PH20 polypeptide into the lateral skin on each side of nude mice. The dye area is then measured, such as with a microcaliper, to determine the ability of the PH20 polypeptide to act as a spreading agent (U.S. Pat. Pub. No. 20060104968).

The functional activity of a PH20 polypeptide can be compared and/or normalized to a reference standard using any of these assays. This can be done to determine what a functionally equivalent amount of a PH20 polypeptide is. For example, the ability of a PH20 polypeptide to act as a spreading or diffusing agent can be assessed by injecting it into the lateral skin of mice with trypan blue, and the amount required to achieve the same amount of diffusion as, for

10

65

example, 100 units of a Hyaluronidase Reference Standard, can be determined. The amount of PH20 polypeptide required is, therefore, functionally equivalent to 100 hyaluronidase units.

2. Solubility

The solubility of a PH20 polypeptide can be determined by any method known to one of the skill in the art. One method for determining solubility is detergent partitioning. For example, a soluble PH20 polypeptide can be distinguished, for example, by its partitioning into the aqueous phase of a Triton® X-114 detergent solution at 37° C. (Bordier et al., (1981) J. Biol. Chem., 256:1604-1607). Membrane-anchored polypeptides, such as lipid-anchored hyaluronidases, including GPI-anchored hyaluronidases, 15 will partition into the detergent-rich phase, but will partition into the detergent-poor or aqueous phase following treatment with Phospholipase C. Phospholipase C is an enzyme that cleaves the phospho-glycerol bond found in GPI-anchored proteins. Treatment with PLC will cause release of 20 GPI-linked proteins from the outer cell membrane.

3. Purity, Crystallization or Aggregation

The stability of a PH20 polypeptide provided herein also 25 can be assessed using other methods and assays known in the art. In addition to assessing stability based on hyaluronidase activity, stability can be assessed by visual inspection, percent recovery, protein purity and apparent melting temperature.

For example, protein purity can be measured by reversed phase high performance liquid chromatography (RP-HPLC). Protein purity, as determined by RP-HPLC, is the percent of the main PH20 protein peak present, as compared to all of the protein species present. Thus, RP-HPLC, and 35 similar methods known to one of skill in the art, can assess degradation of the enzyme. Protein purity can be assessed over time. Protein purity also can be assessed in the presence of one or more denaturation conditions and in varying amounts thereof. Percent recovery also can be determined as 40 the relative percentage of the polypeptide under various conditions (denaturation conditions, time of storage, mode of storage such as vessel or container, or other similar parameters that can be altered) as compared to a reference sample. PH20 polypeptide stability also can be determined 45 by measuring the oxidation of the hyaluronidase by RP-HPLC. Percent oxidation is a measure of sum of the peak areas of the major (ox-1) and minor (ox-2) peaks.

In one example, the melting temperature of a PH20 polypeptide, such as a modified PH20 polypeptide, can be 50 determined by measuring the hydrodynamic radius of particles by dynamic light scattering under various conditions (e.g., denaturation conditions or other storage conditions). An increase in particle size and a decrease in the melting temperature indicates denaturation and subsequent aggrega-55 tion of the hyaluronidase.

Other methods known to one of skill in the art that can be used to determine the stability of the hyaluronidase in the co-formulations provided herein, include polyacrylamide gel electrophoresis (PAGE), immunoblotting, nuclear mag- 60 netic resonance (NMR) spectroscopy, mass spectrometry, circular dichroism (CD) and dye-based fluorescence assays.

4. Pharmacodynamics/Pharmacokinetics

The effect of administration of a PH20 polypeptide, such as a modified PH20 polypeptide, alone or in combination

with another therapeutic agent, on the pharmacokinetic and pharmacodynamic properties of any administered agent also can be assessed in vivo using animal models and/or human subjects, such as in the setting of a clinical trial. Pharmacokinetic or pharmacodynamic studies can be performed using animal models or can be performed during studies with patients administered with a PH20 polypeptide or modified PH20 polypeptide.

Animal models include, but are not limited to, mice, rats, rabbits, dogs, guinea pigs and non-human primate models, such as cynomolgus monkeys or rhesus macaques. In some instances, pharmacokinetic or pharmacodynamic studies are performed using healthy animals. In other examples, the studies are performed using animal models of a disease for which therapy with hyaluronan is considered, such as animal models of any hyaluronan-associated disease or disorder, for example a tumor model.

The pharmacokinetic properties of a PH20 polypeptide, such as a modified PH20 polypeptide, can be assessed by measuring such parameters as the maximum (peak) concentration (Cmax), the peak time (i.e., when maximum concentration occurs; T_{max}), the minimum concentration (i.e., the minimum concentration between doses; Cmin), the elimination half-life $(T_{1/2})$ and area under the curve (i.e., the area under the curve generated by plotting time versus concentration; AUC), following administration. The absolute bioavailability of the hyaluronidase can be determined by comparing the area under the curve of hyaluronidase following subcutaneous delivery (AUCsc) with the AUC of hyaluronidase following intravenous delivery (AUC_{iv}). Absolute bioavailability (F), can be calculated using the formula: F=([AUC], ×dose,)/([AUC], ×dose,). A range of doses and different dosing frequency of dosing can be administered in the pharmacokinetic studies to assess the effect of increasing or decreasing concentrations enzyme, such as modified PH20 polypeptide, in the dose.

H. Methods of Treatment and Combination Therapy

Provided herein are methods and uses of any of the modified PH20 polypeptides provided herein that exhibit hyaluronidase activity based on its ability to degrade glycosaminoglycan(s) such as hyaluronan. Due to such activity, the modified PH20 polypeptides can be used as a spreading factor to increase the delivery and/or bioavailability of subcutaneously administered therapeutic agents. Delivery of any therapeutic agent, including but not limited to, peptides, proteins, small molecule drugs, nucleic acids, or viruses can be facilitated or enhanced by co-administration with a modified PH20 polypeptide provided herein. For example, modified PH20 polypeptides can be used to increase the delivery of therapeutic agents such as antibodies (e.g., monoclonal antibodies), cytokines, Immune Globulin, an Insulin, or coagulation factors, to a desired locus, such as by increasing penetration of chemotherapeutic agents into solid tumors. The modified PH20 polypeptides also can be used to treat a hyaluronan-disease or disorder that is characterized by an excess or accumulation of hyaluronan. For example, modified PH20 polypeptides provided herein can be used to for treating a tumor; for treating glycosaminoglycan accumulation in the brain; for treating a cardiovascular disorder; for treating an ophthalmic disorder; for treating pulmonary disease; for treating cellulite; and/or for treating a proliferative disorder.

Other methods and uses of a modified PH20 polypeptide include any that are known to one of skill in the art. For

55

example, various forms of PH20 hyaluronidases have been prepared and approved for therapeutic use in humans. For example, animal-derived hyaluronidase preparations include Vitrase® hyaluronidase (ISTA Pharmaceuticals), a purified ovine testicular hyaluronidase, and Amphadase® hyaluronidase (Amphastar Pharmaceuticals), a bovine testicular hyaluronidase. Hylenex® hyaluronidase (Halozyme Therapeutics) is a human recombinant hyaluronidase produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing nucleic acid encoding for soluble rHuPH20 (see e.g., U.S. Pat. No. 7,767,429). Approved therapeutic uses for hyaluronidases include use as an adjuvant to increase the absorption and dispersion of other therapeutic agents for hypodermoclysis (subcutaneous fluid administration), and as an adjunct in subcutaneous urography for improving 15 resorption of radiopaque agents. In addition to these indications, hyaluronidases can be used as a therapeutic or cosmetic agent for the treatment of additional diseases and conditions. For example, hyaluronidase is commonly used, for example, for peribulbar block in local anesthesia prior 20 ophthalmic surgery. The presence of the enzyme prevents the need for additional blocks and reduces the time to the onset of akinesia (loss of eye movement). Peribulbar and sub-Tenon's block are the most common applications of hyaluronidase for ophthalmic procedures. Hyaluronidase 25 also can promote akinesia in cosmetic surgery, such as blepharoplasties and face lifts. It is understood that soluble PH20 hyaluronidases provided herein, including esPH20 hyaluronidases, can be used in any method of treatment or combination therapy for which a PH20 hyaluronidase is 30 used (see e.g., U.S. Publication Nos. US20040268425; US20050260186; US20060104968; and U.S. application Ser. No. 12/381,844, published as U.S. Publication No. US20100074885; 12/386,249, published as U.S. Publication No. US20090311237; 12/387,225, published as U.S. Publi- 35 hyaluronidase degrading enzyme. cation No. US20090304665; and Ser. No. 12/386,222, published as U.S. Publication No. US2010003238, each incorporated by reference in their entirety).

Exemplary, non-limiting, methods and uses are described in the following subsections.

1. Methods of Delivering Therapeutic Agents

As noted above, hyaluronidase is a spreading or diffusing substance that modifies the permeability of connective tissue 45 through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue, and of certain specialized tissues, such as the umbilical cord and vitreous humor. When no spreading factor is present, materials injected subcutaneously, such as drugs, 50 proteins, peptides and nucleic acid, spread very slowly. Co-injection with hyaluronidase, however, can cause rapid spreading. The rate of diffusion is proportional to the amount of enzyme, and the extent of diffusion is proportional to the volume of solution.

Modified PH20 polypeptides provided herein can be used to promote or enhance the delivery agents and molecules to any of a variety of mammalian tissues in vivo. It can be used to facilitate the diffusion and, therefore, promote the delivery, of small molecule pharmacologic agents as well as 60 larger molecule pharmacologic agents, such as proteins, nucleic acids and ribonucleic acids, and macromolecular compositions than can contain a combination of components including, but not limited to, nucleic acids, proteins, carbohydrates, lipids, lipid-based molecules and drugs (see e.g., 65 U.S. Publication Nos. US20040268425; US20050260186; and US20060104968). Modified PH20 polypeptides can be

co-administered and/or co-formulated with a therapeutic agent to improve the bioavailability as well as pharmacokinetic (PK) and/or pharmacodynamic (PD) characteristics of co-formulated or co-administered agents. PK/PD parameters that can be improved by using soluble PH20, such as esPH20, include such measures as C_{max} (the maximal concentration of agent achieved following absorption in, e.g., the bloodstream), T_{max} (the time required to achieve maximal concentration), $T_{1/2}$ (the time required for the concentration to fall by half), C_{min} (the minimal concentration of agent following metabolism and excretion), AUC (area under the curve of concentration versus time, a measure of the overall amount of bioavailability), concentrations in various tissues of interest (including, e.g., the rate of achieving desired concentrations, the overall levels, and the duration of maintaining desired levels), and E_{max} (the maximal effect achieved).

The methods of treatment provided herein include combination therapies with a therapeutic agent for the treatment of a disease or disorder for which the therapeutic agent threats. Any therapeutic agent that ameliorates and or otherwise lessens the severity of a disease or condition can be combined with a modified PH20 polypeptide provided herein in order to increase the bioavailability of such therapeutic agent. In particular, modified PH20 polypeptides provided herein can be used in each and all of the combinations described in applications see e.g., U.S. Publication Nos. US20040268425; US20050260186; US20060104968 and U.S. application Ser. No. 12/381,844, published as U.S. Publication No. US20100074885; 12/386,249, published as U.S. Publication No. US20090311237; Ser. No. 12/387,225, published as U.S. Publication No. US20090304665; and Ser. No. 12/386,222, published as U.S. Publication No. US2010003238 in place of the disclosed hyaluronidase or

Modified PH20 polypeptides can be administered prior to, subsequent to, intermittently with or simultaneously with the therapeutic agent preparation. Generally, the modified PH20 polypeptide is administered prior to or simultaneously with 40 administration of the therapeutic agent preparation to permit the PH20 to degrade the hyaluronic acid in the interstitial space. The PH20 can be administered at a site different from the site of administration of the therapeutic molecule or the soluble PH20 can be administered at a site the same as the site of administration of the therapeutic molecule.

Examples of pharmaceutical, therapeutic and cosmetic agents and molecules that can be administered with hyaluronidase include, but are not limited to, a chemotherapeutic or anticancer agent, an analgesic agent, an antibiotic agent, an anti-inflammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonacidal agent, an anti-Parkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti-depressant agent, an anti-arthritic agent, an anti-fungal agent, an antihypertensive agent, an antipyretic agent, an anti-parasitic agent, an antihistamine agent, an alpha-adrenergic agonist agent, an alpha blocker agent, an anesthetic agent, a bronchial dilator agent, a biocide agent, a bactericide agent, a bacteriostatic agent, a beta adrenergic blocker agent, a calcium channel blocker agent, a cardiovascular drug agent, a contraceptive agent, a cosmetic or esthetic agent, a decongestant agent, a diuretic agent, a depressant agent, a diagnostic agent, an electrolyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a psychic energizer agent, a sedative agent, a sleep inducer, a sympathomimetic agent, a tranquilizer agent, a urinary agent, a

vaginal agent, a viricide agent, a vitamin agent, a nonsteroidal anti-inflammatory agent, or an angiotensin converting enzyme inhibitor agent, and any combination thereof. In particular, therapeutic agents include antibodies, including monoclonal antibodies, bisphosphonates, insulins, 5 coagulation factors, cytokines and Immun Globulins.

For example, modified PH20 polypeptides provided herein can be used to increase the delivery of chemotherapeutic agents. Hyaluronidases have also been used to enhance the activity of chemotherapeutics and/or the acces-10 sibility of tumors to chemotherapeutics (Schuller et al., 1991, Proc. Amer. Assoc. Cancer Res. 32:173, abstract no. 1034; Czejka et al., 1990, Pharmazie 45:H.9; Baumgartner et al., (1988) Reg. Cancer Treat. 1:55-58; Zanker et al., (1986) Proc. Amer. Assoc. Cancer Res. 27:390). Combina- 15 tion chemotherapy with hyaluronidase is effective in the treatment of a variety of cancers including urinary bladder cancer (Horn et al., (1985) J. Surg. Oncol. 28:304-307), squamous cell carcinoma (Kohno et al., (1994) J. Cancer Res. Oncol. 120:293-297), breast cancer (Beckenlehner et 20 al., (1992) J. Cancer Res. Oncol. 118:591-596), and gastrointestinal cancer (Scheithauer et al., (1988) Anticancer Res. 8:391-396). In this example, the modified PH20 hyaluronidase enhances penetration of chemotherapeutic or other anti-cancer agents into solid tumors, thereby treating the 25 disease.

Compositions containing soluble PH20 can be injected intratumorally with anti-cancer agents or intravenously for disseminated cancers or hard to reach tumors. The anticancer agent can be a chemotherapeutic, an antibody, a peptide, 30 or a gene therapy vector, virus or DNA. Additionally, hyaluronidase can be used to recruit tumor cells into the cycling pool for sensitization in previously chemorefractory tumors that have acquired multiple drug resistance (St Croix et al., (1998) Cancer Lett September 131(1): 35-44).

Exemplary anti-cancer agents that can be administered after, coincident with or before administration of a soluble PH20, such as an esPH20, include, but are not limited to Acivicins; Aclarubicins; Acodazoles; Acronines; Adozeleinoic Acids); Allopurinols; Altretamines; Alvocidibs; Amba-Ambomycins; zones; Ametantrones; Amifostines: Aminoglutethimides; Amsacrines; Anastrozoles; Anaxirones; Ancitabines; Anthramycins; Apaziquones; Argimesnas; Arsenic Trioxides; Asparaginases; Asperlins; 45 Atrimustines; Azacitidines; Azetepas; Azotomycins; Banoxantrones: Batabulins: Batimastats: BCG Live: Benaxibines; Bendamustines; Benzodepas; Bexarotenes; Bevacizumab; Bicalutamides; Bietaserpines; Biricodars; Bisantrenes; Bisantrenes; Bisnafide Dimesylates; Bizele- 50 sins; Bleomycins; Bortezomibs; Brequinars; Bropirimines; Budotitanes; Busulfans; Cactinomycins; Calusterones; Canertinibs; Capecitabines; Caracemides; Carbetimers; Carboplatins; Carboquones; Carmofurs; Carmustines with Polif-Carmustines; Carubicins; eprosans; Carzelesins; 55 Cedefingols; Celecoxibs; Cemadotins; Chlorambucils; Cioteronels; Ciplactin; Cirolemycins; Cisplatins; Cladribines; Clanfenurs; Clofarabines; Crisnatols; Cyclophosphamides; Cytarabine liposomals; Cytarabines; Dacarbazines; Dactinomycins; Darbepoetin Alfas; Daunorubicin liposo- 60 mals; Daunorubicins/Daunomycins; Daunorubicins; Decitabines; Denileukin Diftitoxes; Dexniguldipines; Dexonas; Dexrazoxanes; Dezaguanines; Diaziquones; Dibrospidiums; Dienogests; Dinalins; Disermolides; Docetaxels; Dofequidars; Doxifluridines; Doxorubicin liposomals; Doxorubicin 65 HCL; Doxorubicin HCL liposome injection; Doxorubicins; Droloxifenes; Dromostanolone Propionates; Duazomycins;

178

Ecomustines; Edatrexates; Edotecarins; Eflornithines; Elacridars; Elinafides; Elliott's B Solutions; Elsamitrucins; Emitefurs; Enloplatins; Enpromates; Enzastaurins; Epipropidines; Epirubicins; Epoetin alfas; Eptaloprosts; Erbulozoles; Esorubicins; Estramustines; Etanidazoles; Etoglucids; Etoposide phosphates; Etoposide VP-16s; Etoposides; Etoprines; Exemestanes; Exisulinds; Fadrozoles; Fazarabines; Fenretinides; Filgrastims; Floxuridines; Fludarabines; Fluorouracils; 5-fluorouracils; Fluoxymesterones; Flurocitabines; Fosquidones; Fostriecins; Fostriecins; Fotretamines; Fulvestrants; Galarubicins; Galocitabines; Gemcitabines; Gemtuzumabs/Ozogamicins; Geroquinols; Gimatecans; Gimeracils; Gloxazones; Glufosfamides; Goserelin acetates; Hydroxyureas; Ibritumomabs/Tiuxetans; Idarubicins; Ifosfamides; Ilmofosines; Ilomastats; Imatinib mesylates; Imexons; Improsulfans; Indisulams; Inproquones; Interferon alfa-2as; Interferon alfa-2bs; Interferon Alfas; Interferon Betas; Interferon Gammas; Interferons; Interleukin-2s and other Interleukins (including recombinant Interleukins); Intoplicines; Iobenguanes [131-I]; Iproplatins; Irinotecans; Irsogladines; Ixabepilones; Ketotrexates; L-Alanosines; Lanreotides; Lapatinibs; Ledoxantrones; Letrozoles; Leucovorins; Leuprolides; Leuprorelins (Leuprolides); Levamisoles; Lexacalcitols; Liarozoles; Lobaplatins; Lometrexols; Lomustines/CCNUs; Lomustines; Lonafamibs; Losoxantrones; Lurtotecans; Mafosfamides; Mannosulfans; Marimastats; Masoprocols; Maytansines; Mechlorethamines; Mechlorethamines/Nitrogen mustards; Megestrol acetates; Megestrols; Melengestrols; Melphalans; Melphalan L-PAMs; Menogarils; Mepitiostanes; Mercaptopurines; 6-Mecaptopurine; Mesnas; Metesinds; Methotrexates; Methoxsalens; Metomidates; Metoprines; Meturedepas; Miboplatins; Miproxifenes; Misonidazoles; Mitindomides; Mitocarcins; Mitocromins; Mitoflaxones; Mitogillins; 35 Mitoguazones; Mitomalcins; Mitomycin Cs; Mitomycins; Mitonafides; Mitoquidones; Mitospers; Mitotanes; Mitox-Mitozolomides; Mivobulins; antrones: Mizoribines: Mofarotenes; Mopidamols; Mubritinibs; Mycophenolic Acids; Nandrolone Phenpropionates; Nedaplatins; Nelarasins; Aldesleukins; Alemtuzumabs; Alitretinoins (9-Cis-Ret- 40 bines; Nemorubicins; Nitracrines; Nocodazoles; Nofetumomabs; Nogalamycins; Nolatrexeds; Nortopixantrones; Octreotides; Oprelvekins; Ormaplatins; Ortataxels; Oteracils; Oxaliplatins; Oxisurans; Oxophenarsines; Paclitaxels; Pamidronates; Patupilones; Pegademases; Pegaspargases; Pegfilgrastims; Peldesines; Peliomycins; Pelitrexols; Pemetrexeds; Pentamustines; Pentostatins; Peplomycins; Perfosfamides; Perifosines; Picoplatins; Pinafides; Pipobromans; Piposulfans; Pirfenidones; Piroxantrones; Pixantrones; Plevitrexeds; Plicamycin Mithramycins; Plicamycins; Plomestanes; Plomestanes; Porfimer sodiums; Porfimers; Porfiromycins; Prednimustines; Procarbazines; Propamidines; Prospidiums; Pumitepas; Puromycins; Pyrazofurins; Quinacrines; Ranimustines; Rasburicases; Riboprines; Ritrosulfans; Rituximabs; Rogletimides; Roquinimexs; Rufocromomycins; Sabarubicins; Safingols; Sargramostims; Satraplatins; Sebriplatins; Semustines; Simtrazenes; Sizofirans; Sobuzoxanes; Sorafenibs; Sparfosates; Sparfosic Acids; Sparsomycins; Spirogermaniums; Spiromustines; Spiroplatins; Spiroplatins; Squalamines; Streptonigrins; Streptovarycins; Streptozocins; Sufosfamides; Sulofenurs; Sunitinib Malate; 6-TG; Tacedinalines; Tales; Talisomycins; Tallimustines; Tamoxifens; Tariquidars; Tauromustines; Tecogalans; Tegafurs; Teloxantrones; Temoporfins; Temozolomides; Teniposides/VM-26s; Teniposides; Teroxirones; Testolactones; Thiamiprines; Thioguanines; Thiotepas; Tiamiprines; Tiazofurins; Tilomisoles; Tilorones; Timcodars; Timonacics; Tirapazamines; Topixantrones;

Topotecans; Toremifenes; Tositumomabs; Trabectedins (Ecteinascidin 743); Trastuzumabs; Trestolones; Tretinoins/ ATRA; Triciribines; Trilostanes; Trimetrexates; Triplatin Tetranitrates; Triptorelins; Trofosfamides; Tubulozoles; Ubenimexs; Uracil Mustards; Uredepas; Valrubicins; Val-5 spodars; Vapreotides; Verteporfins; Vinblastines; Vincristines; Vindesines; Vinepidines; Vinflunines; Vinformides; Vinglycinates; Vinleucinols; Vinleurosines; Vinorelbines; Vintriptols; Vinzolidines; Vinrosidines; Vorozoles; Xanthomycin A's (Guamecyclines); Zeniplatins; Zilascorbs 10 [2-H]; Zinostatins; Zoledronate; Zorubicins; and Zosuquidars, for example:

Aldesleukins (e.g., PROLEUKIN®); Alemtuzumabs (e.g., CAMPATH®); Alitretinoins (e.g., PANRETIN®); Allopurinols (e.g., ZYLOPRIM®); Altretamines (e.g., 15 HEXALEN®); Amifostines (e.g., ETHYOL®); Anastrozoles (e.g., ARIMIDEX®); Arsenic Trioxides (e.g., TRISE-NOX®); Asparaginases (e.g., ELSPAR®); BCG Live (e.g., TICE@BCG); Bexarotenes (e.g., TARGRETIN®); Bevacizumab (AVASTIN®); Bleomycins (e.g., BLENOXANE®); 20 Busulfan intravenous (e.g., BUSULFEX®); Busulfan orals (e.g., MYLERANTM); Calusterones (e.g., METHO-SARB®); Capecitabines (e.g., XELODA®); Carboplatins (e.g., PARAPLATIN®); Carmustines (e.g., BCNU®, BiCNU®); Carmustines with Polifeprosans (e.g., GLIA- 25 DEL@ Wafer); Celecoxibs (e.g., CELEBREX®); Chlorambucils (e.g., LEUKERAN®); Cisplatins (e.g., PLATI-NOL®); Cladribines (e.g., LEUSTATIN®, 2-CdA®); Cyclophosphamides (e.g., CYTOXAN®, NEOSAR®); Cvtarabines (e.g., CYTOSAR-U®); Cytarabine liposomals 30 (e.g., DepoCyt®); Dacarbazines (e.g., DTIC-Domeo): Dactinomycins (e.g., COSMEGEN®); Darbepoetin Alfas (e.g., ARANESP®); Daunorubicin liposomals (e.g. DAUNOX-OME®); Daunorubicins/Daunomycins (e.g., CERU-BIDINE®); Denileukin Diftitoxes (e.g., ONTAK®); Dexra- 35 zoxanes (e.g., ZINECARD®); Docetaxels (e.g., TAXOTERE®); Doxorubicins (e.g., ADRIAMYCIN®, RUBEX®); Doxorubicin liposomals, including Doxorubicin HCL liposome injections (e.g., DOXIL®); Dromostanolone propionates (e.g., DROMOSTANOLONE@ and 40 MASTERONE@ Injection); Elliott's B Solutions (e.g., Elliott's B Solution®); Epirubicins (e.g., ELLENCE®); Epoetin alfas (e.g., EPOGEN®); Estramustines (e.g., EMCYT®); Etoposide phosphates (e.g., ETOPOPHOS®); Etoposide VP-16s (e.g., VEPESID®); Exemestanes (e.g., 45 AROMASIN®); Filgrastims (e.g., NEUPOGEN®); Floxuridines (e.g., FUDR®); Fludarabines (e.g., FLUDARA®); Fluorouracils incl. 5-FUs (e.g., ADRUCIL®); Fulvestrants (e.g., FASLODEX®); Gemcitabines (e.g., GEMZAR®); Gemtuzumabs/Ozogamicins (e.g., MYLOTARG®); Goser- 50 elin acetates (e.g., ZOLADEX®); Hydroxyureas (e.g., HYDREA®); Ibritumomabs/Tiuxetans (e.g., ZEVALIN®); Idarubicins (e.g., IDAMYCIN®); Ifosfamides (e.g., IFEX®); Imatinib mesylates (e.g., GLEEVEC®); Interferon alfa-2as (e.g., ROFERON-AR); Interferon alfa-2bs (e.g., 55 INTRON AR); Irinotecans (e.g., CAMPTOSAR®); Letrozoles (e.g., FEMARA®); Leucovorins (e.g., WELLCO-VORIN®, LEUCOVORIN®); Levamisoles (e.g., ERGAM-ISOL®); Lomustines/CCNUs CeeNU®); (e.g., Mechlorethamines/Nitrogen mustards (e.g., MUSTAR- 60 (e.g., Rituxan®; MabThera®); Bevacizumab (e.g., Avas-GEN®); Megestrol acetates (e.g., MEGACE®); Melphalans/L-PAMs (e.g., ALKERAN®); Mercaptopurine incl. 6-MPs (e.g., PURINETHOL®); Mesnas (e.g., MESNEX®); Methotrexates; Methoxsalens (e.g., UVADEX®); Mitomycin Cs (e.g., MUTAMYCIN®, MITOZYTREX®); Mito- 65 tanes (e.g., LYSODREN®); Mitoxantrones (e.g., NOVAN-TRONE®); Nandrolone Phenpropionates (e.g.,

DURABOLIN-50®); Nofetumomabs (e.g., VERLUMA®); Oprelvekins (e.g., NEUMEGA®); Oxaliplatins (e.g., ELOXATIN®); Paclitaxels (e.g., PAXENE®, TAXOL®); Pamidronates (e.g., AREDIA®); Pegademases (e.g., ADA-GEN®); Pegaspargases (e.g., ONCASPAR®); Pegfil-(e.g., NEULASTA®); Pentostatins (e.g., grastims NIPENT®); Pipobromans (e.g., VERCYTE®); Plicamycin/ Mithramycins (e.g., MITHRACIN®); Porfimer sodiums (e.g., PHOTOFRTN®); Procarbazines (e.g., MATU-LANE®); Quinacrines (e.g., ATABRTNE®); Rasburicases (e.g., ELITEK®); Rituximabs (e.g., RITUXAN®); Sargramostims (e.g., PROKINE®); Streptozocins (e.g., ZANOSAR®); Sunitinib Malates (e.g., SUTENT®); Tales (e.g., SCLEROSOL®); Tamoxifens (e.g., NOLVADEX®); Temozolomides (e.g., TEMODAR®); Teniposides/VM-26s (e.g., VUMON®); Testolactones (e.g., TESLAC®); Thioguanines incl. 6-TG; Thiotepas (e.g., THIOPLEX®); Topotecans (e.g., HYCAMTIN®); Toremifenes (e.g., FARES-TON®); Tositumomabs (e.g., BEXXAR®); Trastuzumabs HERCEPTIN®); Tretinoins/ATRA (e.g., (e.g., VESANOID®); Uracil Mustards; Valrubicins (e.g., VAL-STAR®); Vinblastines (e.g., VELBAN®); Vincristines (e.g., ONCOVIN®); Vinorelbines (e.g., NAVELBINE®); and Zoledronates (e.g., ZOMETA®).

For example, exemplary antibiotic agents include, but are not limited to, Aminoglycosides; Amphenicols; Ansamycins; Carbacephems; Carbapenems; Cephalosporins or Cephems; Cephamycins; Clavams; Cyclic lipopeptides; Diaminopyrimidines; Ketolides; Lincosamides; Macrolides; Monobactams; Nitrofurans; Oxacephems; Oxazolidinones; Penems, thienamycins and miscellaneous beta-lactams; Penicillins; Polypeptides antibiotics; Quinolones; Sulfonamides; Sulfones; Tetracyclines; and other antibiotics (such as Clofoctols, Fusidic acids, Hexedines, Methenamines, Nitrofurantoins Nitroxolines, Ritipenems, Taurolidines, Xibomols).

Also included among exemplary therapeutic agents are coagulation factors or other blood modifiers such as antihemophilic factors, anti-inhibitor coagulant complexes, antithrombin III, coagulation Factor V, coagulation Factor VIII, coagulation Factor IX, plasma protein fractions, von Willebrand factors; antiplatelet agents (including, for example, abciximabs, anagrelides, cilostazols, clopidogrel bisulfates, dipyridamoles, epoprostenols, eptifibatides, tirofibans; colony stimulating factors (CSFs) (including, for example, Granulocyte CSFs and Granulocyte Macrophage CSFs); erythropoiesis stimulators (including, for example, erythropoietins such as darbepoetin alfas) and epoetin alfas; hemostatics and albumins (including, for example, aprotinins, combinations of antihemophilic factors and plasma, Desmopressin Acetates, and albumins); immune globulins, as well as hepatitis B immune globulins; thrombin inhibitors (including for example direct thrombin inhibitors and lepirudin), and drotrecogin alfas; anticoagulants (including, for example, dalteparins, enoxaparins and other heparins, and warfarins).

Exemplary antibodies or other therapeutic agents include, but are not limited to, Cetuximab (e.g., IMC-C225; Erbitux®); Trastuzumab (e.g., Herceptin®); Rituximab tin®); Alemtuzumab (e.g., Campath@; Campath-1H®; Mabcampath®); Panitumumab (e.g., ABX-EGF; Vectibix®); Ranibizumab (e.g., Lucentis®); Ibritumomab; Ibritumomab tiuxetan (e.g., Zevalin®); Tositumomab; Iodine I 131 Tositumomab (e.g., BEXXAR®); Catumaxomab (e.g., Removab®); Gemtuzumab; Gemtuzumab ozogamicin (e.g., Mylotarg®); Abatacept (e.g., CTLA4-Ig;

Orencia®); Belatacept (L104EA29YIg; LEA29Y; LEA); Ipilimumab (e.g., MDX-010; MDX-101); Tremelimumab (e.g., ticilimumab; CP-675,206); PRS-010 (see e.g., US20090042785); PRS-050 (see e.g., U.S. Pat. No. 7,585, 940; US20090305982); Aflibercept (VEGF Trap, AVE005; 5 Holash et al., (2002) PNAS 99:11393-11398); Volociximab (M200); F200 (Chimeric (human/murine) IgG4 Fab fragment of Volociximab (M200)); MORAb-009 Mouse/human chimeric IgG1(US20050054048); Soluble fusion protein: Anti-mesothelin Fv linked to a truncated Pseudomonas 10 exotoxin A (SS1P (CAT-5001); US20070189962); Cixutumumab (IMC-A12); Nimotuzumab (h-R3) (Spicer (2005) Curr OpinMol Ther 7:182-191); Zalutumumab (HuMax-EGFR; Lammerts van Bueren et al. (2008) PNAS 105:6109-14); Necitumumab IMC-11F8 (Li et al. (2008) Structure 15 16:216-227); Sym004 (Pedersen et al. 2010 Cancer Res 70:588-597); and mAb-425.

In particular, therapeutic agents include, but are not limited to, immunoglobulins, Interferon beta, Interferon alpha-2as, Interferon alpha-1s, Interferon alpha-n3s, Inter-20 feron beta-1, Interferon beta-1as, Interferon gamma-1bs, Peg-interferon alpha-2 and Peginterferon alpha-2bs, insulin, a bisphosphate (e.g., Pamidronates or Zoledronates), Docetaxels, Doxorubicins, Doxorubicin liposomals and bevacizumabs. 25

Other exemplary therapeutic agents that can be combined by co-administration and/or co-formulation with a modified PH20 polypeptide provided herein, include, but are not limited to, Adalimumabs, Agalsidase Betas, Alefacepts, Ampicillins, Anakinras, Antipoliomyelitic Vaccines, Anti- 30 Thymocytes, Azithromycins, Becaplermins, Caspofungins, Cefazolins, Cefepimes, Cefotetans, Ceftazidimes, Ceftriaxones, Cetuximabs, Cilastatins, Clavulanic Acids, Clindamycins, Darbepoetin Alfas, Daclizumabs, Diphtheria, Diphtheantitoxins, Diphtheria Toxoids, Efalizumabs, 35 ria Epinephrines, Erythropoietin Alphas, Etanercepts, Filgrastims, Fluconazoles, Follicle-Stimulating Hormones, Follitropin Alphas, Follitropin Betas, Fosphenytoins, Gadodiamides, Gadopentetates, Gatifloxacins, Glatiramers, GM-CSF's, Goserelins, Goserelin acetates, Granisetrons, Hae- 40 mophilus Influenza B's, Haloperidols, Hepatitis vaccines, Hepatitis A Vaccines, Hepatitis B Vaccines, Ibritumomab Tiuxetans, Ibritumomabs, Tiuxetans, Immunoglobulins, Hemophilus influenza vaccines, Influenza Virus Vaccines, Infliximabs, Insulins, Insulin Glargines, Interferons, Inter- 45 feron alphas, Interferon Betas, Interferon Gammas, Interferon alpha-2a's. Interferon alpha-2b's. Interferon alpha-1's. Interferon alpha-n3's, Interferon Betas, Interferon Beta-1a's, Interferon Gammas, Interferon alpha-consensus, Iodixanols, Iohexols, Iopamidols, Ioversols, Ketorolacs, 50 Laronidases, Levofloxacins, Lidocaines, Linezolids, Lorazepams, Measles Vaccines, Measles virus, Mumps viruses, Measles-Mumps-Rubella Virus Vaccines, Rubella vaccines, Medroxyprogesterones, Meropenems, Methylprednisolones, Midazolams, Morphines, Octreotides, Omalizumabs, 55 Ondansetrons, Palivizumabs, Pantoprazoles, Pegaspargases, Pegfilgrastims, Peg-Interferon Alfa-2a's, Peg-Interferon Alfa-2b's, Pegvisomants, Pertussis vaccines, Piperacillins, Pneumococcal Vaccines and Pneumococcal Conjugate Vaccines, Promethazines, Reteplases, Somatropins, Sulbactams, 60 Sumatriptans, Tazobactams, Tenecteplases, Tetanus Purified Toxoids, Ticarcillins, Tositumomabs, Triamcinolones, Triamcinolone Acetonides, Triamcinolone hexacetonides, Vancomycins, Varicella Zoster immunoglobulins, Varicella vaccines, other vaccines, Alemtuzumabs, Alitretinoins, 65 Allopurinols, Altretamines, Amifostines, Anastrozoles, Arsenics, Arsenic Trioxides, Asparaginases, Bacillus

Calmette-Guerin (BCG) vaccines, BCG Live, Bexarotenes, Bleomycins, Busulfans, Busulfan intravenous, Busulfan orals, Calusterones, Capecitabines, Carboplatins, Carmustines, Carmustines with Polifeprosans, Celecoxibs, Chlorambucils, Cisplatins, Cladribines, Cyclophosphamides, Cytarabines. Cytarabine liposomals, Dacarbazines, Dactinomycins, Daunorubicin liposomals, Daunorubicins, Daunomycins, Denileukin Diftitoxes, Dexrazoxanes, Docetaxels, Doxorubicins, Doxorubicin liposomals, Dromostanolone propionates, Elliott's B Solutions, Epirubicins, Epoetin alfas, Estramustines, Etoposides, Etoposide phosphates, Etoposide VP-16s, Exemestanes, Floxuridines, Fludarabines, Fluorouracils, 5-Fluorouracils, Fulvestrants, Gemcitabines, Gemtuzumabs, Ozogamicins, Gemtuzumab ozogamicins, Hydroxyureas, Idarubicins, Ifosfamides, Imatinib mesylates, Irinotecans, Letrozoles, Leucovorins, Levamisoles, Lomustines, CCNUs, Mechlorethamines, Nitrogen mustards, Megestrols, Megestrol acetates, Melphalans, L-PAMs, Mercaptopurines, 6-Mercaptopurines, Mesnas, Methotrexates, Methoxsalens, Mitomycins, Mitomycin C's, Mitotanes, Mitoxantrones, Nandrolones, Nandrolone Phenpropionates, Nofetumomabs, Oprelvekins, Oxaliplatins, Paclitaxels, Pamidronates, Pegademases, Pentostatins, Pipobromans, Plicamycins, Mithramycins, Porfimers, Porfimer sodiums, Procarbazines, Quinacrines, 25 Rasburicases, Rituximabs, Sargramostims, Streptozocins, Tales, Tamoxifens, Temozolomides, Teniposides, Testolactones, Thioguanines, 6-Thioguanines, Triethylenethiophosphoramides (Thiotepas), Topotecans, Toremifenes, Trastuzumabs, Tretinoins, Uracil Mustards, Valrubicins, Vinblastines, Vincristines, Vinorelbines, Zoledronates, Acivicins, Aclarubicins, Acodazoles, Acronines, Adozelesins, Aldesleukins, Retinoic Acids, Alitretinoins, 9-Cis-Retinoic Acids, Alvocidibs, Ambazones, Ambomycins, Ametantrones, Aminoglutethimides, Amsacrines, Anaxirones, Ancitabines, Anthramycins, Apaziquones, Argimesnas, Asperlins, Atrimustines, Azacitidines, Azetepas, Azotomycins, Banoxantrones, Batabulins, Batimastats, Benaxibines, Bendamustines, Benzodepas, Bicalutamides, Bietaserpines, Biricodars, Bisantrenes, Bisnafide Dimesylates, Bizelesins, Bortezomibs, Brequinars, Bropirimines, Budotitanes, Cactinomycins, Canertinibs, Caracemides, Carbetimers, Carboquones, Carmofurs, Carubicins, Carzelesins, Cedefingols, Cemadotins, Chlorambucils, Cioteronels, Cirolemycins, Crisnatols, Clanfenurs. Clofarabines. Decitabines. Dexniguldipines, Dexormaplatins, Dezaguanines, Diaziquones, Dibrospidiums, Dienogests, Dinalins, Disermolides, Dofequidars, Doxifluridines, Droloxifenes, Duazomycins, Ecomustines, Edatrexates, Edotecarins, Eflomithines, Elacridars, Elinafides, Elsamitrucins, Emitefurs, Enloplatins, Enpromates, Enzastaurins, Epipropidines, Eptaloprosts, Erbulozoles, Esorubicins, Etanidazoles, Etoglucids, Etoprines, Exisulinds, Fadrozoles, Fazarabines, Fenretinides, Fluoxymesterones, Flurocitabines, Fosquidones, Fostriecins, Fotretamines, Galarubicins, Galocitabines, Geroquinols, Gimatecans, Gimeracils, Gloxazones, Glufosfamides, Ilmofosines, Ilomastats, Imexons, Improsulfans, Indisulams, Inproquones, Interleukins, Interleukin-2s, recombinant Interleukins, Intoplicines, Iobenguanes, Iproplatins, Irsogladines, Ixabepilones, Ketotrexates, L-Alanosines, Lanreotides, Lapatinibs, Ledoxantrones, Leuprolides, Leuprorelins, Lexacalcitols, Liarozoles, Lobaplatins, Lometrexols, Lonafarnibs, Losoxantrones, Lurtotecans, Mafosfamides, Mannosulfans, Marimastats, Masoprocols, Maytansines, Mechlorethamines, Melengestrols, Melphalans, Menogarils, Mepitiostanes, Metesinds, Metomidates, Metoprines, Meturedepas, Miboplatins, Miproxifenes, Misonidazoles, Mitindomides, Mitocarcins, Mitocromins, Mitoflaxones, Mitogillins, Mitoguazones, Mitomalcins, Mitonafides, Mitoquidones, Mitospers, Mitozolomides, Mivobulins, Mizoribines, Mofarotenes, Mopidamols, Mubritinibs, Mycophenolic Acids, Nedaplatins, Neizarabines, Nemorubicins, 5 Nitracrines, Nocodazoles, Nogalamycins, Nolatrexeds, Nortopixantrones, Ormaplatins, Ortataxels, Oteracils, Oxisurans, Oxophenarsines, Patupilones, Peldesines, Peliomycins, Pelitrexols, Pemetrexeds, Pentamustines, Peplomycins, Perfosfamides, Perifosines, Picoplatins, Pinafides, Piposul-10 fans, Pirfenidones, Piroxantrones, Pixantrones, Plevitrexeds, Plomestanes, Porfiromycins, Prednimustines, Propamidines, Prospidiums, Pumitepas, Puromycins, Pyrazofurins, Ranimustines, Riboprines, Ritrosulfans, Rogletimides, Roquinimexs. Rufocromomycins. Sabarubicins. Safingols, 15 Satraplatins, Sebriplatins, Semustines, Simtrazenes, Sizofirans, Sobuzoxanes, Sorafenibs, Sparfosates, Sparfosic Acids, Sparsomycins, Spirogermaniums, Spiromustines, Spiroplatins, Squalamines, Streptonigrins, Streptovarycins, Sufosfamides, Sulofenurs, Tacedinalines, Talisomycins, Tal- 20 limustines, Tariquidars, Tauromustines, Tecogalans, Tegafurs, Teloxantrones, Temoporfins, Teroxirones, Thiamiprines, Tiamiprines, Tiazofurins, Tilomisoles, Tilorones, Timcodars, Timonacics, Tirapazamines, Topixantrones, Trabectedins, Ecteinascidin 743, Trestolones, Triciribines, 25 Trilostanes, Trimetrexates, Triplatin Tetranitrates, Triptorelins, Trofosfamides, Tubulozoles, Ubenimexs, Uredepas, Valspodars, Vapreotides, Verteporfins, Vinblastines, Vindesines, Vinepidines, Vinflunines, Vinformides, Vinglycinates, Vinleucinols, Vinleurosines, Vinrosidines, Vintriptols, Vinzolidines, Vorozoles, Xanthomycin A's, Guamecyclines, Zeniplatins, Zilascorbs [2-H], Zinostatins, Zorubicins, Zosuquidars, Acetazolamides, Acyclovirs, Adipiodones, Alatrofloxacins, Alfentanils, Allergenic extracts, Alpha 1-proteinase inhibitors, Alprostadils, Amikacins, Amino acids, 35 Aminocaproic acids, Aminophyllines, Amitriptylines, Amobarbitals, Amrinones, Analgesics, Anti-poliomyelitic vaccines, Anti-rabic serums, Anti-tetanus immunoglobulins, tetanus vaccines, Antithrombin Ills, Antivenom serums, Argatrobans, Arginines, Ascorbic acids, Atenolols, Atracu- 40 riums, Atropines, Aurothioglucoses, Azathioprines, Aztreonams, Bacitracins, Baclofens, Basiliximabs, Benzoic acids, Benztropines, Betamethasones, Biotins, Bivalirudins, Botulism antitoxins, Bretyliums, Bumetanides, Bupivacaines, Buprenorphines, Butorphanols, Calcitonins, Calcitriols, 45 Calciums, Capreomycins, Carboprosts, Camitines, Cefamandoles, Cefoperazones, Cefotaximes, Cefoxitins, Ceftizoximes, Cefuroximes, Chloramphenicols, Chloroprocaines, Chloroquines, Chlorothiazides, Chlorpromazines, Chondroitinsulfuric acids, Choriogonadotropin alfas, Chro- 50 miums, Cidofovirs, Cimetidines, Ciprofloxacins, Cisatracuriums, Clonidines, Codeines, Colchicines, Colistins, Collagens, Corticorelin ovine triflutates, Corticotrophins, Cosyntropins, Cyanocobalamins, Cyclosporines, Cysteines, Dacliximabs, Dalfopristins, Dalteparins, Danaparoids, Dan- 55 trolenes, Deferoxamines, Desmopressins, Dexamethasones, Dexmedetomidines, Dexpanthenols, Dextrans, Iron dextrans, Diatrizoic acids, Diazepams, Diazoxides, Dicyclomines, Digibinds, Digoxins, Dihydroergotamines, Diltiazems, Diphenhydramines, Dipyridamoles, Dobutamines, 60 Dopamines, Doxacuriums, Doxaprams, Doxercalciferols, Doxycyclines, Droperidols, Dyphyllines, Edetic acids, Edrophoniums, Enalaprilats, Ephedrines, Epoprostenols, Ergocalciferols, Ergonovines, Ertapenems, Erythromycins, Esmolols, Estradiols, Estrogenics, Ethacrynic acids, Etha- 65 nolamines, Ethanols, Ethiodized oils, Etidronic acids, Etomidates, Factor VIIIs, Famotidines, Fenoldopams, Fenta-

184

nyls, Flumazenils, Fluoresceins, Fluphenazines, Folic acids, Fomepizoles, Fomivirsens, Fondaparinuxs, Foscarnets, Fosphenytoins, Furosemides, Gadoteridols, Gadoversetamides, Ganciclovirs, Gentamicins, Glucagons, Glucoses, Glycines, Glycopyrrolates, Gonadorelins, Gonadotropin chorionics, Haemophilus B polysaccharides, Hemins, Herbals, Histamines, Hydralazines, Hydrocortisones, Hydromorphones, Hydroxocobalamins, Hydroxyzines, Hyoscyamines, Ibutilides, Imiglucerases, Indigo carmines, Indomethacins, Iodides, Iopromides, Iothalamic acids, Ioxaglic acids, Ioxilans, Isoniazids, Isoproterenols, Japanese encephalitis vaccines, Kanamycins, Ketamines, Labetalols, Lepirudins, Levobupivacaines, Levothyroxines, Lincomycins, Liothyronines, Luteinizing hormones, Lyme disease vaccines, Mangafodipirs, Manthtols, Meningococcal polysaccharide vaccines, Meperidines, Mepivacaines, Mesoridazines, Metaraminols, Methadones, Methocarbamols, Methohexitals, Methyldopates, Methylergonovines, Metoclopramides, Metoprolols, Metronidazoles, Minocyclines, Mivacuriums, Morrhuic acids, Moxifloxacins, Muromonab-CD3s, Mycophenolate mofetils, Nafcillins, Nalbuphines, Nalmefenes, Naloxones, Neostigmines, Niacinamides, Nicardipines, Nitroglycerins, Nitroprussides, Norepinephrines, Orphenadrines, Oxacillins, Oxymorphones, Oxytetracyclines, Oxytocins, Pancuroniums, Panthenols, Pantothenic acids, Papaverines, Peginterferon-alpha (e.g., interferon alpha 2a or 2b), Penicillin Gs, Pentamidines, Pentazocines, Pentobarbitals, Perflutrens, Perphenazines, Phenobarbitals, Phentolamines, Phenylephrines, Phenytoins, Physostigmines, Phytonadiones, Polymyxin bs, Pralidoximes, Prilocaines, Procainamides, Procaines, Prochlorperazines, Progesterones, Propranolols, Pyridostigmine hydroxides, Pyridoxines, Quinidines, Quinupristins, Rabies immunoglobulins, Rabies vaccines, Ranitidines, Remifentanils, Riboflavins, Rifampins, Ropivacaines, Samariums, Scopolamines, Seleniums, Sermorelins, Sincalides, Somatrems, Spectinomycins, Streptokinases, Streptomycins, Succinylcholines, Sufentanils, Sulfamethoxazoles, Tacrolimuses, Terbutalines, Teriparatides, Testosterones, Tetanus antitoxins, Tetracaines, Tetradecyl sulfates, Theophyllines, Thiamines, Thiethylperazines, Thiopentals, Thyroid stimulating hormones, Tinzaparins, Tirofibans, Tobramycins, Tolazolines, Tolbutamides, Torsemides, Tranexamic acids, Treprostinils, Trifluoperazines, Trimethobenzamides, Trimethoprims, Tromethamines, Tuberculins, Typhoid vaccines, Urofollitropins, Urokinases, Valproic acids, Vasopressins, Vecuroniums, Verapamils, Voriconazoles, Warfarins, Yellow fever vaccines, Zidovudines, Zincs, Ziprasidone hydrochlorides, Aclacinomycins, Actinomycins, Adriamycins, Azaser-6-Azauridines, Carzinophilins, Chromomycins, ines, Denopterins, 6-Diazo-5-Oxo-L-Norleucines, Enocitabines, Floxuridines, Olivomycins, Pirarubicins, Piritrexims, Pteropterins, Tegafurs, Tubercidins, Alteplases, Arcitumomabs, bevacizumabs, Botulinum Toxin Type A's, Botulinum Toxin Type B's, Capromab Pendetides, Daclizumabs, Dornase alfas, Drotrecogin alfas, Imciromab Pentetates, and Iodine-131's.

Delivery of Insulin

Methods provided herein include methods of co-administering a modified PH20 polypeptide and an insulin to increase subcutaneous delivery of the insulin, such as a fast-acting insulin (see e.g., U.S. Pat. Nos. 7,767,429; 7,846, 431; U.S. Publication No. US20090304665; and U.S. application Ser. Nos. 13/507,263; 13/507,262 and 13/507,261). Such methods include methods of direct administration, and pump and continuous infusion methods, including open and closed pump systems. For example, exemplary insulins that

50

can be administered with a modified PH20 hyaluronidase provided herein are fast-acting insulins or insulin analogs. For example, a co-administered insulin includes a regular insulin, insulin aspart, insulin lispro, insulin glulisine or other similar analog variants. Exemplary insulins are insu-5 lins that contain an A chain set forth in SEQ ID NO:862 and a B chain set forth in SEQ ID NO:863 or variants that contain one or more amino acid modifications compared to a human insulin set forth in SEQ ID NO: 862 and 863 (A and B chains). For example, exemplary insulin analogs are 10 known to one of skill in the art, and include, but are not limited to, those set forth in SEQ ID NO:862 (A-chain) and having a B-chain set forth in any of SEQ ID NOs: 865-867.

The co-formulations can be administered subcutaneously to treat any condition that is amenable to treatment with 15 insulin. Therapeutic uses include, but are not limited to, treatment for type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, and for glycemic control in critically ill patients. For example, the co-formulations of a fast acting insulin and hyaluronan degrading enzyme can be $\ ^{20}$ administered subcutaneously in discrete doses, such as via a syringe or insulin pen, prior to a meal as prandial insulin therapy in subjects with diabetes to achieve glycemic control. The co-formulations also can be administered subcutaneously or intraperitoneally using an insulin pump or in 25 the context of a closed loop system to continuously control blood glucose levels throughout the day and night and/or to control post-prandial glycemic excursions. It is within the skill of a treating physician to identify such diseases or conditions.

For any disease or condition, including all those exemplified above, for which a fast-acting insulin is indicated or has been used and for which other agents and treatments are available, the co-formulations can be used in combination therewith. Depending on the disease or condition to be 35 treated, exemplary combinations include, but are not limited to, combinations with anti-diabetic drugs, including, but not limited to, sulfonylureas, biguanides, meglitinides, thiazolidinediones, alpha-glucosidase inhibitors, peptide analogs, including glucagon-like peptide (GLP) analogs and, gastric 40 inhibitory peptide (GIP) analogs and DPP-4 inhibitors. In another example, the co-formulations of a fast acting insulin and modified PH20 polypeptide described herein can be administered in combination with, prior to, intermittently with, or subsequent to, one or more other insulins, including 45 fast-acting insulin, and basal-acting insulins.

2. Methods of Hyaluronan-Associated Diseases and Conditions (e.g., Tumors)

In particular, PH20 hyaluronidase can be used to treat hyaluronan-associated diseases or conditions. Typically, hyaluronan-associated diseases and conditions are associated with elevated hyaluronan expression in a tissue, cell, or body fluid (e.g., tumor tissue or tumor-associated tissue, 55 blood, or interstitial space) compared to a control, e.g., another tissue, cell or body fluid. The elevated hyaluronan expression can be elevated compared to a normal tissue, cell or body fluid, for example, a tissue, cell or body fluid that is analogous to the sample being tested, but isolated from a 60 different subject, such as a subject that is normal (i.e., does not have a disease or condition, or does not have the type of disease or condition that the subject being tested has), for example, a subject that does not have a hyaluronan-associated disease or condition. The elevated hyaluronan expres-65 sion can be elevated compared to an analogous tissue from another subject that has a similar disease or condition, but

whose disease is not as severe and/or is not hyaluronanassociated or expresses relatively less hyaluronan and thus is hyaluronan-associated to a lesser degree. For example, the subject being tested can be a subject with a hyaluronanassociated cancer, where the HA amounts in the tissue, cell or fluid are relatively elevated compared to a subject having a less severe cancer, such as an early stage, differentiated or other type of cancer. In another example, the cell, tissue or fluid contains elevated levels of hyaluronan compared to a control sample, such as a fluid, tissue, extract (e.g., cellular or nuclear extract), nucleic acid or peptide preparation, cell line, biopsy, standard or other sample, with a known amount or relative amount of HA, such as a sample, for example a tumor cell line, known to express relatively low levels of HA, such as exemplary tumor cell lines described herein that express low levels of HA, for example, the HCT 116 cell line, the HT29 cell line, the NCI H460 cell line, the DU145 cell line, the Capan-1 cell line, and tumors from tumor models generated using such cell lines.

Hyaluronan-associated diseases and conditions include those associated with high interstitial fluid pressure, such as disc pressure, proliferative disorders, such as cancer and benign prostatic hyperplasia, and edema. Edema can result from or be manifested in, for example, organ transplant, stroke or brain trauma. Proliferative disorders include, but are not limited to, cancer, smooth muscle cell proliferation, systemic sclerosis, cirrhosis of the liver, adult respiratory distress syndrome, idiopathic cardiomyopathy, lupus erythematosus, retinopathy, e.g., diabetic retinopathy or other retinopathies, cardiac hyperplasia, reproductive system associated disorders, such as benign prostatic hyperplasia (BPH) and ovarian cysts, pulmonary fibrosis, endometriosis, fibromatosis, hamartomas, lymphangiomatosis, sarcoidosis, desmoid tumors. Cancers include solid and lymphatic/blood tumors and metastatic disease, and undifferentiated tumors. The tumors amenable to treatment typically exhibit cellular and/or stromal expression of a hyaluronan, compared to a non-cancerous tissue of the same tissue type or compared to a non-metastatic tumor of the same tumor-type. Cancers include any one or more of ovarian cancer, in situ carcinoma (ISC), squamous cell carcinoma (SCC), prostate cancer, pancreatic cancer, other gastric cancers, non-small cell lung cancer, breast cancer, brain cancer and colon cancer.

Modified PH20 polypeptides provided herein, such as PEGylated forms thereof, can be used to treat tumors. Thus, in addition to its indirect anticancer effects, hvaluronidases also have direct anticarcinogenic effects. Hyaluronidase prevents growth of tumors transplanted into mice (De Maeyer et al., (1992) Int. J. Cancer 51:657-660) and inhibits tumor formation upon exposure to carcinogens (Pawlowski et al., (1979) Int. J. Cancer 23:105-109; Haberman et al., (1981) Proceedings of the 17th Annual Meeting of the American Society of Clinical Oncology, Washington, D.C., 22:105, abstract no. 415). PH20 hyaluronidase has been shown to treat various tumors (see e.g., U.S. Publication No. US2010/0003238 and U.S. application Ser. No. 13/135,817, published as U.S. Publication No. US20120020951).

The hyaluronan-rich cancer can be a cancer in which the cancer cells produce HALOs, cancers that have elevated expression of hyaluronan (as determined by immunostaining, e.g., histological staining of sections from the tumor), cancers that have elevated HAS2 (Hyaluronan synthase 2), cancers that do not produce hyaluronidase (HYAL1) in vitro. Hyaluronan-rich cancers can be identified by any method for assessing hyaluronan expression, and other known methods for assaying protein/mRNA expression.

Several hyaluronan-rich cancers have been identified. In some cases, hyaluronan expression correlates with poor prognosis, for example, decreased survival rate and/or recurrence-free survival rate, metastases, angiogenesis, cancer cell invasion into other tissues/areas, and other indicators of 5 poor prognosis. Such correlation has been observed, for example, in hyaluronan-rich tumors including ovarian cancer, SCC, ISC, prostate cancer, lung cancer, including nonsmall-cell lung cancer (NSCLC), breast cancer, colon cancer and pancreatic cancer (see, for example, Anttila et al., 10 Cancer Research, 60:150-155 (2000); Karvinen et al., British Journal ofDermatology, 148:86-94 (2003); Lipponen et al., Eur. Journal of Cancer, 849-856 (2001); Pirinen et al., Int. J. Cancer: 95: 12-17 (2001); Auvinen et al., American Journal of Pathology, 156(2):529-536 (2000); Ropponen et 15 al., Cancer Research, 58: 342-347 (1998)). Thus, hyaluronan-rich cancers can be treated by administration of a hyaluronidase, such as a soluble PH20, to treat one or more symptoms of the cancer. Hyaluronan-rich tumors include, but are not limited to those of the prostate, breast, colon, 20 ovarian, stomach, head and neck and other tumors and cancers.

Other hyaluronan-associated diseases or conditions that are associated with excess glycosaminoglycans and that can be treated with a modified PH20 polypeptide provided ²⁵ herein include, but are not limited to, cardiovascular disease (e.g., following ischemia reperfusion; in arteriosclerosis); vitrectomy and ophthalmic disorders and conditions (e.g., in methods to liquefy the vitreous humor of the eye; reduce postoperative pressure; other ocular surgical procedures ³⁰ such as glaucoma, vitreous and retina surgery and in corneal transplantation); in hypodermoclysis (i.e., infusion of fluids and electrolytes into the hypodermis of the skin); cosmetic applications (e.g., in the treatment of cellulite, "pigskin" edema or "orange peel" edema); organ transplantation (e.g., ³⁵ associated with interstitial edemas in connection with grafting of an organ); pulmonary disease.

3. Other Uses

In further examples of its therapeutic use, modified PH20 polypeptides provided herein, can be used for such purposes as an antidote to local necrosis from paravenous injection of necrotic substances such as *vinca* alkaloids (Few et al. (1987) *Amer. J. Matern. Child Nurs.* 12, 23-26), treatment of 45 ganglion cysts (Paul et al. (1997) *J Hand Surg.* 22 (2): 219-21) and treatment of tissue necrosis due to venous insufficiency (Elder et al. (1980) *Lancet* 648-649). Modified PH20 polypeptides also can be used to treat ganglion cysts (also known as a wrist cyst, Bible cyst, or dorsal tendon 50 cyst), which are the most common soft tissue mass of the hand and are fluid filled sacs that can be felt below the skin.

Modified PH20 polypeptides can be used in the treatment of spinal cord injury by degrading chondroitin sulfate proteoglycans (CSPGs). Following spinal cord injury, glial 55 scars containing CSPGs are produced by astrocytes. CSPGs play a crucial role in the inhibition of axon growth. In addition, the expression of CSPG has been shown to increase following injury of the central nervous system (CNS). Soluble PH20 also can be utilized for the treatment 60 of herniated disks in a process known as chemonucleolysis. Chondroitinase ABC, an enzyme cleaving similar substrates as hyaluronidase, can induce the reduction of intradiscal pressure in the lumbar spine. There are three types of disk injuries. A protruded disk is one that is intact but bulging. In 65 an extruded disk, the fibrous wrapper has torn and the NP has oozed out, but is still connected to the disk. In a

sequestered disk, a fragment of the NP has broken loose from the disk and is free in the spinal canal. Chemonucleolysis is typically effective on protruded and extruded disks, but not on sequestered disk injuries.

4. Contraception

Modified PH20 polypeptides provided herein can be used as vaccines in contraceptive applications. PH20 is present in the male reproductive tract, and is expressed in both the testis and epididymis and is present in sperm. PH20 µlays a role in fertilization by facilitating entry of the sperm through the cumulus layer surrounding the unfertilized egg. PH20 also is able to bind to hyaluronic acid (HA) on the zona pellucida during early phases of fertilization. This binding also initiates intracellular signaling that aids in the acrosome reaction. Immunization with PH20 has been shown to be an effective contraceptive in male guinea pigs (Primakoff et al. (1988) Nature 335:543-546, Tung et al. (1997) Biol. Reprod. 56:1133-1141). It also has been shown to be an effective contraceptive in female guinea pigs due to the generation of anti-PH20 antibodies that prevent sperm and egg binding. In examples herein, the modified PH20 polypeptides can be inactive enzymes, such as any described in Sections C.2. The polypeptides can be administered directly or can be administered as a recombinant virus to deliver the antigen.

I. EXAMPLES

The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

Example 1

Generation of Recombinant Human PH20 Hyaluronidase (Rhuph20)

A. Generation of a Soluble rHuPH20-Expressing Cell Line

A recombinant human PH20 hyaluronidase designated rHuPH20 was generated as described in published U.S. Publication No. US20110053247. Briefly, the pCI-PH20-IRES-DHFR-SV40pa (HZ24) plasmid (set forth in SEQ ID NO:5) was used to transfect Chinese Hamster Ovary (CHO cells) (see e.g., U.S. Pat. Nos. 7,767,429 and 7,781,607 and U.S. Publication No. 2006-0104968). The HZ24 µlasmid vector for expression of soluble rHuPH20 contains a pCI vector backbone (Promega), DNA encoding amino acids 1-482 of human PH20 hyaluronidase (SEO ID NO:2), an internal ribosomal entry site (IRES) from the ECMV virus (Clontech), and the mouse dihydrofolate reductase (DHFR) gene. The pCI vector backbone also includes DNA encoding the Beta-lactamase resistance gene (AmpR), an fl origin of replication, a Cytomegalovirus immediate-early enhancer/ promoter region (CMV), a chimeric intron, and an SV40 late polyadenylation signal (SV40). The DNA encoding the soluble rHuPH20 construct contains an NheI site and a Kozak consensus sequence prior to the DNA encoding the methionine at amino acid position 1 of the native 35 amino acid signal sequence of human PH20, and a stop codon following the DNA encoding the tyrosine corresponding to amino acid position 482 of the human PH20 hyaluronidase set forth in SEQ ID NO:2, followed by a BamHI restriction site.

15

20

35

45

Non-transfected DG44 CHO cells growing in GIBCO Modified CD-CHO media for DHFR(-) cells, supplemented with 4 mM Glutamine and 18 mL/L Plurionic F68/L (Gibco), were seeded at 0.5×10^6 cells/mL in a shaker flask in preparation for transfection. Cells were grown at 37° C. 5 in 5% CO₂ in a humidified incubator, shaking at 120 rpm. Exponentially growing non-transfected DG44 CHO cells were tested for viability prior to transfection.

Sixty million viable cells of the non-transfected DG44 CHO cell culture were pelleted and resuspended to a density of 2×10^7 cells in 0.7 mL of $2 \times$ transfection buffer ($2 \times$ HeBS: 40 mM Hepes, pH 7.0, 274 mM NaCl, 10 mM KCl, 1.4 mM Na₂HPO₄, 12 mM dextrose). To each aliquot of resuspended cells, 0.09 mL (250 µg) of the linear HZ24 µlasmid (linearized by overnight digestion with Cla I (New England Biolabs) was added, and the cell/DNA solutions were transferred into 0.4 cm gap BTX (Gentronics) electroporation cuvettes at room temperature. A negative control electroporation was performed with no plasmid DNA mixed with the cells. The cell/plasmid mixes were electroporated with a capacitor discharge of 330 V and 960 μF or at 350 V and 960 μF.

The cells were removed from the cuvettes after electroporation and transferred into 5 mL of Modified CD-CHO 25 media for DHFR(-) cells, supplemented with 4 mM Glutamine and 18 mL/L Plurionic F68/L (Gibco), and allowed to grow in a well of a 6-well tissue culture plate without selection for 2 days at 37° C. in 5% CO₂ in a humidified incubator.

Two days post-electroporation, 0.5 mL of tissue culture media was removed from each well and tested for the presence of hyaluronidase activity, using the microturbidity assay described in Example 8. The results are set forth in Table 6.

TABLE 6

	ase Activity of HZ. Is at 40 hours post-	24 Transfected DG44 transfection
	Dilution	Activity (Units/mL)
Transfection 1 330 V	1 to 10	0.25
Transfection 2 350 V	1 to 10	0.52
Negative Control	1 to 10	0.015

Cells from Transfection 2 (350V) were collected from the tissue culture well, counted and diluted to 1×10^4 to 2×10^4 viable cells per mL. A 0.1 mL aliquot of the cell suspension was transferred to each well of five, 96 well round bottom tissue culture plates. One hundred microliters of CD-CHO 50 media (GIBCO) containing 4 mM GlutaMAXTM_1 supplement (GIBCOTM, Invitrogen Corporation) and without hypoxanthine and thymidine supplements were added to the wells containing cells (final volume 0.2 mL). Ten clones were identified from the 5 plates grown without methotrex- 55 ate (Table 7).

TABLE 7

Hyaluronidase activity of identified clones						
Plate/Well ID	Relative Hyaluronidase					
1C3	261					
2C2	261					
3D3	261					
3E5	243	65				
3C6	174					

190

 Hyaluronidase activity of identified clones									
 Plate/Well ID	Relative Hyaluronidase								
2G8	103								
1B9	304								
2D9	273								
4D10	302								

Six HZ24 clones were expanded in culture and transferred into shaker flasks as single cell suspensions. Clones 3D3, 3E5, 2G8, 2D9, 1E11, and 4D10 were plated into 96-well round bottom tissue culture plates using a two-dimensional infinite dilution strategy in which cells were diluted 1:2 down the plate, and 1:3 across the plate, starting at 5000 cells in the top left hand well. Diluted clones were grown in a background of 500 non-transfected DG44 CHO cells per well, to provide necessary growth factors for the initial days in culture. Ten plates were made per subclone, with 5 plates containing 50 nM methotrexate and 5 µlates without methotrexate.

Clone 3D3 produced 24 visual subclones (13 from the no methotrexate treatment, and 11 from the 50 nM methotrexate treatment). Significant hyaluronidase activity was measured in the supernatants from 8 of the 24 subclones (>50 Units/mL), and these 8 subclones were expanded into T-25 tissue culture flasks. Clones isolated from the methotrexate treatment protocol were expanded in the presence of 50 nM methotrexate. Clone 3D35M was further expanded in 500 nM methotrexate giving rise to clones producing hyaluronidase activity in excess of 1,000 Units/mL in shaker flasks (clone 3D35M; or Gen1 3D35M). A master cell bank (MCB) of the 3D35M cells was then prepared.

B. Production Gen2 Cells Containing Soluble human PH20 (rHuPH20)

The Gen1 3D35M cell line described in Example 1.A was 40 adapted to higher methotrexate levels to produce generation 2 (Gen2) clones. 3D35M cells were seeded from established methotrexate-containing cultures into CD CHO medium containing 4 mM GlutaMAX-1™ and 1.0 µM methotrexate. The cells were adapted to a higher methotrexate level by growing and passaging them 9 times over a period of 46 days in a 37° C., 7% CO₂ humidified incubator. The amplified population of cells was cloned out by limiting dilution in 96-well tissue culture plates containing medium with 2.0 µM methotrexate. After approximately 4 weeks, clones were identified and clone 3E10B was selected for expansion. 3E10B cells were grown in CD CHO medium containing 4 mM GlutaMAX-1TM and 2.0 µM methotrexate for 20 passages. A master cell bank (MCB) of the 3E10B cell line was created and frozen and used for subsequent studies.

Amplification of the cell line continued by culturing 3E10B cells in CD CHO medium containing 4 mM Gluta-MAX-1TM and 4.0 µM methotrexate. After the 12* passage, cells were frozen in vials as a research cell bank (RCB). One vial of the RCB was thawed and cultured in medium 60 containing 8.0 µM methotrexate. After 5 days, the methotrexate concentration in the medium was increased to 16.0 μ M, then 20.0 μ M 18 days later. Cells from the 8* passage in medium containing 20.0 µM methotrexate were cloned out by limiting dilution in 96-well tissue culture plates containing CD CHO medium containing 4 mM GlutaMAX-1TM and 20.0 µM methotrexate. Clones were identified 5-6 weeks later and clone 2B2 was selected for expansion in

20

medium containing 20.0 µM methotrexate. After the 11th passage, 2B2 cells were frozen in vials as a research cell bank (RCB).

The resultant 2B2 cells are dihydrofolate reductase deficient (dhfr-) DG44 CHO cells that express soluble recombinant human PH20 (rHuPH20). The soluble PH20 is present in 2B2 cells at a copy number of approximately 206 copies/cell. Southern blot analysis of Spe I-, Xba I- and BamH I/Hind III-digested genomic 2B2 cell DNA using a rHuPH20-specific probe revealed the following restriction 10 digest profile: one major hybridizing band of ~7.7 kb and four minor hybridizing bands (~13.9, ~6.6, ~5.7 and ~4.6 kb) with DNA digested with Spe I; one major hybridizing band of ~5.0 kb and two minor hybridizing bands (~13.9 and ~6.5 kb) with DNA digested with Xba I; and one single 15 hybridizing band of ~1.4 kb observed using 2B2 DNA digested with BamH I/Hind III.

C. Production of Gen2 soluble rHuPH20 in 300 L Bioreactor Cell Culture

A vial of HZ24-2B2 was thawed and expanded from shaker flasks through 36 L spinner flasks in CD-CHO media (Invitrogen, Carlsbad, CA) supplemented with 20 μ M methotrexate and GlutaMAX-1TM (Invitrogen). Briefly, the 25 vial of cells was thawed in a 37° C. water bath, medium was added and the cells were centrifuged. The cells were resuspended in a 125 mL shake flask with 20 mL of fresh medium and placed in a 37° C., 7% CO2 incubaor. The cells were expanded up to 40 mL in the 125 mL shake flask. When the 30 cell density reached greater than 1.5×10⁶ cells/mL, the culture was expanded into a 125 mL spinner flask in a 100 mL culture volume. The flask was incubated at 37° C., 7% CO_2 . When the cell density reached greater than 1.5×10^6 cells/mL, the culture was expanded into a 250 mL spinner 35 flask in 200 mL culture volume, and the flask was incubated at 37° C., 7% CO₂. When the cell density reached greater than 1.5×10^6 cells/mL, the culture was expanded into a 1 L spinner flask in 800 mL culture volume and incubated at 37° C., 7% CO₂. When the cell density reached greater than 40 1.5×10^6 cells/mL the culture was expanded into a 6 L spinner flask in 5000 mL culture volume and incubated at 37° C., 7% CO_2 . When the cell density reached greater than 1.5×10^6 cells/mL the culture was expanded into a 36 L spinner flask in 32 L culture volume and incubated at 37° C., 7% CO2. 45

A 400 L reactor was sterilized and 230 mL of CD-CHO media were added. Before use, the reactor was checked for contamination. Approximately 30 L cells were transferred from the 36 L spinner flasks to the 400 L bioreactor (Braun) at an inoculation density of 4.0×105 viable cells per mL and 50 a total volume of 260 L. Parameters were: temperature setpoint, 37° C.; Impeller Speed 40-55 RPM; Vessel Pressure: 3 psi; Air Sparge 0.5-1.5 L/Min.; Air Overlay: 3 L/min. The reactor was sampled daily for cell counts, pH verification, media analysis, protein production and retention. Also, 55 during the run nutrient feeds were added. At 120 hrs (day 5), 10.4 L of Feed #1 Medium (4× CD-CHO+33 g/L Glucose+ 160 mL/L Glutamax-1TM+83 mL/L Yeastolate+33 mg/L rHuInsulin) was added. At 168 hours (day 7), 10.8 L of Feed #2 (2× CD-CHO+33 g/L Glucose+80 mL/L Glutamax-1TM+ 60 167 mL/L Yeastolate+0.92 g/L Sodium Butyrate) was added, and culture temperature was changed to 36.5° C. At 216 hours (day 9), 10.8 L of Feed #3 (1× CD-CHO+50 g/L Glucose+50 mL/L Glutamax-1TM+250 mL/L Yeastolate+ 1.80 g/L Sodium Butyrate) was added, and culture tempera-65 ture was changed to 36° C. At 264 hours (day 11), 10.8 L of Feed #4 (1× CD-CHO+33 g/L Glucose+33 mL/L Glutamax-

1TM+250 mL/L Yeastolate+0.92 g/L Sodium Butyrate) was added, and culture temperature was changed to 35.5° C. The addition of the feed media was observed to dramatically enhance the production of soluble rHuPH20 in the final stages of production. The reactor was harvested at 14 or 15 days or when the viability of the cells dropped below 40%. The process resulted in a final productivity of 17,000 Units per mL with a maximal cell density of 12 million cells/mL. At harvest, the culture was sampled for mycoplasma, bioburden, endotoxin and virus in vitro and in vivo, by Transmission Electron Microscopy (TEM) and enzyme activity.

The culture was pumped by a peristaltic pump through four Millistak filtration system modules (Millipore) in parallel, each containing a layer of diatomaceous earth graded to 4-8 m and a layer of diatomaceous earth graded to 1.4-1.1 m, followed by a cellulose membrane, then through a second single Millistak filtration system (Millipore) containing a layer of diatomaceous earth graded to 0.4-0.11 m and a layer of diatomaceous earth graded to <0.1 m, followed by a cellulose membrane, and then through a 0.22 µm final filter into a sterile single use flexible bag with a 350 L capacity. The harvested cell culture fluid was supplemented with 10 mM EDTA and 10 mM Tris to a pH of 7.5. The culture was concentrated 10× with a tangential flow filtration (TFF) apparatus using four Sartoslice TFF 30 kDa molecular weight cut-off (MWCO) polyether sulfone (PES) filter (Sartorious), followed by a 10× buffer exchange with 10 mM Tris, 20 mM Na₂SO₄, pH 7.5 into a 0.22 µm final filter into a 50 L sterile storage bag.

The concentrated, diafiltered harvest was inactivated for virus. Prior to viral inactivation, a solution of 10% Triton® X-100 detergent, and 3% tri (n-butyl) phosphate (TNBP) was prepared. The concentrated, diafiltered harvest was exposed to 1% Triton® X-100 detergent, and 0.3% TNBP for 1 hour in a 36 L glass reaction vessel immediately prior to purification on the Q column.

D. Purification of Gen2 Soluble rHuPH20

A Q Sepharose (Pharmacia) ion exchange column (9 L resin, H=29 cm, D=20 cm) was prepared. Wash samples were collected for a determination of pH, conductivity and endotoxin (LAL assay). The column was equilibrated with 5 column volumes of 10 mM Tris, 20 mM Na₂SO₄, pH 7.5. Following viral inactivation, the concentrated, diafiltered harvest was loaded onto the Q column at a flow rate of 100 cm/hr. The column was washed with 5 column volumes of 10 mM Tris, 20 mM Na₂SO₄, pH 7.5 and 10 mM Hepes, 50 mM NaCl, pH7.0. The protein was eluted with 10 mM Hepes, 400 mM NaCl, pH 7.0 into a 0.22 µm final filter into sterile bag. The eluate sample was tested for bioburden, protein concentration and hyaluronidase activity. A280 absorbance readings were taken at the beginning and end of the exchange.

Phenyl-Sepharose (Pharmacia) hydrophobic interaction chromatography was next performed. A Phenyl-Sepharose (PS) column (19-21 L resin, H=29 cm, D=30 cm) was prepared. The wash was collected and sampled for pH, conductivity and endotoxin (LAL assay). The column was equilibrated with 5 column volumes of 5 mM potassium phosphate, 0.5 M ammonium sulfate, and 0.1 mM CaCl₂, pH 7.0. The protein eluate from the Q sepharose column was supplemented with 2M ammonium sulfate, 1 M potassium phosphate and 1 M CaCl₂ stock solutions to yield final concentrations of 5 mM, 0.5 M and 0.1 mM, respectively. The protein was loaded onto the PS column at a flow rate of 100 cm/hr and the column flow thru collected. The column

was washed with 5 mM potassium phosphate, 0.5 M ammonium sulfate and 0.1 mM CaCl₂ pH 7.0 at 100 cm/hr and the wash was added to the collected flow thru. Combined with the column wash, the flow through was passed through a 0.22 µm final filter into a sterile bag. The flow through was 5 sampled for bioburden, protein concentration and enzyme activity.

An aminophenyl boronate column (Prometics) was prepared. The wash was collected and sampled for pH, conductivity and endotoxin (LAL assay). The column was 10 equilibrated with 5 column volumes of 5 mM potassium phosphate, 0.5 M ammonium sulfate. The PS flow through containing purified protein was loaded onto the aminophenyl boronate column at a flow rate of 100 cm/hr. The column was washed with 5 mM potassium phosphate, 0.5 M ammonium sulfate, pH 7.0. The column was washed with 20 mM bicine, 0.5 M ammonium sulfate, pH 9.0. The column was washed with 20 mM bicine, 100 mM sodium chloride, pH 9.0. The protein was eluted with 50 mM Hepes, 100 mM NaCl, pH 6.9 and passed through a sterile filter into a sterile bag. The eluted sample was tested for bioburden, protein concentration and enzyme activity.

The hydroxyapatite (HAP) column (Biorad) was prepared. The wash was collected and tested for pH, conductivity and endotoxin (LAL assay). The column was equilibrated with 5 mM potassium phosphate, 100 mM NaCl, 0.1 $\,^{25}$ mM CaCl₂, pH 7.0. The aminophenyl boronate purified protein was supplemented to final concentrations of 5 mM potassium phosphate and 0.1 mM CaCl₂ and loaded onto the HAP column at a flow rate of 100 cm/hr. The column was washed with 5 mM potassium phosphate, pH 7, 100 mM 30 NaCl, 0.1 mM CaCl₂. The column was next washed with 10 mM potassium phosphate, pH 7, 100 mM NaCl, 0.1 mM CaCl₂. The protein was eluted with 70 mM potassium phosphate, pH 7.0 and passed through a 0.22 µm sterile filter into a sterile bag. The eluted sample was tested for bioburden, protein concentration and enzyme activity.

The HAP purified protein was then passed through a virus removal filter. The sterilized Viosart filter (Sartorius) was first prepared by washing with 2 L of 70 mM potassium phosphate, pH 7.0. Before use, the filtered buffer was sampled for pH and conductivity. The HAP purified protein was pumped via a peristaltic pump through the 20 nM virus removal filter. The filtered protein in 70 mM potassium phosphate, pH 7.0 was passed through a 0.22 µm final filter into a sterile bag. The filtered sample was tested for protein concentration, enzyme activity, oligosaccharide, monosac- 45 charide and sialic acid profiling. The sample also was tested for process related impurities.

The protein in the filtrate was then concentrated to 10 mg/mL using a 10 kDa molecular weight cut off (MWCO) Sartocon Slice tangential flow filtration (TFF) system (Sar- 50 torius). The filter was first prepared by washing with 10 mM histidine, 130 mM NaCl, pH 6.0 and the permeate was sampled for pH and conductivity. Following concentration, the concentrated protein was sampled and tested for protein concentration and enzyme activity. A 6× buffer exchange 55 was performed on the concentrated protein into the final buffer: 10 mM histidine, 130 mM NaĈl, pH 6.0. Following buffer exchange, the concentrated protein was passed though a 0.22 µm filter into a 20 L sterile storage bag. The protein was sampled and tested for protein concentration, enzyme 60 activity, free sulfydryl groups, oligosaccharide profiling and osmolality. Lot number WRS2 was used as a standard in the assays described below, the results showed that the test description for appearance was clear and colorless; the pH was 7.4; the endotoxin level was <0.01 EU/mL; the osmolality was 308 mOsm/Kg; the density was 1.005 g/mL; the 65 rHuPH20 content was 1.3 ppm; and the hyaluronidase activity was 145 USP U/mL.

The sterile filtered bulk protein was then asceptically dispensed at 20 mL into 30 mL sterile Teflon vials (Nalgene). The vials were then flash frozen and stored at $-20\pm5^{\circ}$ C.

Example 2

GENERATION OF PH20 MUTANT LIBRARY

A. Cloning and Mutagenesis

In this example, a human hyaluronidase PH20 library was created by cloning DNA encoding human PH20 into a plasmid followed by transfection and protein expression.

The library was created by mutagenesis of a PH20 template that is a codon optimized version of PH20 with an Ig Kappa leader sequence. Specifically, for generating the library of variants, the HZ24-PH20(OHO)-IRES-SEAP expression vector (set forth in SEQ ID NO:4) was used as a template, which contains the sequence of nucleotides encoding PH20 set forth in SEQ ID NO: 1, which encodes a precursor PH20 set forth in SEQ ID NO:2 or a mature PH20 set forth in SEQ ID NO:3 lacking residues 1-22 corresponding to the IgK signal sequence. The backbone of the vector was derived from the original HZ24 vector containing the DHFR selection marker (see Example 1 and SEQ ID NO:5) with the addition of an IgK leader sequence and codon optimization. The expression vector also was modified to contain the gene for secreted alkaline phosphatase (SEAP). Hence, in addition to sequence encoding PH20, the HZ24-PH20(OHO)-IRES-SEAP expression vector also contains an internal ribosome entry site (EMCV IRES) that is linked to the coding sequence for the gene for secreted alkaline phosphatase (SEAP), and a single CMV promoter that drives expression of PH20 and SEAP in the construct. It also contains a gene for ampilcillin resistance. With reference to the sequence of nucleotides set forth in SEQ ID NO:4, the sequence of nucleotides encoding PH20 corresponds to nucleotides 1058-2464 (including the IgK leader sequence), the sequence of nucleotides encoding SEAP corresponds to nucleotides 2970-4529, and the ampicillin resistance gene corresponds to nucleotides 5778-6635.

The first library was made to generate encoded variant proteins wherein each of residues 23-469 of SEQ ID NO:2 (corresponding to residues 1-447 of SEQ ID NO:3 or residues 36-482 of SEQ ID NO:6) was changed to one of about 15 amino acid residues, such that each member contained a single amino change. The resulting library contained 6753 variant members, each containing a single amino acid mutation compared to residues 23-469 of SEQ ID NO:2 (corresponding to residues 1-447 of SEQ ID NO:3 or residues 36-482 of SEQ ID NO:6). Glycerol stocks of the resulting library were prepared and stored at -80° C. The amino acid replacements (mut) in each member are listed in Table 8 below, and correspond to amino acid replacements with reference to the sequence of amino acids of PH20 set forth in SEQ ID NO:3 (and SEQ ID NOs: 7 or 32-66, which are the mature sequence of PH20 or other C-terminally truncated fragments thereof). The corresponding mutated codons (cod) of each PH20 variant in the library are also listed in Table 8, and correspond to nucleotide residue changes in the corresponding encoding nucleotide for PH20 set forth as 1058-2464 of SEQ ID NOA4 Each member was expressed and screened for hyaluoridase activity as described below.

195 TABLE 8

					PH20	Variants					
mut	cod										
L001A L001C	GCG TGT	Y066S Y066T	AGT ACG	R132N R132P	AAT CCT	G198T G198V	ACT GTT	V265G V265H	GGT CAT	I331K I331L	AAG CTG
L001C	GAT	Y066V	GTG	R132Q	CAG	G198W	TGG	V265I	ATT	I331Q	CAG
L001E	GAG	I067C	TGT	R132S	AGT	G198Y	TAT	V265K	AAG	I331R	CGT
L001F L001G	TTT GGT	I067D I067E	GAT GAG	R132T R132V	ACT GTG	Y199A Y199C	GCG TGT	V265L V265M	CTG ATG	I331S I331T	AGT ACT
L001U	CAT	1067E 1067F	TTT	R132V R132Y	TAT	Y199E	GAG	V265N	AAT	1331W	TGG
L001K	AAG	I067G	GGG	S133A	GCT	Y199G	GGG	V265P	CCT	I331Y	TAT
L001N L001P	AAT CCG	I067H I067L	CAT TTG	S133D S133E	GAT GAG	Y199H Y199I	CAT ATT	V265Q V265R	CAG AGG	I332A I332C	GCT TGT
L001Q	CAG	1067E	AAT	S133F	TTT	Y199K	AAG	V265S	TCT	I332D	GAT
L001R	CGG	I067P	CCG	S133G	GGG	Y199L	CTT	V265W	TGG	I332E	GAG
L001S L001T	TCT ACG	I067Q I067R	CAG CGG	S133H S133I	CAT ATT	Y199N Y199P	AAT CCT	V265Y F266A	TAT GCG	I332F I332G	TTT GGT
L001V	GTG	1067T	ACG	\$133L	CTG	Y199Q	CAG	F266C	TGT	I332H	CAT
L001W	TGG	1067V	GTT	S133M	ATG	Y199R	AGG	F266D	GAT	I332K	AAG
N002A N002C	GCT TGT	I067W I067Y	TGG TAT	S133N S133P	AAT CCT	Y199S Y199T	TCG ACG	F266G F266H	GGG CAT	I332L I332N	CTG AAT
N002F	TTT	D068A	GCT	S133R	CGG	Y199W	TGG	F266L	CTT	I332P	CCT
N002G	GGG	D068C	TGT	S133T	ACT	N200A	GCT	F266M	CCG	I332R	AGG
N002H N002I	CAT ATT	D068E D068G	GAG GGG	S133V S133W	GTT TGG	N200D N200F	GAT CAG	F266P F266Q	ATG CAG	I332S I332T	AGT ACT
N0021 N002K	AAG	D008U D068H	CAC	I134A	GCT	N200G	GGT	F266R	CGG	1332Y	TAT
N002L	TTG	D068I	ATT	I134C	TGT	N200H	CAT	F266S	TCG	N333A	GCT
N002P N002Q	CCG CAG	D068K D068L	AAG TTG	I134D I134F	GAT TTT	N200K N200L	AAG CTG	F266T F266V	ACG GTG	N333E N333G	GAG GGT
N002Q	AGT	D068P	CCT	1134G	GGG	N200L	ATG	F266W	TGG	N333H	CAT
N002T	ACG	D068Q	CAG	I134H	CAT	N200P	CCT	F266Y	TAT	N333I	ATT
N002V N002W	GTT TGG	D068R D068S	CGG TCG	I134K I134L	AAG TTG	N200Q N200R	CAG AGG	A267D A267E	GAT GAG	N333K N333L	AAG CTG
N002Y	TAT	D0083 D068T	ACT	I134L I134P	CCT	N200K	TCT	A267G	GGT	N333M	ATG
F003A	GCT	D068V	GTG	I134Q	CAG	N200T	ACT	A267H	CAT	N333P	CCT
F003E F003G	GAG GGG	D068Y S069A	TAT GCT	I134R I134S	CGT TCG	N200V N200W	GTG TGG	A267I A267K	ATT AAG	N333R N333S	CGG AGT
F003H	CAT	S069C	TGT	I1345 I134T	ACT	N200Y	TAT	A267L	CTT	N333T	ACT
F003I	ATT	S069E	GAG	I134V	GTG	G201A	GCG	A267M	ATG	N333V	GTT
F003K F003L	AAG TTG	S069F S069G	TTT GGG	I134W E135A	TGG GCT	G201E G201F	GAG TTT	A267N A267P	AAT CCG	N333W N333Y	TGG TAT
F003M	ATG	S069I	ATT	E135C	TGT	G201H	CAT	A267R	AGG	V334A	GCT
F003N	AAT	S069L	CTT	E135D	GAT	G201K	AAG	A267S	TCT	V334C	TGT
F003P F003R	CCT CGT	S069M S069N	ATG AAT	E135F E135G	TTT GGG	G201L G201M	CTT ATG	A267T A267V	GTG ACT	V334D V334E	GAT GAG
F003S	TCG	S069P	CCT	E135H	CAT	G201N	AAT	A267W	TGG	V334G	GGG
F003T	ACT	S069R	CGT	E135K	AAG	G201P	CCT	Y268A	GCT	V334H	CAT
F003V F003Y	GTG TAT	S069T S069V	ACG GTT	E135L E135N	TTG AAT	G201Q G201R	CAG CGT	Y268C Y268F	TGT TTT	V334L V334M	TTG ATG
R004A	GCG	S069W	TGG	E135P	CCT	G201K	TCG	Y268G	GGG	V334N	AAT
R004D	GAT	S069Y	TAT	E135Q	CAG	G201T	ACG	Y268H	CAT	V334P	CCT
R004E R004F	GAG TTT	I070A I070C	GCT TGT	E135R E135S	CGG TCT	G201V G201W	GTG TGG	Y268K Y268L	AAG CTT	V334Q V334R	CAG AGG
R004G	GGG	1070E	TTT	E135W	TGG	S202A	GCG	Y268N	AAT	V334S	TCT
R004I	ATT	I070G	GGG	E135Y	TAT	S202E	GAG	Y268P	CCT	V334T	ACT
R004L R004M	TTG ATG	I070H I070K	CAT AAG	L136A L136C	GCT TGT	S202F S202G	TTT GGT	Y268Q Y268R	CAG CGT	V334Y T335A	TAT GCT
R004N	AAT	1070L	TTG	L136D	GAT	S202G	CAT	Y268S	TCG	T335C	TGT
R004P	CCT	1070N	AAT	L136F	TTT	S202K	AAG	Y268T	ACT	T335F	TTT
R004S R004T	TCT ACG	I070P I070Q	CCG CAG	L136G L136H	GGT CAT	S202M S202N	ATG AAT	Y268V Y268W	GTG TGG	T335G T335H	GGT CAT
R0041 R004V	GTG	1070Q 1070R	CGT	L136I	ATT	S202P	CCT	T269A	GCT	T335I	ATT
R004W	TGG	1070S	TCT	L136M	ATG	S202Q	CAG	T269C	TGT	T335K	AAG
R004Y A005D	TAT GAT	I070T I070V	ACT GTT	L136N L136P	AAT CCT	S202R S202T	CGT ACG	T269D T269E	GAT GAG	T335L T335N	TTG AAT
A005G	GGG	I070Y	TAT	L136Q	CAG	S202V	GTT	T269G	GGT	T335P	CCT
A005H	CAT	T071A	GCT	L136R	CGT	S202W	TGG	T269K	AAG	T335Q	CAG
A005I A005L	ATT CTT	T071C T071D	TGT GAT	L136S L136T	TCG ACT	S202Y C203A	TAT GCG	T269L T269M	CTG ATG	T335S T335V	TCT GTG
A005L A005M	ATG	T071E	GAG	L136W	TGG	C203A C203D	GAT	T269N	AAT	T335W	TGG
A005N	AAT	T071G	GGG	V137A	GCT	C203E	GAG	T269P	CCG	T335Y	TAT
A005P A005Q	CCG CAG	T071H T071L	CAT TTG	V137C V137E	TGT GAG	C203G C203H	GGG CAT	T269Q T269R	CAG AGG	L336A L336E	GCT GAG
A005Q A005R	AGG	T071L	ATG	V137E V137F	TTT	C203H C203L	CTT	T269K	TCG	L336F	TTT
A005S	TCG	T071N	AAT	V137G	GGG	C203M	ATG	T269V	GTG	L336G	GGG
A005T A005V	ACG GTG	T071P T071Q	CCT CAG	V137H V137I	CAT ATT	C203N C203P	AAT CCG	T269Y R270A	TAT GCT	L336H L336K	CAT AAG
A005V A005W	TGG	T071Q	CGG	V137L	TTG	C203P C203Q	CAG	R270A R270C	TGT	L336M	ATG
A005Y	TAT	T071S	TCG	V137N	AAT	C203R	AGG	R270D	GAT	L336N	AAT

TABLE 8-continued

	PH20 Variants										
mut	cod	mut	cod	mut	cod	mut	cod	mut	cod	mut	cod
P006A	GCG	T071V	GTG	V137P	CCT	C203S	AGT	R270E	GAG	L336P	CCT
P006D P006E	GAT GAG	T071Y G072A	TAT GCT	V137Q V137R	CAG CGT	C203T C203V	ACT GTG	R270F R270G	TTT GGG	L336R L336S	AGG TCT
P006F	TTT	G072C	TGT	V137S	TCT	C203W	TGG	R270H	CAT	L336T	ACT
P006G	GGG	G072D	GAT	V137T	ACT	F204A	GCG	R270I	ATT	L336V	GTG
P006H P006K	CAT AAG	G072E G072F	GAG TTT	V137W V137Y	TGG TAT	F204C F204E	TGT GAG	R270M R270N	ATG AAT	L336W L336Y	TGG TAT
P006L	CTT	G072H	CAT	Q138A	GCT	F204G	GGG	R270P	CCT	A337C	TGT
P006N	AAT	G072I	ATT	Q138C	TGT	F204H	CAT	R270Q	CAG	A337F	TTT
P006Q P006R	CAG AGG	G072K G072L	AAG TTG	Q138E Q138F	GAG TTT	F204I F204K	ATT AAG	R270S R270T	TCG ACT	A337G A337H	GGG CAT
P006S	AGT	G072M	ATG	Q138G	GGG	F204L	CTT	R270V	GTG	A337I	ATT
P006T	ACG	G072P	CCT	Q138H	CAT	F204M	ATG	R270Y	TAT	A337K	AAG
P006V P006W	GTG TGG	G072Q G072R	CAG CGG	Q138I Q138L	ATT TTG	F204P F204Q	CCT CAG	I271A I271D	GCT GAT	A337L A337M	TTG ATG
P006Y	TAT	G072S	TCT	Q138M	ATG	F204R	AGG	I271E	GAG	A337N	AAT
P007A	GCT	G072T	ACT	Q138N	AAT	F204S	AGT	I271F	TTT	A337P	CCT
P007C P007D	TGT GAT	G072V G072W	GTG TGG	Q138R Q138S	CGT AGT	F204T F204V	ACT GTG	I271G I271H	GGG CAT	A337R A337S	CGG TCT
P007F	TTT	G072Y	TAT	Q138V	GTT	F204W	TGG	I271K	AAG	A337T	ACT
P007G	GGT	V073A	GCG	Q138W	TGG	N205A	GCG	I271L	CTT	A337V	GTT
P007H P007I	CAT ATT	V073C V073D	TGT GAT	Q138Y Q139A	TAT GCT	N205D N205E	GAT GAG	I271M I271P	ATG CCT	A337W A338C	TGG TGT
P007K	AAG	V073E	TTT	Q139C	TGT	N205E	TTT	I271R	AGG	A338D	GAT
P007L	TTG	V073G	GGG	Q139D	GAT	N205G	GGG	I271S	AGT	A338E	GAG
P007M P007Q	ATG CAG	V073H V073K	CAT AAG	Q139E Q139F	GAG TTT	N205K N205L	AAG CTG	I271T I271V	ACT GTT	A338F A338G	TTT GGG
P007R	CGG	V073L	CTT	Q139G	GGG	N205M	ATG	1271W	TGG	A338H	CAT
P007S	AGT	V073M	ATG	Q139H	CAT	N205P	CCT	V272A	GCT	A338I	ATT
P007T P007V	ACT GTG	V073P V073Q	CCG CAG	Q139K Q139L	AAG CTG	N205R N205S	AGG TCG	V272C V272D	TGT GAT	A338K A338L	AAG CTT
P007W	TGG	V073R	TGG	Q139M	ATG	N205T	ACG	V272E	GAG	A338P	CCT
P007Y	TAT	V073S	TCG	Q139P	CCT	N205V	GTG	V272G	GGG	A338Q	CAG
V008A V008D	GCT GAT	V073T V073W	ACG CGG	Q139R Q139S	CGT TCT	N205W N205Y	TGG TAT	V272H V272K	CAT AAG	A338R A338S	CGT TCG
V008E	GAG	T074A	GCT	Q139T	ACT	V206C	TGT	V272L	TTG	A338T	ACT
V008G	GGT	T074C	TGT	Q139V	GTG	V206D	GAT	V272M	ATG	A338V	GTG
V008H V008I	CAT ATT	T074E T074F	GAG TTT	Q140A Q140C	GCT TGT	V206F V206G	TTT GGG	V272N V272P	AAT CCT	K339D K339E	GAT GAG
V008L	TTG	T074G	GGT	Q140D	GAT	V206H	CAT	V272R	AGG	K339F	TTT
V008M	ATG	T074H	CAT	Q140F	TTT	V206I	ATT	V272S	TCG	K339G	GGG
V008N V008P	AAT CCT	T074K T074L	AAG TTG	Q140G Q140H	GGG CAT	V206K V206L	AAG CTT	V272T V272W	ACT TGG	K339H K339L	CAT CTG
V008Q	CAG	T074M	ATG	Q140I	ATT	V206M	ATG	F273A	GCT	K339M	ATG
V008R	CGG	T074N	AAT	Q140K	AAG	V206P	CCG	F273C	TGT	K339N	AAT
V008S V008T	TCT ACT	T074P T074R	CCG CGG	Q140L Q140M	TTG ATG	V206Q V206R	CAG CGG	F273D F273G	GAT GGG	K339P K339R	CCT CGG
V008W	TGG	T074S	TCG	Q140R	CGG	V206S	TCT	F273H	CAT	K339S	AGT
I009A I009C	GCT TGT	T074V T074W	GTG TGG	Q140S Q140V	AGT GTG	V206T V206Y	ACG TAT	F273I F273L	ATT CTG	K339T K339V	ACT GTT
1009C 1009D	GAT	V075A	GCG	Q140V Q140W	TGG	E207A	GCT	F273L F273P	CCT	K339W	TGG
I009E	GAG	V075C	TGT	Q140Y	TAT	E207F	TTT	F273Q	CAG	K339Y	TAT
I009G I009H	GGG CAT	V075D V075F	GAT TTT	N141A N141D	GCT GAT	E207G E207H	GGG CAT	F273R F273S	CGG TCG	M340A M340C	GCT TGT
1009H 1009K	AAG	V075G	GGG	N141D N141E	GAG	E207H E207I	ATT	F2735 F273T	ACG	M340C M340D	GAT
1009L	CTT	V075H	CAT	N141F	TTT	E207K	AAG	F273V	GTT	M340E	GAG
I009N I009P	AAT CCT	V075L V075M	CTT ATG	N141G N141H	GGT CAT	E207L E207M	TTG ATG	F273W F273Y	TGG TAT	M340F M340G	TTT GGG
1009P 1009Q	CAG	V075N	AAT	N141L	TTG	E207M E207P	CCG	T2731 T274A	GCG		CAT
1009R	CGG	V075P	CCG	N141M	ATG	E207Q	CAG	T274C	TGT	M340K	AAG
I009S I009T	AGT ACG	V075Q V075R	CAG CGT	N141P N141Q	CCT CAG	E207R E207S	AGG TCT	T274E T274F	GAG ATG	M340L M340P	CTG CCT
10091 1009V	GTT	V075S	TCT	N141Q	CGT	E2073 E207T	ACG	T274G	GGG		CGG
P010D	GAT	V075T	ACT	N141S	TCT	E207V	GTT	T274H	CAT	M340S	TCG
P010E P010F	GAG TTT	V075W V075Y	TGG TAT	N141T N141V	ACT GTT	E207W I208A	TGG GCT	T274L T274N	CTG AAT	M340T M340V	ACT GTG
P010G	GGT	N076A	GCT	N141W	TGG	1208C	TGT	T274P	CCT		TGG
P010H	CAT	N076C	TGT	N141Y	TAT	1208D	GAT	T274Q	CAG	C341A	GCT
P010I P010L	ATT CTT	N076D N076F	GAT TTT	V142C V142D	TGT GAT	I208E I208G	GAG GGG	T274R T274S	CGT AGT	C341E C341G	GAG GGG
P010M	ATG	N076G	GGG	V142E	GAG	I208K	AAG	T274V	GTT	C341H	CAT
P010N	AAT	N076I	ATT	V142G	GGG	1208L	TTG	T274W	TGG	C341K	AAG
P010Q P010R	CAG CGG	N076K N076L	AAG CTG	V142H V142I	CAT ATT	I208M I208P	ATG CCG	T274Y D275A	TAT GCT	C341L C341M	TTG ATG
P010S	TCG	N076P	CCT	V142K	AAG	1208Q	CAG	D275C	TGT	C341N	AAT
P010T	ACT	N076Q	CAG	V142L	TTG	I208R	CGT	D275E	GAG	C341Q	CAG

TABLE	8-continued
-------	-------------

					PH20	Variants					
mut	cod	mut	cod	mut	cod	mut	cod	mut	cod	mut	cod
P010W	TGG	N076R	CGT	V142M	ATG	1208S	AGT	D275F	TTT	C341R	AGG
P010Y N011A	TAT GCG	N076S N076T	AGT ACT	V142N V142P	AAT CCT	I208T I208V	ACG GTG	D275G D275I	GGG ATT	C341S C341T	TCT ACT
N011C	TGT	N076V	GTT	V142Q	CAG	1208W	TGG	D275K	AAG	C341V	GTT
N011D	GAT	N076W	TGG	V142R	CGG	K209A	GCG	D275L	CTT	C341W	TGG
N011E	GAG	G077D	GAT	V142S	AGT	K209C	TGT	D275M	ATG	C341Y	TAT
N011F N011G	TTT GGG	G077E G077F	GAG TTT	V142T Q143C	ACT TGT	K209D K209E	GAT GAG	D275Q D275R	CAG CGT	S342A S342D	GCT GAT
N011H	CAT	G077H	CAT	Q143E	GAG	K209E	TTT	D2758	TCG	S342E	GAG
N011I	ATT	G077K	AAG	Q143F	TTT	K209G	GGT	D275T	ACT	S342F	TTT
N011K	AAG	G077L	TTG	Q143G	GGG	K209L	CTG	D275V	GTG	S342G	GGG
N011L N011P	CTG CCG	G077M G077N	ATG AAT	Q143H Q143I	CAT ATT	K209N K209P	AAT CCG	D275W Q276C	TGG TGT	S342H S342I	CAT ATT
N011S	TCG	G077P	CCG	Q143K	AAG	K209R	CGG	Q276D	GAT	S342K	AAG
N011T	ACG	G077Q	CAG	Q143L	TTG	K209S	AGT	Q276E	GAG	S342L	TTG
N011W N011Y	TGG TAT	G077R G077S	CGT TCG	Q143M Q143N	ATG AAT	K209T K209V	ACT GTT	Q276F Q276G	TTT GGG	S342M S342P	ATG CCT
V012A	GCT	G077T	ACG	Q143R	CCT	K209W	TGG	Q276H	CAT	S342Q	CAG
V012D	GAT	G077V	GTG	Q143R	CGG	K209Y	TAT	Q276I	ATT	S342R	CGG
V012E	GAG	G077Y	TAT	Q143S	TCG	R210A	GCG	Q276L	CTT	S342T	ACT
V012G V012H	GGG CAT	G078A G078C	GCG TGT	Q143T Q143V	ACT GTG	R210C R210D	TGT GAT	Q276M Q276P	ATG CCT	S342Y Q343C	TAT TGT
V012I1 V012I	ATT	G078D	GAT	Q143V Q143Y	TAT	R210D	GAG	Q276R	CGT	Q343D	GAT
V012K	AAG	G078H	CAT	L144A	GCT	R210G	GGT	Q276S	AGT	Q343E	GAG
V012L	CTT	G078I	ATT	L144E	GAG	R210K	AAG	Q276V	GTT	Q343F	TTT
V012M V012N	ATG AAT	G078K G078L	AAG TTG	L144F L144G	TTT GGG	R210L R210M	CTG ATG	Q276W Q276Y	TGG TAT	Q343G Q343I	GGG ATT
V012P	CCG	G078M	ATG	L144I	ATT	R210N	AAT	V277A	GCT	Q343L	CTT
V012R	AGG	G078P	CCG	L144K	AAG	R210P	CCT	V277C	TGT	Q343M	ATG
V012S V012T	TCG ACT	G078Q G078R	CAG AGG	L144N L144P	AAT CCT	R210S R210T	TCG ACT	V277D V277E	GAT GAG	Q343P Q343R	CCT AGG
V0121 V012W	TGG	G078K	TCG	L144Q	CAG	R2101 R210V	GTG	V277G	GGG	Q343S	AGT
P013A	GCT	G078T	ACT	L144R	CGT	R210W	TGG	V277H	CAT	Q343T	ACT
P013E	GAG	G078V	GTG	L144S	TCT	R210Y	TAT	V277K	AAG	Q343V	GTG
P013F P013G	TTT GGG	G078Y I079A	TAT GCT	L144T L144V	ACT GTT	N211A N211C	GCG TGT	V277L V277M	TTG ATG	Q343W Q343Y	TGG TAT
P013H	CAT	1079D	GAT	L144W	TGG	N211F	TTT	V277N	AAT	V344E	GAG
P013I	ATT	1079F	TTT	L144Y	TAT	N211G	GGG	V277Q	CAG	V344F	TTT
P013L P013M	CTT ATG	I079G I079H	GGG CAT	S145A S145C	GCT TGT	N211H N211I	CAT ATT	V277R V277S	AGG TCT	V344G V344H	GGG CAT
P013Q	CAG	1079K	AAG	S145D	GAT	N211K	AAG	V277T	ACT	V344I	ATT
P013R	CGT	I079L	TTG	S145E	GAG	N211L	CTG	V277Y	TAT	V344L	CTG
P013S	TCG	1079N	AAT	S145F	TTT	N211M	ATG	L278A	GCT	V344M	ATG
P013T P013V	ACT GTG	I079P I079R	CCG CGT	S145G S145H	GGG CAT	N211P N211R	CCT CGG	L278E L278F	GAG TTT	V344N V344P	AAT CCT
P013W	TGG	1079S	AGT	S145L	TTG	N211S	AGT	L278G	GGG	V344Q	CAG
P013Y	TAT	1079T	ACT	S145M	ATG	N211T	ACT	L278H	CAT	V344R	CGT
F014A F014D	GCG GAT	I079V I079W	GTT TGG	S145N S145P	AAT CCT	N211V N211W	GTT TGG	L278I L278K	ATT AAG	V344S V344T	TCG ACT
F014E	GAG	1079Y	TAT	S145R	CGT	D212A	GCT	L278M	TTT	V344W	TGG
F014G	GGT	P080A	GCG	S145T	ACT	D212E	GAG	L278N	AAT	V344Y	TAT
F014H F014I	CAT ATT	P080D P080E	GAT GAG	S145V S145W	GTT TGG	D212G D212H	GGG CAT	L278P L278R	CCG CGT	L345A L345C	GCT TGT
F0141 F014K	AAG	P080E P080F	TTT	L146A	GCT	D212H D212I	ATT	L278K L278S	TCT	L345D	GAT
F014M	ATG	P080G	GGG	L146C	TGT	D212K	AAG	L278T	ACT	L345E	GAG
F014N	AAT	P080I	ATT	L146E	GAG	D212L	CTG	L278V	GTT	L345G	GGG
F014P F014O	CCT CAG	P080K P080L	AAG CTT	L146G L146H	GGG CAT	D212M D212N	ATG AAT	L278Y K279A	TAT GCG	L345H L345K	CAT AAG
F014Q	CGG	P080M	ATG	L146I	ATT	D212R	CCT	K279C	TGT	L345N	AAT
F014T	ACT	P080N	AAT	L146K	AAG	D212Q	CAG	K279D	GAT	L345P	CCT
F014V F014W	GTG TGG	P080R P080S	AGG TCT	L146N L146P	AAT CCT	D212S D212T	TCG ACT	K279F K279G	TTT GGG	L345Q L345R	CAG CGT
L014W	GCG	P0803 P080T	ACG	L146P	CAG	D2121 D212V	GTG	K279G K279H	CAT	L345K L345T	ACT
L015E	GAG	P080V	GTG	L146R	CGG	D212W	TGG	K279L	CTG	L345V	GTT
L015F	TTT	P080Y	TAT	L146S	TCG	D213A	GCT	K279P	CCT	L345W	TGG
L015G L015K	GGG AAG	Q081A Q081C	GCT TGT	L146T L146V	ACT GTT	D213E D213G	GAG GGG	K279Q K279R	CAG AGG	L345Y C346A	TAT GCT
L015K	ATG	Q081C Q081E	GAG	L146V L146Y	TAT	D2130 D213H	CAT	K279K K279S	TCT	C346A C346D	GAT
L015N	AAT	Q081F	TTT	T147A	GCT	D213K	AAG	K279T	ACG	C346F	TTT
L015P	CCG	Q081G	GGG	T147C	TGT	D213L	CTG	K279V	GTG	C346G	GGG
L015Q L015R	CAG CGG	Q081H Q081L	CAT CTG	T147D T147F	GAT TTT	D213M D213N	ATG AAT	K279W K279Y	TGG TAT	C346I C346K	ATT AAG
L015S	TCG	Q081M	ATG	T147G	GGT	D213P	CCT	F280D	GAT	C346L	CTT
L015T	ACT	Q081N	AAT	T147I	ATT	D213Q	CAG	F280E	GAG	C346M	ATG
L015V L015W	GTT TGG	Q081P Q081R	CCG AGG	T147L T147M	CTT ATG	D213R D213S	CGT TCG	F280G F280H	GGG CAT	C346P C346Q	CCT CAG
LUIJW	100	YOUIK	100	1 1 - 7 / 191		02130	100	1 20011	CAI	C.540Q	0.10

					PH20	Variants					
mut	cod	mut	cod	mut	cod	mut	cod	mut	cod	mut	cod
L015Y	TAT	Q081S	TCT	T147P	CCT	D213V	GTG	F280I	ATT	C346R	CGG
W016A W016C	GCG TGT	Q081V Q081W	GTT TGG	T147Q T147R	CAG CGT	D213W D213Y	TGG TAT	F280L F280M	TTG ATG	C346S C346T	TCT ACT
W016D	GAT	Q081 W	TAT	T147K	AGT	L2131	GCG	F280N	AAT	C346V	GTG
W016E	GAG	K082A	GCT	T147V	GTT	L214C	TGT	F280P	CCT	C346W	TGG
W016F	TTT	K082E	GAG	T147W	TGG	L214D	GAT	F280Q	CAG	Q347A	GCT
W016G	GGT	K082G	GGT	T147Y	TAT	L214E	GAG	F280R	CGT	Q347C	TGT
W016H W016K	CAT AAG	K082H K082I	CAT ATT	E148C E148F	TGT TTT	L214G L214H	GGG CAT	F280S F280T	TCG ACT	Q347E Q347F	GAG TTT
W016L	CTT	K0821 K082L	CTT	E148G	GGG	L214II L214K	AAG	F280V	GTG	Q347G	GGT
W016M	ATG	K082M	ATG	E148H	CAT	L214N	AAT	F280W	TGG	Q347I	ATT
W016P	CCT	K082N	AAT	E148I	ATT	L214P	CCG	L281A	GCG	Q347L	TTG
W016R	CGT	K082P	CCT	E148K	AAG	L214Q	CAG	L281D	GAT	Q347M	ATG
W016S W016T	TCG ACT	K082Q K082R	CAG CGT	E148L E148P	CTG CCT	L214R L214S	CGG TCG	L281F L281G	TTT GGT	Q347P Q347R	CCT AGG
W016Y	TAT	K082K	AGT	E148Q	CAG	L2143 L214T	ACG	L281U	CAT	Q347S	TCT
A017D	GAT	K082T	ACT	E148R	CGG	L214V	GTG	L281I	ATT	Q347T	ACT
A017E	GAG	K082V	GTG	E148S	TCT	L214Y	TAT	L281K	AAG	Q347V	GTG
A017G	GGG	K082W	TGG	E148T	ACT	S215A	GCT	L281N	AAT	Q347W	TGG
A017H A017I	CAT ATT	K082Y I083E	TAT GAG	E148V E148W	GTG TGG	S215C S215D	TGT GAT	L281P L281Q	CCG CAG	Q347Y E348C	TAT TGT
A017L	CTT	1083E 1083F	TTT	E148W E148Y	TAT	S215D S215E	GAG	L281Q L281R	CGG	E348C E348D	GAT
A017N	AAT	10031 1083G	GGT	A149C	TGT	S215E	GGG	L281S	AGT	E348G	GGT
A017P	CCG	I083H	CAT	A149E	GAG	S215H	CAT	L281V	GTT	E348H	CAT
A017Q	CAG	I083K	AAG	A149F	TTT	S215K	AAG	L281W	TGG	E348I	ATT
A017R	AGG	1083L	CTG	A149G	GGT	S215L	TTG	L281Y	TAT	E348L	TTG
A017S A017T	TCG ACG	I083N I083P	AAT CCT	A149K A149L	AAG TTG	S215M S215P	ATG CCG	S282A S282C	GCG TGT	E348M E348P	ATG CCT
A017V	GTG	1083Q	CAA	A149M	ATG	S2150	CAG	S282D	GAT	E348Q	CAG
A017W	TGG	1083R	CGT	A149P	CCT	S215R	CGG	S282E	GAG	E348R	CGG
A017Y	TAT	I083S	TCG	A149Q	CAG	S215T	ACT	S282F	TTT	E348S	TCT
W018C	TGT	I083T	ACT	A149R	CGG	S215V	GTG	S282G	GGT	E348T	ACT
W018D W018F	GAT TTT	I083V I083Y	GTT TAT	A149S A149T	TCT ACT	S215W W216D	TGG GAT	S282L S282M	CTT ATG	E348V E348W	GTT TGG
W018F W018G	GGG	S084D	GAT	A1491 A149V	GTT	W216D W216E	GAG	S282IVI S282P	CCT	E348W E348Y	TAT
W018H	CAT	S084E	GAG	A149W	TGG	W216G	GGT	S282Q	CAG	Q349A	GCT
W018I	ATT	S084F	TTT	A149Y	TAT	W216H	CAT	S282R	CGT	Q349D	GAT
W018L	CTG	S084G	GGT	T150A	GCT	W216I	ATT	S282T	ACT	Q349E	GAG
W018M	ATG	S084H	CAT	T150C	TGT	W216K		S282V	GTT	Q349F	TTT
W018P W018Q	CCG CAG	S084I S084L	ATT CTT	T150D T150E	GAT GAG	W216L W216M	CTG ATG	S282W S282Y	TGG TAT	Q349G Q349H	GGT CAT
W018Q W018R	CGG	S084L	ATG	T150E	TTT	W216N	AAT	Q283A	GCG	Q349K	AAG
W018S	AGT	S084N	AAT	T150G	GGG	W216P	CCT	Q283C	TGT	Q349L	CTG
W018T	ACG	S084P	CCT	T150I	ATT	W216Q	CAG	Q283D	GAT	Q349M	ATG
W018V	GTG	S084Q	CAG	T150L	TTG	W216R	CGG	Q283E	GAG	Q349N	AAT
W018Y	TAT	S084R	CGG	T150N	AAT	W216T	ACG	Q283F	TTT	Q349P	CCT
N019A N019C	GCG TGT	S084T S084W	ACT TGG	T150P T150R	CCT AGG	W216V W216Y	GTG TAT	Q283G Q283H	GGG CAT	Q349R Q349S	CGT TCG
N019E	TTT	S084Y	TAT	T150S	TCT	L217A	GCG	Q283L	CTT	Q349T	ACT
N019G	GGG	L085A	GCT	T150V	GTG	L217C	TGT	Q283N	AAT	Q349V	GTG
N019H	CAT	L085C	TGT	T150W	TGG	L217E	GAG	Q283P	CCG	Q349W	TGG
	ATT	L085D	GAT	T150Y		L217G		-	CGT	· ·	TAT
N019L N019M	CTG ATG	L085E	GAG TTT	E151A E151C	GCT TGT	L217H	CAT ATT	Q283S 0283T	TCT ACT	G350A G350D	GCT GAT
N019M N019P	CCG	L085F L085G	GGG	E151C E151G	GGT	L217I L217M	ATG	Q283T Q283W	TGG	G350D G350E	GAG
N019Q	CAG	L085H	CAT	E151U	CAT	L217P	CCG	Q283Y	TAT	G350E	TTT
N019R	CGT	L085K	AAG	E151K	AAG	L217Q	CAG	D284A	GCT	G350H	CAT
N019S	TCG	L085N	AAT	E151L	TTG	L217R	AGG	D284C	TGT	G350K	AAG
N019V	GTT	L085P	CCT	E151M	ATG	L217S	TCT	D284E	GAG	G350L	CTG
N019W N019Y	TGG TAT	L085Q L085R	CAG CGT	E151N E151Q	AAT CAG	L217T L217V	ACG GTG	D284G D284H	GGT CAT	G350M G350N	ATG AAT
A020D	GAT	L085K	TCG	E151Q E151R	AGG	L217V L217W	TGG	D284H D284I	ATT	G350N G350P	CCT
A020E	GAG	L085T	ACT	E151S	TCG	L217Y	TAT	D284L	TTG	G350R	CGT
A020F	TTT	L085V	GTT	E151T	ACT	W218A	GCT	D284M	ATG	G350S	TCT
A020G	GGG	Q086A	GCT	E151V	GTT	W218D	GAT	D284N	AAT	G350T	ACT
A020H	CAT	Q086C	TGT	E151W	TGG	W218F	TTT	D284P	CCG	G350V	GTG
A020K A020L	AAG CTG	Q086D Q086E	GAT GAG	E151Y K152A	TAT GCT	W218G W218H	GGT CAT	D284Q D284S	CAG TCT	G350Y V351A	TAT GCT
A020L A020N	AAT	Q086E Q086F	TTT	K152A K152C	TGT	W218H W218I	ATT	D2845 D284T	ACG	V351A V351C	TGT
A020P	CCG	Q086G	GGT	K152C	TTT	W218I W218K		D284V	GTT	V351C	GAT
A020Q	CAG	Q086H	CAT	K152G	GGT	W218L	CTT	D284Y	TAT	V351E	GAG
A020R	CCT	Q086I	ATT	K152I	ATT	W218M		E285A	GCG	V351F	TTT
	CGT							DOCE	TTT	172510	COT
A020S	TCT	Q086K	AAG	K152L	TTG	W218P	CCT	E285F	TTT	V351G	
A020T	TCT ACT	Q086K Q086L	CTG	K152M	ATG	W218Q	CAG	E285G	GGG	V351H	CAT
	TCT	Q086K									GGT CAT ATT TTG

TABLE 8-continued

					PH20	Variants					
mut	cod										
P021A	GCG	Q086P	CCT	K152R	AGG	W218T W218V	ACT	E285M E285N	ATG	V351N	AAT
P021C P021D	TGT GAT	Q086R Q086S	CGG TCT	K152S K152T	TCT ACT	W218V N219A	GTG GCG	E285N E285P	AAT CCT	V351Q V351R	CAG AGG
P021E	GAG	Q086T	ACT	K152V	GTG	N219C	TGT	E285Q	CAG	V351S	TCT
P021G	GGG	Q086V	GTG	K152W	TGG	N219D	GAT	E285R	CGT	V351W	TGG
P021H P021I	CAT ATT	Q086W D087A	TGG GCT	K152Y A153C	TAT TGT	N219E N219G	GAG GGG	E285S E285T	AGT ACG	V351Y C352A	TAT GCT
P021K	AAG	D087A D087C	TGT	A153C	GAG	N2190	CAT	E2851 E285V	GTG	C352A C352D	GAT
P021L	CTT	D087E	GAG	A153F	TTT	N219I	ATT	E285W	TGG	C352E	GAG
P021M	ATG	D087G	GGG	A153G	GGT	N219K	AAG	E285Y	TAT	C352F	TTT
P021R P021S	CGT TCT	D087H D087I	CAT ATT	A153H A153I	CAT ATT	N219L N219M	CTT ATG	L286A L286C	GCG TGT	C352G C352K	GGG AAG
P0213 P021T	ACG	D087L	CTG	A153K	AAG	N219M N219P	CCT	L286C	GAT	C352K C352M	ATG
P021V	GTT	D087M	ATG	A153L	CTG	N219R	CGT	L286E	GAG	C352P	CCT
P021W	TGG	D087P	CCT	A153M	ATG	N219S	TCG	L286F	TTT	C352Q	CAG
S022A S022C	GCT TGT	D087Q D087R	CAG AGG	A153P A153Q	CCT CAG	N219T N219W	ACT TGG	L286G L286H	GGT CAT	C352R C352S	CGT AGT
S022C S022D	GAT	D087K	TCG	A153Q	CGT	E220A	GCG	L286K	AAG	C3523	ACT
S022E	GAG	D087T	ACT	A153S	AGT	E220D	GAT	L286M	ATG	C352V	GTG
S022G	GGG	D087V	GTT	A153T	ACT	E220G	GGG	L286P	CCT	C352W	TGG
S022H S022K	CAT AAG	D087Y H088A	TAT GCT	A153V A153W	GTG TGG	E220H E220I	CAT ATT	L286R L286S	AGG AGT	C352Y I353A	TAT GCT
S022K S022L	CTG	H088C	TGT	K154A	GCT	E2201 E220K	AAG	L2803 L286T	ACG	1353A 1353C	TGT
S022M	ATG	H088E	GAG	K154C	TGT	E220L	TTG	L286W	TGG	I353E	GAG
S022N	AAT	H088F	TTT	K154D	GAT	E220M	ATG	L286Y	TAT	I353F	TTT
S022P S022R	CCG CGG	H088G H088I	GGG ATT	K154E K154G	GAG GGT	E220N E220P	AAT CCG	V287A V287C	GCT TGT	I353G I353H	GGG CAT
S022R	ACT	H088K	AAG	K154H	CAT	E220R	CGG	V287D	GAT	1353K	AAG
S022V	GTG	H088L	TTG	K154I	ATT	E220S	TCT	V287E	GAG	I353L	CTT
S022Y	TAT	H088M	ATG	K154L	CTG	E220T	ACG	V287F	TTT	I353M	ATG
E023A E023D	GCT GAT	H088P H088R	CCT CGT	K154P K154R	CCT CGG	E220V E220W	GTG TGG	V287G V287I	GGG ATT	I353Q I353R	CAG CGT
E023F	TTT	H088S	AGT	K154S	AGT	S221A	GCG	V287K	AAG	1353S	TCG
E023G	GGG	H088T	ACT	K154T	ACT	S221C	TGT	V287L	CTT	I353T	ACT
E023H	CAT CTT	H088V H088Y	GTT TAT	K154V K154W	GTG TGG	S221D S221E	GAT	V287N V287P	AAT CCT	1353V 1353W	GTG TGG
E023L E023M	ATG	L089A	GCT	K154W K154Y	TAT	S221E S221G	GAG GGG	V287P V287Q	CAG	R354C	TGT
E023N	AAT	L089C	TGT	Q155A	GCT	S221H	CAT	V287R	CGG	R354D	GAT
E023P	CCT	L089D	GAT	Q155C	TGT	S221I	ATT	V287S	TCT	R354E	GAG
E023Q E023R	CAG CGG	L089E L089G	GAG GGG	Q155D Q155F	GAT TTT	S221K S221L	AAG TTG	V287T Y288D	ACT GAC	R354G R354H	GGT CAT
E023S	TCT	L089K	AAG	Q155G	GGG	S221E S221M	ATG	Y288E	GAG	R354I	ATT
E023T	ACG	L089M	ATG	Q155H	CAT	S221P	CCG	Y288F	TTT	R354K	AAG
E023V	GTG	L089N	AAT	Q155K	AAG	S221Q	CAG	Y288G	GGG	R354L	CTT
E023W F024A	TGG GCG	L089P L089Q	CCT CAG	Q155L Q155M	CTT ATG	S221R S221T	CGG ACT	Y288H Y288I	CAT ATT	R354M R354P	ATG CCT
F024C	TGT	L089R	AGG	Q155P	CCT	S221V	GTG	Y288K	AAG	R354Q	CAG
F024E	GAG	L089S	TCG	Q155R	CGG	T222A	GCG	Y288L	CTG	R354S	TCT
F024G F024H	GGG CAT	L089T L089W	ACT TGG	Q155S Q155T	AGT ACT	T222D T222E	GAT GAG	Y288P Y288Q	CCT CAG	R354V R354W	GTG TGG
F024H F024I	ATT	L089W	TAT	Q1551 Q155V	GTT	T222E	TTT	Y288R	CGT	R354W	TAT
F024K	AAG	D090A	GCT	-	TGG	T222G	GGG	Y288S	TCT	K355D	GAT
F024L	TTG	D090C	TGT	Q155Y	TAT	T222I	ATT	Y288T	ACT	K355F	TTT
F024M F024N	ATG AAT	D090E D090G	GAG GGG	E156A E156C	GCT TGT	T222K T222L	AAA TTG	Y288V Y288W	GTG TGG	K355G K355H	GGG CAT
F024P	CCT	D090H	CAT	E156D	GAT	T222D	AAT	T289A	GCT	K355L	CTG
F024R	CGT	D090I	ATT	E156G	GGT	T222P	CCG	T289C	TGT	K355M	ATG
F024T F024V	ACG GTT	D090K	AAG	E156I	ATT	T222R	CGG	T289E	GAG	K355N K355P	AAT
F024V F024Y	TAT	D090L D090N	CTT AAT	E156K E156L	AAG CTG	T222S T222V	AGT GTT	T289G T289H	GGT CAT	K355P K355Q	CCT CAG
C025D	GAT	D090P	CCT	E156M	ATG	T222W	TGG	T289K	AAG	K355R	CGT
C025E	GAG	D090Q	CAG	E156P	CCT	T222Y	TAT	T289L	CTT	K355S	TCT
C025F C025G	TTT GGG	D090R D090S	AGG AGT	E156Q E156R	CAG CGG	A223C A223D	TGT GAT	T289M T289N	ATG AAT	K355T K355V	ACT GTG
C025G C025H	CAT	D0903 D090T	ACT	E1568	TCT	A223D A223E	GAG	T289N T289P	CCT	K355W	TGG
C025I	ATT	D090W	TGG	E156T	ACT	A223G	GGG	T289Q	CAG	K355Y	TAT
C025K	AAG	K091A	GCT	E156V	GTT	A223H	CAT	T289R	AGG	N356A	GCT
C025L C025N	TTG AAT	K091D K091E	GAT GAG	E156W F157A	TGG GCT	A223K A223L	AAG CTG	T289S T289V	TCG GTG	N356C N356D	TGT GAT
C025P	CCT	K091F	TTT	F157C	TGT	A223P	CCT	T289Y	TAT	N356F	TTT
C025R	CGT	K091G	GGG	F157D	GAT	A223Q	CAG	F290A	GCT	N356G	GGG
C025S C025T	TCT ACT	K091H K091I	CAT ATT	F157E F157G	GAG GGT	A223R A223S	AGG TCT	F290C F290D	TGT GAT	N356H N356K	CAT AAG
C0251 C025V	GTG	K0911 K091L	TTG	F157G	CAT	A2235 A223T	ACG	F290D F290G	GGG	N356L	CTG
C025Y	TAT	K091N	AAT	F157I	ATT	A223V	GTG	F290H	CAT	N356P	CCT
L026A	GCT	K091Q	CAG	F157K	AAG	A223W	TGG	F290I	ATT	N356Q	CAG

FABLE 8-	continued
----------	-----------

					PH20	/ariants					
mut	cod	mut	cod								
L026E	GAG	K091R	CGT	F157L	TTG	A223Y	TAT	F290K	AAG	N356R	CGG
L026G L026H	GGT CAT	K091S K091T	TCT ACT	F157M F157P	ATG CCT	L224A L224D	GCT GAT	F290L F290M	TTG ATG	N356S N356T	AGT ACT
L026I	ATT	K091Y	TAT	F157Q	CAG	L224E	GAG	F290Q	CAG	N356V	GTG
L026K	AAG	A092C	TGT	F157R	CGG	L224F	TTT	F290R	AGG	N356W	TGG
L026M	ATG	A092E	GAG	F157S	TCG	L224G	GGG	F290S	TCG	W357A	GCT
L026P L026Q	CCG CAG	A092F A092G	TTT GGT	F157T F157V	ACT GTG	L224I L224M	ATT ATG	F290T F290V	ACT GTT	W357C W357D	TGT GAT
L026Q	CGG	A092H	CAT	F157W	TGG	L224M	CCG	F290Y	TAT	W357E	GAG
L026S	TCT	A092K	AAG	E158A	GCT	L224Q	CAG	G291A	GCT	W357F	TTT
L026T	ACT	A092L	CTG	E158C	TGT	L224R	AGG	G291C	TGT	W357G	GGG
L026V L026W	GTT TGG	A092M A092P	ATG CCT	E158D E158F	GAT TTT	L224S L224T	AGT ACT	G291D G291E	GAT GAG	W357K W357L	AAG TTG
L026Y	TAT	A092Q	CAG	E158G	GGG	L224V	GTT	G291F	TTT	W357M	ATG
G027A	GCT	A092R	CGT	E158H	CAT	L224W	TGG	G291H	CAT	W357P	CCT
G027C	TGT	A092T	ACT	E158K	AAG	L224Y	TAT	G291L	CTG	W357Q	CAG
G027D G027E	GAT GAG	A092V A092W	GTT TGG	E158L E158N	CTG AAT	Y225A Y225D	GCG GAT	G291M G291N	ATG AAT	W357R W357S	CGT AGT
G027F	TTT	A092Y	TAT	E158P	CCT	Y225E	GAG	G291P	CCT	W357T	ACT
G027H	CAT	K093D	GAT	E158Q	CAG	Y225G	GGT	G291Q	CAG	W357V	GTG
G027I	ATT	K093E	GAG	E158R	CGG	Y225H	CAT	G291R	CGG	N358C N358D	TGT
G027K G027L	AAG CTG	K093F K093G	TTT GGT	E158S E158V	TCG GTG	Y225K Y225L	AAG CTG	G291S G291T	TCT ACT	N358D N358E	GAT GAG
G027P	CCT	K093H	CAT	E158Y	TAT	Y225P	CCG	G291V	GTG	N358G	GGG
G027Q	CAG	K093I	ATT	K159A	GCT	Y225Q	CAG	G291W	TGG	N358H	CAT
G027R G027S	CGG TCG	K093L K093M	CTG ATG	K159D K159E	GAT GAG	Y225R Y225S	AGG TCT	G291Y E292A	TAT GCT	N358I N358K	ATT AAG
G0273 G027T	ACT	K093N	AAT	K159E	TTT	Y225T	ACG	E292R E292C	TGT	N358L	CTG
G027W	TGG	K093P	CCT	K159G	GGT	Y225V	GTG	E292F	TTT	N358P	CCT
K028A	GCG	K093Q	CAG	K159H	CAT	Y225W	TGG	E292G	GGT	N358Q	CAG
K028D K028E	GAT GAG	K093R K093S	CGG AGT	K159L K159M	CTT ATG	P226A P226C	GCG TGT	E292H E292I	CAT ATT	N358R N358S	CGT TCT
K028F	TTT	K093T	ACT	K159N	AAT	P226D	GAT	E292K	AAG	N358T	ACT
K028G	GGG	K093V	GTT	K159Q	CAG	P226E	GAG	E292L	TTG	N358V	GTG
K028I K028L	ATT TTG	K094A K094C	GCT TGT	K159R K159S	CGG TCT	P226F P226G	TTT GGT	E292N E292P	AAT CCT	N358W S359A	TGG GCT
K028L K028M	ATG	K094C K094D	GAT	K1593 K159V	GTG	P226U	CTT	E292P E292Q	CAG	S359A S359C	TGT
K028N	AAT	K094E	GAG	K159W	TGG	P226N	AAT	E292R	CGG	S359D	GAT
K028P	CCT	K094F	TTT	K159Y	TAT	P226Q	CAG	E292T	ACT	S359E	GAG
K028R K028S	CGG AGT	K094G K094H	GGG CAT	A160C A160F	TGT TTT	P226R P226S	AGG TCT	E292V E292W	GTT TGG	S359F S359G	TTT GGG
K028T	ACT	K094L	TTG	A160G	GGG	P226T	ACG	T293A	GCT	S359H	CAT
K028V	GTT	K094M	ATG	A160H	CAT	P226V	GTT	T293C	TGT	S359K	AAG
K028W F029A	TGG GCT	K094N K094P	AAT CCT	A160I A160K	ATT AAG	P226W P226Y	TGG TAT	T293D T293E	GAT GAG	S359L S359M	TTG ATG
F029A F029C	TGT	K094P K094Q	CAG	A160K	CTG	S227A	GCT	T293E T293F	TTT	S359M	CCT
F029E	GAG	K094R	AGG	A160M	ATG	S227F	TTT	T293G	GGT	S359R	CGG
F029G	GGG	K094S	TCT	A160N	AAT	S227G	GGG	T293K	AAG	S359T	ACT
F029H F029I	CAT ATT	K094T D095A	ACT GCT	A160Q A160R	CAG AGG	S227H S227I	CAT ATT	T293L T293M	CTT ATG	S359V S359W	GTT TGG
F029K	AAG	D095C	TGT	A160S	AGT	S227K	AAG	T293N	AAT	S360A	GCT
F029L	CTT	D095E	GAG	A160V	GTG	S227L	TTG	T293P	CCT	S360C	TGT
F029M	ATG	D095F	TTT GGG	A160W	TGG	S227M	ATG	T293Q T293S	CAG	S360E	GAG
F029P F029R	CCG CGG	D095G D095H	CAT	A160Y G161A	TAT GCT	S227P S227Q	CCT CAG	T2938 T293V	TCT GTG	S360F S360G	TTT GGG
F029S	TCG	D095K	AAG	G161C	TGT	S227R	CGG	T293Y	TAT	S360I	ATT
F029T	ACG	D095L	TTG	G161D	GAT	S227T	ACG	V294A	GCT	S360K	AAG
F029V F029W	GTG TGG	D095M D095P	ATG CCT	G161E G161H	GAG CAT	S227V S227W	GTG TGG	V294C V294E	TGT GAG	S360L S360M	CTG ATG
D030A	GCG	D095P D095Q	CAG	G161H	ATT	S227W S227Y	TAT	V294E V294G	GGG	S360M S360N	AAT
D030E	GAG	D095S	TCT	G161K	AAG	I228A	GCG	V294H	CAT	S360P	CCT
D030F	TTT	D095V	GTG	G161L	CTT	I228E	GAG	V294K	AAG	S360Q	CAG
D030G D030H	GGG CAT	D095W D095Y	TGG TAT	G161M G161Q	ATG CAG	I228F I228G	TTT GGG	V294L V294M	TTG ATG	S360R S360T	AGG ACT
D030H	AAG	1096A	GCT	G161Q	CGT	1228U 1228H	CAT	V294M V294N	AAT	\$3601 \$360V	GTT
D030L	TTG	I096C	TGT	G161S	AGT	I228K	AAG	V294P	CCT	D361A	GCT
D030M	ATG	1096D	GAT	G161T	ACT	I228L	TTG	V294Q	CAG	D361C	TGT
D030P D030Q	CCT CAG	1096E 1096F	GAG TTT	G161V G161W	GTG TGG	I228M I28N	ATG AAT	V294R V294S	AGG AGT	D361E D361G	GAG GGG
D030R	CGG	1096G	GGG	K162A	GCT	1228P	CCG	V294T	ACT	D361H	CAT
D030S	TCG	1096H	CAT	K162D	GAT	I228Q	CAG	V294W	TGG	D361L	TTG
D030T D030V	ACT GTT	1096L 1096N	TTG AAT	K162E K162F	GAG TTT	I228R I228S	CGT TCT	A295C A295D	TGT GAT	D361M D361N	ATG AAT
D030W	TGG	1096N 1096P	CCT	K162F K162G	GGG	12285 1228T	ACT	A295D A295E	GAG	D361N	CCT
E031A	GCG	1096R	CGT	K162H	CAT	I228W	TGG	A295F	TTT	D361Q	CAG
E031C	TGT	1096S	AGT	K162L	TTG	Y229E	GAG	A295G	GGG	D361R	AGG

TABLE 8-continued

					PH20	Variants					
mut	cod										
E031G	GGG	1096T	ACT	K162M	ATG	Y229F	TTT	A295H	CAT	D361S	TCG
E031H E031I	CAT ATT	1096V 1096W	GTG TGG	K162P K162Q	CCT CAG	Y229G Y229H	GGT CAT	A295I A295L	ATT CTG	D361V D361W	GTT TGG
E031K	AAG	T097A	GCT	K162R	CGG	Y229I	ATT	A295N	AAT	D361Y	TAT
E031L	CTG	T097C	TGT	K162S	TCG	Y229K	AAG	A295P	CCT	Y362A	GCT
E031N E031P	AAC CCG	T097D T097E	GAT GAG	K162V K162W	GTG TGG	Y229L Y229N	TTG AAT	A295Q A295S	CAG AGT	Y362C Y362E	TGT GAG
E031R	CGG	T097E	TTT	K162Y	TAT	Y229P	CCT	A295T	ACT	Y362G	GGG
E031S	TCT	T097G	GGG	D163A	GCT	Y229Q	CAG	A295V	GTT	Y362H	CAT
E031T E031V	ACG GTG	T097I T097L	ATT CTT	D163C D163E	TGT GAG	Y229R Y229S	CGT TCG	A295Y L296A	TAT GCT	Y362K Y362L	AAG CTT
E031V	TGG	T097L T097N	AAT	D163E	TTT	Y2293	ACT	L296A L296C	TGT	Y362M	ATG
E031Y	TAT	T097P	CCT	D163G	GGG	Y229V	GTG	L296F	TTT	Y362N	AAT
P032A	GCG	T097Q	CAG CGG	D163H	CAC	Y229W	TGG	L296G	GGT	Y362P	CCT
P032C P032F	TGT TTT	T097R T097S	TCG	D163K D163L	AAG CTT	L230A L230E	GCG GAG	L296I L296K	ATT AAG	Y362R Y362S	CGG AGT
P032G	GGG	T097W	TGG	D163P	CCT	L230G	GGG	L296M	ATG	Y362T	ACT
P032H	CAT	T097Y	TAT	D163Q	CAG	L230H	CAT	L296P	CCT	Y362V	GTG
P032K P032L	AAG CTG	F098A F098C	GCT TGT	D163R D163S	AGG TCG	L230I L230K	ATT AAG	L296Q L296R	CAG CGT	Y362W L363A	TGG GCT
P032M	ATG	F098D	GAT	D163T	ACT	L230M	ATG	L296S	TCG	L363C	TGT
P032N	AAT	F098E	GAG	D163V	GTG	L230N	AAT	L296T	ACT	L363D	GAT
P032Q P032R	CAG CGG	F098G F098H	GGG CAT	D163W F164A	TGG GCT	L230P L230R	CCT CGT	L296V L296W	GTT TGG	L363E L363F	GAG TTT
P032S	TCG	F098I	ATT	F164C	TGT	L230K	AGT	L296Y	TAT	L363G	GGG
P032T	ACT	F098L	TTG	F164D	GAT	L230T	ACT	G297A	GCT	L363H	CAT
P032V P032W	GTG TGG	F098M F098P	ATG CCT	F164E F164G	GAG GGG	L230V L230W	GTT TGG	G297C G297E	TGT GAG	L363I L363P	ATT CCT
P032W	TAT	F098F	CAG	F164H	CAT	L230W	TAT	G297E G297H	CAT	L363Q	CAG
L033C	TGT	F098R	CGT	F164L	TTG	N231A	GCT	G297I	ATT	L363R	CGG
L033D	GAT	F098S	TCG	F164M	ATG	N231C	TGT	G297L	CTT	L363S	TCG
L033G L033H	GGG CAT	F098V F098W	GTT TGG	F164N F164P	AAT CCT	N231D N231F	GAT TTT	G297N G297P	AAT CCT	L363T L363V	ACT GTG
L033I	ATT	Y099A	GCT	F164Q	CAG	N231G	GGG	G297Q	CAG	L363W	TGG
L033M	ATG	Y099C	TGT	F164R	CGG	N231H	CAT	G297R	CGG	H364A	GCT
L033N L033P	AAT CCG	Y099E Y099F	GAG TTT	F164S F164V	AGT GTT	N231I N231K	ATT AAG	G297S G297T	AGT ACT	H364C H364D	TGT GAT
L033Q	CAG	Y099G	GGT	F164W	TGG	N231L	CTT	G297V	GTG	H364E	GAG
L033R	AGG	Y099I	ATT	L165A	GCT	N231P	CCT	G297W	TGG	H364F	TTT
L033S L033T	TCG ACT	Y099L Y099N	TTG AAT	L165C L165D	TGT GAT	N231Q N231R	CAG CGT	G297Y A298C	TAT TGT	H364G H364K	GGG AAG
L033V	GTT	Y099P	CCT	L165F	TTT	N231S	TCT	A298E	GAG	H364L	CTG
L033W	TGG	Y099Q	CAG	L165G	GGG	N231T	ACG	A298G	GGG	H364M	ATG
L033Y D034A	TAT GCT	Y099R Y099S	AGG TCG	L165H L165N	CAT AAT	N231V T232A	GTG GCG	A298I A298L	ATT TTG	H364P H364R	CCT CGG
D034E	GAG	Y099T	ACT	L165P	CCT	T232C	TGT	A298M	ATG	H364S	TCT
D034G	GGT	Y099V	GTT	L165Q	CAG	T232F	TTT	A298N	AAT	H364T	ACT
D034H D034I	CAT ATT	Y099W M100C	TGG TGT	L165R L165S	CGG TCG	T232G T232H	GGG CAT	A298P A298Q	CCT CAG	H364V H364Y	GTG TAT
D034K	AAG	M100C M100E	GAG	L165T	ACT	T232K	AAG	A298Q A298R	CGT	L365A	GCT
D034L	CTT	M100F	TTT	L165V	GTG	T232L	CTT	A298S	TCG	L365C	TGT
D034N D034P	AAT CCT	M100G M100K	GGT AAG	L165W L165Y	TGG TAT	T232M T232N	ATG AAT	A298T A298V	ACT GTG	L365D L365E	GAT GAG
D034P D034Q	CAG	M100K M100L	CTG	V166A	GCT	T232N	CCG	A298V A298W	TGG	L365G	GGG
D034R	CGT	M100N	AAT	V166C	TGT	T232Q	CAG	A298Y	TAT	L365I	ATT
D034S D034T	AGT ACG	M100P M100Q	CCT CAG	V166D V166E	GAT GAG	T232R T232S	AGG AGT	S299A S299C	GCT TGT	L365M L365N	ATG AAT
D0341 D034V	GTT	M100Q M100R	CAG	V166E V166F	TTT	T2328 T232V	GTG	S299C S299D	GAT	L365N L365P	CCT
D034W	TGG	M100S	TCT	V166G	GGT	T232Y	TAT	S299E	GAG	L365Q	CAG
M035A	GCG	M100T	ACT	V166H	CAT	Q233A	GCG	S299F	TTT	L365R	CGG
M035D M035F	GAT TTT	M100V M100W	GTT TGG	V166L V166N	CTT AAT	Q233C Q233D	TGT GAT	S299G S299H	GGG CAT	L365S L365T	AGT ACT
M035G	GGG	M100Y	TAT	V166P	CCT	Q233F	TTT	S299I	ATT	L365V	GTG
M035H	CAT	P101A	GCT	V166Q	CAG	Q233G	GGG	S299L	CTT	L365W	TGG
M035I M035L	ATT TTG	P101C P101F	TGT TTT	V166R V166T	CGG ACT	Q233I Q233K	ATT AAG	S299M S299P	ATG CCT	L365Y N366A	TAT GCT
M035N	AAT	P101G	GGG	V166W	TGG	Q233L	CTG	S299Q	CAG	N366C	TGT
M035P	CCG	P101H	CAT	V166Y	TAT	Q233P	CCG	S299R	AGG	N366E	GAG
M035Q M035R	CAG CGT	P101I P101K	ATT AAG	E167A E167D	GCT GAT	Q233R Q233S	AGG TCG	S299T S299Y	ACT TAT	N366F N366G	TTT GGG
M035S	TCT	P101L	CTT	E167F	TTT	Q2335 Q233T	ACG	G300A	GCT	N366K	AAG
M035T	ACT	P101M	ATG	E167G	GGT	Q233V	GTG	G300C	TGT	N366L	TTG
M035V M035Y	GTT TAT	P101N P101Q	AAT CAG	E167H E167K	CAT AAG	Q233W Q233Y	TGG TAT	G300D G300E	GAT GAG	N366M N366P	ATG CCT
S036A	GCG	P101Q	AGG	E167L	TTG	Q2331 Q234A	GCT	G300E G300F	TTT	N366Q	CAG
S036C	TGT	P101S	TCT	E167M	ATG	Q234C	TGT	G300L	CTT	N366R	AGG

TABLE 8-continued

					PH20	Variants					
mut	cod	mut	cod	mut	cod	mut	cod	mut	cod	mut	cod
S036D S036F	GAT TTT	P101T P101Y	ACT TAT	E167N E167P	AAT CCT	Q234D Q234E	GAT GAG	G300M G300N	ATG AAT	N366S N366T	TCT ACT
S036G	GGT	V102A	GCT	E167P E167R	AGG	Q234E Q234G	GAG	G300N G300P	CCT	N366V	GTT
S036H	CAT	V102C	TGT	E167S	TCG	Q234H	CAT	G300Q	CAG	N366W	TGG
S036K	AAG	V102E	GAG	E167T	ACT	Q234L	CTT	G300R	AGG	P367A	GCT
S036L S036N	TTG AAT	V102G V102H	GGT CAT	E167V E167Y	GTT TAT	Q234M Q234N	ATG AAT	G300S G300T	TCG ACT	P367C P367E	TGT GAG
S036P	CCG	V102H V102K	AAG	T168A	GCT	Q234IN Q234P	CCG	G3001 G300V	GTT	P367E	TTT
S036R	CGG	V102L	TTG	T168C	TGT	Q234R	CGG	G300W	TGG	P367G	GGT
S036T	ACG	V102M	ATG	T168D	GAT	Q234S	AGT	I301A	GCT	P367H	CAT
S036V S036W	GTT TGG	V102N V102P	AAT CCT	T168E T168F	GAG TTT	Q234T Q234V	ACT GTG	I301E I301G	GAG GGG	P367I P367K	ATT AAG
S036Y	TAT	V102P	CAG	T168G	GGG	Q234V Q234W	TGG	I301U I301H	CAT	P367L	CTG
L037A	GCG	V102R	AGG	T168H	CAT	\$235A	GCG	I301K	AAG	P367M	ATG
L037C	TGT	V102S	TCT	T168K	AAG	S235E	GAG	I301L	CTG	P367Q	CAG
L037E L037F	GAG TTT	V102T V102W	ACT TGG	T168L T168P	CTG CCT	S235F S235G	TTT GGG	I301M I301N	ATG AAT	P367R P367S	CGT TCG
L037G	GGG	D103A	GCT	T168R	CGG	S235U S235H	CAT	I301R	CCT	P367V	GTT
L037I	ATT	D103E	GAG	T168S	TCT	S235K	AAG	I301Q	CAG	P367W	TGG
L037K	AAG	D103F	TTT	T168V	GTG	S235L	CTT	I301R	CGG	D368A	GCT
L037M L037N	ATG AAT	D103G D103H	GGG CAT	T168W T168Y	TGG TAT	S235M S235P	ATG CCT	I301S I301V	AGT GTT	D368C D368E	TGT GAG
L037P	CCT	D103I	ATT	I169A	GCT	S235Q	CAG	1301 V 1301 W	TGG	D368G	GGT
L037R	AGG	D103L	CTT	I169D	GAT	S235R	CGG	I301Y	TAT	D368H	CAT
L037S	TCT	D103N	AAT	I169F	TTT	S235T	ACG	V302C	TGT	D368K	AAG
L037T L037V	ACG GTG	D103Q D103R	CAG AGG	I169G I169H	GGG CAT	S235V S235W	GTG TGG	V302D V302E	GAT GAG	D368L D368M	CTT ATG
L037W	TGG	D103K	TCG	1169K	AAG	S235Y	TAT	V302E	TTT	D368P	CCT
F038A	GCG	D103T	ACT	I169L	TTG	P236A	GCT	V302G	GGT	D368R	CGT
F038C F038E	TGT GAG	D103V	GTT	I169N	AAT	P236C P236E	TGT	V302H V302I	CAT ATT	D368S	AGT
F038E	GGG	D103W D103Y	TGG TAT	I169P I169Q	CCT CAG	P236E P236G	GAG GGG	V3021 V302L	TTG	D368T D368V	ACT GTT
F038K	AAG	N104A	GCT	I169R	CGG	P236H	CAT	V302M	ATG	D368W	TGG
F038L	CTT	N104C	TGT	I169S	TCG	P236I	ATT	V302P	CCT	D368Y	TAT
F038M F038N	ATG AAT	N104F N104G	TTT GGG	I169T I169V	ACT GTT	P236K P236L	AAG CTG	V302R V302S	AGG TCG	N369A N369C	GCT TGT
F038P	CCT	N104U	CAT	1169Y	TAT	P236N	AAT	V3025 V302T	ACT	N369E	GAG
F038Q	CAG	N104I	ATT	K170A	GCT	P236Q	CAG	V302W	TGG	N369F	TTT
F038R	AGG	N104K	AAG	K170C	TGT	P236R	CGT	V302Y	TAT	N369H	CAT
F038S F038T	TCT ACT	N104L N104M	CTG ATG	K170D K170E	GAT GAG	P236S P236T	AGT ACT	I303A I303C	GCT TGT	N369I N369K	ATT AAG
F038W	TGG	N104P	CCT	K170G	GGG	P236W	TGG	I303D	GAT	N369L	CTT
F038Y	TAT	N104R	AGG	K170I	ATT	P236Y	TAT	I303E	GAG	N369P	CCT
S039A S039C	GCG TGT	N104S N104T	TCT ACT	K170L K170M	TTG ATG	V237A V237C	GCG TGT	I303F I303G	TTT GGT	N369Q N369R	CAG CGG
S039C	GAT	N1041 N104V	GTT	K170M K170N	AAT	V237C V237E	GAG	1303G 1303K	AAG	N369S	TCG
S039F	TTT	N104W	TGG	K170P	CCT	V237F	TTT	I303L	TTG	N369T	ACT
S039G	GGT	L105A	GCT	K170Q	CAG	V237G	GGT	I303M	ATG	N369V	GTG
S039L S039M	TTG ATG	L105C L105D	TGT GAT	K170R K170V	CGT GTT	V237H V237L	CAT TTG	I303P I303R	CCT CGT	N369W F370A	TGG GCT
S039N	AAT	L105E	GAG	K170W	TGG	V237N	AAT	1303S	AGT	F370D	GAT
S039P	CCG	L105G	GGT	K170Y	TAT	V237P	CCT	I303V	GTG	F370E	GAG
S039Q	CAG	L105H	CAT	L171A	GCT	V237Q	CAG	I303W	TGG	F370G	GGG
S039R S039T	CGT ACT	L105I L105M	ATT ATG	L171C L171D	TGT GAT	V237R V237S	CGG TCG	I303Y W304A	TAT GCT	F370H F370I	CAT ATT
S039V	GTT	L105N	AAT	L171G	GGG	V237T	ACG	W304C	TGT	F370K	AAG
S039W	TGG	L105P	CCT	L171H	CAT	V237W	TGG	W304D	GAT	F370L	CTG
S039Y F040A	TAT GCG	L105Q L105R	CAG CGG	L171I L171M	ATT ATG	V237Y A238D	TAT GAT	W304G W304I	GGT ATT	F370N F370P	AAT CCT
F040A F040D	GAT	L105K	TCT	L171M L171N	AAT	A238D A238E	GAG	W3041 W304L	CTG	F370P F370Q	CAG
F040E	GAG	L105T	ACT	L171P	CCT	A238F	TTT	W304M	ATG	F370R	AGG
F040G	GGT	L105V	GTT	L171Q	CAG	A238G	GGT	W304N	AAT	F370S	TCT
F040I F040K	ATT AAG	L105W G106A	TGG GCT	L171R L171S	CGT AGT	A238H A238K	CAT AAG	W304P W304Q	CCT CAG	F370V F370Y	GTG TAT
F040L	CTG	G106A	TGT	L171V	GTG	A238K A238L	CTT	W304Q W304R	CGG	A371C	TGT
F040N	AAT	G106D	GAT	L171W	TGG	A238P	CCG	W304S	AGT	A371E	GAG
F040Q	CAG	G106E	GAG	L171Y	TAT	A238Q	CAG	W304T	ACT	A371F	TTT
F040R F040S	CGG TCT	G106F G106H	TTT CAT	G172A G172C	GCT TGT	A238R A238S	AGG AGT	W304V W304Y	GTG TAT	A371G A371H	GGG CAT
F040T	ACT	G106I	ATT	G172D	GAT	A238T	ACG	G305C	TGT	A371I	ATT
F040V	GTT	G106L	CTG	G172E	GAG	A238V	GTG	G305D	GAT	A371K	AAG
F040W F040Y	TGG TAT	G106M G106N	ATG AAT	G172I G172L	ATT CTT	A238W A238Y	TGG TAT	G305E G305F	GAG TTT	A371L A371M	CTT ATG
F0401 I041A	GCG	G106N	CCT	G172L G172M	ATG	A2381 A239C	TGT	G305F G305H	CAT	A371M A371P	CCT
I041C	TGT	G106S	AGT	G172P	CCT	A239F	TTT	G305K	AAG	A371R	CGT
I041D	GAT	G106V	GTG	G172Q	CAG	A239G	GGT	G305L	CTT	A371S	TCG

					PH20 V	/ariants					
mut	cod	mut	cod	mut	cod	mut	cod	mut	cod	mut	cod
I041E	GAG	G106W	TGG	G172R	CGT	A239H	CAT	G305N	AAT	A371T	ACT
I041F I041G	TTT GGG	G106Y M107A	TAT GCT	G172S G172T	TCT ACT	A239I A239K	ATT AAG	G305P G305Q	CCT CAG	A371V A371W	GTG TGG
I041H	CAT	M107C	TGT	G172V	GTT	T240K	AAG	G305R	CGT	I372A	GCT
I041N	AAT	M107D	GAT	G172W	TGG	A239L	TTG	G305S	TCG	I372D	GAT
I041P	CCG	M107F	TTT	G172Y	TAT	A239N	AAT	G305T	ACT	I372E	GAG
I041Q I041R	CAG AGG	M107G M107H	GGG CAT	K173D K173E	GAT GAG	A239P A239R	CCT AGG	G305V G305Y	GTG TAT	I372F I372G	TTT GGT
I041K	TCT	M107I	ATT	K173G	GGG	A239S	TCT	T306A	GCT	I372H	CAT
I041T	ACG	M107K	AAG	K173H	CAT	A239T	ACT	T306C	TGT	I372K	AAG
I041V	GTT	M107L	CTT	K173I	ATT	A239V	GTT	T306D	GAT	1372L	CTG
I041W G042A	TGG GCT	M107P M107Q	CCT CAG	K173L K173M	CTT ATG	A239W A239Y	TGG TAT	T306E T306F	GAG TTT	I372N I372P	AAT CCT
G042C	TGT	M107R	CGT	K173N	AAT	T240A	GCG	T306G	GGT	1372R	CGG
G042D	GAT	M107S	TCT	K173P	CCT	T240E	GAG	T306H	CAT	I372S	TCT
G042E	GAG	M107V	GTT	K173Q	CAG	T240F	TTT	T306I	ATT CTG	I372T	ACT GTG
G042H G042I	CAT ATT	M107W A108D	TGG GAT	K173R K173S	CGG TCG	T240G T240L	GGG CTT	T306L T306P	CCT	I372V I372W	TGG
G042K	AAG	A108E	GAG	K173V	GTG	T240M	ATG	T306R	AGG	Q373A	GCT
G042L	CTG	A108F	TTT	K173W	TGG	T240N	AAT	T306S	AGT	Q373C	TGT
G042M	ATG	A108G	GGT	K173Y	TAT	T240P	CCT	T306V	GTG	Q373E	GAG
G042P G042Q	CCT CAG	A108H A108K	CAT AAG	L174A L174C	GCT TGT	T240Q T240R	CAG CGT	T306W T306Y	TGG TAT	Q373F Q373G	TTT GGT
G042R	CGG	A108L	TTG	L174G	GGG	T240S	AGT	L307C	TGT	Q373H	CAT
G042S	TCT	A108M	ATG	L174H	CAT	T240V	GTG	L307E	GAG	Q373K	AAG
G042T G042V	ACT GTT	A108N	AAT CCT	L174K	AAG ATG	T240W T240Y	TGG TAT	L307F L307G	TTT	Q373L Q373M	CTG ATG
S043A	GCG	A108P A108Q	CAG	L174M L174N	AAT	L2401 L241A	GCG	L307G L307I	GGG ATT	Q373N	AAT
S043D	GAT	A108R	CGG	L174P	CCT	L241C	TGT	L307K	AAG	Q373P	CCT
S043E	GAG	A108S	TCT	L174Q	CAG	L241D	GAT	L307N	AAT	Q373R	CGT
S043F S043G	TTT GGT	A108T A108V	ACT GTG	L174R L174S	CGT TCG	L241E L241F	GAG TTT	L307P L307Q	CCT CAG	Q373S Q373T	TCT ACT
S043U	CAT	A108Y	TAT	L1745 L174T	ACT	L2411 L241G	GGG	L307Q L307R	AGG	Q373V	GTT
S043I	ATT	V109A	GCT	L174V	GTT	L241I	ATT	L307S	AGT	Q373W	TGG
S043K	AAG	V109C	TGT	L174W	TGG	L241K	AAG	L307T	ACT	L374A	GCT
S043L S043N	CTT AAT	V109D V109E	GAT GAG	L174Y L175C	TAT TGT	L241P L241Q	CCT CAG	L307V L307W	GTG TGG	L374D L374E	GAT GAG
S043P	CCT	V109E	TTT	L175D	GAT	L241Q	CGG	L307Y	TAT	L374G	GGT
S043Q	CAG	V109G	GGG	L175E	GAG	L241S	TCT	S308C	TGT	L374H	CAT
S043R	CGG	V109H	CAT	L175F	TTT	L241T	ACG	S308D	GAT	L374I	ATT
S043T S043V	ACT GTG	V109L V109M	TTG ATG	L175G L175H	GGG CAT	L241V L241W	GTT TGG	S308F S308G	TTT GGT	L374M L374N	ATG AAT
P044A	GCT	V109P	CCT	L175K	AAG	Y242A	GCG	S308H	CAT	L374P	CCT
P044C	TGT	V109Q	CAG	L175N	AAT	Y242C	TGT	S308K	AAG	L374R	AGG
P044E P044F	GAG TTT	V109R V109T	AGG	L175P	CCT CGT	Y242D Y242F	GAT TTT	S308L	CTG ATG	L374S L374T	AGT
P044F P044G	GGG	V1091 V109W	ACT TGG	L175R L175S	TCT	1242F Y242G	GGT	S308M S308N	AAT	L3741 L374V	ACT GTG
P044H	CAT	V109Y	TAT	L175T	ACT	Y242I	ATT	S308P	CCT	L374W	TGG
P044I	ATT	I110A	GCT	L175V	GTG	Y242K	AAG	S308R	CGG	L374Y	TAT
P044L P044N	CTT AAT	I110C I110D	TGT GAT	L175W L175Y	TGG TAT	Y242L Y242M	CTT ATG	S308T S308V	ACT GTT	E375A E375C	GCT TGT
P044Q	CAG	1110D 1110F	TTT	R176A	GCT	Y242P	CCG	S308V S308W	TGG	E375F	TTT
P044R	CGT	I110G	GGG	R176C	TGT	Y242R	CGG	S308Y	TAT	E375G	GGT
P044S	TCT	I110H	CAT	R176E	GAG	Y242S	TCT	I309D	GAT	E375I	ATT
P044T P044W	ACT TGG	I110K I110L	AAG CTG	R176F R176G	TTT GGG	Y242T Y242V	ACG GTT	I309E I309G	GAG GGT	E375K E375L	AAG CTT
P044Y	ACG	III0L III0M	ATG	R176H	CAT	Y242W	TGG	1309H	CAT	E375M	ATG
R045A	GCG	I110N	AAT	R176I	ATT	V243A	GCG	I309K	AAG	E375N	AAT
R045D R045F	GAT TTT	I110P	CCT CGT	R176K R176L	AAG CTT	V243C V243D	TGT GAT	I309L I309M	CTG ATG	E375P E375R	CCT CGT
R045F R045G	GGG	I110R I110S	AGT	R176L R176P	CCT	V243D V243F	TTT	1309M 1309N	AIG	E375K E375S	TCT
R045H	CAT	I110V	GTT	R176Q	CAG	V243G	GGG	I309Q	CAG	E375T	ACT
R045I	ATT	1110W	TGG	R176S	AGT	V243H	CAT	I309R	CGT	E375V	GTT
R045K R045M	AAG ATG	D111C D111E	TGT GAG	R176T R176V	ACT GTG	V243L V243M	CTT ATG	I309S I309T	AGT ACT	E375Y K376A	TAT GCT
R045P	CCT	D111E D111G	GAG	R176W	TGG	V243IVI V243P	CCT	13091 1309V	GTG	K376A K376D	GAT
R045Q	CAG	D111H	CAT	P177A	GCT	V243Q	CAG	I309W	TGG	K376E	GAG
R045S	TCG	D1111	ATT	P177C	TGT	V243R	AGG	I309Y	TAT	K376G	GGG
R045T R045V	ACG GTG	D111K D111L	AAG TTG	P177D P177F	GAT TTT	V243S V243T	AGT ACG	M310A M310C	GCT TGT	K376I K376L	ATT TTG
R045W	TGG	D111M	ATG	P177G	GGG	V243W	TGG	M310E	GAG	K376M	ATG
R045Y	TAT	D111P	ACT	P177H	CAT	V243Y	TAT	M310F	TTT	K376P	CCT
I046A	GCG	D111Q	CAG	P177L	CTT	R244A	GCG	M310G	GGG	K376Q	CAG
I046C I046E	TGT GAG	D111R D111S	CGG AGT	P177M P177Q	ATG CAG	R244D R244G	GAT GGG	M310K M310L	AAG CTG	K376R K376S	CGT AGT
1046F	TTT	D111T	ACT	P177R	CGG	R244H	CAT	M310N	AAT	K376T	ACT

TABLE 8-continued

					PH20	Variants					
mut	cod										
I046H	CAT	D111V	GTT	P177S	TCT	R244I	ATT	M310P	CCT	K376V	GTG
I046L I046M	CTT ATG	D111W D111Y	TGG TAT	P177T P177V	ACT GTT	R244K R244M	AAG ATG	M310Q M310R	CAG CGG	K376W K376Y	TGG TAT
1046N	AAT	W112C	TGT	P177W	TGG	R244N	AAT	M310S	AGT	G377C	TGT
I046P	CCT	W112D	GAT	P177Y	TAT	R244P	CCT	M310V	GTG	G377D	GAT
I046R	CGT	W112E	GAG	N178A	GCT	R244Q	CAG	M310W	TGG	G377E	GAG
I046S I046T	TCT ACT	W112F W112G	TTT GGG	N178D N178E	GAT GAG	R244S R244T	TCT ACG	M310Y R311A	TAT GCT	G377F G377H	TTT CAT
10401 1046V	GTT	W1120	CAT	N178G	GGG	R2441 R244V	GTG	R311C	TGT	G377I	ATT
I046W	TGG	W112I	ATT	N178I	ATT	R244W	TGG	R311E	GAG	G377K	AAG
I046Y N047A	TAT	W112L W112N	CTT AAT	N178K	AAG TTG	R244Y	TAT GCG	R311F	TTT GGT	G377L G377M	CTT ATG
N047A N047D	GCT GAT	W112N W112P	CCT	N178L N178M	ATG	N245A N245C	TGT	R311G R311H	CAT	G377P	CCT
N047F	TTT	W112Q	CAG	N178P	CCT	N245F	TTT	R311I	ATT	G377R	AGG
N047G	GGG	W112R	CGT	N178R	CGG	N245G	GGG	R311K	AAG	G377S	TCG
N047H N047I	CAT ATT	W112S W112V	TCT GTT	N178S N178T	AGT ACT	N245H N245I	CAT ATT	R311L R311P	TTG CCT	G377T G377V	ACT GTG
N047K	AAG	W112Y	TAT	N178V	GTG	N245K	AAG	R311Q	CAG	G377Y	TAT
N047L	CTT	E113A	GCT	N178W	TGG	N245L	CTG	R311S	TCT	G378D	GAT
N047M N047P	ATG	E113C E113D	TGT GAT	N178Y	TAT	N245P N245Q	CCG CAG	R311T	ACT	G378E	GAG TTT
N047P N047Q	CCT CAG	E113D E113F	TTT	H179A H179C	GCT TGT	N245Q N245R	CGG	R311V R311W	GTG TGG	G378F G378I	ATT
N047R	CGG	E113G	GGG	H179E	GAG	N245S	TCG	S312A	GCT	G378K	AAG
N047S	TCT	E113H	CAT	H179G	GGG	N245T	ACG	S312C	TGT	G378L	CTG
N047T N047V	ACG GTG	E113L E113P	CTT CCT	H179I H179K	ATT AAG	N245V N245W	GTG TGG	S312E S312F	GAG TTT	G378M G378N	ATG AAT
N047W	TGG	E1130	CAG	H179L	CTG	R246A	GCG	S312G	GGG	G378Q	CAG
N047Y	TAT	E113R	CGT	H179M	ATG	R246C	TGT	S312H	CAT	G378R	AGG
A048C	TGT	E113S	TCT	H179N	AAT	R246D	GAT	S312K	AAG	G378S	TCT
A048E A048F	GAG TTT	E113T E113V	ACT GTT	H179P H179R	CCT AGG	R246E R246G	GAG GGG	S312L S312M	CTG ATG	G378T G378V	ACT GTG
A048G	GGT	E113W	TGG	H179S	AGT	R246H	CAT	S312N	AAT	G378W	TGG
A048H	CAT	E113Y	CAT	H179T	ACT	R246I	ATT	S312P	CCT	G378Y	TAT
A048I A048K	ATT AAG	E114A E114C	GCT TGT	H179V H179W	GTG TGG	R246K R246L	AAG TTG	S312Q S312R	CAG CGG	K379A K379C	GCT TGT
A048K A048L	CTG	E114C E114D	GAT	L180A	GCT	R246L	ATG	S312K S312T	ACT	K379C	GAG
A048M	ATG	E114G	GGG	L180C	TGT	R246P	CCT	S312V	GTT	K379F	TTT
A048N	AAT	E114H	CAT	L180E	GAG	R246S	AGT	S312W	TGG	K379G	GGG
A048P A048Q	CCT CAG	E114I E114L	ATT CTG	L180F L180G	TTT GGT	R246T R246V	ACG GTT	M313A M313C	GCT TGT	K379H K379I	CAT ATT
A048R	CGG	E114M	ATG	L180H	CAT	R246W	TGG	M313D	GAT	K379L	CTT
A048S	TCT	E114P	CCT	L180I	ATT	V247A	GCG	M313E	GAG	K379M	ATG
A048V A048W	GTT TGG	E114R E114S	CGG TCT	L180K L180M	AAG ATG	V247C V247F	TGT TTT	M313F M313G	TTT GGG	K379N K379R	AAT CGT
A048Y	TAT	E1145 E114T	ACT	L180M	AAT	V247H	CAT	M313U	CAT	K379K	TCT
T049A	GCG	E114V	GTG	L180P	CCT	V247I	ATT	M313K	AAG	K379T	ACT
T049C	TGT	E114W	TGG	L180R	AGG	V247L	CTG	M313L	CTT	K379V	GTT
T049D T049F	GAT TTT	E114Y W115A	TAT GCT	L180S L180T	TCG ACT	V247M V247N	ATG AAT	M313P M313R	CCT CGT	K379W F380A	TGG GCT
T049G	GGG	W115C	TGT	L180W	TGG	V247P	CCT	M313S	TCG	F380C	TGT
T049H	CAT	W115D	GAT	W181A	GCT	V247Q	CAG	M313T	ACT	F380D	GAT
T049I T049K	ATT AAG	W115F W115G	TTT GGT	W181C W181D	TGT GAT	V247R V247S	CGT TCT	M313V M313Y	GTT TAT	F380E F380G	GAG GGG
T049L	TTG	W115H	CAT	W181E	GAG	V2475 V247T	ACT	K314A	GCT	F380I	ATT
T049N	AAT	W115I	ATT	W181F	TTT	V247W	TGG	K314C	TGT	F380L	CTT
T049P T049R	CCG AGG	W115K W115L	AAG CTT	W181H	CAT ATT	V247Y	TAT GCT	K314D K314H	GAT	F380P	CCT CAG
T049R T049S	TCG	W115L W115M	ATG	W181I W181K		R248A R248C	TGT	K314H K314I	CAT ATT	F380Q F380R	CAG
T049V	GTT	W115P	CCT	W181L	CTG	R248D	GAT	K314L	TTG	F380S	AGT
T049W	TGG	W115R	CGG	W181M	ATG	R248E	GAG	K314N	AAT	F380T	ACT
G050A G050C	GCG TGT	W115S W115V	AGT GTG	W181N W181Q	AAT CAG	R248G R248H	GGG CAT	K314P K314Q	CCT CAG	F380V F380W	GTG TGG
G050D	GAT	W115Y	TAT	W181Q	CGT	R248I	ATT	K314Q	CGG	F380Y	TAT
G050E	GAG	R116A	GCT	W181S	TCT	R248L	CTT	K314S	TCG	T381A	AGC
G050F G050H	TTT CAT	R116C R116D	TGT GAT	W181V G182A	GTG GCT	R248M R248P	ATG CCG	K314T K314V	ACT GTT	T381E T381F	GAG TTT
G050H G050L	CAT	R116D	GAG	G182A G182C	TGT	R248P R248S	TCG	K314V K314W	TGG	T381F	GGT
G050M	ATG	R116G	GGG	G182D	GAT	R248T	ACG	K314Y	TAT	T381H	CAT
G050P	CCT	R116H	CAT	G182E	GAG	R248V	GTG	S315A	GCT	T381K	AAG
G050Q G050R	CAG CGG	R116I R116L	ATT CTG	G182H G182L	CAT CTT	R248W R248Y	TGG TAT	S315C S315E	TGT GAG	T381L T381N	TTG AAT
G050K G050S	AGT	R116L	AAT	G182L G182M	ATG	E249A	GCT	S315E S315G	GGT	T381P	CCT
G050V	GTT	R116P	CCT	G182N	AAT	E249G	GGG	S315H	CAT	T381Q	CAG
G050W	TGG	R116Q	CAG	G182P	CCT	E249H	CAT	S315I	ATT	T381R	CGT
G050Y Q051A	TAT GCG	R116S R116T	TCT ACT	G182Q G182R	CAG CGT	E249I E249K	ATT AAG	S315K S315L	AAG CTG	T381S T381V	AGT GTG
200111	000	11101	1101	01021	0.01	LL 7/11	1110	55151	010	1501 4	010

					PH20 V	/ariants					
mut	cod										
Q051C	TGT	R116V	GTG	G182S	AGT	E249L	CTG	S315M	ATG	T381W	TGG
Q051D Q051F	GAT TTT	R116W P117D	TGG GAT	G182T G182V	ACT GTT	E249M E249P	ATG CCT	S315P S315R	CCT CGG	T381Y V382E	TAT GAG
Q051H	CAT	P117E	GAG	G182Y	TAT	E249Q	CAG	S315T	ACT	V382G	GGG
Q051I	ATT	P117F	TTT	Y183A	GCT	E249R	CGG	S315V	GTT	V382H	CAT
Q051K Q051M	AAG ATG	P117G P117H	GGT CAT	Y183C Y183D	TGT GAT	E249S E249T	TCT ACT	S315W S315Y	TGG TAT	V382I V382K	ATT AAG
Q051N	AAT	P117I	ATT	Y183E	GAG	E249V	GTG	C316A	GCT	V382L	TTG
Q051P	CCT	P117K	AAG	Y183G	GGG	E249W	TGG	C316D	GAT	V382M	ATG
Q051R Q051S	CGG TCT	P117N P117Q	AAT CAG	Y183I Y183K	ATT AAG	E249Y A250C	TAT TGT	C316E C316G	GAG GGG	V382N V382P	AAT CCT
Q051T	ACG	P117R	AGG	Y183L	TTG	A250F	TTT	C316I	ATT	V382Q	CAG
Q051W	TGG	P117S	TCG	Y183N	AAT	A250G	GGT CAT	C316K C316L	AAG	V382R	CGG
Q051Y G052A	TAT GCT	P117T P117V	ACT GTT	Y183P Y183Q	CCT CAG	A250H A250K	AAG	C316L C316M	CTG ATG	V382S V382T	TCG ACT
G052C	TGT	P117W	TGG	Y183R	CGT	A250L	CTG	C316P	CCT	V382W	TGG
G052E	GAG	P117Y	TAT	Y183S	TCT	A250M	ATG	C316R	AGG	V382Y	TAT
G052F G052H	TTT CAT	T118C T118D	TGT GAT	Y183V Y183W	GTT TGG	A250N A250P	AAT CCT	C316S C316T	TCT ACT	R383A R383E	GCT GAG
G052K	AAG	T118E	GAG	Y184A	GCT	A250Q	CAG	C316V	GTT	R383F	TTT
G052L	CTT	T118G	GGG	Y184C	TGT	A250R	AGG	C316W	TGG	R383G	GGG
G052N G052P	AAT CCT	T118H T118K	CAT AAG	Y184D Y184E	GAT GAG	A250S A250T	TCT ACG	C316Y L317A	TAT GCT	R383H R383I	CAT ATT
G052Q	CAG	T118L	CTG	Y184F	TTT	A250V	GTG	L317C	TGT	R383K	AAG
G052R	CGG	T118M	ATG	Y184G Y184H	GGT	A250W	TGG	L317D	GAT	R383L	CTG
G052S G052T	AGT ACT	T118N T118P	AAT CCT	Y184H Y184K	CAT AAG	I251C I251D	TGT GAT	L317G L317H	GGG CAT	R383M R383N	ATG AAT
G052W	TGG	T118Q	CAG	Y184L	CTT	I251F	TTT	L317I	ATT	R383P	CCT
G052Y	TAT	T118R	CGT	Y184M	ATG	I251G	GGG	L317K	AAG	R383S	TCG
V053A V053C	GCG TGT	T118V T118W	GTT TGG	Y184P Y184R	CCT AGG	I251H I251K	CAT AAG	L317M L317N	ATG AAT	R383T R383V	ACT GTG
V053D	GAT	T118Y	TAT	Y184S	TCG	I251L	CTT	L317P	CCT	R383W	TGG
V053E	GAG	W119A	GCT GAT	Y184V	GTG	I251M I251P	ATG	L317Q	CAG	G384A	GCT
V053G V053H	GGG CAT	W119D W119E	GAG	Y184W L185A	TGG GCT	1251P 1251Q	CCG CAG	L317R L317S	AGG TCG	G384C G384D	TGT GAT
V053L	CTG	W119F	TTT	L185D	GAT	I251S	AGT	L317T	ACT	G384E	GAG
V053N V053P	AAT CCG	W119G W119I	GGT ATT	L185E L185F	GAG TTT	I251T I251V	ACT GTG	L317W L318C	TGG TGT	G384F G384H	TTT CAT
V053P	CAG	W1191 W119K	AAG	L185G	GGG	1251W	TGG	L318C	GAT	G384I	ATT
V053R	CGG	W119L	CTG	L185I	ATT	I251Y	TAT	L318F	TTT	G384K	AAG
V053S V053T	AGT ACT	W119N W119P	AAT CCT	L185K L185N	AAG AAT	R252A R252D	GCT GAT	L318G L318H	GGG CAT	G384L G384M	CTT ATG
V053W	TGG	W119Q	CAG	L185P	CCT	R252E	GAG	L318I	ATT	G384P	CCT
V053Y	TAT	W119R	CGG	L185R	CGG	R252F	TTT	L318K	AAG	G384Q	CAG
T054A T054D	GCG GAT	W119S W119V	TCT GTT	L185S L185T	TCG ACT	R252G R252H	GGT CAT	L318M L318N	ATG AAT	G384R G384S	AGG TCG
T054E	GAG	W119Y	TAT	L185V	GTG	R252I	ATT	L318P	CCT	G384T	ACT
T054F	TTT	A120C	TGT	L185W	TGG	R252K	AAG	L318Q	CAG	K385A	GCT
T054G T054H	GGG CAT	A120D A120F	GAT TTT	L185Y F186A	TAT GCT	R252L R252N	CTG AAT	L318R L318S	CGG AGT	K385C K385G	TGT GGG
T054I	ATT	A120G	GGG	F186D	GAT	R252P	CCT	L318T	ACT	K385H	CAT
T054M T054N	ATG AAT	A120H A120I	CAT ATT	F186G F186H	GGT CAT	R252S R252T	TCG ACT	L318W L319C	TGG TGT	K385L K385M	CTT ATG
T054N T054P	CCG	A1201 A120L	CTT	F186H F186I	ATT	R2521 R252V	GTG	L319C	GAG	K385M K385N	AIG
T054Q	CAG	A120N	AAT	F186K	AAG	R252Y	TAT	L319F	TTT	K385P	CCG
T054R T054S	CGT AGT	A120P A120R	CCT CGT	F186L F186N	CTT AAT	V253A V253D	GCG GAT	L319G L319H	GGG CAT	K385Q K385R	CAG CGT
T054S T054V	GTT	A120K A120S	TCT	F186P	CCT	V253D V253E	GAG	L319H L319I	ATT	K385S	TCT
T054Y	TAT	A120T	ACT	F186Q	CAG	V253G	GGG	L319K	AAG	K385T	ACG
I055A I055C	GCT TGT	A120V A120W	GTG TGG	F186R F186S	AGG TCT	V253H V253I	CAT ATT	L319M L319P	ATG CCT	K385V K385W	GTT TGG
1055C 1055D	GAT	A120W A120Y	TAT	F186V	GTT	V253L	CTG	L319P L319Q	CAG	K385Y	TAT
I055F	TTT	R121A	GCT	F186W	TGG	V253M	ATG	L319R	AGG	P386A	GCG
I055G I055H	GGG CAT	R121C R121D	TGT GAT	F186Y P187A	TAT GCT	V253N V253P	AAT CCT	L319S L319V	TCG GTT	P386C P386F	TGT TTT
1055L	CTG	R121D R121E	GAG	P187A P187F	TTT	V253Q	CAG	L319W	TGG	P386G	GGG
I055N	AAT	R121F	TTT	P187G	GGG	V253R	CGG	L319Y	TAT	P386H	CAT
I055P I055Q	CCT CAG	R121G R121H	GGT CAT	P187H P187I	CAT ATT	V253S V253T	TCG ACG	D320C D320E	TGT GAG	P386I P386L	ATT CTT
1055Q 1055R	CGT	R121H R121K	AAG	P187L	CTT	V253W	TGG	D320E D320F	TTT	P386M	ATG
1055S	TCG	R121L	CTG	P187M	ATG	S254C	TGT	D320G	GGG	P386N	AAT
1055T 1055V	ACT GTT	R121M R121P	ATG CCT	P187N P187Q	AAT CAG	S254D S254E	GAT GAG	D320H D320I	CAT ATT	P386Q P386R	CAG CGT
1055 Y	TAT	R1215	TCG	P187R	AGG	S254G	GGG	D320K	AAG	P386S	AGT
F056A	GCG	R121T	ACT	P187S	TCG	S254I	ATT	D320L	TTG	P386T	ACG
F056C	TGT	R121V	GTT	P187T	ACT	S254K	AAG	D320M	ATG	P386V	GTT

TABLE 8-continued

mut cod mut cod mut cod mut cod F056E GAG R121W TGG P187V GT S254L TTG D220N AAT P386Y TAT F056G GGG R111 TAT P187W TGG S254P CGG D220N AGT T387E GGG F056G ATG N122E GTG D188C TTT S254P GCG D230W TGG F387F ATT F0566 CTG N122L ATT D1886 GGG S254W TGG D321A GT T387F ATT F0569 CTG N122D CTG D188M ATT S254W TGG D321A GT T387C AGT F056V GTT N122D CTG D188M ATG S254W TGG D321A GT T387C ATG F056V T1122D ATG D188M ATG S255A CG						PH20	Variants					
F056G GG R1122A GCT F187F TTA S254P CAG D320P CCT T387F TTA F056H ATT N122A GG D188F TTT S254P CAG D3208 AGT T387F TTT F056K AG N122I ATT D188G GG S254F CG D320W TGG T387H CAT F056N CG N122L CTG D188H CAT S254W TGG D321A GCT T387K AAG F056N CT N122D CAG D188N AT R525A GCG N321H CAT T387N ATT F056N GG N122T CT D188N AGG R255H CAT N321K AGG T387N ATT F057D GG N122T AGT D188N AGG R255N AGT N321H AGT T387N TAT F057F GGG N122T <td>mut</td> <td>cod</td> <td>mut</td> <td>cod</td> <td>mut</td> <td>cod</td> <td>mut</td> <td>cod</td> <td>mut</td> <td>cod</td> <td>mut</td> <td>cod</td>	mut	cod	mut	cod	mut	cod	mut	cod	mut	cod	mut	cod
PROSEN CAT N122C GCT P132N TAT S254P CCT D20R AGG T387E GAG PROSEN AAG N122E GAG D188A GCT S254P CAG D232N GTG T387F GTG PROSEN AAT N122E TAT D188K CAT S254V GTG D322N TAT T337I ATT POS6N CAT N122L CAG D188N AAT S254V GTG N321H CAT T387N ATG POS6N CTT N122D CAG D188N AAT S252C GTG N321H ATT T387N ATG POS6V TT N122D CAG D188N AGG N321H ATT T387N TAG POS7D GAT N122D TAT D188N ACT S252L TCG N321H CTT L388N CAT POS7D GAG N122D TAT <												
FOS6K AG N12E GG Disk GCT S254P CAG Dizzes AG Disk GG S254P ACT Dizzes AG Disk GG S254P ACT Dizzes TAT TSTFH CAT FOS6N AT N1221 ATT DIsks ATT S254P ATT N321A GCT TSTFH CAT FOS6N CTT N122D CAG DIsks AG ATT N321A CAT TSTFH CAT FOS6F CTT N122D CAG DIsks AG R255D GCT N321H CAT TSTFH TAT FOS6F GTT N122T CAT DISKS GGG N221K AG TSTFH CAT N321H CAT TSTFH TAT N375T TGT TSTFT TGT N375T TGT TSTFT TAT N375T TGT N375T TGT N375T TGT N375T TGT N												
PioS6N AT N1221 TT D188G GG S244 ACT D230W TGG TB37H CAT PioS6N CG N122L KAG D188H CAT S244W TGG D121A CAT TS37K AAG PioS6N CT N122L CAG D188H AT RS25A GCG N321L GAT TS37M ATT PioS6W GG N122L CAG D188N AGG R255D GAT N321L CAT TS37N ATT ViDS7D GAT N122T CAT D188N AGG R255N CAT N321K AGG TS37V GTT ViDS7D GAT N122T CAT D188N ACT R255N CAG N321R CAG L38K AGG ViDS7D GAT N122A GAT C189N GGG R255N GCG N321R CAG L38K CAG ViDS7T ATG												
POS6N AAT N1221 ATT D1886 GGG S244V GTG D120V TAT TAT TAT AAG PO56P CG N122L CG D1884 ATT S254V TAT N321D GAT T387L CTG PO56S TCT N122D CGT D188N AAT R255C GG N321L CAT TS7N AAT PO56V GT N122D CGT D188N AGG R255L CAT N321L CAT TS7N AGG Y057G GAT N122V CTT D188N AGG R255L CGG N321L CAT TS7N TAT Y057F GAT N122V CAT D188N TGG R255L CGG N321L CAT L388L GGT Y057T AGG W122D GAT C188A GGT R252S CAG N321L CAT L388L CAT Y057T TT												
FO56P CCG N122L AGG D188H CAT S254W TGG N121L GAT T387L CTG F056R GCT N121L CAT D188M ATG S255A GCG N321E GAT T387L CTG F056W GTT N122Q CAG D188N CCT S255D GAT N321L CTT T387T TGG F056W TGT N122S TCT D188N AGG K255L CAT N321L ATT T387V TGT Y057E GAG N122V TGG D188V GTG K255P CCA N321L CTL L388L CTT Y057T GTG W123C TGT C189A GCT K255F CCA N321L CTL L388L CTT Y057T GTG W123D GTG C189A GGT K255F CAT N321L GTG L388L ATT Y057T AGG <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>												
FOS65 TCT N122M ATG L325A GCG N321E GAG T387N ATG FOS6F ATT N122Q CAG D188N ACG K255D GAT N321E CAT T387N ATT FOS6W GT N122X CTT D188N AGG K255E CAT N321L ATG T387V GTT Y057D GAG N122V GTG D188N AGG K255E CAG N321L CTG T387V TAT Y057G GGG W122V GTG D188N GTG K255E CAG N321L CTG L38A GCG K36G Y057D CGG W123C CTG C18A GCT K255N CAG N321L CTG L38A GCG K36G Y057N CTG W123D CTG C18A K25N CAG N321L GTG L38A CT Y057D CAG W132A GT K18A K25N <												
FO56V GT N1210 CAT N3216 GAT T337N AAT FO56V GG N122R CGG D1880 CGC F255G GAT N3211 ATT TSTS TGG Y057D GAT N122T ACT D1888 AGT K255L TIG N321L ATG TSTS TGG Y057D GAT N122T ACT D1888 AGT K255N AAT N321L AGT TSSA GG Y057F TTT N122D GAT C189E GG K255N CG N321L CTT L388A GCG Y057T ATG W123D GAT C189E GG C255Y TAT N321L ATT L388A CAG Y057T AGG W123D AGT C186A GCT Y322E GAT L388A CAG Y057X GTG W123A AGT C189A AGT L256C GGT Y322L </td <td></td>												
F056W GTT N122LQ CAG D188P CCT S235D GAT T387.TCG CMG F056W GG N122X CTT D188R AGG K255H CAT N321K AAG TS7.TCG F057D GAG N122Y CTT D188R AGT K255N AAT N321K AGG TS7.TT TT TS7.TT TT N122Y CTT D188V GG K255N CAG N321K CTT L38A GGG Y057T GGG W123C CTT C189A GCT K255N CG N321K CTT L38B CT Y057T CGG W123C GGT C189K AAG K255N GGT N321K AT L38K ATT Y057D CGG W123D ATT C186K CAT L38K ATT L38K ATT L38K AT L38K AT L38K AT L38K AT L38K AT<												
Y057D GCT N182R AGG S235H CAT N321K AAG TAS TAT TAT <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>												
Y057D GAT N122T ACT D188S ACT R255L TIG N321L CIG T387Y TAT Y057F TIT N122W TGG D188V TGG K255P CGG N321P CCT L388A GGG Y0577 ATT W122D TGT C189A GGT K255P CGG N321P ACT L388G GGG Y0577 ATG W123D GAT C189E GGT K255P TAT Y321V GTA L388H ATT Y057P CGG W123L CTT C189L AAG K255V TAT Y322D CAT L388H AAT Y057P CGG W123L CTT C189L TGG K255V TAT Y322D GAT L388H AT Y057S AGG W123P CTT C189L AGG T256C GAT Y322D GAT L388V TGG Y057W TGG <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
Y057E GAG N122V GTT D188T ACT K255N AAT N321M ATG T387A TAT Y057F TT N122N GGT D188W TGG R255R CGG N321P CGG L388A GGG Y0571 ATT W123C GAT C189A GCT K255R CGG N321P ACT L388F TTT Y057P CGG W123E GAG C189K ACT K255T ACT N321P AT L388F ATT Y057P CGG W123L CAT C189M ACT L36C GTT L388F CAT Y0577 AGT W123D CAG C189M ACT L36C GTT L388F CGT Y0577 AGT W123A AGT C189T ACT 1256L CTT Y322L CAT L38RF CTG Y057W TGG W123A AGT C189T AGT Y3												
Y057G GGG W123A GCT D188W TGG K235C CGG N321R CGG L381R TTT Y057L TTG W123D GAT C189E GAG K255S TGG N321R CGC L388F TTT Y057P CGG W123E GAG C189K AAG K255V GTT N321V TG L388H ATG Y057P CGG W123L CAT C189K AAG K255V TGT S122D GAT L388H ATG Y0577 AGG W123M ATG C189M ACT I256C GAT Y322G GAT L388V TAG Y057V GTG W123R AGT C189R AGG 1256D GAT Y322G GAT L388V TAG Y058K GTT W123Y ATT C189V GGG Y322R CGT E389F TTT Y058K ATG K124D GAT <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
Y057L ATT W122C TGT L189A GCT K255R CGG N321S TCT L388F GTT Y057L ATG W123E GAG C189G GGT K255F ACT N321V GTG L388H ATT Y057P CGG W123L CTT C189L AAG K255V TAT Y32LV TAT L388H ATT Y057P CGG W123L CTT C189L AAG K255V TAT Y32LP CAT L388L CCT Y057S CGG W123P CCT C189N ACT 1256L GAG Y322L CAT L388V TGG Y057V GTG W123N AGT C189N CAT L256L GAG Y322L CAT L388V TGG Y058V GTG W123V GTT C189V TGT 1256L CAT Y322L CAT L388V TAC Y058K AGT <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>												
Y057L TIG W12D GAT C189E GAG R255 TCG N321T ACT L388G GGG Y057P ACG W123G GGG C189H CAT K255V TGT N321Y TAT L388H CAT Y057R ACG W123H CAT C189K AAG Y25V TAT Y322D GAT L388H CAT Y0577R ACG W123M ATG C189M ACT I256C CT Y322D GAT L388R CAT Y0577K GTG W123A AGG C189D ACG I256C GGT Y322H CAT L388K TGT Y057W GTG W123S AGT C189T ACG I256H CAT Y322H CAT L388K TGG Y058K AGT K124A CT CT W123Y TAT L58H AAT Y322H CAT E389H AAT Y058K AGA												
Y057M ATG W123E GAG C189G GTR K255V GTC N321V TAT L388I ATT Y057Q CAG W123H CAT C189K AAG K255V TGT N321V TAT L388I ATG Y057R CGG W123L CTT C189M ATG L55C TAT Y322D GAT L388K CCT Y0577 ACG W123R ATG C189M ATG L55C TAT Y322D GAT L388K CGT Y057V TGG W123R AGT C189T ACT 1256L CAT Y322L CTG L388K GTG V058K GAT W123V GTT C189V TAT 1256H CAT Y322L CTG E388K TAG V058K AAG K124A GTT C189V TAT 1256H CAT Y322L CTG E389H CAT V058K AAG												
Y057Q CAG W123H CAT C189K AAG K255W TAT Y322D GAT L388P CCT Y057S AGT W123M ATG C189M ATG I256A GCT Y322D GAG L388P CCT Y057V TGG W123R AGG C189M ACT I256D GAT Y322D GAT L388S TCG Y057V TGG W123R AGT C189V TCT I256H GAT Y322L CAT L388V TAT V058G GAT W123V AGT C189V TAT C156H CAT Y322L CAT L388V TAT V058G GAT W123V ATT C189W TGG I256H CAT Y322L CAT L388V TAT V058G GAT K124A GCT C189W TGG I256H CAG Y322L ACT E389K AAG V058K CAG <t< td=""><td>Y057M</td><td>ATG</td><td>W123E</td><td>GAG</td><td>C189G</td><td>GGT</td><td>K255T</td><td>ACT</td><td>N321V</td><td>GTG</td><td>L388H</td><td>CAT</td></t<>	Y057M	ATG	W123E	GAG	C189G	GGT	K255T	ACT	N321V	GTG	L388H	CAT
YO57R CGG W123L CTT C189L TTG R255Y TAT Y322D GAT L388P CCT Y057N AGG W123P CCT C189N ACT 1256C TGT Y322E GAT L388R CGT Y057V GGG W123Q CAG C189P ACT 1256C GAG Y322H CAT L388R CGT Y057W GGG W123X AGT C189P ACT 1256L CAT Y322L ATT L388V TGT V058K GAT W123V GTT C189V TGT 1256P CAT Y322L CTE E389F TT V058K GAT K124C GTT Y190C GGT 1256P CAG Y322L CTE E389H CAT V058K CAT K124E GAG Y190C TGT 1256P CAG Y322V GGE E389H CAT V058K CGG <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
Y0575 AGT W123M ATG C189M ATG I256A GCT Y322E GAG L388R CGT Y057V GTG W123Q CAG C189P CCT I256D GAT Y322F TTT L388R CGT Y057V GTG W123R AGG C189P CCT I256B GAG Y322H CAT L388V TAT V058K GAT W123V ACT C189V TAT I256H CAT Y322L CAT E388V TAT V058G GAT W123V TAT C189W TAT I256H CAT Y322L CAT E389H ATT V058G GAT K124L GAT TY190G GGG I256P CAG Y322L ACT E389H ATT V058L CAT K124L GAT Y190G GGG I256V GT M323 GAT E389H ATT V058L CAG <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
Y057V GTG W123Q CAG C189P CCT 1256E GAG Y322G GCT L388T ACG Y057W TGG W123R AGG C189P TCG 1256E GAG Y322I ATT L388V TGG V058C GT W123Y ATT C189W TGG 1256L CTT Y322L ATT L388V TGG V058G GGT W123Y ATT C189W TGG 1256L CTT Y322L ATT E389A GTT V058K AAG K124A GCT TTY P190C GAG 1256P CCG Y322F CTF E389H ATT V058K AAG K124F TTT Y190C GAG 1256V GTG M323A GCT E389H AGT V058R CGG K124H ATT Y190D CAT P257T GTG M323F MAG M323G GGG E389H CAT <	Y057S		W123M	ATG			I256A	GCT	Y322E	GAG		CAG
Y057W TGG W123R AGG C189R AGG I256G GGG Y322L CAT L388V GTT Y058C TGT W123T ACT C189F ACT I256G GGG Y322L ATT L388V TGT Y058C GGT W123Y ATT C189V TGG I256L CTT Y322L CTE E389A GCT Y058L CAT K124A GCT C189Y TAT I256N ATG Y322L CTE E389G GTT Y058L ACA K124F TTT Y190C GGG I256U ACG Y322L CTE E389H ATT Y058L CTT K124F GTT Y190C CTT I256V GTT M323A GCT E389H ATT Y058R CGG K124H TT Y190N AAT P257A GCG M323F TT E389H ATT Y058R CGG												
V058A GCT W123S ACT C189S TCG 1256H CAT Y322L CTG L388W TGT V058G GAT W123Y GTT C189V GG 1256L CTT Y322L CAT L388W TGT V058G GGT W123Y TAT C189V TGG 1256N ATT Y322P CCT E389A GCT V058H ATT K124A GCT TTY Y190C TGT Y256P CCG Y322F CCT E389H CAT V058L AAG K124F TTT Y190C GGG 1256R AGG Y322V TGG E389H ATT V058L CAG K124H CAT Y190C CAT Y256R GGG M323F GTT E389H AGT V058R CGG K124H CAT Y190N AAT P257D GAT M323G GG E389H CAT V058R												
V058D GAT W123V TAT C189V TGG I256L CTT Y322P CAT I.388Y TAT V058H CAT K124A GCT V190C TGG I256N AT Y322P CCT E389A GCT V058H ATT K124C TGT Y190C TGT I256P CGG Y322T ACT E389H CAT V058L CTT K124E GAG Y190C GGG I256P CGG Y322T ACT E389H CAT V058L CCTT K124E GAG Y190F TTT I256R GGG Y322V TGT E389H ATT V058L CCG K124H CAT Y190H CAT I256V GTG M323E GAG B389P CT V058R CGG K124H CAT Y190N CAT P257L GAT M323G GGE E389P ACT V058W TAT <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>												
V058G GGT W123Y TAT C189W TGG I256M ATG Y322P CCT E389A GCT V058H CAT K124A GCT C189Y TAT I256P CCG Y322R CGT E389F TTT V058L CTT K124C GGT Y190E GGA I256P CAG Y322V TGE E389H ATT V058L CTT K124E GAG Y190E GCT IZ56N CAG Y322V TGE E389H ATT V058L CTT K124E GTT Y190C GAG IZ56V GTG M323C GGT E389H ATG V058R CGG K124L ATT Y190L CTT P257C GGT M323F TTT E389A CGT V058R TGG K124P CTT Y190D CCT P257L ATG M323L ATG B389A ACG V058R TGG <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>												
V058H CAT K124A GCT C189Y TAT I256N AAT Y322R CGT E389G GGT V058I ATT K124C TGT Y190C TGT I256P CG Y322R ACT E389H CAT V058L CTT K124E GAG Y190F TTT I256R AGG Y322V TGG E389H ATT V058N AAT K124F TTT Y190G GGG IZ56V GTG M323C GCT E389H AAG V058R CGG K124L CTT Y190K AAG P257A GGG M323E GAG E389P CCT V058W TGG K124L CTT Y190C CAG P257G GAG M323E GAG E389P CCT V058W TGG K124L CTT Y190C CAT P257L ATT M323L AGG E389F TT D059A GCT												
V058K AAG K124D GAT Y190E GAG 1256Q CAG Y322T ACT E389H CAT V058L CTT K124E GAG Y190F TT 1256R AGG Y322V TGG E389L ATT V058N CCT K124G GGG Y190H CAT 1256V GT M323A GCT E389L CTG V058R CGG K124H CAT Y190K AAT P257C TGT M323F TTT E389L CAG V058S TCG K124L CTT Y190N AAT P257C TGT M323F TTT E389P CCT V058W TGG K124L CTT Y190N ACT P257D GAT M323G GGG E389V GTT D059G GAG K124R CGG Y190T ACT P257T AAG M323L ATT E389T ACT D059G GAG							I256N					
V058L CTT K124E GAG Y190F TTT 1256R AGG Y322V GTG E3891 ATT V058N AAT K124F TTT Y190G GGG 1256T ACG Y322V TGG E389L CTG V058Q CAG K124H CAT Y190K AAG 1256V GTG M323C TGT E389L CTG V058R CGG K124H CAT Y190N AAT P257A GCG M323F TTT E389Q CAG V058W TGG K124H CAT Y190P CCT P257D GAT M323F TTT E389V CCG V058W TAT K124P CCT Y190P CT P257K AAG M323L TC E389T ACT D059G GGG K124V GTG Y190V TGG P257N AAT M323D ACT D390A GCG D059I ATT												
V058N AAT K124F TTT Y190G GGG 1256V GCT M323A GCT E389K AAG V058P CCG K124H CAT Y190K AAG 1256V GG M323C TGT E389M ATG V058R CGG K124H CAT Y190K CAT P257C TGT M323C GGG E389M CCT V058K TGG K124L CAT Y190P CCT P257D GAT M323C GGG E389R CGG V058W TGG K124L CAT Y190Q CAG P257G GGG M323L TTG E389R CGG D059A GCT K124R CGG Y190V ACT P257L CTT M323L ATT E389Y TAT D059G GGG K124V GTG Y190V ACT P257L CTT M323L ATG D390C GGT D390A AGG D390A							-					
V058Q CAG K124H CAT Y190K AAG I256W TGG M323C TGT E389M ATG V058R CGG K124I ATT Y190L CTT P257A GCG M323F TGT E389Q CAG V058W TGG K124N AAT Y190P CCT P257D GAT M323G GGG E389Q CAG D059B GCT K124P CCT Y190R CAT P257L GAT M323K AAG E389V GTT D059G GGG K124T ACT Y190V TCT P257L ATT M323K AAG E389V GTT D059G GGG K124V TGT Y190V TGG P257N ATG M323R AAT D390A GCG D059H CAT K124V TGG Y190V TGG P257N AAT M323R CGG D390E GAG D059J ATT <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>I256T</td><td></td><td></td><td></td><td></td><td></td></t<>							I256T					
V058R CGG K1241 ATT Y190L CTT P257A GCG M323E GAG E389P CCT V0588 TCG K124L CTT Y190N AAT P257C TGT M323G GGG E389R CCG V058W TAT K124P CCT Y190Q CAG P257C GGG M323I ATT E389S TCG D059A GCT K124R CGG Y190R CCT P257L ATT M323I ATT E389T ATT D059G GGG K124F CT Y190T ACT P257L CTT M323K AAT D390A GCG D059H CAT K124W GG Y190V GG P257N AAT M323K AAT D390A GCG D059L CAT K124W TGG Y190V TGG P257N AAT M323K AGT D390A ATT D059L CAT P												
V0588 TCG K124L CTT Y190N AAT P257C TGT M323F TTT E389Q CAG V058W TGG K124N AAT Y190P CCT P257D GAT M323F CAT E389R CGG D059A GCT K124R CGG Y190C CGT P257L CTT M323I ATT E389Y ACT D059G GGG K124R CGG Y190T ACT P257L CTT M323I AAT D390A GCG D059H CAT K124V GTG Y190V ACG P257N AAT M323F AAT D390A GCG D059L CTT P125A GCT N191A GCT P257R CGT M323F ACT D390F TTT D059L ATT P125D GAT N191F TT P257V GGG M323F ACT D390F TTT D390H CAT <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
V058Y TAT K124P CCT Y190Q CAG P257G GGG M323H CAT E389T ACT D059A GCG K124R CGG Y190R TCT P257I ATT M323I ATT E389V GTT D059G GGG K124T ACT Y190V ACT P257L CT M323I AAT D390A GCG D059H CAT K124V GTG Y190V GTG P257N AAT M323N AAT D390A GCG D059H CAT K124V GTG Y190V GTG P257N AAT M323N AAT D390A GCG D059H ATT P125C GT N191E GAG P257N CG M323S AGT D390G GGG D059N AAT P125D GAT N191F ATT P257N TGG M323S ACT D390F CTT D059P CCT P												
D059A GCT K124R CGG Y190R CGT P257I ATT M323I ATT E389T ACT D059E GAG K124S TCT Y190S TCT P257K AAG M323K AAG E389V GTT D059H CAT K124V GTG Y190V GTG P257L CTT M323N ATD D390A GCG D059H CAT K124V TGG Y190V TGG P257N AAT M323N ACT D390C TGT D059L CTT P125A GCT N191A GCT P257R CGT M323N AGT D390C TGT D059N AAT P125D GAT N191F TTT P257S TCG M323N AGT D390H CAT D059Q CAG P125L CAT N191K AAG P257V GTG E324A GCT D390L CAT D059V CAG <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>												
D059E GAG K124S TCT Y190S TCT P257K AAG M323K AAG E389V GTT D059G GGG K124T ACT Y190V GTG P257L CTT M323L TTG E389Y TAT D059H ATT K124V GTG Y190V GTG P257N ATG M323N AAT D390A GCG D059L CTT P125A GCT N191A GCT P257Q CAG M323R CGG D390F TTT D059N AAT P125D GCT N191E GAG P257R CCT M323S ACT D390F TTT D059N AAT P125G GGG N191F TTT P257N TCG M323T ACT D390H CAT D059Q CAG P125L CAT N191K AAG P257V GG E324A GCT D390N AAT D059V GTG <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
D059H CAT K124V GTG Y190V GTG P257M ATG M323N AAT D390A GCG D059I ATT K124W TGG Y190W TGG P257N AAT M323P CCT D390C TGT D059L CTT P125A GCT N191E GAG P257R CAG M323R AGT D390F TTT D059N AAT P125D GAT N191F TTT P257S TGG M323X ACT D390F TTT D059N AAT P125G GGG N191F TTT P257S TGG M323V GTT D390H CAT D059Q CAG P125H CAT N191K AAG P257V TGG E324C GT D390N AAT D059T ACG P125L CTT N191M ATG D258A GGG E324L GT D390R CGG D059V TGG												
D059I ATT K124W TGG Y190W TGG P257N AAT M323P CCT D390C TGT D059L CTT P125A GCT N191A GCT P257Q CAG M323R CGG D390E GAG D059M AAT P125C TGT N191E GAG P257R CGT M323R ACT D390F TTT D059P CCT P125G GGG N191F TTT P257T ACG M323V GTT D390H CAT D059P CCT P125I CAT N191K AAG P257V ACG M323V GTT D390H CAT D059V CAG P125L CAT N191H ATG D2584 GGE E324L TGT D390R CGG D059V TGG P125L CAT N191R CGG D258E GAG E324F TTT D390V GG D059V TAT <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
D059L CTT P125A GCT N191A GCT P257Q CAG M323R CGG D390E GAG D059M ATG P125C TGT N191E GAG P257R CGT M323S AGT D390F TTT D059N AAT P125D GAT N191F TTT P257S TCG M323S AGT D390F CAT D059P CCT P125G GGG N191F TTT P257V GG E324A GCT D390H CAT D059Q CAG P1251 ATT N191L TTG P257W TGG E324A GCT D390N AAT D059T ACG P125L CTT N191M ATG D258U GGE E324C TGT D390N ACG D059V TTG P125L CAT N191P CCT D258E GGG E324F TTT D390N ACT D059V TGG <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
D059N AAT P125D GAT N191F TTT P257S TCG M323T ACT D390G GGG D059P CCT P125G GGG N191G GGG P257T ACG M323V GTT D390H CAT D059Q CAG P125H CAT N191K AAG P257V GTG E324A GCT D390L CAT D059R CGT P125L CTT N191K ATG D257W TGG E324C TGT D390N AAT D059V GTG P125L CTT N191N ATG D258E GAG E324F TTT D390R CGG D059V TGG P125C CAG N191R CGG D258E GAG E324F TTT D390R CGG D059V TAT P125R CAT N191R CGG D258I CAT E324H CAT D390V TGG R060D GAT <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>												
D059P CCT P125G GGG N191G GGG P257T ACG M323V GTT D390H CAT D059Q CAG P125H CAT N191K AAG P257V GTG E324A GCT D390L CTT D059R CGT P125L CTT N191K ATG P257V TGG E324C GT D390N AAT D059V GTG P125L CTT N191M ATG D258A GCG E324D GAT D390R CGG D059V GTG P125L CTT N191R CGG D258E GAG E324F TTT D390R CGG D059V TAG P125R CAT N191R CGG D258I ATT E324H CAT D390V GTG R060A GCG P125T ACT N191R CGG D258I ATT E324H AAT D390V TAT R060F TTT <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
D059Q CAG P125H CAT N191K AAG P257V GTG E324A GCT D390L CTT D059R CGT P125I ATT N191L TTG P257V TGG E324C TGT D390N AAT D059T ACG P125L CTT N191M ATG D258A GCG E324D GAT D390P CCG D059V GTG P125L CAT N191P CCT D258E GAG E324D GAT D390P CCG D059V TGG P125L CAG N191P CCT D258E GGG E324F TTT D390V ACT D059Y TAT P125R CGT N191R CGG D258H CAT E324L TTG D390V GTG R060A GCG P125V TAT N191T ACT D258L ATT E324N AAT D390V TAT R060G GTT <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>												
D059R CGT P1251 ATT N191L TTG P257W TGG E324C TGT D390N AAT D059T ACG P125L CTT N191M ATG D258A GCG E324D GAT D390P CCG D059V GTG P125L CAT N191P CCT D258E GAG E324F TTT D390R CGG D059W TGG P125C CAG N191P CCT D258E GGG E324F TTT D390R AGT D059Y TAT P125R CGT N191R CGG D258H CAT E324L TG D390V GTG R060D GAT P125T ACT N191T ACT D258L CTT E324L TTG D390V TAT R060D GAT P125V TAT N191T ACT D258L CTT E324N AAT D390V TAT R060G GAT <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
D059V GTG P125N AAT N191P CCT D258E GAG E324F TTT D390R CGG D059W TGG P125Q CAG N191Q CAG D258G GGG E324G GGG D390S AGT D059Y TAT P125R CGT N191R CGG D258H CAT E324H CAT D390V GTG R060A GCG P125T ACT N191R CGG D258I ATT E324H CAT D390V GTG R060D GAT P125T ACT N191T ACT D258I ATT E324H AAT D390V TGG R060F TTT P125V GTG N191V GTT D258N AAT E324H AAT D390V TAT R060G GGT P125V TAT N191V TAT D258N CAG E324P CCT L391A GCT R060H ATT <t< td=""><td>D059R</td><td>CGT</td><td>P125I</td><td>ATT</td><td>N191L</td><td>TTG</td><td>P257W</td><td>TGG</td><td>E324C</td><td>TGT</td><td>D390N</td><td>AAT</td></t<>	D059R	CGT	P125I	ATT	N191L	TTG	P257W	TGG	E324C	TGT	D390N	AAT
D059W TGG P125Q CAG N191Q CAG D258G GGG E324G GGG D390S AGT D059Y TAT P125R CGT N191R CGG D258H CAT E324H CAT D390T ACT R060A GGG P125R TCG N191R TCG D258H ATT E324H CAT D390V GTG R060D GAT P125T ACT N191T ACT D258L ATT E324L TG D390V TGG R060F TTT P125V GTG N191V GTT D258L CTT E324N AAT D390V TAT R060F TTT P125V GTG N191V GTT D258N AAT E324N AAT D390V TAT R060H CAT P125V TAT N191V TAT D258R CGG E324R CGG L391D GAT R060H CAT <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$												
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	D059Y	TAT	P125R	CGT	N191R	CGG	D258H	CAT	E324H	CAT	D390T	ACT
$\begin{array}{cccccccccccccccccccccccccccccccccccc$												
$\begin{array}{cccccccccccccccccccccccccccccccccccc$												
R0601 ATT K126A GCT H192C TGT D258R CGT E324S AGT L391D GAT R060K AAG K126D GAT H192F TTT D258R AGT E324S AGT L391D GAT R060K AAG K126D GAT H192F TTT D258S AGT E324V GG L391G GGG R060L CTT K126E GAG H192G GGT D258T ACG E324W TGG L391H CAT R060N AAT K126G GGT H192L CTT D258W GGT E324Y TAT L391K AAG R060P CCG K126G GGT H192L CTT D258W TAT T325C TGT L391N AAT R060Q CAG K126H CAT H192N AAT A259E GAG T325D GAT L391P CCT R060S TCG <td< td=""><td>R060G</td><td>GGT</td><td>P125W</td><td>TGG</td><td>N191W</td><td>TGG</td><td>D258P</td><td>CCG</td><td>E324P</td><td>CCT</td><td>L391A</td><td>GCT</td></td<>	R060G	GGT	P125W	TGG	N191W	TGG	D258P	CCG	E324P	CCT	L391A	GCT
R060K AAG K126D GAT H192F TTT D258S AGT E324V GTG L391G GGG R060L CTT K126E GAG H192G GGT D258T ACG E324V TGG L391G GGG R060N AAT K126F TTT H192K AAG D258V GTG E324W TG L391K AAT R060P CCG K126G GGT H192L CTT D258V GTG E324Y TAT L391K AAG R060P CCG K126G GGT H192L CTT D258V TGG T325A GCT L391N AAT R060Q CAG K126H CAT H192N AAT A259E GAG T325D GAT L391P CCT R060S TCG K126L CTG H192N AAT A259E GAG T325D GAT L391Q CAG R060T ACG <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
R060L CTT K126E GAG H192G GGT D258T ACG E324W TGG L391H CAT R060N AAT K126F TTT H192K AAG D258V GTG E324W TAG L391H CAT R060P CCG K126F TTT H192L CTT D258V GTG E324Y TAT L391K AAG R060P CCG K126G GGT H192L CTT D258V TAT T325C TGT L391N AAT R060Q CAG K126I ATT H192N AAT D258V TAT T325C TGT L391P CCT R060S TCG K126I ATT H192N AAT A259E GAG T325D GAT L391P CCT R060S TCG K126L CTG H192N AAT A259E GAG T325D GAT L391Q CAG R060V GTT <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>												
R060P CCG K126G GGT H192L CTT D258W TGG T325A GCT L391N AAT R060Q CAG K126H CAT H192M ATG D258Y TAT T325C TGT L391N CAT R060S TCG K126H CAT H192N AAT A259E GAG T325D GAT L391Q CAG R060T ACG K126L CTG H192N AAT A259E GAG T325D GAT L391Q CAG R060T ACG K126L CTG H192P CCT A259E GAG T325D GAT L391Q CAG R060V GTT K126M ATG H192Q CAG A259I ATT T325G GGT L391R CTT R060V TAT K126M ATG H192Q CAG A259I ATG T325H CAT L391T ACT L061A GCT <t< td=""><td>R060L</td><td>CTT</td><td>K126E</td><td>GAG</td><td>H192G</td><td>GGT</td><td>D258T</td><td>ACG</td><td>E324W</td><td>TGG</td><td>L391H</td><td>CAT</td></t<>	R060L	CTT	K126E	GAG	H192G	GGT	D258T	ACG	E324W	TGG	L391H	CAT
R060Q CAG K126H CAT H192M ATG D258Y TAT T325C TGT L391P CCT R060S TCG K126I ATT H192N AAT A259E GAG T325D GAT L391P CCAG R060T ACG K126L CTG H192P CCT A259E GAG T325D GAT L391P CCG R060T ACG K126L CTG H192P CCT A259E GAG T325E GAG L391R CGG R060V GTT K126M ATG H192Q CAG A259I ATT T325G GGT L391R CGT R060V GTT K126N AAT H192Q CAG A259I ATT T325H CAT L391R CTT R060V TAT K126N AAT H192R CGT A259K AG T325H CAT L391V ACT L061A GCT <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>												
R060S TCG K1261 ATT H192N AAT A259E GAG T325D GAT L391Q CAG R060T ACG K126L CTG H192P CCT A259G GGG T325E GAG L391Q CAG R060V GTT K126L CTG H192P CCT A259G GGG T325E GAG L391R CGG R060V GTT K126M ATG H192Q CAG A259I ATT T325G GGT L391S TCT R060Y TAT K126N AAT H192Q CGT A259K AAG T325H CAT L391T ACT L061A GCT K126P CCT H192S TCG A259L TTG T325H CAT L391V GTG L061E GAG K126Q CAG H192T ACT A259M ATG T325K AAG L391V TGG												
R060T ACG K126L CTG H192P CCT A259G GGG T325E GAG L391R CGG R060V GTT K126M ATG H192Q CAG A259I ATT T325G GGT L391R CGG R060V GTT K126M ATG H192Q CAG A259I ATT T325G GGT L391R CTT R060Y TAT K126N AAT H192R CGT A259K AAG T325H CAT L391T ACT L061A GCT K126P CCT H192R TCG A259L TTG T325I ATT L391V GTG L061E GAG K126Q CAG H192T ACT A259M ATG T325K AAG L391V TGG												
R060Y TAT K126N AAT H192R CGT A259K AAG T325H CAT L391T ACT L061A GCT K126P CCT H1928 TCG A259L TTG T325I ATT L391V GTG L061E GAG K126Q CAG H192T ACT A259M ATG T325K AAG L391W TGG												
L061A GCT K126P CCT H192S TCG A259L TTG T325I ATT L391V GTG L061E GAG K126Q CAG H192T ACT A259M ATG T325K AAG L391W TGG												
L061E GAG K126Q CAG H192T ACT A259M ATG T325K AAG L391W TGG												
LU61F TIT K126R AGG H192V GTT A259N AAT T325M ATG L391Y TAT					H192T							TGG
	L061F	ТТТ	K126R	AGG	H192V	GIT	A259N	AAT	T325M	ΑſG	L391Y	TAT

TABLE 3	8-continued
---------	-------------

					PH20 V	/ariants					
mut	cod										
L061G	GGG	K126S	TCT	H192W	TGG	A259P	CCT	T325N	AAT	E392A	GCT
L061H L061I	CAT ATT	K126T K126V	ACT GTG	H192Y H193A	TAT GCT	A259Q A259R	CAG CGT	T325Q T325R	CAG CGG	E392C E392F	TGT TTT
L061M	ATG	K126W	TGG	H193C	TGT	A259S	AGT	T325S	TCG	E392G	GGG
L061N	AAT	K126Y	TAT	H193D	GAT	A259T	ACT	T325V	GTG	E392K	AAG
L061P L061Q	CCT CAG	D127A D127E	GCT GAG	H193F H193G	TTT GGG	A259V A259W	GTG TGG	T325W I326A	TGG GCT	E392L E392M	CTG ATG
L061Q	AGG	D127E D127F	TTT	H1930	AAG	A259W A259Y	TAT	1326A 1326C	TGT	E392M E392P	CCT
L061T	ACT	D127G	GGT	H193L	TTG	K260A	GCG	I326D	GAT	E392Q	CAG
L061V	GTT	D127H	CAT	H193M	ATG	K260C	TGT	I326E	GAG	E392R	AGG
L061W	TGG	D127K	AAG	H193P	CCG	K260D	GAT	I326G	GGG	E392S	AGT
L061Y G062A	TAT GCG	D127L D127M	CTG ATG	H193Q H193R	CAG AGG	K260E K260G	GAG GGG	I326H I326K	CAT AAG	E392T E392V	ACT GTT
G062C	TGT	D127N	AAT	H193S	TCT	K260H	CAT	I326L	CTT	E392W	TGG
G062D	GAT	D127Q	CAG	H193T	ACG	K260L	TTG	I326N	AAT	E392Y	TAT
G062F	TTT	D127R	CGT	H193V	GTG	K260M	ATG	I326P	CCT	Q393A	GCG
G062I G062K	ATT AAG	D127S D127T	AGT ACT	H193Y Y194A	TAT GCT	K260P K260Q	CCG CAG	I326R I326S	CGG TCT	Q393C Q393D	TGT GAT
G062L	CTT	D127V	GTT	Y194C	TGT	K260R	CGG	1326V	GTG	Q393F	TTT
G062M	ATG	D127W	TGG	Y194E	GAG	K260S	TCT	I326W	TGG	Q393G	GGT
G062P	CCT	V128A	GCT	Y194F	TTT	K260V	GTT	I326Y	TAT	Q393H	CAT
G062Q G062R	CAG CGT	V128C V128E	TGT GAG	Y194G Y194I	GGG ATT	K260W K260Y	TGG TAT	L327A L327D	GCT GAT	Q393I Q393K	ATT AAG
G062S	AGT	V128E V128F	TTT	Y194L	TTG	S261A	GCG	L327D L327E	GAG	Q393L	TTG
G062T	ACT	V128G	GGG	Y194N	AAT	S261E	GAG	L327F	TTT	Q393M	ATG
G062V	GTG	V128H	CAT	Y194P	CCT	S261F	TTT	L327G	GGG	Q393N	AAT
G062Y Y063A	TAT GCG	V128I V128K	ATT AAG	Y194Q Y194R	CAG AGG	S261G S261I	GGG ATT	L327H L327M	CAT ATG	Q393P Q393R	CCG CGT
Y063C	TGT	V128L	CTG	Y194S	TCG	S261K	AAG	L327N	AAT	Q393S	TCG
Y063G	GGT	V128P	CCT	Y194T	ACG	S261L	CTT	L327Q	CAG	Q393T	ACG
Y063H	CAT	V128Q	CAG	Y194V	GTG	S261M	ATG	L327R	CGG	F394A	GCG
Y063I Y063K	ATT AAG	V128R V128S	AGG TCG	Y194W K195A	TGG GCG	S261N S261P	AAT CCT	L327S L327T	AGT ACT	F394D F394E	GAT GAG
Y063L	CTG	V128W	TGG	K195A	GAG	S261Q	CAG	L3271 L327V	GTG	F394E	GGG
Y063M	ATG	V128Y	TAT	K195F	TTT	S261R	CGT	L327W	TGG	F394I	ATT
Y063N	AAT	Y129A	GCT	K195G	GGT	S261T	ACT	L327Y	TAT	F394K	AAG
Y063P Y063R	CCT AGG	Y129C Y129D	TGT GAT	K195H K195I	CAT ATT	S261V S261W	GTT TGG	N328A N328C	GCT TGT	F394L F394N	CTG AAT
Y063S	TCT	Y129E	GAG	K195L	TTG	P262A	GCG	N328D	GAT	F394P	CCG
Y063T	ACG	Y129G	GGG	K195N	AAT	P262D	GAT	N328G	GGT	F394Q	CAG
Y063V	GTG	Y129H	CAT	K195Q	CAG	P262E	GAG	N328H	CAT	F394R	CGT
Y063W Y064A	TGG GCT	Y129L Y129M	TTG ATG	K195R K195S	CGT TCT	P262F P262G	TTT GGG	N328I N328K	ATT AAG	F394S F394T	TCG ACT
Y064C	TGT	Y129P	CCT	K195T	ACT	P262H	CAT	N328L	CTT	F394V	GTT
Y064D	GAT	Y129Q	CAG	K195V	GTG	P262I	ATT	N328Q	CAG	F394W	TGG
Y064E	GAG	Y129R	CGG	K195W	TGG	P262K	AAG	N328R	AGG	S395A	GCG
Y064F Y064G	TTT GGT	Y129S Y129T	AGT ACT	K195Y K196A	TAT GCT	P262Q P262R	CAG CGT	N328S N328T	AGT ACT	S395C S395D	TGT GAT
Y064H	CAT	Y129V	GTT	K196C	TGT	P262S	TCT	N328V	GTG	S395E	GAG
Y064I	ATT	Y129W	TGG	K196D	GAT	P262T	ACT	N328W	TGG	S395G	GGG
Y064K	AAG	K130C	TGT	K196E	GAG	P262V	GTG	N328Y	TAT	S395H	CAT
Y064L Y064P	CTT CCT	K130D K130E	GAT GAG	K196G K196I	GGG ATT	P262W P262Y	TGG TAT	P329C P329F	TGT TTT	S395K S395L	AAG CTT
Y064Q	CAG	K130G	GGG	K196L	TTG	L263A	GCT	P329G	GGT	S395M	ATG
Y064R	CGG	K130H	CAT	K196N	AAT	L263E	GAG	P329H	CAT	S395P	CCT
Y064S X064T	AGT	K130I	ATT	K196P	CCG	L263F	TTT	P329I	ATT	S395R	CGG
Y064T Y064V	ACT GTT	K130L K130N	TTG AAT	K196R K196S	CGT TCG	L263G L263H	GGG CAT	P329K P329L	AAG CTG	S395T S395V	ACG GTT
Y064W	TGG	K130Q	CAG	K196T	ACT	L263K	AAG	P329N	AAT	S395W	TGG
P065A	GCT	K130R	AGG	K196V	GTG	L263M	ATG	P329Q	CAG	S395Y	TAT
P065C	TGT	K130S	TCT	K196W K196Y	TGG	L263N	AAT CCG	P329R	CGT	E396A E396C	GCG
P065D P065F	GAT TTT	K130T K130V	ACT GTG	K196Y P197A	TAT GCT	L263P L263Q	CAG	P329S P329T	AGT ACT	E396C E396D	TGT GAT
P065G	GGG	K130W	TGG	P197C	TGT	L263Q	CGG	P329V	GTT	E396F	TTT
P065H	CAT	K130Y	TAT	P197D	GAT	L263S	AGT	P329W	TGG	E396G	GGG
P065I	ATT	N131C	TGT	P197E	GAG	L263T	ACT	P329Y	TAT	E396H	CAT
P065K P065N	AAG AAT	N131E N131F	GAG TTT	P197F P197G	TTT GGT	L263V L263W	GTT TGG	Y330A Y330C	GCT TGT	E396I E396L	ATT CTT
P065R	CGG	N131F N131G	GGG	P197G P197H	CAT	P264A	GCG	Y330D	GAT	E396L E396P	CCG
P065S	TCG	N131H	CAT	P197K	AAG	P264D	GAT	Y330E	GAG	E396Q	CAG
P065T	ACG	N131I	ATT	P197L	TTG	P264E	GAG	Y330F	TTT	E396R	AGG
P065V P065W	GTT TGG	N131L N131M	CTT ATG	P197M	ATG CAG	P264F P264G	TTT GGT	Y330G Y330I	GGT ATT	E396S E396T	TCT ACT
P065W P065Y	TAT	N131M N131P	CCT	P197Q P197R	CAG	P264G P264H	CAT	Y330L	CTG	E3961 E396V	GTG
Y066A	GCG	N131Q	CAG	P197S	AGT	P264L	CTT	Y330M	ATG	E396Y	TAT
Y066C	TGT	N131R	CGG	P197T	ACT	P264M	ATG	Y330N	AAT	K397A	GCT

TABLE 8-continued

					PH20	Variants					
mut	cod	mut	cod	mut	cod	mut	cod	mut	cod	mut	cod
Y066D Y066E	GAT	N131S N131T	AGT ACT	P197W G198A	TGG GCT	P264N P264R	AAT CGG	Y330P Y330R	CCT AGG	K397C K397E	TGT GAG
Y066G	GAG GGT	N1311 N131V	GTG	G198A G198C	TGT	P264K P264S	AGT	Y330S	AGG	K397E K397F	TTT
Y066H	CAT	N131Y	TAT	G198D	GAT	P264T	ACT	Y330V	GTT	K397G	GGT
Y066I	ATT	R132A	GCT	G198E	GAG	P264V	GTT	I331V	GTG	K397I	ATT
Y066K Y066L	AAG CTG	R132C R132E	TGT GAG	G198H G198L	CAT CTG	P264W P264Y	TGG TAT	Y330W I331A	TGG GCT	K397L K397M	TTG ATG
Y066N	AAT	R132E	TTT	G198L G198N	AAT	V265A	GCG	I331A I331C	TGT	K397N K397N	AAT
Y066P	CCT	R132H	CAT	G198P	CCG	V265C	TGT	I331D	GAT	K397P	CCG
Y066R	CGG	R132I	ATT	G198Q	CAG	V265D	GAT	I331E	GAG	K397Q	CAG
K397T K397V	ACT GTT	R132K R132L	AAG TTG	G198R G198S	AGG TCT	V265E V265F	GAG TTT	I331F I331H	TTT CAT	K397R K397S	AGG TCG
F398A	GCT	L406P	CCT	K415G	GGT	C423T	ACT	A432L	TTG	E441D	GAT
F398C	TGT	L406Q	CAG	K415L	CTG	C423V	GTG	A432M	ATG	E441F	TTT
F398E	GAG	L406R	CGG	K415M	ATG	C423W	TGG	A432N	AAT	E441G	GGG
F398G F398H	GGT CAT	L406S L406T	AGT ACG	K415P K415Q	CCG CAG	I424A I424C	GCT TGT	A432P A432R	CCT AGG	E441H E441K	CAT AAG
F398I	ATT	L406V	GTT	K415Q K415R	CGG	I424C I424E	GAG	A4328	TCT	E441L	CTT
F398L	CTT	L406Y	TAT	K415S	TCT	I424G	GGG	A432V	GTG	E441N	AAT
F398N	AAT	S407A	GCG	K415T	ACT	1424H	CAT	A432Y	TAT	E441Q	CAG
F398P F398R	CCT AGG	S407D S407E	GAT GAG	K415V K415W	GTG TGG	I424K I424L	AAG CTT	F433A F433C	GCT TGT	E441R E441S	CGG AGT
F398K F398S	TCT	S407E S407F	TTT	K415W K415Y	TAT	1424L I424N	AAT	F433C F433D	GAT	E4415 E441T	ACT
F398T	ACT	S407G	GGT	D416C	TGT	I424Q	CAG	F433E	GAG	E441V	GTG
F398V	GTT	S407H	CAT	D416F	TTT	I424R	CGG	F433G	GGG	E441Y	TAT
F398W F398Y	TGG TAT	S407L S407M	CTG ATG	D416G D416H	GGT CAT	I424S I424T	TCG ACT	F433H F433I	CAT ATT	E442C E442G	TGT GGG
Y399A	GCG	S407N	AAT	D416I	ATT	I424V	GTT	F433K	AAG	E442H	CAT
Y399C	TGT	S407P	CCT	D416K	AAG	I424W	TGG	F433L	TTG	E442K	AAG
Y399D Y399E	GAT	S407Q	CAG	D416L	CTT AAT	I424Y A425C	TAT TGT	F433P F433R	CCT CGG	E442L	CTT ATG
1 399E Y399G	GAG GGG	S407R S407T	CGG ACG	D416N D416Q	CAG	A425C A425D	GAT	F433K F433S	AGT	E442M E442N	AAT
Y399K	AAG	S407V	GTG	D416R	CGG	A425E	GAG	F433T	ACT	E442P	CCT
Y399M	ATG	S407W	TGG	D416S	TCT	A425G	GGT	F433V	GTG	E442Q	CAG
Y399N Y399P	AAT CCT	C408A C408E	GCG GAG	D416T D416V	ACG GTG	A425I A425K	ATT AAG	F433W L434F	TGG TTT	E442R E442S	CGG AGT
Y399Q	CAG	C408E	TTT	D416W	TGG	A425L	TTG	L434G	GGT	E4423 E442T	ACT
Y399R	CGG	C408G	GGG	D416Y	TAT	A425M	ATG	L434H	CAT	E442V	GTG
Y399S	TCG	C408I	ATT	T417A	GCT	A425N	AAT	L434I	ATT	E442W	TGG
Y399T Y399V	ACG GTT	C408K C408L	AAG CTT	T417D T417E	GAT GAG	A425P A425R	CCT AGG	L434K L434M	AAG ATG	E442Y P443A	TAT GCT
Y399W	TGG	C408N	AAT	T417F	TTT	A425S	AGT	L434N	AAT	P443D	GAT
C400A	GCG	C408P	CCT	T417G	GGG	A425V	GTG	L434P	CCT	P443E	GAG
C400D C400E	GAT GAG	C408R C408S	CGT TCG	T417H T417I	CAT ATT	A425W A425Y	TGG TAT	L434Q L434R	CAG CGG	P443F P443G	TTT GGG
C400E C400F	TTT	C4083 C408T	ACT	T417K	AAG	D426A	GCT	L434K L434S	AGT	P443U P443H	CAT
C400G	GGG	C408V	GTT	T417L	TTG	D426C	TGT	L434T	ACT	P443I	ATT
C400I	ATT	C408W	TGG	T417M	ATG	D426E	GAG	L434V	GTT	P443L	CTT
C400L C400M	CTG ATG	C408Y K409A	TAT GCG	T417P T417Q	CCT CAG	D426F D426G	TTT GGG	L434W L434Y	TGG TAT	P443M P443N	ATG AAT
C400M	CCG	K409/	TGT	T417R	CGT	D4260 D4261	ATT	K435A	GCT	P443Q	CAG
C400Q	CAG	K409D	GAT	T417S	TCG	D426K	AAG	K435C	TGT	P443R	AGG
C400R	CGG	K409E	GAG	T417W	TGG	D426L	CTG	K435E	GAG	P443S	TCT
C400S C400T	AGT ACG	K409G K409H	GGT CAT	D418A D418C	GCT TGT	D426M D426N	ATG AAT	K435F K435G	TTT GGT	P443T P443W	ACT TGG
C400V	GTG	K409I	ATT	D418E	GAG	D426P	CCT	K435H	CAT	Q444C	TGT
C400Y	TAT	K409L	CTG	D418F	TTT	D426Q	CAG	K435I	ATT	Q444D	GAT
S401A S401C	GCT TGT	K409P K409Q	CCG CAG	D418G D418I	GGT ATT	D426R D426S	CGT TCG	K435L K435P	CTG CCT	Q444E Q444F	GAG TTT
S401C S401D	GAT	K409Q K409R	AGG	D4181 D418L	TTG	D4263 D426Y	TAT	K435P K435R	AGG	Q444F Q444G	GGG
S401E	GAG	K409S	TCG	D418M	ATG	G427A	GCT	K435S	TCT	Q444H	CAT
S401F	TTT	K409T	ACG	D418N	AAT	G427C	TGT	K435T	ACT	Q444I	ATT
S401G S401H	GGG CAT	K409V K409W	GTG TGG	D418P D418Q	CCT CAG	G427F G427H	TTT CAT	K435V K435W	GTT TGG	Q444K Q444L	AAG CTG
S401K	AAG	A412Y	TAT	D418Q D418R	CGG	G427I G427I	ATT	K435Y	TAT	Q444L Q444M	ATG
S401L	CTT	E410D	GAT	D418S	TCG	G427K	AAG	P436C	TGT	Q444N	AAT
S401N	AAT	E410G	GGG	D418V	GTG	G427L	CTG	P436D	GAT	Q444R	CGG
S401Q S401R	CAG CGT	E410I E410K	ATT AAG	D418Y A419D	TAT GAT	G427P G427Q	CCT CAG	P436E P436G	GAG GGG	Q444V Q444W	GTT TGG
S401T	ACT	E410L	CTT	A419E	GAG	G427Q G427R	CGT	P436H	CAT	Q444Y	TAT
S401W	TGG	E410M	ATG	A419F	TTT	G427S	AGT	P436I	ATT	I445A	GCT
S401Y C402A	TAT GCT	E410N E410P	AAT CCG	A419G A419H	GGG CAT	G427T G427V	ACT GTG	P436K P436L	AAG CTG	I445C I445D	TGT GAT
C402A C402D	GAT	E410P E410Q	CAG	A419H A419I	ATT	G427V G427W	TGG	P436L P436M	ATG	1445D 1445G	GGG
C402E	GAG	E410R	CGT	A419K	AAG	G427Y	TAT	P436Q	CAG	I445H	CAT
C402F	TTT	E410S	TCG	A419L	CTT	V428A	GCT	P436R	CGG	I445K	AAG

TABLE 8-co	ntinued
------------	---------

					PH20	Variants					
mut	cod	mut	cod	mut	cod	mut	cod	mut	cod	mut	cod
C402G	GGG	E410T	ACG	A419N	AAT	V428C	TGT	P436S	TCT	I445L	CTT
C402L	TTG	E410V	GTG	A419P	CCT	V428D	GAT	P436T	ACT	I445M	ATG
C402M	ATG	E410W E410Y	TGG	A419R	CGG TCT	V428E	GAG	P436W	TGG	I445N 1445D	AAT CCT
C402P C402Q	CCT CAG	K411A	TAT GCT	A419S A419T	ACT	V428F V428G	TTT GGT	P436Y P437A	TAT GCT	I445P I445O	CAG
C402Q C402R	CGG	K411D	GAT	A4191 A419W	TGG	V428U V428H	CAT	P437D	GAT	1445Q 1445R	AGG
C402S	TCT	K411E	GAG	A419Y	TAT	V428L	CTT	P437F	TTT	I445S	AGT
C402T	ACG	K411F	TTT	V420A	GCT	V428M	ATG	P437G	GGT	I445T	ACT
C402V	GTT	K411G	GGG	V420D	GAT	V428N	AAT	P437H	CAT	I445V	GTG
C402W	TGG TAT	K411H	CAT	V420F	TTT	V428P	CCT	P437I	ATT	I445W	TGG
C402Y Y403A	GCT	K411I K411L	ATT CTG	V420G V420H	GGT CAT	V428R V428S	CGG TCG	P437K P437L	AAG CTG	I445Y F446A	TAT GCT
Y403C	TGT	K411L K411N	AAT	V420I	ATT	V4285 V428T	ACT	P437M	ATG	F446C	TGT
Y403E	GAG	K411P	CCT	V420K	AAG	V428Y	TAT	P437Q	CAG	F446D	GAT
Y403F	TTT	K411R	AGG	V420L	CTT	C429A	GCT	P437R	CGT	F446E	GAG
Y403G	GGT	K411S	TCG	V420N	AAT	C429D	GAT	P437S	TCT	F446G	GGG
Y403H	CAT	K411T	ACT	V420P	CCT	C429G	GGT	P437T	ACT	F446H	CAT
Y403K Y403L	AAG TTG	K411V K411W	GTT TGG	V420R V420S	AGG TCT	C429I C429K	ATT AAG	P437W P437Y	TGG TAT	F446I F446K	ATT AAG
Y403L	ATG	A412D	GAT	V4203 V420T	ACT	C429K C429L	TTG	M438A	GCT	F446K	TTG
Y403N	AAT	A412E	GAG	V420W	TGG	C429M	ATG	M438C	TGT	F446M	ATG
Y403P	CCG	A412G	GGG	V420Y	TAT	C429N	AAT	M438D	GAT	F446Q	CAG
Y403Q	CAG	A412H	CAT	D421A	GCT	C429P	CCT	M438E	GAG	F446R	CGG
Y403R	CGG	A412I	ATT	D421E	GAG	C429R	CGG	M438G	GGG	F446T	ACT
Y403S Y403T	TCT	A412L	CTG AAT	D421G D421H	GGT CAT	C429S C429T	TCG	M438L	TTG	F446V	GTT
\$4031 \$404A	ACG GCT	A412N A412P	CCT	D421H D421I	ATT	C4291 C429V	ACT GTT	M438N M438P	AAT CCT	F446W Y447D	TGG GAT
S404C	TGT	A412Q	CAG	D421K	AAG	C429W	TGG	M438Q	CAG	Y447E	GAG
S404D	GAT	A412R	CGG	D421L	TTG	C429Y	TAT	M438R	AGG	Y447F	TTT
S404F	TTT	A412S	AGT	D421M	ATG	I430A	GCT	M438S	TCG	Y447G	GGT
S404G	GGT	A412V	GTT	D421N	AAT	I430D	GAT	M438T	ACT	Y447I	ATT
S404H S404L	CAT CTT	A412W D413A	TGG GCG	D421Q D421R	CAG CGG	I430E I430G	GAG GGG	M438V M438W	GTG TGG	Y447K Y447L	AAG CTT
S404L S404M	ATG	D413A D413E	GAG	D421K D421S	TCG	I430U I430H	CAT	M438W	TAT	Y447M	ATG
S404N	AAT	D413F	TTT	D421T	ACT	I430K	AAG	E439A	GCT	Y447N	AAT
S404P	CCT	D413G	GGT	D421W	TGG	I430L	TTG	E439C	TGT	Y447P	CCT
S404R	AGG	D413H	CAT	D421Y	TAT	I430M	ATG	E439F	TTT	Y447Q	CAG
S404T	ACG	D413I	ATT	V422A V422C	GCT TGT	I430N I430P	AAT CCT	E439G E439H	GGG CAT	Y447R	AGG ACT
S404V S404W	GTG TGG	D413K D413L	AAG CTG	V422C V422D	GAT	1430P 1430R	AGG	E439H E439K	AAG	Y447T Y447V	GTT
S404Y	TAT	D413L	AAT	V422E	GAG	1430K 1430S	TCT	E439L	CTT	Y447W	TGG
T405A	GCG	D413P	CCG	V422G	GGG	I430T	ACT	E439N	AAT		
T405C	TGT	D413Q	CAG	V422H	CAT	I430V	GTT	E439P	CCT		
T405F	TTT	D413R	CGT	V422I	ATT	I430W	TGG	E439Q	CAG		
T405G	GGG	D413S	TCG	V422L V422M	CTG ATG	D431A	GCT	E439R	CGG		
T405I T405K	ATT AAG	D413T D413W	ACT TGG	V422M V422N	AAT	D431E D431G	GAG GGT	E439S E439T	TCG ACT		
T405L	TTG	V414A	GCG	V422P	CCT	D431H	CAT	E439V	GTT		
T405M	ATG	V414D	GAT	V422Q	CAG	D431I	ATT	E439W	TGG		
T405P	CCG	V414E	GAG	V422R	CGT	D431K	AAG	T440A	GCT		
T405Q	CAG	V414F	TTT	V422S	TCG	D431L	CTT	T440D	GAT		
T405R		V414G				D431N					
T405S T405V	TCT GTG	V414H V414I	CAT ATT	V422W V422Y	TGG TAT	D431P D431Q	CCT CAG	T440F T440G	TTT GGG		
T405W	TGG	V414K	AAG	C423A	GCT	D431Q D431R	CGT	T440U	CAT		
T405Y	TAT	V414L	TTG	C423D	GAT	D431S	TCT	T440I	ATT		
L406A	GCT	V414M	ATG	C423E	GAG	D431V	GTT	T440L	CTT		
L406C	TGT	V414Q	CAG	C423F	TTT	D431W	TGG	T440M	ATG		
L406D	GAT	V414R	AGG	C423G	GGG	D431Y	TAT	T440P	CCT		
L406E L406F	GAG TTT	V414S V414T	TCG ACT	C423H C423L	CAT CTG	A432C A432E	TGT GAG	T440Q T440R	CAG AGG		
L406G	GGT	V414Y	TAT	C423L C423M	ATG	A432E A432F	TTT	T440K	AGT		
L406I	ATT	K415A	GCG	C423P	CCT	A432G	GGG	T440V	GTG		
L406N	AAT	K415C	TGT	C423Q	CAG	A432H	CAT	T440Y	TAT		
		K415D	GAT	C423R	AGG	A432I	ATT	E441A	GCT		
		K415E	GAG	C423S	TCG	A432K	AAG	E441C	TGT		

2. Expression

60

For expression of each mutant, HZ24-PH20-IRES-SEAP plasmid DNA containing cDNA encoding one of the variant PH20 or encoding wildtype PH20 was transfected into 65 monolayer CHO—S cells (Invitrogen, Cat. No. 11619-012) using Lipofectamine 2000 (Invitrogen, Cat. No. 11668-027)

according to the protocol suggested by the manufacturer. CHO—S cells were seeded the night before transfection and grown in DMEM with 10% FBS to be 80% confluent the next day. Then, the medium of the CHO—S cells was replaced with Opti-MEM. A mixture of plasmid DNA and lipofectamine was made ($0.2 \mu g$ DNA and $0.5 \mu L$ Lipofetamine). The Lipofectamine/DNA mixture was added to

CHO-S cells and incubated overnight. The next day, the cells were supplemented with CD-CHO serum free medium (Invitrogen, Cat. No. 10743-029). Supernatant from transfected cells was collected at various time points after transfection, and generally 96 hours after transfection. The super-⁵ natant, containing the variant PH20 protein or wildtype PH20 having a sequence of amino acids set forth in SEQ ID NO:3, was stored at -20° C. Activities of the supernatants were screened as described in the following examples.

Example 3

Screening of Library with a Hyaluronidase Activity Assay to Identify Activity Mutants

In this example, supernatants of expressed PH20 variants generated in Example 2 were screened using a hyaluronidase activity assay to assess activity of each mutant. In addition, activity of the secreted alkaline phosphatase (SEAP) was also measured to allow for normalizing PH20 activity of the $\ ^{20}$ expressed mutants to the PH20 wildtype. Active and inactive mutants were identified.

1. Generation of Biotinylated HA (bHA) Substrate

A 1.2-MDa HA (Lifecore) was biotinvlated for use as a substrate in the hyaluronidase activity assay. First, 1.2 grams (g) of 1.2 MDa HA was dissolved at 4° C. in 600 mL ddH₂0 for a week at a concentration of 2 mg/mL with stirring. Next, 645.71 mg Biotin Hydrazide was dissolved in 100 mL 30 DMSO to a concentration of 25 mM (6.458 mg/mL, 247.8 mg in 38.37 mL DMSO). The biotin solution was warmed briefly at 37° C. until the solution was clear. Also, 368.61 mg Sulfo-NHS in 20 mL ddH₂0 was dissolved to make a 100× solution (18.4 mg/mL Sulfo-NHS). A 30 mM (1000×) water- 35 erated as described in Example 1 were diluted in duplicate soluble carbodiimide EDC solution was made by dissolving 17.63 mg EDC in 3 mL ddH20 at a concentration of 5.7513 mg/mL right before the reaction was started.

To four (4) 1000-mL sterile capped bottles, the following components were added at room temperature (RT) and in the 40 rHuPH20 (generated as described in Example 1 with a following order with stirring: 1) 200 mL of 2 mg/mL HA solution; 2) 80 mL of 0.5M MES, pH 5.0 with gentle mixing; and 3) 91.6 mL of ddH_20 with gentle mixing. Next, 24 mL of 25 mM Biotin-Hydrazide and 4 mL of 100× Sulfo-NHS solution were added sequentially, immediately followed by 45 the addition of 500 µL EDC. After the addition of each component, the solution was mixed by inverting three times and stirring. After the addition of the last component, the solution was mixed by stirring overnight at 4° C. Then, Guanidine hydrochloride was added to a final concentration 50 of 4 M by adding 38.2 g per 100 mL and was allowed to dissolve completely before adjusting the solution volume to 600 mL with ddH_20 .

For dialysis, 200 mL from each batch of the conjugated HA guanidine hydrochloride solution was transferred into 55 dialysis membranes. Over the course of three days, the solution was dialyzed against ddH2O with a change in ddH₂0 at least six times. The resulting volume of about 840 mL was adjusted to a final volume of 1000 mL with ddH₂0. The final concentration of the biotinylated hyaluronan 60 (bHA) was 0.4 mg/mL.

2. Hyaluronidase Activity Assay

The enzyme assay was a modification of the method 65 described by Frost et al. (1997) (A Microtiter-Based Assay for Hyaluronidase Activity Not Requiring Specialized

Reagents. Analytical Biochemistry (1997) 251:263-269) that provides a measure of PH20 hyaluronidase activity.

First, biotinylated HA (bHA) substrate was bound to plastic microtiter plates to generate assay plates. Briefly, 100 µl of b-HA at 1 mg/mL in 0.5 M carbonate buffer (pH 9.6) was dispensed into each well of a high bind microplate (Immunolon 4 HBX extra high binding; Thermo Scientific). The plate was covered with a plate sealer and stored between 2-8° C. for 24-48 hours.

Then, the assay plate was washed with 1×phosphate buffered saline (PBS) wash buffer containing 0.05% (v/v) Tween 20 (PBST). PBST was generated from 1× PBS (generated from Catalog No. P5368, Sigma (10 mM Phosphate Buffer, 2.7 mM Potassium Chloride, 137 mM Sodium Chloride, pH 7.4) by placing the contents of one packet of PBS into a 1-L graduated cylinder with 800 mL deionized water, dissolved by stirring or shaking and adding sufficient quantity of water to 1 L) by adding 500 µl Tween 20 (Catalog No. 6505; EMD Bioscience) to 900 mL of 1×PBS and adding sufficient quantity of water to 1 L. Washing was done using the BioTek ELx405 Select CW plate washer (BioTek) by washing five (5) times with 300 µl PBST wash buffer per well for each wash. At the end of each wash, the plate was tapped on a paper towel to remove excess liquid from each well. Prior to incubation with samples, 200 µl Blocking Buffer (1.0% w/v Bovine Serum Albumin (BSA) in PBS) was added to each well and the assay plate was incubated at 37° C. for approximately 1 hour prior. The Blocking buffer was generated by adding 2.5 g of BSA (Catalog No. 001-000-162; Jackson Immuno Research) to 200 mL 1×PBS, stirring, adding a sufficient quantity of 1×PBS to 250 mL and filtering through an 0.2 µM PES filter unit.

Transfected variant or wildtype PH20 supernatants gen-1:25 in assay diluent buffer (pH 7.4 HEPES buffer; 10 mM HEPES, 50 mM NaCl, 1 mM CaCl₂, 1 mg/mL BSA, pH 7.4, 0.05% Tween-20) in uncoated 4XHB high bound microplates. For the standard curve, 1:3 serial dilutions of specific activity of 145 U/mL) were made in assay diluent buffer in duplicate starting from 3 U/mL for standards as follows: 3 U/mL, 1 U/mL, 1/3 U/mL, 1/9 U/mL, 1/27 U/mL, 1/81 U/mL, and 1/243 U/mL. One hundred microliters (100 µl) of each standard and sample were transferred to the assay plates and incubated for approximately 1.5 hours at 37° C.

After the incubation, the plate was washed with PBST using the BioTek ELx405 Select CW plate washer by washing five (5) times with 300 µl PBST wash buffer per well for each wash. At the end of each wash, the plate was tapped on a paper towel to remove excess liquid from each well. Then, 100 µl of 1:5000 diluted Streptavidin-HRP (SA-HRP) was added to each well of the plate and incubated at ambient temperature for approximately 1 hour. For the dilution, a 1 mg/mL stock of Streptavidin-HRP conjugate (Catalog No. 21126; Thermo Scientific) was diluted 1:5000 into dilution buffer (1 mg/mL BSA, 0.025% Tween20, 137 mM NaCl, 20 mM Tris pH 7.5). After the incubation, the plate was washed with PBST using the BioTek ELx405 Select CW plate washer by washing five (5) times with 300 µl PBST wash buffer per well for each wash. At the end of each wash, the plate was tapped on a paper towel to remove excess liquid from each well. Then, 100 µl of TMB solution (Catalog No. 52-00-03, KPL; ambient temperature and protected from light) was added to each well for approximately five (5) minutes at room temperature or until an optimal color development was yielded. To stop the reaction,

100 µl 1.0 N Sulfuric Acid or TMB Stop solution (Catalog No. 50-85-06) were added to each well and the plates tapped to mix. Optical density was measured at 450 nm within 30 minutes of adding the stop solution. Since more PH20 in a standard or sample would lead to less bHA available to bind 5 SA-HRP, the optical density (450 nm) value was inversely proportional to the concentration of hyaluronidase activity in each specimen.

3. SEAP Activity

Activity of secreted alkaline phosphatase (SEAP) in the cell culture supernatant also was measured using a colorimetric assay of placental alkaline phosphatase using pNPP as a phosphatase substrate (Anaspec SensoLyte pNPP SEAP 15 kit; Catalog No. 72144, Anaspec) according to the manufacturer's instructions. The absorbance signal was measured at optical density (OD) of 405 nm.

The criteria for the high throughput (HTP) screening were that the transfected supernatant resulted in a SEAP signal of 20 ≥ 0.1 and the signal for the rHuPH20 wildtype control produced a signal of ≥ 1 U/mL. Also, the criteria for each screen were that the standard curves had a signal to noise ratio (S/N) for the 0 U/mL standard versus the 3 u/mL standard at OD₄₀s of \geq 5, had less than three (3) standards 25 with a coefficient of variation (CV) $\geq 10\%$, and at least four (4) of the standards were in the linear range.

Example 4

Selected pH20 Variants with Altered Hyaluronidase Activity

Each generated variant was screened for hyaluonidase activity as described in Example 3. The SEAP expression

was used to normalize PH20 activity of each variant to the PH20 wildtype. Mutants were identified that exhibited altered hyaluronidase activity compared to wildtype.

1. Active Mutants

Active mutants were selected whereby at least one duplicate sample exhibited greater than 40% of wildtype activity when normalized to SEAP activity. The identified active mutants are set forth in Table 9. The Table sets forth the amino acid replacement compared to the sequence of amino acids of PH20 set forth in SEQ ID NO:3. The amino acid sequence of exemplary mutants also is set forth by reference to a SEQ ID NO. The Table also sets forth the average hyaluronidase activity of tested duplicates normalized by SEAP values compared to average of wildtype PH20 activities in each plate, which were also normalized by their own SEAP values. For example, a value of 0.40 indicates that the variant exhibits 40% of the hyaluronidase activity of wildtype PH20, a value of 1 indicates that the variant exhibits a similar hyaluronidase activity of wildtype and a value of 3.00 indicates that the variant exhibits 300% of the hyaluronidase activity of wildtype PH20 or 3-fold increased activity compared to wildtype.

The results in Table 9 show that over 600 tested mutants exhibit activity that is increased compared to wildtype. For example, about 536 mutants exhibit 120% or greater than 120% of the hyaluronidase activity of wildtype PH20 and about 75 of the mutants exhibit 300% or greater than 300% of the hyaluronidase activity of wildtype PH20. In particular, the results in Table 9 show that that hyaluronidase activity compared to wildtype of mutant S69A is about 22-fold; mutant S69R is about 14-fold; mutant I70K is about 14-fold; and mutant I271L is about 10-fold.

TABLE 9

			A	ACTIVE M	UTANTS			
mutant	SEQ ID NO	AvgNorm Act.	mutant	SEQ ID NO	AvgNorm Act.	mutant	SEQ ID NO	AvgNorm Act.
L001A	74	0.95	Q140G		0.73	T293F	561	1.94
L001C		0.89	Q140H		0.84	T293G		1.00
L001E	75	0.55	Q140I		0.75	T293K	562	1.35
L001F		0.41	Q140K	343	0.93	T293L		1.00
L001G	76	0.62	Q140L		0.51	T293M	563	2.29
L001H	73	1.90	Q140M		0.80	T293P	564	1.64
L001K	77	1.39	Q140R		0.85	T293Q	565	1.83
L001N		0.87	Q140V		0.61	T293S		0.89
L001P		0.92	Q140W		0.59	T293V	566	2.15
L001Q	78	3.27	Q140Y		0.41	T293Y	567	1.49
L001R	79	0.72	N141A		1.12	V294M		0.41
L001S		0.74	N141D		1.09	A298G	568	0.43
L001T		0.99	N141E		0.67	A298I		0.41
L001V		1.00	N141F		0.81	G300R		0.42
L001W		0.88	N141G		1.15	I301A		0.88
N002A		0.61	N141H	344	2.03	I301V		0.88
N002C		0.4	N002I		0.37	V287N		0.35
G291C		0.27	G297A		0.57	V302W		0.46
N002G		0.44	N141L		0.61	V302I		0.45
N002L		0.46	N141M		0.48	I303V		0.47
N002P		0.54	N1410		1.16	W304G		1.13
N002Q		0.84	N141R	345	1.40	W304I		1.17
N002S		0.78	N141S	346	0.72	G305D		1.00
N002T		1.05	N141T		0.45	G305E	569	1.62
N002V		0.65	N141V		0.50	T306D	202	0.76
F003E		0.42	N141W	347	0.83	T306E		0.52
F003H		0.68	N141Y	348	1.55	T306S		1.02
F003L		0.08	V142C	540	0.61	L307K		0.43
F003L F003Y		0.59	V142C V142D	349	0.01	L307K L307N		0.43
				349				
R004A		0.73	V142E		0.87	L307Q		0.61

TABLE 9-continued

			А	CTIVE M	UTANTS			
mutant	SEQ ID NO	AvgNorm Act.	n mutant	SEQ ID NO	AvgNorn Act.	n mutant	SEQ ID NO	AvgNorm Act.
R004I		0.54	V142G	350	0.98	L307S	-	0.86
R004S		0.60	V142H	550	1.11	L3075		1.08
R004T		0.66	V142I		0.81	L307V		0.48
R004V		1.09	V142K	351	1.40	L307W		0.64
A005H		0.44	V142L		0.75	L307Y		0.60
P006A	80	0.78	V142M		0.76	S308D	571	0.92
P006H		0.58	V142N	352	0.98	S308G	572	1.73
P006K		0.80	V142P	353	0.88	S308H		1.15
P006L		0.76	V142Q	354	1.04	S308K	573	1.33
P006N		0.40	V142R	355	1.53	S308N	574	2.33
P006Q		0.89	V142S	356	0.93	S308P		0.65
P006R		0.56	V142T	357	1.19	S308R	575	1.34 0.72
P007M		0.57	Q143E	250	0.77 0.62	S308T		
V008I V008L		1.17 0.53	Q143G Q143I	358	0.62	1309D 1309E	576	0.72 1.99
V008L V008M	81	0.33	Q1431 Q143K	359	1.30	1309E 1309G	577	1.99
V008P	01	0.33	1009Q	82	0.4	1303D	511	0.34
1009K		0.69	Q143L	02	0.56	1309H	578	1.30
1009L		1.08	Q143N		0.73	I309K	010	0.98
1009R		0.53	Q143V		0.57	I309L	579	1.72
1009S		0.98	L144T	361	1.02	I309M	580	1.47
1009V		0.84	L144W		0.79	I309N	581	3.11
P010D		0.62	S145A		0.58	I309Q	582	1.64
P010E		0.66	S145C		0.44	I309R	583	2.27
P010G	83	0.55	S145D		0.48	I309S	584	1.16
P010H	84	0.43	S145E		0.56	I309T	585	2.09
P010N		0.55	S145G		0.94	I309V	586	0.60
P010Q		0.89	S145H		0.56	I309W		0.88
P010R		0.73	S145L		0.44	M310A	587	1.50
P010S		0.55	S145M		0.56	M310G	588	2.73
P010W		0.59	S145N		0.58	M310Q	589	0.59
N011D		0.54	S145P		1.04	M310R	500	0.50
N011G		0.45	S145R		0.97	M310S	590	1.61
N011H		0.69	L146A		0.52	M310V		0.70
N011K N011S	85	0.58 0.39	L146C G305N		0.42 0.36	R311G L307G	570	0.53 0.32
M310F	65	0.39	M310Y		0.30	R311G	570	0.52
V012A		0.56	L146E		0.50	R311H		0.48
V012E	86	1.86	L146G		0.62	R311K		0.72
V012L	87	0.68	L146H		0.78	R311Q		0.43
V012K	88	0.65	L146I		0.82	R311S		0.84
V012L		0.44	L146K		0.84	R311T		0.52
V012N		0.46	L146N		0.57	S312G		0.49
V012R		0.50	L146P	362	0.93	S312N		1.26
V012S		0.75	L146Q		0.84	S312T		0.75
V012T	89	1.50	L146R	363	1.47	M313A	591	1.34
P013H		0.46	L146S		0.71	M313E		0.63
P013S		0.68	L146T		0.74	M313G	592	0.56
P013T		0.90	L146V		0.84	M313H	593	1.23
P013Y		0.51	L146Y		0.80	M313K	594	2.85
F014D		0.64	S312K		0.38	S312L		0.38
F014I		0.42	T147A	364	1.20	M313L	505	1.05
F014M	00	0.47	T147C		0.47	M313P	595	1.11
F014V	90	0.46	T147D	265	0.71	M313R	596	2.30
L015A	02	0.65	T147F T147G	365	1.24	M313S M313T	597	0.88
L015M L015V	92 91	0.45 2.20	T147G T147I		1.05 0.85	M3131 M313V	397	0.67 0.99
A020S	93	0.50	T147L	366	1.30	M313Y	598	1.12
S022H	95	0.50	T147L T147M	500	0.79	K314A	590	0.82
S022H S022M		0.37	T147M T147P		1.09	K314A K314D		0.82
S022WI S022T	94	0.49	T147P		1.09	K314D K314H		1.10
S022Y	~ '	0.45	T147Q	367	2.11	K314I		0.54
E023D		0.97	T147S	368	1.27	K314N		0.57
F024A		0.69	T147V	369	2.04	K314Q		0.62
F024E	95	3.99	T147W		0.97	K314R		0.95
F024G		0.75	T147Y		1.04	K314S	599	0.61
F024H	96	2.07	E148C		0.66	K314T		0.61
F024I		0.70	E148F		0.42	K314Y	600	0.45
F024K		0.96	E148G		1.05	S315A	601	0.85
F024L		0.62	E148H	370	1.24	S315E		0.41
F024M		0.85	E148I		0.73	S315G		0.72
F024N		0.60	E148K	371	1.63	S315H	602	2.04
F024R	97	1.22	E148L		0.85	S315K		0.62
E024T		1.18	E148Q	372	1.44	S315L		0.42
F024T F024V		1.15	E148R		0.97	S315M		0.63

TABLE 9-continued

			A	CTIVE M	UTANTS			
mutant	SEQ ID NO	AvgNorm Act.	mutant	SEQ ID NO	AvgNorm Act.	n mutant	SEQ ID NO	AvgNorm Act.
F024Y		0.90	E148S		1.15	S315R		1.04
L026A	98	1.30	E148T		0.82	S315T		0.97
L026E	99	3.22	E148V		0.99	S315Y	603	0.50
L026G		0.81	E148W		0.43	C316D		0.41
L026H		0.97	E148Y		0.95	L317A	604	1.27
L026I	100	0.51	A149C		1.15	L317D		0.61
L026K	100	1.88 1.43	A149G A149K		0.52 0.51	L317H	605	1.05
L026M L026P	101	0.55	A149K A149L		0.31	L317I L317K	605 606	1.76 5.11
L026Q	102	1.44	A149L		0.88	L317K	000	1.20
L026Q	102	1.43	A149Q		1.15	L317N	607	0.73
L026S	105	0.78	A149R		1.02	L317Q	608	1.67
L026T		0.87	A149S		1.08	L317R	609	2.41
L026V		0.52	A149T	373	1.24	L317S	610	1.03
L026W		0.53	A149V	374	1.34	L317T	611	0.93
L026Y		0.52	T150A	375	1.21	L317W	612	0.84
G027A		0.79	T150C		0.70	L318D	614	0.46
G027D	104	1.22	T150D	376	1.24	L318F		0.51
G027E		1.18	T150E		1.05	L318G		0.49
G027F		0.61	T150F		0.71	L318H	615	0.45
G027H		1.11	T150G	377	2.19	L318I	(1(0.70
G027I G027K	105	0.41 2.71	T150I T150L		0.52 0.70	L318K L318M	616 613	1.36 1.68
G027K G027L	105	0.76	T150L T150N	378	0.70	L318M	015	0.52
G027L G027P		0.76	T150N T150P	510	0.91	L318N		0.32
G0271 G027Q		1.12	T150R		0.88	L318Q	617	1.34
G027Q G027R	106	1.88	T150K	379	0.92	L318S	017	0.71
G027S		0.94	T150W	380	1.25	L318T		0.63
G027T		0.61	T150Y	381	1.36	D320E		0.78
G027W		0.76	E151A	382	1.27	D320G		0.83
K028A		0.78	E151C		1.00	D320H	618	1.75
K028D		0.62	E151G		1.06	D320I		1.00
K028E		0.54	E151H	383	1.34	D320K	619	6.42
K028F		0.75	E151K	384	2.05	D320M		0.79
K028I		0.55	E151L	385	1.03	D320N		0.52
K028L		0.51	E151M	386	1.26	D320R	620	3.19
K028M		0.67	E151N	207	0.95	D320S		1.19
K028N		0.58	E151Q	387	2.01	D320W		0.40
K028P K028R	107	0.40 0.71	D320L E151R	388	0.37 1.61	D320V D320Y		0.35 0.86
K028K K028S	107	0.46	E151K E151S	389	1.01	N321A		1.01
K0285 K028T		0.68	E1515 E151T	390	1.20	N321D		1.25
K028V		0.76	E1511 E151V	391	1.38	N321H		0.92
K028W		0.51	E151W	392	1.31	N321K		1.29
F029A		0.90	E151Y	393	1.31	N321R	621	1.23
F029E	108	4.03	K152A		0.51	N321S	622	1.26
F029G		1.05	K152C		0.52	N321T		0.64
F029H		0.82	K152F		0.61	N321Y		0.40
F029I	109	1.53	K152I		0.65	M323F		0.64
F029K	110	1.34	K152M		0.75	M323I		0.55
F029L	111	2.36	K152R	394	1.85	M323L		0.55
F029M	112	2.08	K152T	395	1.20	E324A		0.59
F029P	113	3.79	K152V		0.82	E324D		1.15
F029R	114	1.24	K152Y		0.67	E324H		0.79
F029S F029T	115	2.21 0.85	A153I		0.93 0.51	E324M E324N	623	0.50 1.01
F0291 F029V	116 117	0.85	A153L K154R		0.51	E324N E324R	623 624	2.28
F029V F029W	11/	0.48	K154K K154T		0.86	E324R E324S	024	0.62
D030A		1.12	K1541 K154V		0.83	T325A	625	1.87
D030F		0.84	Q155A		0.40	T325D	626	1.78
D030G	118	2.02	Q155C		0.60	T325E	627	4.03
D030H	119	1.69	Q155D	397	1.49	T325G	628	4.21
D030K	120	2.63	Q155F		0.70	T325H	629	3.45
D030L	121	1.32	Q155G	398	1.61	T325K	630	4.37
D030M	122	1.85	Q155H		1.03	T325M	631	2.11
D030P		1.19	Q155K	399	1.57	T325N	632	4.64
D030Q		0.84	Q155L		0.86	T325Q	633	5.08
D030R	123	1.82	Q155M		0.97	T325S	634	3.19
D030S	124	1.62	Q155R	400	1.27	T325V	635	1.24
D030T		0.57	Q155S		0.77	T325W		0.62
D030V		0.46	Q155T		0.76	I326K	<i></i>	0.95
D030W	105	0.62	Q155V		0.73	I326L	636	1.50
E031A	125	2.05	Q155W		0.91	I326V	637	6.29
HURLE	126	2.95	E156A		0.79	I326Y		0.77
E031C E031G	127	1.27	E156D	401	1.95	L327M		0.52

TABLE 9-continued

			A	ACTIVE M	UTANTS			
mutant	SEQ ID NO	AvgNorm Act.	mutant	SEQ ID NO	AvgNorm Act.	n mutant	SEQ ID NO	AvgNorr Act.
E031H	128	2.74	E156G		0.49	N328A		0.67
E031I	129	3.89	E156I		0.51	N328C	638	1.25
E031K	130	3.13	E156L		0.43	N328G	639	0.56
E031L	131	2.62	E156M		0.87	N328H		0.88
E031P	132	1.51	E156Q		0.84	N328I	642	1.85
E031R	133	2.27	E156R		0.43	N328K	640	2.12
E031S	134	1.70	E156S		0.62	N328L	641	2.01
E031T	135	3.96	E156T		0.69	N328Q		1.13
E031V	136	4.57	E156V		0.45	N328R		0.68
E031W	137	1.26	E156W		0.49	N328S	643	2.22
E031Y		1.13	F157W		0.61	N328T		0.59
P032A	100	0.92	E158A		0.56	N328V		1.16
P032C	138	0.40	E158F		0.51	N328Y	644	1.66
P032F	139	2.71	E158H		0.54	I331V		0.94
I326C		0.39	I326S		0.95	N328W		0.33
I331C	140	0.27	I331E		0.34	V334T		0.39
P032G	140 141	1.60 2.08	E158L	402	0.44 1.25	V334P T335S	645	0.46
P032H P032K	141	2.08	E158Q E158S	402	0.95	A338Q	043	0.47 0.63
P032L		0.82	K159A	403	0.93	K339M		0.63
P032M		0.67	K159D		0.52	S342A		0.68
P032N		0.70	K159E		0.49	Q343T		0.49
P032Q		1.11	K159H		0.74	Q343V		0.51
P032R		1.17	K159L		0.62	Q347A	646	0.78
P032S		1.01	K159M		0.66	Q347E		0.78
P032T		0.77	K159N		0.73	Q347G	647	2.68
P032V		0.81	K159Q		0.92	Q347M		0.61
P032W		0.54	K159R		0.88	Q347R		0.55
P032Y		1.01	K159S		0.67	Q347S	648	2.38
L033G	143	0.57	K159V		0.41	E348D		0.67
L033M		0.69	A160C		0.61	E348G		0.55
L033P		0.87	A160F		0.79	E348S		0.44
L033Q		0.45	A160G		0.75	Q349A		0.47
L033R		0.61	A160H		0.47	Q349E		0.83
L033S		0.48	A160I		0.43	Q349K		0.93
L033T		0.45	A160K		0.91	Q349M	649	0.70
L033W	142	1.58	A160L		0.67	Q349N		0.44
D034A		0.38	M035Q		0.37	M035V	146	0.37
D034E		0.58	A160M		0.77	Q349R	650	0.73
D034H		0.41	A160N		0.56	Q349T		0.49
D034K		0.54	A160Q		0.65	V351A	(71	1.14
D034Q		0.59	A160R	10.1	0.89	V351S	651	0.92
D034R	1.4.4	1.17	A160S	404	1.35	I353T	(52)	0.42
D034W	144	0.46	A160V		0.73	1353V	652	1.61
M035F		0.87	A160Y		1.07	N356A		0.41
M035H M035L		0.60 0.52	G161A G161C		0.99 0.44	N356D N356H	653	0.79 0.82
M035L M035T		0.32	G161D		0.44	N356S	654	0.82
M035Y		0.83	G161D G161E		0.80	W357A	034	0.40
\$036A		0.78	G161E		0.49	W357C		0.80
5036D		0.32	S036N	148	0.38	L037W		0.36
5036G		0.64	G161S	110	0.77	W357S		0.41
5036H	147	0.54	G161V		0.42	W357T		0.62
5036K	117	0.83	K162A		0.50	N358C		0.66
5036L		0.71	K162D		0.77	N358G		0.41
5036R		1.09	K162E	405	0.51	N358T		0.58
Q347L		0.39	V351C		0.35	V351I		0.36
V351Q		0.34	W357K		0.36	N358L		0.38
S036T		0.51	K162G		0.56	S359D		0.45
_037F	149	3.33	K162H		0.62	S359E	655	1.05
_037I		0.62	K162L		0.54	S359H	656	0.44
_037K		0.43	K162M		1.04	S359K		0.66
_037M	150	1.46	K162P		0.64	S359M		0.63
L037P		0.63	K162Q		0.58	S359T	657	2.11
L037R		0.51	K162R		0.52	S359V		0.65
L037V		0.57	K162S		0.47	S360T		0.50
F038Y	151	1.29	K162V		0.52	P367A	658	0.55
S039A	152	1.06	K162W		1.01	P367C		0.83
S039L	153	0.80	K162Y		0.72	P367G	659	0.47
S039N	154	2.32	D163A	406	1.52	P367K	660	0.57
S039Q		1.10	D163E	407	1.63	P367R		0.46
S039R		0.56	D163G		1.15	P367S	661	0.52
S039T	155	1.57	D163K	408	1.90	D368A	662	1.34
S039Y		0.56	D163L		1.18	D368E	663	1.28
F040L	156	0.92	D163Q	409	1.40	D368G		0.49

TABLE 9-continued

			I	ACTIVE M	UTANTS			
mutant	SEQ ID NO	AvgNorm Act.	n mutant	SEQ ID NO	AvgNorm Act.	mutant	SEQ ID NO	AvgNorm Act.
	110						SEQ ID 110	
F040W I041A		1.11 0.67	D163R D163S	410 411	1.80 1.34	D368H D368K	664	0.96 1.31
I041/C		0.53	D1635	411	1.13	D368L	665	0.64
I041D		0.78	D163V		0.76	D368M	666	0.78
I041E		0.51	F164L		1.13	D368R	667	1.31
I041G		0.76	F164M	412	1.66	D368S		0.93
I041H		0.77	F164V	413	1.23	D368T	668	0.80
I041N I041T	157	0.40 1.47	S043N F164W		0.34 0.72	D361H D368V		0.37 0.41
10411 I041V	137	0.73	L165A		0.72	N369H	669	1.33
I041W		0.66	L165D	414	5.79	N369R	670	0.55
G042A		0.64	L165F	415	1.23	N369S		0.54
S043T		0.43	L165N	416	2.19	A371E		1.05
P044E		0.59	L165R	415	0.59	A371F	671	0.52
R045I R045K		0.45 0.53	L165S L165V	417 418	1.31 1.22	A371H	672	1.20 0.50
I046A		1.04	L165V L165W	416	1.22	A371I A371K	673	1.76
1046C		0.37	A371G		0.38	L374W	075	0.34
I046E		0.43	L165Y		0.66	A371L	674	0.57
I046F		0.73	V166A	419	2.85	A371M		0.57
I046H		0.82	V166C		1.16	A371R	675	1.51
1046L	158	1.08	V166E	420	1.28	A371S	676	1.45
I046M		1.00	V166F	421	1.67	A371V		0.94
I046N I046R	159	0.66 2.29	V166G V166H	422	1.11 1.74	Q373A Q373E		0.65 0.81
1046K 1046S	159	0.64	V166L	423	4.38	Q373E Q373F		0.62
I046T		0.55	V166Q	424	3.61	Q373K		0.73
I046V		1.01	V166R	425	5.56	Q373L		0.84
I046Y		0.76	V166T	426	4.26	Q373M	677	1.43
N047A	1.00	0.48	V166W	427	1.26	Q373R		0.68
N047D	160	0.82	V166Y	428	2.08	Q373S		0.87
N047F N047G	161	1.32 0.82	E167A E167D	429	0.84 0.69	Q373V L374A		1.05 0.60
N047U		1.16	E167G	42)	0.60	L374H	678	1.42
N047K		0.67	E167H		0.89	L374I		0.80
N047M		0.77	E167K		0.91	L374M		1.11
N047Q		0.69	E167M		0.87	L374N		0.43
N047R		0.84	E167N		0.83	L374P	679	0.43
N047S N047T	162	0.85 1.49	E167P E167R		0.58 1.02	L374R L374S		0.83
N0471 N047W	162	0.63	E167K E167S		1.02	L3743 L374T		0.58 0.47
N047Y	105	0.45	E167T		0.59	L374V		0.56
A048F	164	2.51	E167Y		0.55	L374Y		0.66
A048G		0.83	T168H		0.46	E375A	680	0.42
A048H	165	1.99	I169L	430	2.08	E375G	681	0.90
A048I	177	0.64	I169R		0.54	E375K	682	1.49
A048K A048M	166	1.28 0.76	I169V K170N		0.74 0.72	E375L E375M		0.46 0.54
A048N	167	4.25	K170R	431	2.58	E375N		0.81
A048Q	107	1.05	K170K	451	0.58	E375R	683	0.43
A048R		0.66	L171I		0.73	E375S		0.77
A048S		1.06	L171V		0.64	E375T		1.17
A048V		0.60	G172A	432	1.20	K376A	<i></i>	0.95
A048Y		0.81	G172C		1.03	K376D	684	0.78
T049I T049K		0.42 0.85	K173N K173R	433	0.44 0.82	K376E K376M	685	0.88 0.46
T049R	168	1.41	L174A	433	1.20	K376Q	686	0.40
T049S	100	0.92	L174G	434	0.40	K376R	687	0.67
T049V		0.45	L174K	435	2.39	K376S		0.80
G050A		0.93	L174M		0.79	K376T	688	0.53
G050C		0.41	L174N	436	1.36	K376V	689	0.58
G050D	169	1.37	L174Q	405	0.99	K376Y	690	0.42
G050E G050H		0.78 0.74	L174R L174S	437	1.50 0.85	G377D G377E	691 692	1.35 0.59
G050H G050L		0.74 0.43	L1745 L174T	438	1.12	G377E G377H	692 693	0.59 1.49
G050L G050M	171	0.43	L1741 L174V	120	0.62	G377K	694	1.50
G050Q	- / 1	0.86	L174W		0.78	G377P	695	2.30
G050R		0.86	L174Y		1.06	G377R	696	1.28
G050S	170	1.24	L175E		0.43	G377S	697	1.80
G050V		0.3	Q051A		0.34	Q051R	<i></i>	0.36
G050Y		0.58	L175H	420	0.57	G377T	698	3.83
Q051N Q051S		0.60 0.46	L175T L175V	439	1.43 0.94	G378K G378N		1.22 0.64
G052N	172	0.40	L175V L175Y		0.94	G378R		1.03
G052P	.,_	0.43	R176K		0.67	K379G		0.52

TABLE 9-continued

			11		UTANTS			
mutant	SEQ ID NO	AvgNorm Act.	mutant	SEQ ID NO	AvgNorm Act.	n mutant	SEQ ID NO	AvgNorm Act.
G052Q	173	3.71	N178G		0.85	K379H		0.57
G052R	174	0.53	N178K	440	0.85	K379R		0.74
G052S	175	1.32	N178M		0.88	K379S		0.46
E375I		0.36	K376L		0.37	K379T		0.4
F380V		0.39	F380T		0.39	M035Q	145	0.37
G052T	176	0.49	N178R	441	1.10	F380I		0.56
T054A		0.43	H179A		1.06	F380L		0.67
T054F		0.56	H179C		0.94	F380P	(00	0.47
T054N T054Q		0.48 0.91	H179E H179G		0.62 0.86	F380W F380Y	699 700	2.15 1.50
T054Q		0.91	H1790 H179I		0.80	T381H	700	0.48
T054V		0.66	H179K	442	1.39	T381K		1.06
V058C	177	0.55	H179L	112	0.73	T381N		0.51
V058G		0.54	H179M		0.63	T381Q		0.84
V058H	183	1.09	H179N		0.96	T381R		0.87
V058I		0.57	H179P		0.44	T381S	70	0.87
V058K	178	4.08	H179R		0.96	T381V		0.89
V058L	179	1.54	H179S		0.51	R383A		0.51
V058N	184	0.49	H179T		0.43	R383E		0.51
V058P	180	0.90	H179V		0.42	R383H		0.71
V058Q	181	4.54	L180F		0.59	R383I	702	0.71
V058R	182	1.92	L180G		0.62	R383K	703 704	1.30
V058S V058W		0.83 0.65	L180K L180M		0.44 0.64	R383L R383M	704	1.31 0.61
V058Y	185	1.07	W181M		0.88	R383N		0.01
D059Q	165	0.40	L061F		0.88	T381E		0.35
D059N	186	1.27	W181Q		0.88	R383S	705	0.87
R060K		0.69	G182L		0.90	R383T		0.98
L061I		0.42	Y183L		0.70	R383V		1.05
L061M		0.73	F186Y		0.59	K385A	706	1.12
L061V		0.59	H192S		0.49	K385G		0.62
Y063A		0.63	H192T		0.50	K385H		0.50
Y063H		1.07	H193G		0.68	K385N		0.41
Y063I		1.03	H193Q	443	0.82	K385Q	707	0.73
Y063K	187	1.36	H193S		0.42	K385R		0.94
Y063L	188	1.33	H193Y		0.58	K385S		1.05
Y063M	189	1.32 0.96	K195A		0.51	K385T	708	0.46
Y063N Y063R	190	1.40	K195G K195H		0.45 0.45	K385V T387S	708	0.43 0.93
Y063S	190	1.40	K195H K195I		0.43	L388F		0.93
Y063T		1.00	K195L		0.45	L388H		0.47
Y063V		0.43	K195N	445	0.74	L388I		0.98
Y063W	191	1.53	K195Q		0.71	L388M		0.79
P065R		0.57	K195R		0.85	L388R		0.60
Y066H		0.47	K195S		0.42	L388T		0.51
Y066R		0.51	K195T	444	0.58	L388V		0.78
I067F		1.00	K195W		0.49	L388W		0.77
1067L		0.45	K196E	446	0.43	L388Y		1.18
1067R		0.24	D068G		0.37	E392W		0.31
1067V	192	1.80	K196G		0.41	E389A	709	1.14
I067Y		0.55	K196L K196R	447	0.65	E389G E389H	710	0.91
D068E D068H	193	0.72 2.06	K196K K196S	447	0.58 0.68	E389H E389K	712	1.17 1.91
D008H D068K	195	1.08	K1965 K196T		1.18	E389K E389L	712	0.65
D068L		0.43	K196W		0.55	E389M	/11	0.60
D068P	194	0.50	P197A		0.81	E389P		0.75
D068Q	195	1.67	P197D		0.58	E389Q	713	0.69
D068R		0.70	P197E		0.52	E389R		0.94
D068S		0.81	P197F		0.48	E389S	714	1.08
D068T		0.75	P197G		0.75	E389T		0.70
S069A	196	22.06	P197H		0.62	E389Y		0.77
S069C	197	1.97	P197K		0.99	L391C	_	0.90
S069E	198	1.48	P197L		0.56	E392A	715	0.58
S069F	199	8.75	P197M		1.03	E392F	716	0.54
S069G	200	6.06	P197Q		0.69	E392G		1.00
S069I	201	3.12	P197R		0.58	E392K		0.66
S069L	202	3.44	P197S P197T		0.70	E392L E392M	717	0.80
S069M S069P	203 204	2.67 8.14	P197T G198A		0.41 0.80	E392M E3920	717 718	1.54 1.01
S069P S069R	204 205	8.14 14.06	G198A G198D	448	0.80	E392Q E392R	718	0.66
S069R S069T	205	0.58	G198D G198E	++0	0.49	E392R E392S	/19	0.66
		2.18	G198E G198H		0.49	E3923 E392T		0.32
	207		01/011		0.04	12161		0.14
S069W	207 20				0.48	E302V	720	1 27
S069W S069Y I070A	207 20 209	2.71 27.00	G198L G198N		0.48 0.80	E392V E392Y	720	1.27 0.92

TABLE 9-continued

			Α	CTIVE M	UTANTS			
mutant	SEQ ID NO	AvgNorm Act.	mutant	SEQ ID NO	AvgNorm Act.	mutant	SEQ ID NO	AvgNorm Act.
I070F	211	5.69	G198R		0.58	Q393D		0.45
I070G	212	6.22	G198S		0.76	Q393F	721	1.23
I070H	213	9.09	G198T		0.41	Q393H		1.05
1070K	214	14.64	G198Y		0.81	Q393K		0.80
1070L 1070N	215 216	3.05 6.19	N200D S202M		0.46 0.40	Q393L Q393M	722	0.91
1070N 1070P	210	3.03	F204P	449	0.40	Q393M Q393N	122	0.80 0.72
1070R	218	13.95	N205A	450	1.30	Q393R		0.72
1070S	219	3.63	N205D		0.85	Q393S		1.15
I070T	220	5.43	N205E	451	1.94	Q393T		0.41
1070V	221	6.34	N205F		0.52	F394L		0.56
I070Y	222	1.26 0.86	N205G N205K		0.79 0.76	F394W	723	0.41
T071A T071D		0.80	N205K N205M		0.78	S395A S395G	125	1.10 0.77
T071G	223	1.41	N205P		0.75	S395H	724	0.56
T071H		0.93	N205R		0.54	S395K		0.96
T071L		1.09	N205S		0.80	S395R	725	1.98
T071M		0.89	N205T	453	0.85	E396A	726	0.52
T071N	224	1.21	N205V		0.49	E396D	707	0.64
T071Q T071R	225	0.68 2.17	N205W V206H		0.41 0.50	E396H E396Q	727 728	0.47 0.73
T071K	225	1.54	V200H V206I	454	0.94	E396Q E396R	128	0.73
G072A	220	0.45	V206K	455	1.75	E396S	729	0.61
G072D		0.60	V206L	456	1.57	E396T		0.89
S395W		0.4	S395T		0.39	E396L		0.39
G072E		0.69	V206M		0.43	Y399A		1.01
G072H	227	0.46	V206R	457	1.30	Y399C		0.46
G072K G072L	227	1.39 0.43	V206S G072Y		0.72 0.35	Y399E S407L		1.49 0.4
G072L G072M	228	3.11	V206T		0.59	Y399K	730	1.94
G072Q	229	2.33	I208A		0.62	Y399M	731	2.70
G072R		0.65	I208C		0.48	Y399N		0.52
G072S		0.51	I208K		0.91	Y399Q		1.18
V073A	230	1.38	I208L		0.84	Y399R		1.20
V073C V073D		0.84 0.94	I208M I208Q		0.88 0.77	Y399S Y399T	732	1.01 2.40
V073D V073G		1.17	1208Q 1208R		1.14	Y399V	732	1.44
V073H	231	1.54	I208S		0.62	Y399W	734	1.92
V073K	232	1.42	I208T		1.01	S401A	735	0.82
V073L	233	1.59	I208V		1.07	S401E	736	0.46
V073M	22.4	0.68	K209A		0.53	S401N		0.42
V073Q V073R	234 235	0.96 0.72	K209E K209G		0.46 0.44	Y403F S404A	737	0.62 0.63
V073S	255	0.86	K2090		0.50	S404P	151	0.64
K297R		0.34	F398L		0.35	S401G		0.38
S401Q		0.39	S404T		0.37	T405F		0.36
V073T	236	1.34	K209R	458	0.68	T405A		0.56
V073W	237	1.91	K209S K209T		0.50	T405G	738	2.32
T074A T074C	238 239	2.28 2.18	D212N	459	0.50 1.52	T405K T405M		0.74 0.48
T074E	240	1.38	D2121 D212S	460	0.93	T405NI T405P		0.64
T074F	241	1.43	D212T		0.76	T405Q		0.75
T074G	242	2.75	D213A	461	0.85	T405R		0.60
T074H	243	1.40	D213E		0.79	T405S		0.94
T074K	244	1.29	D213G		0.81	T405W		0.73
T074L T074M	245 246	1.43 0.52	D213H D213K		0.75 0.82	T405Y L406A		0.44 0.70
T074N	240	2.12	D213K D213L		0.56	L400A L406C		0.98
T074P	248	2.45	D213D	462	1.56	L406E		0.73
T074R	249	2.22	D213N	463	1.53	L406F	739	1.42
T074S	250	1.80	D213Q		1.04	L406G		1.00
T074V	251	2.27	D213R		0.92	L406I	7.10	0.61
T074W	252	2.13	D213V		0.47	L406N	740	0.76
V075A V075C		0.71 0.46	D213W D213Y		0.49 0.49	L406Q L406S		0.93 0.47
V075F	253	2.00	L214Q		0.49	L4003 L406T		0.83
V075H		0.62	S215A		0.74	L406V		0.87
V075L	254	5.22	S215D		0.62	L406Y		0.74
V075M	255	1.16	S215E		0.74	S407A	741	1.16
V075N		0.81	S215G	161	0.88	S407D	742	1.52
V075Q V075R	256	1.51 3.02	S215H S215K	464	0.91 0.99	S407E S407F	743 744	1.38 1.42
V075K V075S	230	0.76	S215K S215L		0.99	S407F S407G	/-+++	0.75
V075T	257	4.34	S215E S215M	465	1.77	S407H	745	1.34
V075Y		0.63	S215Q		0.79	S407M		0.74
		5.00	X		>			

TABLE 9-continued

			A	ACTIVE M	UTANTS			
	SEQ ID	AvgNorm		SEQ ID	AvgNorm			AvgNorm
mutant	NO	Act.	mutant	NO	Act.	mutant	SEQ ID NO	Act.
G077H		0.32	G077K		0.32	K411H		0.33
1079L	258	1.44	S215R		0.71	S407N	747	0.72
I079T I079V		0.79 1.01	S215T S215V		0.80 0.69	S407P S407Q	747 746	0.94 1.71
Q081P		0.60	S215V S215W		0.69	S407Q S407R	/40	1.71
K082A		0.94	W216Y		0.48	S407V		0.56
K082E		0.50	L217M		0.51	S407W		0.41
K082G		0.64	W218F		0.57	K409A	748	2.18
K082H		0.44	N219A	466	1.29	K409D		0.65
K082I	250	1.01	N219C		0.43	K409E		0.62
K082L K082M	259	0.87 0.58	N219D N219E		0.75 0.95	K409G K409H		0.50 0.64
K082N	260	0.96	N219E		0.95	K409I		0.51
K082Q	200	0.76	N219I	467	0.60	K409P		0.48
K082R		0.85	N219K	468	1.45	K409Q	749	3.33
K082S		0.62	N219L		0.72	K409R		0.84
K082T		0.56	N219M		1.02	K409S		0.72
K082Y		0.32	I083H		0.4	I083K		0.30
K082V I083F		0.57 0.57	N219R N219S	469	1.10 2.48	K409T K409V		0.63 0.48
1083F 1083G	264	1.05	N2195 N219T	+07	0.82	A412Y		0.48
1083C	201	0.93	N2191		0.32	E410D		0.47
I083N		0.82	E220A		0.75	E410K		0.70
I083Q	262	1.07	E220H	470	1.40	E410M		0.42
I083R		0.45	E220I	471	1.34	E410N		0.67
1083S	263	0.79	E220L	472	1.45	E410P		0.73
I083T I083V	261	0.95 0.99	E220S E220T		0.62 0.91	E410Q E410R		0.85 0.61
S084D	201	0.99	E2201 E220V	473	1.35	E410K E410S		0.81
S084E	265	0.52	S221A	175	0.72	E410T	750	1.54
S084F	266	0.72	S221C		0.59	E410V		0.65
S084G	267	8.68	S221M		0.46	E410Y		0.62
S084H		0.96	S221Q	474	1.37	K411A		0.48
S084I		0.90	S221T		0.94	K411N		1.02
S084L S084M		0.92 0.77	S221V T222D		1.04 0.43	K411P K411R		0.42 0.97
S084N	268	0.89	T222F		0.43	K411K K411S		1.21
S084P		0.57	T222G	475	0.49	K411T		0.63
S084Q		0.86	T222K		0.75	K411V		0.99
S084R	269	1.89	T222L		0.64	A412D		0.74
S084T		0.82	T222N		0.80	A412G		0.80
S084W S084Y		0.86 0.30	T222R E220D		0.75 0.39	A412I E220M		0.81 0.36
S221I		0.35	T222I		0.39	P226W		0.50
L085V		0.42	T222S		0.63	A412L		0.65
Q086A	270	2.70	T222V		0.79	A412N		0.86
Q086D		0.88	L224I		0.61	A412P		0.77
Q086E		1.18	L230I		0.87	A412R	752	0.66
Q086F Q086G		0.54	N231T	476	1.10	A412S A412V	753	0.86
Q086G Q086H	271	1.02 1.70	T232F T232S	4/0	0.73 0.76	A412V A412W	155	0.53 0.54
Q086I	2/1	0.65	Q233A		0.70	D413E		0.52
Q086K	272	0.97	Q233F		0.53	D413K		0.42
Q086L		0.92	Q233G	477	0.46	D413N		0.94
Q086M		1.06	Q233K	478	1.69	D413R		0.50
Q086N	273	1.28	Q233L	470	0.69	D413T		0.41
Q086P 0086P		0.42 0.93	Q233R	479	1.50 0.50	V414I V414M		1.12 0.53
Q086R Q086S	274	0.93	Q233Y Q234M	480	1.65	K415G		0.55
Q0865 Q086T	274	0.58	S235A	481	0.47	K4150 K415S		0.40
Q086V		0.97	S235E		1.00	K415W		0.42
Q086W	276	1.21	S235G		0.95	D416F		0.41
D087A		1.00	S235H		0.44	D416G		0.67
D087C	277	1.77	S235K		0.53	D416H		0.57
D087E D087G	278	0.86 1.00	S235T P236A		0.66 1.07	D416I D416K		0.63 0.76
D087G D087H	210	0.72	P236A P236G		1.07	D416K D416L	754	0.76
D087I		0.53	P236H		0.46	D416N	151	0.73
D087L	279	0.55	P236K		0.71	D416Q		0.83
D087M	280	0.58	P236R	482	3.09	D416R		0.46
D087P		0.31	Q234L		0.40	V237C	483	0.35
D087Q	20	1.05	P236S		0.91	D416T		0.85
D087R	28	1.28	V237A V237E	101	0.90	D416V		0.59
D087S D087T	282 283	0.99 1.70	V237E V237F	484	1.93 0.41	D416Y T417I		0.40 1.22
D00/1	203	1.70	v 2371		0.41	141/1		1.22

TABLE 9-continued

			A	CTIVE M	UIANIS			
mutant	SEQ ID NO	AvgNorm Act.	mutant	SEQ ID NO	AvgNorm Act.	n mutant	SEQ ID NO	AvgNorr Act.
A412H		0.39	A412Q	751	0.35	D413A		0.38
D413H		0.31	A413Q		0.38	D413S		0.39
V414K		0.3	V414L		0.36	K415Y		0.39
K415V		0.39	D418G		0.45			
D087V	284	0.66	V237H	485	0.75	D418A		0.92
D087Y	285	2.72	V237L		1.12	D418E	755	1.31
L089C	286	1.46	V237N		0.67	D418F		0.81
L089R L089K		0.34 0.45	L089W V237Q	486	0.26 1.46	L089P D418G		0.38 0.45
L089K		0.43	V237Q V237R	400	0.71	D4180 D418I		0.45
D090A	287	1.48	V237S		1.03	D418L	756	1.28
D090E	288	1.15	V237T	487	1.01	D418M	100	1.09
D090G		0.41	V237W		0.52	D418N		0.91
D090H	289	1.24	A238D		0.75	D418P	757	2.11
D090I		1.10	A238E	488	0.59	D418Q		1.05
D090K	290	1.36	A238H	489	0.60	D418R	758	1.18
D090L		1.15	A238K		0.60	D418S		0.78
D090N	291	1.18	A238Q		1.02	D418V	759	1.43
D090Q	202	1.11	A238R	490	0.49	D418Y		0.97
D090R D090S	292	1.49	A238S A238T	490	2.62 0.44	A419E A419F	760	0.45
D0905 D090T		1.15 1.02	A2381 T240K		1.13	A419F A419G	760	2.17 0.42
D0901 D090W		0.81	T240K T240A	491	0.48	A4190 A419H	761	1.21
K091A		0.89	T240M	. , 1	0.48	A419I	762	1.64
K091Q		0.43	T240P		0.56	A419K	763	1.88
K091R		0.67	T240Q	492	0.75	A419L		0.56
A092C	293	1.97	T240R		0.91	A419N		0.53
A092H		0.22	A239N		0.32	V421I		0.39
A092L	294	1.29	T240S		0.74	A419R	764	1.81
A092M		0.86	T240V		0.77	A419S	765	2.65
A092T		0.70	Y242F		1.08	A419W	7//	0.69
A092V		1.09 0.71	N245H V247I	493	0.50 2.01	A419Y V420I	766	1.44
K093D K093E		0.71	V2471 V247L	495	0.83	V4201 V420P		1.04 0.48
K093E K093F		0.85	V247L V247M		0.52	D421A	767	1.28
K093G		0.97	R248A	494	0.43	D421E	101	0.81
K093H		0.61	R248W		0.52	D421G		0.62
K093I	295	3.25	R248Y		0.67	D421H	768	1.98
R248H		0.4	I251Y		0.37	K255G		0.39
K093L	296	1.53	I251L		0.58	D421K	769	2.42
K093M		0.70	I251M		0.43	D421L		0.73
K093N	207	0.71	V253I		0.76	D421M		0.94
K093Q	297	0.84	K255A		0.40	D421N	770	1.89
K093R K093S	298 299	1.52 1.25	K255N		0.52 0.91	D421Q D421R	771 772	1.54
K0935 K093T	300	3.93	K255Q K255R		0.91	D421K D421S	772	2.21 2.12
K093V	500	0.24	K093P		0.38	K094C	115	0.33
K094A		0.64	K255S		0.43	D421T		0.80
K094D	301	0.93	I256A		0.42	D421Y		0.66
K094E		0.79	I256H		0.51	V422I		0.42
K094F		0.59	I256L		0.64	V422T		0.49
K094H		0.72	I256V		0.51	A425G	774	1.20
K094L		0.52	P257A	101	0.82	A425I	775	0.44
K094M		0.66	P257G	496	0.51	A425K	775	1.75
K094N K094O	302	0.99 1.22	P257I P257K		1.07 0.92	A425M A425N		0.70 0.46
K094Q K094R	302 303	1.22 3.94	P257K P257L		0.92	A425N A425R		0.46
K094K K094S	505	0.94	P257L P257M		0.89	A425K A425S		0.49
K0945 K094T		1.14	P257N		0.90	D426E		0.47
1096D		0.69	P257Q		0.61	D426G		0.85
1096L		0.46	P257R	498	1.38	D426N		0.61
1096V		0.68	P257T	497	2.04	D426P		1.03
Г097А	304	1.25	P257V		0.88	D426Q		0.42
F097C	305	0.53	D258H	10.0	0.84	D426Y		0.43
T097D	306	1.31	D258N	499	1.44	G427K		0.52
T097E	307	1.19	D258R	500	0.45	G427S	770	0.42
T097F		0.75	D258S	500	1.44	V428L	778	1.25
P257C D426K		0.36 0.26	D258G D426S		0.39 0.36	A425Y G427T	777	0.39 0.35
G426K G427H		0.26	D4265 G427I		0.36	G4271 G427Q	776	0.35
G427H T097G	308	0.35 4.84	A259E		0.54	G427Q V428M	770	0.39
T097U	500	0.85	A259E A259G		0.85	V428M V428P		0.42
T097L	309	1.22	A259I		0.46	V428T		0.62
T097N		1.10	A259K		0.76	D431A	779	2.42

TABLE 9-continued

			A	CTIVE M	UTANTS			
mutont	SEQ ID NO	AvgNorm		SEQ ID	AvgNorm		SEO ID NO	AvgNorm
mutant	NU	Act.	mutant	NO	Act.	mutant	SEQ ID NO	Act.
T097Q		1.17	A259N	501	0.49	D431G	780	0.55
T097R T097S	310	0.95 1.21	A259P A259Q	501	1.54 0.70	D431H D431I	782	3.13 1.05
T097W	510	0.53	A259Q A259R		0.70	D431K	783	1.83
T097Y		0.74	A259S		0.63	D431L	784	0.62
F098A		0.60	A259T		0.51	D431N	785	1.30
F098C		0.58	A259V		0.41	D431Q	786	2.16
F098D		0.47	A259W		0.55	D431R	787	2.20
F098E		0.44	A259Y		0.51	D431S	788	1.91
F098H F098I		1.06	K260A		0.66	D431V	789	1.52
F0981 F098L		0.52 0.58	K260D K260E		0.41 0.58	D431W D431Y		0.56 0.85
F098M		0.87	K260H		0.87	A432E		0.60
F098Q		0.65	K260L		0.60	A432G		0.52
P436C		0.39	E249V	495		A432H		0.34
F098R		0.72	K260M	502	0.85	A432N		0.51
F098S		0.56	K260Q		0.58	A432S		0.61
F098V		0.46	K260R		0.83	A432V	700	0.56
F098W Y099A		0.81 0.33	K260S K260G		0.66 0.37	F433A R270T	790	0.97 0.40
Y099R		0.53	K260Y	503	1.73	F433C		0.40
Y099S		0.43	S261A	504	0.74	F433D		0.95
V102A		0.83	S261F		0.73	F433E		0.82
V102C		0.69	S261K	505	2.54	F433G		0.54
V102E		0.90	S261M		0.56	F433H	791	0.83
V102G		0.67	S261N	506	1.98	F433I	792	1.06
V102H V102K		0.88 1.03	S261Q S261R		0.76 1.19	F433K F433L	793 794	1.36 1.87
V102K V102L		0.71	S261T		0.66	F433L	/94	0.95
V102E		0.77	S261V		0.48	F433R	795	1.63
V102N		1.02	S261W		0.44	F433S		0.86
V102Q		1.03	L263A		0.76	F433T	796	1.86
V102R		0.94	L263K	507	2.73	F433V	797	1.63
V102S	311	1.41	L263M	500	0.89	F433W	798	1.28
V102T V102W	312	1.26 0.76	L263R L263T	508	1.63 0.49	L434F L434G		0.41 0.47
D103N		0.39	N104I		0.49	L263H		0.47
N104A		0.69	L263V		0.75	L434I		0.89
N104C		0.41	P264A		0.43	L434M		0.60
N104G		0.48	P264H		0.60	L434V		0.46
N104K		0.88	V265I		0.58	K435A		1.08
N104M	212	0.61	F266Y		0.58	K435C		0.53
N104R N104S	313	1.25 1.03	A267M A267T	509	0.45 1.34	K435E K435G		0.78 0.64
N1045		0.71	T269A	510	1.63	K435H		1.05
L105A		0.54	T269C		0.75	K435R		1.01
L105G		0.51	T269D		0.76	K435S		1.03
L105I		0.94	T269S		1.01	K435T		0.73
L105P		0.84	R270M		0.46	K435V		0.44
L105Q L105R		0.90 0.65	R270N R270S		0.52 0.69	K435Y P436D		0.50 1.19
L105K		0.61	I271F		0.09	P436E		0.74
L1055		0.51	I271G		1.29	P436G		1.19
L105W		0.34	L105C		0.33	L105H		0.36
L105V		0.99	I271L	511	10.62	P436H		0.72
G106V		0.43	V272E		0.39	V272M		0.31
M107F		0.91	I271M	512	3.24	P436I	700	0.84
M107I	214	0.67 1.32	I271S		0.42	P436K	799	2.05
M107L A108G	314	0.47	I271V V272D	513	1.05 1.36	P436L P436M		0.63 0.61
I1100G		0.51	V272R	010	0.74	P436Q		0.86
E114A	315	1.44	V272S		0.96	P436R		1.00
E114G		0.73	V272T	514	1.61	P436S		0.92
E114H		0.75	F273H	515	1.41	P436T		0.59
E114M		0.44	F273T	51/	0.48	P436W		0.43
E114S P117D		0.69 0.56	F273Y T274A	516	0.90 0.51	P436Y P437A		0.49 0.56
T118H		0.56	T274A T274F	517	1.28	P437A P437D		0.56
T118K		0.53	T274S	517	0.62	P437G		0.50
T118L		1.09	Q276C		0.88	P437H		1.11
T118M		0.53	Q276D	518	1.69	P437I	800	2.46
T118N		0.67	Q276E	_	1.05	P437K		0.83
T118Q	316	3.37	Q276H	519	1.20	P437L	001	0.51
T118V		0.79	Q276I		0.51	P437M	801	2.55
W119F		0.53	Q276L		0.48	P437Q		0.96

TABLE 9-continued

$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$				UTANTS	CTIVE M	А			
WI19P 0.36 WI19Q 0.72 D275L MU19Y 1.08 Q276M 520 1.14 P437R A120D 318 2.62 Q276S 521 1.30 P437S A120F 318 2.62 Q276S 522 1.63 P437Y A120H 317 1.11 V277C 0.41 M438C 802 A120H 319 1.33 V277C 0.41 M438L 805 A120N 0.81 V277G 1.18 M438L 805 A120N 0.82 V277H 526 1.09 M438N 806 A120N 0.82 V277N 529 1.15 M438N 806 A120V 0.21 1.53 V277N 529 1.15 M438N 807 N122M 0.56 V277S 532 0.83 M438V 807 N122M 0.56 V277F 532 0.83 M438V 807	AvgNorm Act.	SEQ ID NO							mutant
W119Y 1.08 Q276M S20 1.14 P437R A120F 318 2.62 Q276S S21 1.30 P437Y A120G 1.03 Q276Y S23 1.94 M438A 802 A120H 317 1.11 V277C 0.41 M438C 803 A120N 1.31 V277C 0.41 M438C 804 A120N 0.81 V277E 525 1.02 M438G A120P 0.42 V277K 526 1.09 M438N 806 A120N 0.82 V277K 527 1.51 M438C 807 A120V 320 1.21 V277R 530 0.82 M438C A120V 321 1.53 V277R 531 1.63 M438T 807 N122M 0.59 V277R 531 1.64 M438T 807 N122M 0.54 L278A 531 1.63 M438K 808 <td>0.24</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	0.24								
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	0.24				520				
A120G 1.03 Q276Y 523 1.94 M438A 802 A120H 317 1.11 V277A 524 0.65 M438C 803 A120L 1.25 V277D 0.79 M438E 804 A120N 0.81 V277E 525 1.02 M438G A120P 0.42 V277G 1.18 M438L 806 A120R 0.82 V277K 527 1.51 M438P A120T 0.62 V277K 528 0.94 M438R A120W 0.59 V277R 530 0.82 M438R A120W 0.59 V277R 530 0.83 M438V A120W 0.56 V277S 532 0.83 M438V K124L 0.64 V277Y 533 1.63 M438V K124R 0.64 V278 533 1.36 E439C 809 P125R 0.63 L278E 534 1.33 E439F 1017F 1324 2.33 L278F 535 1.26 E439G	0.57								
A120H 317 1.11 V277A 524 0.65 M438C A120L 1.25 V277C 0.41 M438D 803 A120L 1.25 V277D 0.79 M438E 804 A120N 0.81 V277E 525 1.02 M438B 805 A120R 0.82 V277H 526 1.09 M438L 805 A120R 0.82 V277K 527 1.51 M438C A120 A120V 321 1.53 V277R 529 1.15 M438S S07 A120W 0.59 V277Q 530 0.82 M438S S07 N122M 0.56 V277R 531 1.63 M438T 807 N122M 0.56 V277G 533 0.82 M438V S04 K124L 0.34 K124H 0.35 P125A K124L 0.34 K124F S036 L33 E439C S09 P125R 0.63 L278F 534 1.03 E439C S09 S125A	0.42		P437Y	1.63	522	Q276S	2.62	318	A120F
A1201 319 1.33 V277C 0.41 M438D 803 A1201 0.81 V277E 525 0.79 M438G A120P 0.42 V277G 1.18 M438L 805 A120P 0.42 V277H 526 1.09 M438Q A120R 0.82 V277H 527 1.51 M438R A120V 0.62 V277N 529 1.15 M438R A120W 0.62 V277N 530 0.82 M438T A120W 0.59 V27R 531 1.63 M438T 807 N122M 0.56 V277S 532 0.83 M438V 808 K124L 0.62 V277T 533 1.63 M438W 808 P125B 0.63 L278A 1.13 E439C 809 P125B 0.64 L278E 534 1.03 E439H D127A 0.89 L278K 535 1.26 E439H D127H 0.4 L278K 539 1.4 E439H <td>0.75</td> <td>802</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	0.75	802							
A120L 1.25 V277D 0.79 M438E 804 A120N 0.81 V277E 525 1.02 M438G 805 A120P 0.42 V277G 1.18 M438L 805 A120R 0.82 V277H 526 1.09 M438P A120T 0.62 V277M 528 0.94 M438P A120V 321 1.53 V277R 531 M438P 807 A120W 0.59 V277C 531 1.63 M438V 807 N122M 0.56 V277S 532 0.83 M438V 807 N122M 0.54 V277F 532 0.83 M438V 808 P125H 0.43 V277T 0.66 E439A 808 P125R 0.63 L278A 1.13 E439C 809 P125R 0.64 L278E 535 1.26 E439G 1276 D127A 0.89 L278F 535 1.26 E439G 127 D127G 0.97 L278F <td>0.63</td> <td></td> <td></td> <td></td> <td>524</td> <td></td> <td></td> <td></td> <td></td>	0.63				524				
A120N 0.81 V277E 525 1.02 M438G A120P 0.42 V277G 1.18 M438L 805 A120R 0.82 V277K 526 1.09 M438P A120T 0.62 V277K 527 1.51 M438P A120V 320 1.21 V277K 521 1.51 M438C A120W 0.59 V277R 531 0.82 M438S A120W 0.56 V277S 532 0.83 M438V K124L 0.34 K124H 0.35 P125A K124R 0.62 V277Y 535 1.36 E439F P125R 0.63 L278E 534 1.03 E439F D127A 0.89 L278F 535 1.26 E439G D127A 0.89 L278F 535 1.26 E439F D127A 0.84 L278K 538 1.75 E439F D127M 324 2.33 L278F 538 1.75 E439F D127N 3	0.87							319	
A120P 0.42 V277G 1.18 M438L 805 A120R 0.82 V277H 526 1.09 M438N 806 A120S 320 1.21 V277K 527 1.51 M438P A120V 0.62 V277K 528 0.94 M438Q A120V 0.59 V277R 530 0.82 M438S A120Y 322 1.95 V277R 531 1.63 M438T 807 N122M 0.56 V277S 532 0.83 M438W P125A 809 K124L 0.34 K124H 0.35 P125A 809 P125R 0.63 L278A 1.13 E439C 808 P125R 0.63 L278E 535 1.26 E439H D127G 0.97 L278H 537 4.50 E439F D127G 0.97 L278H 538 1.75 E439P 811 D127H 324 2.33 L278K 538 1.75 E439F 813 D127N 0.51 L278X 539<	0.72 0.83	804			525				
A120R 0.82 V277H 526 1.09 M438N 806 A120T 0.62 V277K 528 0.94 M438Q A120V 321 1.53 V277N 528 0.94 M438R A120W 0.59 V277R 530 0.82 M438R A120W 0.56 V277R 531 1.63 M438T 807 N122M 0.56 V277R 532 0.83 M438V M438V K124L 0.34 K124H 0.35 P125A 808 P125B 0.63 L278A 1.13 E439C 808 P125S 0.54 L278E 534 1.03 E439G D1276 D127A 0.89 L278F 535 1.26 E439H D1276 D127F 323 1.21 L278G 536 1.33 E439L D127G 0.97 L278H 537 4.50 E439H B11 D127M 0.4 D275V 0.4 Q276G D127L D235 1.61 L43	0.85	805			525				
A1208 320 1.21 V277K 527 1.51 M438P A1207 0.62 V277N 528 0.94 M438Q A120W 0.59 V277Q 530 0.82 M438S A120V 322 1.95 V277R 531 1.63 M438V N122M 0.56 V277S 532 0.83 M438V K124L 0.34 K124H 0.35 P125A K124R 0.62 V277Y 533 1.94 M438W P125R 0.63 L278K 531 1.03 E439F D127A 0.89 L278F 535 1.26 E439G D127A 0.89 L278F 535 1.26 E439G D127H 324 2.33 L278I 503 E439L D127N 324 L238 L278K 539 1.74 E439Q 812 D127N 325 1.69 L278K 539 1.74 E439C 813 D127N 325 1.69 L278K 540 <td>1.08</td> <td></td> <td></td> <td></td> <td>526</td> <td></td> <td></td> <td></td> <td></td>	1.08				526				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.81			1.51		V277K		320	
A120W 0.59 V277Q 530 0.82 M438S A120Y 322 1.95 V277R 531 1.63 M438T 807 N122M 0.56 V277F 532 0.83 M438V K124L 0.34 K124H 0.35 P125A K124R 0.62 V277Y 533 1.94 M438W P125R 0.63 L278A 1.13 E439C 809 P125R 0.63 L278E 534 1.03 E439F E439L E127A 0.89 L278F 535 1.26 E439K 810 D127G 0.97 L278H 537 4.50 E439K 810 D127H 324 2.33 L278K 538 1.75 E439F 811 D127M 0.44 L278K 539 1.74 E439Q 812 D127Q 326 1.21 L278K 540 5.87 E439F 813 D127R 327 0.51 L278K 541 1.66 E439V 814 D127V 0.56 <td>0.85</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	0.85								
A120Y 322 1.95 V277R 531 1.63 M438T 807 N122M 0.56 V277S 532 0.83 M438V K124L 0.34 K124H 0.35 P125A K124R 0.62 V277Y 533 1.94 M438W P125H 0.63 L278A 1.13 E439C 808 P125S 0.54 L278E 535 1.26 E439G D127G 0.97 L278H 537 4.50 E439F D127G 0.97 L278K 538 1.75 E439P 811 D127M 324 2.33 L278K 538 1.75 E439Q 812 D127M 0.44 D275V 0.4 Q276G 9127N 325 1.69 L278K 549 541 1.67 E439T 813 D127R 327 0.51 L278K 541 1.66 E439V 814 D127V 0.56 L278Y 544 0.44 T440A 165 V1280 0.53 K279Q <td>0.99</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>321</td> <td></td>	0.99							321	
N122M 0.56 V277S 532 0.83 M438V K124L 0.34 K124H 0.35 P125A K124R 0.62 V277T 533 1.94 M438W P125H 0.43 V277Y 0.66 E439A 808 P125R 0.63 L278A 1.13 E439C 809 D127A 0.89 L278F 535 1.26 E439G D127G 0.97 L278H 537 4.50 E439K 810 D127H 324 2.33 L278I 537 4.50 E439P 811 D127N 0.4 D275V 0.4 Q276G D127N 325 1.69 L278N 539 1.74 E439Q 812 D127N 325 1.69 L278N 539 1.74 E439Q 813 D127N 325 1.69 L278N 541 1.67 E439V 814 D127V 0.56 L278X	0.83	907						222	
K124L 0.34 K124H 0.35 P125A K124R 0.62 V277T 533 1.94 M438W P125H 0.63 L278A 1.13 E439C 809 P125S 0.63 L278F 535 1.26 E439G D127A 0.89 L278F 535 1.26 E439G D127G 0.97 L278H 537 4.50 E439K D127G 0.97 L278K 538 1.75 E439P 811 D127M 0.4 D275V 0.4 Q276G D127N 325 1.69 L278K 539 1.74 E439Q 812 D127R 327 0.51 L278S 541 1.67 E439V 814 D127V 0.56 L278Y 543 1.51 T440A D127V D127V 0.56 L278Y 543 1.51 T440A B15 V128C 0.68 K279Q 0.84 T440E V128C 0.53 K27Q 0.86 T440E V128C 0.55 S	3.99 0.85	807						322	
K124R 0.62 V277T 533 1.94 M438W P125H 0.63 L278A 1.13 E439A 808 P125R 0.63 L278E 534 1.03 E439F D127A 0.89 L278F 535 1.26 E439G D127E 323 1.31 L278G 536 1.33 E439H D127G 0.97 L278K 538 1.75 E439P 811 D127H 324 2.33 L278K 538 1.75 E439P 811 D127N 0.4 D275V 0.4 Q276G 1127N 326 1.21 L278K 540 5.87 E439C 812 D127K 327 0.51 L278S 541 1.67 E439V 814 D127V 0.56 L278Y 543 1.51 T440A 15 D127W 0.56 L278Y 543 1.51 T440A 15 V128A 0.53 K279Q 0.86 T440E 15 V128G 0.49	0.36				552				
P125H 0.43 V277Y 0.66 E439A 808 P125R 0.63 L278A 1.13 E439C 809 P125S 0.54 L278E 534 1.03 E439F D127A 0.89 L278F 535 1.26 E439G D127E 323 1.31 L278G 536 1.33 E439H D127G 0.97 L278H 537 4.50 E439K 810 D127L 0.84 L278K 538 1.75 E439P 811 D127M 0.4 D275V 0.4 Q276G 10127N 325 1.69 L278N 539 1.74 E439Q 812 D127Q 326 1.21 L278R 540 5.87 E439V 813 D127V 0.51 L278T 542 1.66 E439V 814 D127V 0.56 L278Y 543 1.51 T440A 816 D127V 0.56 L278Y 543 0.44 T440E V128C 0.68 T440G V128 <td>0.57</td> <td></td> <td></td> <td></td> <td>533</td> <td></td> <td></td> <td></td> <td></td>	0.57				533				
P125S 0.54 L278F 535 1.03 E439F D127A 0.89 L278F 535 1.26 E439G D127E 323 1.31 L278G 536 1.33 E439H D127G 0.97 L278H 537 4.50 E439K 810 D127H 324 2.33 L278I 0.93 E439L 10127M D127L 0.84 L278K 538 1.75 E439P 811 D127N 325 1.69 L278N 539 1.74 E439Q 812 D127R 326 1.21 L278S 540 5.87 E439F 813 D127R 326 1.21 L278T 542 1.66 E439V 814 D127T 1.11 L278T 542 1.66 E439W 814 D127W 0.56 L278T 543 1.51 T440A D127W 0.56 L278Y 543 1.51 T440A D127W 0.56 L278Y 543 1.51 T440A D127V 0.56 </td <td>1.20</td> <td>808</td> <td>E439A</td> <td></td> <td></td> <td></td> <td>0.43</td> <td></td> <td></td>	1.20	808	E439A				0.43		
D127A 0.89 L278F 535 1.26 E439G D127E 323 1.31 L278G 536 1.33 E439H D127G 0.97 L278H 537 4.50 E439K 810 D127H 324 L233 L278I 0.93 E439L 111 D127M 0.44 D275V 0.4 Q276G 811 D127N 325 1.69 L278N 539 1.74 E439Q 812 D127R 327 0.51 L278S 541 1.67 E439V 814 D127N 3.25 0.56 L278Y 543 1.51 T440A D127V 0.56 L278Y 543 1.51 T440A D127V 0.56 L278Y 543 1.51 T440A D127V 0.56 L278Y 543 1.51 T440E V128C 0.68 K279Q 0.84 T440E V128C V128G	0.58	809		1.13					P125R
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.00								
D127G 0.97 L278H 537 4.50 E439K 810 D127H 324 2.33 L278I 0.93 E439L 1 D127L 0.84 L278K 538 1.75 E439P 811 D127N 0.4 D275V 0.4 Q276G 1 D127R 325 1.69 L278N 539 1.74 E439Q 812 D127R 326 1.21 L278R 540 5.87 E439V 813 D127R 327 0.51 L278Y 541 1.67 E439V 814 D127V 0.56 L278Y 543 1.51 T440A 1404 D127V 0.56 L278Y 543 1.51 T440A 815 V128C 0.68 K279R 1.10 T440F 1404F 1404F 1420F 1238 0.55 S282G 0.54 T440H 816 128 128 0.55 S282G 0.54	1.22							202	
D127H 324 2.33 L278I 0.93 E439L D127L 0.84 L278K 538 1.75 E439P 811 D127M 0.4 D275V 0.4 Q276G 111 D127N 325 1.69 L278N 539 1.74 E439Q 812 D127Q 326 1.21 L278N 540 5.87 E439F 813 D127S 0.51 L278S 541 1.67 E439W 814 D127V 0.56 L278Y 543 1.51 T440A 111 L278V 0.44 T440D 815 V128A 0.53 K279Q 0.84 T440E 140 140F 127W 0.66 K279T 0.86 T440F 140F 128 16 128 16 128 16 128 16 128 16 140F 140F 128 128 16 128 128 140F 140F 128 128	0.74	810						323	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.20 0.88	810			337			324	
D127M 0.4 D275V 0.4 Q276G D127N 325 1.69 L278N 539 1.74 E439Q 812 D127Q 326 1.21 L278R 540 5.87 E439T 813 D127R 327 0.51 L278T 542 1.66 E439V 814 D127R 327 0.51 L278Y 543 1.51 T440A D127V 0.56 L278Y 543 1.51 T440A D127W 0.56 L278Y 543 1.51 T440A D127W 0.56 L278Y 543 1.51 T440D 815 V128A 0.53 K279Q 0.84 T440E 816 V128G 0.68 K279T 0.86 T440H 816 V128G 0.49 K279T 0.86 T440H 816 V128L 0.95 S282D 0.41 T440L V128Q 0.53 S282Q 0.41 T440R 819 <td>1.16</td> <td>811</td> <td></td> <td></td> <td>538</td> <td></td> <td></td> <td>524</td> <td></td>	1.16	811			538			524	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.36								
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.32	812	E439Q	1.74	539	L278N	1.69	325	D127N
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.02								· ·
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.15							327	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.57	814			542				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.62 1.22				5/13				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.03	815							
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.00	010			511				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.85								
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.86		T440G	0.86		K279T	0.49		V128G
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	3.00	816						328	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.04								
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.97 1.08	817							
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.88				545				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.77				0.10				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.17	820	T440S	0.63			0.50		V128W
N131C 0.60 Q283S 546 1.73 E441A 821 N131E 0.44 Q283T 0.65 E441D N131F 0.63 D284A 0.58 E441F 822 N131F 0.63 D284A 0.58 E441F 822 N131G 330 2.47 D284E 1.21 E441G N131H 0.80 D284G 0.60 E441H N131I 331 1.40 D284H 0.51 E441K N131L 0.82 D284L 0.50 E441L N131Q 333 1.24 D284N 0.40 E441Q N131Q 333 1.24 D284N 0.40 E441Q N131R 334 2.81 D284Q 0.95 E441S N131S 0.76 D284S 0.99 E441T N131T 1.02 E285F 0.47 E441V N131V 335 2.08 E285G 0.52 E441Y </td <td>1.02</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	1.02								
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.11				- 16			329	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.47	821			546	-			
N131G 330 2.47 D284E 1.21 E441G N131H 0.80 D284G 0.60 E441H N131I 331 1.40 D284H 0.51 E441K N131I 331 1.40 D284H 0.51 E441K N131I 0.82 D284L 0.50 E441N N131M 332 0.99 D284M 0.56 E441N N131Q 333 1.24 D284N 0.40 E441Q N131R 334 2.81 D284Q 0.95 E441S N131S 0.76 D284S 0.99 E441T N131T 1.02 E285F 0.47 E441Y N131V 335 2.08 E285G 0.52 E441Y N131Y 0.85 E285H 547 1.30 E442C 823 R132A 0.68 E285M 0.43 E442G 824	0.67 3.91	822							
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.87	022						330	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.65								
N131M 332 0.99 D284M 0.56 E441N N131Q 333 1.24 D284N 0.40 E441Q N131R 334 2.81 D284Q 0.95 E441S N131S 0.76 D284S 0.99 E441T N131T 1.02 E285F 0.47 E441V N131Y 335 2.08 E285G 0.52 E441Y N131Y 0.85 E285H 547 1.30 E442C 823 R132A 0.68 E285M 0.43 E442G 824	0.80			0.51		D284H	1.40	331	N131I
N131Q 333 1.24 D284N 0.40 E441Q N131R 334 2.81 D284Q 0.95 E441S N131S 0.76 D284S 0.99 E441T N131T 1.02 E285F 0.47 E441V N131V 335 2.08 E285G 0.52 E441Y N131Y 0.85 E285H 547 1.30 E442C 823 R132A 0.68 E285M 0.43 E442G 824	0.82								
N131R 334 2.81 D284Q 0.95 E441S N131S 0.76 D284S 0.99 E441T N131T 1.02 E285F 0.47 E441V N131V 335 2.08 E285G 0.52 E441Y N131Y 0.85 E285H 547 1.30 E442C 823 R132A 0.68 E285M 0.43 E442G 824	0.82								
N131S 0.76 D284S 0.99 E441T N131T 1.02 E285F 0.47 E441V N131V 335 2.08 E285G 0.52 E441Y N131Y 0.85 E285H 547 1.30 E442C 823 R132A 0.68 E285M 0.43 E442G 824	0.81								
N131T 1.02 E285F 0.47 E441V N131V 335 2.08 E285G 0.52 E441Y N131Y 0.85 E285H 547 1.30 E442C 823 R132A 0.68 E285M 0.43 E442G 824	0.79 0.66							334	
N131V 335 2.08 E285G 0.52 E441Y N131Y 0.85 E285H 547 1.30 E442C 823 R132A 0.68 E285M 0.43 E442G 824	0.54								
N131Y 0.85 E285H 547 1.30 E442C 823 R132A 0.68 E285M 0.43 E442G 824	0.51							335	
	1.38	823	E442C		547	E285H			
R132C 0.58 E285N 0.40 E442H	0.51	824							
	0.76								
R132E 0.70 E285Q 0.59 E442K	0.73								
R132F 0.60 E285Y 0.99 E442P R132H 0.66 L286S 0.46 E442Q	0.91 0.74								
K152H 0.00 L280S 0.40 E442Q K279A 0.27 D284T 0.39 D284Y	0.74								
E285A 0.34 L286R 0.53 L286W	0.37								
R132I 0.56 V287I 0.51 E442R 825	3.94	825							
R132K 1.05 V287T 548 0.50 E442T	0.61		E442T	0.50	548	V287T	1.05		R132K
R132L 337 0.76 Y288L 0.79 E442V	0.65								
R132N 336 1.28 Y288W 0.49 E442Y	0.60	0.5						336	
R132Q 0.69 T289K 0.75 P443A 826	1.63				E 40				
R132S 0.79 T289S 549 0.48 P443E 827 R132T 0.61 F290I 0.41 P443F 828	1.07 0.70				549				
K1521 U.UI 12701 U.41 F445F 828	0.70	020	1 44.01	0.41		1.72201	0.01		N1321

TABLE 9-continued

			A	CTIVE M	UTANTS			
mutant	SEQ ID NO	AvgNorm Act.	mutant	SEQ ID NO	AvgNorm Act.	mutant	SEQ ID NO	AvgNorm Act.
R132V		0.73	F290M		1.03	P443G	829	1.12
R132Y		0.78	G291Q		0.80	P443H		1.08
S133I		0.54	G291R		0.45	P443L		1.19
I134L		1.04	G291S	550	0.41	P443M	830	1.99
I134T		0.60	G291V	551	1.63	P443N	831	1.25
I134V		1.08	E292A		0.66	P443Q		0.96
E135A		0.99	E292C	552	0.71	P443R		1.04
E135C	220	0.77	E292F	553	0.90	P443S		0.99
E135D	338	2.68	E292G		0.41	P443T		0.87
E135F		0.73	E292H	554	1.26	P443W		0.64
E442L	220	0.4	E442W		0.38	Q444M		0.37
E135G	339	2.79	E292K	555	1.27	Q444D	822	0.97
E135H		0.79	E292N		0.99	Q444E	832	1.19
E135K		1.15	E292P	556	1.05	Q444F		0.66
E135L		0.82	E292R	556	0.42	Q444G		0.93
E135N		0.56	E292V	557	1.28	Q444H	833	0.97
E135Q		1.59	E292W		0.83	Q444I		0.58
E135R	340	2.08	T293A	558	1.90	Q444K		1.03
E135S		1.13	T293C	559	1.67	Q444N		1.01
E135W		0.63	T293D	560	1.46	Q444R		0.85
E135Y		0.50	V137C		0.37	Q444V	834	1.12
L136A		0.73	V137S		0.36	Q444W		0.64
L136C		0.56	V137L		0.21	Q444Y		0.67
L136D		0.47	Q143C		0.28	I445A		0.97
L136F		0.96	L144R	360	0.26	I445G		0.98
L136H		1.00	K152W	396	0.37	I445H	835	1.35
L136I		0.65	A153S		0.34	I445L		1.06
L136M		1.05	K154I		0.38	I445M	836	1.57
L136N		0.48	E156C		0.35	I445N	837	1.24
L136Q		0.61	E158G		0.37	I445P	838	1.67
L136R		0.74	K159G		0.38	1445Q	839	1.26
L136S		0.80	A160W		0.39	I445R		1.08
L136T		0.72	G161V		0.42	I445S	840	1.21
L136W		1.11	D163W		0.38	I445T	841	1.38
V137A		0.48	D163F		0.39	I445V	842	1.25
V137I		1.01	L165C		0.27	I445W	843	0.69
V137T		0.51	V166N		0.47	I445Y		0.53
Q138A		0.69	E167F		0.31	F446A	844	1.58
Q138C		0.65	K170A		0.40	F446C		0.75
Q138H		0.71	K170Q		0.40	F446D		1.18
Q138I		0.54	K173Q		0.32	F446E		1.10
Q138L	341	0.59	L174H		0.38	F446G		1.12
Q138M		0.68	R176L		0.40	F446H		1.28
Q138N		0.61	P177V		0.36	F446I		1.06
Q138R		0.53	L180I		0.38	F446K		0.94
Q138S		0.48	W181K		0.29	F446L		0.93
Q138W		0.41	Y183E		0.32	F446M	845	1.31
Q138Y		0.60	Y184W		0.39	F446Q		0.72
Q139A		0.92	H193R		0.33	F446R		0.89
Q139C		0.44	H193F		0.38	F446T		0.89
Q139D		0.48	K195V		0.36	F446V		0.91
Q139E		0.94	K196N		0.39	F446W	846	1.40
Q139E		0.53	K196Y		0.39	Y447D	847	3.25
Q139G		0.65	P197W		0.39	Y447E	848	1.36
Q139U Q139H		0.56	G198W		0.39	Y447E	070	1.30
Q139K		0.73	N200T		0.29	Y447G	849	0.92
Q139K Q139L		0.73	F204W		0.37	Y447I	850	1.36
Q139L Q139M		0.95	N205L	452	0.39	Y447L	050	1.09
				452				
Q139R		0.79	N205Y		0.4	Y447M X447N	051	0.90
Q139S	242	0.81	V206Q		0.33	Y447N X447D	851 852	1.58
Q139T	342	1.31	K209F		0.4	Y447P	852 852	1.46
Q139V		0.77	K209L		0.38	Y447Q	853	2.37
Q140A		0.96	N211L		0.41	Y447R	0.5.1	1.12
Q140C		0.50	N211W		0.51	Y447T	854	1.90
Q140D		0.59	W218M		0.38	Y447V	855	1.38
Q140F		0.66	W218V		0.28	Y447W		1.07

2. Inactive Mutants

The other mutants that exhibited less than 2000 hyaluronidase activity of wildtype PH-20, in at least one of the duplicates, were rescreened to confirm that the dead mutants are inactive. To confirm the inactive mutants, the hyaluronidase activity assay described in Example 3 was modified to incorporate an overnight 37° C. substrate-sample incubation step prior to measurement of enzymatic activity. The modified assay is intended to detect PH20 activities below 0.2 U/mL.

The preparation of the bHA coated plates and blocking of the plates prior to addition of the transfected variant supernatants or wildtype PH20 was the same as described in Example 3. The assay was modified as follows. First, transfected variant supernatants or wildypte PH20 not containing a mutation generated as described in Example 2 were diluted in duplicate 1:25 in assay diluent. For the standard curve, 1:3 serial dilutions of rHuPH20 (generated as described in Example 1) were made in assay diluent in duplicate starting from 0.1 U/mL down to 0.00014 U/mL. A blank well also was included. Then, 100 µl of the diluted samples or standard were added to pre-designated wells of the bHA-coated and blocked plate and allowed to incubate at 37° C. overnight. After the incubation, the plates were washed and binding to bHA detected as described above in Example 3. Optical density was measured at 450 nm within 30 minutes of adding the stop solution.

The identified reconfirmed inactive mutants are set forth in Table 10. The Table sets forth the amino acid replacement compared to the sequence of amino acids of PH20 set forth in SEQ ID NO: 3.

TABLE 10

							2
			Inactive M	Autants			
N002H	R060V	R121W	C189P	P236I	V287N	L336W G377V	
N002K	R060Y	R121Y	C189R	P236L	V287P	L336Y G378D	
N002W	L061A	N122A	C189S	P236N	V287Q	A337C G378E	
N002Y	L061E	N122C	C189T	P236Q	V287R	A337F G378F	
F003A	L061F	N122E	C189V	P236T	V287S	A337G G378I	4
F003G	L061G	N122F	C189W	P236Y	Y288D	A337I G378L	
F003K	L061H	N122I	C189Y	A238F	Y288E	A337K G378M	
F003P	L061N	N122K	Y190C	A238G	Y288F	A337L G378Q	
F003T	L061P	N122Q	Y190E	A238L	Y288G	A337M G378T	
F003V	L061Q	N122R	Y190F	A238P	Y288H	A337R G378W	
R004D	L061R	N122S	Y190G	A238V	Y288I	A337T G378Y	4
R004E	L061T	N122T	Y190H	A238W	Y288K	A337W K379A	
R004F	L061W	N122V	Y190K	A238Y	Y288P	A338C K379C	
R004G	L061Y	W123A	Y190L	A239C	Y288R	A338D K379E	
R004L	G062A	W123C	Y190N	A239F	Y288T	A338E K379F	
R004P	G062C	W123D	Y190Q	A239G	T289A	A338F K379I	
R004W	G062D	W123E	Y190R	A239H	T289C	A338G K379L	4
R004Y	G062F	W123H	Y190S	A239I	T289E	A338H K379M	
A005D	G062I	W123L	Y190T	A239L	T289G	A338I K379W	
A005G	G062K	W123M	Y190V	A239P	T289H	A338K F380C	
A005I	G062L	W123P	Y190W	A239R	T289L	A338L F380D	
A005L	G062M	W123Q	N191A	A239S	T289P	A338P F380E	
A005M	G062P	W123R	N191E	A239T	T289Q	A338R F380G	5
A005N	G062Q	W123S	N191F	A239V	T289R	A338T F380Q	
A005P	G062R	W123T	N191G	A239W	T289S	A338V F380R	
A005Q	G062S	W123V	N191K	A239Y	T289Y	K339D F380S	
A005R	G062T	W123Y	N191L	T240E	F290D	K339E T381G	
A005T	G062V	K124C	N191M	T240F	F290Q	K339F T381L	
A005V	G062Y	K124D	N191P	T240G	F290Y	K339G T381P	e
A005W	Y063C	K124E	N191Q	T240N	G291A	K339H T381W	(
A005Y	Y063G	K124F	N191R	T240W	G291C	K339L T381Y	
P006E	Y063P	K124N	N191S	T240Y	G291D	K339N V382E	
P006F	Y064A	P125C	N191T	L241A	G291E	K339P V382G	
P006T	Y064C	P125D	N191V	L241C	G291F	K339S V382H	
P006V	Y064D	P125G	N191W	L241D	G291M	K339T V382K	
P006Y	Y064E	P125L	N191Y	L241E	G291N	K339V V382L	6
P007C	Y064F	P125N	H192C	L241G	G291T	K339W V382M	

252

TABLE	10-continued

				T	f		
				Inactive M	Autants		
_	P007D	Y064G	P125W	H192F	L241I	G291W	K339Y V382N
5	P007F	Y064H	K126F	H192G	L241P	G291Y	M340A V382P
	P007G	Y064I	K126H	H192K	L241R	E292I	M340C V382Q
	P007H	Y064K	K126I	H192L	L241S	E292L	M340D V382R
	P007I	Y064L	K126L	H192M	L241T	E292T	M340E V382S
	P007K P007L	Y064P Y064Q	K126N K126P	H192N H192P	L241V L241W	T293E T293N	M340F V382T M340G V382W
10	P007L P007Q	Y064R	K120F K126Y	H192P H192Q	Y242A	V294A	M340H V382Y
10	P007R	Y064S	D127K	H192Q H192R	Y242C	V294A V294E	M340K R383G
	P007S	Y064T	V128E	H192V	Y242D	V294G	M340P R383P
	P007T	Y064V	V128P	H192W	Y242G	V294H	M340R G384C
	P007W	Y064W	Y129A	H192Y	Y242I	V294K	M340S G384F
	P007Y	P065A	Y129C	H193A	Y242L	V294L	M340T G384M
15	V008D	P065C	Y129D	H193D	Y242M	V294N	M340V G384Q
	V008E	P065D	Y129E	H193K	Y242P	V294P	M340W G384S
	V008G	P065G	Y129G	H193L	Y242R	V294Q	C341A G384T
	V008H	P065H	Y129H	H193M	Y242S	V294R	C341E K385C
	V008N V008R	P065I P065K	Y129L Y129P	H193P H193V	Y242T Y242V	V294S V294T	C341G K385L C341H K385M
	V008K	P065N	Y129P	Y194A	Y242W	V2941 V294W	C341K K385P
20	V008W	P065R	Y129Q	Y194C	V243C	A295C	C341L K385W
	1009C	P065S	Y129T	Y194I	V243D	A295G	C341M K385Y
	1009D	P065T	Y129V	Y194L	V243F	A295H	C341N P386A
	I009E	P065V	Y129W	Y194P	V243G	A295I	C341Q P386C
	I009G	P065W	K130C	Y194S	V243H	A295L	C341R P386F
25	1009N	P065Y	K130D	Y194T	V243L	A295N	C341S P386G
25	I009P	Y066A	K130G	Y194V	V243M	A295P	C341T P386H
	P010F	Y066C	K130H	K195S	V243P	A295T	C341V P386I
	P010I	Y066D Y066E	K130L	P197C	V243Q V243R	A295V	C341Y P386L S342D P386M
	P010L P010M	Y066G	K130N K130S	G198V G198W	V243R V243S	A295Y L296C	S342D P386M S342E P386N
	P010M P010Y	Y066I	K1303 K130T	Y199E	V2433 V243W	L296C L296F	S342E P386Q
30	N011A	Y066K	K130W	Y199G	V243Y	L296G	S342H P386R
50	N011C	Y066L	K130Y	Y199H	R244A	L296I	S342K P386S
	N011F	Y066N	N131P	Y199I	R244D	L296K	S342L P386T
	N011I	Y066P	R132P	Y199K	R244G	L296M	S342M P386V
	N011L	Y066S	S133D	Y199L	R244I	L296Q	S342P P386Y
	N011P	Y066T	S133E	Y199P	R244V	L296R	S342Q T387C
35	N011T	Y066V	S133F	Y199R	R244Y	L296S	S342R T387E
	N011W	I067D I067E	S133G S133H	Y199S Y199W	N245A N245C	L296T L296V	S342T T387F S342Y T387G
	N011Y V012G	1067E 1067G	S133H S133L	N200A	N245C N245F	L296W	Q343C T387H
	V0120 V012H	1067C	S133L	N200F	N245L	L296W	Q343D T387I
	V012W	1067R	\$133N	N200G	N245P	G297C	Q343F T387L
	P013E	I067T	S133P	N200H	N245Q	G297E	Q343I T387M
40	P013G	I067W	S133R	N200K	N245R	G297H	Q343P T387N
	P013I	D068A	S133T	N200L	N245S	G297L	Q343W T387V
	P013L	D068C	S133V	N200M	N245T	G297N	V344F T387W
	P013M P013V	D068G	S133W	N200P	N245V R246A	G297P	V344G T387Y
	F013V	D068I D068L	I134A I134C	N200Q N200R	R246A R246C	G297Q G297R	V344H L388C V344L L388G
45	F014E	D068P	I134D	N200S	R246D	G297S	V344M L388P
	F014G	D068V	1134F	N200W	R246E	G297T	V344N L388Q
	F014H	D068Y	I134G	N200Y	R246G	G297Y	V344P L388S
	F014K	S069N	I134H	G201A	R246H	A298C	V344Q E389F
	F014N	S069T	I134K	G201F	R246I	A298E	V344R E389V
	F014P	1070Q	I134P	G201L	R246K	A298L	V344S D390A
50	F014Q	T071P	I134Q	G201M	R246L	A298M	V344T D390C
	F014W L015E	G072C G072F	I134R I134S	G201N G201P	R246M R246P	A298N A298P	V344W D390E V344Y D390F
	L015E	G072H	11343 1134W	G201F G201R	R246F	A298P A298Q	L345A D390G
	L015G	G072II G072I	E135P	G201K	R2465 R246T	A298S	L345C D390H
	L015C	G072P	L136P	G2015	R246V	A298T	L345E D390L
55	L015N	G072V	V137F	G201V	R246W	A298W	L345H D390N
55	L015P	G072W	V137G	G201W	V247A	A298Y	L345K D390P
	L015Q	V073P	V137H	S202A	V247C	S299A	L345N D390R
	L015R	V075D	V137N	S202E	V247F	S299C	L345Q D390S
	L015S	V075G	V137P	S202F	V247H	S299D	L345R D390T
	L015Y	V075P	V137R	S202G	V247N	S299F	L345T D390V
60	W016A	N076A N076C	V137W	S202H	V247P	S299G S200H	L345V D390W
	W016C W016D	N076C N076F	V137Y Q138V	S202K S202N	V247Q V247R	S299H S299L	L345Y D390Y C346A L391A
	W016D W016E	N076G	Q138V Q139P	S202N S202P	V247K V247S	S299L S299M	C346D L391D
	W016E W016F	N076I	Q1331 Q143C	S2020	V2473 V247T	S299P	C346F L391G
	W016G	N076K	Q143H	S202Q S202R	V247W	S299Q	C346G L391H
	W016H	N076L	Q143P	S202V	V247Y	S299T	C346I L391K
65	W016K	N076P	Q143R	S202W	R248C	G300A	C346K L391N
	W016M	N076Q	Q143S	S202Y	R248D	G300C	C346L L391P

253

TABLE 10-continued

TABLE 10-continued

		17 11		continu	cu						17 11		continu	cu		
			Inactive 1	Mutants								Inactive M	Mutants			
W016P	N076R	Q143T	C203A	R248E	G300D	C246M	L3910		S022K	H088C	T168D	D212K	S254Y	L307C	12520	S401C
W016F W016R	N076S	L144A	C203A C203D	R248E	G300D G300E		L391Q L391R	5	S022R S022P	H088E	T168E	D212K D212L	K255C	L307C	I353Q I353R	S401C S401F
W016K	N076T	L144A	C203D	R248U	G300E G300F		L391K	5	E023A	H088E	T168F	D212L D212M	K255D	L307I	1353K 1353S	S4011 S401H
W0165	N076V	L144F	C203E	R248M	G300L		L391T		E023F	H088G	T168G	D212IVI D212P	K255L	L307P	1353W	S401K
W016Y	N076W	L144I	C203H	R248P	G300H	C346T			E023L	H088I	T168K	D2121 D212V	K255P	S308C		S401R
A017D	G077D	L144K	C203L	R248T	G300N		L391W		E023M	H088K	T168L	D212W	K255V	S308F		S401W
A017E	G077E	L144P	C203M	E249A	G300P	C346W			E023N	H088L	T168P	D213P	K255W	S308L		
A017G	G077L	L144Q	C203N	E249G	G300Q		E392C	10	E023P	H088M	T168R	D213S	I256C	S308M	R354G	
A017H	G077P	L144S	C203Q	E249H	G300S	Q347F	E392P		E023R	H088P	T168S	L214A	I256D	S308V	R354H	C402D
A017I	G077Q	L144V	C203R	E249I	G300T	Q347I	Q393C		E023S	H088R	T168V	L214C	I256E	S308W	R354I	C402E
A017L	G077R	L144Y	C203S	E249K	G300V	Q347P	Q393P		E023T	H088S	T168W	L214D	I256G	S308Y	R354K	C402F
A017N	G077T	S145T	C203T	E249M	G300W	Q347T	F394A		E023V	H088T	T168Y	L214E	I256P	M310C	R354L	C402L
A017P	G077V	S145W	C203V	E249Q	I301E	Q347V	F394D		C025D	H088V	I169A	L214G	P257D	M310E	R354M	
A017Q	G078A	A149E	F204A	E249S	I301G	Q347W		15	C025E	H088Y	I169D	L214H	D258L	M310F		C402P
A017R	G078D	A149P	F204C	E249Y	I301H		F394G		C025F	L089A	I169F	L214K	D258P	M310K	R354Q	-
A017S	G078I	T150V	F204E	A250C	I301K	E348H			C025G	L089D	I169G	L214N	D258V	M310L		C402R
A017T	G078M	K152L	F204G	A250F	I301M		F394K		C025H	L089E	I169H	L214P	D258W	R311C	R354V	
A017V	G078P	A153E	F204H	A250G	I301N		F394N		C025I	L089G	I169K	L214R	K260C	R311E	R354W	
A017W	G078T	A153F	F204I	A250H	I301P		F394P		C025K	L089Q	I169N	L214S	K260P	R311F	R354Y	
A017Y	G078Y	A153M	F204K	A250K	I301Q		F394Q	20	C025L	L089S	I169P	L214T	S261P	R311I	K355D	
W018C	I079A	A153P	F204Q	A250L	I301R		F394R		C025N	L089T	1169Q	L214Y S215C	P262A	R311L		C402Y
W018D W018F	I079D I079F	A153R	F204R F204S	A250M A250N	I301S I301W	E348T E348V	F394S F394T		C025P C025R	L089W L089Y	I169S I169T	S215C S215P	P262D P262E	R311P R311V	K355G K355H	Y403A Y403C
	1079F 1079G	A153T A153V	F2045 F204T	A250N A250P	1301 W 1301 Y	E348V E348W			C025R C025S	D090C	11691 I169Y	W216D	P262E P262F	R311V R311W	K355H K355L	
W018G W018H	1079G 1079H	A153V K154D	F2041 V206C	A250P A250Q	1301 Y V302C		F394V S395C		C025S C025T	D090C D090G	K170C	W216D W216E	P262F P262G	S312C	K355L K355M	
W018H W018I	1079H 1079K	K154D K154E	V206C V206D	A250Q A250R	V302C V302D	Q349D			C0251 C025V	K091D	K170C K170D	W216E W216G	P262G P262H	S312C S312E		Y403H
W018L	1079K 1079N	K154E K154G	V200D V206F	A250K A250S	V302D V302E		S395L S395M	25	C025V C025Y	K091D K091E	K170D K170E	W216U	P262I	S312E S312M		Y403H
W018L W018M	10791N 1079P	K1540 K154P	V200F	A2503 A250T	V302E V302F	Q349F Q349G			G027C	K091E K091F	K170E K170G	W210H W216I	P262K	S312W		Y403K
W018W	1079F 1079S	K154F K154S	V2000 V206P	A2501 A250V	V302G	-	E396C		L033C	K091G	K1700	W2101 W216K	P262Q	\$312V \$312W		Y403L
W018Q	1079W	K154W	V206Y	A250W	V302H	Q349V			L033D	K091H	K170P	W216L	P262R	M313C		Y403N
W018S	I079Y	K154Y	E207A	I251D	V302L	Q349W			L033H	K091I	K170W	W216M	P262S	K314C		Y403P
W018T	P080A	Q155P	E207F	I251F	V302M	Q349Y			L033N	K091L	K170Y	W216N	P262T	K314L		Y403Q
W018V	P080D	Q155Y	E207G	I251G	V302P		E396P	30	L033V	K091N	L171C	W216P	P262V	K314W	K355W	
W018Y	P080E	E156P	E207M	I251H	V302R	G350D		50	L033Y	K091T	L171D	W216Q	P262W	S315C	K355Y	
N019A	P080F	F157A	E207P	I251K	V302S		K397A		D034I	A092E	L171H	W216R	P262Y	S315I	N356C	
N019C	P080G	F157C	E207Q	I251P	V302T	G350F	K397C		D034L	A092F	L171M	W216T	L263E	S315V	N356G	S404D
N019F	P080I	F157D	E207R	I251S	V302Y	G350H	K397E		D034N	A092H	L17IN	W216V	L263F	C316E	N356K	S404F
N019G	P080K	F157E	E207S	I251T	I303A	G350K	K397F		D034S	A092K	L171R	L217A	L263P	C316G	N356L	S404G
N019H	P080L	F157G	E207T	I251W	I303C	G350L	K397G	35	D034T	A092P	L171S	L217C	L263Q	C316I	N356P	S404H
N019I	P080M	F157H	E207V	R252A	I303D	G350M	K397I	00	D034V	A092Q	L171W	L217G	L263W	C316K	N356R	S404L
N019L	P080N	F157I	E207W	R252D	I303E		K397L		M035A	A092R	L171Y	L217H	P264D	C316L		S404M
N019M	P080R	F157K	I208D	R252E	I303F		K397M		M035D	A092W	G172D	L217P	P264E	C316M	N356V	
N019P	P080S	F157L	I208G	R252F	I303G		K397P		M035G	A092Y	G172E	L217Q	P264F	C316P	N356W	
N019Q	P080T	F157M	I208P	R252G	I303K		K397Q		M035P	K094G	G172I	L217S	P264G	C316R	W357D	
N019R	P080V	F157P	1208W	R252H	I303L		K397T	40	M035R	K094P	G172L	L217T	P264L	C316S	W357E	
N019S	P080Y	F157Q	K209C	R252I	I303M		K397V	10	M035S	D095A	G172P	L217V	P264M	C316T	W357F	
N019V	Q081A	F157R	K209P	R252K	I303R	G350Y			S036C	D095C	G172Q	L217W	P264R	C316V	W357G	
N019W	Q081C	F157S	R210A	R252L R252N	I303W I303Y		F398C		S036F	D095E D095F	G172T	W218A	P264T P264V	C316W	W357L	
N019Y	Q081E Q081G	F157T F157V	R210C R210D	R252N	W304A		F398E F398G		S036V S036W	D095F D095G	G172V G172W	W218I W218K	P264W	C316Y L317G	W357M W357Q	
A020D A020E	Q081G Q081H	E158D	R210D R210E	R252P R252S	W 304A W 304C		F398G F398H		S036W S036Y	D095G D095H	G172W G172Y	W218K W218L	P264W P264Y	L317G L317P	W357Q W357R	
A020E A020F	Q081H Q081L	E158D E158K	R210E	R2523	W304C W304D	V351H		45	L037C	D095H	K173D	W218L W218P	V265A	L317F L318C		C408A
A020H	Q081L Q081N	E158R	R210G	R252Y	W304D W304G	V351N			L037C	D095K	K173D K173E	W218F W218S	V265D	L318C	N358H	
A020K	Q081P		R210K			V351R			L037G		K173G			L318W		C408E
A020L	Q081S	E158Y	R210M		W304M				L037N	D095P		N219P		L319C	N358K	
A020N	Q081V	K159W	R210P	V253E	W304N	V351Y			L037S	D095Q	K173I	E220G	V265H	L319E	N358P	
A020P		K159Y	R210S	V253G	W304P	C352A			F038E	D095S	K173L	E220K	V265K	L319F		C408K
A020R	-	G161W	R210T	V253H	W304Q		F398T	50	F038G	D095V	K173M	E220N	V265L	L319G	N358R	
A020T	K082W	D163C	R210V	V253L	W304S		F398V	20	F038K	D095W	K173P	E220P	V265M		N358W	
A020V	K082Y	D163P		V253M			F398W		F038L	D095Y	K173S	E220R	V265N	L319I		C408R
A020Y	I083E	F164A	R210Y	V253N	W304V	C352G			F038N	I096A	K173V	E220W	V265Q	L319K		C408S
P021A	I083K	F164C	N211C	V253Q	W304Y	C352K			F038Q	I096C	K173W	S221D	V265R	L319M	S359G	C408T
P021C	S084Y	F164D	N211F	V253R	G305L	C352M			F038R	I096G	K173Y	S221E	V265S	L319P	S359L	C408V
P021D	L085A	F164E	N211G	V253S	G305P	C352P	C400A	55	F038T	I096H	L174P	S221H	F266A	L319Q	S359P	C408W
P021E	L085C	F164G		V253W	G305Q		C400D	55	F038W	I096P	L175C	S221K	F266C	L319R	S359W	
P021G	L085D	F164H	N211I	S254C	G305R		C400E		S039C	I096R	L175D	S221P	F266G	L319S		E410W
P021H	L085E	F164N	N211K	S254D	G305S		C400F		S039D	1096S	L175G	S221R	F266H	L319V		K411D
P021I	L085F	F164P	N211M	S254E	G305T		C400G		S039F	I096T	L175K	T222P	F266M	L319W		K411E
P021L	L085G	F164Q	N211P	S254G	G305V	C352V			S039W	1096W	L175P	T222Y	F266P	L319Y		K411F
P021M	L085H	F164R	N211R	S254I	G305Y	C352W		60	F040A	F098P	L175R	A223C	F266Q	D320C		K411G
P021R	L085N	L165C	N211S	S254K	T306A		C400M	00	F040D	Y099C	L175S	A223D	F266R	D320P		A412E
P021S	L085Q	L165H	N211T	S254L	T306C		C400P		F040E	Y099E	R176A	A223E	F266S	D320V		A412H
P021T	L085S	L165P	N211V	S254P	T306H		C400Q		F040G	Y099G	R176C	A223G	F266T	N321E		D413H
P021V	L085T	L165T	N211W	S254Q	T306I		C400R		F040K	Y099I	R176E	A223H	F266V	N321M	S360M	
P021W	Q086C	V166D	D212A	S254R	T306L		C400S		F040N	Y099N	R176F	A223K	F266W	N321P		D413K
S022C	Q086P	E167V	D212G	S254T	T306V		C400T	65	F040R	Y099P	R176G	A223L	A267D	Y322C	-	D413L
S022E	D087P	T168A	D212H	S254V	T306W		C400V	05	F040S	Y099V	R176H	A223P	A267G	Y322D		D413P
S022G	H088A	T168C	D212I	S254W	T306Y	1353M	C400Y		F040T	Y099W	R176I	A223Q	A267H	Y322E	S360V	V414A

255

TABLE 10-continued

TABLE 10-continued

Indicity Junctive			TAE	BLE 10-	continu	ed						TAI	3LE 10-	continu	ed		
DH1Q M100E R176 A2235 A267K Y3221 DS1E V144E Y184H Y228F D278F B31F N166R A428V G01ED M100K R176 A2234 A257K Y223F B316 V144F V108F V108F <th></th> <th></th> <th></th> <th>Inactive N</th> <th>Mutants</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th>Inactive N</th> <th>Autants</th> <th></th> <th></th> <th></th>				Inactive N	Mutants								Inactive N	Autants			
DH1Q M100E R176 A2235 A267K Y3221 DS1E V144E Y 184H Y228F D278F S11F N566R A423Y GGU2D M100F R176 A223Y A267K Y221F DS11F N166R A223Y DS16F V144F Y184F Y228F G276F S11F N566R A223Y GGU2D M100F R170F A223Y A267K Y322F DS10F V144F Y184F Y238F G276F S11F N566R A127F GGU2D M100F P177C L24A Y286K Y228F DS10F V114F T155F T100F L168F L240K R277F S131F P667F D426K GGU2D M100W P177F L244F Y288F M232F M305F N116F L158F L230K R279F S324F P667F D426K GGU2D M100W P177F L244F Y288F M233F M305F M117F M305F M11	F040V	M100C	R176P	A223R	A267I	Y322G	D361A	V414D		V053R	V109E	Y184L	Y229L	D275V	I331D	N366P	A425L
GADES MIONG R1764 A2239 A2578 Y22N GADE Y1884 Y22N G276F Y1814 Y22N G278F Y1814 Y1814 Y23N Y1814 Y23N Y1814 <				A223S		Y322I	D361C	V414E	5		V109L					N366Q	A425P
Gold H. MION R176V A223V A267S S122P DSGM VIAIR VISSY																	
GM2D MIOP R17A L22A M22A M22A <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>																	
GeG2L M100R P177C L224A Y28C Y322E Dolloy V4145 T054E H101C L185A L230A L278 B31E P367T D428R GGUZ M100T P177C L238 Y286F Y322V D561R K415C T054F H10L L185E L230K K279G B31E P367T D428R GGUZ M100F P177G L234F Y285K M325C D561V K415P T055V H110L L185E L230K K279G B312A P567G G427F GGUZ P107F L234V Y285K M322C Y463C H101K L185S L230K K279G B312A P567G G427F GGUZ P107F L234V Y285K M322K Y463C H107F L234K Y280K M322K Y463C H107F L335K M326F																	
GoH2M MIONT P177 L224E Y286G Y322V Dális, K415C T054R HILD L185E L230G K27VE B311 P547L G472A GG12Q MIONV P177L L224G Y286G Y2805 Y2805 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>																	
GG422 M100W P177F L224F Y286H M32A Dalis K k15D T054Y H100 L185G L230H K279G B312 P167G G427E G0428 P101A P177L L224H Y286H M32A Dalis K115P H105H L185G L230H K279G B312 P167G G427E G0428 P101H P177D L224H Y286H M32A Y463G H117F L555H H110L L188E L230H K279F B332E D868W G427P S04145 P101H P177R L224F Y286S M32A Y463G H117F H155W H116L L185E L230F F280H B332H N360H Y428C S04145 P101F P177F L234F Y286K Y428C Y436C Y428F H117 H155W H121L L188F L230H F280H B332H N360H Y428C S04145 P101F P177F L234F Y280F Y436F Y436F									10						I331S		
G6420 M100Y P177H L2340 Y265K M322A D361V K415E T055A H100 L185 L230K K270F G677 G678																	
G0028 P101A P17TL L224W Y268K M322C Dafu Kul5P I055D D11H L185K L230K K27W B322 D868F G472 G412V P101F P17TL L224Q Y268K M322G Y362C H11K L185K L230K K27W B322 D868F G472 S414F P101F P17TL L224V Y268K M321K Y362K T417K D105K D111L L185F L230F F280K B324K M869F G427K S414F P101K P17TK L224K Y26K M323K Y362K T417K D105K W112L L185K L230K R366K V428K S414F P101K P17W Y22AK Y26K T417K D105K W112L L185K L230K R366K V428K S414F P101K P17W Y22AK Y46K Y46K H11K F165K R134K R368K V428K V468K V428K V468K<																	
Globes PIOL <																	
Gu42 Piolit Pit78 L224 Y268 M321 Y362 Piolit DisSH Dillot LisSR L230F P280I B32E DisSR Mised Feature SolisF Piolit Pi77 L224F Y268 M323 Y364 Fi17F IbSSP WilzE LisSR L230F P280I B32E NoeG G427Y SolisF Piolit P177 L234F Y268F M323 Y362F Fi17F IbSSP WilzE LisSR L230F P280I B33E NoeG V427V SolisK Piolit N178F Y225F T260F B32F Y362F T417F IbSSP Wil2F Fi86D B321F B32F NoeG V428V SolisK Piolit N178F Y225F T260F E144F Fi86D B231F P204V B332 NoeG V428V SolisK Piolit N178F Y225F T260F E144F Fi86D B231F E214V B332F NoeG V428V B332F																	
Subia Piolit Pirzs L224 Y280 M328 Viaz Lisss L230 F230 L332 Nie66 C427W Subia Piolit Pirzs L244 Y268 M328 Ya64 Tirliz Lisss L2307 F2801 B332 Nie66 C427W Subia Piolit Pirzs L244 Y268 M328 Ya624 Tirliz Lisss L2307 F2801 B332 Nie66 C427W Subia Piolit Pirzs Tirlize Lisss L2307 F2801 B332 Nie66 C427W Subia Piolit Pirzs Tirlize Lisss L230F F2800 B332 Nie66 C427W Subia Piolit Pirzs L244 Ya628									15								~
Sub3E PIOL PIT7 L224T Y285K M323N Y362K T417E PIS5P W112E L18ST L230F P280K B322K N369F Q423K S0433 PIOIM PIT7T L224V Y286K M323F PIOID B35T W112E L18ST L230V P280K B32K N369F V428C S0434 PIOID N178K Y225D T260F M323F Y362K T417F B055V W112L L18ST L230V F280K B32K N369F V428C S0438 PIOID N178K Y225F T260F H247F F056C F118F F186K N231F F30K V428C S0438 PIOIT N178V Y225F T260F E242V Y362K Y43CT F1065C F118F F186K N231F E31K N368V V428C S0444 PIOIA D103C N178V Y228F T260F E144F F186K N231F E31K N37																	
S0436 P101L P177T L224W Y268T M328T Y362L P117F L234W Y268T M328T Y362L P117F L234W P280M B32H N360F V428C S0138 P1010 P177V Y225A Y268W M321 Y362L P117F P117F Y262F Y362F Y112F F186A X311A F280R B332L N360F V428C S0138 P1017 N178F Y225F T260F F332F Y362F Y112F F186A X311A F280F B332F N360F V428C S0138 P1017 N178F Y225F T260F F334F Y362F Y417F P117F P1117F P1117F P1117F																	
Solida PIOIN PITA Yuzza Yuzza <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>																	
Solat, Solat,		P101M	P177V		Y268V	M323S	Y362L	T417G		1055R	W112H	L185W					
Sona P Pinis Nirag 1222 Pinis Pinis <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>20</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>									20								
S0430 P1015 N1784 V2256 T2690L E324F Y362F T4170 F056A W112S F186C N231D F280V H328 N369V V428N S0438 P104A D103 N178V V225F T2690 E324V Y362T T417R F056E E113F F186L N231L L332T T370A V428S P0444 D103F L180N Y232F T2690 E324V Y362V A1492 F056L E114F F186L N231L L381 N3331 F370C C4290 P0444 D1031 L180P Y225V R270C T228C L363U V420F F056F W115A F186N N231L L281L N333F F370C C429P P0444 D103R W181C P226F R270P L337F L364V V420R F056F W115A F186N N231L L381N R370R C429F P0444 D103R W181F P226L R270P <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>20</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>									20								
S0348 P101T N1738 V225R T269M F324P Y362S T4170 P065C E113R F186I N2316 L2318 L332T L333T L33T																	
P044A D103A N178Y Y225P T260P E324W Y362V A149P F056G E114J F186L D231I L281D B322F F370A V428S P044E D103F L180A Y225R T260R T32SC L363A V420F P066I E114F F186A N231I L281R N333I F370G C420P P044H D103F L180F Y225W R270C G326E L363D V420F P0666 E114F F186A N231I L281N N333K F370H C429R P044H D103L L180F Y226C R270F G320H L363F V420F P0666 W115C F186A N231I L281N N333F F370R C429R P044H D103V W181A P226C R270P L327F L363F V420R P066F W115F P187A T232C L281N N333F F370R C429F P044H D103V W181B P125C																-	
P044E D103E H179W Y22SQ T269Q E324F Y362W A4490 P565 E114L F186N N231K L281G N333F F370E C429A P044H D103I L180C Y22SV R270C L362E L363E V420F P665E E114F F186N N231K L281K N333F F370C C429D P044H D1031 L180P Y22SW R270C L363G V420F P665E E114F F186N N231F L281K N338F F370C C429D P0444 D103T W181C P226C R2701 L327L L363F V420F P665F W115F F186W N231K L281K N333F F370C C429F P0444 D103T W181C P226F R270F L327L L363F V420F P656F W115F F186W N231K L281K N333F F370C C429F P0444F D103W W181F P226C L271F		V102P								F056E	E113V	F186I	N231G		I332T	N369W	V428R
P044E D103F L180A Y225R T226PK T235K L363K V420A P044H D103H L180F Y225W R270C 1326K L363K V420F P044H D103L L180F Y225W R270E 1326G L363F V420F P044H D103L L180F Y226K R270F 1326H L363F V420F P044H D103R W181A P226C R270F 1326H L363F V420F P044K D103F W181A P226C R270F L327F L363F V420F P044K D103F W181D P226F R270F L327F L363F V420F P044Y D103F W181F P226G R270F L327F L363F V420F P044Y D103F W181F P226G R270F L327F L363F V420F P044Y D103F W181F P226G R270F L327F L363F V420F									25								
P044H D103C L180C Y225W R270C T225R L363C V420F F066K E114T F186D N331L D281L N333F F370C C429D P044H D103L L180P Y225W R270C E326H L363F V420F F066F W115A F186K N231F L281F N333F F370C C429D P044H D103V W181C P226C R270T L327L L363F V420F F066F W115A F186V N231F L281P N333F F370C C429F P044W D103T W181C P226F R270P L327E L363G V420F F066F W115F F186V N331F F370C C429F P044W D103W W181F P226F R270P L327E L363G V420F Y057A W115F P187A T232C S282F V334F F370C C429F P044W D103W W181F P226A F127T F136C									23								
P0444 D103H Lisou Y225V R270C 1326L L363F V420C F036L E114V F186Q N331P L281K N333F F370K C429L P0444 D103L L180R P226A R270F 1326H L363F V420K F036F W115A F186V N231F L281R N333F F370K C429F P0444 D103R W181A P226C R270F L327L L363F V420K F065G W115D F186V N231F L281R N333F F370R C429P P0444 D103V W181D P226F R270F L327F L363G V420F Y057F W115S F186V N231F L281R N333F F370R C429P P0444 D103Y W181F P226R I271L L327F L363G V420C Y057F W115S P187T T323L S282F V334C F370C C429P P044Y D104F W181R P226R																	
P0444 D1031 L180P Y225W R270E B326H C326F V420H P0444 D1030 L180S P226A R270G B326H L365G V420H P065R W115C F186S N211R L281P N333F F370L C429D P0444 D1037 W181C P226R R270H L327L L363I V420N P056F W115F P187C T232L L281R N333F F370R C429D P0444 D103W W181E P226R R270P L327E L368V V420F P056W W115F P187T T232L L281K N333W F370R C429D P0444W N104F W181H P226L 1271H L327C L363V V420F Y057A W115E P187T T232L S282V V34A F370C C429F P0445 D105G W181K P226H 1271H L327C L363V V422C Y057F W115F P187T T232L																	
P0444 D103 L1808 P226A R270F IS20F IS20F P336 P370L C429N P0444 D103 W181A P2266 R270F I326K L366S V420K P055S W155 F186V N211 L281N N333F F370L C429P P0444 D103 W181D P226F R270F L327L L363V V420R F056V W115F F186V N211K N333F F370L C429T P0444 D103 W181D P226G R270V L327L L363V V420T Y057D W115F F186V R211K R333F F370L C429T P0444 D103W W181F P226L I271L L327V L363V V422D Y057G W115K P187T T232C S282V V334G F370V C429Y R0455 L106W W181K P226T I271K L327V L364V V422L Y057F W115V P187T T232V Q38																	
P044R D103R W181A P226R R270H 1326W L363H 420L F1086 W113F F180V V231S L281Q N333T F700R C429S P044R D1037 W181D P226R R270P L327L L363P V420R F066F W115F F180W N231V L281R N333T F700R C429S P044T D1037W W181E P226G R270P L337L L363V V420T Y057A W115F F187H T323C L281N V333V F370R C429V P044Y N104P W181L P226R 1271L L337L L363V V420P Y057F W115D P187T T323L S282V V334D A371H H30D R045D U105C W181L P226F 1271L L327F L363V V422C Y057L W115V P187Q T323P S282V V334H 1372L H30H R045D L105C W181R P226F <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>																	
P0448 D103T W181C P226F R2701 L327L L363I V420N F036I W115F P180N V231V L281K N333W F3700 C429T P0444 D103W W181E P226L R271N L363V V420S F036V W115F P187A T232C L281K N33W F370C C429T P044W D103W W181E P226L 1271L L327T L363V V420D Y057D W115F P187A T232L S282V V334E A371P I430A R045D L105C W181L P226R 1271L L327R L363V V422D Y057T W115S P187N T232D S282V V334E A371P I430A R045D L105K W181K P226R 1271L L327T H364L V422D Y057T W115S P187N T232D S282W V334H J372L H30D R045S L106C M181S P226W V221W <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>30</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>									30								
P04445 D103V W181D P2266 R270P L327E L363P V420R P056W W1154 P187A T232C L231S N33W F370R C429V P0444V D103Y W181F P226G R270V L327F L363V V420T Y057A W1154 P187F T232L L221K V334C F370V C429V P044Y N104P W181F P226N IZ11F L327T L363V V420V Y057 W115K P187F T232L S282V V334E A371P H300 R0455 L105W W181R P226V IZ17H L327T H364C V422L Y057F W115V P1870 T232V 2828V V334B A371P H300 R0455 L105M W181R P226V V27L L327T H364C V422L Y057F W115V P1870 T232V Q283C V334B 1372L H300 R046F G1066G G182C S227F <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>																	
Orbit Diag Wisi P226L IZ1A L23G Vision	P044S		W181D		R270P	L327E	L363P	V420R								-	
Portay Niloife Wilsin P226N E71D L353 V120V Y15D W15L P187H T232L S22E V334C F370V C429V RodsA N104P W181I P226R I271H L327N L363T V420Y Y057E W115L P187H T232L S282V V334C A371P H300 RodsF L105C W181L P226F I271H L327R L363V V422C Y057E W115L P187H T232N S282V V334C A371W H300 RodsF L105C W118L P226F I271H L327H H364D V422D Y057D W115S P187D T322V Q283C V334L B372E H300 N046P G106C G182D S227F Y27N H364F V422D Y057V R116A P187V Q233D Q282D V334S 1372E H300 N047V G106F G182D S227F Y27N P329F H36																	
R045A N100P W181T P326Q P371F L327N L363V V420V Y057F W115L P1871 T232L S282L V334D F370V H30A R045D N104W W181K P226S 1271H L327Q L363V V422D Y057G W115N P187L T232V S282V V334G A371P H30A R045F L105N W181R P226V 1271T L327S H364A V422D Y057L W115N P187M T232Q S282V V334G A371W H30A R045F G106A W181V P226V V272A L327V H364D V422L Y057P W115V P187R T232Q S283V V334G 1372F H30A N046W G106D G182D S227F V721H H37H H364F V422P Y057V R116C P187T Q233T Q283D V334S 1372L H302H N047V G106M G182D S227F P																	
R045D N104W W181K P226K IZ71H I.327Q I.337V V422C Y057G W11SP P187L T.232N S282V V334E A371P H300L R045F L105N W181R P226F IZ71T L327S H364A V422C Y057L W11SP P187N T232Q S282V V334E A371W H30L R045F L105N W181S P226V IZ71T L327F H364A V422C Y057L W11SP P187N T232Q S282V V334E A371W H30L R046W G106C G182A P226V V272H L327V H364F V422N Y057V R116D P187V Q233D Q283F T335G T372H H30V N047V G106F G182D S227F V727P P39F H364H V422P Y057V R116D P188V Q234A D284F T335F 1372L A332F T049P G106F G182D S227F <									35								
R0456 L105M W1818 P2267 1271T L3275 H364C V422C Y057L W115S P187N T232Q S282V V334N 1372D H304D R045W G106A W181V P226V V272L L327V H304C V422L Y057P W115S P187N T232V Q283A V334N 1372D H304D R046W G106C G182A P226V V272L L327V H304F V422N Y057R R116A P187S Q233D Q283F T335E I372L H304D N047V G106F G182E S227F V272P P329C H364L V422R Y057V R116A P187V Q233P Q283F T335E I372L H304V T049G G106M G182N S227F P73C P329H H364C C423E V057W R116L P187V Q233P D284L T335L 1372L A432E T049G G106M G182N S227F F273L P329H H364C C423E D059F R116L D188C Q234E				-						Y057G	W115M	P187L	T232N	S282V	V334E	A371P	I430D
R045P L105N W181S P226V 1271W L327T H364C V422L Y057N W115V P187Q T232V Q283A V334N 1372D 430M R045W G106A W181V P226V V272A L327V H364E V422L M15V P187Q T232V Q283A V334N 1372D H30M R046W G106C G182A P226V V272L L327V H364F V422D Y057Q R116A P187V Q233D Q283V T335G 1372L H30V R047W G106F G182B S227F V272P P329F H364K V422V Y057V R116D P187V Q233F Q283W T335L 1372L A432F T0490 G106M G182R S227F F273G P329L H364V C423F D059F R116L D188F Q234E E285F T335U 1372L A432F T049P G1066V G182R S227F F273L <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>																	
R045W G106A W181V P226W V272A L327V H364D V422L Y057P W115Y P187R T222Y Q283C V334R H372E H304D 1046W G106C G182C S227F V272H L327V H364E V422N Y057R R116A P187R C233D Q283D V334R H372E H306T N047V G106F G182C S227F V272P P329C H364E V422N Y057R R116C P187V Q233D Q283D T335E T372L H330C T049G G106H G182P S227F V272P P329H H364L V422N Y057N R116E P187V Q233D Q284C T335E 1372L A432C T049G G106F G182P S227L F273C P329H H364C C423A 5059E R116I D188C Q234L D285K T335E 1372L A432C Q051C G106W G182P S227L F273D P329H H364T C423A 5059E R116D D188C Q234L <td></td>																	
1046P G106C G182A P226Y V272L L327W H364E V422N Y057Q R116A P187S Q233D Q283D V348 J372F H306F 1046W G106D G182D S227A V272L L327W H364F V422N Y057Q R116A P187S Q233D Q283D V348 J372F H306F N047V G106F G182D S227A V272N P329F H364G V422R Y057V R116C P187V Q233D Q283D Q33D Q33F T335F H372F H430F T049G G106L G182N S227F F273D P329H H364F V422F Y057W R116L D188C Q234D E285K T335L I372F A432F T049F G106W G182S S227F F273L P329H H364F C423F D059L R116L D188F Q234L E285F T335F I372F A432F Q051F M107C G182T S227F F273L P329L H364F C423F D059F R116D														-			
1046W G106D G182C S227A V272L 1327Y H364F V422N Y057R R116C P187V Q233I Q283F T335G 1372G 1430T N047V G106F G182D S227F V272P P329F H364K V422R Y057R R116C P187V Q233I Q283F T335G 1372G 1430T T049G G106H G182P S227I F273A P329H H364K V422Y Y057N R116C P187V Q233I Q283F T335L 1372L A432L T049G G106M G182P S227F F273A P329H H364P C423A D059A R116L D188C Q234L D284F T335L 1372L A432L T049G G106S G182S S227F F273I P329L H364C C423F D059F R116L D188C Q234L E285F T335V 1372R A432L Q051F M107A G182Y S227F F273P P329U L365C C423F D059F R116Q D188L Q234H <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>40</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									40								
N047V G106F G182D S227F V272N P329C H364K V422Q Y057V R116D P187V Q233P Q283W T335G I372H I430V T049C G106L G182H S227H V272P P329F H364L V422P Y057V R116D P187V Q233F D284C T335H I372L L432C T049G G106M G182N S227T F273D P329H H364R C423D D059A R116H D188A Q234D D284F T335K I372H A432F T049G G106W G182Q S227F F273D P329L H364S C423F D059L R116L D188C Q234F E28F T335V I372F A432L Q051C G106W G182S S227F F273B P329L H364V C423F D059P R116D D188L Q234H E28F T335V I372C A432L Q051L M107C G182Y S227F <t< td=""><td></td><td>G106D</td><td></td><td>S227A</td><td></td><td></td><td></td><td></td><td></td><td>_</td><td></td><td></td><td>-</td><td>-</td><td></td><td></td><td></td></t<>		G106D		S227A						_			-	-			
T049C G106L G182H S227H V27W P329G H364L V422S V058A R116G P187W Q233 D284L T335I I372L A432F T049G G106M G182N S227I F273A P329H H364P C423A 45 D059A R116H D188A Q234A D284H T335I I372N A432F T049G G106F G182Q S227F F273G P329H H364F C423F D059L R116H D188C Q234G E285K T335F I372R A432F Q051C G106W G182V S227F F273I P329H H364T C423F D059L R116H D188C Q234G E285K T335V I372Z A432E Q051C G106Y G182T S227F F273P P329H H364Y C423F D059P R116D D188H Q234H E285V T335V I372Z A432E Q051F M107T H38D S227F F273V P329F L365C C423F D059F R116V D188H													-	-			
T049D G106M G182N S227I F273A P329H H364M V422Y V088A R116G P187Y Q233T D284I T335I I372L A432F T049G G106F G182P S227K F273C P329H H364P C423A 45 D059A R116H D188C Q234D E285K T335L I372P A432F T049P G106S G182R S227M F273G P329L H364R C423E D059L R116L D188C Q234E E285F T335F I372R A432F Q051C G106V G182T S227P F773L P329R H364V C423G D059L R116D D188H Q234H E285T T335Y I372X A432P Q051I M107C G182Y S227V F773P P329V L365C C423L D059V R116Q D188N Q234V L286L L336G Q373P L434K Q051I M107P Y183G <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Y057W</td><td>R116E</td><td>P187W</td><td></td><td></td><td>T335H</td><td>I372K</td><td>D431P</td></td<>										Y057W	R116E	P187W			T335H	I372K	D431P
T049G G106N G182P S227K F273C P329I H364P C423A 45 D059A R116H D188A Q234A D284F T335K I372R A432F T049P G106F G182Q S227L F273D P329L H364R C423F D059I R116L D188C Q234E E285F T335L I372P A432L Q051C G106W G182T S227P F273L P329L H364Y C423F D059L R116L D188C Q234E E285T T335V I372S A432L Q051F M107A G182Y S227T F273D P329R H364Y C423F D059N R116D D188L Q234F E285T T335E I372V A432P Q051I M107C G182Y S227F F273B P329P L365C C423L D059V R116S D188L Q234F L286L L336C Q373F L434P Q051M M107P Y183E <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>-</td><td></td><td></td><td></td><td></td></td<>													-				
T044P G106S G182R S227M F273G F373G F374F H364S C423E D059I R116L D188F Q234E E285P T335V 1372R A432L Q051C G106Y G182X S227P F273L P329N H364T C423E D059L R116D D188F Q234G E285F T335V 1372R A432L Q051C G106Y G182V S227R F273L P329Q H364V C423F D059L R116D D188H Q234H E285T T335V 1372V A432L Q051I M107C G182V S227F F273V P329S L365C C423H D059F R116S D188N Q234F L286A L336F Q373L L434H Q051F M107P Y183D S227V F273V P329V L365C C423P D059V R116V D188N Q234F L286L L336F Q373L L434H Q051F M107P Y183D S227V F273V P329V L365C C423P D059V P117D D188N <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>45</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									45								
1010000000000000000000000000000000000						P329K	H364R	C423D									
Q051C G106Y G182T S227Q F273L P329R H364V C423G D059M R116P D188H Q234H E285T T335W I372T A432M Q051F M107A G182V S227R F273P P329R H364Y C423H D059P R116D D188L Q234H E285V T335W I372V A432P Q051F M107A G182V S227F F273P P329R L365C C423H D059P R116V D188M Q234F L286L L336A I372W A432P Q051F M107F Y183D S227V F273V P329V L365C C423P D059V R116V D188N Q234F L286L L336E Q372V L434H Q051F M107P Y183E S227V F273V P329V L365C C423P D059V P117D D188Q Q234V L286F L386K L374D L434Q Q051F M107Y Y183E I228F T274E Y330C L365G C423V R060D P117D D188Z S235F <td>T049P</td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td>	T049P												-				
Q051F M107A G182V S227R F273P P329R H364Y C423H D059P R116Q D188L Q234N E285V T335Y 1372V A432P Q051I M107C G182Y S227F F273P P329S L365A C423H 50 D059R R116Q D188L Q234P L286A L336A I372W A432P Q051M M107H Y183C S227V F273V P329V L365C C423P D059F R116V D188N Q234V L286L L336F Q373C L434H Q051F M107P Y183E S227F F273W P329V L365C C423P D059V P117D D188Q Q234V L286F L336G Q373V L434H Q051W M107Q Y183I 1228F T274C P320V L365G C423R D059V P117D D188Q Q234V L286H L336G Q373V L434H Q051W M107V Y183N 1228F T274F Y330C L365N C423F S600D P117K D188Z	00510												-				
Q0511 M107C G182Y S227T F273Q P329S L365A C423L 50 D059R R116S D188M Q234P L286A L336A I372W A432Y Q051M M107H Y183C S227V F273S P329T L365C C423H D059T R116S D188N Q234S L286C L336E Q373C L434H Q051P M107K Y183D S227V F273V P329V L365C C423P D059V R116V D188N Q234F L286D L336F Q373C L434H Q051V M107Q Y183E S227Y F273W P329V L365G C423Q D059V P117D D188Q Q234V L286H L336C L374D L434K Q051V M107V Y183I 1228E T274F Y330C L365N C423V R060A P117I D188R S235F L286H L336C E375F P437T G052E M107V Y183N 1228H T274H Y330L L365R L424V R060F P117N D188V	C												-				
Q051PM107KY183DS227WF273VP329VL365DC423PD059VR116WD188PQ234TL286DL336FQ373PL434KQ051TM107PY183ES227YF273WP329VL365EC423QD059VR116WD188QQ234VL286FL336GQ373WL434PQ051WM107QY183G1228AT274CY30AL365EC423RD059VP117DD188QQ234VL286FL336GQ373WL434QQ051VM107VY183I1228ET274FY30AL365NC423TSSS25FL286KL336DL374EL434QG052EM107WY183N1228GT274HY30DL365PC423WSR060AP117KD188VS235FL286KL336PE375CF437TG052FA108DY183P1228HT274WY330GL365RI424AR060FP117ND188VS235KL286FL336FE375FP437TG052VA108EY183R1228NT274YY330LL365TI424CR060HP117CD188VS235KL286YL336FE375VE439NV053CA108KY184A1228ND275FY330NL365TI424GR060LP117VC189ES235VV287AL336FE375VE439RV053CA108LY184A1228SD275GY330NL365TI424GR060NP117VC189ES235VV287A				S227T	F273Q	P329S			50	D059R	R116S	D188M	Q234P	L286A		I372W	A432Y
Q051T M107P Y183E S227Y F273W P329W L365E C423Q D059W P117D D188Q Q234V L286F L336G Q373W L434P Q051W M107Q Y183G I228A T274C P329Y L365G C423R D059W P117D D188Q Q234V L286F L336G Q373W L434P Q051Y M107S Y1831 I228E T274E Y330A L365M C423S R060A P117I D188S S235F L286K L336N L374E L434Q G052F A108D Y183P I228F T274H Y330C L365P C423V R060D P117K D188V S235F L286H L336R E375F P437F G052P A108F Y183P I228H T274W Y330L L365V I424C R060G P117Q D188V S235F L286F L336F E375F P433T G052V A108F Y183R I228M T274W Y330L L365V I424C R060I P117R C189A S235V <td></td> <td>-</td> <td></td> <td></td> <td>-</td> <td></td>													-			-	
Q051W M107Q Y183G 1228A T274C P329Y L365G C423R D059Y P117G D188R Q234W L286H L336K L344Q Q051Y M107S Y183I 1228E T274E Y330A L365M C423S R060A P117I D188R Q234W L286H L336K L343Q G052C M107V Y183K 1228F T274F Y330C L365N C423T 55 R060D P117K D188R S235L L286H L336R E375C L434W G052C M107V Y183N 1228G T274H Y330D L365D C423V R060D P117K D188T S235L L286H L336R E375F P437T G052W A108E Y183P 1228H T274W Y330L L365S I424C R060H P117R D188W S235L L286F L336F E375F P437T G052Y A108K Y183R 1228H T274W Y330L L365S I424C R060H P117R C189A S235W L286Y													-			-	
Q051Y M107S Y183I 1228E T274E Y330A L365M C423S R060A P117I D188S S235F L286K L336N L374E L434R G052C M107V Y183K 1228F T274G Y330C L365N C423T 55 R060D P117K D188S S235F L286K L36R E375F P437T G052E M107W Y183N 1228F T274H Y330C L365D C423V R060D P117K D188S S235F L286M L336R E375F P437T G052V A108E Y183P 1228H T274W Y330C L365R I424A R060F P117N D188V S235K L286F L336R E375F P437T G052Y A108K Y183R 1228M T274W Y330L L365T I424C R060I P117S C189A S235K L286Y L336F E375F E439R V053A A108K Y183V 1228P D275F Y330L L365T I424E R060L P117V C189A	-											-	-			-	
G052C M107V Y183K 1228F T274G Y330C L365N C423T 55 R6060D P117K D188T S235L L286H L336P E375C L434W G052E M107W Y183N 1228G T274H Y330D L365P C423V 55 R660D P117K D188T S235L L286M L366P E375C L434W G052F A108D Y183P I228H T274H Y330D L365P C423W R060C P117K D188V S235L L286M L336P E375F P437T G052V A108E Y183P I228H T274W Y330L L365S I424C R060C P117N D188V S235L L286T L336S E375P M438Y G052Y A108E Y183R I228N T274Y Y330L L365S I424C R060I P117S C189A S235V L286Y L336V E375V E439N V053C A108L Y184X I228N T274Y Y330L L365V I424F 60 R060L																	-
G052E M10/W Y183N 1228G 12/4H Y330D L365P C423V R060F P117N D188V S235M L286P L336R E375F P437T G052F A108D Y183P I228H T274V Y330E L365D C423W R060F P117N D188V S235M L286P L336R E375F P437T G052V A108E Y183Q I228L T274V Y330L L365R I424A R060F P117N D188V S235K L286T L336S E375F P437T V053A A108K Y183S I228N T274V Y330L L365T I424C R060I P117S C189A S235W L286Y L336C E375F E439R V053C A108K Y183V I228N T274Y Y330L L365T I424F R060I P117V C189E S235W L286Y L336V E375Y E439R V053C A108L Y184Z I228N D275F Y330N L365T I424F 60 R060L P117V C189H	G052C	M107V	Y183K	I228F	T274G	Y330C	L365N	C423T	55								
G052F A108D Y183P 1228H T274V Y330E L365Q C423W R060G P117Q D188W S235R L286T L336S E375P M438Y G052V A108E Y183Q 1228L T274Q Y330G L365R I424A R060G P117Q D188W S235R L286T L336S E375P M438Y G052Y A108F Y183R I228M T274V Y330L L365S I424C R060H P117R C189A S235V L286T L336T E375V E439N V053C A108L Y183V I228P D275A Y330H L365Y I424F R060I P117V C189A S235V V287A L336V E375Y E439N V053C A108H Y184A I228P D275F Y330H L365Y I424F R060L P117V C189G P236C V287C R121H K376P E441R V053E A108P Y184C I228H D275F Y330F N366C I424Q R060Q T118D C189L W119H <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>55</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									55								
G052Y A108F Y183R I228M T274W Y330I L365S I424C R060H P117K C189A S235W L280Y L336V E375V E439N V053A A108K Y183S I228N T274Y Y330L L365T I424E R060I P117K C189A S235W L286Y L336V E375Y E439N V053C A108L Y183V I228N D275F Y330L L365Y I424E R060L P117V C189E S235V V287A L336V E439N V053D A108L Y184Z I228N D275F Y330N L365Y I424F 60 R060L P117V C189E S235V V287A R121H K376I T440Q V053E A108P Y184C I228N D275F Y330N N366C I424P R060P T118C C189K W119N V287D R121K K376F E442N V053H A108T Y184E I228W <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>D188W</td><td></td><td></td><td></td><td></td><td></td></td<>												D188W					
V053A A108K Y183S 1228N T274Y Y330L L365T 1424E R0601 P117S C189E S235Y V287A L36V E375Y E439R V053C A108L Y183V 1228P D275A Y330N L365V 1424E R060L P117V C189E S235Y V287A L36V E375Y E439R V053D A108M Y184A 1228R D275F Y330N L365Y 1424H 60 R060L P117V C189F P236C V287C R121G K376F E441R V053E A108P Y184C 1228S D275G Y330P N366C 1424Q R060P T118C C189K W119N V287C R121L K376F E442R V053G A108Q Y184D 1228T D275L Y330S N366C 1424Q R060Q T118D C189K W119N V287G R121L G377C E442N V053A A108Y Y184F 1228W D275L Y330V N366F 1424S R060T T118D C189N																	
V053C A108L Y183V I228P D275A Y330M L365W I424G R060L P117V C189G P236C V287C R121G K3761 T440Q V053D A108M Y184A I228R D275F Y330N L365Y I424H 60 R060N P117V C189G P236C V287C R121G K3761 T440Q V053D A108M Y184A I228R D275F Y330N L365Y I424H 60 R060N P117V C189H W119L V287D R121H K376P F441R V053G A108P Y184C I228T D275I Y330R N366C I424Q R060Q T118D C189K W119P V287E R121L G377C E442N V053I A108Y Y184F Y229E D275L Y330V N366F I424S R060T T118C C189N W119P V287K R121M G377L E442S V053N A108Y Y1																	
V053D A1080 Y184C 12285 D275G Y330P N366A 1424N R060P T118C C189K W119N V287E R121K K376W E442M V053E A1080 Y184C 12285 D275I Y330P N366C 1424Q R060P T118C C189K W119N V287E R121K K376W E442M V053G A108Q Y184D 1228T D275I Y330R N366C 1424Q R060Q T118D C189L W119P V287G R121L G377C E442N V053L A108V Y184F Y229E D275L Y330V N366E I424S R060S T118C C189N W119R V287K R121M G377L E442S V053L A108V Y184F Y229E D275L Y330V N366E I424S R060T T118C C189N R121A V287L R121P G377L P443D V053N A108Y Y184G Y229F D275U Y330V N366E I424W T118R T118P T118W R121C <td>V053C</td> <td>A108L</td> <td>Y183V</td> <td>I228P</td> <td>D275A</td> <td>Y330M</td> <td>L365W</td> <td>I424G</td> <td>60</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td>	V053C	A108L	Y183V	I228P	D275A	Y330M	L365W	I424G	60								-
V053D A1080 Y184D 1228T D275I Y330R N366C 1424Q R060Q T118D C189L W119P V287G R121L G377C E442N V053H A108T Y184D 1228T D275I Y330R N366C 1424Q R060Q T118D C189L W119P V287G R121L G377C E442N V053H A108V Y184E 1228W D275L Y330V N366E 1424R R060S T118E C189M W119R V287K R121M G377L E442S V053L A108V Y184F Y229E D275L Y330V N366F I424S R060T T118G C189N R121A V287L R121P G377L P443D V053N A108Y Y184G Y229F D275M Y330W N366G I424W T118R T118P T118W R121C R121F G378D G377V G378E V053P V109C Y184H Y229G D275Q I331A N366K I424Y 65 T118Y W119I W119A			Y184A	I228R	D275F				60								
V053H A108T Y184E I228W D275K Y330S N366E I424R R060S T118E C189M W119R V287K R121M G377I E442S V053L A108V Y184F Y229E D275L Y330V N366E I424S R060S T118E C189M W119R V287K R121M G377I E442S V053L A108V Y184F Y229E D275L Y330V N366F I424S R060T T118C C189N R121A V287L R121P G377L P443D V053N A108Y Y184G Y229F D275M Y330W N366E I424W T118R T118P T118W R121C R121F G378D G377V G378E V053P V109C Y184H Y229G D275Q I331A N366K I424Y 65 T118Y W119I W119A W119K R121E G378F G378I																	
V053L A108V Y184F Y229E D275L Y330V N366F I424S R060T T118G C189N R121A V287L R121P G377L P443D V053N A108Y Y184G Y229F D275M Y330W N366G I424W T118R T118P T118W R121A V287L R121P G377L P443D V053N A108Y Y184G Y229F D275M Y330W N366G I424W T118R T118V R121C R121F G378D G377V G378E V053P V109C Y184H Y229G D275Q I331A N366K I424Y 65 T118Y W119I W119A W119K R121E G378F G378I																	
V053N A108Y Y184G Y229F D275M Y330W N366G I424W T118R T118P T118W R121C R121F G378D G377V G378E V053P V109C Y184H Y229G D275Q I331A N366K I424Y 65 T118Y W119A W119K R121E G378F G378I																	
V053P V109C Y184H Y229G D275Q I331A N366K I424Y 65 T118Y W119I W119A W119K R121E G378F G378I	V053N		Y184G	Y229F	D275M												
V053Q V109D Y184K Y229K D275T I331C N366M A425E									65	T118Y	W119I	W119A	W119K	R121E	G378F	G378I	
	V053Q	V109D	Y184K	Y229K	D275T	I331C	N366M	A425E									

Example 5

Assay for Hyaluronidase Activity Under Temperature and Phenophilic Conditions

Supernatants from PH20 activity variants set forth in Table 9, as identified in Example 4, were tested for stability under thermophilic and/or phenophilic conditions. The assay to measure hyaluronidase activity under temperature and phenophile conditions using biotinylated-HA (bHA) as sub-¹⁰ strate for measuring hyaluronidase activity was modified from the original assay described in Example 3 in that it incorporated a 4-hour 37° C. incubation of samples with or without m-cresol prior to measurement of enzymatic activity. The assay was used to identify PH20 mutants with ¹⁵ thermophilic properties (activity greater at 37° C. condition than at 4° C.) and/or with phenolphilic properties (greater activity in the presence of m-cresol than wildtype PH20).

1. Primary Screen

Prior to incubating samples with bHA, variant PH20 samples were diluted into designated wells of an uncoated 4XHB plate for pre-incubation at 37° C. for 4 hours under the following conditions: 1) pre-incubation at 37° C. with 25 0.4% m-cresol; and 2) pre-incubation at 37° C. without 0.4% m-cresol. For the preincubation at 37° C. with 0.4% m-cresol, a 1% m-cresol intermediate stock was prepared from 50% (v/v) m-cresol stock solution. Briefly, in a 2 mL Wheaton glass vial a 50% stock of m-cresol (Fluka, Catalog 30 No. 65996; Spectrum, Catalog No. C2773) was made in methanol based on the density (D=1.034 g/L). The vial was sealed and stored at -20° C. with protection from light in small aliquotes. Then, the 1% intermediate stock was generated by dilution in HEPES assay buffer (10 mM HEPES, 35 50 mM NaCl, 1 mM CaCl₂, 1 mg/mL BSA, pH 7.4, 0.05% Tween-20) daily immediately prior to use in a fume hood with vortexing.

Then, duplicates of transfected variant supernatant samples set forth in Table 9, generated as described above in 40 Example 2, were each separately subjected to a 1:2.5 dilution of 1% m-cresol in HEPES assay buffer/transfected supernatant to obtain 0.4% final concentration of m-cresol. For the preincubation at 37° C. without 0.4% m-cresol, transfected variant supernatant samples were subjected to a 45 1:2.5 dilution in HEPES assay buffer/transfected supernatant. In addition, for each condition, an internal killing control was also tested by spiking in 3 U/mL of rHuPH20 in pH 7.4 HEPES buffer (generated as described in Example 1) that was diluted the same as described above for the trans-50 fected samples. The plates were sealed with plate sealers and incubated at 37° C. for 4 hours.

The preparation of the bHA coated plates and blocking of the plates prior to addition of the transfected variant supernatants or wildtype PH20 was the same as described in 55 Example 3. The assay was further modified as follows. First, samples were diluted in duplicate 1:10 in HEPES assay buffer in 4XHB plates. For each variant, the samples that were tested were 1) non-preincubated transfected variant supernatant (no incubation; 4° C.); 2) preincubated trans-60 fected variant supernatants preincubated at 37° C. for 4 hours with 0.4% m-cresol (Cresol); or 3) preincubated transfected variant supernatant preincubated at 37° C. for 4 hours without 0.4% m-cresol (no cresol; 37° C.). In addition, the spiked-in samples also were tested. A standard curve 65 using rHuPH20 was made as described in Example 3 without m-cresol. One hundred microliters (100 µl) of each

standard and sample were transferred to pre-designated wells of the bHA-coated and blocked plate and incubated for approximately 1.5 hours at 37° C. Thus, each sample of each variant was tested in quadruplicate due to the preincubation
of duplicate samples of each transfected variant supernatants in the pre-incubation step and the further duplicate of each sample in the bHA assay.

After the incubation, the plates were washed and binding to bHA detected as described above in Example 3. Optical density was measured at 450 nm within 30 minutes of adding the stop solution.

The U/mL activity was calculated from the standard curve and compared. The results were depicted as the percent (%) activity remaining under each of the following parameters: 15 ratio of activity at 1) 37° C. preincubation without m-cresol/ 4° C.; 2) 37° C. after preincubation with m-cresol/4° C.; and 3) 37° C. after preincubation with m-cresol/after preincubation at 37° C. without m-cresol. Initial phenophile hits for reconfirmation were identified as those that in a duplicate 20 assay exhibited a percentage of remaining activity under condition 3) of ≥20% of the original activity at 37° C.

Initial Hits were rescreened using a 6-well plate rescreen assay. For the rescreen, plasmid DNA corresponding to the potential Hit was transformed into *E. coli* bacteria and plasmid DNA prepared and purified using MaxiPrep according to the manufacturers instructions. The DNA sequence was confirmed.

The plasmid DNA was transfected into monolayer CHO—S cells (Invitrogen, Cat. No. 11619-012) grown on 6-well plates at a density of about 50-80% confluency using Lipofectamine 2000 (Invitrogen, Cat. No. 11668-027) according to the protocol suggested by the manufacturer. Transfections were performed in duplicate. The cells were incubated at 37° C. in a CO₂ incubator for 96 hours post-transfection before collecting the supernatant for the assay. As controls, cells also were transfected with the HZ24-PH20 (OHO)-IRES-SEAP expression vector (SEQ ID NO: 4) that contains a codon-optimized wildtype PH20 sequence (OHO). Mock cells also were included as controls.

Ninety-Six (96) hours post-transfections, supernatant was collected from each sample, including the OHO and mock controls, and assayed for hyaluronidase activity under various conditions as described above: 1) non-preincubated transfected variant supernatant (no incubation; 4° C.); 2) preincubated transfected variant supernatants preincubated at 37° C. for 4 hours with 0.4% m-cresol (Cresol; 37° C.); or 3) preincubated transfected variant supernatant preincubated at 37° C. for 4 hours without 0.4% m-cresol (no cresol; 37° C.). Hyaluronidase activity was determined as described above using the bHA assay.

The results were assessed as described above. Absolute hyaluronidase activity (U/mL) was generated from the standard curve. In addition, percent activity was determined as a ratio of activity at 37° C./4° C., 37° C. plus m-cresol/4° C., and 37° C. plus m-cresol/37° C. The results are set forth in Tables 11 and 12 below.

TABLE 11

)			Absolute	e Hyaluronio	lase Activity	7	
	Mutant		ubation C.)		no cresol ' C.)	37° C. m-cr (37° C m-cre	esol . plus
5	L001A L001E	2.993 2.669	2.511 2.539	3.529 2.862	3.214 3.179	0.287 0.376	0.295 0.341

259

TABLE 11-continued

TABLE 11-continued

		Absolut	e Hyaluroni	dase Activity	T					Absolut	e Hyaluroni	dase Activity	T	
		71050101	<u>c rryaluronn</u>	dase receivity						71030100	e fryaturonik	aase retivity		
					37° C. m-cr	esol	5						37° C m-cr	
Mutant		ubation C.)		o cresol C.)	(37° C m-cre	. plus		Mutant		ubation C.)	37° C. n (37°	o cresol C.)	(37° C m-cr	C. plus
L001G	0.348	0.583	0.596	0.676	0.055	0.031		Q086S	2.528	2.082	2.539	2.149	0.173	0.241
L001Q L001R	5.135 5.603	6.443 4.390	6.133 6.576	5.719 7.042	0.621 0.458	0.636 0.396	10	Q086T D087G	3.018 2.755	2.542 2.176	2.832 2.252	4.562 1.971	0.290 0.034	0.406 0.122
P006A	2.965	3.208	4.088	3.495	0.404	0.435	10	D087L	2.070	2.277	2.195	2.311	0.324	0.299
V008M	1.376	1.401	1.856	1.678	0.000	0.008		D087M	2.262	2.325	2.510	2.038	0.191	0.335
1009Q	0.447	0.381	0.469	0.476	0.031	0.030		D087S	5.210	10.305	6.983	14.399	0.569	0.928
P010G P010H	0.747 0.473	0.564 0.485	0.820 0.624	0.688 0.548	0.123 0.000	0.114 0.000		D087V D090E	1.361 8.251	1.364 12.299	1.553 7.666	1.187 19.836	0.142 1.093	0.189 1.234
N011S	0.862	0.962	1.313	1.263	0.000	0.064	15	D090E D090N	2.812	2.775	3.123	2.737	0.379	0.290
V012E	11.019	5.519	5.312	5.528	0.753	0.934	15	K093Q	2.491	2.065	2.267	1.971	0.132	0.131
V012I	2.804	3.844	3.610	6.566	0.106	0.090		K093R	2.986	2.862	3.094	2.842	0.362	0.465
V012K	1.691	1.963	2.479	2.243	0.330	0.321		K094D	2.393	2.088	2.071	2.132	0.135	0.211
F014V L015M	0.144 0.902	0.165 1.073	0.222 1.026	0.242 0.901	0.003 0.017	0.000 0.017		K094R T097C	1.407 0.330	1.542 0.618	1.764 0.545	1.676 0.505	0.158 0.044	0.166 0.087
A020S	1.494	2.205	2.822	2.620	0.413	0.397	• •	T097D	0.520	0.565	0.643	0.664	0.055	0.073
S022T	3.035	3.788	3.375	3.273	0.684	0.748	20	T097E	1.096	1.410	1.394	1.623	0.217	0.262
L026M	1.482	1.226	2.027	1.704	0.224	0.178		T097L	0.899	1.198	1.065	1.241	0.246	0.300
K028R F029R	0.944 1.195	0.845 1.511	1.043 1.848	0.925 1.839	0.112 0.140	0.095 0.140		N104R A120H	2.508 2.155	2.356 2.551	2.876 2.028	2.790 2.883	0.279 0.168	0.238 0.199
F029K	3.019	3.615	3.566	3.521	0.140	0.283		D127R	0.264	0.339	0.149	0.199	0.105	0.068
F029T	1.451	1.712	1.839	2.065	0.220	0.212		V128I	3.120	3.313	3.546	3.401	0.389	0.504
P032C	0.370	0.419	0.476	0.534	0.006	0.040	25	N131M	15.335	20.678	27.143	15.899	0.505	0.447
L033G D034W	0.566 0.340	0.700 0.321	0.686 0.499	0.627 0.471	0.001 0.076	0.026 0.069		N131R N131V	8.195 1.656	8.748 1.870	7.724 2.280	8.392 1.962	1.645 0.233	1.626 0.214
M035V	0.340	0.521	0.499	0.652	0.076	0.009		R132L	3.306	3.235	3.259	2.966	0.233	0.214
S036H	1.109	0.752	1.178	1.135	0.117	0.026		Q138L	1.494	1.660	1.611	1.521	0.410	0.347
S036N	0.797	0.933	0.893	0.859	0.171	0.260		Q140K	2.829	4.065	4.996	4.464	0.546	0.559
L037M	0.574	0.404	0.455	0.353	0.049	0.032	30	N141R	1.290	1.320	1.334	1.527	0.058	0.035
F040L I046L	2.603 3.027	3.941 2.959	3.515 4.011	4.148 3.342	0.277 0.513	0.361 0.557		N141S N141W	2.201 1.475	2.708 1.568	2.900 1.927	2.966 1.643	0.135 0.100	0.164 0.105
N047D	2.222	2.359	2.573	2.639	0.032	0.021		V142D	2.552	2.186	2.914	3.193	0.128	0.067
N047W	0.404	0.415	0.423	0.456	0.000	0.017		V142G	1.357	1.796	1.597	1.621	0.211	0.219
A048N	12.398	45.971	14.252	23.873	0.797	0.902		V142K	3.532	2.381	3.867	3.681	0.571	0.575
T049R G050D	7.893 3.287	13.334 3.148	9.685 3.084	12.102 3.020	0.563 0.242	0.649 0.264	35	V142N V142P	0.432 4.624	0.567 7.213	0.672 7.722	0.589 7.021	0.103 1.074	0.087 1.081
G050D G050M	1.763	2.333	2.780	3.244	0.242	0.393		V142Q	5.090	6.900	7.618	6.897	0.678	0.678
G052N	7.217	9.809	6.939	13.978	1.109	1.083		V142R	1.968	2.595	2.941	2.689	0.364	0.330
G052T	1.542	1.224	1.795	1.433	0.381	0.463		V142S	2.789	2.988	4.763	3.497	0.416	0.591
G052S V058C	2.152 1.428	1.999 1.312	2.120 1.321	1.963 1.301	0.498 0.212	0.566 0.210		V142T Q143G	1.926 3.922	3.260 4.903	4.313 5.632	4.031 4.846	0.495 0.782	0.472 0.780
V058C V058K	28.000	28.000	61.016	61.016	23.586	23.586	40	Q1430 Q143K	3.634	3.671	7.285	5.008	1.043	1.039
V058R	5.719	4.688	5.542	4.822	3.134	3.149		L144R	3.810	4.581	5.191	5.107	0.556	0.520
V058N	1.200	1.175	1.550	1.525	0.200	0.175		L144T	1.496	1.681	1.941	1.831	0.285	0.219
V058Y V058Q	1.040 11.956	0.770 15.363	1.071 18.458	1.088 45.092	0.388 1.567	0.454 2.166		L146P T147S	0.818 0.984	0.782 1.149	0.954 1.399	0.904 1.497	0.011 0.055	0.031 0.039
V058Q V058P	3.360	2.949	2.799	5.121	0.592	0.884		T1475 T150N	0.984	0.585	0.622	0.684	0.033	0.039
V058H	3.790	5.074	7.590	9.222	0.826	1.205	45	T150S	1.747	1.400	1.875	1.988	0.120	0.121
D068P	0.215	0.215	0.213	0.180	0.001	0.184		E151A	2.870	2.269	2.965	2.860	0.359	0.337
S069T I070P	1.927 1.284	2.179 1.593	2.671 1.306	2.671 1.589	0.289 0.010	0.240 0.032		E151L E151S	3.365 5.187	3.289 4.591	4.446 5.987	4.007 6.262	0.218 0.371	0.251 0.294
1070P 1070V	1.284	2.437	3.099	3.335	0.010	0.032		E1515 E151T	2.442	4.591 3.000	3.134	6.262 3.309	0.371	0.294
V073Q	4.846	5.441	5.880	5.827	0.383	0.477		E151V	3.998	4.247	4.459	4.232	0.326	0.314
V073R	0.522	0.803	0.720	0.804	0.018	0.059	50	E151W	7.166	14.248	11.352	13.524	0.131	0.121
T074E T074M	2.903 0.569	3.834 0.744	3.868 0.656	3.871 0.771	0.666 0.079	0.626 0.083		K152T K152W	1.204 2.084	1.377 1.795	1.796 2.549	1.883 2.406	0.100 0.063	0.067 0.069
T074M T074N	2.792	0.744 1.905	2.565	2.995	0.079	0.083		E152W	2.084 0.339	0.397	2.349 0.451	2.406 0.407	0.003	0.009
T074P	2.331	1.593	2.525	2.648	0.309	0.265		K162E	0.168	0.195	0.114	0.080	0.004	0.024
T074R	0.999	0.820	0.806	1.066	0.060	0.023		L165F	4.775	5.250	5.075	5.075	0.600	0.725
T074V V075M	1.186 0.917	1.280	1.365	1.460	0.101	0.080	55	V166Q	1.883 0.993	2.507	2.937	2.958	0.392	0.324 0.235
V075M K082L	1.362	1.087 1.311	1.233 1.563	1.321 3.302	0.003 0.325	0.028 0.354		V166T E167D	0.993	1.315 0.910	1.821 1.109	1.800 1.480	0.231 0.111	0.235
K082N	3.202	3.411	3.396	3.244	0.792	0.861		1169L	1.812	1.796	2.540	2.196	0.335	0.341
I083V	3.706	2.633	5.194	3.615	1.552	1.017		K170R	1.578	2.054	2.536	1.995	0.209	0.201
1083Q	2.376	1.946	2.665	3.674	0.720	0.510		G172A	0.413	0.581	0.692	0.777	0.052	0.056
I083S I083G	0.841 2.276	1.054 2.443	0.880 2.418	1.005 1.866	0.235 0.545	0.268 0.601	60	K173R L174G	1.654 0.184	1.551 0.087	1.766 0.210	2.083 0.230	0.173 0.026	0.156 0.031
S084E	1.470	1.484	1.834	1.683	0.343	0.001		L1740 L174N	1.616	2.276	2.494	2.872	0.331	0.543
S084F	1.179	1.212	0.982	1.103	0.025	0.000		L174T	0.552	0.566	0.689	0.820	0.090	0.050
S084N	2.255	1.888	3.268	2.476	0.597	0.547		N178K	2.931	4.375	4.891	4.513	0.258	0.362
S084R Q086A	8.534 2.084	14.779 2.120	10.230 2.845	30.016 3.310	1.117 0.405	1.494 0.322		N178R H193Q	8.160 1.060	13.820 1.367	16.287 2.264	20.033 1.888	0.665 0.346	0.790 0.346
Q086A Q086H	2.084	1.000	2.845	1.296	0.405	0.322	65	K195U	1.060	0.806	2.264 1.548	1.888	0.346	0.346
Q086K	0.127	0.110	0.126	0.072	0.032	0.023		K195N	1.266	1.437	1.649	1.385	0.369	0.353
		-	-											

261

262

ed

37° C. with m-cresol (37° C. plus m-cresol)

		TAE	BLE 11-co	ontinued						TAE	BLE 11-c	ontinued
		Absolut	e Hyaluronio	lase Activity	7					Absolut	e Hyaluroni	dase Activity
Mutant		ubation C.)	37° C. n (37°		37° C. m-cr (37° C m-cre	esol . plus	5	Mutant		ubation C.)		no cresol ° C.)
K196E	0.732	0.660	0.663	1.017	0.244	0.239		I309L	0.326	0.403	0.501	0.431
K196R	2.246	2.285	2.383	2.174	0.315	0.384		I309M	2.809	2.473	3.467	3.383
F204P	3.500	4.550	2.925	3.750	2.475	4.725	10	I309N	4.865	5.191	5.444	5.054
N205A	0.515	0.837	0.717	0.854	0.153	0.160		I309S	10.719	28.759	18.217	158.604
N205E	1.011	2.004	1.627	1.870	0.314	0.346		I309T	3.052	2.509	2.989	3.735
N205L	1.084	1.029	1.165	0.000	0.123	0.088		I309V	1.705	1.292	1.929	1.787
N205T	0.295	0.367	0.428	0.406	0.043	0.053		M310G	4.514	6.397	7.568	7.084
V206I	0.317	0.508	0.600	0.565	0.079	0.088		M310Q	3.648	3.179	3.912	3.380
K209R	2.041	2.453	2.445	1.951	0.291	0.077	15	M313G	0.252	0.325	0.348	0.355
D212N	5.568	4.549	6.271	6.016	0.167	0.322		M313H	3.767	5.276	10.243	10.395
D212S	1.987	1.502	2.442	2.222	0.204	0.152		M313K	12.689	12.122	15.085	12.984
D213A	0.235 1.664	0.283	0.432	0.438 2.046	0.116	0.060 0.142		M313P	4.050	2.951 10.863	4.198	3.919
D213M S215H	2.448	2.080 3.056	2.650 2.670	2.046	0.181 0.268	0.142		M313R	4.634 2.903	4.474	7.288 4.705	3.568 4.467
S215H S215M	1.497	2.175	2.618	1.630	0.208	0.139		M313T M313Y	1.063	1.262	1.276	1.300
N219I	0.338	0.250	0.860	0.728	0.076	0.082	20	K314S	2.848	4.450	4.042	5.879
E220V	3.783	3.828	4.993	4.349	0.371	0.082		K3143 K314Y	0.093	0.131	0.226	0.182
T222G	3.528	5.262	5.399	5.549	0.033	0.044		S315A	1.472	1.082	1.345	1.484
T232F	0.539	1.242	0.716	0.781	0.089	0.153		S315H	2.412	3.242	3.648	3.414
Q233G	0.041	0.095	0.115	0.121	0.000	0.000		S315Y	0.279	0.626	0.477	0.362
Q234M	6.029	6.031	5.764	4.871	1.286	0.988		L317A	3.254	2.845	4.019	3.776
\$235A	0.550	0.502	0.714	0.607	0.079	0.073	25	L317I	1.078	1.524	2.021	1.687
V237C	0.623	0.708	0.860	0.824	0.000	0.000		L317K	12.129	9.382	11.668	12.591
V237H	0.303	0.316	0.370	0.459	0.046	0.034		L317N	2.907	3.066	3.703	3.717
V237T	0.152	0.196	0.254	0.247	0.054	0.053		L317R	8.631	15.187	20.585	15.106
A238E	2.050	1.800	1.945	2.559	0.159	0.171		L317S	11.586	29.267	10.535	25.114
A238H	0.579	0.363	0.345	0.743	0.090	0.062		L317T	1.338	1.073	1.953	1.656
T240A	1.107	0.900	1.564	1.302	0.143	0.118	30	L317W	0.810	1.128	1.326	1.665
T240Q	0.333	0.510	0.542	0.617	0.080	0.085		L318D	1.750	1.970	1.847	1.930
R248A	2.274	2.499	2.575	3.115	0.027	0.075		L318H	1.073	0.806	1.072	1.005
E249V	3.001	3.894	4.284	4.325	0.655	0.712		L318R	2.856	3.464	4.583	4.187
P257G	3.981	4.452	4.985	5.022	0.039	0.034		N321R	3.069	4.409	5.059	4.946
K260M	0.719	0.960	0.839	0.935	0.072	0.068		N321S	0.683	0.710	0.700	0.772
S261A	3.253	3.117	1.872	2.686	1.264	1.451	35	E324N	4.309	2.530	4.508	3.321
S261K	6.089	5.421	9.860	6.297	1.583	1.437		T325E	1.071	1.270	1.337	1.352
S261N	14.149	40.257	20.219	14.303	2.115	1.917		N328G	0.379	0.504	0.747	0.553
A267T F273H	0.052 0.340	0.095 0.436	0.102 0.417	0.106 0.519	0.036 0.025	0.041 0.031		N328Y T335S	2.629 0.905	4.543 0.787	4.758 0.977	4.543 0.986
F273Y	0.558	0.430	0.668	0.519	0.023	0.051		Q347A	8.316	11.961	8.432	11.508
Q276H	2.706	1.877	2.027	1.997	0.181	0.201		Q347G	1.358	1.120	3.021	2.319
Q276M	0.775	0.768	0.762	0.806	0.043	0.000	40	Q349M	1.493	1.629	1.486	1.760
Q276R	6.080	9.717	7.383	14.593	0.807	1.281		Q349R	0.451	0.572	0.663	0.598
Q276S	1.353	1.212	1.497	1.681	0.149	0.147		V351S	1.379	1.633	1.804	1.647
V277A	1.202	1.643	1.692	2.129	0.118	0.110		I353V	2.335	1.954	3.090	2.697
V277E	2.440	2.340	4.289	4.577	0.161	0.239		N356H	0.445	0.451	0.445	0.588
V277H	5.548	5.302	7.181	7.300	0.227	0.512		N356S	0.262	0.253	0.136	0.318
V277K	8.950	8.996	33.627	33,627	4.442	4.045	45	S359E	2.616	2.635	3.547	3,560
V277M	1.279	1.622	1.754	1.818	0.264	0.270		S359H	0.403	0.371	0.445	0.374
V277N	14.351	4.306	12.865	11.772	0.938	0.796		P367A	0.643	0.782	1.074	0.996
V277Q	5.459	5.461	6.547	6.343	0.373	0.493		P367G	0.593	0.530	0.686	0.650
V277R	18.300	12.038	17.581	20.641	2.737	2.023		P367K	0.707	0.767	0.890	0.513
V277S	14.351	10.444	9.509	15.135	0.727	0.716		P367S	3.967	3.478	2.946	3.073
V277T	8.412	7.804	8.497	11.184	0.679	0.871	50	D368A	1.762	2.321	2.143	1.895
L278E	4.416	2.795	3.330	2.800	0.170	0.202		D368E	3.464	4.944	5.772	4.842
L278G	7.502	7.456	9.173	7.760	0.596	0.612		D368L	0.557	0.566	0.607	0.619
K279H	0.888	1.087	1.234	1.339	0.185	0.269		D368M	0.861	1.065	1.031	1.104

Mutant	(4-	C.)	(3/*	C.)	m-cre	esol)		Mutant	(4-	C.)	(37	· C.)	m-cro	esol)
K196E	0.732	0.660	0.663	1.017	0.244	0.239		I309L	0.326	0.403	0.501	0.431	0.048	0.047
K196E	2.246	2.285	2.383	2.174	0.315	0.239		1309L 1309M	2.809	2.473	3.467	3.383	0.278	0.239
F204P	3.500	4.550	2.925	3.750	2.475	4.725	10	I309N	4.865	5.191	5.444	5.054	0.380	0.327
N205A	0.515	0.837	0.717	0.854	0.153	0.160		I309S	10.719	28.759	18.217	158.604	0.748	1.367
N205E	1.011	2.004	1.627	1.870	0.314	0.346		I309T	3.052	2.509	2.989	3.735	0.228	0.207
N205L	1.084	1.029	1.165	0.000	0.123	0.088		I309V	1.705	1.292	1.929	1.787	0.029	0.062
N205T	0.295	0.367	0.428	0.406	0.043	0.053		M310G	4.514	6.397	7.568	7.084	0.866	0.915
V206I	0.317	0.508	0.600	0.565	0.079	0.088		M310Q	3.648	3.179	3.912	3.380	1.088	0.955
K209R	2.041	2.453	2.445	1.951	0.291	0.077		M313G	0.252	0.325	0.348	0.355	0.034	0.036
							15							
D212N	5.568	4.549	6.271	6.016	0.167	0.322		M313H	3.767	5.276	10.243	10.395	0.380	0.404
D212S	1.987	1.502	2.442	2.222	0.204	0.152		M313K	12.689	12.122	15.085	12.984	0.129	0.072
D213A	0.235	0.283	0.432	0.438	0.116	0.060		M313P	4.050	2.951	4.198	3.919	0.209	0.177
D213M	1.664	2.080	2.650	2.046	0.181	0.142		M313R	4.634	10.863	7.288	3.568	0.337	0.296
S215H	2.448	3.056	2.670	2.414	0.268	0.139		M313T	2.903	4.474	4.705	4.467	0.331	0.313
S215M	1.497	2.175	2.618	1.630	0.110	0.146		M313Y	1.063	1.262	1.276	1.300	0.096	0.089
N219I		0.250	0.860	0.728	0.076	0.082	20	K314S	2.848	4.450	4.042	5.879	0.391	
	0.338													0.533
E220V	3.783	3.828	4.993	4.349	0.371	0.257		K314Y	0.093	0.131	0.226	0.182	0.013	0.020
T222G	3.528	5.262	5.399	5.549	0.033	0.044		S315A	1.472	1.082	1.345	1.484	0.222	0.148
T232F	0.539	1.242	0.716	0.781	0.089	0.153		S315H	2.412	3.242	3.648	3.414	0.440	0.371
Q233G	0.041	0.095	0.115	0.121	0.000	0.000		S315Y	0.279	0.626	0.477	0.362	0.146	0.143
Q234M	6.029	6.031	5.764	4.871	1.286	0.988		L317A	3.254	2.845	4.019	3.776	0.280	0.317
S235A	0.550	0.502	0.714	0.607	0.079	0.988	25	L317A L317I	1.078	1.524	2.021		0.280	0.317
							20					1.687		
V237C	0.623	0.708	0.860	0.824	0.000	0.000		L317K	12.129	9.382	11.668	12.591	0.402	0.445
V237H	0.303	0.316	0.370	0.459	0.046	0.034		L317N	2.907	3.066	3.703	3.717	0.445	0.540
V237T	0.152	0.196	0.254	0.247	0.054	0.053		L317R	8.631	15.187	20.585	15.106	0.796	0.857
A238E	2.050	1.800	1.945	2.559	0.159	0.171		L317S	11.586	29.267	10.535	25.114	1.637	1.613
A238H	0.579	0.363	0.345	0.743	0.090	0.062		L317T	1.338	1.073	1.953	1.656	0.136	0.018
T240A	1.107	0.900	1.564	1.302	0.143	0.118	30	L317W	0.810	1.128	1.326	1.665	0.158	0.171
T240A T240Q	0.333	0.900	0.542	0.617	0.080	0.085	50	L317W	1.750	1.128	1.320	1.930	0.138	0.322
R248A	2.274	2.499	2.575	3.115	0.027	0.075		L318H	1.073	0.806	1.072	1.005	0.046	0.074
E249V	3.001	3.894	4.284	4.325	0.655	0.712		L318R	2.856	3.464	4.583	4.187	0.258	0.260
P257G	3.981	4.452	4.985	5.022	0.039	0.034		N321R	3.069	4.409	5.059	4.946	0.482	0.426
K260M	0.719	0.960	0.839	0.935	0.072	0.068		N321S	0.683	0.710	0.700	0.772	0.058	0.035
S261A	3.253	3.117	1.872	2.686	1.264	1.451		E324N	4.309	2.530	4.508	3.321	0.348	0.303
S261K	6.089		9.860	6.297		1.437	35	T325E			1.337	1.352	0.193	0.143
		5.421			1.583				1.071	1.270				
S261N	14.149	40.257	20.219	14.303	2.115	1.917		N328G	0.379	0.504	0.747	0.553	0.031	0.040
A267T	0.052	0.095	0.102	0.106	0.036	0.041		N328Y	2.629	4.543	4.758	4.543	0.490	0.477
F273H	0.340	0.436	0.417	0.519	0.025	0.031		T335S	0.905	0.787	0.977	0.986	0.113	0.062
F273Y	0.558	0.505	0.668	0.519	0.052	0.050		Q347A	8.316	11.961	8.432	11.508	0.918	1.266
Q276H	2.706	1.877	2.027	1.997	0.181	0.201		Q347G	1.358	1.120	3.021	2.319	0.253	0.209
Q276M	0.775	0.768	0.762	0.806	0.043	0.000	40	Q349M	1.493	1.629	1.486	1.760	0.178	0.217
Q276R	6.080	9.717	7.383	14.593	0.807	1.281		Q349R	0.451	0.572	0.663	0.598	0.078	0.079
Q276S	1.353	1.212	1.497	1.681	0.149	0.147		V351S	1.379	1.633	1.804	1.647	0.000	0.000
V277A	1.202	1.643	1.692	2.129	0.118	0.110		I353V	2.335	1.954	3.090	2.697	0.323	0.321
V277E	2.440	2.340	4.289	4.577	0.161	0.239		N356H	0.445	0.451	0.445	0.588	0.038	0.023
V277H	5.548	5.302	7.181	7.300	0.227	0.512		N356S	0.262	0.253	0.136	0.318	0.000	0.008
V277K	8.950	8.996	33.627	33.627	4.442	4.045	45	S359E	2.616	2.635	3.547	3.560	0.382	0.333
V277M	1.279	1.622	1.754	1.818	0.264	0.270		S359H	0.403	0.371	0.445	0.374	0.000	0.000
V277N	14.351	4.306	12.865	11.772	0.938	0.796		P367A	0.643	0.782	1.074	0.996	0.139	0.131
V277Q	5.459	5.461	6.547	6.343	0.373	0.493		P367G	0.593	0.530	0.686	0.650	0.000	0.000
V277R	18.300	12.038	17.581	20.641	2.737	2.023		P367K	0.707	0.767	0.890	0.513	0.045	0.052
V277S	14.351	10.444	9.509	15.135	0.727	0.716		P367S	3.967	3.478	2.946	3.073	0.424	0.505
V277T	8.412	7.804	8.497	11.184	0.679	0.871	50	D368A	1.762	2.321	2.143	1.895	0.031	0.040
L278E	4.416	2.795	3.330	2.800	0.170	0.202		D368E	3.464	4.944	5.772	4.842	0.530	0.555
L278G	7.502	7.456	9.173	7.760	0.596	0.612		D368L	0.557	0.566	0.607	0.619	0.000	0.006
K279H	0.888	1.087	1.234	1.339	0.185	0.269		D368M	0.861	1.065	1.031	1.104	0.028	0.028
V287T	0.580	0.667	0.843	0.832	0.139	0.209		D368R	4.503	5.270	7.418		0.754	0.735
												6.226		
T289S	0.783	1.019	0.819	1.001	0.008	0.007		D368T	2.345	1.993	2.512	2.525	0.072	0.085
G291S	0.227	0.322	0.419	0.385	0.051	0.016	55	N369R	1.548	2.719	2.503	2.022	0.160	0.125
G291V	3.662	3.707	4.131	5.599	0.821	0.706	20	A371F	2.760	5.207	4.974	3.980	0.308	0.222
E292C	1.344	1.599	1.711	1.617	0.138	0.144		A371H	8.101	86.587	77.531	77.531	1.403	1.316
E292F	6.106	4.697	8.422	6.216	0.520	0.363		A371H	3.509	4.058	3.900	3.879	0.000	0.334
E292H	2.620	3.316	4.458	3.830	0.389	0.451		A371K	2.903	3.546	3.963	4.055	0.509	0.505
E292R	2.810	2.178	3.155	2.829	0.398	0.339		A371L	11.018	40.668	76.587	43.516	1.159	0.964
E292V	0.891	1.121	1.453	1.494	0.193	0.177	60	A371L	3.328	3.445	3.472	2.075	0.000	0.025
T293A	1.986	3.110	2.546	1.789	0.086	0.076	00	A371R	25.855	25.855	n/a	n/a	2.851	3.634
A298G	0.161	0.274	0.342	0.236	0.030	0.022		A371R	6.592	7.733	7.987	7.576	0.000	0.196
L307G	0.616	0.661	0.726	0.605	0.000	0.000		A371S	3.329	3.505	4.916	4.611	0.412	0.781
S308D	0.264	0.325	0.337	0.344	0.014	0.010		L374P	2.939	7.129	11.522	8.771	0.665	0.646
S308K	0.651	0.722	0.826	0.716	0.011	0.000		E375A	0.627	0.507	0.557	0.683	0.000	0.014
S308N	3.995	4.406	6.808	6.128	0.386	0.362	65	E375G	1.596	1.299	2.025	1.806	0.209	0.265
I309E	3.166	2.819	3.921	3.663	0.637	0.528	65	E375R	0.937	1.132	1.529	1.318	0.201	0.260
I309G	6.651	5.429	6.824	6.194	0.503	0.400		K376D	0.458	0.312	0.518	0.515	0.064	0.026

263 TABLE 11-continued

D431Q 6.077

9.828

14.157

10.760

1.533

1.153

264

TABLE 11-continued Absolute Hyaluronidase Activity

	Absolute	Hyaluronida	ase Activity				_
No incu (4°		37° C. no (37°)		37° C. m-cre (37° C. m-cre	sol plus	5	
1.572	1.094	1.572	1.674	0.213	0.174		_
0.727	0.940	0.910	0.846	0.116	0.102		
2.086	1.351	1.704	2.690	0.539	0.279	10	
0.847	1.001	1.026	1.135	0.153	0.064	10	
0.834	0.861	1.036	1.021	0.033	0.026		
1.316	0.777	1.353	0.747	0.125	0.097		
1.159	1.332	1.285	1.763	0.202	0.186		
0.877	0.926	1.144	1.189	0.092	0.088		
3.037	3.432	4.460	3.598	0.372	0.364	15	
3.445	4.101	6.405	4.911	0.283	0.245	15	
1.096	1.257	1.312	1.191	0.077	0.085		
0.453	0.452	0.492	0.457	0.034	0.036		
2.198	2.313	2.474	2.522	0.424	0.461		

	No inc	ubation	37° C r	no cresol	37° C. m-cr (37° C	esol	5						37° C. m-cr	
Mutant		C.)	(37°		m-cre			Mutant	No inc (4°	ubation C.)	37° C. n (37°		(37° C m-cre	-
K376E	1.572	1.094	1.572	1.674	0.213	0.174			(.	0.)	(57	0.)		
K376Q	0.727	0.940	0.910	0.846	0.116	0.102		D431S	14.523	10.220	11.338	9.075	0.853	0.829
K376R K376T	2.086 0.847	1.351 1.001	1.704 1.026	2.690 1.135	0.539 0.153	0.279 0.064	10	F433A	4.035	4.673	5.943	4.649	0.581	0.595
K376V	0.834	0.861	1.020	1.021	0.033	0.004		F433H	1.836	2.397	2.574	2.108	0.347	0.356
K376Y	1.316	0.777	1.353	0.747	0.125	0.020		F433I	2.754	2.643	2.990	2.299	0.338	0.382
G377D	1.159	1.332	1.285	1.763	0.202	0.186		F433K	17.815	14.495	16.240	49.615	1.806	1.790
G377E	0.877	0.926	1.144	1.189	0.092	0.088		F433R	8.198	6.719	10.572	8.960	1.113	0.857
G377H	3.037	3.432	4.460	3.598	0.372	0.364	15	F433T	6.005	5.941	9.716	8.019	1.327	1.542
G377K G377R	3.445 1.096	4.101 1.257	6.405 1.312	4.911 1.191	0.283 0.077	0.245 0.085		F433V	10.645	7.762	150.315	8.696	2.415	1.505
G377S	0.453	0.452	0.492	0.457	0.034	0.036		F433W	0.526	0.795	0.784	0.903	0.082	0.068
G377T	2.198	2.313	2.474	2.522	0.424	0.461		P437I	0.759	0.996	1.130	1.066	0.027	0.019
F380W	17.497	27.987	25.734	29.353	2.566	2.716		M438A	1.996	1.518	2.125	2.060	0.214	0.210
T381S	2.861	3.161	3.886	3.558	0.521	0.367	20	M438D	2.849	2.522	3.002	2.857	0.305	0.074
R383I R383S	1.959 2.429	6.936 2.548	10.340 3.228	6.820 3.044	0.655 0.339	0.513 0.321	20	M438E	4.681	4.992	5.386	5.680	0.431	0.518
K385A	0.479	0.669	0.604	0.754	0.028	0.000		M438L	10.127	5.268	6.663	11.324	0.670	0.739
K385Q	1.746	2.089	2.403	2.609	0.217	0.196		M438N	6.172	5.531	8.050	5.568	0.649	0.662
K385V	1.232	1.750	1.387	1.410	0.071	0.042		M438T	2.218	2.411	2.308	2.500	0.309	0.304
E389A	6.872	10.944	21.081	24.610	0.449	0.449	25	E439A	3.557	4.432	4.883	4.235	0.568	0.596
E389G E389L	0.166 1.814	0.203 2.142	0.188 2.598	0.284 2.403	0.004 0.370	0.000 0.303	25	E439A	1.099	0.998	1.694	1.470	0.080	0.109
E389L E389Q	2.547	3.432	2.398	3.423	0.370	0.303		E439C	0.148	0.256	0.286	0.286	0.042	0.045
E389S	1.847	2.640	3.059	2.456	0.000	0.007		E439K	0.466	0.588	0.580	0.616	0.077	0.065
E392A	1.797	1.370	2.021	2.133	0.147	0.136		E439P	2.868	3.736	3.394	3.267	0.529	0.490
E392F	1.575	1.407	1.821	2.023	0.071	0.079		E439Q	1.070	0.848	1.087	1.080	0.116	0.115
E392Q	5.826	4.653	6.583	4.364	0.693	0.729	30	E439T	1.965	1.889	2.179	2.323	0.313	0.263
E392R E392V	4.555 3.817	5.306 2.936	5.900 4.747	6.548 4.544	0.218 0.367	0.193 0.291		T440D	4.148	4.443	4.931	3.533	0.568	0.651
Q393F	1.754	2.930	2.455	2.222	0.260	0.291		T440H	2.317	1.982	3.297	2.595	0.147	0.196
Q393M	1.252	1.826	1.749	1.588	0.028	0.049		T440M	3.397	3.305	2.878	2.873	0.254	0.367
S395A	4.220	6.127	8.788	6.906	1.141	0.856		T440P	3.562	3.593	3.987	3.277	0.540	0.566
S395H	1.609	2.261	2.574	2.564	0.323	0.268	35	T440S	2.522	2.207	2.533	2.895	0.283	0.284
E396A E396H	1.135 0.357	1.184 0.532	1.497 0.751	1.524 0.684	0.126 0.069	0.149 0.022		E441F	1.402	1.407	1.813	1.560	0.204	0.178
E396Q	1.310	1.625	1.611	1.559	0.009	0.022		E442G	2.871	3.340	3.193	3.347	0.327	0.367
E396S	3.375	5.709	5.274	6.380	0.146	0.129		P443E	0.907	0.710	0.856	0.928	0.044	0.063
Y399T	2.538	3.250	3.313	3.989	0.000	0.002		P443F	1.830	2.370	2.683	2.321	0.301	0.286
Y399V	2.738	2.697	3.028	3.129	0.484	0.557	40	P443G	4.077	2.921	9.751	4.614	0.835	0.756
Y399W S401A	1.400 2.636	1.883 3.171	1.715 3.216	1.946 3.148	0.236 0.447	0.233 0.410	40	Q444E	8.293	3.861	6.800	6.213	0.581	0.594
S401A S401E	1.685	1.601	2.110	2.060	0.344	0.309		Q444H	3.823	3.936	5.746	4.710	0.486	0.513
S404A	1.288	1.635	1.924	1.724	0.000	0.019		Q444V	2.193	2.107	2.847	2.583	0.384	0.284
L406F	0.706	0.490	0.867	0.716	0.000	0.000		I445M	5.265	4.438	4.480	4.489	0.773	0.691
L406N	0.617	0.795	0.943	1.044	0.060	0.070	4.5	I445N	3.375	4.024	3.592	3.515	0.499	0.455
S407A S407D	2.428 2.090	2.949 5.790	3.432 5.038	3.255 5.682	0.389 0.569	0.548 0.575	45	I445W	2.289	2.694	2.683	2.695	0.314	0.296
S407D S407P	2.660	2.708	3.812	3.301	0.261	0.366		Y447E	2.373	2.464	2.363	2.685	0.391	0.345
A412Q	2.001	2.918	2.925	2.902	0.279	0.247		Y447G	0.945	1.352	1.358	1.401	0.187	0.162
A412R	4.562	5.132	6.390	6.347	0.570	0.596		Y447P	0.991	1.383	1.379	1.490	0.190	0.183
A412V	2.581	3.451	3.789	3.511	0.189	0.189	_ 1	positive	2.919	2.173	2.773	2.105	0.145	0.178
D416L D418R	0.610 4.541	0.817 4.847	0.737 5.347	1.043 5.438	0.130 0.406	0.160 0.583	50	control	3.984	4.463	4.215	4.823	0.189	0.253
A419H	10.409	20.311	25.109	38.221	2.214	2.293		(OHO)	3 2.501	2.725	3	3.325	0.1 0.452	0.125
A419K	12.835	10.298	24.536	208.289	2.556	3.173			7.629	2.883 2.989	2.370 10.835	3.158 3.914	0.432	0.522 0.219
D421A	5.968	5.617	6.094	16.940	0.761	0.764			5.783	5.356	2.609	3.643	0.485	0.219
D421H	48.012	48.012	160.106	32.481	16.300	28.113			5.279					0.402
D421K D421N	5.527 9.060	5.225 8.635	6.864 10.039	5.346 8.645	0.523 1.502	0.725 1.422	55		5.279 4.775	5.422 4.385	2.815 2.845	4.026 3.327	0.618 0.718	0.401
D421N D421Q	9.000 7.529	5.581	7.858	8.045	0.842	0.994			4.775	4.385 4.264	2.845 3.322	3.327 3.427	0.718	0.340
D421R	6.637	5.463	9.211	7.537	0.815	0.737			5.881	4.204	5.522 5.518	4.359	0.033	0.479
D421S	5.556	5.355	7.899	8.898	0.869	0.762			6.754	4.932	3.902	4.339	0.743	0.848
A425G	10.421	8.827	7.796	10.676	0.827	1.189			3.911	4.952 3.494	3.902 3.911	4.120 5.179	0.003	0.724
G427Q G427T	1.008 1.330	1.252 1.380	1.342 1.664	1.230 1.643	0.031 0.080	0.106 0.065	60		5.406	5.494 7.559	4.018	5.179 4.620	0.726	0.841
V428L	2.138	2.769	2.930	3.029	0.080	0.003			4.015	3.887	4.018 3.9400	4.620 3.4080	0.733	0.429
D431E	2.810	2.220	1.972	2.112	0.519	0.438			2.604	2.339	2.4430	2.3910	0.3340	0.2330
D431H	2.154	3.185	4.017	3.028	0.294	0.301			3.736	2.559 3.473	2.4430 3.6210	3.0560	0.2350	0.2330
D431K	8.123	16.953	19.563	11.575	2.272	2.339			3.759	3.509	3.6330	3.0300	0.3600	0.2770
D431L	1.211	1.215	1.564	1.448	0.164	0.170 1.399	65		5.139	5.509	5.0550	5.0470	0.5000	0.5050
D431N D4310	11.819	12.063 9.828	16.358 14.157	15.131	1.601	1.399	00	nla (nat avu	ilahlar a a	havond da	tection limit)			

n/a (not available; e.g., beyond detection limit)

			Percent (%) A	ctivity				
		duplicate 1		duplicate 2				
	% activity at 37° C./4° C.	% activity 37° C. + m-cresol/37° C.	% activity 37° C. + m-cresol/4° C.	% activity at 37° C./4° C.	% activity 37° C. + m-cresol/37° C.	% activity 37° C. + m-cresol/4° C		
L001A	117.908	8.13	9.59	127.997	9.179	11.75		
LOOIE	107.231	13.14	14.09	125.207	10.727	13.43		
L001G	171.264	9.23	15.80	115.952	4.586	5.32		
L001Q L001R	119.435 117.366	10.13 6.96	12.09 8.17	88.763 160.410	11.121 5.623	9.87 9.02		
P006A	137.875	9.88	13.63	100.410	12.446	13.56		
V008M	134.884	0.00	0.00	119.772	0.477	0.57		
1009Q	104.922	6.61	6.94	124.934	6.303	7.87		
P010G	109.772	15.00	16.47	121.986	16.570	20.21		
P010H	131.924	0.00	0.00	112.990	0.000	0.00		
N011S	152.320	7.16	10.90	131.289	5.067	6.65		
V012E	48.208	14.18	6.83	100.163	16.896	16.92		
V012I	128.745	2.94	3.78	170.812	1.371	2.34		
V012K	146.600	13.31	19.52	114.264	14.311	16.35		
F014V	154.167	1.35	2.08	146.667	0.000	0.00		
L015M	113.747	1.66 14.64	1.88 27.64	83.970	1.887 15.153	1.58		
A020S S022T	188.889 111.203	20.27	22.54	118.821 86.404	22.854	18.00 19.75		
L026M	136.775	11.05	15.11	138.989	10.446	19.75		
K028R	110.487	10.74	11.86	109.467	10.270	11.24		
F029R	154.644	7.58	11.72	121.707	7.613	9.27		
F029S	118.119	7.01	8.28	97.400	8.037	7.83		
F029T	126.740	11.96	15.16	120.619	10.266	12.38		
P032C	128.649	1.26	1.62	127.446	7.491	9.55		
L033G	121.201	0.15	0.18	89.571	4.147	3.71		
D034W	146.765	15.23	22.35	146.729	14.650	21.50		
M035V	81.285	16.09	13.08	102.034	3.528	3.60		
S036H	106.222	9.93	10.55	150.931	2.291	3.46		
5036N	112.045	19.15	21.46	92.069	30.268	27.87		
L037M	79.268	10.77	8.54	87.376	9.065	7.92		
F040L	135.036 132.507	7.88 12.79	10.64 16.95	105.252	8.703 16.667	9.16		
1046L N047D	132.307 115.797	1.24	1.44	112.944 111.869	0.796	18.82 0.89		
N047D	104.703	0.00	0.00	109.880	3.728	4.10		
A048N	114.954	5.59	6.43	51.931	3.778	1.96		
T049R	122.704	5.81	7.13	90.760	5.363	4.87		
G050D	93.824	7.85	7.36	95.934	8.742	8.39		
G050M	157.686	8.99	14.18	139.048	12.115	16.85		
G052N	96.148	15.98	15.37	142.502	7.748	11.04		
G052T	116.407	21.23	24.71	117.075	32.310	37.83		
G052S	98.513	23.49	23.14	98.199	28.833	28.31		
V058C	92.507	16.05	14.85	99.162	16.141	16.01		
V058K	217.914	38.66	84.24	217.914	38.655	84.24		
V058R	96.905	56.55	54.80	102.858	65.305	67.17		
V058N V058Y	129.167 102.981	12.90 36.23	16.67 37.31	129.787 141.299	11.475 41.728	14.89 58.96		
V0581 V058Q	154.383	8.49	13.11	293.510	41.728	14.10		
V058Q	83.304	21.15	17.62	173.652	17.262	29.98		
V058H	200.264	10.88	21.79	181.750	13.067	23.75		
D068P	99.070	0.47	0.47	83.721	102.222	85.58		
5069T	138.609	10.82	15.00	122.579	8.985	11.01		
070P	101.713	0.77	0.78	99.749	2.014	2.01		
070V	170.462	13.97	23.82	136.849	10.885	14.90		
V073Q	121.337	6.51	7.90	107.094	8.186	8.77		
V073R	137.931	2.50	3.45	100.125	7.338	7.35		
Г074E	133.241	17.22	22.94	100.965	16.172	16.33		
F074M	115.290	12.04	13.88	103.629	10.765	11.16		
F074N	91.870 108.323	10.96	10.06	157.218	6.811	10.71		
Г074Р Г074R	80.681	12.24 7.44	13.26 6.01	166.227 130.000	10.008 2.158	16.64 2.80		
Г074К Г074V	115.093	7.44	8.52	114.063	5.479	6.25		
V075M	134.460	0.24	0.33	121.527	2.120	2.58		
K082L	114.758	20.79	23.86	251.869	10.721	27.00		
K082N	106.059	23.32	24.73	95.104	26.541	25.24		
1083V	140.151	29.88	41.88	137.296	28.133	38.63		
1083Q	112.163	27.02	30.30	188.798	13.881	26.21		
1083S	104.637	26.70	27.94	95.351	26.667	25.43		
I083G	106.239	22.54	23.95	76.381	32.208	24.60		
S084E	124.762	6.27	7.82	113.410	6.833	7.75		
S084F	83.291	2.55	2.12	91.007	0.000	0.00		
S084N	144.922	18.27	26.47	131.144	22.092	28.97		
S084R	119.873	10.92	13.09	203.099	4.977	10.11		

TABLE 12-continued

			Percent (%) Ad	ctivity		
		duplicate 1			duplicate 2	
	% activity at 37° C./4° C.	% activity 37° C. + m-cresol/37° C.	% activity 37° C. + m-cresol/4° C.	% activity at 37° C./4° C.	% activity 37° C. + m-cresol/37° C.	% activity 37° C. + m-cresol/4° C.
Q086A	136.516	14.24	19.43	156.132	9.728	15.19
Q086H	102.612	7.14	7.33	129.600	5.015	6.50
Q086K	99.213	25.40	25.20	65.455	31.944	20.91
Q086S Q086T	100.435 93.837	6.81 10.24	6.84 9.61	103.218 179.465	11.215 8.900	11.58 15.97
D087G	81.742	1.51	1.23	90.579	6.190	5.61
D087L	106.039	14.76	15.65	101.493	12.938	13.13
D087M	110.964	7.61	8.44	87.656	16.438	14.41
D087S	134.031	8.15	10.92	139.728	6.445	9.01
D087V D090E	114.107 92.910	9.14 14.26	10.43 13.25	87.023 161.281	15.922 6.221	13.86 10.03
D090N	111.060	12.14	13.48	98.631	10.596	10.45
K093Q	91.008	5.82	5.30	95.448	6.646	6.34
K093R	103.617	11.70	12.12	99.301	16.362	16.25
K094D	86.544	6.52	5.64	102.107	9.897	10.11
K094R T097C	125.373 165.152	8.96 8.07	11.23 13.33	108.690 81.715	9.905 17.228	10.77 14.08
T097D	123.654	8.55	10.58	117.522	10.994	12.92
T097E	127.190	15.57	19.80	115.106	16.143	18.58
T097L	118.465	23.10	27.36	103.589	24.174	25.04
N104R	114.673	9.70	11.12	118.421	8.530	10.10
A120H D127R	94.107 56.439	8.28 70.47	7.80 39.77	113.015 58.702	6.903 34.171	7.80 20.06
V128I	113.654	10.97	12.47	102.656	14.819	15.21
N131M	177.000	1.86	3.29	76.888	2.811	2.16
N131R	94.253	21.30	20.07	95.930	19.376	18.59
N131V	137.681	10.22	14.07	104.920	10.907	11.44
R132L Q138L	98.578 107.831	10.34 25.45	10.19 27.44	91.685 91.627	14.498 22.814	13.29 20.90
Q138L Q140K	176.600	10.93	19.30	109.815	12.522	13.75
N141R	103.411	4.35	4.50	115.682	2.292	2.65
N141S	131.758	4.66	6.13	109.527	5.529	6.06
N141W	130.644	5.19	6.78	104.783	6.391	6.70
V142D V142G	114.185 117.686	4.39 13.21	5.02 15.55	146.066 90.256	2.098 13.510	3.06 12.19
V142K	109.485	14.77	16.17	154.599	15.621	24.15
V142N	155.556	15.33	23.84	103.880	14.771	15.34
V142P	166.998	13.91	23.23	97.338	15.397	14.99
V142Q V142R	149.666 149.441	8.90 12.38	13.32 18.50	99.957 103.622	9.830 12.272	9.83 12.72
V142K V142S	170.778	8.73	14.92	117.035	16.900	12.72
V142T	223.936	11.48	25.70	123.650	11.709	14.48
Q143G	143.600	13.88	19.94	98.837	16.096	15.91
Q143K	200.468	14.32	28.70	136.421	20.747	28.30
L144R L144T	136.247 129.746	10.71 14.68	14.59 19.05	111.482 108.923	10.182 11.961	11.35 13.03
L1441 L146P	116.626	1.15	1.34	115.601	3.429	3.96
T147S	142.175	3.93	5.59	130.287	2.605	3.39
T150N	140.724	6.27	8.82	116.923	6.725	7.86
T150S	107.327	6.40	6.87	142.000	6.087	8.64
E151A E151L	103.310 132.125	12.11 4.90	12.51 6.48	126.047 121.830	11.783 6.264	14.85 7.63
E151L E151S	132.123	6.20	7.15	121.830	4.695	6.40
E1515	128.337	0.00	0.00	110.300	0.000	0.00
E151V	111.531	7.31	8.15	99.647	7.420	7.39
E151W	158.415	1.15	1.83	94.919	0.895	0.85
K152T K152W	149.169 122.313	5.57 2.47	8.31 3.02	136.747 134.039	3.558 2.868	4.87 3.84
E158S	133.038	0.00	0.00	102.519	0.000	0.00
K162E	67.857	3.51	2.38	41.026	30.000	12.31
L165F	106.283	11.82	12.57	96.667	14.286	13.81
V166Q	155.975	13.35	20.82	117.990	10.953	12.92
V166T E167D	183.384 136.745	12.69 10.01	23.26 13.69	136.882 162.637	13.056 3.784	17.87 6.15
E167D I169L	136.745 140.177	13.19	13.69 18.49	162.637 122.272	3.784 15.528	6.15 18.99
K170R	160.710	8.24	13.24	97.128	10.075	9.79
G172A	167.554	7.51	12.59	133.735	7.207	9.64
K173R	106.771	9.80	10.46	134.300	7.489	10.06
L174G	114.130	12.38	14.13	264.368	13.478	35.63
L174N L 174T	154.332	13.27	20.48	126.186	18.907	23.86
L174T N178K	124.819 166.871	13.06 5.27	16.30 8.80	144.876 103.154	6.098 8.021	8.83 8.27
111/01	100.071	5.21	0.00	105.154	0.021	0.27

TABLE 12-continued

			Percent (%) Ad	etivity		
		duplicate 1			duplicate 2	
	% activity at 37° C./4° C.	% activity 37° C. + m-cresol/37° C.	% activity 37° C. + m-cresol/4° C.	% activity at 37° C./4° C.	% activity 37° C. + m-cresol/37° C.	% activity 37° C. + m-cresol/4° C.
N178R	199.596	4.08	8.15	144.957	3.943	5.72
H193Q	213.585	15.28	32.64	138.113	18.326	25.31
K195T K195N	126.161 130.253	22.48 22.38	28.36 29.15	237.097 96.381	15.280 25.487	36.23 24.57
K195R	90.574	36.80	33.33	154.091	23.500	36.21
K196R	106.100	13.22	14.02	95.142	17.663	16.81
F204P	83.571	84.62	70.71	82.418	126.000	103.85
N205A N205E	139.223 160.930	21.34 19.30	29.71 31.06	102.031 93.313	18.735 18.503	19.12 17.27
N205L	100.930	10.56	11.35	0.000	#DIV/0!	8.55
N205T	145.085	10.05	14.58	110.627	13.054	14.44
V206I	189.274	13.17	24.92	111.220	15.575	17.32
K209R	119.794	11.90	14.26	79.535	3.947	3.14
D212N D212S	112.626 122.899	2.66 8.35	3.00 10.27	132.249 147.936	5.352 6.841	7.08 10.12
D2123 D213A	183.830	26.85	49.36	154.770	13.699	21.20
D213M	159.255	6.83	10.88	98.365	6.940	6.83
S215H	109.069	10.04	10.95	78.992	5.758	4.55
S215M	174.883	4.20	7.35	74.943	8.957	6.71
N219I E220V	254.438 131.985	8.84 7.43	22.49 9.81	291.200 113.610	11.264 5.909	32.80 6.71
T222G	153.033	0.61	0.94	105.454	0.793	0.84
T232F	132.839	12.43	16.51	62.882	19.590	12.32
Q233G	280.488	0.00	0.00	127.368	0.000	0.00
Q234M	95.605	22.31	21.33	80.766	20.283	16.38
S235A V237C	129.818 138.042	11.06 0.00	14.36 0.00	120.916 116.384	12.026	14.54 0.00
V237C V237H	122.112	12.43	15.18	145.253	0.000 7.407	10.76
V237T	167.105	21.26	35.53	126.020	21.457	27.04
A238E	94.878	8.17	7.76	142.167	6.682	9.50
A238H	59.585	26.09	15.54	204.683	8.345	17.08
T240A	141.283	9.14	12.92 24.02	144.667	9.063	13.11
T240Q R248A	162.763 113.237	14.76 1.05	1.19	120.980 124.650	13.776 2.408	16.67 3.00
E249V	142.752	15.29	21.83	111.068	16.462	18.28
P257G	125.220	0.78	0.98	112.803	0.677	0.76
K260M	116.690	8.58	10.01	97.396	7.273	7.08
S261A S261K	57.547 161.931	67.52 16.05	38.86 26.00	86.173 116.159	54.021 22.820	46.55 26.51
S261N	142.901	10.05	14.95	35.529	13.403	4.76
A267T	196.154	35.29	69.23	111.579	38.679	43.16
F273H	122.647	6.00	7.35	119.037	5.973	7.11
F273Y	119.713	7.78	9.32	102.772	9.634	9.90
Q276H Q276M	74.908 98.323	8.93 5.64	6.69 5.55	106.393 104.948	10.065 0.000	10.71 0.00
Q276R	121.431	10.93	13.27	150.180	8.778	13.18
Q276S	110.643	9.95	11.01	138.696	8.745	12.13
V277A	140.765	6.97	9.82	129.580	5.167	6.70
V277E	175.779	3.75	6.60	195.598	5.222	10.21
V277H V277K	129.434 375.721	3.16 13.21	4.09 49.63	137.684 373.799	7.014 12.029	9.66 44.96
V277K V277M	137.138	15.05	20.64	112.084	14.851	16.65
V277N	89.645	7.29	6.54	273.386	6.762	18.49
V277Q	119.930	5.70	6.83	116.151	7.772	9.03
V277R	96.071	15.57	14.96	171.465	9.801	16.81
V277S V277T	66.260 101.010	7.65 7.99	5.07 8.07	144.916 143.311	4.731 7.788	6.86 11.16
L278E	75.408	5.11	3.85	145.511 100.179	7.214	7.23
L278G	122.274	6.50	7.94	104.077	7.887	8.21
K279H	138.964	14.99	20.83	123.183	20.090	24.75
V287T	145.345	16.49	23.97	124.738	12.019	14.99
T289S G291S	104.598 184.581	0.98 12.17	1.02 22.47	98.234 119.565	0.699 4.156	0.69 4.97
G2918 G291V	184.581 112.807	12.17 19.87	22.47	151.039	4.156	4.97
E292C	127.307	8.07	10.27	101.126	8.905	9.01
E292F	137.930	6.17	8.52	132.340	5.840	7.73
E292H	170.153	8.73	14.85	115.501	11.775	13.60
E292R	112.278	12.61	14.16	129.890	11.983	15.56
E292V T293A	163.075 128.197	13.28 3.38	21.66 4.33	133.274 57.524	11.847 4.248	15.79 2.44
A298G	212.422	8.77	4.55	86.131	9.322	8.03
L307G	117.857	0.00	0.00	91.528	0.000	0.00

			Percent (%) Ad	ctivity		
		duplicate 1			duplicate 2	
	% activity at 37° C./4° C.	% activity 37° C. + m-cresol/37° C.	% activity 37° C. + m-cresol/4° C.	% activity at 37° C./4° C.	% activity 37° C. + m-cresol/37° C.	% activity 37° C. + m-cresol/4° C.
S308D	127.652	4.15	5.30	105.846	2.907	3.08
S308K S308N	126.882	1.33 5.67	1.69 9.66	99.169 139.083	0.000 5.907	0.00 8.22
I309E	170.413 123.847	16.25	20.12	129.085	14.414	8.22 18.73
1309E	102.601	7.37	7.56	114.091	6.458	7.37
I309L	153.681	9.58	14.72	106.948	10.905	11.66
I309M	123.425	8.02	9.90	136.797	7.065	9.66
I309N	111.901	6.98	7.81	97.361	6.470	6.30
I309S I309T	169.951 97.936	4.11 7.63	6.98 7.47	551.493 148.864	0.862 5.542	4.75 8.25
1309V	113.138	1.50	1.70	138.313	3.470	4.80
M310G	167.656	11.44	19.18	110.739	12.916	14.30
M310Q	107.237	27.81	29.82	106.323	28.254	30.04
M313G	138.095	9.77	13.49	109.231	10.141	11.08
M313H M313K	271.914 118.882	3.71 0.86	10.09 1.02	197.024 107.111	3.886 0.555	7.66 0.59
M313R M313P	103.654	4.98	5.16	132.802	4.516	6.00
M313R	157.272	4.62	7.27	32.845	8.296	2.72
M313T	162.074	7.04	11.40	99.844	7.007	7.00
M313Y	120.038	7.52	9.03	103.011	6.846	7.05
K314S	141.924	9.67	13.73	132.112	9.066	11.98
K314Y S315A	243.011 91.372	5.75 16.51	13.98 15.08	138.931 137.153	10.989 9.973	15.27 13.68
S315A S315H	151.244	12.06	18.24	105.305	10.867	11.44
S315Y	170.968	30.61	52.33	57.827	39.503	22.84
L317A	123.510	6.97	8.60	132.724	8.395	11.14
L317I	187.477	12.72	23.84	110.696	10.670	11.81
L317K	96.199	3.45	3.31	134.204	3.534	4.74
L317N L317R	127.382 238.501	12.02 3.87	15.31 9.22	121.233 99.467	14.528 5.673	17.61 5.64
L317K L317S	90.929	15.54	14.13	85.810	6.423	5.51
L317T	145.964	6.96	10.16	154.334	1.087	1.68
L317W	163.704	11.92	19.51	147.606	10.270	15.16
L318D	105.543	17.43	18.40	97.970	16.684	16.35
L318H	99.907	4.29	4.29	124.690	7.363	9.18
L318R N321R	160.469 164.842	5.63 9.53	9.03 15.71	120.872 112.180	6.210 8.613	7.51 9.66
N321S	102.489	8.29	8.49	108.732	4.534	4.93
E324N	104.618	7.72	8.08	131.265	9.124	11.98
T325E	124.837	14.44	18.02	106.457	10.577	11.26
N328G	197.098	4.15	8.18	109.722	7.233	7.94
N328Y T335S	180.981 107.956	10.30 11.57	18.64 12.49	100.000 125.286	10.500 6.288	10.50 7.88
Q347A	107.950	10.89	11.04	96.213	11.001	10.58
Q347G	222.459	8.37	18.63	207.054	9.013	18.66
Q349M	99.531	11.98	11.92	108.042	12.330	13.32
Q349R	147.007	11.76	17.29	104.545	13.211	13.81
V351S	130.819	0.00	0.00	100.857	0.000	0.00
1353V N356H	132.334 100.000	10.45 8.54	13.83 8.54	138.025 130.377	11.902 3.912	16.43 5.10
N356S	51.908	0.00	0.00	125.692	2.516	3.16
S359E	135.589	10.77	14.60	135.104	9.354	12.64
S359H	110.422	0.00	0.00	100.809	0.000	0.00
P367A	167.030	12.94	21.62	127.366	13.153	16.75
P367G P367K	115.683 125.884	0.00 5.06	0.00 6.36	122.642 66.884	0.000 10.136	0.00 6.78
P367S	74.263	14.39	10.69	88.355	16.433	14.52
D368A	121.623	1.45	1.76	81.646	2.111	1.72
D368E	166.628	9.18	15.30	97.937	11.462	11.23
D368L	108.977	0.00	0.00	109.364	0.969	1.06
D368M D368R	119.744 164.735	2.72 10.16	3.25 16.74	103.662	2.536 11.805	2.63 13.95
D368K D368T	104.735	2.87	3.07	118.140 126.693	3.366	4.26
N369R	161.693	6.39	10.34	74.366	6.182	4.60
A371F	180.217	6.19	11.16	76.436	5.578	4.26
A371H	957.055	1.81	17.32	89.541	1.697	1.52
A371H	111.143	0.00	0.00	95.589	8.610	8.23
A371K	136.514 695.108	12.84 1.51	17.53 10.52	114.354	12.454	14.24 2.37
		1.31	10.52	107.003	2.215	2.37
A371L				60 232	1 205	0.73
	104.327 #VALUE!	0.00 #VALUE!	0.00 11.03	60.232 #VALUE!	1.205 #VALUE!	0.73 14.06

TABLE 12-continued

			Percent (%) Ad	ctivity		
		duplicate 1			duplicate 2	
	%	% activity	% activity	%	% activity	% activity
	activity at 37° C./4° C.	37° C. + m-cresol/37° C.	37° C. + m-cresol/4° C.	activity at 37° C./4° C.	37° C. + m-cresol/37° C.	37° C. + m-cresol/4° C.
A371S	147.672	8.38	12.38	131.555	16.938	22.28
L374P	392.038	5.77	22.63	123.033	7.365	9.06
E375A E375G	88.836 126.880	0.00 10.32	0.00 13.10	134.714 139.030	2.050 14.673	2.76 20.40
E375G E375R	163.180	13.15	21.45	116.431	19.727	22.97
K376D	113.100	12.36	13.97	165.064	5.049	8.33
K376E	100.000	13.55	13.55	153.016	10.394	15.90
K376Q	125.172	12.75	15.96 25.84	90.000	12.057	10.85
K376R K376T	81.687 121.133	31.63 14.91	18.06	199.112 113.387	10.372 5.639	20.65 6.39
K376V	124.221	3.19	3.96	118.583	2.547	3.02
K376Y	102.812	9.24	9.50	96.139	12.985	12.48
G377D	110.871	15.72	17.43	132.357	10.550	13.96
G377E G377H	130.445 146.855	8.04 8.34	10.49 12.25	128.402 104.837	7.401 10.117	9.50 10.61
G377K	185.922	4.42	8.21	119.751	4.989	5.97
G377R	119.708	5.87	7.03	94.749	7.137	6.76
G377S	108.609	6.91	7.51	101.106	7.877	7.96
G377T	112.557	17.14	19.29	109.036	18.279	19.93
F380W T381S	147.077 135.827	9.97 13.41	14.67 18.21	104.881 112.559	9.253 10.315	9.70 11.61
R383I	527.820	6.33	33.44	98.328	7.522	7.40
R383S	132.894	10.50	13.96	119.466	10.545	12.60
K385A	126.096	4.64	5.85	112.706	0.000	0.00
K385Q	137.629	9.03	12.43	124.892	7.512	9.38
K385V E389A	112.581 306.767	5.12 2.13	5.76 6.53	80.571 224.872	2.979 1.824	2.40 4.10
E389G	113.253	2.13	2.41	139.901	0.000	0.00
E389L	143.219	14.24	20.40	112.185	12.609	14.15
E389Q	135.807	11.88	16.14	99.738	12.767	12.73
E389S E392A	165.620 112.465	0.00 7.27	0.00 8.18	93.030	0.285 6.376	0.27 9.93
E392A E392F	112.403	3.90	4.51	155.693 143.781	3.905	5.61
E392Q	112.993	10.53	11.89	93.789	16.705	15.67
E392R	129.528	3.69	4.79	123.407	2.947	3.64
E392V	124.365	7.73	9.61	154.768	6.404	9.91
Q393F Q393M	139.966 139.696	10.59 1.60	14.82 2.24	101.647 86.966	10.171 3.086	10.34 2.68
\$395A	208.246	12.98	27.04	112.714	12.395	13.97
S395H	159.975	12.55	20.07	113.401	10.452	11.85
E396A	131.894	8.42	11.10	128.716	9.777	12.58
E396H E396Q	210.364 122.977	9.19 10.06	19.33 12.37	128.571 95.938	3.216 10.263	4.14 9.85
E396Q E396S	156.267	2.77	4.33	111.753	2.022	2.26
Y399T	130.536	0.00	0.00	122.738	0.050	0.06
Y399V	110.592	15.98	17.68	116.018	17.801	20.65
Y399W	122.500	13.76	16.86	103.346	11.973	12.37
S401A S401E	122.003 125.223	13.90 16.30	16.96 20.42	99.275 128.670	13.024 15.000	12.93 19.30
S401E S404A	149.379	0.00	0.00	105.443	1.102	19.30
L406F	122.805	0.00	0.00	146.122	0.000	0.00
L406N	152.836	6.36	9.72	131.321	6.705	8.81
S407A S407D	141.351	11.33	16.02 27.22	110.376	16.836 10.120	18.58 9.93
S407D S407P	241.053 143.308	11.29 6.85	9.81	98.135 121.898	11.088	13.52
A412Q	146.177	9.54	13.94	99.452	8.511	8.46
A412R	140.070	8.92	12.49	123.675	9.390	11.61
A412V	146.804	4.99	7.32	101.739	5.383	5.48
D416L D418R	120.820 117.749	17.64 7.59	21.31 8.94	127.662 112.193	15.340 10.721	19.58 12.03
A419H	241.224	8.82	21.27	112.195	5.999	11.29
A419K	191.165	10.42	19.91	2022.616	1.523	30.81
D421A	102.111	12.49	12.75	301.584	4.510	13.60
D421H	333.471	10.18	33.95	67.652	86.552	58.55
D421K D421N	124.190 110.806	7.62 14.96	9.46 16.58	102.316 100.116	13.562 16.449	13.88 16.47
D421N D421Q	104.370	10.72	11.18	143.630	12.400	17.81
D421R	138.783	8.85	12.28	137.964	9.778	13.49
D421S	142.171	11.00	15.64	166.162	8.564	14.23
A425G	74.810	10.61	7.94	120.947	11.137	13.47
G427Q G427T	133.135	2.31 4.81	3.08	98.243	8.618	8.47 4.71
G427T	125.113	4.01	6.02	119.058	3.956	4./1

TABLE 12-continued

		duplicate 1			duplicate 2	
	% activity at	% activity 37° C. +	% activity 37° C. +	% activity at	% activity 37° C. +	% activity 37° C. +
		m-cresol/37° C.			m-cresol/37° C.	
V428L	137.044	1.81	2.48	109.390	0.990	1.08
D431E	70.178	26.32	18.47	95.135	20.739	19.73
D431H	186.490	7.32	13.65	95.071	9.941	9.45
D431K	240.835	11.61	27.97	68.277	20.207	13.80
D431L D431N	129.149 138.404	10.49 9.79	13.54 13.55	119.177 125.433	11.740 9.246	13.99 11.60
D4310 D431Q	232.960	10.83	25.23	125.455	9.246	11.00
D431Q	78.069	7.52	5.87	88.796	9.135	8.11
F433A	147.286	9.78	14.40	99.486	12.798	12.73
F433H	140.196	13.48	18.90	87.943	16.888	14.85
F433I	108.569	11.30	12.27	86.984	16.616	14.45
F433K	91.159	11.12	10.14	342.290	3.608	12.35
F433R	128.958	10.53	13.58	133.353	9.565	12.75
F433T	161.799	13.66	22.10	134.977	19.229	25.96
F433V	1412.071	1.61	22.69	112.033	17.307	19.39
F433W	149.049	10.46	15.59	113.585	7.530	8.55
P437I M438A	148.880 106.463	2.39	3.56 10.72	107.028	1.782	1.91
M438A M438D	106.463	10.07 10.16	10.72	135.705 113.283	10.194 2.590	13.83 2.93
M438D M438E	105.570	8.00	9.21	113.285	2.390 9.120	10.38
M438L	65.794	10.06	6.62	214.958	6.526	14.03
M438N	130.428	8.06	10.52	100.669	11.889	11.97
M438T	104.058	13.39	13.93	103.691	12.160	12.61
E439A	137.279	11.63	15.97	95.555	14.073	13.45
E439A	154.140	4.72	7.28	147.295	7.415	10.92
E439C	193.243	14.69	28.38	111.719	15.734	17.58
E439K	124.464	13.28	16.52	104.762	10.552	11.05
E439P	118.340	15.59	18.44	87.446	14.998	13.12
E439Q	101.589	10.67	10.84	127.358	10.648	13.56
E439T	110.891	14.36	15.93	122.975	11.322	13.92
T440D T440H	118.877 142.296	11.52 4.46	13.69 6.34	79.518 130.928	18.426 7.553	14.65 9.89
T440M	84.722	8.83	7.48	86.929	12.774	11.10
T440P	111.931	13.54	15.16	91.205	17.272	15.75
T440S	100.436	11.17	11.22	131.174	9.810	12.87
E441F	129.315	11.25	14.55	110.874	11.410	12.65
E442G	111.216	10.24	11.39	100.210	10.965	10.99
P443E	94.377	5.14	4.85	130.704	6.789	8.87
P443F	146.612	11.22	16.45	97.932	12.322	12.07
P443G	239.171	8.56	20.48	157.960	16.385	25.88
Q444E	81.997	8.54	7.01	160.917	9.561	15.38
Q444H	150.301	8.46	12.71	119.665	10.892	13.03
Q444V I445M	129.822 85.090	13.49 17.25	17.51 14.68	122.591 101.149	10.995 15.393	13.48 15.57
1445M 1445N	106.430	17.25	14.08	87.351	12.945	13.37
I445W	117.213	11.70	13.72	100.037	10.983	10.99
Y447E	99.579	16.55	16.48	108.969	12.849	14.00
Y447G	143.704	13.77	19.79	103.624	11.563	11.98
Y 447P	139.152	13.78	19.17	107.737	12.282	13.23
positive	94.998	5.23	4.97	96.871	8.456	8.19
control	105.798	4.48	4.74	108.066	5.246	5.67
(OHO)	100.000	3.33	3.33	82.7780	3.759	4.59
	94.762	19.07	18.07	109.539	16.529	18.11
	142.024 45.115	4.48 20.77	6.36 9.37	130.947 68.017	5.595 11.035	7.33 7.51
	53.324	21.95	9.57	74.253	9.960	7.31
	59.581	25.24	15.04	74.233	16.231	12.31
	91.844	19.05	17.50	80.371	13.977	11.23
	93.828	13.47	12.63	96.630	19.454	18.80
	57.773	17.04	9.85	83.536	17.573	14.68
	100.000	18.56	18.56	148.226	16.239	24.07
	74.325	18.29	13.60	61.119	9.286	5.68
	98.132	8.48	8.32	87.677	10.006	8.77
	93.817	9.62	9.02	102.223	9.745	9.96
	96.922	8.56	8.30	87.993	9.064	7.98
	96.648	9.91	9.58	86.891	9.938	8.63

n/a (not available; e.g., beyond detection limit)

50

2. Summary of Results for F204P

For mutant F204P, the results above of tested supernatant from transient transfection of CHO-S cells incubated in the presence of m-cresol in a bHA enzymatic activity assay 5 showed that the F204P mutant protein was highly resistant to 0.4% m-cresol treatment. The results showed that the activity that remained after 4 hours incubation with 0.40 om-cresol at 37° C. was approximately equal to the activity observed when the enzyme was incubated at either 4° C. or at 37° C. in the absence of m-cresol. The positive control (WT PH20-OHO) showed a reduction in activity of 75% and 83% on the day of the assay (as assayed from two different OHO transfections). This demonstrated that the F204P phenophile was able to retain 60% to 90% or greater of its 15 activity above the residual activity of the wildtype PH20 control enzyme.

In order to confirm the stability of F204P upon m-cresol treatment or exposure to increased temperature, a second transfection of F204P was performed in duplicate using 20 CHO-S cells, and clarified supernatant was again tested for its stability at 4° C., at 37° C. for 4 hours with 0.4% m-cresol and at 37° C. for 4 hours without 0.4% m-cresol. The results confirmed that the F204P mutant enzyme retained a high amount of hyaluronidase activity after the 4 hour incubation 25 in m-cresol at 37° C. The results were similar to the results seen in the first screening of the mutant, with F204P retaining anywhere from 57% to greater than 90% of its activity above the residual activity of the wildtype PH20 control enzyme after the 4 hour incubation.

A summary of the enzyme activity of F204P compared to the wildtype control is set forth in Table 13.

for 96 hours, whereupon the cells and media were harvested and pooled. The cells were pelleted by centrifugation ($4000 \times$ g, 20'), and the supernatant retained for purification of the F204P protein (approximately 4.5 liters).

The crude supernatant was concentrated $10 \times$ using a 30 kDa Tangential flow filter (TFF) system (Millipore Pellicon XL, Bimax 30, 200 mL void volume; 50 cm² filter surface area) until the volume was approximately 450 mL. The permeate was saved for assay to detect flow through of the F204P protein. A free-flow buffer exchange for the retentate was then performed using 4 liters of buffer (10 mM NaPO₄; 25 mM NaCl, pH 7.2). The volume of the retentate was reduced again to approximately 200 mL, and then the remaining permeate in the system was purged (void volume ~200 mL) and the system was flushed using approximately 50 mL of buffer to yield a final concentrated product of approximately 450 mL.

An anti-rHuPH20 affinity column was prepared by coupling antigen affinity purified Rabbit anti-rHuPH20 IgG to CNBr-activated Sepharose 4 Fast Flow (GEHealth catalog No. 17-0981-01). Briefly, 0.7 g of pre-activated Sepharose 4 powder was suspended in 1 mM HCl in a 10 mL glass column for 30 minutes to allow the powder to swell. The solution was drained from the column and washed with 15 gel volumes (about 30 mL) of cold 1 mM HCl by gravity. The column was washed with 5 gel volumens of coupling buffer (0.1M NaHCO₃, 0.5M NaCl at pH 8.3). Next, 5 mg of Rabbit anti-rHuPH20 IgG at >1.0 mg/mL in coupling buffer was added to the column at a protein/gel ratio of 2-3 mg/mL gel. The column was rotated head to head at 4° C. overnight. The flow-through was collected for coupling efficiency determination. The gel was washed with 2 gel

	INDLE 15								
	Summary of Enzyme Activity								
Transfectior	after 4		Net % Increase in Activity Over	after 4		Net % Increase _in Activity Over			
#	F204P	WT (OHO)	WT (37° C.)	F204P	WT (OHO)	WT (4° C.)			
1 2	73.6% 122.3%	16.4% 25.2%	57.2% 97.1%	86.0% 109.7%	25.3% 16.6%	60.7% 93.1%			

TABLE 13

Example 6

Large Scale Expression and Purification of PH20 Hit Variant

1. Expression and Purification

HZ24-PH20-IRES-SEAP plasmid DNA containing cDNA encoding one of the variant PH20 was transfected into monolayer CHO-S cells as generally described in 55 Example 2. CHO-S cells were cultured in shaker flasks using CD-CHO media supplemented with GlutaMAX (8 mM). On the day of transfection, 15 flasks were prepared of approximately 300 mL volume containing the CHO-S cells at an approximate density of 1.0×10⁶ cells/mL. Each 300 mL 60 flask was transfected using 375 µg of plasmid DNA encoding the F204P mutant combined with 375 µL of Freestyle MAX transfection reagent. The transfected plasmid DNA had a sequence of nucleotides set forth in SEQ ID NO:4 containing a codon change of TTC to CCT at nucleotide 65 positions 1733-1735, thereby encoding the F204P mutant. The transfected cells were then allowed to remain in culture

volumes of coupling buffer, and then washed and resuspended in 1 M ethanolaminine pH 9.5 for 2 hours at room temperature to block unused activated sites. The gel was washed 6 times with 5 gel volumes per wash alternating coupling buffer and 0.1 NaAc, 0.5M NaCl, pH 4.5. The gel was then washed with 10 gel volumes of TBS (20 mM Tris-HCl, 0.15 M NaCl, pH 7.5). The coupling efficiency was determined (1-post-coupling protein concentration/precoupling protein concentration×100%). The antibody coupled gel was stored in TBS with 0.02% NaN₃ at 4° C.

The concentrated supernatant product was subsequently loaded onto a anti-rHuPH20 affinity column at an approximate rate of 5 mL/min. The elution was performed according to standard procedure using a GETM AKTA FPLC purification system (GE Healthcare, Product No. 18-1900-26), whereby the protein was eluted via a low pH glycine wash (0.1 M glycine-HCl, pH 2.5) in 1 mL fractions. Each fraction was immediately neutralized by the addition of 100 µL of 1M Tris, pH 7.5.

10

The eluted protein was assayed by resolving protein bands on a 4-20% SDS-PAGE gradient Tris-glycine gel. SeeBlue®Plus2 Pre-stained MW standards (Life Teechnologies; Catalog No. LC5925) were used as molecular weight standards, and 50 ng rHuPH20 (as described in Example 1) was used as a positive control. The polyacrylamide gel was stained with Instant Blue to show total protein from each fraction. To confirm the bands on the gel are PH20, the gel was transferred to a PVDF membrane (Invitrogen), which was subjected to Western Blot using a Rabbit anti-PH20 primary antibody generated by immunizing rabbits with rHuPH20 and an HRP-Goat anti-rabbit secondary antibody (Calbiochem, Cat. No. DC03L).

Then, the flow-through from the initial loading of the affinity column was re-loaded onto the column twice due to the low capacity of the affinity column. All fractions con-¹⁵ taining the protein were then combined resulting in a total volume that was approximately 13 mL. This product was then dialyzed overnight versus four liters of buffer (10 mM NaPO₄, 140 mM NaCl, pH 7.2) using a Slide-A-Lyzer Dialysis Cassette G2 (20,000 MWCO) with a 15 mL capac-²⁰ ity. The buffer was then changed and the product dialyzed against a second fresh four liters of the same buffer. The F204P protein was then concentrated using an Amicon Ultra Centrifugation column (Millipore; 10,000 MWCO) to a final volume of approximately 450 μ L (10 minutes at 4000×g). ²⁵

2. Characterization of Protein

The purified protein was characterized for its protein concentration, activity, and purity.

To determine the protein concentration of the purified protein, a quantification ELISA was performed as described in Example 7. Also, hyaluronidase activity was determined as described in Example 3. The protein concentration after centrifugation was estimated to be approximately 400 35 µg/mL. The purified protein also was resolved on a 4-20% SDS-PAGE gradient Tris-glycine gel, which was then stained with Instant Blue. The staining results demonstrated that the protein was essentially a single molecular weight protein of approximately 63 kDa, similar to the rHuPH20 40 control. No appreciable degradative products were detected by this method. Approximate yields of the protein at various timepoints and activity during the purification are described in Table 14.

TABLE 14

Characterization of Purification Steps									
		Activity A	ssay	Quant EL	Specific				
Purification Step	Volume (mL)	Activity (U/mL)	Total Activity (U)	Protein Conc. (µg/mL)	Total Protein (µg)	Activity (U/µg)			
Supernatant Conc. after TFF & Buffer Exchange	4500 450	2.66 42	11,700 18,900	0.046 0.4	207 178	56.5 105.9			
Pooled Fractions 5-7 after AC, Dialysis & Conc A280	0.45	11,741	5283	396	180	35.3			

The purity of the purified protein was determined by Reverse Phase HPLC (RP-HPLC). The elution time from the reverse phase column was essentially identical as that observed with the recombinant human hyaluronidase 65 (HUB), and provides a basis for crude estimation of the purity of the sample at approximately 80-90%.

Example 7

Quantification Using ELISA

The quantification of PH20 or variants were performed using an ELISA that captures the protein using a monoclonal anti-rHuPH20 capture antibody. Specifically, one day prior to performing the ELISA, 96-well 4HBX plates were coated with capture antibody (Protein G purified rabbit polyclonal anti-PH20 antibody generated by immunizing rabbits with rHuPH20; 1 mg/mL stock) at 1 µg/mL in 100 mM phosphate (pH 7.2) in a total volume of 100 µL per well. The plates were stored at 4° C. overnight. On the next day, the plates were washed 5× with 1×PBS at 300 µL/well with a plate washer. After each wash, the plated were patted dry on paper towels. Then, the plates were blocked with 200 µL PBS containing Tween 20 (1×PBST) per well at room temperature for 1 hour.

The standards and samples were added to the plate. For generation of the standard, a 1 mg/mL stock of rHuPH20 (Example 1) was freshly diluted to 50 µg/mL in HEPES pH 7.4 assay buffer as an intermediate stock. Then, for the standards, the 50 µg/mL stock was diluted in duplicates into 360 µL of 0.5×PBST at 300 ng/mL for the first standard (first row). For the other standard rows, 240 µL 0.5×PBST were added to each well, and 1:3 serial dilutions made. For the transfected supernatant samples, 360 µL per well was added in duplicate into the first row, and each were also serially diluted as described above into 0.5× PBST. For purified samples, 100 µL was added per well. The plates were incubated for 2 hours at room temperature. After incubation, the plates were washed 5× with 1×PBST at 300 µL/well using a plate washer. After each wash, the plates were patted dry on paper towels.

An HRP-conjugated anti-PH20 antibody was prepared for detection using an HRP conjugation kit (Pierce, Thermo-Fisher; Catalog No. 31489). 1 mg of a Protein G purified rabbit polyclonal antibody generated by immunizing rabbits with rHuPH20 was diluted in 1 mL PBS and 1 mL of $2\times$ carbonate kit buffer. Next, 100 µL of peroxidase were added to 1 mL of the above antibody solution and incubated at room temperature for 1 hour. Then, 10 µL NaBH₄ stock was added in a fume hood, and the sample incubated at room temperature for 20 minutes. To quench the reaction, 20 µL

of ethanolamine was added and incubated at room temperature for 15 minutes. To this, $\frac{1}{25}$ volume 5% human serum albumin (0.1 mL syringe) was added to give a 2 mg/mL albumin stock reaction. The pH was adjusted to about 7.9 by addition of 250 µL of 1 M Tris pH 7.4. The concentration of the stock was 400 µg/mL. The stock solution was further

diluted 1/10 in PBS Tween20 (0.05%) containing 0.5% human serum albumin and preservatives, and then was sterile filtered. The stock was stored at 4° C. or was frozen at -20° C.

Antibodies were detecting using the HRP-conjugated ⁵ anti-PH20 antibody that was diluted 1000× into 0.5× PBST. 100 µL of the diluted antibody was added to all wells of the plate and the plate incubated for a further 2 hours at room temperature. After incubation, the plates were washed $5 \times$ with 1×PBST at 300 µL/well using a plate washer. After each wash, the plates were patted dry on paper towels. Then, 100 µL of TMB substrate were added to each well and the reaction was stopped after 5-10 minutes by adding 100 µL of stop solution per well. The plate was read at OD_{450} .

Example 8

Determination of Enzymatic Activity of PH20

Enzymatic activity of PH20 in samples such as cell 20 cultures, purification fractions and purified solutions was determined using a turbidimetric assay, which is based on the formation of an insoluble precipitate when hyaluronic acid binds with cetylpyridinium chloride (CPC). The activity is measured by incubating PH20 with hyaluronan for a 25 set period of time (30 minutes) and then precipitating the undigested hyaluronan with the addition of CDC. The turbidity of the resulting sample is measured at 640 nm. The decrease in turbidity resulting from enzyme activity on the hyaluronan substrate is a measure of the PH20 enzymatic

282

Example 9

Stability of F204P-pH20 Variant in Preservative

To confirm the screening results, an amount estimated to be about 450 U/mL of the purified F204P protein as described in Example 6 was formulated in 10 mM sodium phosphate, pH 6.5, 120 mM NaCl, 10 mM methionine, 0.01% Pluronic F-68, 0.1% phenol and 0.15% m-cresol. A test article that also contained an amount estimated to be about 450 U/mL wild type rHuPH20 (generated as described in Example 1) in the same formulation was also prepared to serve as a control. Each formulation solution was aliquotted in 0.5 mL and filled into 2 mL USP Type I borosilicate glass with a chlorobutyl rubber stopper and an aluminum seal. The vials were incubated at 5° C., 30° C. or 37° C. Samples were withdrawn from the incubator at various times and enzymatic activity was measured as described in Example 8.

The results of the enzymatic activity measurements are shown in Table 15. As can be seen, the rHuPH20 wild type control showed a rapid decrease in activity when incubated at 37° C. in the presence of phenolic preservatives. In contrast, the F204P mutant showed no significant loss in activity throughout the study. The results also show that activity of PH20 is retained after incubation for up to 4 weeks at 5° C. and 30° C. compared to the activity of the rHuPH20 wildtype control not containing the mutation. These results confirm that F204P tolerates EPB level of preservative (0.1% phenol and 0.15% m-cresol) and is stable at 37° C. for at least up to 6 days at at 5° C. and 30° C. for greater than one month.

TABLE 15

	F		20 wildty 1 at with		tive				
		20 rela y (%) a			H20 relati y (%) at		-	H20 rela ty (%) at	
ID	Т0	2 w	4 w	6 d	2 w	4 w	2 d	4 d	6 d
F204P wildtype control	100 100	_	91.8 81.9	84.1 66.7	100 61.7	96.6 60.5	105 48.6	91.1 29.6	95.9 15.2

activity. The method is run using a calibration curve generated with dilutions of a PH20 assay working reference 45 standard (rHuPH20 standard generated as described in Example 1), and sample activity measurements are made relative to this calibration curve.

Dilutions of the sample and standards were prepared in Enzyme Diluent Solution (70 mM NaCl, 0.10% human 50 serum albumin [HSA], 0.67 g/L gelatin hydrolysate in 25 mM PIPES buffer, pH 5.5). The samples were diluted to an appropriate concentration. Hyaluronic acid (HA, average MW of 20-50 kDa) from Lifecore Biomedical (Chaska, MN) also was prepared at 1 mg/mL in substrate solution that contains 25 mM PIPES, 70 mM NaCl at pH 5.5. Equal amounts of the above two solutions were mixed to prepare a 1 mL reaction mixture and incubated at 37° C. for 30 min. The reaction was stopped by addition of 4 mL of Cetylpyri- 60 dinium Chloride Solution (CPC, 5.0 mg/mL). After brief vortexing, the turbidity of the sample mixture was read at 640 nm and the activity was determined by fitting against a standard curve. Specific activity (Units/mg) was calculated 65 by dividing the enzyme activity (U/mL) by the protein concentration (mg/mL).

Example 10

Stability of F204P-PH20 Variant in Insulin Coformulation

The PH20 variant F204P was tested for its stability in a coformulation containing an insulin analog (insulin aspart or insulin lispro).

In the tested coformulations, the insulin lispro was a commercial product (Insulin Lispro: Eli Lilly Humalog® (insulin Lispro) 100 U/mL, Lot A572364).

In the tested coformulations, the insulin aspart analog was a reprocessed aspart prepared by pooling 12 vials (10 mL each) of a commercial product (Insulin Aspart: Novo Nordisk, NovoRapid® (insulin Aspart), Lot XS60195), which was then concentrated using an Amicon Ultracel-10 K column concentrator until the final concentration was about 5 times the original concentration. The insulin analog was precipitated by addition of 1 M sodium acetate, pH 5.3 and 30 mM zinc chloride (ZnCl₂, EMD, Cat No. ZX0065-1) at 1/10 of the protein solution volume. The solution was placed on ice for 30 minutes followed by centrifugation at 5600 rpm for 20 minutes in an Avanti J-E Centrifuge with JS-5.3 swinging bucket rotor (Beckman Coulter). The supernatant

15

was decanted and the pellet was resuspended and washed with 20 mM sodium acetate, 2 mM zinc chloride, pH 5.5 solution. The resuspended solution was centrifuged as described above. The washing step was repeated a total of 5 times. A final wash was performed with 20 mM sodium acetate, pH 5.5 to remove all traces of zinc chloride. The resulting protein paste was dissolved with water containing 20 mM HCl. After complete dissolution, 250 mM Tris, pH 10.7 was added to a final Tris concentration of 20 mM. The pH of the resulting solution was adjusted such that the 10 insulin analog was formulated as described below and the protein concentration was adjusted to about 15-20 mg/mL. An insulin analog prepared in this way typically had a yield of about 90%, with a residual preservative concentration at less than 100 times the starting material.

Briefly, three (3) formulations were generated each containing 600 Units (U) of PH20-F204P or wildtype rHuPH20 (generated as described in Example 1) for a total of 6 formulations as set forth in Table 16:

284

dramatic (Table 17; F1 and F5 vs. F2 and F6). When the preservative concentration was reduced to an EPB level (F3 and F4), the F204P still outperformed wildtype rHuPH20, although there was slightly higher rHuPH20 stability compared to EPA conditions. In both EPA and EPB preservative levels, PH20-F204P was able to maintain its activity up to 14 days at 30° C. when 100 mM of NaCl was included in the formulation.

TABLE 17

Enzymatic activity of rHuPH20 wild type and F204P mutant incubated at 37° C.									
	PH20 act	ivity U/mL,	(% of rema	ining activit	y)				
ID	Initial Activity	2 d	4 d	6 d	2 w				
F1. Humalog + F204P	583 (100%)	61 (10%)	15 (3%)	10 (2%)	_				

TABLE 1	6
---------	---

		Summary	of Insu	ılin Formu	lations			
	_	Bu	ıffer		Conicity nodifier	Anti-Ox		Metal
ID	pH	NaPO ₄	Tris/	/HCl	NaCl	Methionine	Glycerin	Zn
F1.Humalog + F204P	7.0-7.8	13.2 mM					173.7 mM	0.242 mM
F2.Humalog + wt	7.0-7.8	13.2 mM					173.7 mM	0.242 ml
F3.Aspart + F204P	7.3		30 1	mM 1	00 mM	5 mM		
F4.Aspart + wt	7.3		30 1	mM 1	00 mM	5 mM		
F5.Aspart + F204P	7.3		30 1	mM 1	00 mM	5 mM		
F6.Aspart + wt	7.3		30 1	mM 1	00 mM	5 mM		
							API	
		Surfa	ctant	Prese	ervatives	PH	H20	Analog
	ID	F6	8	Phenol	m-Cre	sol (U/	mL)	(mg/mL)
F1.H	umalog + F204	Р			0.315	% 6	00	3.5
	umalog + wt				0.315	% 6	00	3.5
	.Aspart + F2041	P 0.01	0%	0.100%	0.150	% 6	00	3.5
	.Aspart + wt	0.01	0%	0.100%	0.150	% 6	00	3.5
	Aspart + F204	P 0.01	0%		0.315	% 6	00	3.5
	.Aspart + wt	0.01	0%		0.315	% 6	00	3.5

Each formulation solution was dispensed in 0.5 mL 45 aliquots into 2 mL USP Type I borosilicate glass vials with a chlorobutyl rubber stopper and an aluminum seal. The vials were incubated at 5° C., 30° C. and 37° C. Samples were withdrawn from the incubator at scheduled time points $_{50}$ for enzymatic activity measurements as described in Example 8.

The results of the enzymatic activity measurements for samples incubated at 37° C., 30° C. and 5° C. are shown in Tables 17-19, respectively. At 37° C., the enzymatic activity 55 of samples containing wildtype rHuPH20 (F2, F4 and F6) were almost totally lost within two days of incubation. In contrast, after 6 days incubation at 37° C., formulation F3 and F5, which contains PH20-F204P, lost only about 10% and 30%, respectively. The PH20-F204P formulated in 60 commercial Humalog (F1) lost most of its activity within 2 days at 37° C. most likely due to the lack of NaCl in the formulation.

A similar trend for enzymatic activities of ampoules incubated at 30° C. was noted between the PH20-F204P and 65 rHuPH20. For formulations that contain an EPA preservative level, the differences between wild type and F204P were

TABLE 17-continued

Enzymatic activity of rHuPH20 wild type and

E204P mutant incubated at 37° C

	F204P mu	tant incubate	d at 37° C.		
	PH20 ac	tivity U/mL,	(% of rema	ining activit	y)
ID	Initial Activity	2 d	4 d	6 d	2 w
F2. Humalog + wt	439 (100%)	4 (1%)	—	—	_
F3. Aspart + F204P	625 (100%)	613 (98%)	496 (79%)	570 (91%)	532 (85%)
F4. Aspart + wt	566 (100%)	58 (10%)	24 (4%)	4 (1%)	_
F5. Aspart +	657 (100%)	484 (74%)	462 (70%)	478 (73%)	360
F204P					(55%)
F6. Aspart + wt	596 (100%)	-1 (0%)	—	—	—

	28	55	
TA	ъτ	\mathbf{D}	10

IABLE 18								
Enzymatic activity of rHuPH20 wild type and F204P mutant incubated at 30° C.								
PH20 activity U/mL, (% of remaining activity)								
ID	Initial Activity	6 d	2 w	4 w				
F1. Humalog + F204P	583 (100%)	345 (59%)	250 (43%)	111 (19%)				
F2. Humalog + wt	439 (100%)	1 (0%)	16 (4%)	-1				
F3. Aspart + F204P	625 (100%)	601 (96%)	650 (104%)	579 (93%)				
F4. Aspart + wt	566 (100%)	428 (76%)	390 (69%)	277 (49%)				
F5. Aspart + F204P	657 (100%)	632 (96%)	655 (100%)	561 (85%)				
F6. Aspart + wt	596 (100%)	145 (24%)	65 (11%)	9 (1.5%)				

TABLE 19

Enzymatic Activity at 5° C.							
	PH20 activ	ity (U/mL) at	5° C.				
ID	Initial Activity	2 w	4 w				
F1. Humalog + F204P	583	544	565				
F2. Humalog + wt	439	428	404	25			
F3. Aspart + F204P	625	647	607				
F4. Aspart + wt	566	580	496				
F5. Aspart + F204P	657	695	574				
F6. Aspart + wt	596	583	519				

Example 11

Stability of V58R-PH20 in Insulin Coformulation

A. Stability of V58R-PH20

The PH20 variant V58R was expressed in CHO—S cells as described in Example 2 or Example 6. The transfected plasmid DNA had a sequence of nucleotides set forth in SEQ 40 ID NO:4 containing a codon change of GTG to CGG at nucleotide positions 1295-1297, thereby encoding the V58R mutant. The V58R mutant was tested for its stability in a coformulation containing insulin aspart (insulin aspart analog prepared as described in Example 10) and under EPA or EPB preservative levels. Briefly, four (4) formulations were generated each containing 600 Units (U) of PH20-V58R or wildtype rHuPH20 (generated as described in Example 1) as set forth in Table 20. Formulations F1 and F2 represent the EPB preservative levels while formulations F3 and F4 represent the EPA preservative levels.

286

Each formulation solution was dispensed in 0.5 mL aliquots into 2 mL USP Type I borosilicate glass vials with a chlorobutyl rubber stopper and an aluminum seal. The vials were incubated at 30° C. and 37° C. Samples were withdrawn from the incubator at scheduled time points for enzymatic activity measurements as described in Example 8.

The results of the enzymatic activity measurements for samples incubated at 37° C. and 30° C. are shown in Table 21 and Table 22. At 37° C., the enzymatic activity of samples 10 containing wildtype rHuPH20 (F2 and F4) were almost totally lost within two days of incubation. In contrast, after 6 days incubation at 37° C., formulations F4 (EPB) and F3 (EPA), containing V58R—PH20, lost only about 25% and 40% activity, respectively. At 30° C., the enzymatic activity 15 of samples containing wildtype rHuPH20 also was dramatically reduced in the presence of EPA or EPB preservatives levels within one month of incubation, although there was a slightly less dramatic loss in activity in the presence of EPB preservative levels. In contrast, for V58R—PH20, there was 20 no loss of enzymatic activity for either tested formulation up to 1 month.

TABLE 21

Enzymatic activity of rHuPH20 wild type and V58R mutant incubated at 37° C.							
]	PH20 acti	vity U/mL				
Formulation	Initial Activity	2 d	4 d	6 d			
F1.Aspart + V58R	1350	1099	1094	1006			
F2.Aspart + rHuPH20 wt	677	53	-3	_			
F3.Aspart + V58R	1189	793	581	464			
F4.Aspart + rHuPH20 wt	744	12	-9	_			

TABLE 22

Enzymatic activity of rHuPH20 wild type and V58R mutant incubated at 30° C.

_	PH20 activity U/mL					
Formulation	Initial Activity	2 weeks	4 weeks			
F1. Aspart + V58R	1350	1368	1208			
F2. Aspart + rHuPH20 wt	677	422	256			
F3. Aspart + V58R	1189	1228	1171			
F4. Aspart + rHuPH20 wt	744	21	-5			

B. Comparison of Stability of F204P and V58R

The PH20 variant V58R—PH20 was compared to F204P for its stability in a coformulation containing insulin aspart

TABLE 2	20
---------	----

3

35

Summary of Insulin Formulations											
	Tonicity								API		
	-	Buf	fer	modifier	Anti-Ox	Metal	Surfactant	Prese	rvatives	PH20	Analog
ID	pН	NaPO ₄	Tris/HCl	NaCl	Methionine Glycerir	ı Zn	F68	Phenol	m-Cresol	(U/mL)	(mg/mL)
F1.Aspart + V58R	7.3		30 mM	100 mM	5 mM		0.010%	0.100%	0.150%	600	3.5
F2.Aspart + rHuPH20 wt	7.3		30 mM	100 mM	5 mM		0.010%	0.100%	0.150%	600	3.5
F3.Aspart + V58R	7.3		30 mM	100 mM	5 mM		0.010%		0.315%	600	3.5
F4.Aspart + rHuPH20 wt	7.3		30 mM	100 mM	5 mM		0.010%		0.315%	600	3.5

287

(insulin aspart analog prepared as described in Example 10) and under EPA or EPB preservative levels. Briefly, eight (8) formulations were generated as set forth in Table 23. Formulations F1-F4 represent the EPB preservative levels while formulations 1F5-1F8 represent the EPA preservative levels. Formulations F3 and F4 and formulations F7 and F8 were identical and represent the wildtype control formulations formulations used for the EPB or EPA studies, respectively.

288

PH20(F204P)-IRES-GFP-Bsd vector contains an ampicillin resistance gene (AmpR) located at nucleotides 8611-9471, an EF1a promoter at residues 1933 to 2327, an IRES at residues 4786-5370, a GFP-Bsd at residues 5394-6527 and nucleotides encoding F204P—PH20 at residues 3369-4781.

Lentivirus was produced as described in Bandaranayake et al. ((2011) Nucleic Acids Research, 39:e143). Briefly, 293T cells (ATCC) were plated at 6×10^6 cells onto 10 cm

TABLE 23

Summary of Insulin Formulations											
		But	ffer	Tonicity						A	API
			Tris/	modifier	Anti-Ox	Metal	Surfactant	Prese	rvatives	PH20	Analog
ID	pН	NaPO ₄	HCl	NaCl	Methionine Glycerin	Zn	F68	Phenol	m-Cresol	U/mL	mg/mL
F1.Aspart + V58R	7.3		30 mM	100 mM	5 mM		0.010%	0.100%	0.150%	600	3.5
F2 Aspart + F204P	7.3		30 mM	100 mM	5 mM		0.010%	0.100%	0.150%	600	3.5
F3.Aspart + rHuPH20 wt(1)	7.3		30 mM	100 mM	5 mM		0.010%	0.100%	0.150%	600	3.5
F4.Aspart + rHuPH20 wt(2)	7.3		30 mM	100 mM	5 mM		0.010%	0.100%	0.150%	600	3.5
F5.Aspart + V58R	7.3		30 mM	100 mM	5 mM		0.010%		0.315%	600	3.5
F6 Aspart + F204P	7.3		30 mM	100 mM	5 mM		0.010%		0.315%	600	3.5
F7.Aspart + rHuPH20 wt(1)	7.3		30 mM	100 mM	5 mM		0.010%		0.315%	600	3.5
F8.Aspart + rHuPH20 wt(2)	7.3		30 mM	100 mM	5 mM		0.010%		0.315%	600	3.5

aliquots into 2 mL USP Type I borosilicate glass vials with a chlorobutyl rubber stopper and an aluminum seal. The vials were incubated at 30° C. and 37° C. Samples were withdrawn from the incubator at scheduled time points for enzymatic activity measures as described in Example 8.

The results show that the percentage hyaluronidase activity in the tested formulations after preincubation at 37° C. was slightly greater for both PH20 mutants when formulated in EPB and not EPA preservative levels. While the percent of activity remaining was greater than 80% for both tested 40 mutants after 6 days incubation in formulations containing EPB preservative levels, it was less in the presence of EPA preservative levels. For example, the activity remaining at 6 days in EPA preservative levels was slightly less than 80% after 6 days for F204P-PH20, while it was only about 40% 45 for V58R—PH20. Hence, the results also show that at 37° C., V58R—PH20 is somewhat less stable than the F204P— PH20, in particular in a formulation with EPA preservative levels. After incubation at 30° C. for at least a week, the F204P—PH20 and V58R—PH20 were stable and exhibited 50 almost 100% initial activity in the presence of both EPA and EPB preservative levels. In contrast, rHuPH20 exhibited only about 40% of its initial activity after 4 weeks at 30° C. in the presence of EPB preservative levels, while it exhibited no detectable activity after 4 weeks at 30° C. in the presence 55 of EPA preservative levels.

Example 12

Expression of F204P-PH20 Using a Lentivirus Expression Vector

A lentivirus expression vector, pLV-EF1a-PH20(F204P)-IRES-GFP-Bsd was generated containing a codon-optimized mutant hyaluronidase cDNA encoding F204P- 65 PH20. The sequence of pLV-EF1a-PH20(F204P)-IRES-GFP-Bsd is set forth in SEQ ID NO:925. The pLV-EF1a-

Each formulation solution was dispensed in 0.5 mL 30 tissue culture plates. After 24 hours, 6 µg of psPAX2 (SEQ ID NO:926; Addgene plasmid No. 12260), 3 µg of PMD2.G (SEQ ID NO:927; Addgene plasmid #12259) and 9 µg lentiviral vector plasmid pLV-EF1a-PH20(F204P)-IRES-GFP-Bsd were mixed in 1.5 mL Opti-MEM (Life Technolo-35 gies). 45 µL of Lipofectamine 2000 (LF2000; Life Technologies) were diluted into 1.5 mL Opti-MEM (Life Technologies). The DNA and LF2000 were mixed gently, and incubated at room temperature for 20 minutes to allow the DNA and lipid to form complexes. In the meantime, the overnight culture medium was replaced with 5.0 mL DMEM+10% FBS without antibiotics. A volume of 3.0 mL containing the DNA-LF2000 complexes were added to the 293T cells. The medium containing the DNA-LF2000 complexes was replaced with 10 mL complete medium at 12-16 hours post-transfection. The supernatant was collected at 48 hours post-transfection and the medium was transferred to a polypropylene storage tube. The virus-containing medium was spun at 1300 rpm for 5 minutes to pellet any 293T cells that were carried over during collection. The supernatant was carefully transferred to a sterile polypropylene storage tube

> CHO-S cells (Invitrogen) were grown in CHO-S media (Invitrogen) with shaking at 120 rpm at 37° C. and 5% CO₂ in vented 125-mL shake flasks (Nalgene). For transduction, CHO-S cells were added to wells of a six-well plate at 2×10⁶ cells per well in 2 ml of CHO-S media containing 4 µg/mL hexadimethrine bromide at a final concentration of 4 µg/mL (Polybrene; SIGMA). Virus was added to each well at a multiplicity of infection (MOI) of 10 and the cells were 60 incubated with shaking (120 rpm) at 37° C. and 5% CO_2 for 6 hours. The cells were then harvested and pelleted by low speed centrifugation (500×g, 5 min). The transduction medium was removed and replaced with 10 mL of fresh CHO-S medium (Invitrogen) supplemented with Gluta-Max (50 mL/liter) and transferred to a T-25 flask. Three days post infection, blasticidin (Invitrogen) was added to the growth medium at a concentration of 1 µg/mL. The medium

was changed regularly at 3-4 day intervals, and the cells were transferred to a T75 flask for expansion. Two weeks after the initial infection, the cells were expanded to shaker flasks and maintained in culture using medium containing 1 µg/mL blasticidin. F204P—PH20 protein secreted into the CHO—S medium was collected and purified by affinity chromatography using an anti-rHuPH20 affinity column as described in Example 6. The protein was prepared in standard API buffer (10 mM Histidine, 130 mM NaCl, pH 6.5).

Example 13

Analysis of Secondary Structure and Melting Temperature

The secondary structure and melting temperature of the PH20 variant F204P was tested and compared to wild-type rHuPH20 (generated as described in Example 1) to further ²⁰ assess stability of the variant. The secondary structure was tested by circular dichroism. A Jasco J-810-150S equipped with PTC-424S was employed for the CD spectral measurement and the CD spectra were collected by Spectra Manager (Version 1.5, Jasco). Procedures for instrumental set up and ²⁵ data collection are described in Table 24.

TABLE 24

Parameters	Conditions	
Nitrogen flow rate	25 ft ³ /h	
Sample temperature	30-75° C.	
Sample concentration	Approx. 0.1 mg/mL	3
Cell pathlength	1 mm	
Wavelength	220 nm	
Data pitch	1° C.	
Delay time	60 seconds	
Temperature slope	1° C./min	
Sensitivity	standard	4
Response	4 seconds	
Band width	1 nm	

1. Sample Preparation and Measurement

Two hundred (200) µL of a 0.1 mg·mL protein sample diluted in Mcllvaine's buffer (McIlvaine (1921) JBC 49:183) adjusted to pH 6.5 were prepared. A series of 50 samples of the F204P variant were also generated that varied in pH by adjustment using Mcllvaine's buffer to a pH range from 5.0 to 7.5 as set forth in Table 25. In addition, samples also were generated by adjusting the NaCl concentration to 17.5 mM to 140 mM as set forth in Table 26. Samples were filtered using a 0.2 µm syringe filter prior to measurement. Similar samples were generated for rHuPH20. Then, 200 µL samples were transferred to a rectangular cuvetted having a 1 mm width and seated on Jasco J-810 spectropolarimeter. 60 CD spectra of the samples were collected under the conditions described in Table 20. The melting temperature (T_m) was calculated using Spectra Manager (v 1.5, Jasco) from the CD spectral intensity measured at the temperature range from 30° C. to 75° C. The cuvettes were cleaned by 65 Chromerge® cleaner (C577-12, Fisher scientific) between individual sample loading and after the run.

2	9	U	

TABLE	25
-------	----

	Sample pH and concentration								
Target pH	Actual pH	F204P (µL)	Buffer (µL)	F204P concentration (mg/mL)					
5.0	4.92	25	175	0.1					
5.5	5.38	25	175	0.1					
6.0	5.99	25	175	0.1					
6.5	6.49	25	175	0.1					
7.0	7.00	25	175	0.1					
7.5	7.5	25	175	0.1					

TABLE 26

Sodium Concentration in Samples at pH 6.5									
Target NaCl concentration (mM)	NaCl, 2.8M (µL)	F204P (µL)	Buffer at pH 6.5 (µL)	F204P concentration (mg/mL)					
17.5	0.00	25	175	0.1					
50.0	2.32	25	172.7	0.1					
75.0	4.11	25	170.9	0.1					
100.0	5.89	25	169.1	0.1					
140.0	8.75	25	166.3	0.1					

2. Results

³⁰ The results show that the secondary structure of F204P is similar to rHuPH20. As a function of temperature, circular dichroism showed that a change in the absorption was measured with increasing temperatures. As a function of pH, the T_m distribution was closely comparable for both F204P ³⁵ and rHuPH20 and the highest T_m for each was obtained between pH 5.5 and pH 6.0. The results, however, showed that T_m of the F204P variant was approximately 9° C. higher at all tested ranges than wildtype rHuPH20. This result indicated that the F204P mutant is more stable against thermal stress conditions. As a function of salt, the results show that the F204P and wildtype rHuPH20 both exhibited an increasing T_m with higher salt concentration, showing that both have a proportional inclination toward salt con-45

Example 14

Assessment of Enzymatic Activity In an Intradermal Trypan Blue Dispersion Assay

Spreading activity of the PH20 variant F204P was assessed using a dye dispersion in vivo assay. Briefly, purified PH20 variant F204P (prepared as described in Example 12) and wild-type rHuPH20 (prepared as described in Example 1) were both formulated in API buffer (10 mM Histidine, 130 mM NaCl, pH 6.5) at a concentration of 10,000 U/mL. The stocks were further diluted to three target concentrations of 1000, 100 and 10 U/mL by serial 1:10 dilutions in API buffer. Purified proteins (either rHuPH20 or F204P—PH20) were diluted 1:1 with 0.4% Trypan Blue (0.4% liquid solution; Catalog No. 15250, Invitrogen) to give a final concentration of 5, 50 and 500 U/mL protein, each containing 0.2% trypan blue. A vehicle control (API buffer) also was prepared. Forty-two (42) female NCr nu/nu homozygous mice were used in the study with six mice used per group as set forth in Table 27.

Group	No. of Mice	Test Article	Final Dose with Trypan Blue (Units/mL)	Trypan Blue	Injection Volume (mL)
1	6	Control	0	0.2%	0.04
2	6	rHuPH20	5	0.2%	0.04
3	6	rHuPH20	50	0.2%	0.04
4	6	rHuPH20	500	0.2%	0.04
5	6	F204P-PH20	5	0.2%	0.04
6	6	F204P-PH20	50	0.2%	0.04
7	6	F204P-PH20	500	0.2%	0.04

Forty (40) µL of samples were administered by a single intradermal injection. The area of dye dispersion was measured at 2.5, 5, 10, 15 and 20 minutes post-injection and was recorded by photographic imaging by photograph of the injection site with a Nikon D90 digital camera with 60 mm 20 homozygous mice were used in the study with three animals prime micro-lens. A laser distance meter (Leica D3) was used to accurately position the camera at a pre-determined distance from the Trypan Blue dye area on the animal. The area of the dye was determined using Image-Pro Analyzer 7.0 (MediaCybernetics, Inc). The calculated areas were 25 expressed as mm².

The results are set forth in Table 28. The results showed that the dispersion activity of the PH20 variant F204P was substantially identical to the dispersion activity of rHuPH20. 30 The ability to increase the area of dye dispersion was dose-dependent, with both proteins having greatest activity at 500 U/mL. The results also showed that the area of dye dispersion increased with time post-intradermal injection. The areas of dye dispersion of rHuPH20 and F204P—PH20 35 were significantly greater than the areas of dye dispersion for the controls (p<0.05) at all time points when formulated at all concentrations (5, 50 and 500 U/mL) with the exception of rHuPH20 at the lowest concentration (5 U/mL). When compared to each other, rHuPH20 and F204P-PH20 40 showed similar dispersion effects, although there was a significant difference in dispersion between the two groups at 5 U/mL and 500 U/mL but not at 50 U/mL. In sum, the results show that both rHuPH20 and F204P-PH20 provided a statistically significant increase in the area of dye $\,^{45}$ dispersion compared to the vehicle control.

TABLE 28

	Trypan Blue Dispersion								
Group		Area (mm2)							
Avg. (n = 6)	2.5 min	5 min	10 min	15 min	20 min				
1: Control	37.44 ± 2.81	38.16 ± 3.33	43.71 ± 2.12	45.70 ± 2.38	48.77 ± 2.14	55			
2: rHuPH20 (5 U/mL)	36.68 ± 2.83	42.31 ± 2.57	45.41 ± 2.75	46.72 ± 3.35	49.61 ± 2.97				
3: rHuPH20 (50 U/mL)	39.24 ± 1.20		46.96 ± 1.70	50.08 ± 2.07	53.50 ± 1.59				
4: rHuPH20 (500 U/mL)	44.72 ±	50.21 ± 1.92	57.47 ± 1.29	59.77 ± 1.25	57.17 ± 3.28	60			
5: F204P (5 U/mL)	39.65 ± 1.53	46.09 ± 2.73	48.07 ± 1.43	52.54 ± 2.01	54.11 ± 1.01				
6: F204P (50 U/mL)	38.10 ± 1.92	47.07 ± 2.12	51.48 ± 2.14	55.24 ± 1.90	58.34 ± 2.89				
(500 U/mL) (500 U/mL)	46.58 ± 1.67		58.96 ± 1.85	64.37 ± 1.72	64.44 ± 2.17	65			
			58.96 ± 1.85	64.37 ± 1.72	64.44 ± 2.17	65			

292

Example 15

Assessment of Enzymatic Activity By Dermal Barrier Reconstitution

Activity of F12041P-1PH20 was assessed and compared to rHuPH20 to measure the amount of time required for the dermal barrier to reconstitute itself after intradermal hyaluronidase administration. Dermal reconstitution was evaluated by comparing the duration of the hyaluronidase spreading activity as assessed by monitoring the area of diffusion of 0.4% Trypan Blue over time. The proteins used in the study were purified PH20 variant F204P (prepared as described in Example 12) and wild-type rHuPH20 (prepared as described in Example 1) that were both formulated in API buffer (10 mM Histidine, 130 mM NaCl, pH 6.5). Vehicle (API buffer) was used as a control. Male NCr nu/nu per time point for a total of fifteen mice used per group as set forth in Table 29.

TABLE 29

	Summary of Treatment Groups for Dermal Barrier Reconstitution Study								
1	Group	No. of Mice	Time Points (h)	Test Article	Final Dose (Units/mL)	Injection Volume (mL)			
	1	15	0.5, 1, 4, 24, 48	Control	0	0.04			
	2	15	0.5, 1, 4, 24, 48	rHuPH20	100	0.04			
	3	15	0.5, 1, 4, 24, 48	F204P	100	0.04			

All mice received two intradermal doses of vehicle control or rHuPH20 or F204P-PH20 at 100 U/mL in 0.04 mL at study time 0. The same control or test article was injected on the opposing lateral sides of each animal (right, R; left, L). Injection sites were marked with a permanent marker. Trypan Blue Stain (0.4% liquid solution; 15250, Invitrogen) was administered at a volume of 0.04 mL by intradermal injection at the same injection site at 0.5, 1, 4, 24 and 48 hours post-injection of test article or control. At 5 and 20 50 minutes post-injection of the Trypan Blue Stain, the area of the dye at the injection site was measured by digital imaging of the region as described in Example 14.

The results are set forth in Table 30. The results show that when the area of dye dispersion was measured at various time points after administration of the test article or control, there was a statistically significant increase in the area of dye dispersion at 30 min and 1 hour post-injection of rHuPH20 or F204P-PH20. By 4 hours post-administration of the enzymes, however, there was not a statistically significant increase in the area of dye dispersion compared to control. In addition, no statistically significant differences in the area of dye dispersion was observed between the rHuPH20 and F204P—PH20 treatment groups. Therefore, the duration of 55 the spreading activity of rHuPH20 and F204P were similar and show that rHuPH20 and F204P-PH20 have comparable in vivo performance.

Dermal Reconstitution						
time Point	min post- injection	Vehicle	rHuPH20	F204P-PH20		
30	5	49.96 ± 2.05	80.84 ± 8.03	80.76 ± 4.46		
	20	64.42 ± 2.49	94.55 ± 7.09	95.75 ± 5.18		
l hour	5	58.01 ± 3.21	82.56 ± 6.40	77.11 ± 3.18		
	20	65.19 ± 6.21	96.19 ± 6.39	91.45 ± 1.73		
hour	5	52.10 ± 3.47	67.19 ± 2.39	67.33 ± 3.93		
	20	57.69 ± 3.92	81.15 ± 4.45	82.21 ± 4.14		
hour	5	49.87 ± 3.25	59.01 ± 2.15	54.91 ± 3.54		
	20	57.15 ± 3.47	67.65 ± 2.27	62.91 ± 3.30		
hour	5	53.64 ± 2.99	53.53 ± 4.88	55.64 ± 7.19		
	20	61.57 ± 4.02	66.33 ± 4.12	63.11 ± 5.97		

Example 16

In Vivo Pharmacokinetics of F204P—PH20 Compared to rHuPH20

The pharmacokinetics (PK) of rHuPH20 and F204P-25 PH20 were compared following intravenous tail-vein administration by measuring the plasma hyaluronidase levels over time after administration. The proteins used in the study were purified PH20 variant F204P (prepared as described in Example 12; batch concentration 1.02 mg/mL) 30 and wild-type rHuPH20 (prepared as described in Example 1; batch concentration 0.95 mg/mL) formulated in API buffer (10 mM Histidine, 130 mM NaCl, pH 6.5). The proteins were prepared at a concentration of 0.087 mg/mL in API buffer for a dose volume of about 5 mL. An animal that ³⁵ was not administered with protein was used a control (pre-dose control). Forty two (42) male CD-1 mice (~20-30 grams) were used in the study with six animals per treatment group as set forth in Table 31.

Т

 Pharmacokinetics of Single Intravenous Dose of rHuPH20 or F204P- PH20							
Group	number of animals (No.)	Test Article	Dose (mg/kg)	Dose Volume (mL/kg)	Euthanasia		
1	6 (Nos. 1-6)	no treatment	N/A	N/A	pre-dose		
2	6 (Nos. 7-12)	rHuPH20	0.433	5	1 min		
3	6 (Nos. 13-18)	rHuPH20	0.433	5	$5 \pm 1 \min$		
4	6 (Nos. 19-24)	rHuPH20	0.433	5	$10 \pm 2 \min$		
5	6 (Nos. 25-30)	F204P-PH20	0.433	5	1 min		
6	6 (Nos. 21-36)	F204P-PH20	0.433	5	$5 \pm 1 \min$		
7	6 (Nos. 37-42)	F204P-PH20	0.433	5	$10 \pm 2 \min$		

Mice were intravenously administered 0.433 mg/kg rHuPH20 or F204P—PH20 by tail vein injection. Blood samples were obtained from animals 1 minute, 5 minutes and 10 minutes post-administration. Blood samples were obtained by terminal bleed (cardiac puncture) and collected into blood collection tubes containing the anti-coagulant EDTA for the preparation of plasma. Blood samples were centrifuged at 500 g for 10 minutes and the plasma removed and frozen at -80° C. until assessment of hyaluronidase activity using the microturbidity assay described in Example 8.

The results are set forth in Table 32. The results show that hyaluronidase activity is detected in plasma prior to treatment with the hyaluronidase. Within 1 minute post-treatment with either rHuPH2 or F204P—PH20 hyaluronidase, there is a detectably high amount of hyaluronidase activity present in the plasma, which is similar between both treatment groups. Over time, the hyaluronidase activity rapidly decreases for both treatment groups, although there is detectably hyaluronidase activity present in the plasma to the plasma 10 minutes post-administration. At the 5 minute and 10 minute post-administration time points, activity in the plasma in animals treated with F204P—PH20 is greater than in animals treated with rHuPH20. This shows that F204P—PH20 exhibits somewhat greater activity for a prolonged time period, and therefore exhibits greater half-life in vivo than rHuPH20.

TABLE 32

rHuPH20 and F204P-PH20 Activity (U/mL) in Mouse Plasma K2EDTA								
	Time Point (min)							
	Predose		1 minute		5 minute		10 minute	
Protein	Animal No.	U/mL	Animal No.	U/mL	Animal No.	U/mL	Animal No.	U/mL
rHuPH20	1	BQL	7	235 ^a	13	18.3	19	3.76
	2	BQL	8	13.5	14	7.70	20	3.70
	3	BQL	9	278	15	8.85	21	2.64
	4	BQL	10	328	16	10.5	22	2.70
	5	BQL	11	356	17	12.8	23	2.36
	6	BQL	12	287	18	18.0	24	2.80
F204P-PH20	1	BQL	25	249	31	48.0	37	11.5
	2	BQL	26	223	32	21.6	38	11.4
	3	BQL	27	246	33	38.4	39	10.1
	4	BQL	28	246	34	38.6	40	12.2
	5	BQL	20	0.696	35	38.2	41	10.8
	6	BQL	30	257	36	28.5	42	10.2

BQL - Below Quantifiable Limit <0.625 U/mL with minimum required dilution

^aHemolyzed

BQL— Below Quantifiable Limit <0.625 U/mL with minimum required dilution

^a— Hemolyzed

Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

296

SEQUENCE LISTING

The patent contains a lengthy sequence listing. A copy of the sequence listing is available in electronic form from the USPTO web site (https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US12110520B2). An electronic copy of the sequence listing will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

35

55

What is claimed:

1. A modified PH20 polypeptide, comprising one or more amino acid modifications in an unmodified PH20 polypep- $_{20}$ tide, wherein:

- the unmodified PH20 polypeptide consists of the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 7 and 32-66;
- amino acid modifications are selected from the group 25 consisting of amino acid replacements(s), deletion(s), and/or insertion(s);
- the modified PH20 polypeptide comprises an amino acid replacement at a position corresponding to residue 324, with reference to amino acid positions set forth in SEQ ³⁰ ID NO: 3;
- the replacement at the position corresponding to residue 324 is selected from the group consisting of A, D, H, M, N, R and S;
- corresponding amino acid positions are identified by alignment of the PH20 polypeptide with the polypeptide having the amino acid sequence of SEQ ID NO: 3; and
- the modified PH20 polypeptide has at least 91% sequence 40 identity to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 7 and 32-66.

2. The modified PH20 polypeptide of claim **1**, wherein the modified PH20 polypeptide has at least 95% sequence 45 identity to the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 7, and 32-66.

3. The modified PH20 polypeptide of claim **1** that has increased resistance to or stability in denaturing conditions compared to an unmodified PH20 polypeptide that does not 50 contain the amino acid modification(s).

4. The modified PH20 polypeptide of claim **1** that exhibits increased hyaluronidase activity compared to the unmodified PH20 polypeptide not containing the amino acid replacement at position 324.

5. The modified PH20 polypeptide of claim **1** that is a soluble PH20 polypeptide.

6. The modified PH20 polypeptide of claim **1**, wherein the replacement at the position corresponding to residue 324 is D.

7. The modified PH20 polypeptide of claim **1**, wherein the replacement at the position corresponding to residue 324 is N or R.

8. The modified PH20 polypeptide of claim **1**, wherein the unmodified PH20 polypeptide consists of the amino acid 65 sequence selected from the group consisting of SEQ ID NO: 3 and 32-66.

9. The modified PH20 polypeptide of claim **7**, wherein the unmodified PH20 polypeptide consists of the amino acid sequence selected from the group consisting of SEQ ID NO: 3 and 32-66.

10. The modified PH20 polypeptide of claim **6**, wherein the unmodified PH20 polypeptide consists of the amino acid sequence selected from among the group consisting of SEQ ID NO: 3 and 32-66.

11. The modified PH20 polypeptide of claim **1**, wherein the unmodified PH20 polypeptide consists of the amino acid sequence of SEQ ID NO:35.

12. The modified PH20 polypeptide of claim **1**, wherein the unmodified PH20 polypeptide consists of the amino acid sequence of SEQ ID NO:32.

13. The modified PH20 polypeptide of claim **6**, wherein the unmodified PH20 polypeptide consists of the amino acid sequence of SEQ ID NO:35.

14. The modified PH20 polypeptide of claim **6**, wherein the unmodified PH20 polypeptide consists of the amino acid sequence of SEQ ID NO:32.

15. The modified PH20 polypeptide of claim **1**, comprising a sequence of amino acids that exhibits at least 91% sequence identity to the sequence of amino acids selected from the group consisting of SEQ ID NO: 3, and 32-66 and that contains an amino acid replacement D at the residue corresponding to residue 324 with reference to SEQ ID NO: 3.

16. The modified PH20 polypeptide of claim **1** that is C-terminally truncated, whereby the polypeptide is soluble.

17. The modified PH20 polypeptide of claim **1** that comprises one or more post-translational modifications of the polypeptide selected from the group consisting of gly-cosylation, sialylation, albumination, farnesylation, carboxylation, hydroxylation, and phosphorylation.

18. The modified PH20 polypeptide of claim **17**, wherein the post-translational modification is glycosylation.

19. The modified PH20 polypeptide of claim **18**, wherein the polypeptide is a glycoprotein that comprises an N-acetyl-glucosamine moiety linked to each of at least three asparagine (N) residues.

20. The modified PH20 polypeptide of claim **1** that is 60 conjugated to a polymer.

21. The modified PH20 polypeptide of claim **20**, wherein the polymer is dextran or polyethylene glycol (PEG).

22. The modified PH20 polypeptide of claim **1**, further comprising a heterologous signal sequence, wherein the unmodified PH20 polypeptide consists of the amino acid sequence selected from the group consisting of SEQ ID NO: 3 and 32-66.

Petitioner Merck, Ex. 1001, p. 174

23. A chimeric polypeptide, comprising the modified PH20 polypeptide of claim **1**.

24. A pharmaceutical composition, comprising the modified PH20 polypeptide of claim **1**.

- **25**. The modified PH20 polypeptide of claim **6**, wherein: 5 the unmodified PH20 polypeptide consists of the amino acid sequence of SEQ ID NO:32; and
- the amino acid sequence of the modified PH20 polypeptide has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:32.
- **26**. The modified PH20 polypeptide of claim **6**, wherein: the unmodified PH20 polypeptide consists of the amino acid sequence of SEQ ID NO:35; and
- the amino acid sequence of the modified PH20 polypeptide has at least 95% sequence identity to the amino 15 acid sequence of SEQ ID NO:35.

27. The pharmaceutical composition of claim **24**, further comprising a therapeutically active agent formulated in the same composition or in a separate composition.

28. The pharmaceutical composition of claim **27**, wherein 20 the therapeutically active agent is a polypeptide, a protein, a nucleic acid, a drug, a small molecule, or an organic molecule.

29. The pharmaceutical composition of claim **27**, wherein the therapeutically active agent is selected from the group 25 consisting of a chemotherapeutic agent, an analgesic agent, an anti-inflammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonacidal agent, an anti-Parkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti-depressant agent, an antiarthritics agent, an anti- 30 fungal agent, an antihypertensive agent, an antipyretic agent, an anti-parasite agent, an antihistamine agent, an alpha-adrenergic agonist agent, an alpha blocker agent, an anes-

thetic agent, a bronchial dilator agent, a biocide agent, a bactericide agent, a bacteriostat agent, a beta adrenergic blocker agent, a calcium channel blocker agent, a cardiovascular drug agent, a contraceptive agent, a decongestant agent, a diuretic agent, a depressant agent, a diagnostic agent, an electrolyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a psychic energizer agent, a sedative agent, a sympathomimetic agent, a viricide agent, a vitamin agent, a non-steroidal anti-inflammatory agent, an agiotensin converting enzyme inhibitor agent, and a sleep inducer.

30. The pharmaceutical composition of claim **27**, wherein the therapeutically active agent is an antibody.

31. A method for treating a hyaluronan-associated disease or condition, comprising administering to a subject a modified PH20 polypeptide of claim **1**.

32. The method of claim **31**, wherein the hyaluronanassociated disease or condition is an inflammatory disease or a tumor or cancer.

33. The method of claim **32**, wherein the hyaluronan-associated disease or condition is a solid tumor.

34. The modified PH20 polypeptide of claim 1 that is further modified by conjugation to a moiety selected from the group consisting of a multimerization domain, a toxin, a detectable label, and a drug.

35. The modified PH20 polypeptide of claim **34**, wherein the modified PH20 polypeptide is conjugated to a multimerization domain that is an Fc domain.

* * * * *